



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07H 21/04, C07K 14/47, C12N 15/63, 1/21, 15/85		A1	(11) International Publication Number: WO 99/37660
			(43) International Publication Date: 29 July 1999 (29.07.99)
(21) International Application Number: PCT/US99/01313			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 22 January 1999 (22.01.99)			
(30) Priority Data: 60/072,298 23 January 1998 (23.01.98) US 60/098,539 28 August 1998 (28.08.98) US			
(71)(72) Applicants and Inventors: IRUELA-ARISPE, Luisa [ES/US]; 1342 Holmby Avenue, Los Angeles, CA 90024 (US). HASTINGS, Gregg, A. [US/US]; 1615 Medowen Glen Court, Thousand Oaks, CA 91320 (US). RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US).			
(74) Agents: STEFFE, Eric, K.; Sterne, Kessler, Goldstein & Fox P.L.L.C., Suite 600, 1100 New York Avenue, N.W., Washington, D.C. 20005-3934 (US) et al.			
Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments. With an indication in relation to deposited biological material furnished under Rule 13bis separately from the description.</i>			
(54) Title: METH1 AND METH2 POLYNUCLEOTIDES AND POLYPEPTIDES			
(57) Abstract <p>The present invention relates to novel anti-angiogenic proteins, related to thrombospondin. More specifically, isolated nucleic acid molecules are provided encoding human METH1 and METH2. METH1 and METH2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for the prognosis of cancer and therapeutic methods for treating individuals in need of an increased amount of METH1 or METH2.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

METH1 and METH2 Polynucleotides and Polypeptides

Background of the Invention

Federally-Sponsored Research and Development

Part of the work performed during development of this invention utilized
5 U.S. Government funds. The U.S. Government has certain rights in this invention.

Field of the Invention

The present invention relates to novel anti-angiogenic proteins, related to
thrombospondin. More specifically, isolated nucleic acid molecules are provided
encoding human METH1 and METH2 (ME, for metalloprotease, and TH, for
10 thrombospondin). METH1 and METH2 polypeptides are also provided, as are
vectors, host cells and recombinant methods for producing the same. Also
provided are diagnostic methods for the prognosis of cancer and therapeutic
methods for treating individuals in need of an increased amount of METH1 or
METH2.

Related Art

Angiogenesis, the formation of new blood vessels from pre-existing
vasculature, is a tightly regulated process in normal adults. Under physiological
circumstances, growth of new capillaries is tightly controlled by an interplay of
growth regulatory proteins which act either to stimulate or to inhibit blood vessel
20 growth. Normally, the balance between these forces is tipped in favor of inhibition
and consequently blood vessel growth is restrained. Under certain pathological
circumstances, however, local inhibitory controls are unable to restrain the
increased activity of angiogenic inducers. Angiogenesis is a key step in the
metastasis of cancer (Folkman, *Nature Med.* 1:27-31 (1995)) and in abnormal
25 wound healing, inflammation, rheumatoid arthritis, psoriasis, and diabetic
retinopathy, it is integral to the pathology (Folkman *et al.*, *Science* 235:442-447
(1987)), engendering the hope that these pathological entities could be regulated

by pharmacological and/or genetic suppression of blood vessel growth (Iruela-Arispe *et al.*, *Thromb. Haem.* 78:672-677 1997)).

Thrombospondin-1 (TSP-1) is a 450 kDa, anti-angiogenic adhesive glycoprotein released from activated platelets and secreted by growing cells (reviewed in Adams, *Int. J. Biochem. Cell. Biol.* 29:861-865 (1997)). TSP-1 is a homotrimer, with each subunit comprised of a 1152 amino acid residue polypeptide, post-translationally modified by *N*-linked glycosylation and beta-hydroxylation of asparagine residues.

TSP-1 protein and mRNA levels are regulated by a variety of factors. TSP-1 protein levels are downregulated by IL-1 alpha and TNF alpha. TSP-1 mRNA and protein levels are upregulated by polypeptide growth factors including PDGF, TGF-beta, and bFGF (Bornstein, *Faseb J.* 6: 3290-3299 (1992)) and are also regulated by the level of expression of the p53 tumor suppressor gene product (Dameron *et al.*, *Science* 265:1582-1584 (1994)). At least four other members of the thrombospondin family have been identified: TSP-2, TSP-3, TSP-4, and TSP-5 (also called COMP). There is a need in the art to identify other molecules involved in the regulation of angiogenesis.

Summary of the Invention

The present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding the METH1 polypeptide having the amino acid sequence shown in SEQ ID NO:2 or the amino acid sequence encoded by the cDNA clone deposited in a bacterial host as ATCC Deposit Number 209581 on January 15, 1998.

The present invention also provides isolated nucleic acid molecules comprising a polynucleotide encoding the METH2 polypeptide having the amino acid sequence shown in SEQ ID NO:4 or the amino acid sequence encoded by the cDNA clone deposited in a bacterial host as ATCC Deposit Number 209582 on January 15, 1998.

The present invention also relates to recombinant vectors, which include the isolated nucleic acid molecules of the present invention, and to host cells containing the recombinant vectors, as well as to methods of making such vectors and host cells and for using them for production of METH1 or METH2 polypeptides or peptides by recombinant techniques.

The invention further provides an isolated METH1 or METH2 polypeptide having an amino acid sequence encoded by a polynucleotide described herein.

The invention further provides a diagnostic method useful during diagnosis or prognosis of cancer.

An additional aspect of the invention is related to a method for treating an individual in need of an increased level of METH1 or METH2 activity in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an isolated METH1 or METH2 polypeptide of the invention or an agonist thereof.

Brief Description of the Figures

Figure 1 shows the nucleotide (SEQ ID NO:1) and deduced amino acid (SEQ ID NO:2) sequences of METH1. The protein has a predicted leader sequence of about 28 amino acid residues (underlined).

Figure 2 shows the nucleotide (SEQ ID NO:3) and deduced amino acid (SEQ ID NO:4) sequences of METH2. The protein has a predicted leader sequence of about 23 amino acid residues (underlined).

Figure 3 shows a comparison of the amino acid sequence of METH1 (SEQ ID NO:2) and METH2 (SEQ ID NO:4) with that of their closest homologue, a bovine metalloprotease (pNPI) (SEQ ID NO:5). Identical amino acids are boxed. Functional domains predicted by sequence and structural homology are labeled, including the signal peptide (single line), the potential cleavage site for mammalian subtilisin (double underlined), the zinc-binding-site (dotted line) in the metalloprotease domain, and the putative disintegrin loops (arrows).

Figure 4 shows the primary structure of METH1, METH2 and pNPI which includes a prodomain, a catalytic metalloprotease domain, a cysteine rich disintegrin domain, a TSP-like domain, a spacer region and a different number of TSP-like domains, three for METH1, two for METH2, and four for pNPI.

5 Figure 5 shows a comparison of the TSP-like domain of METH1 (SEQ ID NO:2) and METH2 (SEQ ID NO:4) with those of TSP1 (SEQ ID NOs:6, 7, and 8) and TSP2 (SEQ ID NOs:9, 10, and 11), cysteines are numbered 1 to 6, tryptophans are marked by asterisks.

10 Figure 6 shows that peptides and recombinant protein derived from the TSP-like domain of METH1 and METH2 block VEGF-induced angiogenesis. Angiogenesis was induced on CAMs from 12-14-day-old embryos using a nylon mesh containing VEGF casted on matrigel and in the presence or absence of the peptides or recombinant protein. Capillary density was evaluated as described in Example 4. Positive and negative control included VEGF alone and vehicle alone, respectively. (A) Quantification of the angiogenic response induced by VEGF in the presence of recombinant proteins. TSP1, purified platelet TSP1, GST, purified GST, GST-TSP1, GST-METH1, and GST-METH2 are described in Example 4. (B) Quantification of the angiogenic response induced by VEGF in the presence or absence of the peptides; P-TSP1, P-METH1, and P-METH2 (peptide derived from the Type I repeats of TSP, METH1 and METH2, respectively); SC1 and SC2 are scramble peptides used as controls. (C) Dose-response of the VEGF-induced angiogenesis in the presence of GST-METH1. (D) Dose-response of the VEGF-induced angiogenesis in the presence of GST-METH2. The angiogenic index was expressed considering the vascular response from the VEGF-matrigel as 100% and subtracting the background levels (matrigel alone). Assays were repeated, at least, twice. Each treatment was done in triplicate. Values represent the mean, bars indicate standard deviations. *p<0.001.

25 Figure 7 shows the effect of METH1 and METH2 recombinant proteins on bFGF-stimulated cell proliferation. Cells were cultured on 24-well plates in media containing bFGF and the recombinant protein to be tested (3µg/ml, unless

30

indicated in the graph). Controls included vehicle or GST recombinant protein alone. (A), HDEC, human dermal endothelial cells; (B), HMEC, human mammary epithelial cells; (C), HDF, human dermal fibroblasts; (D), SMC, smooth muscle cells; (E) Dose-response of GST-METH1 and GST-METH2 on HDEC proliferation. Experiments were repeated, at least, twice. Each treatment was done in triplicate. Values represent the mean, bars indicate standard deviations. * $p < 0.01$.

Figure 8 shows a schematic representation of the pHE4-5 expression vector (SEQ ID NO:12) and the subcloned METH1 or METH2 cDNA coding sequence. The locations of the kanamycin resistance marker gene, the METH1 or METH2 coding sequence, the oriC sequence, and the *lacIq* coding sequence are indicated.

Figure 9 shows the nucleotide sequence of the regulatory elements of the pHE promoter (SEQ ID NO:13). The two *lac* operator sequences, the Shine-Delgarno sequence (S/D), and the terminal *HindIII* and *NdeI* restriction sites (italicized) are indicated.

Figure 10 shows an analysis of the METH1 amino acid sequence. Alpha, beta, turn and coil regions; hydrophilicity and hydrophobicity; amphipathic regions; flexible regions; antigenic index and surface probability are shown, and all were generated using the default settings. In the "Antigenic Index or Jameson-Wolf" graph, the positive peaks indicate locations of the highly antigenic regions of the METH1 or METH2 protein, i.e., regions from which epitope-bearing peptides of the invention can be obtained. The domains defined by these graphs are contemplated by the present invention. Tabular representation of the data summarized graphically in Figure 10 can be found in Table 1.

Figure 11 shows an analysis of the METH2 amino acid sequence. Alpha, beta, turn and coil regions; hydrophilicity and hydrophobicity; amphipathic regions; flexible regions; antigenic index and surface probability are shown, and all were generated using the default settings. In the "Antigenic Index or Jameson-Wolf" graph, the positive peaks indicate locations of the highly antigenic

regions of the METH1 or METH2 protein, i.e., regions from which epitope-bearing peptides of the invention can be obtained. The domains defined by these graphs are contemplated by the present invention. Tabular representation of the data summarized graphically in Figure 11 can be found in Table 2.

Table 1

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emni Surfa...
Met	1	A	A	0.41	*	.	.	-0.30	0.60
Gly	2	.	A	C	0.91	*	.	.	0.50	0.81
Asn	3	A	A	0.71	*	.	.	0.75	1.24
Ala	4	A	A	0.89	*	.	.	1.09	1.26
Glu	5	A	A	0.93	*	.	F	1.58	1.97
Arg	6	.	A	B	1.23	.	.	F	1.92	1.21
Ala	7	.	.	B	.	.	T	.	1.69	.	.	F	2.66	1.61
Pro	8	T	T	.	1.39	.	.	F	3.40	1.82
Gly	9	T	T	.	1.28	.	.	F	3.06	1.25
Ser	10	T	T	.	0.93	.	.	F	2.42	1.07
Arg	11	T	T	.	0.61	.	*	F	1.93	0.68
Ser	12	T	T	.	0.34	*	.	F	1.74	1.07
Phe	13	.	.	B	.	.	T	.	0.34	*	.	F	0.25	0.59
Gly	14	.	.	B	.	.	T	.	0.38	*	.	F	0.25	0.47
Pro	15	.	.	B	B	.	.	.	-0.13	*	.	F	-0.45	0.50
Val	16	.	.	B	B	.	.	.	-1.06	*	.	F	-0.45	0.48
Pro	17	.	.	B	B	.	.	.	-1.57	.	.	F	-0.45	0.40
Thr	18	.	A	B	-1.68	.	.	F	-0.45	0.21
Leu	19	.	A	B	-1.92	.	.	.	-0.60	0.24
Leu	20	A	A	-2.30	.	.	.	-0.60	0.15
Leu	21	A	A	-2.03	.	.	.	-0.60	0.11

5

10

15

20

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James.. Antig...	Emini Surfa...
Leu	22	A	A	-2.63	.	.	.	-0.60	0.13
Ala	23	A	A	-3.13	.	.	.	-0.60	0.13
Ala	24	A	A	-2.91	.	.	.	-0.60	0.13
Ala	25	A	A	-2.96	.	.	.	-0.60	0.16
Leu	26	A	A	.	B	.	.	.	-2.44	.	.	.	-0.60	0.12
Leu	27	A	A	.	B	.	.	.	-1.63	.	.	.	-0.60	0.16
Ala	28	A	A	.	B	.	.	.	-1.63	.	.	.	-0.30	0.26
Val	29	A	A	.	B	.	.	.	-1.86	.	.	.	-0.30	0.32
Ser	30	A	A	-1.61	*	*	.	-0.30	0.32
Asp	31	A	A	-0.69	*	*	F	-0.15	0.31
Ala	32	A	A	-0.09	.	*	F	0.75	0.83
Leu	33	.	A	C	0.20	*	.	F	1.55	0.96
Gly	34	.	A	C	1.06	*	*	F	1.85	0.77
Arg	35	T	C	1.36	*	*	F	2.70	1.32
Pro	36	T	C	1.36	*	*	F	3.00	2.76
Ser	37	T	C	1.94	*	.	F	2.70	4.66
Glu	38	A	T	.	2.76	*	.	F	2.20	4.12
Glu	39	A	A	2.29	*	*	F	1.50	4.61
Asp	40	A	A	1.32	*	*	F	1.20	2.84
Glu	41	A	A	0.68	.	.	F	0.90	1.22
Glu	42	A	A	0.77	.	.	F	0.75	0.52
Leu	43	A	A	0.77	.	.	.	0.60	0.48

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James... Antig...	Emini Surfa...
Val	44	A	A	-0.04	.	.	.	0.60	0.48
Val	45	A	A	-0.04	*	.	.	-0.30	0.23
Pro	46	A	A	0.07	*	.	.	-0.30	0.48
Glu	47	A	-0.52	*	.	F	1.10	1.27
Leu	48	A	0.08	*	.	F	1.41	1.73
Glu	49	A	0.59	*	.	F	1.72	1.73
Arg	50	A	1.41	*	.	F	1.88	0.99
Ala	51	A	T	.	1.28	*	.	F	2.24	1.64
Pro	52	T	T	.	0.97	*	.	F	3.10	0.93
Gly	53	T	T	.	1.47	*	*	F	2.49	0.69
His	54	T	C	1.58	*	*	F	1.38	0.98
Gly	55	C	0.66	*	*	F	1.62	1.25
Thr	56	C	1.36	.	*	F	0.71	1.04
Thr	57	.	A	B	0.76	.	*	F	0.60	1.49
Arg	58	.	A	B	1.07	.	*	F	0.60	1.25
Leu	59	.	A	B	0.51	.	*	.	0.45	1.17
Arg	60	.	A	B	0.16	.	*	.	0.30	0.82
Leu	61	.	A	B	0.47	.	*	.	-0.30	0.36
His	62	.	A	B	0.78	.	*	.	-0.30	0.74
Ala	63	A	A	0.67	.	*	.	0.30	0.65
Phe	64	A	A	0.67	.	*	.	-0.15	1.37
Asp	65	A	A	0.56	.	*	F	-0.15	0.83

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James.. Antig...	Emini Surfa...
Gln	66	A	A	0.56	.	*	F	0.60	1.37
Gln	67	A	A	0.59	.	*	F	0.60	1.30
Leu	68	A	A	0.37	*	*	F	0.90	1.35
Asp	69	A	A	1.18	*	*	.	0.30	0.64
Leu	70	.	A	B	0.97	.	*	.	0.94	0.73
Glu	71	.	A	B	0.97	.	*	.	1.43	1.37
Leu	72	.	A	B	0.67	.	*	.	1.77	1.37
Arg	73	T	C	1.18	*	*	F	2.86	2.22
Pro	74	T	T	.	0.48	*	*	F	3.40	1.72
Asp	75	T	T	.	0.48	.	*	F	2.76	1.80
Ser	76	T	C	-0.11	.	*	F	2.07	0.76
Ser	77	.	.	B	0.49	*	*	F	0.73	0.50
Phe	78	.	.	B	0.03	*	*	.	0.24	0.46
Leu	79	.	.	B	-0.46	.	.	.	-0.40	0.34
Ala	80	.	.	B	.	.	T	.	-0.77	.	.	.	-0.20	0.22
Pro	81	.	.	B	.	.	T	.	-1.28	.	.	.	-0.20	0.37
Gly	82	T	T	.	-0.98	.	.	.	0.20	0.37
Phe	83	.	.	B	.	.	T	.	-0.28	.	.	.	-0.20	0.63
Thr	84	.	.	B	B	.	.	.	-0.32	.	.	.	-0.60	0.65
Leu	85	.	.	B	B	.	.	.	-0.08	*	*	.	-0.60	0.49
Gln	86	.	.	B	B	.	.	.	0.24	*	.	.	-0.29	0.56
Asn	87	.	.	B	.	.	T	.	0.63	*	.	F	0.87	0.76

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Val	88	.	.	B	.	.	T	.	1.03	*	*	F	1.93	1.84
Gly	89	T	C	1.00	*	.	F	2.74	1.42
Arg	90	T	T	.	1.51	*	.	F	3.10	0.87
Lys	91	T	C	1.51	*	.	F	2.74	1.58
Ser	92	T	C	1.20	*	.	F	2.43	2.76
Gly	93	T	C	1.84	.	.	F	2.38	2.04
Ser	94	T	C	1.38	.	.	F	2.33	1.57
Glu	95	C	1.06	.	.	F	1.63	0.97
Thr	96	C	1.01	.	.	F	2.04	1.51
Pro	97	C	1.00	.	.	F	2.60	1.96
Leu	98	C	1.34	.	.	F	2.04	1.63
Pro	99	A	0.83	.	.	F	1.58	1.89
Glu	100	A	A	0.24	.	.	F	1.12	1.01
Thr	101	A	A	0.52	.	.	F	0.86	1.23
Asp	102	A	A	0.07	.	.	F	0.60	1.08
Leu	103	A	A	0.18	.	.	.	0.30	0.34
Ala	104	A	A	0.14	.	.	.	-0.60	0.20
His	105	.	A	B	-0.16	*	.	.	-0.60	0.19
Cys	106	.	A	B	-0.19	*	.	.	-0.60	0.31
Phe	107	.	A	B	-0.50	*	.	.	-0.60	0.30
Tyr	108	.	.	B	.	.	T	.	-0.54	.	.	.	-0.20	0.32
Ser	109	T	T	.	0.04	.	*	F	0.35	0.44

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Gly	110	T	T	.	-0.27	.	*	F	0.35	0.82
Thr	111	T	T	.	0.40	.	*	F	0.59	0.52
Val	112	.	.	B	B	.	.	.	0.89	.	*	F	0.93	0.65
Asn	113	.	.	.	B	T	.	.	0.83	.	*	F	1.72	1.01
Gly	114	.	.	.	B	.	.	C	0.83	.	*	F	1.61	0.94
Asp	115	T	C	0.59	.	*	F	2.40	1.69
Pro	116	T	C	0.31	.	*	F	2.16	1.06
Ser	117	T	C	0.58	.	*	F	1.92	1.08
Ser	118	A	T	.	-0.23	.	.	F	1.33	0.66
Ala	119	A	A	-0.19	.	.	.	-0.06	0.35
Ala	120	A	A	-1.00	.	.	.	-0.30	0.35
Ala	121	A	A	-1.46	.	.	.	-0.60	0.22
Leu	122	A	A	-1.16	.	.	.	-0.60	0.11
Ser	123	A	A	-1.20	.	.	.	-0.30	0.20
Leu	124	A	A	-1.47	*	*	.	-0.30	0.19
Cys	125	.	A	B	-0.77	*	*	.	-0.30	0.17
Glu	126	.	A	B	-0.52	*	*	.	0.30	0.25
Gly	127	A	-0.30	*	*	F	0.65	0.30
Val	128	A	-0.70	*	*	F	0.65	0.57
Arg	129	.	.	B	-0.13	*	*	F	0.65	0.29
Gly	130	.	.	B	B	.	.	.	-0.28	*	*	.	-0.60	0.45
Ala	131	.	.	B	B	.	.	.	-1.09	*	*	.	-0.60	0.50

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyle... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James.. Antig...	Emini Surfa...
Phe	132	.	.	B	B	.	.	.	-1.09	*	*	.	-0.60	0.21
Tyr	133	.	.	B	B	.	.	.	-0.23	*	*	.	-0.60	0.21
Leu	134	.	A	B	B	.	.	.	-0.93	*	*	.	-0.60	0.36
Leu	135	.	A	B	B	.	.	.	-0.83	.	*	.	-0.60	0.42
Gly	136	A	A	.	B	.	.	.	-0.94	.	.	.	-0.60	0.42
Glu	137	A	A	-1.13	.	.	.	-0.60	0.44
Ala	138	A	A	.	B	.	.	.	-0.89	.	.	.	-0.60	0.38
Tyr	139	.	.	B	B	.	.	.	-0.29	.	.	.	-0.60	0.66
Phe	140	.	.	B	B	.	.	.	-0.29	.	.	.	-0.60	0.59
Ile	141	.	.	B	B	.	.	.	-0.16	.	.	.	-0.60	0.48
Gln	142	.	.	B	B	.	.	.	-0.74	.	.	.	-0.60	0.48
Pro	143	.	.	B	B	.	.	.	-0.74	.	.	.	-0.60	0.55
Leu	144	.	A	C	-0.80	*	.	.	-0.40	0.80
Pro	145	.	A	C	-0.10	*	.	.	-0.10	0.62
Ala	146	A	A	0.90	*	*	.	0.30	0.69
Ala	147	A	A	0.09	*	.	.	0.75	1.64
Ser	148	A	A	-0.29	*	.	F	0.75	0.88
Glu	149	A	A	0.21	*	.	F	0.45	0.88
Arg	150	A	A	-0.17	*	.	F	0.60	1.25
Leu	151	A	A	-0.17	*	.	.	0.30	0.94
Ala	152	A	A	0.21	*	*	.	0.30	0.55
Thr	153	A	A	0.17	*	*	.	0.04	0.43

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ala	154	A	A	0.17	.	.	.	0.08	0.52
Ala	155	T	C	0.10	.	*	F	2.07	0.89
Pro	156	T	C	0.70	.	.	F	2.86	1.24
Gly	157	T	T	.	1.08	.	.	F	3.40	1.90
Glu	158	T	C	0.80	.	.	F	2.86	2.90
Lys	159	C	1.18	.	.	F	2.32	1.90
Pro	160	C	0.96	.	*	F	1.98	2.97
Pro	161	C	1.17	.	*	F	1.64	1.41
Ala	162	A	A	0.81	.	*	F	0.60	1.22
Pro	163	A	A	0.78	.	*	.	-0.60	0.68
Leu	164	A	A	-0.08	.	*	.	-0.60	0.60
Gln	165	A	A	-0.68	*	*	.	-0.60	0.49
Phe	166	.	A	B	-0.36	*	*	.	-0.60	0.26
Ile	167	.	A	B	0.34	*	*	.	-0.26	0.62
Leu	168	.	A	B	0.56	*	*	.	0.38	0.70
Leu	169	.	A	B	1.48	*	*	.	0.87	1.31
Arg	170	T	T	.	1.48	*	.	F	3.06	1.88
Arg	171	T	T	.	1.83	*	.	F	3.40	3.96
Asn	172	T	T	.	1.87	*	.	F	3.06	4.75
Arg	173	T	T	.	1.82	*	.	F	2.72	4.05
Gln	174	T	.	.	2.29	.	.	F	2.43	1.53
Gly	175	T	.	.	1.83	.	.	F	2.19	0.94

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James.. Antig...	Emini Surfa...
Asp	176	T	T	.	1.41	.	*	F	2.30	0.48
Val	177	.	.	B	.	.	T	.	0.74	*	.	F	1.85	0.40
Gly	178	T	T	.	0.29	*	.	F	2.50	0.22
Gly	179	.	.	B	.	.	T	.	-0.57	.	*	F	1.85	0.13
Thr	180	.	.	B	B	.	.	.	-1.08	.	*	F	0.30	0.13
Cys	181	.	.	B	B	.	.	.	-1.08	.	.	.	-0.10	0.10
Gly	182	.	.	B	B	.	.	.	-0.22	.	.	.	-0.05	0.16
Val	183	.	.	B	B	.	.	.	0.12	.	.	.	0.30	0.19
Val	184	.	.	B	B	.	.	.	0.26	*	*	.	0.90	0.60
Asp	185	.	.	B	.	.	T	.	0.68	*	*	F	1.75	0.94
Asp	186	.	.	B	.	.	T	.	1.13	*	*	F	2.20	2.49
Glu	187	.	.	B	.	.	T	.	1.17	*	*	F	2.50	5.18
Pro	188	T	C	1.68	*	*	F	3.00	4.48
Arg	189	T	C	2.58	*	*	F	2.70	2.66
Pro	190	T	C	1.99	*	*	F	2.40	3.07
Thr	191	T	C	1.99	*	*	F	2.10	2.00
Gly	192	T	C	1.68	*	*	F	1.80	1.77
Lys	193	A	A	1.89	*	*	F	0.90	1.65
Ala	194	A	A	1.78	*	*	F	0.90	1.98
Glu	195	A	A	1.99	.	*	F	0.90	3.35
Thr	196	A	A	2.30	.	*	F	0.90	2.90
Glu	197	A	A	2.64	.	*	F	0.90	4.79

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Asp	198	A	A	2.26	.	*	F	0.90	4.79
Glu	199	A	A	2.53	.	.	F	0.90	3.29
Asp	200	A	T	.	2.53	.	.	F	1.30	2.74
Glu	201	A	T	.	2.50	.	.	F	1.30	2.84
Gly	202	A	T	.	2.50	.	.	F	1.30	1.62
Thr	203	A	T	.	2.50	.	.	F	1.30	1.68
Glu	204	A	A	2.50	*	.	F	0.90	1.62
Gly	205	A	A	2.16	*	.	F	1.20	2.84
Glu	206	A	A	1.94	*	.	F	1.50	1.95
Asp	207	.	A	.	.	T	.	.	2.29	*	.	F	2.20	1.74
Glu	208	.	A	C	2.31	*	.	F	2.30	3.04
Gly	209	T	C	2.01	*	.	F	3.00	1.85
Pro	210	T	T	.	2.14	.	.	F	2.60	1.48
Gln	211	T	T	.	2.14	.	.	F	2.30	1.32
Trp	212	T	C	2.14	.	.	F	1.44	2.32
Ser	213	C	1.93	.	.	F	1.78	2.50
Pro	214	T	T	.	1.69	.	.	F	2.12	2.23
Gln	215	T	C	1.09	.	.	F	1.56	2.15
Asp	216	T	C	1.09	.	*	F	2.40	1.32
Pro	217	T	C	1.03	.	.	F	2.16	1.48
Ala	218	T	.	.	0.48	.	.	F	1.77	0.85
Leu	219	.	.	B	0.34	*	.	F	0.53	0.38

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James.. Antig...	Emini Surfa...
Gln	220	.	.	B	0.34	*	.	F	-0.01	0.24
Gly	221	.	.	B	.	.	T	.	0.13	*	*	F	-0.05	0.41
Val	222	.	.	B	.	.	T	.	0.03	*	.	F	-0.05	0.77
Gly	223	.	.	B	.	.	T	.	0.28	*	.	F	0.25	0.64
Gln	224	.	.	B	.	.	T	.	0.78	*	*	F	0.25	0.64
Pro	225	.	.	B	0.43	.	.	F	0.20	1.25
Thr	226	T	.	.	0.48	.	*	F	0.60	1.25
Gly	227	T	C	0.44	*	*	F	0.45	0.97
Thr	228	.	.	B	.	.	T	.	0.90	*	*	F	0.25	0.44
Gly	229	.	.	B	.	.	T	.	0.94	.	*	F	0.85	0.60
Ser	230	.	.	B	.	.	T	.	1.20	.	*	F	1.30	1.20
Ile	231	.	A	B	1.62	.	*	F	0.90	1.67
Arg	232	.	A	B	1.27	.	*	F	0.90	3.30
Lys	233	.	A	B	0.72	.	.	F	0.90	2.13
Lys	234	.	A	B	B	.	.	.	0.77	.	.	F	0.90	2.26
Arg	235	.	A	B	B	.	.	.	0.77	.	.	F	0.90	1.55
Phe	236	.	.	B	B	.	.	.	1.62	.	*	.	0.75	1.04
Val	237	.	.	B	B	.	.	.	1.62	.	*	.	0.30	0.71
Ser	238	.	.	B	.	.	T	.	1.33	*	*	.	0.70	0.71
Ser	239	T	C	0.43	*	.	.	0.15	1.28
His	240	T	C	0.32	*	*	.	0.45	1.28
Arg	241	T	C	0.71	*	.	.	1.05	1.65

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James... Antig...	Emini Surfa...
Tyr	242	A	.	.	B	.	.	.	0.97	*	.	.	0.45	1.78
Val	243	A	.	.	B	.	.	.	0.46	*	.	.	0.45	1.29
Glu	244	.	.	B	B	.	.	.	-0.10	*	.	.	-0.30	0.54
Thr	245	.	.	B	B	.	.	.	-0.66	*	.	.	-0.60	0.26
Met	246	A	.	B	B	.	.	.	-0.77	*	.	.	-0.60	0.35
Leu	247	A	.	.	B	.	.	.	-0.52	.	.	.	0.30	0.34
Val	248	A	.	.	B	.	.	.	0.03	.	.	.	-0.30	0.41
Ala	249	A	.	.	B	.	.	.	-0.57	.	.	.	-0.30	0.55
Asp	250	A	T	.	-0.84	.	.	F	0.25	0.66
Gln	251	A	T	.	-0.24	.	.	F	0.25	0.90
Ser	252	A	T	.	-0.13	.	.	F	1.30	1.54
Met	253	A	T	.	0.69	.	*	.	0.70	0.80
Ala	254	A	0.93	.	*	.	-0.10	0.63
Glu	255	A	0.63	.	*	.	-0.10	0.46
Phe	256	A	0.29	.	*	.	-0.10	0.63
His	257	A	T	.	-0.22	*	.	.	0.10	0.61
Gly	258	A	T	.	0.42	*	.	F	0.25	0.29
Ser	259	A	T	.	0.98	*	*	F	0.25	0.68
Gly	260	A	T	.	0.73	*	*	F	0.85	0.68
Leu	261	A	A	0.62	.	.	F	0.00	1.07
Lys	262	A	A	-0.16	.	.	.	-0.60	0.66
His	263	.	A	A	B	.	.	.	-0.12	*	.	.	-0.60	0.55

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Tyr	264	.	A	B	-0.63	*	.	.	-0.60	0.96
Leu	265	.	A	B	-0.99	*	.	.	-0.60	0.40
Leu	266	.	A	B	-0.48	*	.	.	-0.60	0.25
Thr	267	.	A	B	-1.38	*	.	.	-0.60	0.22
Leu	268	.	A	B	-1.93	*	.	.	-0.60	0.19
Phe	269	A	A	-2.28	*	*	.	-0.60	0.24
Ser	270	A	A	-1.36	*	*	.	-0.60	0.17
Val	271	A	A	-1.36	*	*	.	-0.60	0.39
Ala	272	A	A	-1.29	*	*	.	-0.60	0.38
Ala	273	A	A	-0.43	*	*	.	-0.60	0.44
Arg	274	A	A	0.23	*	*	.	-0.15	1.18
Leu	275	A	A	0.32	*	*	.	0.45	1.59
Tyr	276	T	.	.	0.88	*	*	.	1.39	2.44
Lys	277	.	.	B	0.58	*	*	F	1.48	1.67
His	278	.	.	B	.	.	T	.	1.28	.	*	F	1.12	1.42
Pro	279	.	.	B	.	.	T	.	1.17	.	*	F	2.36	1.77
Ser	280	T	T	.	1.68	.	*	F	3.40	1.43
Ile	281	.	.	B	.	.	T	.	1.07	.	*	F	2.36	1.41
Arg	282	.	.	B	B	.	.	.	0.72	.	*	F	1.47	0.67
Asn	283	.	.	B	B	.	.	.	-0.06	*	*	F	1.13	0.67
Ser	284	.	.	B	B	.	.	.	-0.70	*	*	F	0.19	0.79
Val	285	.	.	B	B	.	.	.	-1.26	*	*	.	-0.30	0.30

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ser	286	.	.	B	B	.	.	.	-1.22	.	*	.	-0.60	0.14
Leu	287	.	.	B	B	.	.	.	-1.29	.	*	.	-0.60	0.08
Val	288	.	.	B	B	.	.	.	-2.18	*	.	.	-0.60	0.21
Val	289	.	.	B	B	.	.	.	-2.69	.	*	.	-0.60	0.11
Val	290	.	.	B	B	.	.	.	-2.69	.	.	.	-0.60	0.11
Lys	291	.	.	B	B	.	.	.	-3.28	.	.	.	-0.60	0.11
Ile	292	.	.	B	B	.	.	.	-2.50	.	.	.	-0.60	0.10
Leu	293	.	.	B	B	.	.	.	-1.64	.	*	.	-0.60	-0.19
Val	294	.	.	B	B	.	.	.	-0.79	.	.	.	-0.30	0.16
Ile	295	.	.	B	B	.	.	.	0.07	.	*	.	0.00	0.39
His	296	A	.	.	B	.	.	.	0.07	.	*	.	0.90	0.81
Asp	297	A	.	.	B	.	.	.	0.61	.	.	F	1.80	2.19
Glu	298	A	1.21	*	.	F	2.30	3.09
Gln	299	T	.	.	2.07	*	.	F	3.00	3.51
Lys	300	C	2.10	.	.	F	2.50	3.64
Gly	301	T	C	1.82	.	.	F	2.40	1.56
Pro	302	T	C	1.52	.	.	F	2.10	1.30
Glu	303	.	.	B	.	.	T	.	1.52	*	.	F	1.45	0.87
Val	304	A	T	.	0.93	*	.	F	1.00	1.42
Thr	305	A	T	.	0.30	.	*	F	0.85	0.93
Ser	306	A	T	.	-0.17	.	*	F	0.85	0.54
Asn	307	A	T	.	-0.27	.	*	F	-0.05	0.60

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ala	308	A	T	.	-1.08	*	*	.	-0.20	0.60
Ala	309	A	-0.11	*	*	.	-0.40	0.37
Leu	310	A	0.20	*	*	.	-0.10	0.45
Thr	311	.	.	B	-0.20	*	*	.	-0.10	0.72
Leu	312	.	.	B	-0.87	*	*	.	-0.40	0.61
Arg	313	.	.	B	-0.28	*	*	.	-0.40	0.40
Asn	314	T	.	.	0.02	*	*	.	0.30	0.44
Phe	315	T	T	.	0.83	*	*	.	0.20	0.57
Cys	316	T	T	.	1.19	*	*	.	0.20	0.50
Asn	317	T	T	.	2.00	*	*	.	0.20	0.62
Trp	318	T	T	.	1.86	*	.	.	0.35	1.25
Gln	319	T	.	.	1.86	.	.	.	0.45	3.16
Lys	320	T	.	.	2.34	*	.	F	0.60	3.16
Gln	321	T	.	.	2.80	.	.	F	0.94	4.65
His	322	C	2.50	*	.	F	1.68	4.15
Asn	323	C	2.79	*	.	F	2.02	2.78
Pro	324	T	C	2.90	.	.	F	2.56	2.68
Pro	325	T	T	.	2.86	*	.	F	3.40	3.86
Ser	326	T	C	2.27	.	.	F	2.86	4.01
Asp	327	T	C	2.30	.	.	F	2.52	2.62
Arg	328	A	A	2.27	.	.	F	1.58	2.94
Asp	329	A	A	2.23	*	.	F	1.24	2.98

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James... Antig...	Emini Surfa...
Ala	330	A	A	2.44	*	.	.	0.90	2.80
Glu	331	A	A	2.43	*	.	.	0.75	2.38
His	332	A	T	.	1.84	*	.	.	1.15	2.06
Tyr	333	A	T	.	0.84	*	.	.	0.85	2.06
Asp	334	A	T	.	0.03	.	.	.	0.70	0.83
Thr	335	A	T	.	-0.08	.	.	.	-0.20	0.51
Ala	336	A	A	-0.39	*	.	.	-0.60	0.28
Ile	337	A	A	-0.24	*	.	.	-0.60	0.24
Leu	338	.	A	B	0.00	.	.	.	-0.60	0.33
Phe	339	.	A	B	0.00	.	*	.	-0.60	0.56
Thr	340	.	A	B	-0.50	.	.	F	0.00	1.34
Arg	341	.	A	B	-0.58	.	*	F	0.25	1.34
Gln	342	.	A	.	.	T	.	.	-0.03	.	*	F	1.35	-0.83
Asp	343	.	A	.	.	T	.	.	0.48	.	*	F	1.60	0.57
Leu	344	.	A	.	.	T	.	.	1.18	*	.	F	2.15	0.39
Cys	345	T	T	.	1.18	.	*	F	2.50	0.39
Gly	346	T	T	.	0.40	.	*	F	2.25	0.34
Ser	347	T	T	.	0.40	.	.	F	1.10	0.22
Gln	348	.	.	B	.	.	T	.	0.09	.	.	F	1.35	0.68
Thr	349	.	.	B	0.09	.	.	F	0.90	0.99
Cys	350	.	.	B	0.41	.	.	F	0.05	0.61
Asp	351	.	.	B	.	.	T	.	0.16	*	.	F	0.25	0.35

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James... Antig...	Emini Surfa...
Thr	352	.	.	B	.	.	T	.	-0.13	.	.	F	0.25	0.24
Leu	353	.	.	B	.	.	T	.	-0.13	.	.	.	0.10	0.45
Gly	354	.	.	B	.	.	T	.	-0.68	.	.	.	0.70	0.45
Met	355	.	.	B	-0.36	.	.	.	-0.10	0.23
Ala	356	.	.	B	-0.67	.	.	.	-0.10	0.28
Asp	357	.	.	B	.	.	T	.	-1.21	.	.	.	0.10	0.41
Val	358	.	.	B	.	.	T	.	-1.07	.	.	.	0.10	0.30
Gly	359	.	.	B	.	.	T	.	-0.72	.	.	.	0.10	0.16
Thr	360	.	.	B	.	.	T	.	-0.33	.	.	.	0.70	0.16
Val	361	.	.	B	-0.04	.	*	.	0.24	0.34
Cys	362	.	.	B	0.07	*	.	.	1.18	0.46
Asp	363	.	.	B	.	.	T	.	0.62	*	.	F	1.87	0.62
Pro	364	T	T	.	0.30	*	.	F	3.06	1.12
Ser	365	T	T	.	0.31	*	.	F	3.40	1.12
Arg	366	T	T	.	0.31	*	.	F	2.91	0.90
Ser	367	.	.	.	B	T	.	.	0.09	*	.	F	1.87	0.43
Cys	368	.	.	B	B	.	.	.	0.09	*	.	.	0.38	0.22
Ser	369	.	.	B	B	.	.	.	0.30	*	.	.	0.64	0.20
Val	370	.	.	B	B	.	.	.	0.60	*	.	.	0.30	0.25
Ile	371	.	.	B	B	.	.	.	0.14	*	.	.	0.60	0.77
Glu	372	.	.	B	B	.	.	.	-0.37	.	.	.	0.60	0.57
Asp	373	A	T	.	0.30	.	.	F	1.15	0.63

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Asp	374	A	T	.	0.01	*	.	.	1.30	1.56
Gly	375	A	T	.	0.28	.	.	.	1.00	0.91
Leu	376	A	T	.	0.47	*	.	.	0.70	0.55
Gln	377	A	A	0.16	.	.	.	-0.30	0.29
Ala	378	A	A	-0.16	*	.	.	-0.60	0.42
Ala	379	A	A	-0.74	*	.	.	-0.60	0.73
Phe	380	A	A	-0.43	*	.	.	-0.60	0.43
Thr	381	A	A	0.38	*	*	.	-0.60	0.57
Thr	382	A	A	-0.43	*	.	.	-0.30	0.98
Ala	383	A	A	-0.19	*	.	.	-0.60	0.94
His	384	A	A	0.37	*	.	.	-0.30	0.64
Glu	385	A	A	0.21	*	.	.	-0.30	0.61
Leu	386	A	A	-0.18	*	.	.	-0.30	0.45
Gly	387	A	.	.	B	.	.	.	0.13	*	.	.	-0.60	0.28
His	388	A	.	.	B	.	.	.	0.12	*	.	.	-0.60	0.26
Val	389	A	.	.	B	.	.	.	-0.06	*	.	.	-0.60	0.32
Phe	390	A	.	.	B	.	.	.	-0.09	*	.	.	-0.60	0.49
Asn	391	.	.	B	B	.	.	.	0.72	*	.	.	-0.60	0.49
Met	392	.	.	B	.	.	T	.	1.07	*	.	.	0.25	1.11
Pro	393	A	T	.	0.51	*	.	.	0.85	2.14
His	394	T	T	.	1.41	*	.	F	1.70	1.34
Asp	395	A	T	.	2.11	*	.	F	1.30	2.72

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Asp	396	A	A	1.44	*	.	F	0.90	3.04
Ala	397	A	A	1.46	*	.	F	0.90	1.20
Lys	398	A	A	1.37	*	*	F	0.75	0.73
Gln	399	A	A	0.59	.	*	.	0.60	0.58
Cys	400	.	A	B	0.59	.	*	.	-0.30	0.48
Ala	401	.	A	B	0.24	.	*	.	0.30	0.38
Ser	402	.	.	B	.	.	T	.	-0.02	.	*	.	0.10	0.22
Leu	403	.	.	B	.	.	T	.	-0.07	.	.	.	0.04	0.30
Asn	404	T	T	.	-0.07	.	.	.	0.68	0.48
Gly	405	T	T	.	0.60	.	.	F	1.37	0.62
Val	406	C	0.89	.	.	F	1.96	1.26
Asn	407	T	C	1.16	.	.	F	2.40	1.05
Gln	408	A	T	.	1.37	*	.	F	1.96	1.44
Asp	409	A	T	.	0.77	*	.	F	1.72	1.92
Ser	410	A	T	.	0.52	.	.	.	1.33	1.18
His	411	A	A	1.08	.	*	.	-0.06	0.69
Met	412	A	A	0.48	.	.	.	0.30	0.55
Met	413	A	A	-0.33	.	.	.	-0.60	0.41
Ala	414	A	A	-0.63	.	.	.	-0.60	0.25
Ser	415	A	A	-0.33	*	.	.	-0.60	0.34
Met	416	A	A	-1.11	*	*	.	-0.60	0.55
Leu	417	A	T	.	-0.51	*	.	.	-0.20	0.45

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ser	418	A	T	.	0.06	*	.	.	0.38	0.56
Asn	419	A	T	.	0.34	.	.	.	0.66	0.76
Leu	420	T	C	0.64	.	.	.	1.29	1.24
Asp	421	T	T	.	1.03	.	.	.	2.37	1.60
His	422	T	T	.	1.56	.	.	F	2.80	1.54
Ser	423	T	C	1.56	.	.	F	1.72	1.97
Gln	424	T	C	1.34	.	.	F	1.44	1.58
Pro	425	T	.	.	1.49	.	.	F	0.86	1.79
Trp	426	T	.	.	1.19	.	.	F	0.43	0.72
Ser	427	T	C	0.63	.	.	F	0.15	0.55
Pro	428	T	T	.	0.69	.	.	F	0.35	0.36
Cys	429	T	T	.	0.09	.	.	.	0.20	0.54
Ser	430	.	.	B	.	.	T	.	-0.59	.	.	.	-0.20	0.40
Ala	431	.	.	B	B	.	.	.	-0.61	.	.	.	-0.60	0.18
Tyr	432	.	.	B	B	.	.	.	-0.61	.	.	.	-0.60	0.49
Met	433	.	.	B	B	.	.	.	-1.10	.	.	.	-0.60	0.49
Ile	434	.	.	B	B	.	.	.	-1.24	*	.	.	-0.60	0.42
Thr	435	.	.	B	B	.	.	.	-0.94	*	.	.	-0.60	0.22
Ser	436	.	.	B	B	.	.	.	-0.36	*	.	.	-0.60	0.37
Phe	437	.	.	B	B	.	.	.	-0.46	*	.	.	-0.60	0.85
Leu	438	.	.	B	.	.	T	.	0.11	*	.	F	0.56	0.58
Asp	439	T	T	.	0.66	*	.	F	1.27	0.59

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James... Antig...	Emini Surfa...
Asn	440	T	C	0.97	.	.	F	1.38	0.68
Gly	441	T	T	.	0.60	.	.	F	2.94	1.42
His	442	T	T	.	0.49	.	.	F	3.10	0.46
Gly	443	A	T	.	0.70	.	.	F	1.49	0.23
Glu	444	A	T	.	0.70	.	.	.	1.03	0.23
Cys	445	.	.	B	.	.	T	.	0.74	.	*	.	1.32	0.29
Leu	446	.	A	B	0.88	.	.	.	1.25	0.58
Met	447	.	A	B	0.91	*	.	.	1.28	0.52
Asp	448	.	A	.	.	T	.	.	1.26	*	.	F	2.02	1.67
Lys	449	.	A	C	1.04	*	.	F	2.16	3.26
Pro	450	T	T	.	0.82	*	*	F	3.40	5.10
Gln	451	T	T	.	1.63	*	*	F	3.06	2.14
Asn	452	.	.	B	.	.	T	.	1.42	*	*	F	2.02	1.85
Pro	453	.	.	B	.	.	T	.	1.21	*	*	F	0.63	0.99
Ile	454	.	.	B	0.82	*	*	F	0.09	0.88
Gln	455	.	.	B	1.03	*	*	F	-0.25	0.54
Leu	456	.	.	B	.	.	T	.	0.22	*	*	F	0.25	0.59
Pro	457	.	.	B	.	.	T	.	0.01	*	*	F	0.25	0.69
Gly	458	.	.	B	.	.	T	.	-0.12	.	*	F	0.25	0.62
Asp	459	.	.	B	.	.	T	.	0.46	.	*	F	0.25	0.74
Leu	460	T	C	0.16	.	*	F	1.05	0.69
Pro	461	.	.	B	.	.	T	.	0.72	.	*	F	0.85	0.93

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James.. Antig...	Emini Surfa...
Gly	462	.	.	B	.	.	T	.	0.93	.	.	F	0.25	0.88
Thr	463	.	.	B	.	.	T	.	0.69	.	*	F	0.74	1.78
Ser	464	.	.	B	0.69	*	.	F	1.48	1.16
Tyr	465	T	.	.	1.61	*	.	F	2.22	1.88
Asp	466	T	T	.	1.82	.	.	.	2.61	2.56
Ala	467	T	T	.	1.50	*	.	F	3.40	3.31
Asn	468	T	T	.	1.81	.	*	F	2.76	1.13
Arg	469	.	.	B	.	.	T	.	1.41	.	*	F	2.32	1.17
Gln	470	.	.	B	B	.	.	.	1.34	*	*	.	0.53	1.01
Cys	471	.	.	B	B	.	.	.	0.64	*	*	.	0.04	0.90
Gln	472	.	.	B	B	.	.	.	0.89	.	.	.	-0.60	0.40
Phe	473	.	.	B	B	.	.	.	0.89	.	.	.	-0.26	0.23
Thr	474	.	.	B	B	.	.	.	0.78	.	.	.	0.08	0.74
Phe	475	.	.	.	B	T	.	.	0.48	.	*	.	1.72	0.71
Gly	476	T	T	.	1.19	.	*	F	2.76	1.10
Glu	477	T	T	.	1.16	.	*	F	3.40	1.52
Asp	478	T	T	.	1.19	*	.	F	3.06	2.39
Ser	479	T	T	.	1.29	*	.	F	2.72	1.30
Lys	480	T	.	.	1.99	*	.	F	2.43	1.16
His	481	T	.	.	1.74	*	.	F	2.34	1.16
Cys	482	T	C	1.16	*	.	F	2.10	0.87
Pro	483	A	T	.	0.86	.	.	F	2.15	0.44

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni... Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James.. Antig...	Emini Surfa...
Asp	484	T	T	.	0.84	*	.	F	2.50	0.43
Ala	485	A	T	.	0.13	*	.	F	2.00	1.17
Ala	486	A	-0.13	.	.	F	1.40	0.41
Ser	487	.	.	B	.	T	T	.	0.22	.	.	F	1.75	0.33
Thr	488	.	.	B	.	.	T	.	-0.38	*	.	F	0.50	0.46
Cys	489	.	.	B	.	.	T	.	-0.67	*	.	F	-0.05	0.38
Ser	490	.	.	B	.	.	T	.	-0.74	.	.	F	-0.05	0.30
Thr	491	.	.	B	B	.	.	.	-0.47	.	.	.	-0.60	0.11
Leu	492	.	.	B	B	.	.	.	-0.51	.	.	.	-0.60	0.30
Trp	493	.	.	B	B	.	.	.	-0.51	.	.	.	-0.60	0.22
Cys	494	.	.	B	B	.	.	.	-0.14	.	.	.	-0.60	0.22
Thr	495	.	.	B	B	T	.	.	-0.19	.	.	F	-0.05	0.36
Gly	496	.	.	.	B	T	.	.	-0.22	.	.	F	-0.05	0.34
Thr	497	T	T	.	-0.27	.	.	F	0.65	0.62
Ser	498	T	T	.	-0.79	.	.	F	0.65	0.32
Gly	499	T	T	.	-0.98	.	.	F	0.35	0.27
Gly	500	T	T	.	-1.33	.	.	F	0.35	0.14
Val	501	.	.	B	B	.	.	.	-0.99	.	.	.	-0.60	0.05
Leu	502	.	.	B	B	.	.	.	-0.99	.	.	.	-0.60	0.10
Val	503	.	.	B	B	.	.	.	-0.64	.	.	.	-0.60	0.14
Cys	504	.	.	B	.	.	T	.	-0.33	.	.	.	-0.20	0.38
Gln	505	.	.	B	.	.	T	.	-0.69	.	.	.	0.10	0.62

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Thr	506	.	.	B	.	.	T	.	-0.04	.	.	F	0.25	0.72
Lys	507	.	.	B	.	.	T	.	0.48	.	.	F	0.40	2.09
His	508	C	0.74	.	.	.	-0.05	1.27
Phe	509	.	.	B	1.41	.	.	.	-0.40	0.89
Pro	510	T	.	.	1.07	.	.	.	0.30	0.74
Trp	511	T	T	.	1.07	.	.	.	0.20	0.54
Ala	512	T	T	.	0.72	.	.	.	0.51	0.90
Asp	513	T	T	.	0.09	.	.	F	1.27	0.78
Gly	514	T	T	.	0.44	.	.	F	1.58	0.40
Thr	515	T	T	.	0.66	.	.	F	2.49	0.39
Ser	516	T	T	.	0.60	.	*	F	3.10	0.40
Cys	517	T	T	.	1.23	.	*	F	2.49	0.40
Gly	518	T	T	.	0.94	.	*	F	2.48	0.56
Glu	519	T	.	.	0.62	.	*	F	1.67	0.44
Gly	520	T	.	.	0.04	.	*	F	1.36	0.44
Lys	521	T	.	.	0.34	.	*	F	0.45	0.31
Trp	522	T	.	.	0.67	.	*	.	0.90	0.29
Cys	523	.	.	B	.	.	T	.	1.06	.	*	.	-0.20	0.29
Ile	524	.	.	B	.	.	T	.	0.39	.	*	.	0.70	0.29
Asn	525	T	T	.	-0.12	.	*	.	0.20	0.15
Gly	526	T	T	.	-0.17	*	*	F	0.65	0.20
Lys	527	T	.	.	0.17	*	*	F	0.45	0.47

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Cys	528	T	T	.	0.52	.	*	.	1.40	0.58
Val	529	.	.	B	.	.	T	.	1.41	*	*	.	1.04	0.85
Asn	530	.	.	B	.	.	T	.	1.52	*	.	F	1.83	0.71
Lys	531	.	.	B	.	.	T	.	1.91	*	.	F	2.32	2.58
Thr	532	.	.	B	.	.	T	.	1.83	*	.	F	2.66	6.96
Asp	533	T	T	.	1.80	*	.	F	3.40	5.89
Arg	534	T	T	.	2.66	*	.	F	3.06	2.55
Lys	535	.	.	B	.	.	T	.	2.34	*	.	F	2.32	2.95
His	536	.	.	B	2.09	*	.	F	1.78	2.55
Phe	537	.	.	B	1.70	*	.	F	1.44	2.01
Asp	538	.	.	B	1.67	*	.	F	0.65	0.87
Thr	539	.	.	B	1.21	*	.	F	-0.25	0.87
Pro	540	C	0.87	*	*	F	-0.05	1.00
Phe	541	T	.	.	0.61	.	*	F	0.45	0.80
His	542	T	T	.	0.97	.	*	.	0.20	0.58
Gly	543	T	T	.	0.37	.	*	.	0.20	0.37
Ser	544	T	T	.	0.39	.	*	.	0.20	0.43
Trp	545	T	T	.	0.26	.	*	.	0.20	0.33
Gly	546	C	0.74	.	*	.	-0.20	0.33
Met	547	T	.	.	0.49	.	.	.	0.00	0.38
Trp	548	T	.	.	0.49	.	.	.	0.00	0.38
Gly	549	T	C	0.79	.	.	.	0.00	0.38

-31.1-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James... Antig...	Emini Surfa...
Pro	550	T	T	.	0.41	.	.	F	0.35	0.64
Trp	551	T	T	.	0.46	*	.	F	0.66	0.33
Gly	552	T	T	.	1.17	*	.	F	1.27	0.44
Asp	553	T	.	.	1.14	*	.	F	1.98	0.56
Cys	554	T	T	.	0.82	*	.	F	2.49	0.77
Ser	555	T	T	.	0.69	*	.	F	3.10	0.42
Arg	556	T	T	.	0.63	*	.	F	2.79	0.25
Thr	557	T	T	.	0.63	*	.	F	2.18	0.46
Cys	558	T	T	.	-0.22	*	.	F	1.87	0.34
Gly	559	T	T	.	0.44	*	.	F	1.56	0.13
Gly	560	T	T	.	0.50	*	.	F	0.65	0.15
Gly	561	T	T	.	0.08	*	*	F	0.35	0.45
Val	562	.	.	B	B	.	.	.	-0.21	*	*	.	-0.60	0.65
Gln	563	.	.	B	B	.	.	.	0.57	*	*	.	-0.60	0.65
Tyr	564	.	.	B	B	.	.	.	0.91	*	*	.	-0.15	1.29
Thr	565	.	.	B	B	.	.	.	0.59	*	*	.	0.79	3.01
Met	566	.	.	B	B	.	.	.	0.93	*	*	.	0.98	0.93
Arg	567	.	.	B	B	.	.	.	1.79	*	*	.	1.62	0.99
Glu	568	T	.	.	1.58	*	*	F	2.86	1.11
Cys	569	T	T	.	0.97	*	.	F	3.40	1.73
Asp	570	T	T	.	1.07	*	..	F	2.91	0.66

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.2-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James.. Antig...	Emini Surfa...
Asn	571	T	C	1.71	*	.	F	2.37	0.59
Pro	572	T	C	1.60	*	.	F	2.52	2.18
Val	573	C	1.26	*	.	F	2.32	2.10
Pro	574	T	T	.	1.58	*	.	F	2.42	1.29
Lys	575	T	T	.	1.62	*	.	F	2.61	0.83
Asn	576	T	T	.	1.38	*	.	F	3.40	2.23
Gly	577	T	T	.	0.92	*	.	F	3.06	2.26
Gly	578	T	T	.	1.78	*	.	F	2.27	0.61
Lys	579	.	.	B	.	.	T	.	1.64	.	.	F	1.53	0.65
Tyr	580	.	.	B	.	.	T	.	1.64	.	.	F	1.19	0.65
Cys	581	.	.	B	.	.	T	.	1.76	.	.	F	1.30	1.32
Glu	582	.	.	B	1.24	.	*	F	1.10	1.29
Gly	583	.	.	B	B	.	.	.	1.70	.	*	F	0.75	0.61
Lys	584	.	.	B	B	.	.	.	1.41	.	*	F	0.90	2.24
Arg	585	.	.	B	B	.	.	.	1.77	.	*	F	1.15	2.02
Tyr	586	.	.	B	B	.	.	.	2.13	.	*	.	1.25	4.01
Arg	587	.	.	B	B	.	.	.	1.47	*	*	.	1.50	2.68
Tyr	588	.	.	B	.	.	T	.	1.81	*	*	.	2.00	0.73
Arg	589	T	T	.	0.96	*	*	.	2.50	1.59
Ser	590	T	T	.	0.84	*	*	.	2.10	0.67
Cys	591	T	T	.	1.70	.	*	.	1.85	0.74
Asn	592	.	A	.	.	T	.	.	0.92	.	*	.	1.50	0.63

5

10

15

20

-31.3-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Leu	593	.	A	B	0.96	.	.	.	0.89	0.25
Glu	594	.	A	B	0.84	.	.	F	1.13	0.73
Asp	595	.	A	.	.	T	.	.	1.17	.	.	F	2.17	0.76
Cys	596	.	.	B	.	.	T	.	1.81	.	.	F	2.66	1.48
Pro	597	T	T	.	1.47	*	*	F	3.40	1.37
Asp	598	T	T	.	2.32	*	*	F	2.91	0.81
Asn	599	T	T	.	2.01	*	.	F	3.02	3.03
Asn	600	T	T	.	1.31	*	.	F	2.98	2.83
Gly	601	T	T	.	2.09	*	.	F	2.94	1.47
Lys	602	T	C	2.30	*	*	F	2.70	1.79
Thr	603	T	C	2.30	*	.	F	3.00	1.92
Phe	604	A	A	2.30	*	.	F	2.10	3.37
Arg	605	A	A	1.63	.	.	F	1.80	2.91
Glu	606	A	A	1.98	*	.	F	1.50	1.08
Glu	607	A	A	1.34	*	.	F	1.20	2.17
Gln	608	A	A	1.62	*	.	F	0.90	1.12
Cys	609	A	A	2.32	*	*	.	0.60	0.88
Glu	610	A	A	2.21	.	*	.	0.60	0.81
Ala	611	A	A	1.51	.	*	.	0.60	0.81
His	612	A	A	1.21	*	.	.	0.45	1.32
Asn	613	A	A	1.26	*	*	.	0.45	1.02
Glu	614	A	A	1.33	*	.	.	0.45	2.02

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.4-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Phe	615	A	A	1.03	*	*	F	0.60	1.50
Ser	616	A	A	0.92	.	.	F	0.90	1.25
Lys	617	A	A	0.61	.	.	F	0.45	0.62
Ala	618	.	A	.	.	T	.	.	0.31	.	.	F	0.25	0.71
Ser	619	.	A	.	.	T	.	.	-0.03	.	.	F	0.85	0.71
Phe	620	T	.	.	0.46	.	.	F	1.26	0.35
Gly	621	T	T	.	0.17	.	.	F	1.07	0.54
Ser	622	T	C	-0.73	.	*	F	1.08	0.41
Gly	623	T	C	-0.14	.	.	F	0.99	0.35
Pro	624	T	C	-0.13	.	.	F	2.10	0.61
Ala	625	.	A	C	-0.32	.	.	F	0.89	0.48
Val	626	.	A	B	-0.19	*	.	.	0.03	0.34
Glu	627	.	A	B	0.16	*	.	.	-0.18	0.34
Trp	628	.	A	B	0.26	*	.	.	-0.09	0.67
Ile	629	.	.	B	-0.12	*	.	.	-0.25	1.42
Pro	630	.	.	B	.	.	T	.	0.12	*	.	.	0.10	0.83
Lys	631	T	T	.	0.12	*	.	.	0.20	0.78
Tyr	632	T	T	.	-0.18	*	.	.	0.20	0.82
Ala	633	T	T	.	-0.10	*	.	.	0.84	0.71
Gly	634	T	.	.	0.83	*	.	.	0.98	0.55
Val	635	.	.	B	1.04	.	*	.	0.92	0.70
Ser	636	.	.	B	.	.	T	.	1.11	.	*	F	2.66	1.17

5

10

15

20

-31.5-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Pro	637	T	T	.	0.69	.	*	F	3.40	2.31
Lys	638	T	T	.	1.32	.	*	F	3.06	1.67
Asp	639	T	T	.	0.86	.	*	F	2.72	2.49
Arg	640	A	A	0.82	.	*	F	1.58	1.33
Cys	641	A	A	0.46	*	*	F	1.09	0.46
Lys	642	.	A	B	0.67	*	*	.	0.30	0.15
Leu	643	.	A	B	0.03	.	*	.	0.30	0.13
Ile	644	.	A	B	0.08	.	*	.	-0.60	0.25
Cys	645	.	A	B	-0.38	.	*	.	0.30	0.25
Gln	646	.	A	B	-0.60	*	*	.	-0.30	0.30
Ala	647	.	A	B	-0.99	*	*	.	-0.30	0.30
Lys	648	.	A	B	-0.42	*	*	F	-0.15	0.55
Gly	649	T	T	.	-0.23	*	.	F	0.65	0.50
Ile	650	T	T	.	-0.27	.	*	.	0.20	0.43
Gly	651	.	.	B	.	.	T	.	-1.12	.	*	.	-0.20	0.18
Tyr	652	.	.	B	.	.	T	.	-1.34	.	.	.	-0.20	0.14
Phe	653	.	.	B	B	.	.	.	-1.39	.	.	.	-0.60	0.16
Phe	654	.	.	B	B	.	.	.	-1.26	.	*	.	-0.60	0.29
Val	655	.	.	B	B	.	.	.	-0.32	.	*	.	-0.60	0.28
Leu	656	.	.	B	B	.	.	.	-0.83	.	*	.	-0.60	0.65
Gln	657	.	.	B	.	.	T	.	-1.44	.	.	.	-0.20	0.56
Pro	658	.	.	B	.	.	T	.	-0.74	*	.	F	-0.05	0.56

5

10

15

20

-31.6-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James... Antig...	Emini Surfa...
Lys	659	T	T	.	-0.39	.	*	F	1.40	1.13
Val	660	.	.	B	.	.	T	.	0.16	.	.	F	0.85	0.65
Val	661	.	.	B	.	.	T	.	0.76	.	*	F	0.85	0.60
Asp	662	.	.	B	.	.	T	.	0.09	.	.	F	1.06	0.47
Gly	663	.	.	B	.	.	T	.	0.00	*	.	F	0.67	0.34
Thr	664	.	.	B	.	.	T	.	-0.26	*	.	F	1.48	0.61
Pro	665	.	.	B	0.60	.	.	F	1.49	0.56
Cys	666	T	.	.	1.16	.	.	F	2.10	0.95
Ser	667	T	C	0.84	.	.	F	1.89	0.88
Pro	668	T	T	.	0.89	.	.	F	1.88	0.82
Asp	669	T	T	.	0.34	.	.	F	1.82	2.06
Ser	670	T	T	.	-0.11	.	.	F	1.61	1.14
Thr	671	.	.	.	B	T	.	.	-0.30	.	*	F	0.85	0.39
Ser	672	.	.	B	B	.	.	.	0.00	.	*	F	-0.15	0.18
Val	673	.	.	B	B	.	.	.	-0.13	.	*	.	-0.60	0.23
Cys	674	.	.	B	B	.	.	.	-0.13	.	*	.	-0.60	0.16
Val	675	.	.	B	B	.	.	.	-0.50	.	*	.	-0.60	0.20
Gln	676	.	.	B	B	.	.	.	-1.04	.	*	F	-0.45	0.15
Gly	677	.	.	B	B	.	.	.	-0.70	.	*	F	-0.45	0.20
Gln	678	.	.	B	B	.	.	.	-0.43	.	*	F	-0.15	0.54
Cys	679	.	.	B	B	.	.	.	-0.11	.	.	.	0.30	0.32
Val	680	.	.	B	B	.	.	.	0.08	*	*	.	0.30	0.32

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.7-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Lys	681	.	.	B	.	.	T	.	0.08	*	.	.	0.10	0.10
Ala	682	.	.	B	.	.	T	.	0.53	*	.	.	0.70	0.30
Gly	683	.	.	B	.	.	T	.	-0.36	*	.	.	1.00	0.80
Cys	684	.	.	B	.	.	T	.	-0.58	*	.	.	1.00	0.28
Asp	685	A	.	.	B	.	.	.	0.28	*	.	.	0.30	0.20
Arg	686	A	.	.	B	.	.	.	-0.07	*	.	.	0.60	0.33
Ile	687	A	.	.	B	.	.	.	0.57	*	.	.	0.60	0.82
Ile	688	A	.	.	B	.	.	.	0.96	*	.	F	0.75	0.99
Asp	689	A	T	.	1.67	*	*	F	1.30	1.01
Ser	690	A	T	.	0.97	*	*	F	1.30	2.88
Lys	691	A	T	.	0.86	*	.	F	1.61	3.55
Lys	692	T	T	.	1.79	*	*	F	2.32	3.55
Lys	693	T	.	.	2.01	*	*	F	2.43	5.30
Phe	694	T	.	.	1.67	*	*	F	2.74	1.42
Asp	695	T	T	.	1.11	*	.	F	3.10	0.70
Lys	696	.	.	B	.	.	T	.	0.40	*	.	F	2.39	0.26
Cys	697	.	.	B	.	.	T	.	0.01	*	.	.	1.63	0.16
Gly	698	.	.	B	.	.	T	.	-0.38	*	.	.	1.32	0.10
Val	699	.	.	B	0.32	*	.	.	0.21	0.05
Cys	700	T	.	.	-0.02	.	.	.	0.00	0.14
Gly	701	T	T	.	-0.37	.	.	F	0.65	0.14
Gly	702	T	T	.	-0.01	.	.	F	0.65	0.26

5

10

15

20

-31.8-

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni... Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Asn	703	T	T	.	-0.33	.	.	F	0.65	0.69
Gly	704	T	T	.	0.57	.	.	F	0.65	0.37
Ser	705	T	T	.	1.28	.	.	F	1.25	0.76
Thr	706	.	.	B	.	.	T	.	0.73	.	.	F	1.41	0.94
Cys	707	.	.	B	.	.	T	.	0.78	.	*	F	1.37	0.67
Lys	708	.	.	B	.	.	T	.	0.43	.	*	F	1.63	0.67
Lys	709	.	.	B	0.48	*	*	F	1.69	0.46
Ile	710	.	.	B	.	.	T	.	-0.08	*	*	F	2.60	1.14
Ser	711	.	.	B	.	.	T	.	-0.08	*	*	F	1.89	0.42
Gly	712	.	.	B	.	.	T	.	0.29	*	*	F	1.03	0.31
Ser	713	.	.	B	.	.	T	.	-0.34	*	*	F	0.77	0.58
Val	714	.	.	B	B	.	.	.	-0.34	.	*	F	0.11	0.44
Thr	715	.	.	B	B	.	.	.	0.33	.	.	F	0.73	0.89
Ser	716	.	.	B	B	.	.	.	0.29	.	.	F	1.16	1.03
Ala	717	.	.	B	0.39	.	.	F	1.64	1.37
Lys	718	T	C	0.66	.	.	F	2.32	1.49
Pro	719	T	T	.	1.51	*	.	F	2.80	1.51
Gly	720	T	T	.	0.93	*	.	F	2.52	2.50
Tyr	721	.	.	B	.	.	T	.	0.34	*	.	.	1.54	0.88
His	722	.	.	B	B	.	.	.	0.62	*	.	.	-0.04	0.40
Asp	723	.	.	B	B	.	.	.	-0.31	*	.	.	-0.32	0.58
Ile	724	.	.	B	B	.	.	.	-0.31	*	.	.	-0.60	0.26

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.9-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James... Antig...	Emini Surfa...
Ile	725	.	.	B	B	.	.	.	-0.28	*	.	.	-0.60	0.29
Thr	726	.	.	B	B	.	.	.	-0.38	*	.	.	-0.60	0.25
Ile	727	.	.	B	.	.	T	.	-0.93	*	.	.	-0.20	0.36
Pro	728	.	.	B	.	.	T	.	-1.24	*	.	F	-0.05	0.52
Thr	729	T	C	-0.36	*	.	F	0.15	0.52
Gly	730	T	C	-0.36	.	*	F	0.30	1.19
Ala	731	.	.	.	B	.	.	C	-0.04	.	*	F	-0.25	0.54
Thr	732	.	.	.	B	.	.	C	-0.01	.	*	F	0.65	0.65
Asn	733	.	.	B	B	.	.	.	0.24	.	*	F	-0.15	0.48
Ile	734	.	.	B	B	.	.	.	0.56	.	*	F	0.45	0.96
Glu	735	.	.	B	B	.	.	.	1.01	.	*	F	0.60	1.15
Val	736	.	.	B	B	.	.	.	1.60	.	*	F	0.90	1.40
Lys	737	.	.	B	B	.	.	.	1.91	.	*	F	1.24	3.21
Gln	738	.	.	B	2.02	.	*	F	1.78	3.21
Arg	739	.	.	B	2.57	*	*	F	2.12	8.48
Asn	740	.	.	B	.	.	T	.	2.27	*	*	F	2.66	4.20
Gln	741	T	T	.	3.23	*	*	F	3.40	3.25
Arg	742	T	T	.	3.19	*	.	F	3.06	3.25
Gly	743	T	T	.	3.19	*	.	F	3.00	3.25
Ser	744	T	.	.	2.73	*	.	F	2.74	3.02
Arg	745	C	2.43	*	*	F	2.48	1.52
Asn	746	T	T	.	1.73	*	.	F	2.82	2.06

5

10

15

20

-31.10-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Asn	747	T	T	.	0.81	*	.	F	2.80	1.33
Gly	748	T	C	0.57	.	*	F	1.57	0.56
Ser	749	.	.	B	.	.	T	.	-0.02	.	*	F	0.79	0.35
Phe	750	.	A	B	-0.09	.	*	.	-0.04	0.15
Leu	751	.	A	B	-0.68	.	.	.	-0.32	0.31
Ala	752	.	A	B	-1.27	*	.	.	-0.60	0.23
Ile	753	.	A	B	-0.92	.	.	.	-0.60	0.27
Lys	754	A	A	-0.97	.	.	.	0.30	0.55
Ala	755	A	A	-0.58	.	.	.	0.30	0.54
Ala	756	A	A	-0.01	.	.	F	0.60	1.12
Asp	757	A	T	.	-0.31	.	.	F	0.85	0.87
Gly	758	.	.	B	.	.	T	.	-0.23	.	*	F	0.25	0.61
Thr	759	.	.	B	.	.	T	.	-0.28	.	.	F	-0.05	0.50
Tyr	760	.	.	B	.	.	T	.	-0.03	.	*	.	-0.20	0.48
Ile	761	.	.	B	0.56	.	*	.	-0.40	0.48
Leu	762	.	.	B	0.31	.	*	.	-0.40	0.55
Asn	763	.	.	B	.	.	T	.	0.34	.	*	F	-0.50	0.55
Gly	764	T	T	.	-0.16	.	*	F	0.50	1.14
Asp	765	T	T	.	-0.21	.	*	F	0.50	1.14
Tyr	766	T	C	0.37	.	*	F	0.45	0.95
Thr	767	.	.	B	B	.	.	.	0.37	.	*	.	-0.15	1.38
Leu	768	.	.	B	B	.	.	.	0.37	*	*	.	-0.60	0.68

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.11-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ser	769	.	.	B	B	.	.	.	0.71	*	.	F	-0.45	0.75
Thr	770	.	.	B	B	.	.	.	0.71	*	*	F	-0.15	0.90
Leu	771	A	.	.	B	.	.	.	0.07	*	.	F	0.60	1.83
Glu	772	A	.	.	B	.	.	.	-0.22	*	.	F	0.45	0.96
Gln	773	A	.	.	B	.	.	.	0.34	*	*	F	0.45	0.66
Asp	774	A	.	.	B	.	.	.	0.69	.	*	F	0.00	1.25
Ile	775	A	.	.	B	.	.	.	0.66	.	*	.	0.75	1.44
Met	776	A	.	.	B	.	.	.	0.61	.	*	.	0.30	0.82
Tyr	777	.	.	B	B	.	.	.	-0.24	.	*	.	-0.30	0.37
Lys	778	.	.	B	B	.	.	.	-1.06	.	*	.	-0.60	0.39
Gly	779	.	.	B	B	.	.	.	-0.94	.	*	.	-0.60	0.32
Val	780	.	.	B	B	.	.	.	-0.30	.	*	.	-0.30	0.40
Val	781	.	.	B	B	.	.	.	0.00	.	*	.	-0.30	0.32
Leu	782	.	.	B	B	.	.	.	-0.10	.	*	.	-0.60	0.43
Arg	783	.	.	B	B	.	.	.	-0.44	.	*	.	-0.60	0.57
Tyr	784	.	.	B	.	.	T	.	-0.40	*	*	.	0.25	1.03
Ser	785	T	T	.	-0.13	.	*	F	0.80	1.68
Gly	786	T	C	0.13	*	*	F	1.05	0.86
Ser	787	T	C	0.13	.	*	F	0.45	0.56
Ser	788	.	A	C	0.02	.	*	F	0.05	0.34
Ala	789	A	A	0.38	*	.	F	0.45	0.60
Ala	790	A	A	-0.21	*	*	.	0.60	0.88

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.12-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Leu	791	A	A	0.24	*	*	.	0.30	0.46
Glu	792	A	A	0.24	*	*	.	0.60	0.89
Arg	793	.	A	B	B	.	.	.	-0.16	*	*	F	0.90	1.18
Ile	794	A	A	.	B	.	.	.	0.13	*	*	F	0.60	1.24
Arg	795	A	A	.	B	.	.	.	0.51	*	*	F	0.75	0.96
Ser	796	.	A	.	.	T	.	.	0.51	.	*	F	1.13	0.76
Phe	797	C	0.56	.	*	F	0.81	0.89
Ser	798	T	C	0.44	.	*	F	1.89	0.91
Pro	799	T	C	1.12	*	*	F	2.32	1.17
Leu	800	T	T	.	0.20	*	*	F	2.80	2.10
Lys	801	T	C	0.19	*	*	F	2.32	1.29
Glu	802	C	0.00	.	*	F	1.84	1.20
Pro	803	A	.	.	B	.	.	.	0.30	.	*	F	1.16	1.02
Leu	804	A	.	.	B	.	.	.	-0.34	.	*	F	0.73	0.89
Thr	805	.	.	B	B	.	.	.	-0.34	.	*	.	-0.30	0.38
Ile	806	.	.	B	B	.	.	.	-0.70	.	*	.	-0.60	0.20
Gln	807	.	.	B	B	.	.	.	-1.56	.	.	.	-0.60	0.35
Val	808	.	.	B	B	.	.	.	-1.69	.	*	.	-0.60	0.18
Leu	809	.	.	B	B	.	.	.	-0.88	.	*	.	-0.60	0.26
Thr	810	.	.	B	B	.	.	.	-1.16	.	.	.	-0.60	0.24
Val	811	.	.	B	B	.	.	.	-1.08	.	*	.	-0.60	0.33
Gly	812	.	.	B	B	.	.	.	-0.97	*	*	.	-0.60	0.33

5

10

15

20

-31.13-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James.. Antig...	Emini Surfa...
Asn	813	A	-0.32	*	*	.	0.12	0.44
Ala	814	A	0.53	*	*	.	0.34	0.92
Leu	815	A	-0.04	*	*	F	1.76	1.86
Arg	816	.	.	B	0.86	*	*	F	1.53	0.81
Pro	817	.	.	B	0.96	*	*	F	2.20	1.61
Lys	818	.	.	B	B	.	.	.	0.64	*	*	F	1.48	3.05
Ile	819	.	.	B	B	.	.	.	0.99	.	*	F	1.56	2.25
Lys	820	.	.	B	B	.	.	.	1.10	*	*	F	0.44	2.28
Tyr	821	.	.	B	B	.	.	.	0.13	*	*	.	-0.38	0.99
Thr	822	.	.	B	B	.	.	.	0.39	.	*	.	-0.45	1.04
Tyr	823	A	.	.	B	.	.	.	0.39	.	*	.	-0.45	1.04
Phe	824	A	.	.	B	.	.	.	1.32	.	*	.	-0.45	1.33
Val	825	A	.	.	B	.	.	.	1.32	.	.	.	0.45	1.85
Lys	826	A	.	.	B	.	.	.	1.57	.	.	F	0.90	2.36
Lys	827	A	A	1.58	*	.	F	0.90	4.71
Lys	828	A	A	1.12	*	.	F	0.90	8.51
Lys	829	A	A	1.82	*	.	F	0.90	3.68
Glu	830	A	A	2.09	*	.	F	0.90	2.96
Ser	831	A	A	1.16	*	.	F	0.90	1.50
Phe	832	A	A	0.90	.	.	.	0.30	0.52
Asn	833	.	A	B	0.54	*	.	.	-0.30	0.47
Ala	834	.	.	B	-0.20	*	*	.	-0.40	0.50

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.14-

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni... Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ile	835	C	-0.50	*	.	.	-0.20	0.50
Pro	836	T	C	-0.79	.	.	.	0.00	0.42
Thr	837	T	T	.	-0.38	*	*	.	0.20	0.42
Phe	838	A	T	.	-1.23	*	.	.	-0.20	0.63
Ser	839	T	C	-1.53	*	.	.	0.00	0.30
Ala	840	.	A	B	B	.	.	.	-0.64	*	.	.	-0.60	0.15
Trp	841	.	A	B	B	.	.	.	-0.43	.	.	.	-0.60	0.29
Val	842	A	A	.	B	.	.	.	-0.41	.	.	.	-0.30	0.38
Ile	843	A	A	.	B	.	.	.	-0.06	*	.	.	-0.60	0.40
Glu	844	A	A	.	B	.	.	.	0.24	*	.	.	-0.60	0.37
Glu	845	A	A	0.17	*	.	.	0.30	0.87
Trp	846	A	A	0.16	*	.	.	0.61	0.66
Gly	847	A	A	1.06	*	.	F	1.37	0.51
Glu	848	.	A	.	.	T	.	.	1.64	*	.	F	2.08	0.59
Cys	849	.	A	.	.	T	.	.	0.98	*	.	F	2.09	0.76
Ser	850	T	T	.	0.98	.	.	F	3.10	0.41
Lys	851	T	T	.	0.46	.	.	F	2.79	0.41
Ser	852	T	T	.	0.46	.	.	F	2.18	0.63
Cys	853	T	T	.	0.17	*	*	.	2.02	0.47
Glu	854	A	A	0.83	*	.	.	0.61	0.24
Leu	855	A	A	1.24	.	.	.	-0.30	0.32
Gly	856	.	A	1.31	.	*	.	0.85	1.16

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.15-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Trp	857	A	A	0.80	*	*	.	0.75	1.31
Gln	858	A	A	0.61	*	*	.	-0.15	1.31
Arg	859	A	A	0.61	*	*	.	-0.30	0.98
Arg	860	.	A	B	0.76	.	*	.	0.45	1.61
Leu	861	.	A	B	1.21	*	.	.	0.60	0.50
Val	862	.	A	B	1.50	*	.	.	0.60	0.50
Glu	863	.	A	B	0.61	.	.	.	0.94	0.43
Cys	864	.	A	B	0.50	.	.	.	0.98	0.36
Arg	865	.	A	.	.	T	.	.	0.04	.	.	F	2.17	0.78
Asp	866	T	T	.	0.86	.	.	F	2.91	0.45
Ile	867	T	T	.	1.50	.	.	F	3.40	1.45
Asn	868	T	T	.	0.91	.	.	F	3.06	1.14
Gly	869	T	C	1.28	.	.	F	2.07	0.69
Gln	870	T	C	1.17	.	*	F	1.28	1.32
Pro	871	T	C	0.50	.	*	F	1.54	1.42
Ala	872	T	C	0.80	.	*	F	1.05	0.77
Ser	873	A	T	.	0.84	*	.	F	0.85	0.45
Glu	874	A	A	1.19	*	.	F	0.75	0.58
Cys	875	A	A	0.33	*	.	.	0.60	1.00
Ala	876	A	A	0.59	*	.	.	0.60	0.55
Lys	877	A	A	0.97	*	.	F	0.75	0.64
Glu	878	A	A	0.68	*	.	F	0.90	1.84

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.16-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Val	879	A	A	0.38	*	.	F	0.90	1.84
Lys	880	A	A	0.73	*	.	F	0.90	1.23
Pro	881	A	T	.	1.43	*	.	F	1.30	1.03
Ala	882	T	T	.	1.18	*	.	F	2.01	2.71
Ser	883	T	T	.	0.51	.	*	F	2.32	2.10
Thr	884	T	T	.	0.78	.	*	F	2.18	0.73
Arg	885	.	.	B	.	.	T	.	0.73	.	*	F	2.09	0.73
Pro	886	T	T	.	0.91	.	*	F	3.10	0.91
Cys	887	T	T	.	1.29	.	*	.	2.64	0.85
Ala	888	T	T	.	0.92	.	*	.	2.43	0.67
Asp	889	T	.	.	1.02	.	*	.	1.72	0.23
His	890	T	C	0.91	.	*	.	1.51	0.67
Pro	891	T	T	.	0.83	.	.	.	1.65	1.16
Cys	892	T	T	.	1.50	.	*	.	1.00	0.73
Pro	893	T	T	.	1.28	.	*	.	0.60	0.93
Gln	894	.	A	.	.	T	.	.	0.93	.	.	.	0.10	0.49
Trp	895	.	A	B	0.97	.	.	.	-0.40	0.91
Gln	896	.	A	B	0.89	.	.	.	-0.05	1.02
Leu	897	.	A	B	1.26	.	.	.	-0.60	0.62
Gly	898	T	.	.	1.17	.	.	.	0.00	0.79
Glu	899	T	.	.	0.50	.	.	F	0.45	0.61
Trp	900	T	.	.	0.49	.	.	F	0.45	0.40

5

10

15

20

-31.17-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James... Antig...	Emini Surfa...
Ser	901	T	T	.	0.53	.	.	F	0.65	0.54
Ser	902	T	T	.	1.03	.	.	F	1.25	0.62
Cys	903	T	T	.	0.71	.	*	F	0.65	0.85
Ser	904	T	T	.	0.37	*	*	F	1.25	0.34
Lys	905	T	.	.	0.70	*	*	F	1.05	0.25
Thr	906	T	.	.	0.66	*	*	F	1.69	0.94
Cys	907	T	.	.	0.71	*	.	F	2.03	0.69
Gly	908	T	T	.	1.42	*	*	F	2.27	0.54
Lys	909	T	T	.	1.77	*	*	F	2.61	0.75
Gly	910	T	T	.	1.83	*	*	F	3.40	2.81
Tyr	911	T	T	.	1.84	.	.	F	3.06	5.57
Lys	912	.	A	B	1.70	*	.	F	1.92	3.73
Lys	913	.	A	B	2.09	*	.	F	1.58	3.11
Arg	914	.	A	B	1.38	*	.	F	1.24	3.97
Ser	915	.	A	B	0.91	*	.	F	0.90	1.06
Leu	916	.	A	B	0.86	*	.	F	0.75	0.44
Lys	917	.	A	B	0.78	*	.	.	0.30	0.30
Cys	918	.	A	B	0.73	*	.	.	-0.30	0.30
Leu	919	.	A	B	0.28	*	.	.	0.30	0.62
Ser	920	.	.	B	0.23	.	.	.	0.50	0.31
His	921	.	.	B	.	.	T	.	0.19	*	.	F	0.85	0.56
Asp	922	T	T	.	-0.67	*	.	F	0.65	0.51

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.18-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James.. Antig...	Emini Surfa...
Gly	923	T	T	.	-0.30	.	.	F	0.65	0.31
Gly	924	T	T	.	0.48	.	.	F	0.65	0.31
Val	925	.	.	B	0.78	.	.	.	-0.10	0.25
Leu	926	.	.	B	0.51	.	.	.	-0.10	0.44
Ser	927	.	.	B	-0.16	.	.	.	-0.10	0.59
His	928	.	.	B	.	.	T	.	0.19	.	.	.	0.10	0.43
Glu	929	.	.	B	.	.	T	.	0.32	.	.	F	0.85	0.87
Ser	930	A	T	.	0.37	*	.	F	1.30	1.00
Cys	931	A	T	.	1.22	*	.	F	0.85	0.61
Asp	932	A	T	.	1.57	*	.	F	1.15	0.70
Pro	933	A	T	.	1.39	*	.	F	1.30	1.05
Leu	934	A	T	.	1.43	*	.	F	1.30	3.02
Lys	935	A	T	.	1.70	*	.	F	1.30	3.62
Lys	936	A	A	1.67	*	.	F	0.90	3.18
Pro	937	A	A	0.78	*	.	F	0.90	3.34
Lys	938	A	A	0.99	*	*	F	0.90	1.17
His	939	A	A	1.10	*	*	.	0.60	0.98
Phe	940	.	A	B	0.39	*	*	.	-0.30	0.55
Ile	941	.	A	B	0.03	*	*	.	-0.30	0.15
Asp	942	A	A	-0.36	*	*	.	-0.60	0.16
Phe	943	A	A	-0.99	*	*	.	-0.60	0.18
Cys	944	A	A	-0.96	.	.	.	-0.60	0.26

5

10

15

20

-31.19-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Thr	945	A	A	-0.92	.	*	.	0.30	0.27
Met	946	A	A	-0.33	.	*	.	-0.60	0.16
Ala	947	A	A	-0.72	.	.	.	-0.30	0.41
Glu	948	A	A	-0.41	.	.	.	0.30	0.36
Cys	949	A	A	-0.13	.	.	.	0.30	0.47
Ser	950	A	A	-0.21	.	.	.	0.30	0.60

-31.20-

Table 2

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Met	1	.	.	B	-0.37	.	.	.	-0.40	0.50
Phe	2	.	.	B	-0.57	.	.	.	-0.40	0.61
Pro	3	.	.	B	-0.77	.	.	.	-0.40	0.48
Ala	4	C	-0.59	.	*	.	-0.20	0.49
Pro	5	C	-0.09	.	*	.	-0.20	0.87
Ala	6	C	0.22	*	*	.	0.85	1.11
Ala	7	T	C	0.11	*	*	.	0.45	1.15
Pro	8	A	T	.	0.11	*	.	.	-0.20	0.61
Arg	9	T	T	.	0.00	*	.	.	0.20	0.94
Trp	10	.	.	B	.	.	T	.	-0.60	*	.	.	-0.20	0.81
Leu	11	.	A	B	-0.82	*	.	.	-0.60	0.43
Pro	12	.	A	B	-1.04	*	.	.	-0.60	0.18
Phe	13	.	A	B	-1.64	*	.	.	-0.60	0.14
Leu	14	A	A	-2.57	*	.	.	-0.60	0.14
Leu	15	A	A	-3.09	.	.	.	-0.60	0.08
Leu	16	A	A	-3.09	.	.	.	-0.60	0.07
Leu	17	A	A	-3.69	.	.	.	-0.60	0.07
Leu	18	A	A	-3.80	.	.	.	-0.60	0.07
Leu	19	A	A	-3.20	.	.	.	-0.60	0.07
Leu	20	A	A	-3.20	.	.	.	-0.60	0.14

5

10

15

20

-31.21-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Leu	21	A	A	-2.98	*	.	.	-0.60	0.14
Leu	22	.	A	B	-2.06	*	.	.	-0.60	0.17
Pro	23	.	A	B	-1.59	*	.	.	-0.60	0.39
Leu	24	A	A	-1.37	*	.	.	-0.60	0.47
Ala	25	A	A	-0.77	*	.	.	-0.04	0.58
Arg	26	.	A	B	-0.54	*	.	.	0.82	0.58
Gly	27	.	A	B	0.38	.	.	F	0.63	0.71
Ala	28	.	.	B	0.38	.	.	F	2.14	1.37
Pro	29	C	0.60	.	.	F	2.60	1.08
Ala	30	.	.	B	0.60	.	.	F	1.84	1.11
Arg	31	.	.	B	0.14	.	.	F	1.58	1.11
Pro	32	.	.	B	0.14	.	*	F	1.17	0.71
Ala	33	.	.	B	.	.	T	.	0.73	.	*	F	1.11	0.69
Ala	34	A	T	.	0.36	.	*	F	0.85	0.61
Gly	35	T	C	0.64	.	*	F	0.45	0.40
Gly	36	T	C	0.53	.	*	F	0.45	0.53
Gln	37	A	-0.07	.	.	F	0.65	0.91
Ala	38	.	.	B	-0.33	.	.	F	0.65	0.76
Ser	39	.	.	B	B	B	.	.	-0.60	.	.	F	-0.15	0.57
Glu	40	.	.	B	B	B	.	.	-0.47	.	.	F	-0.15	0.24
Leu	41	.	.	B	B	B	.	.	-0.43	.	*	.	-0.30	0.37
Val	42	.	.	B	B	B	.	.	-0.32	.	*	.	-0.30	0.40

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.22-

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni.. Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Val	43	.	.	B	B	B	.	.	-0.54	.	*	.	0.30	0.46
Pro	44	.	.	B	B	B	.	.	-0.46	.	*	F	-0.24	0.46
Thr	45	.	.	B	B	B	.	.	-0.80	.	*	F	0.27	0.95
Arg	46	.	.	B	B	B	.	.	-0.29	.	*	F	0.63	1.26
Leu	47	T	C	-0.02	.	*	F	2.04	1.10
Pro	48	T	C	0.49	*	*	F	2.10	0.77
Gly	49	T	C	0.70	*	*	F	1.89	0.39
Ser	50	T	C	0.20	*	*	F	1.68	0.81
Ala	51	A	A	-0.50	*	*	F	0.87	0.43
Gly	52	A	A	-0.50	.	.	F	0.66	0.44
Glu	53	A	A	-0.32	.	*	.	-0.30	0.27
Leu	54	A	A	-0.79	.	*	.	-0.30	0.37
Ala	55	A	A	-0.79	.	*	.	-0.60	0.31
Leu	56	A	A	-0.79	.	*	.	-0.60	0.24
His	57	A	A	-1.14	.	*	.	-0.60	0.29
Leu	58	A	A	-1.49	*	*	.	-0.60	0.25
Ser	59	A	A	-0.63	*	*	.	-0.60	0.30
Ala	60	A	A	-0.39	*	*	.	-0.30	0.44
Phe	61	A	A	-0.28	*	*	.	-0.30	0.53
Gly	62	T	T	.	-1.10	*	.	.	0.50	0.34
Lys	63	A	T	.	-1.10	.	*	F	-0.05	0.25
Gly	64	.	.	B	.	.	T	.	-0.69	.	*	.	-0.20	0.24

5

10

15

20

-31.23-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emni Surfa...
Phe	65	.	.	B	.	.	T	.	-0.91	.	*	.	0.70	0.47
Val	66	.	.	B	B	.	.	.	-0.80	*	*	.	-0.30	0.19
Leu	67	.	.	B	B	.	.	.	-0.67	*	*	.	-0.30	0.20
Arg	68	.	.	B	B	.	.	.	-0.71	.	*	.	0.00	0.35
Leu	69	.	.	B	B	.	.	.	-0.37	*	*	.	1.20	0.80
Ala	70	T	C	0.03	.	*	.	2.55	1.61
Pro	71	T	C	0.19	*	*	F	3.00	1.10
Asp	72	T	T	.	0.19	.	*	F	2.60	1.16
Asp	73	A	T	.	-0.51	.	*	F	1.75	0.95
Ser	74	A	A	0.09	.	.	.	0.90	0.62
Phe	75	A	A	0.68	.	.	.	0.60	0.57
Leu	76	A	A	0.19	.	*	.	0.30	0.59
Ala	77	A	A	0.23	.	*	.	-0.60	0.38
Pro	78	A	A	-0.66	.	*	.	-0.30	0.89
Glu	79	A	A	-0.36	*	*	F	-0.15	0.75
Phe	80	A	A	0.46	*	.	F	0.90	1.29
Lys	81	A	A	0.46	*	*	F	0.90	1.63
Ile	82	A	A	0.70	*	.	F	0.75	0.78
Glu	83	A	A	0.57	*	*	F	0.45	0.89
Arg	84	A	A	0.27	*	*	F	0.75	0.44
Leu	85	.	A	.	.	T	.	.	0.62	*	*	F	0.85	0.84
Gly	86	.	A	.	.	T	.	.	0.69	*	*	F	1.15	0.48

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.24-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Gly	87	T	C	0.99	*	*	F	1.35	0.48
Ser	88	T	C	0.68	*	*	F	1.05	0.59
Gly	89	T	C	0.22	*	*	F	1.05	0.86
Arg	90	.	.	B	.	.	T	.	0.69	.	*	F	1.19	0.86
Ala	91	T	C	1.03	.	*	F	1.73	0.63
Thr	92	.	.	B	.	.	T	.	1.49	.	*	F	2.32	1.11
Gly	93	.	.	B	.	.	T	.	1.44	.	*	F	2.66	1.11
Gly	94	T	T	.	0.98	*	*	F	3.40	1.09
Glu	95	.	.	B	0.98	*	*	F	2.31	0.62
Arg	96	.	.	B	1.22	*	.	F	2.12	1.23
Gly	97	T	.	.	0.87	*	*	F	2.18	1.23
Leu	98	.	.	B	.	.	T	.	0.51	*	.	F	1.49	0.38
Arg	99	.	.	B	.	.	T	.	0.16	*	.	.	0.70	0.17
Gly	100	.	.	B	.	.	T	.	-0.14	*	.	.	-0.20	0.15
Cys	101	.	.	B	.	.	T	.	-0.60	*	.	.	-0.20	0.24
Phe	102	.	.	B	-0.57	.	*	.	-0.10	0.12
Phe	103	.	.	B	.	.	T	.	-0.61	.	*	.	-0.20	0.18
Ser	104	.	.	B	.	.	T	.	-0.72	.	*	F	-0.05	0.24
Gly	105	T	C	-0.72	.	*	F	0.15	0.45
Thr	106	T	C	-0.06	*	*	F	0.45	0.52
Val	107	.	.	.	B	.	.	C	0.43	.	*	F	1.25	0.67
Asn	108	.	.	.	B	.	.	C	1.13	.	*	F	1.70	1.05

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.25-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Gly	109	.	.	.	B	.	.	C	1.13	.	*	F	2.30	1.26
Glu	110	T	C	0.67	.	*	F	3.00	2.27
Pro	111	A	T	.	0.39	.	*	F	2.50	1.16
Glu	112	A	T	.	0.66	.	*	F	2.20	1.19
Ser	113	A	T	.	-0.20	.	.	F	1.75	0.69
Leu	114	A	A	.	B	.	.	.	-0.16	.	.	.	0.00	0.33
Ala	115	A	A	.	B	.	.	.	-0.97	.	.	.	-0.30	0.26
Ala	116	A	A	.	B	.	.	.	-1.42	.	.	.	-0.60	0.16
Val	117	A	A	.	B	.	.	.	-1.31	.	.	.	-0.60	0.10
Ser	118	.	A	B	B	.	.	.	-1.36	*	.	.	-0.30	0.20
Leu	119	.	.	B	B	.	.	.	-1.36	*	.	.	-0.30	0.20
Cys	120	.	.	B	.	.	T	.	-1.07	*	.	.	0.10	0.22
Arg	121	.	.	B	.	.	T	.	-0.82	*	.	.	0.10	0.22
Gly	122	T	T	.	-0.27	*	.	F	0.65	0.26
Leu	123	T	T	.	-0.67	*	.	F	1.25	0.65
Ser	124	T	C	-0.67	*	.	F	0.45	0.29
Gly	125	.	.	B	.	.	T	.	-0.81	.	*	F	-0.05	0.24
Ser	126	.	.	B	.	.	T	.	-0.92	.	*	F	-0.05	0.24
Phe	127	.	.	B	.	.	T	.	-0.92	.	*	.	0.10	0.30
Leu	128	.	A	B	.	.	.	C	-0.11	.	*	.	-0.30	0.30
Leu	129	.	A	0.19	.	*	F	0.65	0.39
Asp	130	A	A	-0.17	.	.	F	0.45	0.77

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.26-

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni.. Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Gly	131	A	A	-0.18	.	.	F	0.45	0.81
Glu	132	A	A	-0.37	.	*	F	0.90	1.42
Glu	133	A	A	0.44	.	*	F	0.75	0.60
Phe	134	A	A	1.04	.	*	.	0.45	1.04
Thr	135	.	A	B	1.04	.	*	.	0.30	0.93
Ile	136	.	.	B	1.04	.	*	F	0.05	0.93
Gln	137	.	.	B	0.46	.	*	F	-0.10	1.06
Pro	138	C	0.11	.	*	F	0.25	0.75
Gln	139	T	.	.	0.47	.	*	F	0.60	1.05
Gly	140	T	C	0.48	.	*	F	0.45	0.60
Ala	141	T	T	.	0.56	.	*	F	1.25	0.52
Gly	142	T	C	-0.03	.	.	F	0.45	0.25
Gly	143	T	C	0.18	.	.	F	0.65	0.25
Ser	144	C	-0.03	.	.	F	0.65	0.43
Leu	145	.	.	B	0.28	*	.	F	0.65	0.68
Ala	146	.	.	B	0.98	*	.	F	0.85	0.93
Gln	147	.	.	B	.	.	T	.	0.51	.	*	F	2.00	1.36
Pro	148	.	.	B	.	.	T	.	0.86	*	.	.	1.05	1.36
His	149	.	.	B	.	.	T	.	1.27	*	.	.	1.45	2.34
Arg	150	.	.	B	.	.	T	.	1.79	*	.	.	1.55	2.64
Leu	151	.	.	B	2.03	*	.	.	0.85	1.80
Gln	152	.	.	B	1.82	*	.	.	0.65	1.31

5

10

15

20

-31.27-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Arg	153	T	.	.	1.44	*	.	.	1.05	1.03
Trp	154	T	.	.	1.13	*	.	F	0.84	1.26
Gly	155	T	C	0.43	*	.	F	0.93	0.72
Pro	156	T	C	1.36	*	.	F	1.17	0.37
Ala	157	T	T	.	1.14	*	.	F	1.61	0.69
Gly	158	T	C	0.22	*	.	F	2.40	1.08
Ala	159	C	0.30	*	*	F	1.81	0.58
Arg	160	.	.	.B	0.76	*	*	F	1.37	0.89
Pro	161	.	.	B	0.62	*	*	F	1.58	1.75
Leu	162	C	1.00	*	*	F	1.84	1.72
Pro	163	C	1.34	*	*	F	1.90	1.35
Arg	164	C	1.64	*	*	F	2.20	1.52
Gly	165	T	C	1.53	*	*	F	2.40	1.93
Pro	166	T	C	0.89	*	.	F	3.00	2.17
Glu	167	T	C	1.70	*	.	F	2.55	0.82
Trp	168	A	T	.	1.60	*	.	.	2.05	1.44
Glu	169	A	1.14	*	.	.	1.85	1.34
Val	170	A	1.49	.	.	F	1.85	0.77
Glu	171	A	1.36	.	*	F	2.00	1.26
Thr	172	A	1.36	.	*	F	2.15	0.72
Gly	173	T	C	1.76	.	.	F	3.00	1.68
Glu	174	A	T	.	1.76	.	.	F	2.50	1.90

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.28-

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni.. Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Gly	175	A	T	.	2.61	.	.	F	2.20	2.28
Gln	176	A	T	.	2.72	.	.	F	1.90	4.00
Arg	177	A	A	2.69	.	*	F	1.54	4.52
Gln	178	A	A	3.03	.	*	F	1.58	4.52
Glu	179	.	A	.	.	T	.	.	3.00	*	*	F	2.32	4.36
Arg	180	.	A	.	.	T	.	.	3.34	*	.	F	2.66	3.03
Gly	181	T	T	.	3.34	.	*	F	3.40	3.03
Asp	182	T	C	3.23	.	.	F	2.86	3.03
His	183	T	C	2.93	.	*	F	2.52	2.58
Gln	184	T	C	2.93	.	*	F	2.18	3.50
Glu	185	.	A	C	2.82	.	*	F	1.44	3.63
Asp	186	A	A	3.17	.	.	F	0.90	4.61
Ser	187	A	A	2.87	.	.	F	0.90	4.61
Glu	188	A	A	2.90	.	.	F	0.90	3.57
Glu	189	A	A	2.90	.	.	F	0.90	3.70
Glu	190	A	A	2.90	.	.	F	0.90	4.79
Ser	191	A	A	2.90	.	.	F	0.90	4.79
Gln	192	A	A	2.61	.	.	F	0.90	4.79
Glu	193	A	A	2.61	.	.	F	0.90	2.79
Glu	194	A	A	2.27	.	.	F	0.90	3.61
Glu	195	A	A	1.68	.	.	F	0.90	2.06
Ala	196	A	A	1.68	.	.	F	1.16	1.20

5

10

15

20

-31.29-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Glu	197	A	A	1.68	.	.	F	1.27	0.93
Gly	198	A	A	1.47	.	.	F	1.53	0.93
Ala	199	.	A	.	.	T	.	.	1.26	.	.	F	2.34	1.42
Ser	200	C	1.04	.	.	F	2.60	1.27
Glu	201	C	1.42	*	.	F	2.04	1.99
Pro	202	C	0.61	.	.	F	1.78	3.04
Pro	203	C	0.61	.	.	F	1.52	1.87
Pro	204	T	C	0.61	.	.	F	1.46	1.07
Pro	205	T	C	0.60	.	.	F	0.45	0.70
Leu	206	T	C	0.30	*	*	F	0.45	0.65
Gly	207	.	.	B	.	.	T	.	0.62	.	*	F	0.51	0.57
Ala	208	.	.	B	0.52	.	*	F	1.17	0.72
Thr	209	.	.	B	0.78	*	*	F	1.58	1.25
Ser	210	.	.	B	.	.	T	.	1.10	*	.	F	2.34	2.53
Arg	211	.	.	B	.	.	T	.	1.21	*	.	F	2.60	4.91
Thr	212	.	.	B	.	.	T	.	0.70	*	.	F	2.34	2.95
Lys	213	.	.	B	.	.	T	.	0.99	*	.	F	2.08	1.63
Arg	214	.	.	B	B	.	.	.	1.30	*	.	F	1.42	1.12
Phe	215	.	.	B	B	.	.	.	1.01	*	*	.	1.01	1.34
Val	216	.	.	B	B	.	.	.	1.01	*	*	.	0.60	0.68
Ser	217	A	.	.	B	.	.	.	0.62	*	*	.	0.60	0.68
Glu	218	A	A	-0.28	*	*	.	-0.30	0.68

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.30-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ala	219	A	A	.	B	.	.	.	-0.39	*	*	.	0.30	0.68
Arg	220	A	A	.	B	.	.	.	0.00	*	*	.	0.60	0.87
Phe	221	A	A	.	B	.	.	.	0.04	*	.	.	0.60	0.73
Val	222	A	A	.	B	.	.	.	-0.47	*	*	.	-0.30	0.59
Glu	223	A	A	.	B	.	.	.	-1.32	*	*	.	-0.30	0.25
Thr	224	A	A	.	B	.	.	.	-1.32	*	*	.	-0.60	0.21
Leu	225	A	A	.	B	.	.	.	-1.43	*	*	.	-0.60	0.29
Leu	226	A	A	.	B	.	.	.	-1.32	.	.	.	0.30	0.28
Val	227	A	A	.	B	.	.	.	-0.77	.	.	.	-0.60	0.20
Ala	228	A	A	.	B	.	.	.	-1.37	.	.	.	-0.30	0.32
Asp	229	A	A	.	B	.	.	.	-1.64	.	.	.	-0.30	0.38
Ala	230	A	A	-1.42	.	.	.	-0.30	0.52
Ser	231	A	A	-1.31	.	.	.	0.30	0.52
Met	232	A	A	-0.70	.	.	.	-0.30	0.27
Ala	233	A	A	-0.46	.	.	.	-0.60	0.42
Ala	234	A	A	-1.04	.	.	.	-0.60	0.31
Phe	235	A	A	-0.46	.	.	.	-0.60	0.32
Tyr	236	A	A	-0.97	.	.	.	-0.60	0.52
Gly	237	A	A	-0.37	.	.	.	-0.60	0.43
Ala	238	A	A	0.22	.	.	.	-0.60	0.86
Asp	239	A	A	0.78	*	*	.	-0.30	0.88
Leu	240	A	A	0.59	*	.	.	0.45	1.21

5

10

15

20

-31.31-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Gln	241	A	A	.	B	.	.	.	0.02	*	*	.	-0.30	0.84
Asn	242	A	A	.	B	.	.	.	0.06	*	.	.	-0.30	0.41
His	243	.	A	B	B	.	.	.	-0.17	*	*	.	-0.60	0.72
Ile	244	.	A	B	B	.	.	.	-0.77	*	.	.	-0.60	0.35
Leu	245	.	A	B	B	.	.	.	-0.26	*	.	.	-0.60	0.21
Thr	246	.	A	B	B	.	.	.	-1.11	*	.	.	-0.60	0.21
Leu	247	.	A	B	B	.	.	.	-1.70	*	.	.	-0.60	0.22
Met	248	A	A	.	B	.	.	.	-2.26	*	*	.	-0.60	0.27
Ser	249	A	A	.	B	.	.	.	-1.26	*	*	.	-0.60	0.19
Val	250	A	A	.	B	.	.	.	-1.33	*	*	.	-0.30	0.45
Ala	251	A	A	.	B	.	.	.	-1.27	*	*	.	-0.30	0.32
Ala	252	A	A	.	B	.	.	.	-0.41	*	*	.	-0.60	0.37
Arg	253	A	A	.	B	.	.	.	0.16	*	*	.	-0.15	1.01
Ile	254	A	A	.	B	.	.	.	0.24	*	*	.	0.45	1.36
Tyr	255	A	0.80	*	*	.	0.99	2.08
Lys	256	.	.	B	0.50	*	*	.	1.33	1.42
His	257	.	.	B	.	.	T	.	1.13	.	*	F	1.12	1.42
Pro	258	T	C	1.02	.	*	F	2.56	1.81
Ser	259	T	T	.	1.61	.	*	F	3.40	1.46
Ile	260	T	T	.	0.97	.	*	F	2.76	1.44
Lys	261	.	.	B	0.92	.	*	F	1.67	0.65
Asn	262	T	.	.	0.14	*	*	F	1.73	0.78

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.32-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ser	263	.	.	B	B	.	.	.	-0.24	*	*	F	0.19	0.92
Ile	264	.	.	B	B	.	.	.	-0.80	*	*	.	-0.30	0.45
Asn	265	.	.	B	B	.	.	.	-0.77	*	*	.	-0.60	0.21
Leu	266	.	.	B	B	.	.	.	-0.77	.	*	.	-0.60	0.12
Met	267	A	.	.	B	.	.	.	-1.62	*	.	.	-0.60	0.33
Val	268	.	.	B	B	.	.	.	-2.13	.	*	.	-0.60	0.15
Val	269	.	.	B	B	.	.	.	-2.13	.	.	.	-0.60	0.15
Lys	270	A	.	.	B	.	.	.	-2.99	.	.	.	-0.60	0.11
Val	271	.	.	B	B	.	.	.	-2.18	.	.	.	-0.60	0.11
Leu	272	.	.	B	B	.	.	.	-1.58	.	.	.	-0.30	0.25
Ile	273	A	.	.	B	.	.	.	-0.72	.	.	.	0.30	0.21
Val	274	A	.	.	B	.	.	.	0.18	.	*	.	0.30	0.49
Glu	275	A	.	.	B	.	.	.	-0.16	.	.	.	0.75	1.19
Asp	276	A	A	0.36	.	.	F	0.90	1.79
Glu	277	A	A	0.96	*	.	F	0.90	2.39
Lys	278	.	A	.	.	T	.	.	1.84	*	*	F	1.30	2.13
Trp	279	.	A	C	1.84	.	*	F	1.10	2.21
Gly	280	T	C	1.54	*	.	F	1.35	0.95
Pro	281	T	C	1.54	*	*	F	1.36	0.64
Glu	282	.	.	B	.	.	T	.	1.54	*	*	F	1.62	1.01
Val	283	.	.	B	.	.	T	.	1.16	*	*	F	2.23	1.64
Ser	284	T	C	1.10	.	*	F	2.74	1.05

5

10

15

20

-31.33-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Asp	285	T	T	.	0.63	.	.	F	3.10	0.60
Asn	286	T	T	.	0.53	.	*	F	2.49	0.67
Gly	287	T	T	.	-0.28	*	*	F	2.18	0.72
Gly	288	T	.	.	0.69	*	*	F	1.07	0.35
Leu	289	.	.	B	0.99	*	*	F	0.36	0.43
Thr	290	.	.	B	0.29	*	*	.	-0.10	0.70
Leu	291	.	.	B	-0.38	*	*	.	-0.40	0.61
Arg	292	.	.	B	-0.03	*	*	.	-0.40	0.40
Asn	293	.	.	B	0.02	*	*	.	-0.10	0.44
Phe	294	T	T	.	0.83	*	*	.	0.20	0.57
Cys	295	T	T	.	1.26	*	*	.	0.20	0.50
Asn	296	T	T	.	2.18	*	*	.	0.20	0.61
Trp	297	T	T	.	1.37	*	*	.	0.65	1.38
Gln	298	T	.	.	1.37	*	.	.	0.45	2.23
Arg	299	T	.	.	2.07	*	.	.	1.05	2.23
Arg	300	T	.	.	2.52	*	*	F	1.20	3.67
Phe	301	T	.	.	2.22	*	*	F	1.84	3.28
Asn	302	T	.	.	2.51	*	*	F	2.18	2.24
Gln	303	T	C	2.62	*	.	F	2.52	1.91
Pro	304	T	C	2.48	*	.	F	2.86	4.33
Ser	305	T	T	.	2.16	*	*	F	3.40	3.66
Asp	306	T	T	.	2.86	*	.	F	3.06	3.27

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.34-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Arg	307	C	2.82	*	.	F	2.32	3.66
His	308	C	2.58	*	.	F	1.98	3.72
Pro	309	C	2.79	*	.	F	1.64	3.49
Glu	310	T	.	.	2.78	*	.	F	1.50	2.97
His	311	A	T	.	2.19	*	.	F	1.00	3.15
Tyr	312	A	T	.	1.19	*	.	F	1.00	2.06
Asp	313	A	T	.	0.41	.	.	F	0.85	0.83
Thr	314	A	T	.	-0.19	.	.	.	-0.20	0.51
Ala	315	A	.	.	B	.	.	.	-0.50	*	.	.	-0.60	0.27
Ile	316	.	.	B	B	.	.	.	-0.36	*	.	.	-0.60	0.23
Leu	317	.	.	B	B	.	.	.	-0.11	.	.	.	-0.60	0.31
Leu	318	.	.	B	B	.	.	.	-0.11	.	*	.	-0.60	0.53
Thr	319	.	.	B	B	.	.	.	-0.50	.	.	F	0.00	1.23
Arg	320	.	.	B	B	.	.	.	-0.58	.	*	F	-0.08	1.29
Gln	321	.	.	.	B	T	.	.	-0.03	.	*	F	0.69	0.84
Asn	322	T	T	.	0.78	.	*	F	1.31	0.57
Phe	323	T	T	.	1.59	.	.	.	1.98	0.51
Cys	324	T	T	.	1.56	.	*	.	2.20	0.51
Gly	325	T	T	.	0.63	.	*	F	1.53	0.31
Gln	326	T	.	.	-0.03	.	.	F	1.11	0.30
Glu	327	T	.	.	-0.03	.	.	F	0.89	0.30
Gly	328	T	.	.	0.36	.	.	F	1.27	0.50

5

10

15

20

-31.35-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Leu	329	.	.	B	0.21	.	.	F	0.65	0.42
Cys	330	.	.	B	0.21	.	.	.	0.50	0.20
Asp	331	.	.	B	.	.	T	.	-0.64	.	.	.	0.10	0.20
Thr	332	.	.	B	.	.	T	.	-1.23	*	.	.	-0.20	0.18
Leu	333	.	.	B	.	.	T	.	-0.89	.	.	.	0.10	0.34
Gly	334	.	.	B	.	.	T	.	-0.97	.	.	.	0.70	0.34
Val	335	.	.	B	-0.64	.	.	.	-0.40	0.16
Ala	336	.	.	B	-0.96	.	.	.	-0.10	0.20
Asp	337	.	.	B	.	.	T	.	-1.53	.	.	.	0.10	0.29
Ile	338	.	.	B	.	.	T	.	-1.39	.	.	.	-0.20	0.27
Gly	339	.	.	B	.	.	T	.	-1.04	*	.	.	0.10	0.14
Thr	340	.	.	B	.	.	T	.	-0.40	.	.	.	0.70	0.14
Ile	341	.	.	B	0.19	.	.	.	0.24	0.32
Cys	342	.	.	B	0.23	.	.	.	1.18	0.52
Asp	343	.	.	B	.	.	T	.	0.82	*	.	F	1.87	0.72
Pro	344	T	T	.	0.50	.	.	F	3.06	1.37
Asn	345	T	T	.	0.51	.	.	F	3.40	1.37
Lys	346	T	T	.	0.54	*	.	F	3.06	1.10
Ser	347	.	.	.	B	T	.	.	0.32	.	.	F	1.87	0.53
Cys	348	.	.	B	B	.	.	.	0.32	*	.	.	0.38	0.23
Ser	349	.	.	B	B	.	.	.	0.53	*	.	.	0.64	0.20
Val	350	.	.	B	B	.	.	.	0.53	*	.	.	0.30	0.25

5

10

15

20

-31.36-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ile	351	.	.	B	B	.	.	.	0.14	*	.	.	0.60	0.80
Glu	352	A	.	.	B	.	.	.	-0.37	.	.	.	0.60	0.59
Asp	353	A	A	0.30	.	.	F	0.75	0.66
Glu	354	A	A	0.01	*	.	F	0.90	1.62
Gly	355	A	A	0.28	*	.	F	0.75	0.95
Leu	356	A	A	1.13	*	.	.	0.30	0.57
Gln	357	A	A	0.82	*	.	.	-0.30	0.45
Ala	358	A	A	0.01	*	.	.	-0.60	0.66
Ala	359	A	A	-0.58	*	.	.	-0.60	0.66
His	360	A	A	-0.27	*	.	.	-0.60	0.38
Thr	361	A	A	0.54	*	.	.	-0.60	0.52
Leu	362	A	A	-0.27	*	.	.	-0.30	0.88
Ala	363	A	A	-0.02	*	.	.	-0.30	0.54
His	364	A	A	0.53	*	.	.	-0.30	0.37
Glu	365	A	A	-0.29	*	.	.	-0.30	0.61
Leu	366	A	A	.	B	.	.	.	-0.79	*	.	.	-0.30	0.45
Gly	367	A	A	.	B	.	.	.	-0.28	*	.	.	-0.60	0.27
His	368	A	A	.	B	.	.	.	-0.29	*	.	.	-0.30	0.21
Val	369	A	A	.	B	.	.	.	-0.47	*	.	.	-0.60	0.25
Leu	370	.	A	B	B	.	.	.	-0.50	*	.	.	-0.26	0.39
Ser	371	.	A	B	B	.	.	.	0.31	*	.	.	0.08	0.39
Met	372	.	.	B	0.66	.	.	.	0.92	0.88

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.37-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Pro	373	T	.	.	0.39	*	.	.	2.41	1.78
His	374	T	T	.	1.29	*	.	F	3.40	1.78
Asp	375	T	T	.	1.89	.	.	F	3.06	3.61
Asp	376	T	T	.	1.52	.	.	F	2.89	3.61
Ser	377	T	T	.	1.81	*	*	F	2.72	1.42
Lys	378	.	.	B	.	.	T	.	2.13	*	*	F	2.15	1.23
Pro	379	T	T	.	1.36	*	*	F	2.38	1.44
Cys	380	.	.	B	.	.	T	.	0.66	*	*	F	1.70	0.89
Thr	381	.	.	B	.	.	T	.	0.31	*	*	F	1.53	0.38
Arg	382	.	.	B	B	.	.	.	0.40	*	*	F	0.36	0.25
Leu	383	.	.	B	B	.	.	.	-0.24	*	*	.	0.04	0.71
Phe	384	.	.	B	B	.	.	.	-0.38	*	.	.	-0.43	0.49
Gly	385	.	.	.	B	.	.	C	0.33	*	.	F	0.05	0.25
Pro	386	T	C	0.61	*	*	F	0.45	0.59
Met	387	T	T	.	0.47	*	*	F	0.65	0.93
Gly	388	A	T	.	0.42	.	.	F	1.00	1.29
Lys	389	A	T	.	0.52	.	.	.	0.10	0.62
His	390	A	A	0.28	.	.	.	-0.30	0.62
His	391	A	A	0.28	.	*	.	-0.30	0.63
Val	392	.	A	B	0.07	.	.	.	-0.30	0.49
Met	393	A	A	-0.29	.	*	.	-0.60	0.30
Ala	394	A	A	-1.19	.	*	.	-0.60	0.19

5

20

15

20

SUBSTITUTE SHEET (RULE 26)

-31.38-

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni.. Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Pro	395	A	A	-1.19	.	*	.	-0.60	0.19
Leu	396	A	A	-1.97	.	*	.	-0.60	0.26
Phe	397	A	A	-1.11	*	*	.	-0.60	0.21
Val	398	A	A	-0.51	*	.	.	-0.60	0.22
His	399	.	A	B	-0.23	*	*	.	-0.60	0.46
Leu	400	.	A	B	-0.83	*	*	.	-0.60	0.77
Asn	401	.	A	.	.	T	.	.	-0.23	*	*	F	-0.05	0.85
Gln	402	.	A	.	.	T	.	.	0.18	.	*	F	-0.05	0.97
Thr	403	.	A	.	.	T	.	.	0.73	.	*	F	0.10	1.24
Leu	404	.	A	C	0.56	.	*	F	-0.10	1.03
Pro	405	T	.	.	0.70	.	.	.	0.00	0.92
Trp	406	T	.	.	0.40	.	.	.	0.00	0.34
Ser	407	T	C	-0.19	.	.	.	0.00	0.55
Pro	408	T	T	.	-0.48	.	.	.	0.20	0.36
Cys	409	T	T	.	0.09	.	.	.	0.20	0.34
Ser	410	.	.	B	.	.	T	.	-0.51	.	.	.	-0.20	0.40
Ala	411	.	A	B	-0.53	.	.	.	-0.60	0.21
Met	412	.	A	B	-0.23	.	.	.	-0.60	0.57
Tyr	413	.	A	B	-0.83	.	.	.	-0.60	0.74
Leu	414	.	A	B	-0.98	*	.	.	-0.60	0.60
Thr	415	.	A	B	-0.68	*	.	.	-0.60	0.50
Glu	416	A	A	-0.43	*	.	.	-0.30	0.54

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.39-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Leu	417	A	A	-0.18	*	.	F	0.76	0.64
Leu	418	A	T	.	0.03	*	.	F	1.47	0.44
Asp	419	T	T	.	0.50	*	.	F	2.18	0.35
Gly	420	T	T	.	0.81	.	.	F	1.89	0.42
Gly	421	T	T	.	0.14	.	.	F	3.10	0.84
His	422	T	T	.	0.14	.	.	F	2.79	0.27
Gly	423	T	T	.	0.14	.	.	F	1.58	0.23
Asp	424	.	.	B	.	.	T	.	0.14	.	*	.	0.72	0.19
Cys	425	.	.	B	.	.	T	.	-0.10	.	*	.	1.01	0.23
Leu	426	.	.	B	0.03	.	*	.	0.50	0.24
Leu	427	.	.	B	-0.28	.	*	.	0.50	0.22
Asp	428	.	.	B	-0.52	*	*	.	-0.10	0.40
Ala	429	.	.	B	.	.	T	.	-1.11	*	.	F	0.25	0.49
Pro	430	A	T	.	-1.26	.	.	F	0.25	0.60
Gly	431	T	T	.	-0.66	.	.	F	0.65	0.30
Ala	432	.	.	B	.	.	T	.	-0.66	.	.	.	-0.20	0.46
Ala	433	.	.	B	-0.87	.	.	.	-0.40	0.24
Leu	434	.	.	B	-0.59	.	.	.	-0.40	0.38
Pro	435	.	.	B	-0.72	.	.	.	-0.40	0.54
Leu	436	.	.	B	.	.	T	.	-1.19	.	.	.	-0.20	0.53
Pro	437	.	.	B	.	.	T	.	-0.81	.	.	F	0.00	0.53
Thr	438	T	T	.	-0.57	.	*	F	0.45	0.53

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.40-

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni.. Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen-... Alpha	Eisen-... Beta	Karpl-... Flexi...	James-... Antig...	Emini Surfa...
Gly	439	T	C	0.36	.	*	F	0.30	0.64
Leu	440	T	C	-0.03	.	*	F	1.25	0.81
Pro	441	.	.	B	.	.	T	.	0.19	.	*	F	0.50	0.55
Gly	442	.	.	B	.	.	T	.	-0.41	.	*	F	0.45	0.57
Arg	443	.	.	B	.	.	T	.	-0.34	.	*	.	0.25	0.57
Met	444	.	A	B	0.00	.	*	.	-0.50	0.57
Ala	445	.	A	B	0.00	*	*	.	-0.10	1.00
Leu	446	.	A	B	0.21	*	.	.	-0.60	0.42
Tyr	447	.	A	B	0.56	*	*	.	-0.60	0.71
Gln	448	.	A	B	0.44	*	*	.	-0.45	1.22
Leu	449	A	A	0.38	*	*	.	-0.15	2.57
Asp	450	A	A	1.08	*	*	F	-0.15	0.88
Gln	451	.	A	B	1.89	*	*	F	0.75	0.99
Gln	452	.	A	B	1.24	*	*	F	0.90	2.09
Cys	453	.	A	B	0.54	*	*	F	0.75	0.88
Arg	454	.	A	B	1.01	*	*	.	-0.30	0.44
Gln	455	.	A	B	0.80	*	*	.	-0.30	0.25
Ile	456	.	A	B	0.80	*	.	.	-0.30	0.72
Phe	457	.	A	.	.	T	.	.	0.10	*	*	.	0.70	0.62
Gly	458	T	C	0.88	*	*	.	0.00	0.31
Pro	459	T	T	.	0.73	*	*	F	0.65	0.86
Asp	460	T	T	.	0.07	*	*	F	1.40	1.35

5

10

15

20

-31.41-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Phe	461	T	T	.	0.74	*	*	.	1.35	0.73
Arg	462	T	.	.	1.44	*	*	.	1.40	0.73
His	463	T	.	.	1.48	*	*	.	1.65	0.71
Cys	464	T	C	1.39	*	*	.	1.45	1.18
Pro	465	T	T	.	0.80	*	.	F	2.50	0.80
Asn	466	T	T	.	1.50	*	*	F	1.65	0.60
Thr	467	T	T	.	1.39	*	*	F	1.55	1.93
Ser	468	.	A	.	.	T	.	.	0.57	*	.	F	1.50	2.08
Ala	469	.	A	.	.	T	.	.	0.57	.	.	F	1.10	0.96
Gln	470	.	A	B	0.19	.	.	F	0.45	0.36
Asp	471	.	A	B	0.19	*	*	F	0.45	0.27
Val	472	.	A	B	-0.31	*	.	.	-0.30	0.46
Cys	473	.	A	B	-0.30	*	.	.	-0.30	0.22
Ala	474	.	A	B	-0.38	*	*	.	-0.60	0.14
Gln	475	.	A	B	-0.41	.	*	.	-0.60	0.10
Leu	476	.	A	B	-0.72	*	*	.	-0.60	0.25
Trp	477	.	A	B	0.13	.	*	.	-0.60	0.36
Cys	478	.	A	B	0.46	.	.	.	-0.26	0.35
His	479	T	T	.	0.46	.	.	.	0.88	0.42
Thr	480	T	T	.	0.46	.	*	.	1.52	0.40
Asp	481	T	T	.	1.06	.	.	F	3.06	1.30
Gly	482	T	T	.	0.53	.	.	F	3.40	1.48

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.42-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ala	483	T	.	C	0.53	*	.	F	2.41	0.85
Glu	484	A	0.53	*	.	F	1.67	0.27
Pro	485	A	0.53	.	.	F	0.73	0.37
Leu	486	A	0.58	*	.	.	0.24	0.53
Cys	487	A	0.92	.	.	.	0.78	0.62
His	488	.	.	B	1.17	.	.	F	0.61	0.64
Thr	489	T	T	.	0.87	.	.	F	1.49	0.77
Lys	490	T	T	.	0.27	.	.	F	2.52	1.92
Asn	491	T	T	.	0.87	.	.	F	2.80	1.16
Gly	492	T	T	.	1.24	.	.	F	2.52	1.25
Ser	493	C	0.69	.	.	F	1.09	0.66
Leu	494	C	1.00	.	.	.	0.36	0.41
Pro	495	.	.	B	0.61	.	.	.	0.18	0.69
Trp	496	T	T	.	0.30	.	.	.	0.50	0.51
Ala	497	.	.	B	.	.	T	.	0.43	.	.	.	0.05	0.90
Asp	498	T	T	.	0.07	.	.	F	1.15	0.90
Gly	499	T	T	.	0.53	.	.	F	1.40	0.46
Thr	500	T	C	0.53	.	.	F	2.05	0.45
Pro	501	T	T	.	0.48	.	.	F	2.50	0.42
Cys	502	T	T	.	1.03	.	*	F	1.65	0.42
Gly	503	T	C	0.22	.	.	F	1.20	0.39
Pro	504	T	.	.	-0.10	.	.	F	0.65	0.21

5

10

15

20

-31.43-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Gly	505	T	.	.	-0.09	.	.	.	0.25	0.21
His	506	.	.	B	0.12	.	.	.	-0.40	0.28
Leu	507	.	.	B	0.44	.	.	.	0.50	0.32
Cys	508	.	.	B	.	.	T	.	0.49	.	*	.	0.91	0.32
Ser	509	T	T	.	0.03	.	.	F	1.67	0.31
Glu	510	T	T	.	-0.43	.	.	F	1.28	0.20
Gly	511	T	T	.	-0.61	*	.	F	1.49	0.31
Ser	512	T	.	.	0.20	*	.	F	2.10	0.36
Cys	513	.	A	C	0.87	.	.	F	1.79	0.36
Leu	514	.	A	C	1.17	.	.	F	1.58	0.63
Pro	515	A	A	0.31	.	.	F	1.17	0.81
Glu	516	A	A	0.66	*	.	F	1.11	1.13
Glu	517	A	A	1.07	*	.	F	0.90	2.37
Glu	518	A	A	1.52	.	.	F	0.90	3.00
Val	519	A	A	2.38	.	.	F	0.90	2.68
Glu	520	A	A	2.38	*	.	F	0.90	3.09
Arg	521	A	T	.	1.52	*	.	F	1.30	2.76
Pro	522	A	T	.	0.67	*	*	F	1.30	2.76
Lys	523	A	T	.	0.67	*	*	F	1.30	1.18
Pro	524	.	.	B	.	.	T	.	1.18	*	*	F	1.30	1.01
Val	525	.	.	B	0.83	*	*	F	0.65	0.65
Val	526	.	.	B	0.43	.	*	F	0.65	0.32

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.44-

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni.. Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Asp	527	.	.	B	.	.	T	.	0.06	*	.	F	-0.05	0.22
Gly	528	.	.	B	.	.	T	.	-0.20	*	.	F	-0.05	0.30
Gly	529	T	T	.	-0.28	.	.	F	0.65	0.62
Trp	530	T	C	0.23	.	.	.	0.00	0.39
Ala	531	C	0.88	.	.	.	-0.20	0.39
Pro	532	T	.	.	0.59	.	.	.	0.00	0.61
Trp	533	T	.	.	0.59	.	.	.	0.00	0.61
Gly	534	T	C	0.93	.	.	.	0.00	0.59
Pro	535	T	T	.	0.56	.	.	F	0.35	0.66
Trp	536	T	T	.	0.84	*	.	F	0.66	0.34
Gly	537	T	C	1.17	*	.	F	1.07	0.46
Glu	538	T	.	.	1.14	*	.	F	1.98	0.58
Cys	539	T	T	.	0.82	*	.	F	2.49	0.80
Ser	540	T	T	.	0.69	*	.	F	3.10	0.43
Arg	541	T	T	.	0.63	*	.	F	2.79	0.25
Thr	542	T	T	.	0.63	*	.	F	2.18	0.46
Cys	543	T	T	.	-0.22	*	.	F	1.87	0.34
Gly	544	T	T	.	0.44	*	.	F	1.56	0.13
Gly	545	T	T	.	0.04	*	*	F	0.65	0.15
Gly	546	T	T	.	-0.37	*	*	F	0.35	0.25
Val	547	.	.	B	B	.	.	.	-0.09	*	*	.	-0.60	0.33
Gln	548	.	.	B	B	.	.	.	0.69	*	*	.	-0.60	0.46

5

10

15

20

-31.45-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Phe	549	.	.	B	B	.	.	.	1.03	*	*	.	-0.30	0.91
Ser	550	.	.	B	B	.	.	.	0.71	*	*	.	0.79	2.13
His	551	.	.	B~	1.10	*	*	.	1.18	0.66
Arg	552	T	.	.	1.96	*	*	.	2.37	1.52
Glu	553	T	.	.	1.74	*	*	F	2.86	1.89
Cys	554	T	T	.	2.44	*	.	F	3.40	2.15
Lys	555	T	T	.	2.53	*	.	F	3.06	1.90
Asp	556	T	C	2.57	*	.	F	2.52	1.70
Pro	557	T	C	2.46	*	.	F	2.52	5.49
Glu	558	C	2.11	.	.	F	2.32	4.41
Pro	559	T	T	.	2.43	.	*	F	2.72	2.62
Gln	560	T	T	.	2.50	.	*	F	2.76	1.67
Asn	561	T	T	.	2.26	*	*	F	3.40	1.89
Gly	562	T	T	.	1.80	*	*	F	2.76	1.92
Gly	563	T	T	.	0.99	*	*	F	2.27	0.59
Arg	564	.	.	B	.	.	T	.	0.86	*	.	F	0.93	0.30
Tyr	565	.	.	B	.	.	T	.	0.97	.	.	.	0.44	0.30
Cys	566	.	.	B	.	.	T	.	1.08	.	.	.	1.00	0.60
Leu	567	.	.	B	0.83	.	*	.	1.40	0.60
Gly	568	.	.	B	1.22	.	*	F	1.55	0.39
Arg	569	.	.	B	0.87	.	*	F	2.30	1.45
Arg	570	T	.	.	1.11	*	*	F	3.00	2.75

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.46-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ala	571	T	.	.	1.48	*	*	F	2.70	4.82
Lys	572	T	.	.	1.62	*	*	F	2.40	3.30
Tyr	573	T	T	.	1.93	*	.	F	1.85	0.90
Gln	574	T	T	.	1.51	.	.	F	1.10	1.22
Ser	575	T	T	.	1.40	.	*	.	0.50	0.88
Cys	576	T	T	.	1.99	.	.	.	0.50	0.97
His	577	.	A	B	1.28	.	.	.	0.60	0.97
Thr	578	.	A	.	.	T	.	.	1.31	.	.	F	0.85	0.39
Glu	579	.	A	.	.	T	.	.	1.10	.	.	F	1.00	1.12
Glu	580	.	A	.	.	T	.	.	1.40	.	.	F	1.64	1.27
Cys	581	.	A	B	1.72	.	*	F	1.58	1.47
Pro	582	T	C	1.80	.	*	F	2.37	0.84
Pro	583	T	T	.	1.81	*	.	F	2.91	0.97
Asp	584	T	T	.	1.11	*	.	F	3.40	2.43
Gly	585	T	T	.	1.22	*	.	F	3.06	1.36
Lys	586	.	A	.	.	T	.	.	1.89	*	.	F	2.32	1.72
Ser	587	A	A	2.10	.	.	F	1.58	1.79
Phe	588	A	A	2.31	.	.	F	1.24	3.13
Arg	589	A	A	1.64	.	.	F	0.90	2.71
Glu	590	A	A	1.99	.	.	F	0.60	1.08
Gln	591	A	A	1.99	.	.	F	0.90	2.17
Gln	592	A	A	2.04	.	*	F	0.90	2.21

5

10

15

20

-31.47-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Cys	593	A	A	2.74	.	*	F	1.15	2.00
Glu	594	.	A	.	.	T	.	.	2.04	.	.	F	1.50	1.86
Lys	595	.	A	.	.	T	.	.	1.80	.	.	F	1.75	1.08
Tyr	596	T	.	.	1.80	.	.	.	2.05	3.17
Asn	597	T	T	.	1.56	.	.	.	2.50	2.94
Ala	598	T	T	.	1.91	.	.	.	1.35	2.30
Tyr	599	.	.	B	.	.	T	.	1.91	.	.	.	0.70	2.12
Asn	600	.	.	B	.	.	T	.	1.27	.	*	.	0.75	2.20
Tyr	601	.	.	B	1.51	.	.	.	0.25	2.16
Thr	602	.	.	B	1.17	.	*	F	0.70	2.30
Asp	603	.	.	B	.	.	T	.	1.76	.	*	F	1.75	1.42
Met	604	.	.	B	.	.	T	.	1.19	.	*	F	2.00	1.45
Asp	605	T	T	.	0.38	*	.	F	2.50	0.83
Gly	606	.	.	B	.	.	T	.	0.62	*	*	F	1.85	0.41
Asn	607	.	.	B	B	.	.	.	0.64	*	*	F	0.60	0.72
Leu	608	A	.	.	B	.	.	.	-0.21	*	*	.	-0.10	0.45
Leu	609	.	.	B	B	.	.	.	0.18	*	*	.	-0.35	0.34
Gln	610	.	.	B	B	.	.	.	0.22	*	.	.	-0.60	0.33
Trp	611	.	.	B	B	.	.	.	0.32	*	.	.	-0.60	0.79
Val	612	.	.	B	B	.	.	.	-0.27	*	.	.	-0.45	1.50
Pro	613	.	.	B	.	.	T	.	0.20	*	.	.	-0.20	0.88

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.48-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Lys	614	.	.	B	.	.	T	.	0.16	*	*	.	-0.20	0.82
Tyr	615	.	.	B	.	.	T	.	-0.14	.	.	.	0.10	0.82
Ala	616	T	T	.	-0.07	*	*	.	0.50	0.71
Gly	617	T	.	.	0.90	*	.	.	0.64	0.55
Val	618	.	.	B	1.11	.	*	.	0.58	0.69
Ser	619	.	.	B	.	.	T	.	1.18	.	*	F	2.32	1.14
Pro	620	.	.	B	.	.	T	.	0.76	.	*	F	2.66	2.26
Arg	621	T	T	.	1.39	.	*	F	3.40	1.63
Asp	622	T	T	.	0.92	.	*	F	3.06	2.43
Arg	623	.	A	.	.	T	.	.	1.08	.	*	F	2.32	1.30
Cys	624	.	A	B	0.71	*	*	F	1.43	0.57
Lys	625	.	A	B	1.03	*	*	.	0.64	0.18
Leu	626	.	A	B	0.33	*	*	.	0.30	0.18
Phe	627	.	A	B	0.44	.	*	.	0.04	0.35
Cys	628	.	A	B	-0.01	.	*	.	0.98	0.34
Arg	629	.	A	B	0.77	*	*	.	1.32	0.41
Ala	630	A	T	.	0.42	*	*	.	2.36	0.92
Arg	631	T	T	.	1.23	.	*	F	3.40	2.31
Gly	632	T	T	.	1.23	.	*	F	3.06	2.04
Arg	633	T	T	.	1.94	.	*	F	2.72	1.75
Ser	634	A	A	0.98	*	*	F	1.58	1.79

5

10

15

20

-31.49-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Glu	635	A	A	0.87	*	*	F	1.24	1.34
Phe	636	A	A	0.76	*	*	F	0.45	0.59
Lys	637	A	A	0.51	*	*	.	0.30	0.77
Val	638	A	A	0.44	*	*	.	0.30	0.45
Phe	639	A	A	-0.11	.	.	.	0.45	1.03
Glu	640	A	A	-1.00	*	.	.	0.30	0.38
Ala	641	A	.	.	B	.	.	.	-0.30	*	.	.	-0.30	0.36
Lys	642	A	.	.	B	.	.	.	-0.69	.	.	.	0.30	0.70
Val	643	A	.	.	B	.	.	.	-0.14	.	.	.	0.60	0.40
Ile	644	A	.	.	B	.	.	.	-0.26	.	*	F	0.45	0.57
Asp	645	.	.	B	B	.	.	.	-0.92	.	.	F	0.45	0.23
Gly	646	.	.	B	B	.	.	.	-0.68	*	.	F	-0.45	0.17
Thr	647	.	.	B	B	.	.	.	-0.93	*	.	F	-0.15	0.24
Leu	648	.	.	.	B	.	.	C	-0.08	.	.	F	0.05	0.22
Cys	649	.	.	.	B	T	.	.	0.50	*	*	.	0.10	0.39
Gly	650	T	C	-0.31	.	.	F	0.45	0.39
Pro	651	T	T	.	-0.56	.	.	F	0.65	0.39
Glu	652	A	T	.	-1.13	.	.	F	0.25	0.73
Thr	653	A	T	.	-0.99	.	.	F	0.25	0.52
Leu	654	A	.	.	B	.	.	.	-1.18	*	*	.	-0.30	0.18
Ala	655	.	.	B	B	.	.	.	-0.72	*	*	.	-0.60	0.08
Ile	656	.	.	B	B	.	.	.	-0.86	.	*	.	-0.60	0.10

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.50-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Cys	657	.	.	B	B	.	.	.	-0.86	.	*	.	-0.60	0.13
Val	658	A	.	.	B	.	.	.	-1.21	.	*	.	-0.30	0.21
Arg	659	.	.	B	B	.	.	.	-1.26	.	*	.	-0.30	0.16
Gly	660	.	.	.	B	T	T	.	-0.62	.	*	F	0.25	0.23
Gln	661	.	.	B	B	.	.	.	-0.32	.	*	F	0.45	0.61
Cys	662	.	.	B	B	.	.	.	0.00	.	*	.	0.30	0.32
Val	663	.	.	B	B	.	.	.	0.19	.	*	.	0.30	0.32
Lys	664	.	.	B	.	.	T	.	0.08	.	*	.	0.10	0.10
Ala	665	.	.	B	.	.	T	.	0.39	*	.	.	0.70	0.30
Gly	666	.	.	B	.	.	T	.	-0.47	*	.	.	0.70	0.56
Cys	667	.	.	B	.	.	T	.	-0.66	*	*	.	0.70	0.21
Asp	668	.	.	B	B	.	.	.	0.20	*	*	.	-0.30	0.15
His	669	.	.	B	B	.	.	.	-0.14	*	.	.	0.30	0.26
Val	670	.	.	B	B	.	.	.	0.23	*	.	.	0.30	0.64
Val	671	.	.	B	B	.	.	.	0.69	*	.	.	0.64	0.59
Asp	672	.	.	B	B	.	.	.	1.40	*	.	F	1.13	0.86
Ser	673	.	.	B	.	.	T	.	0.59	*	.	F	2.32	2.31
Pro	674	A	T	.	0.62	*	.	F	2.66	2.56
Arg	675	T	T	.	1.52	*	.	F	3.40	2.56
Lys	676	T	T	.	1.71	*	.	F	3.06	3.82
Leu	677	T	.	.	1.37	*	.	F	2.52	1.33
Asp	678	T	T	.	0.81	*	.	F	2.23	0.67

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.51-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Lys	679	.	.	B	.	.	T	.	0.36	*	.	F	1.49	0.25
Cys	680	.	.	B	.	.	T	.	-0.10	*	.	.	0.70	0.16
Gly	681	.	.	B	.	.	T	.	-0.49	*	.	.	0.70	0.10
Val	682	.	.	B	0.37	*	.	.	-0.10	0.05
Cys	683	.	.	B	.	.	T	.	0.02	.	.	.	0.10	0.18
Gly	684	T	T	.	-0.02	.	.	F	1.59	0.18
Gly	685	T	T	.	0.34	.	.	F	1.93	0.38
Lys	686	T	T	.	0.02	.	.	F	2.27	0.96
Gly	687	T	.	.	0.99	.	.	F	2.41	0.52
Asn	688	T	T	.	1.70	.	.	F	3.40	1.03
Ser	689	.	.	B	.	.	T	.	1.19	.	.	F	2.66	1.03
Cys	690	.	.	B	.	.	T	.	1.23	.	.	F	2.34	0.77
Arg	691	.	.	B	.	.	T	.	0.84	.	.	F	2.17	0.64
Lys	692	.	.	B	0.89	*	.	F	1.80	0.47
Val	693	.	.	B	.	.	T	.	0.08	*	.	F	1.98	1.18
Ser	694	.	.	B	.	.	T	.	0.07	*	.	F	1.70	0.50
Gly	695	.	.	B	.	.	T	.	0.52	*	.	F	0.93	0.36
Ser	696	.	.	B	.	.	T	.	0.10	*	.	F	0.46	0.75
Leu	697	.	.	B	0.06	.	*	F	0.39	0.81
Thr	698	.	.	B	0.67	.	.	F	0.37	1.31
Pro	699	.	.	B	.	.	T	.	0.62	.	.	F	0.10	1.53
Thr	700	T	T	.	0.72	.	.	F	0.50	1.84

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.52-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Asn	701	.	.	B	.	.	T	.	1.02	.	.	F	0.10	2.00
Tyr	702	T	T	.	1.83	*	.	.	0.35	2.08
Gly	703	T	T	.	1.26	*	.	.	0.65	2.41
Tyr	704	T	T	.	0.61	*	.	.	0.35	1.05
Asn	705	.	.	B	.	.	T	.	0.61	*	.	.	-0.20	0.50
Asp	706	.	.	B	.	.	T	.	-0.28	*	.	.	0.10	0.72
Ile	707	.	.	B	B	.	.	.	-0.24	*	.	.	-0.60	0.32
Val	708	.	.	B	B	.	.	.	-0.49	.	.	.	-0.30	0.31
Thr	709	.	.	B	B	.	.	.	-0.59	*	.	.	-0.60	0.19
Ile	710	.	.	B	B	.	.	.	-1.18	.	.	.	-0.60	0.27
Pro	711	.	.	B	.	.	T	.	-1.49	*	.	.	-0.20	0.36
Ala	712	.	.	B	.	.	T	.	-0.60	*	.	.	-0.20	0.36
Gly	713	T	C	-0.63	.	*	.	0.00	0.83
Ala	714	T	C	-0.32	.	*	F	0.15	0.38
Thr	715	.	.	B	B	.	.	.	-0.29	.	*	F	0.45	0.62
Asn	716	.	.	B	B	.	.	.	-0.03	.	*	F	-0.15	0.47
Ile	717	.	.	B	B	.	.	.	0.56	.	*	F	0.45	0.92
Asp	718	.	.	B	B	.	.	.	1.01	.	*	F	0.60	1.11
Val	719	.	.	B	B	.	.	.	1.30	.	*	F	0.90	1.35
Lys	720	.	.	B	B	.	.	.	1.58	.	*	F	0.90	2.58
Gln	721	.	.	B	1.37	.	*	F	1.10	2.10
Arg	722	.	.	B	1.91	.	*	F	1.10	4.38

5

10

15

20

-31.53-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ser	723	C	1.06	*	*	F	1.30	2.17
	724	T	C	1.91	*	*	F	1.05	0.93
His														
Pro	725	T	C	1.87	.	*	F	1.33	0.82
Gly	726	T	T	.	1.87	*	*	F	1.21	0.99
Val	727	.	.	B	.	.	T	.	1.41	*	*	F	1.84	1.21
Gln	728	.	.	B	1.71	.	*	F	1.77	0.77
Asn	729	.	.	B	.	T	T	.	1.50	*	.	F	2.80	1.26
Asp	730	T	T	.	0.90	*	.	F	1.92	2.66
Gly	731	T	T	.	0.66	.	.	F	1.64	1.27
Asn	732	.	.	B	.	.	T	.	0.70	.	*	F	0.81	0.80
Tyr	733	.	A	B	0.74	.	.	.	-0.32	0.39
Leu	734	.	A	B	0.43	*	.	.	-0.60	0.79
Ala	735	.	A	B	-0.16	*	.	.	-0.60	0.71
Leu	736	.	A	B	0.19	.	.	.	-0.40	0.46
Lys	737	.	A	B	-0.16	.	.	F	0.85	0.93
Thr	738	.	.	B	.	.	T	.	0.09	.	.	F	1.45	0.91
Ala	739	A	T	.	0.66	.	.	F	2.10	1.91
Asp	740	.	.	B	.	.	T	.	0.43	.	.	F	2.00	1.50
Gly	741	.	.	B	.	.	T	.	0.43	.	*	F	1.05	0.86
Gln	742	.	.	B	0.39	.	*	F	0.35	0.70
Tyr	743	.	.	B	0.36	.	*	.	0.30	0.67

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.54-

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni.. Turn	Chou-... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emni Surfa...
Leu	744	.	.	B	0.94	.	*	.	-0.20	0.67
Leu	745	.	.	B	0.13	.	*	.	-0.40	0.63
Asn	746	.	.	B	.	.	T	.	-0.11	.	*	F	-0.05	0.33
Gly	747	T	T	.	-1.00	.	*	F	0.35	0.40
Asn	748	T	C	-1.06	.	*	.	0.00	0.34
Leu	749	T	C	-0.83	.	*	.	0.00	0.29
Ala	750	A	A	B	-0.91	.	*	.	-0.60	0.29
Ile	751	.	A	B	-0.91	*	*	.	-0.60	0.13
Ser	752	.	A	B	-0.57	*	.	.	-0.60	0.27
Ala	753	A	A	-0.57	*	*	.	-0.30	0.46
Ile	754	A	A	-0.64	*	.	.	0.45	1.09
Glu	755	A	A	-0.87	*	.	F	0.45	0.57
Gln	756	A	.	.	B	.	.	.	-0.83	.	*	F	0.45	0.47
Asp	757	A	.	.	B	.	.	.	-0.49	.	*	F	-0.15	0.49
Ile	758	A	.	.	B	.	.	.	-0.24	.	*	.	0.60	0.57
Leu	759	A	.	.	B	.	.	.	0.33	.	*	.	0.30	0.33
Val	760	A	.	.	B	.	.	.	-0.56	.	*	.	0.30	0.28
Lys	761	A	.	.	B	.	.	.	-1.37	.	*	F	-0.45	0.28
Gly	762	.	.	B	B	.	.	.	-1.32	.	*	F	-0.45	0.28
Thr	763	.	.	B	B	.	.	.	-0.68	.	*	F	0.45	0.76
Ile	764	.	.	B	B	.	.	.	-0.17	.	.	F	-0.15	0.59
Leu	765	.	.	B	B	.	.	.	0.34	.	*	.	-0.60	0.80

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.55-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Lys	766	.	.	B	B	.	.	.	0.00	.	*	F	-0.45	0.55
Tyr	767	.	.	B	.	.	T	.	-0.54	*	*	F	0.40	1.05
Ser	768	T	C	-0.82	*	*	F	0.45	0.89
Gly	769	T	C	-0.24	*	.	F	0.45	0.45
Ser	770	T	C	-0.24	.	*	F	0.15	0.42
Ile	771	.	A	B	-0.29	*	*	.	-0.60	0.26
Ala	772	.	A	B	0.07	*	.	.	-0.30	0.45
Thr	773	.	A	B	-0.44	*	*	.	0.30	0.66
Leu	774	.	A	B	-0.10	*	.	.	-0.30	0.77
Glu	775	A	A	-0.10	*	.	.	0.45	1.32
Arg	776	.	A	B	0.09	.	.	F	0.60	1.23
Leu	777	.	A	.	.	T	.	.	0.79	.	.	F	1.00	1.29
Gln	778	.	A	.	.	T	.	.	0.89	.	.	F	1.30	1.46
Ser	779	.	A	.	.	T	.	.	0.89	.	.	F	1.00	1.15
Phe	780	.	.	B	0.68	*	.	F	0.41	1.15
Arg	781	C	0.57	.	*	F	0.82	1.03
Pro	782	C	1.17	*	.	F	1.63	1.33
Leu	783	T	C	0.36	*	.	F	2.04	2.37
Pro	784	T	C	0.34	*	*	F	2.10	1.00
Glu	785	T	C	0.19	*	*	F	1.29	0.93
Pro	786	.	.	B	.	.	T	.	0.08	*	*	F	0.88	0.84
Leu	787	.	.	B	B	.	.	.	-0.52	.	*	F	0.27	0.94

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.56-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Thr	788	.	.	B	B	.	.	.	-0.52	.	*	.	-0.09	0.45
Val	789	.	.	B	B	.	.	.	-0.62	.	.	.	-0.60	0.24
Gln	790	.	.	B	B	.	.	.	-1.48	.	.	.	-0.60	0.42
Leu	791	.	.	B	B	.	.	.	-1.48	.	.	.	-0.60	0.21
Leu	792	.	.	B	B	.	.	.	-1.01	.	*	.	-0.60	0.45
Thr	793	.	.	B	B	.	.	.	-0.70	.	*	.	-0.60	0.26
Val	794	.	.	B	.	.	T	.	-0.70	*	.	F	0.25	0.54
Pro	795	.	.	B	.	.	T	.	-1.40	*	.	F	0.25	0.48
Gly	796	.	.	B	.	.	T	.	-0.80	*	.	F	-0.05	0.29
Glu	797	.	.	B	.	.	T	.	-0.20	.	*	F	0.25	0.60
Val	798	.	.	B	0.16	.	*	F	0.05	0.60
Phe	799	.	.	B	0.16	.	*	F	1.00	1.22
Pro	800	.	.	B	.	.	T	.	0.41	*	*	F	1.25	0.52
Pro	801	T	T	.	0.51	*	*	F	2.00	1.41
Lys	802	T	T	.	0.20	*	*	F	1.60	2.55
Val	803	.	.	B	.	.	T	.	0.36	.	*	F	2.00	2.38
Lys	804	.	.	B	B	.	.	.	0.36	.	*	F	0.80	1.33
Tyr	805	.	.	B	B	.	.	.	-0.29	.	*	.	0.00	0.58
Thr	806	.	.	B	B	.	.	.	-0.29	.	*	.	-0.20	0.58
Phe	807	.	.	B	B	.	.	.	-0.33	.	*	.	-0.40	0.45
Phe	808	.	.	B	B	.	.	.	0.52	*	*	.	-0.60	0.46
Val	809	.	.	B	.	.	T	.	-0.38	*	*	.	-0.20	0.53

5

10

15

20

-31.57-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Pro	810	.	.	B	.	.	T	.	-0.13	.	*	F	-0.05	0.45
Asn	811	T	T	.	-0.52	.	*	F	1.25	0.88
Asp	812	T	T	.	-0.12	.	*	F	1.40	1.02
Val	813	A	-0.02	*	*	F	0.65	0.89
Asp	814	A	0.83	*	*	.	0.50	0.54
Phe	815	A	0.74	.	*	.	0.80	0.57
Ser	816	A	0.44	.	*	.	0.65	1.02
Met	817	A	0.49	.	*	.	1.40	0.82
Gln	818	A	T	.	1.34	.	*	F	2.20	1.89
Ser	819	T	C	1.46	.	*	F	3.00	2.44
Ser	820	T	C	1.57	.	*	F	2.70	4.84
Lys	821	A	T	.	1.56	.	*	F	2.20	2.82
Glu	822	A	1.84	.	*	F	1.70	3.04
Arg	823	A	.	.	B	.	.	.	1.84	*	*	F	1.20	3.27
Ala	824	A	.	.	B	.	.	.	1.26	*	*	F	0.90	2.63
Thr	825	.	.	B	B	.	.	.	0.67	*	*	F	0.60	1.06
Thr	826	.	.	B	B	.	.	.	0.62	*	*	F	-0.15	0.38
Asn	827	.	.	B	B	.	.	.	0.41	*	*	.	-0.60	0.65
Ile	828	.	.	B	B	.	.	.	-0.51	*	*	.	-0.60	0.70
Ile	829	.	.	B	B	.	.	.	-0.73	*	.	.	-0.60	0.40
Gln	830	.	A	B	-0.46	*	.	.	-0.60	0.21
Pro	831	.	A	B	-0.73	*	.	.	-0.60	0.40

5

10

15

20

-31.58-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Leu	832	.	A	B	-0.73	*	*	.	-0.60	0.57
Leu	833	.	A	B	-0.13	.	.	.	-0.60	0.57
His	834	.	A	B	-0.10	.	*	.	-0.60	0.39
Ala	835	.	A	B	B	.	.	.	-0.91	.	*	.	-0.60	0.35
Gln	836	.	A	B	B	.	.	.	-1.04	.	.	.	-0.60	0.35
Trp	837	.	A	B	B	.	.	.	-0.23	.	.	.	-0.60	0.26
Val	838	.	A	B	B	.	.	.	0.29	.	*	.	-0.60	0.42
Leu	839	.	.	B	.	.	T	.	0.02	*	.	.	-0.20	0.26
Gly	840	T	T	.	0.61	*	.	.	0.45	0.33
Asp	841	T	T	.	-0.06	.	.	F	1.15	0.76
Trp	842	T	T	.	-0.07	.	.	F	2.00	0.50
Ser	843	T	C	0.49	*	.	F	2.05	0.67
Glu	844	T	T	.	0.99	.	.	F	2.50	0.54
Cys	845	T	T	.	0.67	.	.	F	1.65	0.74
Ser	846	T	T	.	0.32	.	.	F	2.00	0.30
Ser	847	T	.	.	0.02	.	.	F	1.55	0.17
Thr	848	T	.	.	-0.02	.	.	F	0.70	0.32
Cys	849	T	.	.	-0.31	.	.	F	0.45	0.24
Gly	850	T	T	.	0.36	*	.	.	0.20	0.18
Ala	851	T	T	.	0.77	.	.	.	0.20	0.22
Gly	852	T	T	.	1.18	.	.	.	0.50	0.81
Trp	853	T	T	.	1.18	*	.	.	1.25	1.60

5

10

15

20

-31.59-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Gln	854	.	.	B	B	.	.	.	0.99	*	.	F	0.60	2.29
Arg	855	.	.	B	B	.	.	.	1.33	*	.	F	0.60	1.72
Arg	856	.	.	B	B	.	.	.	1.26	.	*	F	0.90	2.83
Thr	857	.	.	B	B	.	.	.	1.71	.	.	F	1.05	0.87
Val	858	.	.	B	B	.	.	.	2.00	.	.	.	1.20	0.87
Glu	859	.	.	B	B	.	.	.	1.79	.	.	.	1.50	0.75
Cys	860	T	.	.	1.38	.	*	.	2.40	0.80
Arg	861	T	.	.	0.92	.	.	F	3.00	1.44
Asp	862	T	C	1.23	.	*	F	2.55	0.82
Pro	863	T	T	.	1.50	.	*	F	2.60	2.66
Ser	864	T	T	.	1.20	.	*	F	2.30	1.37
Gly	865	T	T	.	1.28	.	.	F	1.70	1.10
Gln	866	A	0.86	.	*	F	0.05	0.72
Ala	867	.	.	B	0.19	.	*	F	0.05	0.78
Ser	868	.	.	B	0.40	.	*	.	-0.10	0.42
Ala	869	A	0.74	.	*	.	-0.10	0.39
Thr	870	A	T	.	0.50	*	.	.	0.70	0.77
Cys	871	A	T	.	-0.31	*	.	.	0.70	0.58
Asn	872	A	T	.	0.32	*	.	.	0.10	0.48
Lys	873	A	T	.	0.41	.	.	F	0.85	0.66
Ala	874	A	1.00	*	.	F	0.80	1.90
Leu	875	A	1.31	*	.	F	1.10	2.05

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.60-

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni.. Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Lys	876	A	T	.	1.39	.	.	F	1.30	1.71
Pro	877	A	T	.	1.43	.	.	F	1.30	1.71
Glu	878	A	T	.	1.18	.	.	F	1.30	4.14
Asp	879	A	T	.	1.10	.	.	F	1.30	3.20
Ala	880	A	1.91	.	.	F	1.10	1.11
Lys	881	A	T	.	1.57	.	.	F	1.30	1.11
Pro	882	A	T	.	1.78	*	.	F	1.15	0.89
Cys	883	A	T	.	0.97	*	.	F	1.30	1.53
Glu	884	A	T	.	0.30	.	.	F	1.15	0.63
Ser	885	A	A	0.68	*	.	F	-0.15	0.22
Gln	886	.	A	B	-0.18	*	.	F	-0.15	0.63
Leu	887	.	A	B	-0.36	.	.	.	-0.30	0.30
Cys	888	.	A	B	-0.08	.	.	.	-0.60	0.29
Pro	889	.	A	B	-0.47	.	.	.	-0.60	0.21
Leu	890	.	.	B	-0.56	.	.	.	-0.40	0.33

5

10

15

SUBSTITUTE SHEET (RULE 26)

Detailed Description

By screening cDNA libraries with cDNA encoding the anti-angiogenic domain of TSP-1, the present inventors have identified two novel proteins, METH1 and METH2 (also called VEGA-1 and VEGA-2, respectively, for vascular endothelial growth antagonist) which contain the anti-angiogenic domain of TSP-1, a metalloproteinase domain, and a disintegrin-like domain. The present inventors have demonstrated that both METH1 and METH2 have anti-angiogenic activity.

Thus, the present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding a METH1 polypeptide having the amino acid sequence shown in SEQ ID NO:2, which was determined by sequencing a cloned cDNA. The METH1 protein of the present invention shares sequence homology with thrombospondin-1 and pNPI. The nucleotide sequence shown in SEQ ID NO:1 was obtained by sequencing a cDNA clone, which was deposited on January 15, 1998 at the American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209, and given accession number 209581. The cDNA clone contained in ATCC Deposit No. 209581 contains a METH1 sequence, encoding amino acids 1 to 950 of SEQ ID NO:2.

The present invention also provides isolated nucleic acid molecules comprising a polynucleotide encoding a METH2 polypeptide having the amino acid sequence shown in SEQ ID NO:4, which was partially determined by sequencing a cloned cDNA. The METH2 protein of the present invention shares sequence homology with thrombospondin-1 and pNPI. The nucleotide sequence shown in SEQ ID NO:3 was partially obtained by sequencing a cDNA clone, which was deposited on January 15, 1998 at the American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209, and given accession number 209582. The cDNA clone contained in ATCC Deposit No. 209582 contains a partial METH2 sequence, encoding amino acids 112-890 of SEQ ID NO:4.

Nucleic Acid Molecules

Some of the nucleotide sequences determined by sequencing a DNA molecule herein were determined using an automated DNA sequencer (such as the Model 373 from Applied Biosystems, Inc.), and all amino acid sequences of polypeptides encoded by DNA molecules determined herein were predicted by translation of a DNA sequence determined as above. Therefore, as is known in the art for any DNA sequence determined by this automated approach, any nucleotide sequence determined herein may contain some errors. Nucleotide sequences determined by automation are typically at least about 90% identical, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of the sequenced DNA molecule. The actual sequence can be more precisely determined by other approaches including manual DNA sequencing methods well known in the art. As is also known in the art, a single insertion or deletion in a determined nucleotide sequence compared to the actual sequence will cause a frame shift in translation of the nucleotide sequence such that the predicted amino acid sequence encoded by a determined nucleotide sequence will be completely different from the amino acid sequence actually encoded by the sequenced DNA molecule, beginning at the point of such an insertion or deletion.

Using the information provided herein, such as the nucleotide sequence in SEQ ID NO: 1 or SEQ ID NO:3, a nucleic acid molecule of the present invention encoding a METH1 or METH2 polypeptide may be obtained using standard cloning and screening procedures, such as those for cloning cDNAs using mRNA as starting material. Illustrative of the invention, the nucleic acid molecule described in SEQ ID NO: 1 was discovered in a cDNA library derived from human heart and the nucleic acid molecule described in SEQ ID NO:3 was discovered in a cDNA library derived from human lung. The determined nucleotide sequence of the METH1 cDNA of SEQ ID NO:1 contains an open reading frame encoding

a protein of about 950 amino acid residues, including a predicted leader sequence of about 28 amino acid residues. The present inventors have determined that the nucleotide sequence of the METH2 cDNA of SEQ ID NO:3 contains an open reading frame encoding a protein of about 890 amino acid residues, including a predicted leader sequence of about 23 amino acid residues.

The present invention also provides the mature form(s) of the METH1 and METH2 proteins of the present invention. According to the signal hypothesis, proteins secreted by mammalian cells have a signal or secretory leader sequence which is cleaved from the mature protein once export of the growing protein chain across the rough endoplasmic reticulum has been initiated. Most mammalian cells and even insect cells cleave secreted proteins with the same specificity. However, in some cases, cleavage of a secreted protein is not entirely uniform, which results in two or more mature species on the protein. Further, it has long been known that the cleavage specificity of a secreted protein is ultimately determined by the primary structure of the complete protein, that is, it is inherent in the amino acid sequence of the polypeptide. Therefore, the present invention provides a nucleotide sequence encoding the mature METH1 polypeptide having the amino acid sequence encoded by the cDNA clone contained in the host identified as ATCC Deposit No. 209581 and as shown in SEQ ID NO:2. The present invention also provides a nucleotide sequence encoding the mature METH2 polypeptide having the amino acid sequence as shown in SEQ ID NO:4. By the mature METH1 protein having the amino acid sequence encoded by the cDNA clone contained in the host identified as ATCC Deposit No. 209581 is meant the mature form(s) of the METH1 protein produced by expression in a mammalian cell (e.g., COS cells, as described below) of the complete open reading frame encoded by the human DNA sequence of the clone contained in the vector in the deposited host. As indicated below, the mature METH1 having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209581 may or may not differ from the predicted "mature" METH1 protein shown in SEQ ID NO:2 (amino acids from about 29 to about 950) depending on the accuracy of

the predicted cleavage site based on computer analysis; and the mature METH2 may or may not differ from the predicted "mature" METH2 protein shown in SEQ ID NO: 4 (amino acids from about 24 to about 890) depending on the accuracy of the predicted cleavage site based on computer analysis.

5 Methods for predicting whether a protein has a secretory leader as well as the cleavage point for that leader sequence are available. For instance, the methods of McGeoch (*Virus Res.* 3:271-286 (1985)) and von Heinje (*Nucleic Acids Res.* 14:4683-4690 (1986)) can be used. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of these methods is in the range of 75-80%. von Heinje, *supra*. However, the two methods do not
10 always produce the same predicted cleavage point(s) for a given protein.

 In the present case, the predicted amino acid sequence of the complete METH1 and METH2 polypeptides of the present invention were analyzed by a computer program ("PSORT") (K. Nakai and M. Kanehisa, *Genomics* 14:897-911
15 (1992)), which is an expert system for predicting the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis by the PSORT program predicted the cleavage site between amino acids 28 and 29 in SEQ ID NO:2 and amino acids 23 and 24 in SEQ ID NO:4.
20 Thereafter, the complete amino acid sequences were further analyzed by visual inspection, applying a simple form of the (-1,-3) rule of von Heinje. von Heinje, *supra*. Thus, the leader sequence for the METH1 protein is predicted to consist of amino acid residues from about 1 to about 28 in SEQ ID NO:2, while the mature METH1 protein is predicted to consist of residues from about 29 to about
25 950; and the leader sequence for the METH2 protein is predicted to consist of amino acid residues from about 1 to about 23 in SEQ ID NO:4, while the mature METH2 protein is predicted to consist of residues from about 24 to about 890. An alternative predicted mature METH1 protein consists of residues 30 to 950 in SEQ ID NO:2.

As one of ordinary skill would appreciate, due to the possibilities of sequencing errors, as well as the variability of cleavage sites for leaders in different known proteins, the predicted METH1 polypeptide encoded by the deposited cDNA comprises about 950 amino acids, but may be anywhere in the range of 910-990 amino acids; and the predicted leader sequence of this protein is about 28 amino acids, but may be anywhere in the range of about 18 to about 38 amino acids. Also, the predicted METH2 polypeptide comprises about 890 amino acids, but may be anywhere in the range of 850 to about 930 amino acids; and the predicted leader sequence of this protein is about 23 amino acids, but may be anywhere in the range of about 13 to about 33 amino acids.

As indicated, nucleic acid molecules of the present invention may be in the form of RNA, such as mRNA, or in the form of DNA, including, for instance, cDNA and genomic DNA obtained by cloning or produced synthetically. The DNA may be double-stranded or single-stranded. Single-stranded DNA or RNA may be the coding strand, also known as the sense strand, or it may be the non-coding strand, also referred to as the anti-sense strand.

By "isolated" nucleic acid molecule(s) is intended a nucleic acid molecule, DNA or RNA, which has been removed from its native environment. For example, recombinant DNA molecules contained in a vector are considered isolated for the purposes of the present invention. Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include *in vivo* or *in vitro* RNA transcripts of the DNA molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically.

Isolated nucleic acid molecules of the present invention include DNA molecules comprising an open reading frame (ORF) shown in SEQ ID NO:1; DNA molecules comprising the coding sequence for the mature METH1 protein; and DNA molecules which comprise a sequence substantially different from those described above but which, due to the degeneracy of the genetic code, still encode

the METH1 protein. Also included are DNA molecules comprising an open reading frame (ORF) shown in SEQ ID NO:3; DNA molecules comprising the coding sequence for the mature METH2 protein; and DNA molecules which comprise a sequence substantially different from those described above but which, due to the degeneracy of the genetic code, still encode the METH2 protein. Of course, the genetic code is well known in the art. Thus, it would be routine for one skilled in the art to generate such degenerate variants.

In another aspect, the invention provides isolated nucleic acid molecules encoding the METH1 or METH2 polypeptides having an amino acid sequence as encoded by the cDNA clones contained in the plasmids deposited as ATCC Deposit No. 209581 on January 15, 1998 or ATCC Deposit No. 209582 on January 15, 1998, respectively. In a further embodiment, nucleic acid molecules are provided encoding the mature METH1 or METH2 polypeptide or the full-length METH1 or METH2 polypeptide lacking the N-terminal methionine. The invention also provides an isolated nucleic acid molecule having the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:3 or the nucleotide sequence of the METH1 or METH2 cDNA contained in the above-described deposited clones, or a nucleic acid molecule having a sequence complementary to one of the above sequences. Such isolated molecules, particularly DNA molecules, are useful as probes for gene mapping, by *in situ* hybridization with chromosomes, and for detecting expression of the METH1 or METH2 gene in human tissue, for instance, by Northern blot analysis.

The present invention is further directed to fragments of the isolated nucleic acid molecules described herein. By a fragment of an isolated nucleic acid molecule having the nucleotide sequence of the deposited cDNA or the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:3 is intended fragments at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt in length which are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700,

750, 800, 850, 900, 950, 1000, 1050, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, or 3000 nt in length are also useful according to the present invention as are fragments corresponding to most, if not all, of the nucleotide sequence of the deposited cDNA or as shown in SEQ ID NO:1 or SEQ ID NO:3. By a fragment at least 20 nt in length, for example, is intended fragments which include 20 or more contiguous bases from the nucleotide sequence of the deposited cDNA or the nucleotide sequence as shown in SEQ ID NO:1 or SEQ ID NO:3.

Preferred nucleic acid fragments of the present invention include nucleic acid molecules encoding epitope-bearing portions of the METH1 or METH2 protein. Methods for determining epitope-bearing portions of the METH1 and METH2 proteins are described in detail below.

Other preferred nucleic acid fragments of the present invention include nucleic acid molecules encoding: the metalloprotease domain of METH1, amino acids 235 to 459 in SEQ ID NO:2; the disintegrin domain of METH1, amino acids 460 to 544 in SEQ ID NO:2; the first TSP-like domain of METH1, amino acids 545 to 598 in SEQ ID NO:2; the second TSP-like domain of METH1, amino acids 841 to 894 in SEQ ID NO:2; the third TSP-like domain of METH1, amino acids 895 to 934 in SEQ ID NO:2; amino acids 536 to 613 in SEQ ID NO:2; amino acids 549 to 563 in SEQ ID NO:2; the metalloprotease domain of METH2, amino acids 214 to 439 in SEQ ID NO:4; the disintegrin domain of METH2, amino acids 440 to 529 in SEQ ID NO:4; the first TSP-like domain of METH2, amino acids 530 to 583 in SEQ ID NO:4; the second TSP-like domain of METH2, amino acids 837 to 890 in SEQ ID NO:4; amino acids 280 to 606 in SEQ ID NO:4; and amino acids 529 to 548 in SEQ ID NO:4.

In addition, the present inventors have identified the following cDNA clones related to portions of the sequence shown in SEQ ID NO:1: HOUQC17RA (SEQ ID NO:14), HPLBM11R (SEQ ID NO:15), HGBI07R (SEQ ID NO:16), HNTMA49R (SEQ ID NO:17), HNALE27R (SEQ ID NO:18), and HIBDB45R (SEQ ID NO:19).

The following public ESTs, which relate to portions of SEQ ID NO:1, have also been identified: D67076 (SEQ ID NO:20), AB001735 (SEQ ID NO:21), X14787 (SEQ ID NO:22), U64857 (SEQ ID NO:23), X04665 (SEQ ID NO:24), M64866 (SEQ ID NO:25), L07803 (SEQ ID NO:26), U08006 (SEQ ID NO:27), M16974 (SEQ ID NO:28), L13855 (SEQ ID NO:29), AL021529 (SEQ ID NO:30), D86074 (SEQ ID NO:31), L05390 (SEQ ID NO:32), Z69361 (SEQ ID NO:33), X99599 (SEQ ID NO:34), AF018073 (SEQ ID NO:35), L23760 (SEQ ID NO:36), Z46970 (SEQ ID NO:37), AC004449 (SEQ ID NO:38), Z69589 (SEQ ID NO:39), Z22279 (SEQ ID NO:40), and X17524 (SEQ ID NO:41).

The present inventors have also identified the following cDNA clones related to portions of SEQ ID NO:3: HCE4D69FP02 (SEQ ID NO:42), HIBDB45F (SEQ ID NO:43), HKIXH64R (SEQ ID NO:44), HIBDB45R (SEQ ID NO:19), HCE3Z95R (SEQ ID NO:45), HTLEQ90R (SEQ ID NO:46), HMWEF45R (SEQ ID NO:47), HTOFC34RA (SEQ ID NO:48), HHFDI20R (SEQ ID NO:49), HMSHY47R (SEQ ID NO:50), HCESF90R (SEQ ID NO:51), HMCAO46R (SEQ ID NO:52), HTTAQ67R (SEQ ID NO:53), HFKCF19F (SEQ ID NO:54), HMCAS31R (SEQ ID NO:55), HMWGP26R (SEQ ID NO:56), HLHTP36R (SEQ ID NO:57), HE8AN11R (SEQ ID NO:58), HEONN73R (SEQ ID NO:59), HBNBG53R (SEQ ID NO:60), and HMSCH94R (SEQ ID NO:61).

The following public ESTs, which relate to portions of the sequence shown in SEQ ID NO:3, have also been identified: D67076 (SEQ ID NO:20), AB001735 (SEQ ID NO:21), AB005287 (SEQ ID NO:62), X87619 (SEQ ID NO:63), X14787 (SEQ ID NO:22), X04665 (SEQ ID NO:24), M87276 (SEQ ID NO:64), M62458 (SEQ ID NO:65), AB002364 (SEQ ID NO:66), AB005297 (SEQ ID NO:67), X69161 (SEQ ID NO:68), X16619 (SEQ ID NO:69), I36448 (SEQ ID NO:70), L12260 (SEQ ID NO:71), I36352 (SEQ ID NO:72), X15898 (SEQ ID NO:73), I07789 (SEQ ID NO:74), I08144 (SEQ ID NO:75) U31814 (SEQ ID NO:76), and AF001444 (SEQ ID NO:77).

In specific embodiments, the polynucleotides of the invention are less than 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, or 7.5 kb in length. In a further embodiment, polynucleotides of the invention comprise at least 15 contiguous nucleotides of METH1 or METH2 coding sequence, but do not comprise all or a portion of any METH1 or METH2 intron. In another embodiment, the nucleic acid comprising METH1 or METH2 coding sequence does not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the METH1 or METH2 gene in the genome).

In another aspect, the invention provides an isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent hybridization conditions to a portion of the polynucleotide in a nucleic acid molecule of the invention described above, for instance, the cDNA clones contained in ATCC Deposit No. 209581 or ATCC Deposit No. 209582. By "stringent hybridization conditions" is intended overnight incubation at 42°C in a solution comprising: 50% formamide, 5x SSC (750 mM NaCl, 75mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65°C.

By a polynucleotide which hybridizes to a "portion" of a polynucleotide is intended a polynucleotide (either DNA or RNA) hybridizing to at least about 15 nucleotides (nt), and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably about 30, 40, 50, 60 or 70 nt of the reference polynucleotide. These are useful as diagnostic probes and primers as discussed above and in more detail below.

By a portion of a polynucleotide of "at least 20 nt in length," for example, is intended 20 or more contiguous nucleotides from the nucleotide sequence of the reference polynucleotide (e.g., the deposited cDNAs or the nucleotide sequence as shown in SEQ ID NO:1 or SEQ ID NO:3). Of course, a polynucleotide which hybridizes only to a poly A sequence (such as the 3' terminal poly(A) tract of the METH1 or METH2 cDNA shown in SEQ ID NO:1 and SEQ ID NO:3,

respectively) or to a complementary stretch of T (or U) residues, would not be included in a polynucleotide of the invention used to hybridize to a portion of a nucleic acid of the invention, since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).

Also contemplated are nucleic acid molecules that hybridize to the METH1 or METH2 polynucleotides at moderately high stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, moderately high stringency conditions include an overnight incubation at 37 degree C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH_2PO_4 ; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 $\mu\text{g/ml}$ salmon sperm blocking DNA; followed by washes at 50°C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA⁺ sequences (such as any 3' terminal polyA⁺ tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).

The METH1 or METH2 polynucleotide can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, METH1 or METH2 polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the METH1 or METH2 polynucleotides can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. METH1 or METH2 polynucleotides may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

"SEQ ID NO:1" refers to a METH1 polynucleotide sequence while "SEQ ID NO:2" refers to a METH1 polypeptide sequence. "SEQ ID NO:3" refers to a METH2 polynucleotide sequence while "SEQ ID NO:4" refers to a METH2 polypeptide sequence.

As indicated, nucleic acid molecules of the present invention which encode a METH1 or METH2 polypeptide may include, but are not limited to, those encoding the amino acid sequence of the mature polypeptide, by itself; the coding sequence for the mature polypeptide and additional sequences, such as those encoding the leader or secretory sequence, such as a pre-, or pro- or prepro-protein sequence; the coding sequence of the mature polypeptide, with or without the aforementioned additional coding sequences, together with additional, non-coding sequences, including for example, but not limited to introns and non-coding 5' and 3' sequences, such as the transcribed, non-translated sequences that play a role in transcription, mRNA processing, including splicing and polyadenylation signals, for example - ribosome binding and stability of mRNA;

an additional coding sequence which codes for additional amino acids, such as those which provide additional functionalities. Thus, the sequence encoding the polypeptide may be fused to a marker sequence, such as a sequence encoding a peptide which facilitates purification of the fused polypeptide. In certain preferred
5 embodiments of this aspect of the invention, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (Qiagen, Inc.), among others, many of which are commercially available. As described in Gentz *et al.*, *Proc. Natl. Acad. Sci. USA* 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. The "HA" tag is
10 another peptide useful for purification which corresponds to an epitope derived from the influenza hemagglutinin protein, which has been described by Wilson *et al.*, *Cell* 37:767-778 (1984). As discussed below, other such fusion proteins include the METH1 or METH2 fused to Fc at the N- or C-terminus.

The present invention further relates to variants of the nucleic acid
15 molecules of the present invention, which encode portions, analogs or derivatives of the METH1 or METH2 protein. Variants may occur naturally, such as a natural allelic variant. By an "allelic variant" is intended one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. Lewin, B., ed., *Genes II*, John Wiley & Sons, New York (1985). Non-naturally occurring
20 variants may be produced using art-known mutagenesis techniques.

Such variants include those produced by nucleotide substitutions, deletions or additions, which may involve one or more nucleotides. The variants may be altered in coding regions, non-coding regions, or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions,
25 deletions or additions. Especially preferred among these are silent substitutions, additions and deletions, which do not alter the properties and activities of the METH1 or METH2 protein or portions thereof. Also especially preferred in this regard are conservative substitutions.

Further embodiments of the invention include isolated nucleic acid
30 molecules comprising a polynucleotide having a nucleotide sequence at least 95%

identical, and more preferably at least 96%, 97%, 98% or 99% identical to: a nucleotide sequence encoding the polypeptide having the amino acid sequence in SEQ ID NO:2; a nucleotide sequence encoding the polypeptide having the amino acid sequence in SEQ ID NO:2, but lacking the N-terminal methionine; a nucleotide sequence encoding the polypeptide having the amino acid sequence at positions from about 29 to about 950 in SEQ ID NO:2; a nucleotide sequence encoding the polypeptide having the amino acid sequence at position from about 30 to about 950 in SEQ ID NO:2; a nucleotide sequence encoding the polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209581; a nucleotide sequence encoding the mature METH1 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209581; a nucleotide sequence encoding amino acids 235 to 459 in SEQ ID NO:2 (the metalloprotease domain of METH1); a nucleotide sequence encoding amino acids 460 to 544 in SEQ ID NO:2 (the disintegrin domain of METH1); a nucleotide sequence encoding amino acids 545 to 598 in SEQ ID NO:2 (the first TSP-like domain of METH1); a nucleotide sequence encoding amino acids 841 to 894 in SEQ ID NO:2 (the second TSP-like domain of METH1); a nucleotide sequence encoding amino acids 895 to 934 in SEQ ID NO:2 (the third TSP-like domain of METH1); a nucleotide sequence encoding amino acids 536 to 613 in SEQ ID NO:2; a nucleotide sequence encoding amino acids 549 to 563 in SEQ ID NO:2; a nucleotide sequence encoding the polypeptide having the amino acid sequence in SEQ ID NO:4; a nucleotide sequence encoding the polypeptide having the amino acid sequence in SEQ ID NO:4, but lacking the N-terminal methionine; a nucleotide sequence encoding the polypeptide having the amino acid sequence at positions from about 24 to about 890 in SEQ ID NO:4; a nucleotide sequence encoding the polypeptide having the amino acid sequence at positions from about 112 to about 890 in SEQ ID NO:4; a nucleotide sequence encoding the polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209582; a nucleotide sequence encoding the mature METH2 polypeptide having the amino

acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209582; a nucleotide sequence encoding amino acids 214 to 439 in SEQ ID NO:4 (the metalloprotease domain of METH2); a nucleotide sequence encoding amino acids 440 to 529 in SEQ ID NO:4 (the disintegrin domain of METH2); a nucleotide sequence encoding amino acids 530 to 583 in SEQ ID NO:4 (the first TSP-like domain of METH2); a nucleotide sequence encoding amino acids 837 to 890 in SEQ ID NO:4 (the second TSP-like domain of METH2); a nucleotide sequence encoding amino acids 280 to 606 in SEQ ID NO:4; a nucleotide sequence encoding amino acids 529 to 548 in SEQ ID NO:4; or a nucleotide sequence complementary to any of the above nucleotide sequences .

By a polynucleotide having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence encoding a METH1 or METH2 polypeptide is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the METH1 or METH2 polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular nucleic acid molecule is at least 95%, 96%, 97%, 98% or 99% identical to, for instance, the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:3 or to the nucleotide sequence of the deposited cDNA clones can be determined conventionally using known computer programs such as the Bestfit program (Wisconsin Sequence Analysis

Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711). Bestfit uses the local homology algorithm of Smith and Waterman, *Advances in Applied Mathematics* 2: 482-489 (1981), to find the best segment of homology between two sequences. When
5 using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for instance, 95% identical to a reference sequence according to the present invention, the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference nucleotide
10 sequence and that gaps in homology of up to 5% of the total number of nucleotides in the reference sequence are allowed.

A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag *et al.*, *Comp. Appl. Biosci.*
15 6:237-245 (1990). In a sequence alignment, the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30,
20 Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made
25 to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned,
30 as a percent of the total bases of the query sequence. Whether a nucleotide is

matched/aligned is determined by the results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and, therefore, the FASTDB alignment does not show a match/alignment of the first 10 bases at the 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence), so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal, so that there are no bases on the 5' or 3' ends of the subject sequence which are not matched/aligned with the query. In this case, the percent identity calculated by FASTDB is not manually corrected. One again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

The present application is directed to nucleic acid molecules at least 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequence shown in SEQ ID NO:1 or SEQ ID NO:3 or to the nucleic acid sequence of the deposited cDNAs, irrespective of whether they encode a polypeptide having METH1 or METH2 activity. This is because even where a particular nucleic acid molecule does not encode a polypeptide having METH1 or METH2 activity, one of skill in the art would still know how to use the nucleic acid molecule, for instance, as a

hybridization probe or a polymerase chain reaction (PCR) primer. Uses of the nucleic acid molecules of the present invention that do not encode a polypeptide having METH1 or METH2 activity include, *inter alia*, (1) isolating the METH1 or METH2 gene or allelic variants thereof in a cDNA library; (2) *in situ* hybridization (e.g., "FISH") to metaphase chromosomal spreads to provide precise chromosomal location of the METH1 or METH2 gene, as described in Verma *et al.*, *Human Chromosomes: A Manual of Basic Techniques*, Pergamon Press, New York (1988); and (3) Northern Blot analysis for detecting METH1 or METH2 mRNA expression in specific tissues.

Preferred, however, are nucleic acid molecules having sequences at least 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequence shown in SEQ ID NO:1 or SEQ ID NO:3 or to a nucleic acid sequence of the deposited cDNAs which do, in fact, encode a polypeptide having METH1 or METH2 protein activity. By "a polypeptide having METH1 activity" is intended polypeptides exhibiting METH1 activity in a particular biological assay. For example, METH1 protein activity can be measured using the chorioallantoic membrane assay (Iruela-Arispe *et al.*, *Thrombosis and Haemostasis* 78(1):672-677 (1997)) or the cornea pocket assay (Tolsma *et al.*, *J. Cell. Biol.* 122:497-511 (1993)), both described in Example 4, below. By "a polypeptide having METH2 activity" is intended polypeptides exhibiting METH2 activity in a particular biological assay. For example, METH2 protein activity can also be measured using the chorioallantoic membrane assay (Iruela-Arispe *et al.*, *Thrombosis and Haemostasis* 78(1):672-677 (1997)) or the cornea pocket assay (Tolsma *et al.*, *J. Cell. Biol.* 122:497-511 (1993)), both described in Example 4, below.

Briefly, in the chorioallantoic assay, the potentially anti-angiogenic compound of interest is added to type I collagen pellets (Vitrogen), along with an angiogenic growth factor, such as bFGF. The samples are mixed and placed onto nylon meshes, and allowed to polymerize. After polymerization is complete, the meshes are placed onto the chorioallantoic membrane of 12 day old chick embryos and placed at 37°C for 24 hours. The embryos then injected with a fluorescent

agent, such as FITC-dextran, and the meshes are fixed and mounted for observation under a fluorescent microscope.

In the cornea pocket assay, hydron pellets containing the compound of interest and an angiogenic growth factor, such as bFGF, are implanted 1 to 2mm from the limbus of the cornea of rats or mice. Response is examined after a period of time, for example 5 days. The extent of angiogenesis is evaluated by measuring the capillaries migrating from the limb of the cornea.

Of course, due to the degeneracy of the genetic code, one of ordinary skill in the art will immediately recognize that a large number of the nucleic acid molecules having a sequence at least 95%, 96%, 97%, 98%, or 99% identical to a nucleic acid sequence of the deposited cDNAs or a nucleic acid sequence shown in SEQ ID NO:1 or SEQ ID NO:3 will encode a polypeptide "having METH1 or METH2 protein activity." In fact, since degenerate variants of these nucleotide sequences all encode the same polypeptide, this will be clear to the skilled artisan even without performing the above described comparison assay. It will be further recognized in the art that, for such nucleic acid molecules that are not degenerate variants, a reasonable number will also encode a polypeptide having METH1 or METH2 protein activity. This is because the skilled artisan is fully aware of amino acid substitutions that are either less likely or not likely to significantly effect protein function (e.g., replacing one aliphatic amino acid with a second aliphatic amino acid).

For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J. U. *et al.*, "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," *Science* 247:1306-1310 (1990), wherein the authors indicate that proteins are surprisingly tolerant of amino acid substitutions.

Vectors and Host Cells

The present invention also relates to vectors which include the isolated DNA molecules of the present invention, host cells which are genetically engineered with the recombinant vectors, and the production of METH1 or METH2 polypeptides or fragments thereof by recombinant techniques.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged *in vitro* using an appropriate packaging cell line and then transduced into host cells.

The DNA insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the *E. coli lac*, *trp* and *tac* promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination and, in the transcribed region, a ribosome binding site for translation. The coding portion of the mature transcripts expressed by the constructs will preferably include a translation initiating at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase or neomycin resistance for eukaryotic cell culture and tetracycline or ampicillin resistance genes for culturing in *E. coli* and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as yeast cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

-51-

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from Qiagen; pBS vectors, Phagescript vectors, Bluescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

In addition to the use of expression vectors in the practice of the present invention, the present invention further includes novel expression vectors comprising operator and promoter elements operatively linked to nucleotide sequences encoding a protein of interest. One example of such a vector is pHE4-5 which is described in detail below.

As summarized in Figures 8 and 9, components of the pHE4-5 vector (SEQ ID NO:12) include: 1) a neomycinphosphotransferase gene as a selection marker, 2) an *E. coli* origin of replication, 3) a T5 phage promoter sequence, 4) two *lac* operator sequences, 5) a Shine-Delgarno sequence, 6) the lactose operon repressor gene (*lacIq*). The origin of replication (*oriC*) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences were made synthetically. Synthetic production of nucleic acid sequences is well known in the art. CLONTECH 95/96 Catalog, pages 215-216, CLONTECH, 1020 East Meadow Circle, Palo Alto, CA 94303. A nucleotide sequence encoding METH1 (SEQ ID NO:2) or METH2 (SEQ ID NO:4), is operatively linked to the promoter and operator by inserting the nucleotide sequence between the NdeI and Asp718 sites of the pHE4-5 vector.

As noted above, the pHE4-5 vector contains a *lacIq* gene. *LacIq* is an allele of the *lacI* gene which confers tight regulation of the *lac* operator. Amann, E. et al., *Gene* 69:301-315 (1988); Stark, M., *Gene* 51:255-267 (1987). The *lacIq* gene encodes a repressor protein which binds to *lac* operator sequences and blocks transcription of down-stream (*i.e.*, 3') sequences. However, the *lacIq* gene

product dissociates from the *lac* operator in the presence of either lactose or certain lactose analogs, *e.g.*, isopropyl B-D-thiogalactopyranoside (IPTG). METH1 or METH2 thus is not produced in appreciable quantities in uninduced host cells containing the pHE4-5 vector. Induction of these host cells by the addition of an agent such as IPTG, however, results in the expression of the METH1 or METH2 coding sequence.

The promoter/operator sequences of the pHE4-5 vector (SEQ ID NO:13) comprise a T5 phage promoter and two *lac* operator sequences. One operator is located 5' to the transcriptional start site and the other is located 3' to the same site. These operators, when present in combination with the *lacIq* gene product, confer tight repression of down-stream sequences in the absence of a *lac* operon inducer, *e.g.*, IPTG. Expression of operatively linked sequences located downstream from the *lac* operators may be induced by the addition of a *lac* operon inducer, such as IPTG. Binding of a *lac* inducer to the *lacIq* proteins results in their release from the *lac* operator sequences and the initiation of transcription of operatively linked sequences. *Lac* operon regulation of gene expression is reviewed in Devlin, T., TEXTBOOK OF BIOCHEMISTRY WITH CLINICAL CORRELATIONS, 4th Edition (1997), pages 802-807.

The pHE4 series of vectors contain all of the components of the pHE4-5 vector except for the METH1 or METH2 coding sequence. Features of the pHE4 vectors include optimized synthetic T5 phage promoter, *lac* operator, and Shine-Delgarno sequences. Further, these sequences are also optimally spaced so that expression of an inserted gene may be tightly regulated and high level of expression occurs upon induction.

Among known bacterial promoters suitable for use in the production of proteins of the present invention include the *E. coli lacI* and *lacZ* promoters, the T3 and T7 promoters, the *gpt* promoter, the lambda PR and PL promoters and the *trp* promoter. Suitable eukaryotic promoters include the CMV immediate early promoter, the HSV thymidine kinase promoter, the early and late SV40 promoters, the promoters of retroviral LTRs, such as those of the Rous Sarcoma

Virus (RSV), and metallothionein promoters, such as the mouse metallothionein-I promoter.

The pHE4-5 vector also contains a Shine-Delgarno sequence 5' to the AUG initiation codon. Shine-Delgarno sequences are short sequences generally located about 10 nucleotides up-stream (*i.e.*, 5') from the AUG initiation codon. These sequences essentially direct prokaryotic ribosomes to the AUG initiation codon.

Thus, the present invention is also directed to expression vector useful for the production of the proteins of the present invention. This aspect of the invention is exemplified by the pHE4-5 vector (SEQ ID NO:12).

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection or other methods. Such methods are described in many standard laboratory manuals, such as Davis *et al.*, *Basic Methods In Molecular Biology* (1986).

The polypeptide may be expressed in a modified form, such as a fusion protein, and may include not only secretion signals, but also additional heterologous functional regions. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence in the host cell, during purification, or during subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to polypeptides to engender secretion or excretion, to improve stability and to facilitate purification, among others, are familiar and routine techniques in the art. A preferred fusion protein comprises a heterologous region from immunoglobulin that is useful to solubilize proteins. For example, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is

thoroughly advantageous for use in therapy and diagnosis and thus results, for example, in improved pharmacokinetic properties (EP-A 0232 262). On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified in the advantageous manner described. This is the case when the Fc portion proves to be a hindrance to use in therapy and diagnosis, for example when the fusion protein is to be used as an antigen for immunizations. In drug discovery, for example, human proteins, such as the hIL5-receptor, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. See, D. Bennett *et al.*, *J. Mol. Recognition* 8:52-58 (1995) and K. Johanson *et al.*, *J. of Biol. Chem.* 270(16):9459-9471 (1995).

The METH1 or METH2 protein can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification. Polypeptides of the present invention include naturally purified products, products of chemical synthetic procedures, and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes.

METH1 and METH2 Polypeptides and Fragments

The invention further provides an isolated METH1 polypeptide having the amino acid sequence encoded by the deposited cDNA, or the amino acid sequence in SEQ ID NO:2, or a peptide or polypeptide comprising a portion of the above polypeptides. The invention also provides an isolated METH2 polypeptide having the amino acid sequence encoded by the deposited cDNA, or the amino acid sequence in SEQ ID NO:4, or a peptide or polypeptide comprising a portion of the above polypeptides.

METH1 or METH2 polypeptides can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The METH1 or METH2 polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in the METH1 or METH2 polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given METH1 or METH2 polypeptide. Also, a given METH1 or METH2 polypeptide may contain many types of modifications. METH1 or METH2 polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic METH1 or METH2 polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation,

demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter *et al.*, *Meth Enzymol* 182:626-646 (1990); Rattan *et al.*, *Ann NY Acad Sci* 663:48-62 (1992).)

It will be recognized in the art that some amino acid sequences of the METH1 and METH2 polypeptides can be varied without significant effect of the structure or function of the protein. If such differences in sequence are contemplated, it should be remembered that there will be critical areas on the protein which determine activity.

The present inventors have shown that METH1 and METH2 inhibit angiogenesis *in vitro* and *in vivo*. METH1 and METH2 each contain a metalloprotease domain, a disintegrin domain, and TSP-like domains. The metalloprotease domain may be catalytically active. The disintegrin domain may play a role in inhibiting angiogenesis by interacting with integrins, since integrins are essential for the mediation of both proliferative and migratory signals. The present inventors have shown that peptides derived from the TSP-like domains of METH1 and METH2 inhibit angiogenesis *in vitro* and *in vivo*.

Thus, the invention further includes variations of the METH1 polypeptide which show substantial METH1 polypeptide activity or which include regions of METH1 protein such as the protein portions discussed below; and variations of the METH2 polypeptide which show substantial METH2 polypeptide activity or which include regions of METH2 protein such as the protein portions discussed below. Such mutants include deletions, insertions, inversions, repeats, and type

substitutions. As indicated above, guidance concerning which amino acid changes are likely to be phenotypically silent can be found in Bowie, J.U., *et al.*, "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," *Science* 247:1306-1310 (1990).

5 Thus, the fragment, derivative or analog of the polypeptide of SEQ ID NO:2 or SEQ ID NO:4, or that encoded by the deposited cDNA, may be (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the
10 genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the mature polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) one in which the additional amino acids are fused to the mature polypeptide, such as an IgG Fc fusion region peptide or
15 leader or secretory sequence or a sequence which is employed for purification of the mature polypeptide or a proprotein sequence. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art from the teachings herein.

 Of particular interest are substitutions of charged amino acids with another
20 charged amino acid and with neutral or negatively charged amino acids. The latter results in proteins with reduced positive charge to improve the characteristics of the METH1 or METH2 proteins. The prevention of aggregation is highly desirable. Aggregation of proteins not only results in a loss of activity but can also be problematic when preparing pharmaceutical formulations, because they can be
25 immunogenic. (Pinckard *et al.*, *Clin. Exp. Immunol.* 2:331-340 (1967); Robbins *et al.*, *Diabetes* 36:838-845 (1987); Cleland *et al.*, *Crit. Rev. Therapeutic Drug Carrier Systems* 10:307-377 (1993)).

 As indicated, changes are preferably of a minor nature, such as conservative amino acid substitutions that do not significantly affect the folding
30 or activity of the protein (see Table 3).

TABLE 3. Conservative Amino Acid Substitutions.

Aromatic	Phenylalanine Tryptophan Tyrosine
Hydrophobic	Leucine Isoleucine Valine
Polar	Glutamine Asparagine
Basic	Arginine Lysine Histidine
Acidic	Aspartic Acid Glutamic Acid
Small	Alanine Serine Threonine Methionine Glycine

Of course, the number of amino acid substitutions a skilled artisan would make depends on many factors, including those described above. Generally speaking, the number of amino acid substitutions for any given METH1 or METH2 polypeptide will not be more than 50, 40, 30, 20, 10, 5, or 3.

Amino acids in the METH1 and METH2 proteins of the present invention that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, *Science* 244:1081-1085 (1989)). The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity such as *in vitro* or *in vivo* inhibition of angiogenesis. Sites that are critical for inhibition of angiogenesis can also be determined by structural analysis such as crystallization, nuclear magnetic

resonance or photoaffinity labeling (Smith *et al.*, *J. Mol. Biol.* 224:899-904 (1992) and de Vos *et al.*, *Science* 255:306-312 (1992)).

5 The polypeptides of the present invention are preferably provided in an isolated form. By "isolated polypeptide" is intended a polypeptide removed from its native environment. Thus, a polypeptide produced and/or contained within a recombinant host cell is considered isolated for purposes of the present invention. Also intended as an "isolated polypeptide" are polypeptides that have been purified, partially or substantially, from a recombinant host cell or from a native source. For example, a recombinantly produced version of the METH1 or
10 METH2 polypeptide can be substantially purified by the one-step method described in Smith and Johnson, *Gene* 67:31-40 (1988).

The polypeptides of the present invention include the METH1 polypeptide encoded by the deposited cDNA including the leader; the mature METH1 polypeptide encoded by the deposited the cDNA minus the leader (i.e., the mature protein);
15 a polypeptide comprising amino acids about 1 to about 950 in SEQ ID NO:2; a polypeptide comprising amino acids about 2 to about 950 in SEQ ID NO:2; a polypeptide comprising amino acids about 29 to about 950 in SEQ ID NO:2; a polypeptide comprising amino acids about 30 to about 950 in SEQ ID NO:2; a polypeptide comprising the metalloprotease domain of METH1, amino acids 235 to 459 in SEQ ID NO:2; a polypeptide comprising the disintegrin domain of METH1, amino acids 460 to 544 in SEQ ID NO:2; a polypeptide comprising the first TSP-like domain of METH1, amino acids 545 to 598 in SEQ ID NO:2; a polypeptide comprising the second TSP-like domain of METH1, amino acids 841 to 894 in SEQ ID NO:2; a polypeptide comprising the third TSP-like domain of METH1, amino acids 895 to 934 in SEQ ID NO:2; a polypeptide comprising amino acids 536 to 613 in SEQ ID NO:2; a polypeptide comprising amino acids 549 to 563 in SEQ ID NO:2; the METH2 polypeptide encoded by the deposited cDNA including the leader; the mature METH2 polypeptide encoded by the deposited the cDNA minus the leader (i.e., the mature protein);
25 a polypeptide comprising amino acids about 1 to about 890 in SEQ ID NO:4; a
30

polypeptide comprising amino acids about 2 to about 890 in SEQ ID NO:4; a polypeptide comprising amino acids about 24 to about 890 in SEQ ID NO:4; a polypeptide comprising amino acids about 112 to about 890 in SEQ ID NO:4; a polypeptide comprising the metalloprotease domain of METH2, amino acids 214 to 439 in SEQ ID NO:4; a polypeptide comprising the disintegrin domain of METH2, amino acids 440 to 529 in SEQ ID NO:4; a polypeptide comprising the first TSP-like domain of METH2, amino acids 530 to 583 in SEQ ID NO:4; a polypeptide comprising the second TSP-like domain of METH2, amino acids 837 to 890 in SEQ ID NO:4; a polypeptide comprising amino acids 280 to 606 in SEQ ID NO:4; a polypeptide comprising amino acids 529 to 548 in SEQ ID NO:4; as well as polypeptides which are at least 95% identical, and more preferably at least 96%, 97%, 98% or 99% identical to the polypeptides described above and also include portions of such polypeptides with at least 30 amino acids and more preferably at least 50 amino acids.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a reference amino acid sequence of a METH1 or METH2 polypeptide is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of the METH1 or METH2 polypeptide. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a reference amino acid sequence, up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:4 or to the amino acid sequence encoded by deposited cDNA clones can be determined conventionally using known computer programs such the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711). When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for instance, 95% identical to a reference sequence according to the present invention, the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference amino acid sequence and that gaps in homology of up to 5% of the total number of amino acid residues in the reference sequence are allowed.

A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag *et al.*, *Comp. App. Biosci.* 6:237-245 (1990). In a sequence alignment, the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number

of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total residues of the query sequence. Whether a residue is matched/aligned is determined by the results of the FASTDB sequence alignment.

5 This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are

10 considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at

15 the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a match/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB

20 program. If the remaining 90 residues were perfectly matched, the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time, the deletions are internal, so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case, the percent identity calculated

25 by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are made for the purposes of the present invention.

The polypeptides of the present invention are useful as a molecular weight marker on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art.

In another aspect, the invention provides a peptide or polypeptide comprising an epitope-bearing portion of a polypeptide of the invention. The epitope of this polypeptide portion is an immunogenic or antigenic epitope of a polypeptide described herein. An "immunogenic epitope" is defined as a part of a protein that elicits an antibody response when the whole protein is the immunogen. On the other hand, a region of a protein molecule to which an antibody can bind is defined as an "antigenic epitope." The number of immunogenic epitopes of a protein generally is less than the number of antigenic epitopes. See, for instance, Geysen *et al.*, *Proc. Natl. Acad. Sci. USA* 81:3998-4002 (1983).

As to the selection of peptides or polypeptides bearing an antigenic epitope (i.e., that contain a region of a protein molecule to which an antibody can bind), it is well known in that art that relatively short synthetic peptides that mimic part of a protein sequence are routinely capable of eliciting an antiserum that reacts with the partially mimicked protein. See, for instance, Sutcliffe, J. G. *et al.*, "Antibodies that react with predetermined sites on proteins", *Science* 219:660-666 (1983). Peptides capable of eliciting protein-reactive sera are frequently represented in the primary sequence of a protein, can be characterized by a set of simple chemical rules, and are confined neither to immunodominant regions of intact proteins (i.e., immunogenic epitopes) nor to the amino or carboxyl terminals.

Antigenic epitope-bearing peptides and polypeptides of the invention are therefore useful to raise antibodies, including monoclonal antibodies, that bind specifically to a polypeptide of the invention. See, for instance, Wilson *et al.*, *Cell* 37:767-778 (1984) at 777.

Antigenic epitope-bearing peptides and polypeptides of the invention preferably contain a sequence of at least seven, more preferably at least nine and

most preferably between about at least about 15 to about 30 amino acids contained within the amino acid sequence of a polypeptide of the invention.

The epitope-bearing peptides and polypeptides of the invention may be produced by any conventional means. Houghten, R. A., "General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids", *Proc. Natl. Acad. Sci. USA* 82:5131-5135 (1985). This "Simultaneous Multiple Peptide Synthesis (SMPS)" process is further described in U.S. Patent No. 4,631,211 to Houghten *et al.* (1986).

As one of skill in the art will appreciate, METH1 or METH2 polypeptides of the present invention and the epitope-bearing fragments thereof described above can be combined with parts of the constant domain of immunoglobulins (IgG), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life *in vivo*. This has been shown, e.g., for chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins (EPA 394,827; Traunecker *et al.*, *Nature* 331:84-86 (1988)). Fusion proteins that have a disulfide-linked dimeric structure due to the IgG part can also be more efficient in binding and neutralizing other molecules than the monomeric METH1 or METH2 protein or protein fragment alone (Fountoulakis *et al.*, *J. Biochem.* 270:3958-3964 (1995)).

METH1 and METH2 Polynucleotide and Polypeptide Fragments

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence contained in the deposited clones or shown in SEQ ID NO:1 or SEQ ID NO:3. The short nucleotide fragments are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt in length. A fragment "at least 20 nt in length," for example, is intended to include

20 or more contiguous bases from the cDNA sequence contained in the deposited clones or the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:3. These nucleotide fragments are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of METH1 or METH2 polynucleotide fragments include, for example, fragments having a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:1 or SEQ ID NO:3 or the cDNA contained in the deposited clones. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein.

In the present invention, a "polypeptide fragment" refers to a short amino acid sequence contained in SEQ ID NO:2 or SEQ ID NO:4 or encoded by the cDNA contained in the deposited clones. Protein fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, 161-180, 181-200, 201-220, 221-240, 241-260, 261-280, or 281 to the end of the coding region or SEQ ID NO:2 or SEQ ID NO:4. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes

the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes.

Preferred polypeptide fragments include the secreted METH1 or METH2 protein as well as the mature form. Further preferred polypeptide fragments include the secreted METH1 or METH2 protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted METH1 or METH2 polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted METH1 or METH2 protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotide fragments encoding these METH1 or METH2 polypeptide fragments are also preferred.

Particularly, N-terminal deletions of the METH1 polypeptide can be described by the general formula m-950, where m is an integer from 2 to 949, where m corresponds to the position of the amino acid residue identified in SEQ ID NO:2. Preferably, N-terminal deletions of the METH1 polypeptide of the invention shown as SEQ ID NO:2 include polypeptides comprising the amino acid sequence of residues: G-2 to S-950; N-3 to S-950; A-4 to S-950; E-5 to S-950; R-6 to S-950; A-7 to S-950; P-8 to S-950; G-9 to S-950; S-10 to S-950; R-11 to S-950; S-12 to S-950; F-13 to S-950; G-14 to S-950; P-15 to S-950; V-16 to S-950; P-17 to S-950; T-18 to S-950; L-19 to S-950; L-20 to S-950; L-21 to S-950; L-22 to S-950; A-23 to S-950; A-24 to S-950; A-25 to S-950; L-26 to S-950; L-27 to S-950; A-28 to S-950; V-29 to S-950; S-30 to S-950; D-31 to S-950; A-32 to S-950; L-33 to S-950; G-34 to S-950; R-35 to S-950; P-36 to S-950; S-37 to S-950; E-38 to S-950; E-39 to S-950; D-40 to S-950; E-41 to S-950; E-42 to S-950; L-43 to S-950; V-44 to S-950; V-45 to S-950; P-46 to S-950; E-47 to S-950; L-48 to S-950; E-49 to S-950; R-50 to S-950; A-51 to S-950; P-52 to S-950; G-53 to S-950; H-54 to S-950; G-55 to S-950; T-56 to S-950; T-57 to S-950; R-58 to S-950; L-59 to S-950; R-60 to S-950; L-61 to S-950; H-62 to S-

950; A-63 to S-950; F-64 to S-950; D-65 to S-950; Q-66 to S-950; Q-67 to S-950; L-68 to S-950; D-69 to S-950; L-70 to S-950; E-71 to S-950; L-72 to S-950; R-73 to S-950; P-74 to S-950; D-75 to S-950; S-76 to S-950; S-77 to S-950; F-78 to S-950; L-79 to S-950; A-80 to S-950; P-81 to S-950; G-82 to S-950; F-83 to S-950; T-84 to S-950; L-85 to S-950; Q-86 to S-950; N-87 to S-950; V-88 to S-950; G-89 to S-950; R-90 to S-950; K-91 to S-950; S-92 to S-950; G-93 to S-950; S-94 to S-950; E-95 to S-950; T-96 to S-950; P-97 to S-950; L-98 to S-950; P-99 to S-950; E-100 to S-950; T-101 to S-950; D-102 to S-950; L-103 to S-950; A-104 to S-950; H-105 to S-950; C-106 to S-950; F-107 to S-950; Y-108 to S-950; S-109 to S-950; G-110 to S-950; T-111 to S-950; V-112 to S-950; N-113 to S-950; G-114 to S-950; D-115 to S-950; P-116 to S-950; S-117 to S-950; S-118 to S-950; A-119 to S-950; A-120 to S-950; A-121 to S-950; L-122 to S-950; S-123 to S-950; L-124 to S-950; C-125 to S-950; E-126 to S-950; G-127 to S-950; V-128 to S-950; R-129 to S-950; G-130 to S-950; A-131 to S-950; F-132 to S-950; Y-133 to S-950; L-134 to S-950; L-135 to S-950; G-136 to S-950; E-137 to S-950; A-138 to S-950; Y-139 to S-950; F-140 to S-950; I-141 to S-950; Q-142 to S-950; P-143 to S-950; L-144 to S-950; P-145 to S-950; A-146 to S-950; A-147 to S-950; S-148 to S-950; E-149 to S-950; R-150 to S-950; L-151 to S-950; A-152 to S-950; T-153 to S-950; A-154 to S-950; A-155 to S-950; P-156 to S-950; G-157 to S-950; E-158 to S-950; K-159 to S-950; P-160 to S-950; P-161 to S-950; A-162 to S-950; P-163 to S-950; L-164 to S-950; Q-165 to S-950; F-166 to S-950; H-167 to S-950; L-168 to S-950; L-169 to S-950; R-170 to S-950; R-171 to S-950; N-172 to S-950; R-173 to S-950; Q-174 to S-950; G-175 to S-950; D-176 to S-950; V-177 to S-950; G-178 to S-950; G-179 to S-950; T-180 to S-950; C-181 to S-950; G-182 to S-950; V-183 to S-950; V-184 to S-950; D-185 to S-950; D-186 to S-950; E-187 to S-950; P-188 to S-950; R-189 to S-950; P-190 to S-950; T-191 to S-950; G-192 to S-950; K-193 to S-950; A-194 to S-950; E-195 to S-950; T-196 to S-950; E-197 to S-950; D-198 to S-950; E-199 to S-950; D-200 to S-950; E-201 to S-950; G-202 to S-950; T-203 to S-950; E-204 to S-950; G-205 to S-950; E-206 to S-950; D-207 to S-950; E-

208 to S-950; G-209 to S-950; P-210 to S-950; Q-211 to S-950; W-212 to S-950;
S-213 to S-950; P-214 to S-950; Q-215 to S-950; D-216 to S-950; P-217 to S-
950; A-218 to S-950; L-219 to S-950; Q-220 to S-950; G-221 to S-950; V-222
to S-950; G-223 to S-950; Q-224 to S-950; P-225 to S-950; T-226 to S-950; G-
5 227 to S-950; T-228 to S-950; G-229 to S-950; S-230 to S-950; I-231 to S-950;
R-232 to S-950; K-233 to S-950; K-234 to S-950; R-235 to S-950; F-236 to S-
950; V-237 to S-950; S-238 to S-950; S-239 to S-950; H-240 to S-950; R-241
to S-950; Y-242 to S-950; V-243 to S-950; E-244 to S-950; T-245 to S-950; M-
246 to S-950; L-247 to S-950; V-248 to S-950; A-249 to S-950; D-250 to S-950;
10 Q-251 to S-950; S-252 to S-950; M-253 to S-950; A-254 to S-950; E-255 to S-
950; F-256 to S-950; H-257 to S-950; G-258 to S-950; S-259 to S-950; G-260
to S-950; L-261 to S-950; K-262 to S-950; H-263 to S-950; Y-264 to S-950; L-
265 to S-950; L-266 to S-950; T-267 to S-950; L-268 to S-950; F-269 to S-950;
S-270 to S-950; V-271 to S-950; A-272 to S-950; A-273 to S-950; R-274 to S-
15 950; L-275 to S-950; Y-276 to S-950; K-277 to S-950; H-278 to S-950; P-279
to S-950; S-280 to S-950; I-281 to S-950; R-282 to S-950; N-283 to S-950; S-
284 to S-950; V-285 to S-950; S-286 to S-950; L-287 to S-950; V-288 to S-950;
V-289 to S-950; V-290 to S-950; K-291 to S-950; I-292 to S-950; L-293 to S-
950; V-294 to S-950; I-295 to S-950; H-296 to S-950; D-297 to S-950; E-298
to S-950; Q-299 to S-950; K-300 to S-950; G-301 to S-950; P-302 to S-950; E-
20 303 to S-950; V-304 to S-950; T-305 to S-950; S-306 to S-950; N-307 to S-950;
A-308 to S-950; A-309 to S-950; L-310 to S-950; T-311 to S-950; L-312 to S-
950; R-313 to S-950; N-314 to S-950; F-315 to S-950; C-316 to S-950; N-317
to S-950; W-318 to S-950; Q-319 to S-950; K-320 to S-950; Q-321 to S-950; H-
25 322 to S-950; N-323 to S-950; P-324 to S-950; P-325 to S-950; S-326 to S-950;
D-327 to S-950; R-328 to S-950; D-329 to S-950; A-330 to S-950; E-331 to S-
950; H-332 to S-950; Y-333 to S-950; D-334 to S-950; T-335 to S-950; A-336
to S-950; I-337 to S-950; L-338 to S-950; F-339 to S-950; T-340 to S-950; R-
341 to S-950; Q-342 to S-950; D-343 to S-950; L-344 to S-950; C-345 to S-950;
30 G-346 to S-950; S-347 to S-950; Q-348 to S-950; T-349 to S-950; C-350 to S-

950; D-351 to S-950; T-352 to S-950; L-353 to S-950; G-354 to S-950; M-355
to S-950; A-356 to S-950; D-357 to S-950; V-358 to S-950; G-359 to S-950; T-
360 to S-950; V-361 to S-950; C-362 to S-950; D-363 to S-950; P-364 to S-950;
S-365 to S-950; R-366 to S-950; S-367 to S-950; C-368 to S-950; S-369 to S-
5 950; V-370 to S-950; I-371 to S-950; E-372 to S-950; D-373 to S-950; D-374
to S-950; G-375 to S-950; L-376 to S-950; Q-377 to S-950; A-378 to S-950; A-
379 to S-950; F-380 to S-950; T-381 to S-950; T-382 to S-950; A-383 to S-950;
H-384 to S-950; E-385 to S-950; L-386 to S-950; G-387 to S-950; H-388 to S-
950; V-389 to S-950; F-390 to S-950; N-391 to S-950; M-392 to S-950; P-393
10 to S-950; H-394 to S-950; D-395 to S-950; D-396 to S-950; A-397 to S-950; K-
398 to S-950; Q-399 to S-950; C-400 to S-950; A-401 to S-950; S-402 to S-950;
L-403 to S-950; N-404 to S-950; G-405 to S-950; V-406 to S-950; N-407 to S-
950; Q-408 to S-950; D-409 to S-950; S-410 to S-950; H-411 to S-950; M-412
to S-950; M-413 to S-950; A-414 to S-950; S-415 to S-950; M-416 to S-950; L-
15 417 to S-950; S-418 to S-950; N-419 to S-950; L-420 to S-950; D-421 to S-950;
H-422 to S-950; S-423 to S-950; Q-424 to S-950; P-425 to S-950; W-426 to S-
950; S-427 to S-950; P-428 to S-950; C-429 to S-950; S-430 to S-950; A-431 to
S-950; Y-432 to S-950; M-433 to S-950; I-434 to S-950; T-435 to S-950; S-436
to S-950; F-437 to S-950; L-438 to S-950; D-439 to S-950; N-440 to S-950; G-
20 441 to S-950; H-442 to S-950; G-443 to S-950; E-444 to S-950; C-445 to S-950;
L-446 to S-950; M-447 to S-950; D-448 to S-950; K-449 to S-950; P-450 to S-
950; Q-451 to S-950; N-452 to S-950; P-453 to S-950; I-454 to S-950; Q-455 to
S-950; L-456 to S-950; P-457 to S-950; G-458 to S-950; D-459 to S-950; L-460
to S-950; P-461 to S-950; G-462 to S-950; T-463 to S-950; S-464 to S-950; Y-
25 465 to S-950; D-466 to S-950; A-467 to S-950; N-468 to S-950; R-469 to S-950;
Q-470 to S-950; C-471 to S-950; Q-472 to S-950; F-473 to S-950; T-474 to S-
950; F-475 to S-950; G-476 to S-950; E-477 to S-950; D-478 to S-950; S-479
to S-950; K-480 to S-950; H-481 to S-950; C-482 to S-950; P-483 to S-950; D-
484 to S-950; A-485 to S-950; A-486 to S-950; S-487 to S-950; T-488 to S-950;
30 C-489 to S-950; S-490 to S-950; T-491 to S-950; L-492 to S-950; W-493 to S-

950; C-494 to S-950; T-495 to S-950; G-496 to S-950; T-497 to S-950; S-498
to S-950; G-499 to S-950; G-500 to S-950; V-501 to S-950; L-502 to S-950; V-
503 to S-950; C-504 to S-950; Q-505 to S-950; T-506 to S-950; K-507 to S-950;
H-508 to S-950; F-509 to S-950; P-510 to S-950; W-511 to S-950; A-512 to S-
5 950; D-513 to S-950; G-514 to S-950; T-515 to S-950; S-516 to S-950; C-517
to S-950; G-518 to S-950; E-519 to S-950; G-520 to S-950; K-521 to S-950; W-
522 to S-950; C-523 to S-950; I-524 to S-950; N-525 to S-950; G-526 to S-950;
K-527 to S-950; C-528 to S-950; V-529 to S-950; N-530 to S-950; K-531 to S-
950; T-532 to S-950; D-533 to S-950; R-534 to S-950; K-535 to S-950; H-536
10 to S-950; F-537 to S-950; D-538 to S-950; T-539 to S-950; P-540 to S-950; F-
541 to S-950; H-542 to S-950; G-543 to S-950; S-544 to S-950; W-545 to S-950;
G-546 to S-950; M-547 to S-950; W-548 to S-950; G-549 to S-950; P-550 to S-
950; W-551 to S-950; G-552 to S-950; D-553 to S-950; C-554 to S-950; S-555
to S-950; R-556 to S-950; T-557 to S-950; C-558 to S-950; G-559 to S-950; G-
15 560 to S-950; G-561 to S-950; V-562 to S-950; Q-563 to S-950; Y-564 to S-950;
T-565 to S-950; M-566 to S-950; R-567 to S-950; E-568 to S-950; C-569 to S-
950; D-570 to S-950; N-571 to S-950; P-572 to S-950; V-573 to S-950; P-574
to S-950; K-575 to S-950; N-576 to S-950; G-577 to S-950; G-578 to S-950; K-
579 to S-950; Y-580 to S-950; C-581 to S-950; E-582 to S-950; G-583 to S-950;
20 K-584 to S-950; R-585 to S-950; V-586 to S-950; R-587 to S-950; Y-588 to S-
950; R-589 to S-950; S-590 to S-950; C-591 to S-950; N-592 to S-950; L-593
to S-950; E-594 to S-950; D-595 to S-950; C-596 to S-950; P-597 to S-950; D-
598 to S-950; N-599 to S-950; N-600 to S-950; G-601 to S-950; K-602 to S-950;
T-603 to S-950; F-604 to S-950; R-605 to S-950; E-606 to S-950; E-607 to S-
25 950; Q-608 to S-950; C-609 to S-950; E-610 to S-950; A-611 to S-950; H-612
to S-950; N-613 to S-950; E-614 to S-950; F-615 to S-950; S-616 to S-950; K-
617 to S-950; A-618 to S-950; S-619 to S-950; F-620 to S-950; G-621 to S-950;
S-622 to S-950; G-623 to S-950; P-624 to S-950; A-625 to S-950; V-626 to S-
950; E-627 to S-950; W-628 to S-950; I-629 to S-950; P-630 to S-950; K-631
30 to S-950; Y-632 to S-950; A-633 to S-950; G-634 to S-950; V-635 to S-950; S-

-71-

636 to S-950; P-637 to S-950; K-638 to S-950; D-639 to S-950; R-640 to S-950;
C-641 to S-950; K-642 to S-950; L-643 to S-950; I-644 to S-950; C-645 to S-
950; Q-646 to S-950; A-647 to S-950; K-648 to S-950; G-649 to S-950; I-650
to S-950; G-651 to S-950; Y-652 to S-950; F-653 to S-950; F-654 to S-950; V-
5 655 to S-950; L-656 to S-950; Q-657 to S-950; P-658 to S-950; K-659 to S-950;
V-660 to S-950; V-661 to S-950; D-662 to S-950; G-663 to S-950; T-664 to S-
950; P-665 to S-950; C-666 to S-950; S-667 to S-950; P-668 to S-950; D-669 to
S-950; S-670 to S-950; T-671 to S-950; S-672 to S-950; V-673 to S-950; C-674
to S-950; V-675 to S-950; Q-676 to S-950; G-677 to S-950; Q-678 to S-950; C-
10 679 to S-950; V-680 to S-950; K-681 to S-950; A-682 to S-950; G-683 to S-950;
C-684 to S-950; D-685 to S-950; R-686 to S-950; I-687 to S-950; I-688 to S-
950; D-689 to S-950; S-690 to S-950; K-691 to S-950; K-692 to S-950; K-693
to S-950; F-694 to S-950; D-695 to S-950; K-696 to S-950; C-697 to S-950; G-
698 to S-950; V-699 to S-950; C-700 to S-950; G-701 to S-950; G-702 to S-950;
15 N-703 to S-950; G-704 to S-950; S-705 to S-950; T-706 to S-950; C-707 to S-
950; K-708 to S-950; K-709 to S-950; I-710 to S-950; S-711 to S-950; G-712 to
S-950; S-713 to S-950; V-714 to S-950; T-715 to S-950; S-716 to S-950; A-717
to S-950; K-718 to S-950; P-719 to S-950; G-720 to S-950; Y-721 to S-950; H-
722 to S-950; D-723 to S-950; I-724 to S-950; I-725 to S-950; T-726 to S-950;
20 I-727 to S-950; P-728 to S-950; T-729 to S-950; G-730 to S-950; A-731 to S-
950; T-732 to S-950; N-733 to S-950; I-734 to S-950; E-735 to S-950; V-736 to
S-950; K-737 to S-950; Q-738 to S-950; R-739 to S-950; N-740 to S-950; Q-741
to S-950; R-742 to S-950; G-743 to S-950; S-744 to S-950; R-745 to S-950; N-
746 to S-950; N-747 to S-950; G-748 to S-950; S-749 to S-950; F-750 to S-950;
25 L-751 to S-950; A-752 to S-950; I-753 to S-950; K-754 to S-950; A-755 to S-
950; A-756 to S-950; D-757 to S-950; G-758 to S-950; T-759 to S-950; Y-760
to S-950; I-761 to S-950; L-762 to S-950; N-763 to S-950; G-764 to S-950; D-
765 to S-950; Y-766 to S-950; T-767 to S-950; L-768 to S-950; S-769 to S-950;
T-770 to S-950; L-771 to S-950; E-772 to S-950; Q-773 to S-950; D-774 to S-
30 950; I-775 to S-950; M-776 to S-950; Y-777 to S-950; K-778 to S-950; G-779

to S-950; V-780 to S-950; V-781 to S-950; L-782 to S-950; R-783 to S-950; Y-784 to S-950; S-785 to S-950; G-786 to S-950; S-787 to S-950; S-788 to S-950; A-789 to S-950; A-790 to S-950; L-791 to S-950; E-792 to S-950; R-793 to S-950; I-794 to S-950; R-795 to S-950; S-796 to S-950; F-797 to S-950; S-798 to S-950; P-799 to S-950; L-800 to S-950; K-801 to S-950; E-802 to S-950; P-803 to S-950; L-804 to S-950; T-805 to S-950; I-806 to S-950; Q-807 to S-950; V-808 to S-950; L-809 to S-950; T-810 to S-950; V-811 to S-950; G-812 to S-950; N-813 to S-950; A-814 to S-950; L-815 to S-950; R-816 to S-950; P-817 to S-950; K-818 to S-950; I-819 to S-950; K-820 to S-950; Y-821 to S-950; T-822 to S-950; Y-823 to S-950; F-824 to S-950; V-825 to S-950; K-826 to S-950; K-827 to S-950; K-828 to S-950; K-829 to S-950; E-830 to S-950; S-831 to S-950; F-832 to S-950; N-833 to S-950; A-834 to S-950; I-835 to S-950; P-836 to S-950; T-837 to S-950; F-838 to S-950; S-839 to S-950; A-840 to S-950; W-841 to S-950; V-842 to S-950; I-843 to S-950; E-844 to S-950; E-845 to S-950; W-846 to S-950; G-847 to S-950; E-848 to S-950; C-849 to S-950; S-850 to S-950; K-851 to S-950; S-852 to S-950; C-853 to S-950; E-854 to S-950; L-855 to S-950; G-856 to S-950; W-857 to S-950; Q-858 to S-950; R-859 to S-950; R-860 to S-950; L-861 to S-950; V-862 to S-950; E-863 to S-950; C-864 to S-950; R-865 to S-950; D-866 to S-950; I-867 to S-950; N-868 to S-950; G-869 to S-950; Q-870 to S-950; P-871 to S-950; A-872 to S-950; S-873 to S-950; E-874 to S-950; C-875 to S-950; A-876 to S-950; K-877 to S-950; E-878 to S-950; V-879 to S-950; K-880 to S-950; P-881 to S-950; A-882 to S-950; S-883 to S-950; T-884 to S-950; R-885 to S-950; P-886 to S-950; C-887 to S-950; A-888 to S-950; D-889 to S-950; H-890 to S-950; P-891 to S-950; C-892 to S-950; P-893 to S-950; Q-894 to S-950; W-895 to S-950; Q-896 to S-950; L-897 to S-950; G-898 to S-950; E-899 to S-950; W-900 to S-950; S-901 to S-950; S-902 to S-950; C-903 to S-950; S-904 to S-950; K-905 to S-950; T-906 to S-950; C-907 to S-950; G-908 to S-950; K-909 to S-950; G-910 to S-950; Y-911 to S-950; K-912 to S-950; K-913 to S-950; R-914 to S-950; S-915 to S-950; L-916 to S-950; K-917 to S-950; C-918 to S-950; L-919 to S-950; S-920 to S-950; H-921 to S-950; D-922

to S-950; G-923 to S-950; G-924 to S-950; V-925 to S-950; L-926 to S-950; S-927 to S-950; H-928 to S-950; E-929 to S-950; S-930 to S-950; C-931 to S-950; D-932 to S-950; P-933 to S-950; L-934 to S-950; K-935 to S-950; K-936 to S-950; P-937 to S-950; K-938 to S-950; H-939 to S-950; F-940 to S-950; I-941 to S-950; D-942 to S-950; F-943 to S-950; C-944 to S-950; T-945 to S-950; of SEQ ID NO:2.

Moreover, C-terminal deletions of the METH1 polypeptide can also be described by the general formula 1-n, where n is an integer from 2 to 950, where n corresponds to the position of amino acid residue identified in SEQ ID NO:2.

Preferably, C-terminal deletions of the METH1 polypeptide of the invention shown as SEQ ID NO:2 include polypeptides comprising the amino acid sequence of residues: M-1 to C-949; M-1 to E-948; M-1 to A-947; M-1 to M-946; M-1 to T-945; M-1 to C-944; M-1 to F-943; M-1 to D-942; M-1 to I-941; M-1 to F-940; M-1 to H-939; M-1 to K-938; M-1 to P-937; M-1 to K-936; M-1 to K-935; M-1 to L-934; M-1 to P-933; M-1 to D-932; M-1 to C-931; M-1 to S-930; M-1 to E-929; M-1 to H-928; M-1 to S-927; M-1 to L-926; M-1 to V-925; M-1 to G-924; M-1 to G-923; M-1 to D-922; M-1 to H-921; M-1 to S-920; M-1 to L-919; M-1 to C-918; M-1 to K-917; M-1 to L-916; M-1 to S-915; M-1 to R-914; M-1 to K-913; M-1 to K-912; M-1 to Y-911; M-1 to G-910; M-1 to K-909; M-1 to G-908; M-1 to C-907; M-1 to T-906; M-1 to K-905; M-1 to S-904; M-1 to C-903; M-1 to S-902; M-1 to S-901; M-1 to W-900; M-1 to E-899; M-1 to G-898; M-1 to L-897; M-1 to Q-896; M-1 to W-895; M-1 to Q-894; M-1 to P-893; M-1 to C-892; M-1 to P-891; M-1 to H-890; M-1 to D-889; M-1 to A-888; M-1 to C-887; M-1 to P-886; M-1 to R-885; M-1 to T-884; M-1 to S-883; M-1 to A-882; M-1 to P-881; M-1 to K-880; M-1 to V-879; M-1 to E-878; M-1 to K-877; M-1 to A-876; M-1 to C-875; M-1 to E-874; M-1 to S-873; M-1 to A-872; M-1 to P-871; M-1 to Q-870; M-1 to G-869; M-1 to N-868; M-1 to I-867; M-1 to D-866; M-1 to R-865; M-1 to C-864; M-1 to E-863; M-1 to V-862; M-1 to L-861; M-1 to R-860; M-1 to R-859; M-1 to Q-858; M-1 to W-857; M-1 to G-856; M-1 to L-855; M-1 to E-854; M-1 to C-853; M-1 to S-852; M-1 to K-851; M-1 to S-850; M-1 to C-

849; M-1 to E-848; M-1 to G-847; M-1 to W-846; M-1 to E-845; M-1 to E-844;
M-1 to I-843; M-1 to V-842; M-1 to W-841; M-1 to A-840; M-1 to S-839; M-1
to F-838; M-1 to T-837; M-1 to P-836; M-1 to I-835; M-1 to A-834; M-1 to N-
833; M-1 to F-832; M-1 to S-831; M-1 to E-830; M-1 to K-829; M-1 to K-828;
5 M-1 to K-827; M-1 to K-826; M-1 to V-825; M-1 to F-824; M-1 to Y-823; M-1
to T-822; M-1 to Y-821; M-1 to K-820; M-1 to I-819; M-1 to K-818; M-1 to P-
817; M-1 to R-816; M-1 to L-815; M-1 to A-814; M-1 to N-813; M-1 to G-812;
M-1 to V-811; M-1 to T-810; M-1 to L-809; M-1 to V-808; M-1 to Q-807; M-1
to I-806; M-1 to T-805; M-1 to L-804; M-1 to P-803; M-1 to E-802; M-1 to K-
10 801; M-1 to L-800; M-1 to P-799; M-1 to S-798; M-1 to F-797; M-1 to S-796;
M-1 to R-795; M-1 to I-794; M-1 to R-793; M-1 to E-792; M-1 to L-791; M-1
to A-790; M-1 to A-789; M-1 to S-788; M-1 to S-787; M-1 to G-786; M-1 to S-
785; M-1 to Y-784; M-1 to R-783; M-1 to L-782; M-1 to V-781; M-1 to V-780;
M-1 to G-779; M-1 to K-778; M-1 to Y-777; M-1 to M-776; M-1 to I-775; M-1
15 to D-774; M-1 to Q-773; M-1 to E-772; M-1 to L-771; M-1 to T-770; M-1 to S-
769; M-1 to L-768; M-1 to T-767; M-1 to Y-766; M-1 to D-765; M-1 to G-764;
M-1 to N-763; M-1 to L-762; M-1 to I-761; M-1 to Y-760; M-1 to T-759; M-1
to G-758; M-1 to D-757; M-1 to A-756; M-1 to A-755; M-1 to K-754; M-1 to
I-753; M-1 to A-752; M-1 to L-751; M-1 to F-750; M-1 to S-749; M-1 to G-748;
20 M-1 to N-747; M-1 to N-746; M-1 to R-745; M-1 to S-744; M-1 to G-743; M-1
to R-742; M-1 to Q-741; M-1 to N-740; M-1 to R-739; M-1 to Q-738; M-1 to
K-737; M-1 to V-736; M-1 to E-735; M-1 to I-734; M-1 to N-733; M-1 to T-
732; M-1 to A-731; M-1 to G-730; M-1 to T-729; M-1 to P-728; M-1 to I-727;
M-1 to T-726; M-1 to I-725; M-1 to I-724; M-1 to D-723; M-1 to H-722; M-1
25 to Y-721; M-1 to G-720; M-1 to P-719; M-1 to K-718; M-1 to A-717; M-1 to S-
716; M-1 to T-715; M-1 to V-714; M-1 to S-713; M-1 to G-712; M-1 to S-711;
M-1 to I-710; M-1 to K-709; M-1 to K-708; M-1 to C-707; M-1 to T-706; M-1
to S-705; M-1 to G-704; M-1 to N-703; M-1 to G-702; M-1 to G-701; M-1 to C-
700; M-1 to V-699; M-1 to G-698; M-1 to C-697; M-1 to K-696; M-1 to D-695;
30 M-1 to F-694; M-1 to K-693; M-1 to K-692; M-1 to K-691; M-1 to S-690; M-1

to D-689; M-1 to I-688; M-1 to I-687; M-1 to R-686; M-1 to D-685; M-1 to C-684; M-1 to G-683; M-1 to A-682; M-1 to K-681; M-1 to V-680; M-1 to C-679; M-1 to Q-678; M-1 to G-677; M-1 to Q-676; M-1 to V-675; M-1 to C-674; M-1 to V-673; M-1 to S-672; M-1 to T-671; M-1 to S-670; M-1 to D-669; M-1 to P-668; M-1 to S-667; M-1 to C-666; M-1 to P-665; M-1 to T-664; M-1 to G-663; M-1 to D-662; M-1 to V-661; M-1 to V-660; M-1 to K-659; M-1 to P-658; M-1 to Q-657; M-1 to L-656; M-1 to V-655; M-1 to F-654; M-1 to F-653; M-1 to Y-652; M-1 to G-651; M-1 to I-650; M-1 to G-649; M-1 to K-648; M-1 to A-647; M-1 to Q-646; M-1 to C-645; M-1 to I-644; M-1 to L-643; M-1 to K-642; M-1 to C-641; M-1 to R-640; M-1 to D-639; M-1 to K-638; M-1 to P-637; M-1 to S-636; M-1 to V-635; M-1 to G-634; M-1 to A-633; M-1 to Y-632; M-1 to K-631; M-1 to P-630; M-1 to I-629; M-1 to W-628; M-1 to E-627; M-1 to V-626; M-1 to A-625; M-1 to P-624; M-1 to G-623; M-1 to S-622; M-1 to G-621; M-1 to F-620; M-1 to S-619; M-1 to A-618; M-1 to K-617; M-1 to S-616; M-1 to F-615; M-1 to E-614; M-1 to N-613; M-1 to H-612; M-1 to A-611; M-1 to E-610; M-1 to C-609; M-1 to Q-608; M-1 to E-607; M-1 to E-606; M-1 to R-605; M-1 to F-604; M-1 to T-603; M-1 to K-602; M-1 to G-601; M-1 to N-600; M-1 to N-599; M-1 to D-598; M-1 to P-597; M-1 to C-596; M-1 to D-595; M-1 to E-594; M-1 to L-593; M-1 to N-592; M-1 to C-591; M-1 to S-590; M-1 to R-589; M-1 to Y-588; M-1 to R-587; M-1 to V-586; M-1 to R-585; M-1 to K-584; M-1 to G-583; M-1 to E-582; M-1 to C-581; M-1 to Y-580; M-1 to K-579; M-1 to G-578; M-1 to G-577; M-1 to N-576; M-1 to K-575; M-1 to P-574; M-1 to V-573; M-1 to P-572; M-1 to N-571; M-1 to D-570; M-1 to C-569; M-1 to E-568; M-1 to R-567; M-1 to M-566; M-1 to T-565; M-1 to Y-564; M-1 to Q-563; M-1 to V-562; M-1 to G-561; M-1 to G-560; M-1 to G-559; M-1 to C-558; M-1 to T-557; M-1 to R-556; M-1 to S-555; M-1 to C-554; M-1 to D-553; M-1 to G-552; M-1 to W-551; M-1 to P-550; M-1 to G-549; M-1 to W-548; M-1 to M-547; M-1 to G-546; M-1 to W-545; M-1 to S-544; M-1 to G-543; M-1 to H-542; M-1 to F-541; M-1 to P-540; M-1 to T-539; M-1 to D-538; M-1 to F-537; M-1 to H-536; M-1 to K-535; M-1 to R-534; M-1 to D-533; M-1 to T-532; M-1 to K-531; M-1 to N-530;

M-1 to V-529; M-1 to C-528; M-1 to K-527; M-1 to G-526; M-1 to N-525; M-1 to I-524; M-1 to C-523; M-1 to W-522; M-1 to K-521; M-1 to G-520; M-1 to E-519; M-1 to G-518; M-1 to C-517; M-1 to S-516; M-1 to T-515; M-1 to G-514; M-1 to D-513; M-1 to A-512; M-1 to W-511; M-1 to P-510; M-1 to F-509; M-1 to H-508; M-1 to K-507; M-1 to T-506; M-1 to Q-505; M-1 to C-504; M-1 to V-503; M-1 to L-502; M-1 to V-501; M-1 to G-500; M-1 to G-499; M-1 to S-498; M-1 to T-497; M-1 to G-496; M-1 to T-495; M-1 to C-494; M-1 to W-493; M-1 to L-492; M-1 to T-491; M-1 to S-490; M-1 to C-489; M-1 to T-488; M-1 to S-487; M-1 to A-486; M-1 to A-485; M-1 to D-484; M-1 to P-483; M-1 to C-482; M-1 to H-481; M-1 to K-480; M-1 to S-479; M-1 to D-478; M-1 to E-477; M-1 to G-476; M-1 to F-475; M-1 to T-474; M-1 to F-473; M-1 to Q-472; M-1 to C-471; M-1 to Q-470; M-1 to R-469; M-1 to N-468; M-1 to A-467; M-1 to D-466; M-1 to Y-465; M-1 to S-464; M-1 to T-463; M-1 to G-462; M-1 to P-461; M-1 to L-460; M-1 to D-459; M-1 to G-458; M-1 to P-457; M-1 to L-456; M-1 to Q-455; M-1 to I-454; M-1 to P-453; M-1 to N-452; M-1 to Q-451; M-1 to P-450; M-1 to K-449; M-1 to D-448; M-1 to M-447; M-1 to L-446; M-1 to C-445; M-1 to E-444; M-1 to G-443; M-1 to H-442; M-1 to G-441; M-1 to N-440; M-1 to D-439; M-1 to L-438; M-1 to F-437; M-1 to S-436; M-1 to T-435; M-1 to I-434; M-1 to M-433; M-1 to Y-432; M-1 to A-431; M-1 to S-430; M-1 to C-429; M-1 to P-428; M-1 to S-427; M-1 to W-426; M-1 to P-425; M-1 to Q-424; M-1 to S-423; M-1 to H-422; M-1 to D-421; M-1 to L-420; M-1 to N-419; M-1 to S-418; M-1 to L-417; M-1 to M-416; M-1 to S-415; M-1 to A-414; M-1 to M-413; M-1 to M-412; M-1 to H-411; M-1 to S-410; M-1 to D-409; M-1 to Q-408; M-1 to N-407; M-1 to V-406; M-1 to G-405; M-1 to N-404; M-1 to L-403; M-1 to S-402; M-1 to A-401; M-1 to C-400; M-1 to Q-399; M-1 to K-398; M-1 to A-397; M-1 to D-396; M-1 to D-395; M-1 to H-394; M-1 to P-393; M-1 to M-392; M-1 to N-391; M-1 to F-390; M-1 to V-389; M-1 to H-388; M-1 to G-387; M-1 to L-386; M-1 to E-385; M-1 to H-384; M-1 to A-383; M-1 to T-382; M-1 to T-381; M-1 to F-380; M-1 to A-379; M-1 to A-378; M-1 to Q-377; M-1 to L-376; M-1 to G-375; M-1 to D-374; M-1 to D-373; M-1 to E-372; M-1 to I-371; M-1 to V-

370; M-1 to S-369; M-1 to C-368; M-1 to S-367; M-1 to R-366; M-1 to S-365;
M-1 to P-364; M-1 to D-363; M-1 to C-362; M-1 to V-361; M-1 to T-360; M-1
to G-359; M-1 to V-358; M-1 to D-357; M-1 to A-356; M-1 to M-355; M-1 to
G-354; M-1 to L-353; M-1 to T-352; M-1 to D-351; M-1 to C-350; M-1 to T-
5 349; M-1 to Q-348; M-1 to S-347; M-1 to G-346; M-1 to C-345; M-1 to L-344;
M-1 to D-343; M-1 to Q-342; M-1 to R-341; M-1 to T-340; M-1 to F-339; M-1
to L-338; M-1 to I-337; M-1 to A-336; M-1 to T-335; M-1 to D-334; M-1 to Y-
333; M-1 to H-332; M-1 to E-331; M-1 to A-330; M-1 to D-329; M-1 to R-328;
M-1 to D-327; M-1 to S-326; M-1 to P-325; M-1 to P-324; M-1 to N-323; M-1
10 to H-322; M-1 to Q-321; M-1 to K-320; M-1 to Q-319; M-1 to W-318; M-1 to
N-317; M-1 to C-316; M-1 to F-315; M-1 to N-314; M-1 to R-313; M-1 to L-
312; M-1 to T-311; M-1 to L-310; M-1 to A-309; M-1 to A-308; M-1 to N-307;
M-1 to S-306; M-1 to T-305; M-1 to V-304; M-1 to E-303; M-1 to P-302; M-1
to G-301; M-1 to K-300; M-1 to Q-299; M-1 to E-298; M-1 to D-297; M-1 to
15 H-296; M-1 to I-295; M-1 to V-294; M-1 to L-293; M-1 to I-292; M-1 to K-291;
M-1 to V-290; M-1 to V-289; M-1 to V-288; M-1 to L-287; M-1 to S-286; M-1
to V-285; M-1 to S-284; M-1 to N-283; M-1 to R-282; M-1 to I-281; M-1 to S-
280; M-1 to P-279; M-1 to H-278; M-1 to K-277; M-1 to Y-276; M-1 to L-275;
M-1 to R-274; M-1 to A-273; M-1 to A-272; M-1 to V-271; M-1 to S-270; M-1
20 to F-269; M-1 to L-268; M-1 to T-267; M-1 to L-266; M-1 to L-265; M-1 to Y-
264; M-1 to H-263; M-1 to K-262; M-1 to L-261; M-1 to G-260; M-1 to S-259;
M-1 to G-258; M-1 to H-257; M-1 to F-256; M-1 to E-255; M-1 to A-254; M-1
to M-253; M-1 to S-252; M-1 to Q-251; M-1 to D-250; M-1 to A-249; M-1 to
V-248; M-1 to L-247; M-1 to M-246; M-1 to T-245; M-1 to E-244; M-1 to V-
25 243; M-1 to Y-242; M-1 to R-241; M-1 to H-240; M-1 to S-239; M-1 to S-238;
M-1 to V-237; M-1 to F-236; M-1 to R-235; M-1 to K-234; M-1 to K-233; M-1
to R-232; M-1 to I-231; M-1 to S-230; M-1 to G-229; M-1 to T-228; M-1 to G-
227; M-1 to T-226; M-1 to P-225; M-1 to Q-224; M-1 to G-223; M-1 to V-222;
M-1 to G-221; M-1 to Q-220; M-1 to L-219; M-1 to A-218; M-1 to P-217; M-1
30 to D-216; M-1 to Q-215; M-1 to P-214; M-1 to S-213; M-1 to W-212; M-1 to

Q-211; M-1 to P-210; M-1 to G-209; M-1 to E-208; M-1 to D-207; M-1 to E-206; M-1 to G-205; M-1 to E-204; M-1 to T-203; M-1 to G-202; M-1 to E-201; M-1 to D-200; M-1 to E-199; M-1 to D-198; M-1 to E-197; M-1 to T-196; M-1 to E-195; M-1 to A-194; M-1 to K-193; M-1 to G-192; M-1 to T-191; M-1 to P-190; M-1 to R-189; M-1 to P-188; M-1 to E-187; M-1 to D-186; M-1 to D-185; M-1 to V-184; M-1 to V-183; M-1 to G-182; M-1 to C-181; M-1 to T-180; M-1 to G-179; M-1 to G-178; M-1 to V-177; M-1 to D-176; M-1 to G-175; M-1 to Q-174; M-1 to R-173; M-1 to N-172; M-1 to R-171; M-1 to R-170; M-1 to L-169; M-1 to L-168; M-1 to H-167; M-1 to F-166; M-1 to Q-165; M-1 to L-164; M-1 to P-163; M-1 to A-162; M-1 to P-161; M-1 to P-160; M-1 to K-159; M-1 to E-158; M-1 to G-157; M-1 to P-156; M-1 to A-155; M-1 to A-154; M-1 to T-153; M-1 to A-152; M-1 to L-151; M-1 to R-150; M-1 to E-149; M-1 to S-148; M-1 to A-147; M-1 to A-146; M-1 to P-145; M-1 to L-144; M-1 to P-143; M-1 to Q-142; M-1 to I-141; M-1 to F-140; M-1 to Y-139; M-1 to A-138; M-1 to E-137; M-1 to G-136; M-1 to L-135; M-1 to L-134; M-1 to Y-133; M-1 to F-132; M-1 to A-131; M-1 to G-130; M-1 to R-129; M-1 to V-128; M-1 to G-127; M-1 to E-126; M-1 to C-125; M-1 to L-124; M-1 to S-123; M-1 to L-122; M-1 to A-121; M-1 to A-120; M-1 to A-119; M-1 to S-118; M-1 to S-117; M-1 to P-116; M-1 to D-115; M-1 to G-114; M-1 to N-113; M-1 to V-112; M-1 to T-111; M-1 to G-110; M-1 to S-109; M-1 to Y-108; M-1 to F-107; M-1 to C-106; M-1 to H-105; M-1 to A-104; M-1 to L-103; M-1 to D-102; M-1 to T-101; M-1 to E-100; M-1 to P-99; M-1 to L-98; M-1 to P-97; M-1 to T-96; M-1 to E-95; M-1 to S-94; M-1 to G-93; M-1 to S-92; M-1 to K-91; M-1 to R-90; M-1 to G-89; M-1 to V-88; M-1 to N-87; M-1 to Q-86; M-1 to L-85; M-1 to T-84; M-1 to F-83; M-1 to G-82; M-1 to P-81; M-1 to A-80; M-1 to L-79; M-1 to F-78; M-1 to S-77; M-1 to S-76; M-1 to D-75; M-1 to P-74; M-1 to R-73; M-1 to L-72; M-1 to E-71; M-1 to L-70; M-1 to D-69; M-1 to L-68; M-1 to Q-67; M-1 to Q-66; M-1 to D-65; M-1 to F-64; M-1 to A-63; M-1 to H-62; M-1 to L-61; M-1 to R-60; M-1 to L-59; M-1 to R-58; M-1 to T-57; M-1 to T-56; M-1 to G-55; M-1 to H-54; M-1 to G-53; M-1 to P-52; M-1 to A-51; M-1 to R-50; M-1 to E-49; M-1 to L-48; M-1

to E-47; M-1 to P-46; M-1 to V-45; M-1 to V-44; M-1 to L-43; M-1 to E-42; M-1 to E-41; M-1 to D-40; M-1 to E-39; M-1 to E-38; M-1 to S-37; M-1 to P-36; M-1 to R-35; M-1 to G-34; M-1 to L-33; M-1 to A-32; M-1 to D-31; M-1 to S-30; M-1 to V-29; M-1 to A-28; M-1 to L-27; M-1 to L-26; M-1 to A-25; M-1 to A-24; M-1 to A-23; M-1 to L-22; M-1 to L-21; M-1 to L-20; M-1 to L-19; M-1 to T-18; M-1 to P-17; M-1 to V-16; M-1 to P-15; M-1 to G-14; M-1 to F-13; M-1 to S-12; M-1 to R-11; M-1 to S-10; M-1 to G-9; M-1 to P-8; M-1 to A-7; of SEQ ID NO:2. For example, any of the above listed N- or C-terminal deletions can be combined to produce a N- and C-terminal deleted METH1 polypeptide.

Moreover, N-terminal deletions of the METH2 polypeptide can be described by the general formula m-890, where m is an integer from 2 to 889, where m corresponds to the position of the amino acid residue identified in SEQ ID NO:4. Preferably, N-terminal deletions of the METH2 polypeptide of the invention shown as SEQ ID NO:4 include polypeptides comprising the amino acid sequence of residues: F-2 to L-890; P-3 to L-890; A-4 to L-890; P-5 to L-890; A-6 to L-890; A-7 to L-890; P-8 to L-890; R-9 to L-890; W-10 to L-890; L-11 to L-890; P-12 to L-890; F-13 to L-890; L-14 to L-890; L-15 to L-890; L-16 to L-890; L-17 to L-890; L-18 to L-890; L-19 to L-890; L-20 to L-890; L-21 to L-890; L-22 to L-890; P-23 to L-890; L-24 to L-890; A-25 to L-890; R-26 to L-890; G-27 to L-890; A-28 to L-890; P-29 to L-890; A-30 to L-890; R-31 to L-890; P-32 to L-890; A-33 to L-890; A-34 to L-890; G-35 to L-890; G-36 to L-890; Q-37 to L-890; A-38 to L-890; S-39 to L-890; E-40 to L-890; L-41 to L-890; V-42 to L-890; V-43 to L-890; P-44 to L-890; T-45 to L-890; R-46 to L-890; L-47 to L-890; P-48 to L-890; G-49 to L-890; S-50 to L-890; A-51 to L-890; G-52 to L-890; E-53 to L-890; L-54 to L-890; A-55 to L-890; L-56 to L-890; H-57 to L-890; L-58 to L-890; S-59 to L-890; A-60 to L-890; F-61 to L-890; G-62 to L-890; K-63 to L-890; G-64 to L-890; F-65 to L-890; V-66 to L-890; L-67 to L-890; R-68 to L-890; L-69 to L-890; A-70 to L-890; P-71 to L-890; D-72 to L-890; D-73 to L-890; S-74 to L-890; F-75 to L-890; L-76 to L-890; A-77 to L-890; P-78 to L-890; E-79 to L-890; F-80 to L-890; K-81 to L-

890; I-82 to L-890; E-83 to L-890; R-84 to L-890; L-85 to L-890; G-86 to L-890; G-87 to L-890; S-88 to L-890; G-89 to L-890; R-90 to L-890; A-91 to L-890; T-92 to L-890; G-93 to L-890; G-94 to L-890; E-95 to L-890; R-96 to L-890; G-97 to L-890; L-98 to L-890; R-99 to L-890; G-100 to L-890; C-101 to L-890; F-102 to L-890; F-103 to L-890; S-104 to L-890; G-105 to L-890; T-106 to L-890; V-107 to L-890; N-108 to L-890; G-109 to L-890; E-110 to L-890; P-111 to L-890; E-112 to L-890; S-113 to L-890; L-114 to L-890; A-115 to L-890; A-116 to L-890; V-117 to L-890; S-118 to L-890; L-119 to L-890; C-120 to L-890; R-121 to L-890; G-122 to L-890; L-123 to L-890; S-124 to L-890; G-125 to L-890; S-126 to L-890; F-127 to L-890; L-128 to L-890; L-129 to L-890; D-130 to L-890; G-131 to L-890; E-132 to L-890; E-133 to L-890; F-134 to L-890; T-135 to L-890; I-136 to L-890; Q-137 to L-890; P-138 to L-890; Q-139 to L-890; G-140 to L-890; A-141 to L-890; G-142 to L-890; G-143 to L-890; S-144 to L-890; L-145 to L-890; A-146 to L-890; Q-147 to L-890; P-148 to L-890; H-149 to L-890; R-150 to L-890; L-151 to L-890; Q-152 to L-890; R-153 to L-890; W-154 to L-890; G-155 to L-890; P-156 to L-890; A-157 to L-890; G-158 to L-890; A-159 to L-890; R-160 to L-890; P-161 to L-890; L-162 to L-890; P-163 to L-890; R-164 to L-890; G-165 to L-890; P-166 to L-890; E-167 to L-890; W-168 to L-890; E-169 to L-890; V-170 to L-890; E-171 to L-890; T-172 to L-890; G-173 to L-890; E-174 to L-890; G-175 to L-890; Q-176 to L-890; R-177 to L-890; Q-178 to L-890; E-179 to L-890; R-180 to L-890; G-181 to L-890; D-182 to L-890; H-183 to L-890; Q-184 to L-890; E-185 to L-890; D-186 to L-890; S-187 to L-890; E-188 to L-890; E-189 to L-890; E-190 to L-890; S-191 to L-890; Q-192 to L-890; E-193 to L-890; E-194 to L-890; E-195 to L-890; A-196 to L-890; E-197 to L-890; G-198 to L-890; A-199 to L-890; S-200 to L-890; E-201 to L-890; P-202 to L-890; P-203 to L-890; P-204 to L-890; P-205 to L-890; L-206 to L-890; G-207 to L-890; A-208 to L-890; T-209 to L-890; S-210 to L-890; R-211 to L-890; T-212 to L-890; K-213 to L-890; R-214 to L-890; F-215 to L-890; V-216 to L-890; S-217 to L-890; E-218 to L-890; A-219 to L-890; R-220 to L-890; F-221 to L-890; V-222 to L-890; E-223 to L-890; T-224 to L-890; L-

225 to L-890; L-226 to L-890; V-227 to L-890; A-228 to L-890; D-229 to L-890;
A-230 to L-890; S-231 to L-890; M-232 to L-890; A-233 to L-890; A-234 to L-
890; F-235 to L-890; Y-236 to L-890; G-237 to L-890; A-238 to L-890; D-239
to L-890; L-240 to L-890; Q-241 to L-890; N-242 to L-890; H-243 to L-890; I-
5 244 to L-890; L-245 to L-890; T-246 to L-890; L-247 to L-890; M-248 to L-890;
S-249 to L-890; V-250 to L-890; A-251 to L-890; A-252 to L-890; R-253 to L-
890; I-254 to L-890; Y-255 to L-890; K-256 to L-890; H-257 to L-890; P-258
to L-890; S-259 to L-890; I-260 to L-890; K-261 to L-890; N-262 to L-890; S-
263 to L-890; I-264 to L-890; N-265 to L-890; L-266 to L-890; M-267 to L-890;
10 V-268 to L-890; V-269 to L-890; K-270 to L-890; V-271 to L-890; L-272 to L-
890; I-273 to L-890; V-274 to L-890; E-275 to L-890; D-276 to L-890; E-277
to L-890; K-278 to L-890; W-279 to L-890; G-280 to L-890; P-281 to L-890; E-
282 to L-890; V-283 to L-890; S-284 to L-890; D-285 to L-890; N-286 to L-890;
G-287 to L-890; G-288 to L-890; L-289 to L-890; T-290 to L-890; L-291 to L-
15 890; R-292 to L-890; N-293 to L-890; F-294 to L-890; C-295 to L-890; N-296
to L-890; W-297 to L-890; Q-298 to L-890; R-299 to L-890; R-300 to L-890; F-
301 to L-890; N-302 to L-890; Q-303 to L-890; P-304 to L-890; S-305 to L-890;
D-306 to L-890; R-307 to L-890; H-308 to L-890; P-309 to L-890; E-310 to L-
890; H-311 to L-890; Y-312 to L-890; D-313 to L-890; T-314 to L-890; A-315
20 to L-890; I-316 to L-890; L-317 to L-890; L-318 to L-890; T-319 to L-890; R-
320 to L-890; Q-321 to L-890; N-322 to L-890; F-323 to L-890; C-324 to L-890;
G-325 to L-890; Q-326 to L-890; E-327 to L-890; G-328 to L-890; L-329 to L-
890; C-330 to L-890; D-331 to L-890; T-332 to L-890; L-333 to L-890; G-334
to L-890; V-335 to L-890; A-336 to L-890; D-337 to L-890; I-338 to L-890; G-
25 339 to L-890; T-340 to L-890; I-341 to L-890; C-342 to L-890; D-343 to L-890;
P-344 to L-890; N-345 to L-890; K-346 to L-890; S-347 to L-890; C-348 to L-
890; S-349 to L-890; V-350 to L-890; I-351 to L-890; E-352 to L-890; D-353
to L-890; E-354 to L-890; G-355 to L-890; L-356 to L-890; Q-357 to L-890; A-
358 to L-890; A-359 to L-890; H-360 to L-890; T-361 to L-890; L-362 to L-890;
30 A-363 to L-890; H-364 to L-890; E-365 to L-890; L-366 to L-890; G-367 to L-

890; H-368 to L-890; V-369 to L-890; L-370 to L-890; S-371 to L-890; M-372 to L-890; P-373 to L-890; H-374 to L-890; D-375 to L-890; D-376 to L-890; S-377 to L-890; K-378 to L-890; P-379 to L-890; C-380 to L-890; T-381 to L-890; R-382 to L-890; L-383 to L-890; F-384 to L-890; G-385 to L-890; P-386 to L-890; M-387 to L-890; G-388 to L-890; K-389 to L-890; H-390 to L-890; H-391 to L-890; V-392 to L-890; M-393 to L-890; A-394 to L-890; P-395 to L-890; L-396 to L-890; F-397 to L-890; V-398 to L-890; H-399 to L-890; L-400 to L-890; N-401 to L-890; Q-402 to L-890; T-403 to L-890; L-404 to L-890; P-405 to L-890; W-406 to L-890; S-407 to L-890; P-408 to L-890; C-409 to L-890; S-410 to L-890; A-411 to L-890; M-412 to L-890; Y-413 to L-890; L-414 to L-890; T-415 to L-890; E-416 to L-890; L-417 to L-890; L-418 to L-890; D-419 to L-890; G-420 to L-890; G-421 to L-890; H-422 to L-890; G-423 to L-890; D-424 to L-890; C-425 to L-890; L-426 to L-890; L-427 to L-890; D-428 to L-890; A-429 to L-890; P-430 to L-890; G-431 to L-890; A-432 to L-890; A-433 to L-890; L-434 to L-890; P-435 to L-890; L-436 to L-890; P-437 to L-890; T-438 to L-890; G-439 to L-890; L-440 to L-890; P-441 to L-890; G-442 to L-890; R-443 to L-890; M-444 to L-890; A-445 to L-890; L-446 to L-890; Y-447 to L-890; Q-448 to L-890; L-449 to L-890; D-450 to L-890; Q-451 to L-890; Q-452 to L-890; C-453 to L-890; R-454 to L-890; Q-455 to L-890; I-456 to L-890; F-457 to L-890; G-458 to L-890; P-459 to L-890; D-460 to L-890; F-461 to L-890; R-462 to L-890; H-463 to L-890; C-464 to L-890; P-465 to L-890; N-466 to L-890; T-467 to L-890; S-468 to L-890; A-469 to L-890; Q-470 to L-890; D-471 to L-890; V-472 to L-890; C-473 to L-890; A-474 to L-890; Q-475 to L-890; L-476 to L-890; W-477 to L-890; C-478 to L-890; H-479 to L-890; T-480 to L-890; D-481 to L-890; G-482 to L-890; A-483 to L-890; E-484 to L-890; P-485 to L-890; L-486 to L-890; C-487 to L-890; H-488 to L-890; T-489 to L-890; K-490 to L-890; N-491 to L-890; G-492 to L-890; S-493 to L-890; L-494 to L-890; P-495 to L-890; W-496 to L-890; A-497 to L-890; D-498 to L-890; G-499 to L-890; T-500 to L-890; P-501 to L-890; C-502 to L-890; G-503 to L-890; P-504 to L-890; G-505 to L-890; H-506 to L-890; L-507 to L-890; C-508 to L-890; S-509 to L-890; E-

510 to L-890; G-511 to L-890; S-512 to L-890; C-513 to L-890; L-514 to L-890;
P-515 to L-890; E-516 to L-890; E-517 to L-890; E-518 to L-890; V-519 to L-
890; E-520 to L-890; R-521 to L-890; P-522 to L-890; K-523 to L-890; P-524
to L-890; V-525 to L-890; V-526 to L-890; D-527 to L-890; G-528 to L-890; G-
529 to L-890; W-530 to L-890; A-531 to L-890; P-532 to L-890; W-533 to L-
890; G-534 to L-890; P-535 to L-890; W-536 to L-890; G-537 to L-890; E-538
to L-890; C-539 to L-890; S-540 to L-890; R-541 to L-890; T-542 to L-890; C-
543 to L-890; G-544 to L-890; G-545 to L-890; G-546 to L-890; V-547 to L-
890; Q-548 to L-890; F-549 to L-890; S-550 to L-890; H-551 to L-890; R-552
to L-890; E-553 to L-890; C-554 to L-890; K-555 to L-890; D-556 to L-890; P-
557 to L-890; E-558 to L-890; P-559 to L-890; Q-560 to L-890; N-561 to L-890;
G-562 to L-890; G-563 to L-890; R-564 to L-890; Y-565 to L-890; C-566 to L-
890; L-567 to L-890; G-568 to L-890; R-569 to L-890; R-570 to L-890; A-571
to L-890; K-572 to L-890; Y-573 to L-890; Q-574 to L-890; S-575 to L-890; C-
576 to L-890; H-577 to L-890; T-578 to L-890; E-579 to L-890; E-580 to L-890;
C-581 to L-890; P-582 to L-890; P-583 to L-890; D-584 to L-890; G-585 to L-
890; K-586 to L-890; S-587 to L-890; F-588 to L-890; R-589 to L-890; E-590
to L-890; Q-591 to L-890; Q-592 to L-890; C-593 to L-890; E-594 to L-890; K-
595 to L-890; Y-596 to L-890; N-597 to L-890; A-598 to L-890; Y-599 to L-
890; N-600 to L-890; Y-601 to L-890; T-602 to L-890; D-603 to L-890; M-604
to L-890; D-605 to L-890; G-606 to L-890; N-607 to L-890; L-608 to L-890; L-
609 to L-890; Q-610 to L-890; W-611 to L-890; V-612 to L-890; P-613 to L-
890; K-614 to L-890; Y-615 to L-890; A-616 to L-890; G-617 to L-890; V-618
to L-890; S-619 to L-890; P-620 to L-890; R-621 to L-890; D-622 to L-890; R-
623 to L-890; C-624 to L-890; K-625 to L-890; L-626 to L-890; F-627 to L-890;
C-628 to L-890; R-629 to L-890; A-630 to L-890; R-631 to L-890; G-632 to L-
890; R-633 to L-890; S-634 to L-890; E-635 to L-890; F-636 to L-890; K-637
to L-890; V-638 to L-890; F-639 to L-890; E-640 to L-890; A-641 to L-890; K-
642 to L-890; V-643 to L-890; I-644 to L-890; D-645 to L-890; G-646 to L-890;
T-647 to L-890; L-648 to L-890; C-649 to L-890; G-650 to L-890; P-651 to L-

890; E-652 to L-890; T-653 to L-890; L-654 to L-890; A-655 to L-890; I-656 to L-890; C-657 to L-890; V-658 to L-890; R-659 to L-890; G-660 to L-890; Q-661 to L-890; C-662 to L-890; V-663 to L-890; K-664 to L-890; A-665 to L-890; G-666 to L-890; C-667 to L-890; D-668 to L-890; H-669 to L-890; V-670 to L-890; V-671 to L-890; D-672 to L-890; S-673 to L-890; P-674 to L-890; R-675 to L-890; K-676 to L-890; L-677 to L-890; D-678 to L-890; K-679 to L-890; C-680 to L-890; G-681 to L-890; V-682 to L-890; C-683 to L-890; G-684 to L-890; G-685 to L-890; K-686 to L-890; G-687 to L-890; N-688 to L-890; S-689 to L-890; C-690 to L-890; R-691 to L-890; K-692 to L-890; V-693 to L-890; S-694 to L-890; G-695 to L-890; S-696 to L-890; L-697 to L-890; T-698 to L-890; P-699 to L-890; T-700 to L-890; N-701 to L-890; Y-702 to L-890; G-703 to L-890; Y-704 to L-890; N-705 to L-890; D-706 to L-890; I-707 to L-890; V-708 to L-890; T-709 to L-890; I-710 to L-890; P-711 to L-890; A-712 to L-890; G-713 to L-890; A-714 to L-890; T-715 to L-890; N-716 to L-890; I-717 to L-890; D-718 to L-890; V-719 to L-890; K-720 to L-890; Q-721 to L-890; R-722 to L-890; S-723 to L-890; H-724 to L-890; P-725 to L-890; G-726 to L-890; V-727 to L-890; Q-728 to L-890; N-729 to L-890; D-730 to L-890; G-731 to L-890; N-732 to L-890; Y-733 to L-890; L-734 to L-890; A-735 to L-890; L-736 to L-890; K-737 to L-890; T-738 to L-890; A-739 to L-890; D-740 to L-890; G-741 to L-890; Q-742 to L-890; Y-743 to L-890; L-744 to L-890; L-745 to L-890; N-746 to L-890; G-747 to L-890; N-748 to L-890; L-749 to L-890; A-750 to L-890; I-751 to L-890; S-752 to L-890; A-753 to L-890; I-754 to L-890; E-755 to L-890; Q-756 to L-890; D-757 to L-890; I-758 to L-890; L-759 to L-890; V-760 to L-890; K-761 to L-890; G-762 to L-890; T-763 to L-890; I-764 to L-890; L-765 to L-890; K-766 to L-890; Y-767 to L-890; S-768 to L-890; G-769 to L-890; S-770 to L-890; I-771 to L-890; A-772 to L-890; T-773 to L-890; L-774 to L-890; E-775 to L-890; R-776 to L-890; L-777 to L-890; Q-778 to L-890; S-779 to L-890; F-780 to L-890; R-781 to L-890; P-782 to L-890; L-783 to L-890; P-784 to L-890; E-785 to L-890; P-786 to L-890; L-787 to L-890; T-788 to L-890; V-789 to L-890; Q-790 to L-890; L-791 to L-890; L-792 to L-890; T-793 to L-890; V-

794 to L-890; P-795 to L-890; G-796 to L-890; E-797 to L-890; V-798 to L-890; F-799 to L-890; P-800 to L-890; P-801 to L-890; K-802 to L-890; V-803 to L-890; K-804 to L-890; Y-805 to L-890; T-806 to L-890; F-807 to L-890; F-808 to L-890; V-809 to L-890; P-810 to L-890; N-811 to L-890; D-812 to L-890; V-813 to L-890; D-814 to L-890; F-815 to L-890; S-816 to L-890; M-817 to L-890; Q-818 to L-890; S-819 to L-890; S-820 to L-890; K-821 to L-890; E-822 to L-890; R-823 to L-890; A-824 to L-890; T-825 to L-890; T-826 to L-890; N-827 to L-890; I-828 to L-890; I-829 to L-890; Q-830 to L-890; P-831 to L-890; L-832 to L-890; L-833 to L-890; H-834 to L-890; A-835 to L-890; Q-836 to L-890; W-837 to L-890; V-838 to L-890; L-839 to L-890; G-840 to L-890; D-841 to L-890; W-842 to L-890; S-843 to L-890; E-844 to L-890; C-845 to L-890; S-846 to L-890; S-847 to L-890; T-848 to L-890; C-849 to L-890; G-850 to L-890; A-851 to L-890; G-852 to L-890; W-853 to L-890; Q-854 to L-890; R-855 to L-890; R-856 to L-890; T-857 to L-890; V-858 to L-890; E-859 to L-890; C-860 to L-890; R-861 to L-890; D-862 to L-890; P-863 to L-890; S-864 to L-890; G-865 to L-890; Q-866 to L-890; A-867 to L-890; S-868 to L-890; A-869 to L-890; T-870 to L-890; C-871 to L-890; N-872 to L-890; K-873 to L-890; A-874 to L-890; L-875 to L-890; K-876 to L-890; P-877 to L-890; E-878 to L-890; D-879 to L-890; A-880 to L-890; K-881 to L-890; P-882 to L-890; C-883 to L-890; E-884 to L-890; S-885 to L-890; of SEQ ID NO:4.

Moreover, C-terminal deletions of the METH2 polypeptide can also be described by the general formula 1-n, where n is an integer from 2 to 890 where n corresponds to the position of amino acid residue identified in SEQ ID NO:4. Preferably, C-terminal deletions of the METH2 polypeptide of the invention shown as SEQ ID NO:4 include polypeptides comprising the amino acid sequence of residues: M-1 to P-889; M-1 to C-888; M-1 to L-887; M-1 to Q-886; M-1 to S-885; M-1 to E-884; M-1 to C-883; M-1 to P-882; M-1 to K-881; M-1 to A-880; M-1 to D-879; M-1 to E-878; M-1 to P-877; M-1 to K-876; M-1 to L-875; M-1 to A-874; M-1 to K-873; M-1 to N-872; M-1 to C-871; M-1 to T-870; M-1 to A-869; M-1 to S-868; M-1 to A-867; M-1 to Q-866; M-1 to G-865; M-1 to S-

864; M-1 to P-863; M-1 to D-862; M-1 to R-861; M-1 to C-860; M-1 to E-859;
M-1 to V-858; M-1 to T-857; M-1 to R-856; M-1 to R-855; M-1 to Q-854; M-1
to W-853; M-1 to G-852; M-1 to A-851; M-1 to G-850; M-1 to C-849; M-1 to
T-848; M-1 to S-847; M-1 to S-846; M-1 to C-845; M-1 to E-844; M-1 to S-843;
5 M-1 to W-842; M-1 to D-841; M-1 to G-840; M-1 to L-839; M-1 to V-838; M-1
to W-837; M-1 to Q-836; M-1 to A-835; M-1 to H-834; M-1 to L-833; M-1 to
L-832; M-1 to P-831; M-1 to Q-830; M-1 to I-829; M-1 to I-828; M-1 to N-827;
M-1 to T-826; M-1 to T-825; M-1 to A-824; M-1 to R-823; M-1 to E-822; M-1
to K-821; M-1 to S-820; M-1 to S-819; M-1 to Q-818; M-1 to M-817; M-1 to S-
10 816; M-1 to F-815; M-1 to D-814; M-1 to V-813; M-1 to D-812; M-1 to N-811;
M-1 to P-810; M-1 to V-809; M-1 to F-808; M-1 to F-807; M-1 to T-806; M-1
to Y-805; M-1 to K-804; M-1 to V-803; M-1 to K-802; M-1 to P-801; M-1 to P-
800; M-1 to F-799; M-1 to V-798; M-1 to E-797; M-1 to G-796; M-1 to P-795;
M-1 to V-794; M-1 to T-793; M-1 to L-792; M-1 to L-791; M-1 to Q-790; M-1
15 to V-789; M-1 to T-788; M-1 to L-787; M-1 to P-786; M-1 to E-785; M-1 to P-
784; M-1 to L-783; M-1 to P-782; M-1 to R-781; M-1 to F-780; M-1 to S-779;
M-1 to Q-778; M-1 to L-777; M-1 to R-776; M-1 to E-775; M-1 to L-774; M-1
to T-773; M-1 to A-772; M-1 to I-771; M-1 to S-770; M-1 to G-769; M-1 to S-
768; M-1 to Y-767; M-1 to K-766; M-1 to L-765; M-1 to I-764; M-1 to T-763;
20 M-1 to G-762; M-1 to K-761; M-1 to V-760; M-1 to L-759; M-1 to I-758; M-1
to D-757; M-1 to Q-756; M-1 to E-755; M-1 to I-754; M-1 to A-753; M-1 to S-
752; M-1 to I-751; M-1 to A-750; M-1 to L-749; M-1 to N-748; M-1 to G-747;
M-1 to N-746; M-1 to L-745; M-1 to L-744; M-1 to Y-743; M-1 to Q-742; M-1
to G-741; M-1 to D-740; M-1 to A-739; M-1 to T-738; M-1 to K-737; M-1 to
25 L-736; M-1 to A-735; M-1 to L-734; M-1 to Y-733; M-1 to N-732; M-1 to G-
731; M-1 to D-730; M-1 to N-729; M-1 to Q-728; M-1 to V-727; M-1 to G-726;
M-1 to P-725; M-1 to H-724; M-1 to S-723; M-1 to R-722; M-1 to Q-721; M-1
to K-720; M-1 to V-719; M-1 to D-718; M-1 to I-717; M-1 to N-716; M-1 to T-
715; M-1 to A-714; M-1 to G-713; M-1 to A-712; M-1 to P-711; M-1 to I-710;
30 M-1 to T-709; M-1 to V-708; M-1 to I-707; M-1 to D-706; M-1 to N-705; M-1

to Y-704; M-1 to G-703; M-1 to Y-702; M-1 to N-701; M-1 to T-700; M-1 to
P-699; M-1 to T-698; M-1 to L-697; M-1 to S-696; M-1 to G-695; M-1 to S-694;
M-1 to V-693; M-1 to K-692; M-1 to R-691; M-1 to C-690; M-1 to S-689; M-1
to N-688; M-1 to G-687; M-1 to K-686; M-1 to G-685; M-1 to G-684; M-1 to
5 C-683; M-1 to V-682; M-1 to G-681; M-1 to C-680; M-1 to K-679; M-1 to D-
678; M-1 to L-677; M-1 to K-676; M-1 to R-675; M-1 to P-674; M-1 to S-673;
M-1 to D-672; M-1 to V-671; M-1 to V-670; M-1 to H-669; M-1 to D-668; M-1
to C-667; M-1 to G-666; M-1 to A-665; M-1 to K-664; M-1 to V-663; M-1 to
C-662; M-1 to Q-661; M-1 to G-660; M-1 to R-659; M-1 to V-658; M-1 to C-
10 657; M-1 to I-656; M-1 to A-655; M-1 to L-654; M-1 to T-653; M-1 to E-652;
M-1 to P-651; M-1 to G-650; M-1 to C-649; M-1 to L-648; M-1 to T-647; M-1
to G-646; M-1 to D-645; M-1 to I-644; M-1 to V-643; M-1 to K-642; M-1 to A-
641; M-1 to E-640; M-1 to F-639; M-1 to V-638; M-1 to K-637; M-1 to F-636;
M-1 to E-635; M-1 to S-634; M-1 to R-633; M-1 to G-632; M-1 to R-631; M-1
15 to A-630; M-1 to R-629; M-1 to C-628; M-1 to F-627; M-1 to L-626; M-1 to K-
625; M-1 to C-624; M-1 to R-623; M-1 to D-622; M-1 to R-621; M-1 to P-620;
M-1 to S-619; M-1 to V-618; M-1 to G-617; M-1 to A-616; M-1 to Y-615; M-1
to K-614; M-1 to P-613; M-1 to V-612; M-1 to W-611; M-1 to Q-610; M-1 to
L-609; M-1 to L-608; M-1 to N-607; M-1 to G-606; M-1 to D-605; M-1 to M-
20 604; M-1 to D-603; M-1 to T-602; M-1 to Y-601; M-1 to N-600; M-1 to Y-599;
M-1 to A-598; M-1 to N-597; M-1 to Y-596; M-1 to K-595; M-1 to E-594; M-1
to C-593; M-1 to Q-592; M-1 to Q-591; M-1 to E-590; M-1 to R-589; M-1 to F-
588; M-1 to S-587; M-1 to K-586; M-1 to G-585; M-1 to D-584; M-1 to P-583;
M-1 to P-582; M-1 to C-581; M-1 to E-580; M-1 to E-579; M-1 to T-578; M-1
25 to H-577; M-1 to C-576; M-1 to S-575; M-1 to Q-574; M-1 to Y-573; M-1 to K-
572; M-1 to A-571; M-1 to R-570; M-1 to R-569; M-1 to G-568; M-1 to L-567;
M-1 to C-566; M-1 to Y-565; M-1 to R-564; M-1 to G-563; M-1 to G-562; M-1
to N-561; M-1 to Q-560; M-1 to P-559; M-1 to E-558; M-1 to P-557; M-1 to D-
556; M-1 to K-555; M-1 to C-554; M-1 to E-553; M-1 to R-552; M-1 to H-551;
30 M-1 to S-550; M-1 to F-549; M-1 to Q-548; M-1 to V-547; M-1 to G-546; M-1

to G-545; M-1 to G-544; M-1 to C-543; M-1 to T-542; M-1 to R-541; M-1 to S-540; M-1 to C-539; M-1 to E-538; M-1 to G-537; M-1 to W-536; M-1 to P-535; M-1 to G-534; M-1 to W-533; M-1 to P-532; M-1 to A-531; M-1 to W-530; M-1 to G-529; M-1 to G-528; M-1 to D-527; M-1 to V-526; M-1 to V-525; M-1 to P-524; M-1 to K-523; M-1 to P-522; M-1 to R-521; M-1 to E-520; M-1 to V-519; M-1 to E-518; M-1 to E-517; M-1 to E-516; M-1 to P-515; M-1 to L-514; M-1 to C-513; M-1 to S-512; M-1 to G-511; M-1 to E-510; M-1 to S-509; M-1 to C-508; M-1 to L-507; M-1 to H-506; M-1 to G-505; M-1 to P-504; M-1 to G-503; M-1 to C-502; M-1 to P-501; M-1 to T-500; M-1 to G-499; M-1 to D-498; M-1 to A-497; M-1 to W-496; M-1 to P-495; M-1 to L-494; M-1 to S-493; M-1 to G-492; M-1 to N-491; M-1 to K-490; M-1 to T-489; M-1 to H-488; M-1 to C-487; M-1 to L-486; M-1 to P-485; M-1 to E-484; M-1 to A-483; M-1 to G-482; M-1 to D-481; M-1 to T-480; M-1 to H-479; M-1 to C-478; M-1 to W-477; M-1 to L-476; M-1 to Q-475; M-1 to A-474; M-1 to C-473; M-1 to V-472; M-1 to D-471; M-1 to Q-470; M-1 to A-469; M-1 to S-468; M-1 to T-467; M-1 to N-466; M-1 to P-465; M-1 to C-464; M-1 to H-463; M-1 to R-462; M-1 to F-461; M-1 to D-460; M-1 to P-459; M-1 to G-458; M-1 to F-457; M-1 to I-456; M-1 to Q-455; M-1 to R-454; M-1 to C-453; M-1 to Q-452; M-1 to Q-451; M-1 to D-450; M-1 to L-449; M-1 to Q-448; M-1 to Y-447; M-1 to L-446; M-1 to A-445; M-1 to M-444; M-1 to R-443; M-1 to G-442; M-1 to P-441; M-1 to L-440; M-1 to G-439; M-1 to T-438; M-1 to P-437; M-1 to L-436; M-1 to P-435; M-1 to L-434; M-1 to A-433; M-1 to A-432; M-1 to G-431; M-1 to P-430; M-1 to A-429; M-1 to D-428; M-1 to L-427; M-1 to L-426; M-1 to C-425; M-1 to D-424; M-1 to G-423; M-1 to H-422; M-1 to G-421; M-1 to G-420; M-1 to D-419; M-1 to L-418; M-1 to L-417; M-1 to E-416; M-1 to T-415; M-1 to L-414; M-1 to Y-413; M-1 to M-412; M-1 to A-411; M-1 to S-410; M-1 to C-409; M-1 to P-408; M-1 to S-407; M-1 to W-406; M-1 to P-405; M-1 to L-404; M-1 to T-403; M-1 to Q-402; M-1 to N-401; M-1 to L-400; M-1 to H-399; M-1 to V-398; M-1 to F-397; M-1 to L-396; M-1 to P-395; M-1 to A-394; M-1 to M-393; M-1 to V-392; M-1 to H-391; M-1 to H-390; M-1 to K-389; M-1 to G-388; M-1 to M-387;

M-1 to P-386; M-1 to G-385; M-1 to F-384; M-1 to L-383; M-1 to R-382; M-1 to T-381; M-1 to C-380; M-1 to P-379; M-1 to K-378; M-1 to S-377; M-1 to D-376; M-1 to D-375; M-1 to H-374; M-1 to P-373; M-1 to M-372; M-1 to S-371; M-1 to L-370; M-1 to V-369; M-1 to H-368; M-1 to G-367; M-1 to L-366; M-1 to E-365; M-1 to H-364; M-1 to A-363; M-1 to L-362; M-1 to T-361; M-1 to H-360; M-1 to A-359; M-1 to A-358; M-1 to Q-357; M-1 to L-356; M-1 to G-355; M-1 to E-354; M-1 to D-353; M-1 to E-352; M-1 to I-351; M-1 to V-350; M-1 to S-349; M-1 to C-348; M-1 to S-347; M-1 to K-346; M-1 to N-345; M-1 to P-344; M-1 to D-343; M-1 to C-342; M-1 to I-341; M-1 to T-340; M-1 to G-339; M-1 to I-338; M-1 to D-337; M-1 to A-336; M-1 to V-335; M-1 to G-334; M-1 to L-333; M-1 to T-332; M-1 to D-331; M-1 to C-330; M-1 to L-329; M-1 to G-328; M-1 to E-327; M-1 to Q-326; M-1 to G-325; M-1 to C-324; M-1 to F-323; M-1 to N-322; M-1 to Q-321; M-1 to R-320; M-1 to T-319; M-1 to L-318; M-1 to L-317; M-1 to I-316; M-1 to A-315; M-1 to T-314; M-1 to D-313; M-1 to Y-312; M-1 to H-311; M-1 to E-310; M-1 to P-309; M-1 to H-308; M-1 to R-307; M-1 to D-306; M-1 to S-305; M-1 to P-304; M-1 to Q-303; M-1 to N-302; M-1 to F-301; M-1 to R-300; M-1 to R-299; M-1 to Q-298; M-1 to W-297; M-1 to N-296; M-1 to C-295; M-1 to F-294; M-1 to N-293; M-1 to R-292; M-1 to L-291; M-1 to T-290; M-1 to L-289; M-1 to G-288; M-1 to G-287; M-1 to N-286; M-1 to D-285; M-1 to S-284; M-1 to V-283; M-1 to E-282; M-1 to P-281; M-1 to G-280; M-1 to W-279; M-1 to K-278; M-1 to E-277; M-1 to D-276; M-1 to E-275; M-1 to V-274; M-1 to I-273; M-1 to L-272; M-1 to V-271; M-1 to K-270; M-1 to V-269; M-1 to V-268; M-1 to M-267; M-1 to L-266; M-1 to N-265; M-1 to I-264; M-1 to S-263; M-1 to N-262; M-1 to K-261; M-1 to I-260; M-1 to S-259; M-1 to P-258; M-1 to H-257; M-1 to K-256; M-1 to Y-255; M-1 to I-254; M-1 to R-253; M-1 to A-252; M-1 to A-251; M-1 to V-250; M-1 to S-249; M-1 to M-248; M-1 to L-247; M-1 to T-246; M-1 to L-245; M-1 to I-244; M-1 to H-243; M-1 to N-242; M-1 to Q-241; M-1 to L-240; M-1 to D-239; M-1 to A-238; M-1 to G-237; M-1 to Y-236; M-1 to F-235; M-1 to A-234; M-1 to A-233; M-1 to M-232; M-1 to S-231; M-1 to A-230; M-1 to D-229; M-1 to A-228;

M-1 to V-227; M-1 to L-226; M-1 to L-225; M-1 to T-224; M-1 to E-223; M-1 to V-222; M-1 to F-221; M-1 to R-220; M-1 to A-219; M-1 to E-218; M-1 to S-217; M-1 to V-216; M-1 to F-215; M-1 to R-214; M-1 to K-213; M-1 to T-212; M-1 to R-211; M-1 to S-210; M-1 to T-209; M-1 to A-208; M-1 to G-207; M-1 to L-206; M-1 to P-205; M-1 to P-204; M-1 to P-203; M-1 to P-202; M-1 to E-201; M-1 to S-200; M-1 to A-199; M-1 to G-198; M-1 to E-197; M-1 to A-196; M-1 to E-195; M-1 to E-194; M-1 to E-193; M-1 to Q-192; M-1 to S-191; M-1 to E-190; M-1 to E-189; M-1 to E-188; M-1 to S-187; M-1 to D-186; M-1 to E-185; M-1 to Q-184; M-1 to H-183; M-1 to D-182; M-1 to G-181; M-1 to R-180; M-1 to E-179; M-1 to Q-178; M-1 to R-177; M-1 to Q-176; M-1 to G-175; M-1 to E-174; M-1 to G-173; M-1 to T-172; M-1 to E-171; M-1 to V-170; M-1 to E-169; M-1 to W-168; M-1 to E-167; M-1 to P-166; M-1 to G-165; M-1 to R-164; M-1 to P-163; M-1 to L-162; M-1 to P-161; M-1 to R-160; M-1 to A-159; M-1 to G-158; M-1 to A-157; M-1 to P-156; M-1 to G-155; M-1 to W-154; M-1 to R-153; M-1 to Q-152; M-1 to L-151; M-1 to R-150; M-1 to H-149; M-1 to P-148; M-1 to Q-147; M-1 to A-146; M-1 to L-145; M-1 to S-144; M-1 to G-143; M-1 to G-142; M-1 to A-141; M-1 to G-140; M-1 to Q-139; M-1 to P-138; M-1 to Q-137; M-1 to I-136; M-1 to T-135; M-1 to F-134; M-1 to E-133; M-1 to E-132; M-1 to G-131; M-1 to D-130; M-1 to L-129; M-1 to L-128; M-1 to F-127; M-1 to S-126; M-1 to G-125; M-1 to S-124; M-1 to L-123; M-1 to G-122; M-1 to R-121; M-1 to C-120; M-1 to L-119; M-1 to S-118; M-1 to V-117; M-1 to A-116; M-1 to A-115; M-1 to L-114; M-1 to S-113; M-1 to E-112; M-1 to P-111; M-1 to E-110; M-1 to G-109; M-1 to N-108; M-1 to V-107; M-1 to T-106; M-1 to G-105; M-1 to S-104; M-1 to F-103; M-1 to F-102; M-1 to C-101; M-1 to G-100; M-1 to R-99; M-1 to L-98; M-1 to G-97; M-1 to R-96; M-1 to E-95; M-1 to G-94; M-1 to G-93; M-1 to T-92; M-1 to A-91; M-1 to R-90; M-1 to G-89; M-1 to S-88; M-1 to G-87; M-1 to G-86; M-1 to L-85; M-1 to R-84; M-1 to E-83; M-1 to I-82; M-1 to K-81; M-1 to F-80; M-1 to E-79; M-1 to P-78; M-1 to A-77; M-1 to L-76; M-1 to F-75; M-1 to S-74; M-1 to D-73; M-1 to D-72; M-1 to P-71; M-1 to A-70; M-1 to L-69; M-1 to R-68; M-1 to L-67; M-1 to V-66; M-

1 to F-65; M-1 to G-64; M-1 to K-63; M-1 to G-62; M-1 to F-61; M-1 to A-60; M-1 to S-59; M-1 to L-58; M-1 to H-57; M-1 to L-56; M-1 to A-55; M-1 to L-54; M-1 to E-53; M-1 to G-52; M-1 to A-51; M-1 to S-50; M-1 to G-49; M-1 to P-48; M-1 to L-47; M-1 to R-46; M-1 to T-45; M-1 to P-44; M-1 to V-43; M-1 to V-42; M-1 to L-41; M-1 to E-40; M-1 to S-39; M-1 to A-38; M-1 to Q-37; M-1 to G-36; M-1 to G-35; M-1 to A-34; M-1 to A-33; M-1 to P-32; M-1 to R-31; M-1 to A-30; M-1 to P-29; M-1 to A-28; M-1 to G-27; M-1 to R-26; M-1 to A-25; M-1 to L-24; M-1 to P-23; M-1 to L-22; M-1 to L-21; M-1 to L-20; M-1 to L-19; M-1 to L-18; M-1 to L-17; M-1 to L-16; M-1 to L-15; M-1 to L-14; M-1 to F-13; M-1 to P-12; M-1 to L-11; M-1 to W-10; M-1 to R-9; M-1 to P-8; M-1 to A-7; of SEQ ID NO:4. Preferably, any of the above listed N- or C-terminal deletions can be combined to produce a N- and C-terminal deleted METH2 polypeptide.

The invention also provides polypeptides having one or more amino acids deleted from both the amino and the carboxyl termini, which may be described generally as having residues m-n of SEQ ID NO:2 or SEQ ID NO:4, where n and m are integers as described above.

Also preferred are METH1 or METH2 polypeptide and polynucleotide fragments characterized by structural or functional domains. Preferred embodiments of the invention include fragments that comprise alpha-helix and alpha-helix forming regions ("alpha-regions"), beta-sheet and beta-sheet-forming regions ("beta-regions"), turn and turn-forming regions ("turn-regions"), coil and coil-forming regions ("coil-regions"), hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. As set out in the Figures, such preferred regions include Garnier-Robson alpha-regions, beta-regions, turn-regions, and coil-regions, Chou-Fasman alpha-regions, beta-regions, and turn-regions, Kyte-Doolittle hydrophilic regions and hydrophobic regions, Eisenberg alpha and beta amphipathic regions, Karplus-Schulz flexible regions, Emini surface-forming regions, and Jameson-Wolf high

antigenic index regions. Polypeptide fragments of SEQ ID NO:2 falling within conserved domains are specifically contemplated by the present invention. (See Figures 10 & 11 and Tables 1 & 2.) Moreover, polynucleotide fragments encoding these domains are also contemplated.

5 Other preferred fragments are biologically active METH1 or METH2 fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the METH1 or METH2 polypeptide. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

10 However, many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:1 or SEQ ID NO:3 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present
15 invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 936 of SEQ ID NO:1, b is an integer of 15 to 950, where both a and b correspond to the positions of nucleotide residues shown in
20 SEQ ID NO:1, and where the b is greater than or equal to a + 14. Moreover, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 876 of SEQ ID NO:3, b is an integer of 15 to 890, where both a and b correspond to the positions of nucleotide residues shown in
25 SEQ ID NO:3, and where the b is greater than or equal to a + 14.

Epitopes & Antibodies

In the present invention, "epitopes" refer to METH1 or METH2 polypeptide fragments having antigenic or immunogenic activity in an animal, especially in a human. A preferred embodiment of the present invention relates

to a METH1 or METH2 polypeptide fragment comprising an epitope, as well as the polynucleotide encoding this fragment. A region of a protein molecule to which an antibody can bind is defined as an "antigenic epitope." In contrast, an "immunogenic epitope" is defined as a part of a protein that elicits an antibody response. (See, for instance, Geysen *et al.*, *Proc. Natl. Acad. Sci. USA* 81:3998-4002 (1983).)

Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, R. A., *Proc. Natl. Acad. Sci. USA* 82:5131-5135 (1985) further described in U.S. Patent No. 4,631,211.)

In the present invention, antigenic epitopes preferably contain a sequence of at least seven, more preferably at least nine, and most preferably between about 15 to about 30 amino acids. Antigenic epitopes are useful to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. (See, for instance, Wilson *et al.*, *Cell* 37:767-778 (1984); Sutcliffe, J. G. *et al.*, *Science* 219:660-666 (1983).)

Similarly, immunogenic epitopes can be used to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe *et al.*, *supra*; Wilson *et al.*, *supra*; Chow, M. *et al.*, *Proc. Natl. Acad. Sci. USA* 82:910-914; and Bittle, F. J. *et al.*, *J. Gen. Virol.* 66:2347-2354 (1985).) A preferred immunogenic epitope includes the secreted protein. The immunogenic epitopes may be presented together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse) or, if it is long enough (at least about 25 amino acids), without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting.)

Using DNASTAR analysis, SEQ ID NO:2 was found antigenic at amino acids: 2-14, 32-44, 47-60, 66-78, 87-103, 109-118, 146-162, 168-180, 183-219, 223-243, 275-284, 296-306, 314-334, 341-354, 357-376, 392-399, 401-410, 418-429, 438-454, 456-471, 474-488, 510-522, 524-538, 550-561, 565-626, 630-643,

659-671, 679-721, 734-749, 784-804, 813-820, 825-832, 845-854, 860-894, 899-917, 919-924 and 928-939. Thus, these regions could be used as epitopes to produce antibodies against the protein encoded by METH1 cDNA.

Using DNASTar analysis, SEQ ID NO:4 was found antigenic at amino acids: 26-38, 45-52, 69-76, 80-99, 105-113, 129-136, 138-217, 254-263, 273-289, 294-313, 321-331, 339-356, 371-383, 417-427, 438-443, 459-471, 479-505, 507-526, 535-546, 550-607, 615-640, 648-653, 660-667, 669-681, 683-704, 717-732, 737-743, 775-787, 797-804, 811-825, 840-867 and 870-884. Thus, these regions could be used as epitopes to produce antibodies against the protein encoded by METH2 cDNA.

As used herein, the term "antibody" (Ab) or "monoclonal antibody" (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and F(ab')₂ fragments) which are capable of specifically binding to protein. Fab and F(ab')₂ fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody. (Wahl *et al.*, *J. Nucl. Med.* 24:316-325 (1983).) Thus, these fragments are preferred, as well as the products of a FAB or other immunoglobulin expression library. Moreover, antibodies of the present invention include chimeric, single chain, and humanized antibodies.

Fusion Proteins

Any METH1 or METH2 polypeptide can be used to generate fusion proteins. For example, the METH1 or METH2 polypeptide, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the METH1 or METH2 polypeptide can be used to indirectly detect the second protein by binding to the METH1 or METH2. Moreover, because secreted proteins target cellular locations based on trafficking signals, the METH1 or METH2 polypeptides can be used as a targeting molecule once fused to other proteins.

Examples of domains that can be fused to METH1 or METH2 polypeptides include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

Moreover, fusion proteins may also be engineered to improve characteristics of the METH1 or METH2 polypeptide. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the METH1 or METH2 polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the METH1 or METH2 polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the METH1 or METH2 polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

Moreover, METH1 or METH2 polypeptides, including fragments, and specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgG), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker *et al.*, *Nature* 331:84-86 (1988).) Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis *et al.*, *J. Biochem.* 270:3958-3964 (1995).)

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.)

Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).)

Moreover, the METH1 or METH2 polypeptides can be fused to marker sequences, such as a peptide which facilitates purification of METH1 or METH2. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz *et al.*, *Proc. Natl. Acad. Sci. USA* 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., *Cell* 37:767 (1984).)

Thus, any of these above fusions can be engineered using the METH1 or METH2 polynucleotides or the polypeptides.

Biological Activities of METH1 or METH2

METH1 or METH2 polynucleotides and polypeptides can be used in assays to test for one or more biological activities. If METH1 or METH2 polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that METH1 or METH2 may be involved in the diseases associated with the biological activity. Therefore, METH1 or METH2 could be used to treat the associated disease.

Immune Activity

METH1 or METH2 polypeptides or polynucleotides may be useful in treating deficiencies or disorders of the immune system, by activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune deficiencies or disorders may be genetic, somatic, such as cancer or some autoimmune disorders, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, METH1 or METH2 polynucleotides or polypeptides can be used as a marker or detector of a particular immune system disease or disorder.

METH1 or METH2 polynucleotides or polypeptides may be useful in treating or detecting deficiencies or disorders of hematopoietic cells. METH1 or METH2 polypeptides or polynucleotides could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat those disorders associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to: blood protein disorders (e.g. agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

Moreover, METH1 or METH2 polypeptides or polynucleotides can also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, METH1 or METH2 polynucleotides or polypeptides could be used to treat blood coagulation disorders (e.g., afibrinogenemia, factor deficiencies), blood platelet disorders (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, METH1 or METH2 polynucleotides or polypeptides

that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting, important in the treatment of heart attacks (infarction), strokes, or scarring.

METH1 or METH2 polynucleotides or polypeptides may also be useful in treating or detecting autoimmune disorders. Many autoimmune disorders result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of METH1 or METH2 polypeptides or polynucleotides that can inhibit an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

Examples of autoimmune disorders that can be treated or detected by METH1 or METH2 include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitis, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated by METH1 or METH2 polypeptides or polynucleotides. Moreover, METH1 or METH2 can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

METH1 or METH2 polynucleotides or polypeptides may also be used to treat and/or prevent organ rejection or graft-versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues.

The administration of METH1 or METH2 polypeptides or polynucleotides that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

5 Similarly, METH1 or METH2 polypeptides or polynucleotides may also be used to modulate inflammation. For example, METH1 or METH2 polypeptides or polynucleotides may inhibit the proliferation and differentiation of cells involved in an inflammatory response. These molecules can be used to treat inflammatory conditions, both chronic and acute conditions, including
10 inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1.)

15 *Hyperproliferative Disorders*

METH1 or METH2 polypeptides or polynucleotides can be used to treat or detect hyperproliferative disorders, including neoplasms. METH1 or METH2 polypeptides or polynucleotides may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, METH1 or METH2
20 polypeptides or polynucleotides may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative disorders can be treated.
25 This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating hyperproliferative disorders, such as a chemotherapeutic agent.

Examples of hyperproliferative disorders that can be treated or detected by METH1 or METH2 polynucleotides or polypeptides include, but are not limited to neoplasms located in the: abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative disorders can also be treated or detected by METH1 or METH2 polynucleotides or polypeptides. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenström's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

Infectious Disease

METH1 or METH2 polypeptides or polynucleotides can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, METH1 or METH2 polypeptides or polynucleotides may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by METH1 or METH2 polynucleotides or polypeptides. Examples of viruses, include, but are not limited to the following DNA and RNA viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g.,

Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza), Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within
5 these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiollitis, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza,
10 Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. METH1 or METH2 polypeptides or polynucleotides can be used to treat or detect any of these symptoms or diseases.

Similarly, bacterial or fungal agents that can cause disease or symptoms
15 and that can be treated or detected by METH1 or METH2 polynucleotides or polypeptides include, but not limited to, the following Gram-Negative and Gram-positive bacterial families and fungi: Actinomycetales (e.g., Corynebacterium, Mycobacterium, Norcardia), Aspergillosis, Bacillaceae (e.g., Anthrax, Clostridium), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia, Brucellosis,
20 Candidiasis, Campylobacter, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, Enterobacteriaceae (Klebsiella, Salmonella, Serratia, Yersinia), Erysipelothrix, Helicobacter, Legionellosis, Leptospirosis, Listeria, Mycoplasmatales, Neisseriaceae (e.g., Acinetobacter, Gonorrhea, Meningococcal), Pasteurellaceae Infections (e.g., Actinobacillus, Haemophilus, Pasteurella),
25 Pseudomonas, Rickettsiaceae, Chlamydiaceae, Syphilis, and Staphylococcal. These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's
30 Disease, respiratory tract infections, such as Whooping Cough or Empyema,

sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea, meningitis, Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections. METH1 or METH2 polypeptides or polynucleotides can be used to treat or detect any of these symptoms or diseases.

Moreover, parasitic agents causing disease or symptoms that can be treated or detected by METH1 or METH2 polynucleotides or polypeptides include, but not limited to, the following families: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas. These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), Malaria, pregnancy complications, and toxoplasmosis. METH1 or METH2 polypeptides or polynucleotides can be used to treat or detect any of these symptoms or diseases.

Preferably, treatment using METH1 or METH2 polypeptides or polynucleotides could either be by administering an effective amount of METH1 or METH2 polypeptide to the patient, or by removing cells from the patient, supplying the cells with METH1 or METH2 polynucleotide, and returning the engineered cells to the patient (*ex vivo* therapy). Moreover, the METH1 or METH2 polypeptide or polynucleotide can be used as an antigen in a vaccine to raise an immune response against infectious disease.

Regeneration

METH1 or METH2 polynucleotides or polypeptides can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, *Science* 276:59-87 (1997).) The regeneration of tissues could be used to

repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

5 Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vascular (including vascular endothelium), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also
10 may include angiogenesis.

 Moreover, METH1 or METH2 polynucleotides or polypeptides may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. METH1
15 or METH2 polynucleotides or polypeptides of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

20 Similarly, nerve and brain tissue could also be regenerated by using METH1 or METH2 polynucleotides or polypeptides to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular
25 disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the METH1 or
30 METH2 polynucleotides or polypeptides.

Chemotaxis

METH1 or METH2 polynucleotides or polypeptides may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

METH1 or METH2 polynucleotides or polypeptides may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. As a chemotactic molecule, METH1 or METH2 could also attract fibroblasts, which can be used to treat wounds.

It is also contemplated that METH1 or METH2 polynucleotides or polypeptides may inhibit chemotactic activity. These molecules could also be used to treat disorders. Thus, METH1 or METH2 polynucleotides or polypeptides could be used as an inhibitor of chemotaxis.

Binding Activity

METH1 or METH2 polypeptides may be used to screen for molecules that bind to METH1 or METH2 or for molecules to which METH1 or METH2 binds. The binding of METH1 or METH2 and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the METH1 or METH2 or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of METH1 or METH2, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See; Coligan *et al.*, *Current Protocols in*

Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which METH1 or METH2 binds, or at least, a fragment of the receptor capable of being bound by METH1 or METH2 (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express METH1 or METH2, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing METH1 or METH2 (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either METH1 or METH2 or the molecule.

The assay may simply test binding of a candidate compound to METH1 or METH2, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to METH1 or METH2.

Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing METH1 or METH2, measuring METH1 or METH2/molecule activity or binding, and comparing the METH1 or METH2/molecule activity or binding to a standard.

Preferably, an ELISA assay can measure METH1 or METH2 level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure METH1 or METH2 level or activity by either binding, directly or indirectly, to METH1 or METH2 or by competing with METH1 or METH2 for a substrate.

All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat disease or to

bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the METH1 or METH2 molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of METH1 or METH2 from suitably manipulated cells or tissues.

5 Therefore, the invention includes a method of identifying compounds which bind to METH1 or METH2 comprising the steps of: (a) incubating a candidate binding compound with METH1 or METH2; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate
10 compound with METH1 or METH2, (b) assaying a biological activity, and (b) determining if a biological activity of METH1 or METH2 has been altered.

Other Activities

15 METH1 or METH2 polypeptides or polynucleotides may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

20 METH1 or METH2 polypeptides or polynucleotides may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, METH1 or METH2 polypeptides or polynucleotides may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

25 METH1 or METH2 polypeptides or polynucleotides may be used to change a mammal's mental state or physical state by influencing biorhythms, circadian rhythms, depression (including depressive disorders), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

 METH1 or METH2 polypeptides or polynucleotides may also be used as a food additive or preservative, such as to increase or decrease storage

capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

Cancer Diagnosis and Prognosis

It is believed that certain tissues in mammals with cancer express significantly diminished levels of the METH1 or METH2 protein and mRNA encoding the METH1 or METH2 protein when compared to a corresponding "standard" mammal, i.e., a mammal of the same species not having the cancer. Further, it is believed that diminished levels of the METH1 or METH2 protein can be detected in certain body fluids (e.g., sera, plasma, urine, and spinal fluid) from mammals with cancer when compared to sera from mammals of the same species not having the cancer. Thus, the invention provides a diagnostic method useful during tumor diagnosis, which involves assaying the expression level of the gene encoding the METH1 protein in mammalian cells or body fluid and comparing the gene expression level with a standard METH1 gene expression level, whereby a decrease in the gene expression level under the standard is indicative of certain tumors. The invention also provides a diagnostic method useful during tumor diagnosis, which involves assaying the expression level of the gene encoding the METH2 protein in mammalian cells or body fluid and comparing the gene expression level with a standard METH2 gene expression level, whereby a decrease in the gene expression level under the standard is indicative of certain tumors.

Where a tumor diagnosis has already been made according to conventional methods, the present invention is useful as a prognostic indicator, whereby patients exhibiting diminished METH1 or METH2 gene expression will experience a worse clinical outcome relative to patients expressing the gene at a lower level.

By "assaying the expression level of the gene encoding the METH1 or METH2 protein" is intended qualitatively or quantitatively measuring or estimating the level of the METH1 or METH2 protein or the level of the mRNA encoding the METH1 or METH2 protein in a first biological sample either directly (e.g., by determining or estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the METH1 or METH2 protein level or mRNA level in a second biological sample).

Preferably, the METH1 or METH2 protein level or mRNA level in the first biological sample is measured or estimated and compared to a standard METH1 or METH2 protein level or mRNA level, the standard being taken from a second biological sample obtained from an individual not having the cancer. As will be appreciated in the art, once a standard METH1 or METH2 protein level or mRNA level is known, it can be used repeatedly as a standard for comparison.

By "biological sample" is intended any biological sample obtained from an individual, cell line, tissue culture, or other source which contains METH1 or METH2 protein or mRNA. Biological samples include mammalian body fluids (such as sera, plasma, urine, synovial fluid and spinal fluid) which contain secreted mature METH1 or METH2 protein, and adrenal, thyroid, stomach, brain, heart, placenta, lung, liver, muscle, kidney, pancreas, testis and ovarian tissue (for METH1); and prostate, small intestine, colon, brain and lung tissue (for METH2).

The present invention is useful for detecting cancer in mammals. In particular the invention is useful during diagnosis of the of following types of cancers in mammals: breast, ovarian, prostate, liver, lung, pancreatic, colon, and testicular. Preferred mammals include monkeys, apes, cats, dogs, cows, pigs, horses, rabbits and humans. Particularly preferred are humans.

Total cellular RNA can be isolated from a biological sample using the single-step guanidinium-thiocyanate-phenol-chloroform method described in Chomczynski and Sacchi, *Anal. Biochem.* 162:156-159 (1987). Levels of mRNA encoding the METH1 or METH2 protein are then assayed using any appropriate method. These include Northern blot analysis (Harada *et al.*, *Cell* 63:303-312

(1990)), S1 nuclease mapping (Fujita *et al.*, *Cell* 49:357- 367 (1987)), the polymerase chain reaction (PCR), reverse transcription in combination with the polymerase chain reaction (RT-PCR) (Makino *et al.*, *Technique* 2:295-301 (1990)), and reverse transcription in combination with the ligase chain reaction (RT-LCR).

Assaying METH1 or METH2 protein levels in a biological sample can occur using antibody-based techniques. For example, METH1 or METH2 protein expression in tissues can be studied with classical immunohistological methods (Jalkanen, M., *et al.*, *J. Cell. Biol.* 101:976-985 (1985); Jalkanen, M., *et al.*, *J. Cell. Biol.* 105:3087-3096 (1987)).

Other antibody-based methods useful for detecting METH1 or METH2 protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA).

Suitable labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine (^{125}I , ^{121}I), carbon (^{14}C), sulfur (^{35}S), tritium (^3H), indium (^{112}In), and technetium ($^{99\text{m}}\text{Tc}$), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

Modes of administration

It is recognized that an increase in the vascular supply plays a central role in tumor progression and metastasis; therefore, inhibitors of angiogenesis can prove effective as adjuvant therapy for cancer patients. Some of the currently recognized angiogenic suppressors are poor candidates for systemic treatment due to severe collateral effect. The present inventors have found that METH1 and METH2 are potent inhibitors of angiogenesis both *in vitro* and *in vivo*. The advantage of METH1 and METH1 is that these inhibitors are normally associated with suppression of physiological angiogenesis; therefore, they offer lack of toxicity and endothelial specificity over other angiogenic inhibitors. Furthermore,

METH1 and METH2 present a restricted pattern of expression providing a possible advantage on organ specificity.

Accordingly, the polypeptides of the present invention may be employed to treat cancer. The METH1 and METH2 polypeptides of the present invention can also be used to treat individuals with other disorders that are related to angiogenesis, including abnormal wound healing, inflammation, rheumatoid arthritis, psoriasis, endometrial bleeding disorders, diabetic retinopathy, some forms of macula degeneration, hemangiomas, and arterial-venous malformations.

Thus, the invention provides a method of inhibiting angiogenesis in an individual comprising administering to such an individual a pharmaceutical composition comprising an effective amount of an isolated METH1 polypeptide of the invention, effective to increase the METH1 activity level in such an individual. The invention also provides a method of inhibiting angiogenesis in an individual comprising administering to such an individual a pharmaceutical composition comprising an effective amount of an isolated METH2 polypeptide of the invention, effective to increase the METH2 activity level in such an individual.

METH1 polypeptides which may be used to inhibit angiogenesis in this manner include: METH1 polypeptide encoded by the deposited cDNA including the leader; the mature METH1 polypeptide encoded by the deposited the cDNA minus the leader (i.e., the mature protein); a polypeptide comprising amino acids about 1 to about 950 in SEQ ID NO:2; a polypeptide comprising amino acids about 2 to about 950 in SEQ ID NO:2; a polypeptide comprising amino acids about 29 to about 950 in SEQ ID NO:2; a polypeptide comprising amino acids about 30 to about 950 in SEQ ID NO:2; a polypeptide comprising the metalloprotease domain of METH1, amino acids 235 to 459 in SEQ ID NO:2; a polypeptide comprising the disintegrin domain of METH1, amino acids 460 to 544 in SEQ ID NO:2; a polypeptide comprising the first TSP-like domain of METH1, amino acids 545 to 598 in SEQ ID NO:2; a polypeptide comprising the second TSP-like domain of METH1, amino acids 841 to 894 in SEQ ID NO:2; a

-111-

polypeptide comprising the third TSP-like domain of METH1, amino acids 895 to 934 in SEQ ID NO:2; a polypeptide comprising amino acids 536 to 613 in SEQ ID NO:2; and a polypeptide comprising amino acids 549 to 563 in SEQ ID NO:2.

METH2 polypeptides which may be used to inhibit angiogenesis in this manner include: the METH2 polypeptide encoded by the deposited cDNA including the leader; the mature METH2 polypeptide encoded by the deposited the cDNA minus the leader (i.e., the mature protein); a polypeptide comprising amino acids about 1 to about 890 in SEQ ID NO:4; a polypeptide comprising amino acids about 2 to about 890 in SEQ ID NO:4; a polypeptide comprising amino acids about 24 to about 890 in SEQ ID NO:4; a polypeptide comprising amino acids about 112 to about 890 in SEQ ID NO:4; a polypeptide comprising the metalloprotease domain of METH2, amino acids 214 to 439 in SEQ ID NO:4; a polypeptide comprising the disintegrin domain of METH2, amino acids 440 to 529 in SEQ ID NO:4; a polypeptide comprising the first TSP-like domain of METH2, amino acids 530 to 583 in SEQ ID NO:4; a polypeptide comprising the second TSP-like domain of METH2, amino acids 837 to 890 in SEQ ID NO:4; a polypeptide comprising amino acids 280 to 606 in SEQ ID NO:4; and a polypeptide comprising amino acids 529 to 548 in SEQ ID NO:4.

As a general proposition, the total pharmaceutically effective amount of METH1 or METH2 polypeptide administered parenterally per dose will be in the range of about 1 µg/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the polypeptide. If given continuously, the METH1 or METH2 polypeptide is typically administered at a dose rate of about 1 µg/kg/hour to about 50 µg/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed.

Pharmaceutical compositions containing the METH1 or METH2 of the invention may be administered orally, rectally, parenterally, intracistemally,

intravaginally, intraperitoneally, topically (as by powders, ointments, drops or transdermal patch), buccally, or as an oral or nasal spray. By "pharmaceutically acceptable carrier" is meant a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Chromosome Assays

The nucleic acid molecules of the present invention are also valuable for chromosome identification. The sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome. The mapping of DNAs to chromosomes according to the present invention is an important first step in correlating those sequences with genes associated with disease.

In certain preferred embodiments in this regard, the cDNA herein disclosed is used to clone genomic DNA of a METH1 or METH2 protein gene. This can be accomplished using a variety of well known techniques and libraries, which generally are available commercially. The genomic DNA then is used for *in situ* chromosome mapping using well known techniques for this purpose.

In addition, in some cases, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the cDNA. Computer analysis of the 3' untranslated region of the gene is used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes.

Fluorescence *in situ* hybridization ("FISH") of a cDNA clone to a metaphase chromosomal spread can be used to provide a precise chromosomal location in one step. This technique can be used with probes from the cDNA as

short as 50 or 60 bp. For a review of this technique, see Verma *et al.*, *Human Chromosomes: A Manual Of Basic Techniques*, Pergamon Press, New York (1988).

5 Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, for example, in V. McKusick, *Mendelian Inheritance In Man*, available on-line through Johns Hopkins University, Welch Medical Library. The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage
10 analysis (coinheritance of physically adjacent genes).

Next, it is necessary to determine the differences in the cDNA or genomic sequence between affected and unaffected individuals. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease.

15 Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

Examples

Example 1: Identification and cloning of METH1 and METH2

20 To search for novel genes with TSP-like domains, a large human cDNA database consisting of approximately 900,00 expressed sequence tags (ESTs) was screened for sequences homologous to the second type I repeat of TSP1. Several ESTs were predicted to encode proteins with TSP-like domains. Two cDNA clones originated from human heart and lung libraries were further sequenced and
25 chosen for functional analysis.

The amino-terminal end of METH1 was obtained using 5' rapid amplification of cDNA ends (RACE) PCR technique (Marathon cDNA amplification kit, Clontech) according to manufacturer instructions. The amino-terminal end of METH2 was obtained partially through 5'RACE PCR and later confirmed and completed by genomic screening. For the genomic screen, BAC clones (Genome Systems) were initially identified by PCR. Positive BAC clones containing 150-200bp of sequence were subsequently subcloned into pGEM vector as small fragments and sequenced.

Analysis and comparison of the deduced amino acid sequence with the GenBank, EMBL and SwissProt databases suggested that these genes belong to a new family of metalloproteases with homology to the reprolysin family in their NH₂-terminal end and with several TSP-like motifs in the COOH-terminal end. These cDNAs were named METH1 and METH2; ME, for metalloprotease and TH, for thrombospondin. The mouse homologue of METH1 was identified and named ADAMTS1 (Kuno, K., *et al.*, *J. Biol. Chem.* 272:556-562 (1997)). Direct comparison of the human and mouse sequences revealed a high level of conservation (83.4% amino acid identity). Thus far no homologues for METH2 have been identified.

Interestingly, a recently identified protein named pNPI (procollagen I N-proteinase; (Colidge, A., *et al.*, *Proc. Natl. Acad. Sci. USA* 94:2374-2379 (1997)) showed a striking sequence and structural similarity to METH1 and METH2 (Figure 3). As the novel proteins described here, pNPI also contains metalloproteinase (reprolysin subfamily) and TSP domains at the carboxy-terminal end. Although the sequence for pNPI is of bovine origin, sequence alignment revealed identical structural features. The amino acid similarity between METH1 and METH2 is 51.7%, and between METH1 or METH2 and pNPI the homology is lesser 33.9% and 36.3%, respectively.

Sequence analysis showed that the ORF of METH1 and METH2 coded for proteins of 950 and 890 amino acids, respectively. In all three proteins, the NH₂ terminal end contains a putative signal peptide followed by another putative

transmembrane domain around amino acid 300, deduced from the hydrophilicity plots. It is not clear whether these proteins are bound to the membrane. However, given preliminary data, it is more likely that this second transmembrane domain will consist of a hydrophobic pocket and that METH1, METH2 and pNPI are in fact secreted proteins. The NH₂-terminal end past the signal peptide has homology to the superfamily of zinc metalloproteases and can be subdivided in a prodomain, a metalloprotease domain, and a cysteine-rich region.

The double underlined sequence in METH1 and METH2 in Figure 3 localized at the boundary between the prodomain and the metalloprotease domain, are potential cleavage sites for mammalian subtilisins, such as furins (Barr, 1991). Proteolytical processing occurs in SVMs to yield soluble metalloproteases and disintegrins (Bjarnason, J.B. & Fox, J.W., *Methods Enzymol.* 248:345-368 (1995)) and has also been detected in some ADAMs (reviewed by Wolsberg, T.G. & White, J.M., *Developmental Biology* 180:389-401 (1996)). At this point, preliminary experiments suggest that proteolytical processing occurs, at least in METH1. Additionally, both METH1 and METH2 present a Zn²⁺-binding site (dotted line in Figure 3) that is presumed to be catalytically active due to the conservation of certain functionally important amino acids (Rawlings, N.D. & Barrett, A.J., *Methods Enzymol.* 248:183-228 (1995)) suggesting that these proteins may be active proteases. Following the metalloprotease domain, there is a cysteine-rich region which contains two putative disintegrin loops (Wolsberg, T.G. & White, J.M., *Developmental Biology* 180:389-401 (1996)) (marked by arrows in Figure 3). Disintegrin domains are found within the superfamily of metalloproteases in snake venom metalloproteases (SVMs) and ADAMs (mammalian proteins containing a disintegrin and a metalloprotease domain) and have a possible function inhibiting binding of integrins to their ligands in SVMs. Conversely, the ADAM-disintegrin-like domain, as part of membrane anchored proteins, may promote rather than disrupt, cell-cell interactions (Wolsberg, T.G. & White, J.M., *Developmental Biology* 180:389-401 (1996)). The TSP-like domains are located in the COOH-half of METH1 and METH2 proteins. METH1

contains two conserved TSP domains separated by a spacer region with unknown function, and a subdomain with less homology, and only 5 cysteines, following the second anti-angiogenic region. METH2 contains two TSP domains separated by the spacer region. The alignment of the TSP-like domains of METH1 and METH2 with those of TSP1 and TSP2 are shown in Figure 5. The homology varies between 19.2% to 52% amino acid similarity among all the TSP repeats. The cysteines, numbered 1 to 6, and the tryptophans, labeled by asterisks, are highly conserved.

Southern blot of human genomic DNA revealed the presence of METH1 and METH2 in the genome. METH1 and METH2 probes revealed bands of different size suggesting that they are transcribed from different genes.

The consensus sequence for the type I repeats includes 16 residues with 6 perfectly conserved cysteines. Typically it begins with the sequence motif WSXWS (SEQ ID NO:82) that has also been shown to bind to heparin (Guo, N., *et al.*, *J. Biol. Chem.* 267:19349-19355 (1992)). The affinity of this region to heparin has been proposed to the part of the anti-angiogenic activity of TSP-1 (Guo, N., *et al.*, *J. Peptide Res.* 49 (1997)). Among the five members of the TSP family of proteins, only TSP-1 and TSP-2 inhibit angiogenesis and contain the type I repeats (Tolsma, S.S., *et al.*, *J. Cell. Biol.* 122:497-511 (1993); Kyriakides, T.R., *et al.*, *J. Cell Biol.* 140:419-430 (1998)). The type I or properdin repeats were probably added to the precursor of TSP1 and 2 by exon shuffling between 500 and 900 years ago (Adams, J., *et al.*, *The Thrombospondin Gene Family*, 1 Ed. Molecular Biology Intelligence Unit (Springer, Ed.), R.G. Landes Company, Germany (1995)). It is likely that the acquisition of this domain provided the precursor of TSP1 and TSP2 with functions, such as regulation of new vessel formation. More recently, BAI-1 (brain angiogenic inhibitor-1), a protein isolated from a brain library for its ability to be regulated by p53, has also been shown to contain the type I repeat of TSP-1 and to provide anti-angiogenic potential to this molecule (Nishimori, H., *et al.*, *Oncogene* 15:2145-2150 (1997)). Nevertheless, it appears that additional sequences or context are also important, since other

-117-

proteins containing the type I repeats appear not to have clear or more established anti-angiogenic properties such as: properdin, F-spondin, and other members of the complement family.

Because of the presence of TSP-repeats in METH1 and METH2, along with their anti-angiogenic properties, these proteins were originally considered members of the TSP superfamily. Nevertheless, they have no additional homology to other TSPs, and in fact, the similarity to TSP1 and TSP2 is restricted to the type I repeats. Furthermore, the proteins also have strong sequence and structural homology to members of the ADAM family. These features led Kuno and colleagues to name ADAMTS to the mouse homolog of METH1 (Kuno, K., *et al.*, *J. Biol. Chem.* 272:556-562 (1997)). The recent identification of pNPI and its striking sequence homology to the proteins here described, prompt all these three proteins to be grouped in a subfamily named metallopondins. At this point, it is not clear whether pNIP has anti-angiogenic properties or whether METH1 and/or METH2 participate in the cleavage of the amino terminal pro-peptide of $\alpha 1(I)$ procollagen.

Example 2: Northern and Southern blot analysis

Total RNA was purified from cells by guanidinium-isothiocyanate extraction, as previously described (Chomczynski, P. & Sacchi, N., *Anal. Biochem.* 162:156-159 (1987)) Poly(A)+RNA was extracted using a Boehringer Mannheim (BMB, Indianapolis, IN) kit according to the manufacturer conditions. Other poly(A)+RNA blots were purchased from Clontech (Palo Alto, CA). Pre-hybridization was performed in a solution containing: 50% formamide, 6X SSPE, 1X Denhardt's solution, 0.1% SDS and 100 μ g/ml of heat denatured salmon sperm DNA for 12-18h at 42°C. Hybridization with labeled cDNA probes proceeded in the same solution at 42°C for 12-18h. TSP1 and METH1 probes corresponded to the entire human cDNAs. METH2 probe corresponded to a *KpnI-EcoRI* fragment from the human cDNA. A 1.3Kb *PstI* fragment of the glyceraldehyde-3-

phosphate-dehydrogenase (GPDH) was used to normalize for loading and transfer efficiency. Membranes were exposed to Kodak Biomax MS film (Kodak, New Haven, CT).

5 For Southern blots, human genomic DNA, purchased from Promega (Madison, WI), was heated at 65°C for 10 min and digested with *EcoRI* and *PstI* overnight at 37°C. 5µg of digested DNA was separated in a 1% agarose gel, transferred to a nytran membrane and cross-linked by ultraviolet light. cDNA probes, as well as, prehybridization and hybridization conditions were identical to those described for Northern blots. Blots were washed with high stringency (0.2X
10 SSC, 0.2% SDS at 50°C).

The expression pattern of METH1 and METH2 was examined in both adult and embryonic tissues. Northern blot analysis was performed under high-stringency conditions with blots that included poly(A)+RNA from human tissues. METH1 and METH2 transcripts revealed a single band of 4.6 and 3.7Kb,
15 respectively. Abundant METH1 mRNA expression was observed in adrenal, heart, placenta, followed by skeletal muscle, thyroid and stomach. From the embryonic tissues analyzed, kidney showed the highest expression of METH1 mRNA. Nevertheless, weaker expression of METH1 mRNA was seen in all tissues analyzed. Distribution of METH2 mRNA was more restricted and weaker
20 than that of METH1. The highest expression was seen in lung, both embryonic and adult. Interestingly, METH1 and METH2 expression do not appear to overlap. In combination, the structural similarities and their pattern of expression suggest functional redundancy yet different transcriptional regulation. The expression levels of TSP1 transcripts in the same blots were also analyzed, for
25 purpose of comparison. TSP1 mRNA highest expression was seen in the adult placenta and in all embryonic tissues analyzed. In contrast to METH1 and METH2 we observed constant levels of TSP1 transcript in all the other tissues examined.

30 The cell type distribution was also studied by Northern blot analysis of poly(A)+RNA. METH1 mRNA was detectable, at low levels; in dermal

fibroblasts, vascular smooth muscle, endometrial stromal cells, and in two cancer cell lines, HeLa and G631, an adenocarcinoma and a melanoma, respectively. METH2 mRNA was detected only on SW480, a colon carcinoma cell line, but no expression was seen in any other of the cell lines or primary strains analyzed.

5 The possibility that groups of angiogenic and anti-angiogenic factors regulate vascular network formation in specific organs has been a frequently discussed hypothesis likely to be true, yet unproven. The expression patterns of METH1 and METH2, which are clearly distinct and almost non-overlapping, were puzzling, at least with concern to overall levels. TSP1 and TSP2 also share
10 identical structure, high level of amino acid similarity, yet their pattern of expression differs significantly (Iruela-Arispe, M.L., *Dev. Dyn.* 197:40-56 (1993)). The differences are likely based on dissimilar cis-acting elements in their promoters and different regulatory mechanisms, as previously suggested. Although the promoters for METH1 and 2 have not been characterized, it is likely
15 that they provide unique features for the regulation of each gene. Nevertheless, the possibility that one motif, the anti-angiogenic / type 1 repeat, with demonstrated anti-angiogenic properties is present in several proteins with different tissue specificities is appealing. Alternatively, the small differences in sequence between closely related members of the same family could possess
20 significance that goes beyond functional redundancy. In the case of TSP1 and TSP2, aside from the striking structural similarities and perhaps having functionally common anti-angiogenic properties, TSP1 and TSP2 also appear to display functions of their own and not likely shared by their similar relative. This became evident with the outcome of the two knock-outs for these genes. TSP1
25 null animals exhibited primarily lung disorders (Lawler, J., *et al.*, *J. Clin. Invest.* 101:982-992 (1998)) and secondarily vascular abnormalities, but only under specific pathological settings or on a restricted set of organs. In contrast TSP2 knock-out mice exhibited unpredicted collagen assembly anomalies, with carry-on consequences to the skin, tendons, and bone (Kyriakides, T.R., *et al.*, *J. Cell Biol.*
30 140:419-430 (1998)). In addition, these animals also appear to have overall

increase in capillary density in the dermis. It is not understood how the resemblance between the newly described members of the metallospondin family translate functionally. Clearly, pNIP has been shown to display active proteolytic activity by cleaving the N-terminus of type I procollagen (Colidge, A., *et al.*, *Proc. Natl. Acad. Sci. USA* 94:2374-2379 (1997)).

A second region of functional interest corresponds to the disintegrin domain. This domain has been more fully characterized in related members of the snake venom metalloproteases that have been shown to bind to α IIb β 3 and inhibit platelet interaction blocking coagulation (Pfaff, M., *et al.*, *Cell Adhes Commun.* 2:491-501 (1994); Usami, Y., *et al.*, *Biochem. Biophys. Res. Commun.* 201:331-339 (1994)). The disintegrin motif consists of a thirteen to fifteen domain which frequently contain an RGD or a negatively charged residue at the position of the aspartic acid. The RGD, or equivalent, binds to integrins and serve as antagonist or signaling ligands (Wolsberg, T.G. & White, J.M., *Developmental Biology* 180:389-401 (1996)). METH2, but not METH1, has an RGD sequence located amino-terminal to the disintegrin domain. In addition, both molecules present relatively high, but not perfect, degree of conservation of cysteines within the disintegrin motif. This appears to display an important role in the tertiary structure of this region and its ability to interact with integrins. In addition, some of these domains have been shown to act as functional adhesion molecules, particularly those with transmembrane regions (Wolsberg, T.G. & White, J.M., *Developmental Biology* 180:389-401 (1996)). It is unlikely that this will be the case for METH1 and METH2, since both these proteins appear to be secreted.

Example 3: Expression and purification of recombinant proteins

Recombinant constructs for expression of truncated fusion proteins were as follows: (1) pRSET-METH1-Type I: METH1 nt 1605-1839 (from the start codon) was amplified by polymerase chain reaction using the following primers: 5'-GCA TTT TGG ATC CGC CTT TTC ATG-3' (SEQ ID NO:78) and 5'-GTT

-121-

GTG TGC TGC AGA TTG TTC C-3' (SEQ ID NO:79). The amplified fragment was then subcloned into the *Bam*HI and *Pst*I sites of the pRSET vector; (2) pGEX-METH1-TSP was generated by ligating the *Bam*HI-*Eco*RI fragment from the pRSET-METH1-TSP into the *Sma*I site of the pGEX-5X vector (Pharmacia Biotech Inc., Piscataway, NJ) by blunt-end ligation; (3) pGEX-1.0-METH2: the fragment nt 838-1818 of METH2 cDNA (from the start codon) was ligated into *Bam*HI-*Eco*RI sites of pGEM-2TK. The METH2 fragment was amplified by PCR using the following primers: 5'-GAAAAATGGGGATCCGAGGTG-3' (SEQ ID NO:80) and 5'-GCAGGAGAATTCCGTCCATG-3' (SEQ ID NO:81) to generate *Bam*HI and *Eco*RI restriction sites; (4) pGEX-METH2-TSP: a 0.5Kb *Xma*I-*Eco*RI fragment isolated from pGEX-1.0-METH2 was subcloned into the *Xma*I and *Eco*RI sites of pGEX-2TK vector. All constructs were sequenced to verify sequence fidelity and correct open reading frame.

The recombinant proteins were named 6H-METH1, the recombinant protein expressed with the plasmid pRSET-METH1-TSP, GST-METH1, the protein expressed with the plasmid pGEX-METH1-TSP and GST-METH2, the protein expressed with the plasmid pGEX-METH2-TSP.

Expression plasmids were transformed into BL21:DE3 *E. coli* strain (Stratagene Cloning Systems, La Jolla, CA) and fusion proteins were induced following manufacturer recommendations. Briefly, induced bacteria pellets were resuspended in PBS and sonicated on ice for 1 min. The suspension was, subsequently, incubated at RT for 20min in the presence of 1% triton X-100 and centrifuged at 4°C. Histidine tagged fusion proteins were then purified on Ni-NTA beads (Qiagen, Chatsworth, CA) by incubating 20ml of supernatant with 1ml of beads (50% slurry) for 2h at 4°C. The suspension was transferred into a column and washed with 10 columns volume of PBS containing 10mM imidazole, followed by 50mM imidazole and finally 100mM imidazole. The protein was eluted with 500mM imidazole in PBS. Fractions containing the recombinant protein were dialyzed against phenol-red free DMEM. Samples were centrifuged for 30min at 4°C, part of the protein was not soluble and was lost during

centrifugation. The supernatant was stored at -70°C and used for proliferation, cornea pocket and chorioallantoic membrane (CAM) assays.

For purification of GST-fusion proteins, the extract was cleared by centrifugation and applied to a GST-affinity column (Pharmacia). The column was washed with PBS-1% triton X-100 in the presence of 0.1mM reduced glutathione and, subsequently, with the same buffer in the presence of 0.5mM reduced glutathione. Fusion proteins were eluted with 10mM reduced glutathione in 50mM Tris-HCl, pH 7.5. Fractions containing the protein were dialyzed against DMEM, stored at -70°C and used for proliferation, cornea pocket and chorioallantoic membrane (CAM) assays.

Integrity and purity of recombinant proteins was analyzed in 12.5% or 15% acrylamide gels stained with Coomassie blue.

A recombinant GST fusion protein containing the first two type I repeats of TSP was also dialyzed against DMEM before used in functional assays. Intact TSP1 was purified from platelets as previously described (Roberts, D.D., *et al.*, *J. Tissue Cult. Methods* 16:217-222 (1994)).

To test the hypothesis that METH1 and METH2 TSP domains could function as regulators of angiogenesis recombinant fusion proteins were generated in bacteria. The constructs included the first TSP domain of METH1 or METH2. This domain is the most conserved, 52% amino acid similarity with the second type I repeat of TSP1, (this domain contains a putative binding site for CD36). All recombinant proteins were isolated under native conditions to preserve their secondary structure as much as possible. 6H-METH1 and GST-METH1 contained the first TSP-like domain of METH1 fused to a histidine tag or a GST, respectively. METH1 recombinant protein was made with two different tags because of purification and structural advantages. The differences in size are due to the size of the tag, 6KDa the histidine and 27KDa the GST. GST-METH2 contained the first TSP domain of METH2 also fused to a GST. A fragment corresponding to the last two type I repeats of TSP1, also fused to a GST, and

intact TSP1 purified from platelets were used as positive controls. In addition, GST alone was included in all experiments as negative control.

Example 4: TSP domains in METH1 and METH2 disrupt angiogenesis in vivo

Cornea pocket assay

5 Swiss Webster females and males, were purchased from Charles River (Boston, MA) and used between 8-10 weeks-old for implantation of the pellets. Cornea pockets were performed as described by Kenyon and colleagues (Kenyon, B.M., *et al.*, *Invest. Ophthalmol. Vis. Sci.* 37:1625-1632 (1996)) with few
10 modifications. Briefly, a solution of 10µg of recombinant bFGF plus 5 mg of sucralfate were mixed with 10µl of Hydron (200mg/ml in ethanol; New Brunswick, NJ) and the recombinant protein of interest (2µg). The suspension was then smeared onto a sterile nylon mesh square (pore size 500µm; Tetko Inc., Briarcliff Manor, NY) and allowed to dry for 30min. The fibers of the mesh were pulled to produce pellets of 500µm³ that were stored at -20°C. Uniformly sized
15 pellets were selected under a microscope and used for the assays.

Mice were anesthetized with Avertin. An incision was made in the cornea using a Nikon SMZ-U dissecting microscope with the aid of a surgical blade. A single pellet was implanted into the pocket. Five days after pellet implantation, corneal angiogenesis was evaluated and photographed.

20 CAM assay

Chorioallantoic membrane assays were performed on Leghorn chicken embryos (SPAFAS, MA) at 12-14 days of embryonic development. Matrigel (750µg/ml), VEGF (250ng/mesh) and the protein or peptide to be tested were mixed, placed onto nylon meshes (pore size 250µm; Tetko Inc.) and incubated
25 sequentially at 37°C for 30min and at 4°C for 2h to induce polymerization. A positive (matrigel and VEGF) and a negative (VEGF alone) control were also prepared for each CAM. Polymerized meshes were placed onto the third outer

region of the CAM and incubated for 24h. To visualize vessels, 400µl of fluorescein isothiocyanate dextran (10mg/ml, SIGMA) was injected in the chick blood stream. After 5-10min incubation, the chick was topically fixed with 3.7% formaldehyde for 5min. The meshes were then dissected and mounted onto slides. Fluorescence intensity was analyzed with a computer-assisted image program (NIH Image 1.59).

Peptides used on these assays were synthesized by Chiron (Raleigh, NC). Sequence corresponded to amino acids: P-TSP1, 430-447; P-METH1, 549-563; P-METH2, 529-548.

The evaluation of angiogenic or anti-angiogenic responses relies heavily on the sensitivity and specificity of the assays used to assess the response. To evaluate the anti-angiogenic activity of these fragments *in vivo*, two popular and well-accepted angiogenesis assays were used: the corneal pocket and the chorioallantoic membrane. The visibility, accessibility, and avascularity of the cornea are highly advantageous and facilitate the visualization of the neovascular response and the topical application of the test substances. A known amount of angiogenesis factor(s) is implanted, as a pellet, in a pocket made in the cornea eye. To test an angiogenesis inhibitor, the molecule is implanted with the stimulator in the same pellet, and the response is compared to the stimulator alone.

In these experiments, bFGF was used as the vascularization stimulator. Pellets containing the recombinant protein were implanted in mouse corneas and their ability to inhibit the bFGF-induced angiogenic response was compared to that of controls. When a bFGF pellet containing GST was implanted new capillary vessels grew from the cornea limbus, across the cornea and into the pellet within 5 days. In contrast, addition of GST-METH1 or GST-METH2 to the bFGF pellets completely abolished blood vessel growth. Table 4 contains a summary of the results obtained from 41 assays performed. Intact TSP1 purified from platelets and GST-TSP1 were used as positive controls. All assays were performed at identical concentrations, suggesting that METH1 and METH2 have similar potency to that of TSP1 in the inhibition of angiogenesis. In addition, when half

of the standard concentration was used, a weak, however noticeable response was seen, indicating a dose-dependent effect.

Table 4.
Activity of METH1 and METH2 recombinant proteins in the corneal pocket assay

bFGF Pellets	Vascularized corneas/Total corneas
Vehicle	5/5
TSP1	0/5
GST	11/11
GST-TSP1-TI	1/4
GST-METH1-TSP	0/8
GST-METH2-TSP	0/8

In the CAM assay, the angiogenic response is analyzed by measuring the number of vessels that grow within a matrix polymer containing the angiogenic growth factor. To determine whether recombinant METH1 and METH2 proteins inhibited neovascularization in the CAM assay induced by VEGF, a matrigel polymer containing VEGF and the recombinant protein were implanted in the CAM. Quantitative analysis of the experiments, which included three different polymers per treatment are shown in Figure 6A. Matrigels polymers containing VEGF plus 5 μ g of GST-METH1 or GST-METH2 caused greater than 80% inhibition in blood vessel growth. A similar potency was found using the GST recombinant protein derived from the type I repeats of TSP1. Furthermore, the anti-angiogenic effect of the TSP domains in METH1 and METH2 was dose-dependent with a complete inhibition of blood vessel growth when 15 μ g/ml of protein was used (Figure 6C and D). GST alone, at identical concentrations, had no significant effect on VEGF-stimulated angiogenesis.

Synthetic peptides from the second or the third type I repeats of human TSP1 can mimic that anti-angiogenic effects of the intact TSP1 (Tolsma, S.S., *et al.*, *J. Cell. Biol.* 122:497-511 (1993)). In fact, a 19-residue polypeptide was shown to be sufficient to block *in vivo* neovascularization in the rat cornea and to inhibit the bFGF-induced migration of cultured endothelial cells (Vogel, T., *et al.*, *J. Cell. Biochem.* 53:74-84 (1993); Tolsma, S.S., *et al.*, *J. Cell. Biol.* 122:497-511 (1993)). To test whether the same was true for the METH1 and METH2 TSP domains, peptides derived from the same region were synthesized and their anti-angiogenic activity was evaluated in the CAM assay. The results are shown in Figure 6B. Peptides derived from both the TSP domain of METH1 and METH2 blocked VEGF-induced angiogenesis similarly to that of TSP1. In contrast, scramble peptides had no significant effects.

Example 5: Proliferation assays

Human dermal endothelial cells (HDEC) were isolated and grown on Vitrogen™ coated petri-dishes in EBM (Clonetics, San Diego, CA) supplemented with 15% fetal calf serum, 25µg/ml cAMP, and 1µg/ml of hydrocortisone-21-acetate and were used from passages 3 to 6. Cells were made quiescent by incubation of confluent monolayers with phenol red-free EBM containing 0.2% BSA for 48h. Human dermal fibroblasts were isolated from neonatal foreskin and by enzymatic dissociation. Both fibroblasts and smooth muscle cells were maintained in DMEM supplemented with 10% fetal calf serum. Human mammary epithelial cells (HMEC) were purchased from Clonetics and maintained in the recommended media (mammary epithelial growth media, MEGM).

Quiescent human dermal endothelial cells, between passage 3 and 6, were plated on Vitrogen™ coated 24-well plates in EBM supplemented with 0.2% BSA, 0.1% fetal calf serum and 1 ng/ml of bFGF in the presence or absence of the recombinant protein and incubated at 5% CO₂ at 37°C for 48h. For vascular smooth muscle (VSM) and fibroblast proliferation assays, cells were incubated

under the same conditions but using DMEM instead of EBM. Human mammary epithelial cells were incubated on their growth media. A pulse of [³H]-Thymidine (1 μCi/μl) was added during the last 4h prior harvesting. Cells were washed and fixed in 10% TCA. Incorporation of [³H]-thymidine was determined by scintillation counting, as previously described (Iruela-Arispe, M.L. & Sage, E.H., *J. Cell. Biochem.* 52:414 (1993)).

Statistical analysis were done using In-Stat software (Graph Pad Software) for Macintosh. Assuming normal distributions, data were analyzed by one-way ANOVA, followed by either T-test Dunnett test for comparisons between groups, or student-Newman-Kleus test for multiple comparisons between groups.

To gain insight into the mechanism by which METH1 and METH2 inhibit neovascularization, the direct effect of the purified recombinant fusion proteins on endothelial cell proliferation was tested. Serum-starved endothelial cells were plated into growth medium containing bFGF and FCS. Recombinant proteins (3 μg/ml) were added at the same time of plating. 40% (GST-METH1), 45% (6H-GST) or 36% (GST-METH2) inhibition was observed, in contrast to a non-significant effect when GST alone was added. The recombinant protein from the type I repeats of TSP1 had similar inhibitory effects. (Figure 7A). Furthermore, suppression of proliferation mediated by METH1 or METH2 were dose-dependent, as shown in Figure 7E. The inhibition was observed as early as one day after treatment and the inhibitory effect was not toxic and reversible since the removal of the recombinant protein and subsequent addition of growth factor alone led to the resumption of endothelial cell proliferation.

The cell specificity of the anti-proliferative effects for METH1 and METH2 on the endothelium was evaluated by additional proliferation assays on a variety of non-endothelial cells. No significant inhibition of proliferation was seen on fibroblasts or smooth muscle cell cultures. In contrast, a non significant, but reproducible stimulation of proliferation for these two cell types could be observed. This result rules out the presence of any potential nonspecific inhibitor of cell growth in the recombinant protein preparations. On mammary epithelial

cell, however, METH1 and METH2 inhibited cell proliferation to the same degree as to endothelial cells. Interestingly, TSP1 also suppresses mammary epithelial cell proliferation both *in vitro* and in a transgenic model.

The possibility that METH1 and METH2 might act as disintegrins is consistent with their anti-angiogenic properties. Clearly blockade of $\alpha v\beta 3$ and $\beta 1$ integrins with antibodies has been shown to inhibit neovascularization both during development and in tumors (Brooks, P.C., *et al.*, *Cell* 85:683-693 (1996); Brooks, P.C., *et al.*, *Cell* 92:391-400 (1998); Senger, D.R., *et al.*, *Proc. Natl. Acad. Sci. USA* 94:13612-13617 (1997)). Integrins are essential for the mediation of both proliferative and migratory signals (Schwartz, M.A. & Ingber, D.E., *Mol. Biol. Cell* 5:389-393 (1994)), therefore interference with those signals can be highly deleterious to the angiogenic process. The angiogenic functional assays were performed with recombinant protein containing only the type I repeats in METH1 and METH2.

The mechanism of action of METH1 and METH2 with regards to their angio-inhibitory activity is not known. To date we have evidence that these proteins are secreted and bind to endothelial cells. Further investigations are guided towards the identification of receptors and signal transduction mechanisms. A likely hypothesis resulting from the lessons learned from TSP1 is that both METH1 and METH2 bind to CD36. Recently, this scavenger receptor has been implicated in the mediation of signals by which TSP-1 exert its anti-angiogenic effects (Dawson, D.W., *et al.*, *J. Cell. Biol.* 138:707-717 (1997)). Both the CSVTCG (SEQ ID NO:83) (Asch, A.S., *et al.*, *Nature* 262:1436-1439 (1993); Catimel, B., *et al.*, *Biochem. J.* 284:231-236 (1992)) and the GCQXR (SEQ ID NO:84) sequences have been proposed as primary binding motifs to CD36 (Dawson, D.W., *et al.*, *J. Cell. Biol.* 138:707-717 (1997)). METH1 and METH2 have almost entire conservation in both these regions. A complementary and also likely occurrence is binding of METH1 and METH2 to bFGF. Binding to heparin and bFGF has been proposed as part of the anti-angiogenic activity of TSP1 (Guo, N., *et al.*, *J. Peptide Res.* 49 (1997)). This property appears to be mediated

through the WSXWS (SEQ ID NO:82) motif, also conserved in METH1 and METH2. Future efforts will focus on the signals implicated in the anti-angiogenic properties mediated by these novel proteins and on their potential as proteases of the extracellular milieu.

5 ***Example 6: Isolation of the METH1 or METH2 cDNA Clone From the Deposited Sample***

Two approaches can be used to isolate METH1 or METH2 from the deposited sample. First, the deposited clone is transformed into a suitable host (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. A single colony is then used to generate DNA using nucleic acid isolation techniques well known to those skilled in the art. (e.g.,
10 Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press.)

Alternatively, two primers of 17-20 nucleotides derived from both ends of the SEQ ID NO:1 or SEQ ID NO:3 (i.e., within the region of SEQ ID NO:1 or SEQ ID NO:3 bounded by the 5' NT and the 3' NT of the clone) are synthesized and used to amplify the METH1 or METH2 cDNA using the deposited cDNA plasmids as templates. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 µl of reaction mixture with 0.5 µg of the above cDNA template. A convenient reaction mixture is 1.5-5 mM MgCl₂, 0.01% (w/v) gelatin, 20 uM each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and
20 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94 degree C for 1 min; annealing at 55 degree C for 1 min; elongation at 72 degree C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product

is verified to be the selected sequence by subcloning and sequencing the DNA product.

Several methods are available for the identification of the 5' or 3' non-coding portions of the METH1 or METH2 gene which may not be present in the deposited clones. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine *et al.*, *Nucleic Acids Res.* 21(7):1683-1684 (1993).)

Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the METH1 or METH2 gene of interest is used to PCR amplify the 5' portion of the METH1 or METH2 full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

This above method starts with total RNA isolated from the desired source, although poly-A⁺ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known

sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the METH1 or METH2 gene.

Example 7: Bacterial Expression of METH1 or METH2

5 A METH1 or METH2 polynucleotide encoding a METH1 or METH2 polypeptide invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 5, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end
10 of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp^r), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a
15 6-histidine tag (6-His), and restriction enzyme cloning sites. The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the
20 lacI repressor and also confers kanamycin resistance (Kan^r). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

25 Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.⁶⁰⁰) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final

concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4 degree C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified METH1 or METH2 protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the METH1 or METH2 protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified METH1 or METH2 protein is stored at 4°C or frozen at -80°C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a METH1 or METH2 polynucleotide, called pHE4a. (ATCC Accession Number 209645, deposited February 25, 1998.) This vector contains:

1) a neomycinphosphotransferase gene as a selection marker, 2) an *E. coli* origin

of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (*lacIq*). The origin of replication (*oriC*) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

5 DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 5, using PCR primers having restriction sites for NdeI (5' primer) and XbaI, 10 BamHI, XhoI, or Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

15 ***Example 8: Purification of METH1 or METH2 Polypeptide from an Inclusion Body***

The following alternative method can be used to purify METH1 or METH2 polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 20 4-10°C.

Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10 degree C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein 25 required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The

homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4 degree C overnight to allow further GuHCl extraction.

Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4 degree C without mixing for 12 hours prior to further purification steps.

To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 um membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the METH1 or METH2 polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant A_{280} monitoring

-135-

of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant METH1 or METH2 polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Coomassie blue stained 16% SDS-PAGE gel when 5 ug of purified protein is loaded. The purified METH1 or METH2 protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

Example 9: Cloning and Expression of METH1 or METH2 in a Baculovirus Expression System

In this example, the plasmid shuttle vector pA2 is used to insert METH1 or METH2 polynucleotide into a baculovirus to express METH1 or METH2. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak *Drosophila* promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned METH1 or METH2 polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., *Virology* 170:31-39 (1989).

Specifically, the METH1 or METH2 cDNA sequence contained in the deposited clone, including the AUG initiation codon and any naturally associated leader sequence, is amplified using the PCR protocol described in Example 5. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five ug of a plasmid containing the polynucleotide is co-transfected with 1.0 ug of a commercially available linearized baculovirus DNA ("BaculoGold^a baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987).

One ug of BaculoGold^a virus DNA and 5 ug of the plasmid are mixed in a sterile

well of a microtiter plate containing 50 ul of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 ul Lipofectin plus 90 ul Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27 degrees C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27 degrees C for four days.

After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 ul of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4 degree C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 uCi of ³⁵S-methionine and 5 uCi ³⁵S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by

centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced METH1 or METH2 protein.

Example 10: Expression of METH1 or METH2 in Mammalian Cells

METH1 or METH2 polypeptide can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLV1, HIV1 and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2DHFR (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

Alternatively, METH1 or METH2 polypeptide can be expressed in stable cell lines containing the METH1 or METH2 polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as DHFR, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected METH1 or METH2 gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., *et al.*, *J. Biol. Chem.* 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., *Biochem. et Biophys. Acta* 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., *Biotechnology* 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy *et al.*, *Biochem J.* 227:277-279 (1991); Bebbington *et al.*, *Bio/Technology* 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

Derivatives of the plasmid pSV2-DHFR (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No. 209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen *et al.*, *Molecular and Cellular Biology*, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart *et al.*, *Cell* 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of METH1 or METH2. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

If a naturally occurring signal sequence is used to produce a secreted protein, the vector does not need a second signal peptide. Alternatively, if a naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence in an effort to secrete the protein from the cell. (See, e.g., WO 96/34891.)

The amplified fragment is then digested with the appropriate restriction enzyme and purified on a 1% agarose gel using a commercially available kit

("GeneClean," BIO 101 Inc., La Jolla, Ca.). The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 or pC4 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five μ g of the expression plasmid pC6 or pC4 is cotransfected with 0.5 μ g of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1 μ M, 2 μ M, 5 μ M, 10 μ M, 20 μ M). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 μ M. Expression of METH1 or METH2 is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

Example 11: Construction of N-Terminal and/or C-Terminal Deletion Mutants

The following general approach may be used to clone a N-terminal or C-terminal deletion METH1 or METH2 deletion mutant. Generally, two oligonucleotide primers of about 15-25 nucleotides are derived from the desired 5' and 3' positions of a polynucleotide of SEQ ID NO:1 or SEQ ID NO:3. The 5' and 3' positions of the primers are determined based on the desired METH1 or

METH2 polynucleotide fragment. An initiation and stop codon are added to the 5' and 3' primers respectively, if necessary, to express the METH1 or METH2 polypeptide fragment encoded by the polynucleotide fragment. Preferred METH1 or METH2 polynucleotide fragments are those encoding the N-terminal and C-terminal deletion mutants disclosed above in the "Polynucleotide and Polypeptide Fragments" section of the Specification.

Additional nucleotides containing restriction sites to facilitate cloning of the METH1 or METH2 polynucleotide fragment in a desired vector may also be added to the 5' and 3' primer sequences. The METH1 or METH2 polynucleotide fragment is amplified from genomic DNA or from the deposited cDNA clone using the appropriate PCR oligonucleotide primers and conditions discussed herein or known in the art. The METH1 or METH2 polypeptide fragments encoded by the METH1 or METH2 polynucleotide fragments of the present invention may be expressed and purified in the same general manner as the full length polypeptides, although routine modifications may be necessary due to the differences in chemical and physical properties between a particular fragment and full length polypeptide.

As a means of exemplifying but not limiting the present invention, the polynucleotide encoding the METH1 polypeptide fragment D-40 to S-950 or the METH2 polypeptide fragment L-20 to L-890 is amplified and cloned as follows: A 5' primer is generated comprising a restriction enzyme site followed by an initiation codon in frame with the polynucleotide sequence encoding the N-terminal portion of the polypeptide fragment beginning with D-40 or L-20, respectively. A complementary 3' primer is generated comprising a restriction enzyme site followed by a stop codon in frame with the polynucleotide sequence encoding C-terminal portion of the METH1 or METH2 polypeptide fragment ending with S-950 or L-890, respectively.

The amplified polynucleotide fragment and the expression vector are digested with restriction enzymes which recognize the sites in the primers. The digested polynucleotides are then ligated together. The METH1 or METH2

polynucleotide fragment is inserted into the restricted expression vector, preferably in a manner which places the METH1 or METH2 polypeptide fragment coding region downstream from the promoter. The ligation mixture is transformed into competent *E. coli* cells using standard procedures and as described in the Examples herein. Plasmid DNA is isolated from resistant colonies and the identity of the cloned DNA confirmed by restriction analysis, PCR and DNA sequencing.

Example 12: Protein Fusions of METH1 or METH2

METH1 or METH2 polypeptides are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of METH1 or METH2 polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 7; see also EP A 394,827; Traunecker, *et al.*, *Nature* 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the half-life time in vivo. Nuclear localization signals fused to METH1 or METH2 polypeptides can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 7.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site

should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and METH1 or METH2 polynucleotide, isolated by the PCR protocol described in Example 5, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:

GGGATCCGGAGCCCAAATCTTCTGACAAAACCTCACACATGCCCACC
GTGCCCAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCC
CCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGT
CACATGCGTGGTGGTGGACGTAAGCCACGAAGACCCTGAGGTCAAG
TTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAA
AGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGT
CCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAG
TGCAAGGTCTCCAACAAAGCCCTCCCAACCCCCATCGAGAAAACCA
TCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCT
GCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACC
TGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGTGGAGTGGG
AGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCTCCCGT
GCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGG
ACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGAT
GCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTG
TCTCCGGGTAAATGAGTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID
NO:85)

Example 13: Production of an Antibody

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) For example, cells expressing METH1 or METH2 is administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of METH1 or METH2 protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology. (Kohler *et al.*, *Nature* 256:495 (1975); Kohler *et al.*, *Eur. J. Immunol.* 6:511 (1976); Kohler *et al.*, *Eur. J. Immunol.* 6:292 (1976); Hammerling *et al.*, in: *Monoclonal Antibodies and T-Cell Hybridomas*, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures involve immunizing an animal (preferably a mouse) with METH1 or METH2 polypeptide or, more preferably, with a secreted METH1 or METH2 polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56 degree C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 ug/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands *et al.* (*Gastroenterology* 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify

clones which secrete antibodies capable of binding the METH1 or METH2 polypeptide.

Alternatively, additional antibodies capable of binding to METH1 or METH2 polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the METH1 or METH2 protein-specific antibody can be blocked by METH1 or METH2. Such antibodies comprise anti-idiotypic antibodies to the METH1 or METH2 protein-specific antibody and can be used to immunize an animal to induce formation of further METH1 or METH2 protein-specific antibodies.

It will be appreciated that Fab and F(ab')₂ and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂ fragments). Alternatively, secreted METH1 or METH2 protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, *Science* 229:1202 (1985); Oi *et al.*, *BioTechniques* 4:214 (1986); Cabilly *et al.*, U.S. Patent No. 4,816,567; Taniguchi *et al.*, EP 171496; Morrison *et al.*, EP 173494; Neuberger *et al.*, WO 8601533; Robinson *et al.*, WO 8702671; Boulianne *et al.*, *Nature* 312:643 (1984); Neuberger *et al.*, *Nature* 314:268 (1985).)

Example 14: Production Of METH1 or METH2 Protein For High-Throughput Screening Assays

The following protocol produces a supernatant containing METH1 or METH2 polypeptide to be tested. This supernatant can then be used in the Screening Assays described in Examples 16-23.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at 2×10^5 cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in Examples 10-12, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not

spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37 degree C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or HGS CHO-5 media (116.6 mg/L of CaCl_2 (anhyd); 0.00130 mg/L $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$; 0.050 mg/L of $\text{Fe}(\text{NO}_3)_3 \cdot 9\text{H}_2\text{O}$; 0.417 mg/L of $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$; 311.80 mg/L of KCl; 28.64 mg/L of MgCl_2 ; 48.84 mg/L of MgSO_4 ; 6995.50 mg/L of NaCl; 2400.0 mg/L of NaHCO_3 ; 62.50 mg/L of $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$; 71.02 mg/L of Na_2HPO_4 ; .4320 mg/L of $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$; .002 mg/L of Arachidonic Acid; 1.022 mg/L of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitic Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml of L-Asparagine- H_2O ; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL- H_2O ; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL- H_2O ; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-2 H_2O ; and 99.65 mg/ml of L-Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; 0.680 mg/L of Vitamin B₁₂; 25 mM of HEPES Buffer; 2.39 mg/L of

Na Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed with Oleic Acid; 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal Acetate. Adjust osmolarity to 327 mOsm) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person B adds 1.5ml appropriate media to each well. Incubate at 37 degree C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants from each well can then be used in the assays described in Examples 16-23.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the METH1 or METH2 polypeptide directly (e.g., as a secreted protein) or by METH1 or METH2 inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

Example 15: Construction of GAS Reporter Construct

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the

Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

5 GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after
10 treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

 The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase
15 ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

 The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, *Ann. Rev. Biochem.*
20 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN-a, IFN-g, and IL-10. The Class
25 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:82)).

 Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

-150-

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.)

Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

	JAKs				STATs	GAS(elements) or ISRE
Ligand	tyk2	Jak1	Jak2	Jak3		
IFN family						
IFN-a/B	+	+	-	-	1,2,3	ISRE GAS (IRF1>Lys6>IFP)
IFN-g		+	+	-	1	
IL-10	+	?	?	-	1,3	
gp130 family						
IL-6 (Pleiotrophic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
IL-11(Pleiotrophic)	?	+	?	?	1,3	
OnM(Pleiotrophic)	?	+	+	?	1,3	
LIF(Pleiotrophic)	?	+	+	?	1,3	
CNTF(Pleiotrophic)	-/+	+	+	?	1,3	
G-CSF(Pleiotrophic)	?	+	?	?	1,3	
IL-12(Pleiotrophic)	+	-	+	+	1,3	
g-C family						
IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP >>Ly6)(IgH)
IL-7 (lymphocytes)	-	+	-	+	5	GAS
IL-9 (lymphocytes)	-	+	-	+	5	GAS
IL-13 (lymphocyte)	-	+	?	?	6	GAS
IL-15	?	+	?	+	5	GAS
gp140 family						
IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IF1>>Ly6)
IL-5 (myeloid)	-	-	+	-	5	GAS
GM-CSF (myeloid)	-	-	+	-	5	GAS
Growth hormone family						
GH	?	-	+	-	5	GAS(B-CAS>IRF1=IFP>>Ly6)
PRL	?	+/-	+	-	1,3,5	
EPO	?	-	+	-	5	
Receptor Tyrosine Kinases						
EGF	?	+	+	-	1,3	GAS (IRF1)
PDGF	?	+	+	-	1,3	GAS (not IRF1)
CSF-1	?	+	+	-	1,3	

-151-

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 16-17, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman *et al.*, *Immunity* 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

5':GCGCCTCGAGATTTCCCGGAAATCTAGATTTCCCGGAAATGATTT
CCCGGAAATGATTTCCCGGAAATATCTGCCATCTCAATTAG:3' (SEQ ID
NO:86)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTGGCAAAGCCTAGGC:3' (SEQ ID NO:87)

PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

5':CTCGAGATTTCCCGGAAATCTAGATTTCCCGGAAATGATTTCCCG
GAAATGATTTCCCGGAAATATCTGCCATCTCAATTAGTCAGCAACCA
TAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGT
TCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCA
GAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAG
GAGGCTTTTTTGGAGGCCCTAGGCTTTTGCAAAAAGCTT:3' (SEQ ID
NO:88)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter

-152-

molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 16-17.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 18 and 19. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

-153-

Example 16: High-Throughput Screening Assay for T-cell Activity

The following protocol is used to assess T-cell activity of METH1 or METH2 by determining whether METH1 or METH2 supernatant proliferates and/or differentiates T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 15. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4⁺ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells (10^7 per transfection), and resuspend in OPTI-MEM to a final concentration of 10^7 cells/ml. Then add 1ml of 1×10^7 cells in OPTI-MEM to T25 flask and incubate at 37 degree C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

-154-

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Gentamicin, and 1% Pen-Strep. These cells are treated with supernatants containing METH1 or METH2 polypeptides or METH1 or METH2 induced polypeptides as produced by the protocol described in Example 14.

5 On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

10 Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100,000 cells per well).

 After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

15 The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophene covers) and stored at -20 degree C until SEAP assays are performed according to Example 20. The plates containing the remaining treated cells are placed at 4 degree C and serve as a source of material for repeating the assay on a specific well if desired.

20 As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

-155-

Example 17: High-Throughput Screening Assay Identifying Myeloid Activity

The following protocol is used to assess myeloid activity of METH1 or METH2 by determining whether METH1 or METH2 proliferates and/or differentiates myeloid cells. Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 15. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 15, a DEAE-Dextran method (Kharbanda *et. al.*, 1994, *Cell Growth & Differentiation* 5:259-265) is used. First, harvest 2×10^7 U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$, 1 mM MgCl_2 , and 675 uM CaCl_2 . Incubate at 37 degree C for 45 min.

Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37 degree C for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

These cells are tested by harvesting 1×10^8 cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of 5×10^5 cells/ml. Plate 200 ul cells per well in the 96-well plate (or 1×10^5 cells/well).

-156-

Add 50 ul of the supernatant prepared by the protocol described in Example 14. Incubate at 37 degree C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 20.

Example 18: High-Throughput Screening Assay Identifying Neuronal Activity

When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed by METH1 or METH2.

Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat phenochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor). The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells by METH1 or METH2 can be assessed.

The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K *et al.*, *Oncogene* 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:89)

5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:90)

-157-

Using the GAS:SEAP/Neo vector produced in Example 15, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 14. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as 5×10^5 cells/ml.

Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to 1×10^5 cells/well). Add 50 ul supernatant produced by Example 14, 37 degree

-158-

C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 20.

5 ***Example 19: High-Throughput Screening Assay for T-cell Activity***

NF-KB (Nuclear Factor KB) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF-KB
10 regulates the expression of genes involved in immune cell activation, control of apoptosis (NF- KB appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

In non-stimulated conditions, NF- KB is retained in the cytoplasm with I-
KB (Inhibitor KB). However, upon stimulation, I- KB is phosphorylated and
15 degraded, causing NF- KB to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- KB include IL-2, IL-6, GM-CSF, ICAM-1 and class 1 MHC.

Due to its central role and ability to respond to a range of stimuli, reporter
constructs utilizing the NF-KB promoter element are used to screen the
20 supernatants produced in Example 14. Activators or inhibitors of NF-KB would be useful in treating diseases. For example, inhibitors of NF-KB could be used to treat those diseases related to the acute or chronic activation of NF-KB, such as rheumatoid arthritis.

To construct a vector containing the NF-KB promoter element, a PCR
25 based strategy is employed. The upstream primer contains four tandem copies of the NF-KB binding site (GGGGACTTTC) (SEQ ID NO:91), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:

-159-

5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCG
GGACTTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:92)

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:

5 5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:93)

PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene) Sequencing with the T7 and T3 primers confirms the insert contains
10 the following sequence:

5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGGACT
TTCCATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAA
CTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCG
CCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGC
15 CTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAG
GGCCTAGGCTTTTGCAAAAAGCTT:3' (SEQ ID NO:88)

Next, replace the SV40 minimal promoter element present in the pSEAP2- promoter plasmid (Clontech) with this NF-KB/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and
20 therefore, is not preferred for mammalian expression systems.

In order to generate stable mammalian cell lines, the NF-KB/SV40/SEAP cassette is removed from the above NF-KB/SEAP vector using restriction enzymes Sall and NotI, and inserted into a vector containing neomycin resistance. Particularly, the NF-KB/SV40/SEAP cassette was inserted into pGFP-1
25 (Clontech), replacing the GFP gene, after restricting pGFP-1 with Sall and NotI.

Once NF-KB/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 16. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described in Example 16. As a positive control, exogenous TNF alpha (0.1, 1,

-160-

10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

Example 20: Assay for SEAP Activity

As a reporter molecule for the assays described in Examples 16-19, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 ul of 2.5x dilution buffer into Optiplates containing 35 ul of a supernatant. Seal the plates with a plastic sealer and incubate at 65 degree C for 30 min. Separate the Optiplates to avoid uneven heating.

Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 ml Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 ul Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

Reaction Buffer Formulation:

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5

-161-

	19	105	5.25
	20	110	5.5
	21	115	5.75
	22	120	6
5	23	125	6.25
	24	130	6.5
	25	135	6.75
	26	140	7
	27	145	7.25
10	28	150	7.5
	29	155	7.75
	30	160	8
	31	165	8.25
	32	170	8.5
15	33	175	8.75
	34	180	9
	35	185	9.25
	36	190	9.5
	37	195	9.75
20	38	200	10
	39	205	10.25
	40	210	10.5
	41	215	10.75
	42	220	11
25	43	225	11.25
	44	230	11.5
	45	235	11.75
	46	240	12
	47	245	12.25
30	48	250	12.5
	49	255	12.75
	50	260	13

Example 21: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability

35 Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to

-162-

detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-3, used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO₂ incubator for 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-3 is made in 10% pluronic acid DMSO. To load the cells with fluo-3, 50 ul of 12 ug/ml fluo-3 is added to each well. The plate is incubated at 37 degree C in a CO₂ incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to 2-5x10⁶ cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-3 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37 degree C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1x10⁶ cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-3. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates

-163-

an extracellular signaling event caused by the a molecule, either METH1 or METH2 or a molecule induced by METH1 or METH2, which has resulted in an increase in the intracellular Ca^{++} concentration.

Example 22: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine kinase activity, identifying whether METH1 or METH2 or a molecule induced by METH1 or METH2 is capable of activating tyrosine kinase signal transduction pathways is of interest. Therefore, the following protocol is designed to identify such molecules capable of activating the tyrosine kinase signal transduction pathways.

Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses

-164-

with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed with PBS and stored at 4 degree C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 14, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na₃VO₄, 2 mM Na₄P₂O₇ and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 4°C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4 degree C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

-165-

Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg²⁺ (5mM ATP/50mM MgCl₂), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl₂, 5 mM MnCl₂, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30 degree C for 2 min. Initial the reaction by adding 10ul of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mM EDTA and place the reactions on ice.

Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37 degree C for 20 min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37 degree C for one hour. Wash the well as above.

Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

-166-

Example 23: High-Throughput Screening Assay Identifying Phosphorylation Activity

As a potential alternative and/or compliment to the assay of protein tyrosine kinase activity described in Example 22, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4 degree C until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 14 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place

of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard

-167-

procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation by METH1 or METH2 or a molecule induced by METH1 or METH2.

Example 24: Method of Determining Alterations in the METH1 or METH2 Gene

RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:1. Suggested PCR conditions consist of 35 cycles at 95 degree C for 30 seconds; 60-120 seconds at 52-58 degree C; and 60-120 seconds at 70 degree C, using buffer solutions described in Sidransky, D. *et al.*, *Science* 252:706 (1991).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons of METH1 or METH2 is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations in METH1 or METH2 is then cloned and sequenced to validate the results of the direct sequencing.

PCR products of METH1 or METH2 are cloned into T-tailed vectors as described in Holton, T.A. and Graham, M.W., *Nucleic Acids Research* 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations in METH1 or METH2 not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in the METH1 or METH2 gene. Isolated genomic clones are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Mannheim),

-168-

and FISH performed as described in Johnson, Cg. et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the METH1 or METH2 genomic locus.

5 Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength
10 filters. (Johnson, Cv. et al., Genet. Anal. Tech. Appl. 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region of METH1 or METH2 (hybridized by the probe) are identified as insertions, deletions, and
15 translocations. These METH1 or METH2 alterations are used as a diagnostic marker for an associated disease.

Example 25: Method of Detecting Abnormal Levels of METH1 or METH2 in a Biological Sample

METH1 or METH2 polypeptides can be detected in a biological sample,
20 and if an increased or decreased level of METH1 or METH2 is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect METH1 or
25 METH2 in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies to METH1 or METH2, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 13. The wells are blocked so that non-specific binding of METH1 or METH2 to the well is reduced.

-169-

The coated wells are then incubated for > 2 hours at RT with a sample containing METH1 or METH2. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded METH1 or METH2.

5 Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

10 Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot METH1 or METH2 polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the
15 METH1 or METH2 in the sample using the standard curve.

Example 26: Formulating a Polypeptide

The METH1 or METH2 composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the
20 METH1 or METH2 polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

25 As a general proposition, the total pharmaceutically effective amount of METH1 or METH2 administered parenterally per dose will be in the range of about 1ug/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and

-170-

1 mg/kg/day for the hormone. If given continuously, METH1 or METH2 is typically administered at a dose rate of about 1 ug/kg/hour to about 50 ug/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Pharmaceutical compositions containing METH1 or METH2 are administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

METH1 or METH2 is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules. Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. *et al.*, *Biopolymers* 22:547-556 (1983)), poly (2-hydroxyethyl methacrylate) (R. Langer *et al.*, *J. Biomed. Mater. Res.* 15:167-277 (1981), and R. Langer, *Chem. Tech.* 12:98-105 (1982)), ethylene vinyl acetate (R. Langer *et al.*) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also include liposomally entrapped METH1 or METH2 polypeptides. Liposomes containing the METH1 or METH2 are prepared by methods known per se: DE 3,218,121; Epstein *et al.*, *Proc. Natl. Acad. Sci. USA* 82:3688-3692 (1985); Hwang *et al.*, *Proc. Natl. Acad. Sci. USA* 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324.

-171-

Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

5 For parenteral administration, in one embodiment, METH1 or METH2 is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the
10 formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides.

Generally, the formulations are prepared by contacting METH1 or METH2 uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired
15 formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

20 The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than
25 about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as

-172-

EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

METH1 or METH2 is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

METH1 or METH2 used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

METH1 or METH2 polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous METH1 or METH2 polypeptide solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized METH1 or METH2 polypeptide using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, METH1 or METH2 may be employed in conjunction with other therapeutic compounds.

-173-

Example 27: Method of Treating Decreased Levels of METH1 or METH2

The present invention relates to a method for treating an individual in need of a decreased level of METH1 or METH2 activity in the body comprising, administering to such an individual a composition comprising a therapeutically effective amount of METH1 or METH2 antagonist. Preferred antagonists for use in the present invention are METH1 or METH2-specific antibodies.

Moreover, it will be appreciated that conditions caused by a decrease in the standard or normal expression level of METH1 or METH2 in an individual can be treated by administering METH1 or METH2, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of METH1 or METH2 polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of METH1 or METH2 to increase the activity level of METH1 or METH2 in such an individual.

For example, a patient with decreased levels of METH1 or METH2 polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 26.

Example 28: Method of Treating Increased Levels of METH1 or METH2

The present invention also relates to a method for treating an individual in need of an increased level of METH1 or METH2 activity in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of METH1 or METH2 or an agonist thereof.

Antisense technology is used to inhibit production of METH1 or METH2. This technology is one example of a method of decreasing levels of METH1 or METH2 polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.

-174-

For example, a patient diagnosed with abnormally increased levels of METH1 or METH2 is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 26.

Example 29: Method of Treatment Using Gene Therapy - Ex Vivo

One method of gene therapy transplants fibroblasts, which are capable of expressing METH1 or METH2 polypeptides, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37 degree C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. *et al.*, *DNA* 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding METH1 or METH2 can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 5. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus

-175-

linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector contains properly inserted METH1 or METH2.

The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the METH1 or METH2 gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the METH1 or METH2 gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether METH1 or METH2 protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

-176-

Example 30: Method of Treatment Using Gene Therapy - In Vivo

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) METH1 or METH2 sequences into an animal to increase or decrease the expression of the METH1 or METH2 polypeptide. The METH1 or METH2 polynucleotide may be operatively linked to a promoter or any other genetic elements necessary for the expression of the METH1 or METH2 polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 5705151, 5580859; Tabata H. *et al.* (1997) *Cardiovasc. Res.* 35(3):470-479, Chao, J *et al.* (1997) *Pharmacol. Res.* 35(6):517-522, Wolff J.A. (1997) *Neuromuscul. Disord.* 7(5):314-318, Schwartz, B. *et al.* (1996) *Gene Ther.* 3(5):405-411, Tsurumi Y. *et al.* (1996) *Circulation* 94(12):3281-3290 (incorporated herein by reference).

The METH1 or METH2 polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The METH1 or METH2 polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the METH1 or METH2 polynucleotides may also be delivered in liposome formulations (such as those taught in Felgner P.L. *et al.* (1995) *Ann. NY Acad. Sci.* 772:126-139 and Abdallah B. *et al.* (1995) *Biol. Cell* 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

-177-

The METH1 or METH2 polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The METH1 or METH2 polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked METH1 or METH2 polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about

-178-

0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked METH1 or METH2 polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected METH1 or METH2 polynucleotide in muscle *in vivo* is determined as follows. Suitable METH1 or METH2 template DNA for production of mRNA coding for METH1 or METH2 polypeptide is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The METH1 or METH2 template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for METH1 or METH2 protein expression. A time course for METH1 or METH2 protein expression may

-179-

be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of METH1 or METH2 DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be use to extrapolate proper dosages and other treatment parameters in humans and other animals using METH1 or METH2 naked DNA.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples.

Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

The entire disclosure of all publications (including patents, patent applications, journal articles, laboratory manuals, books, or other documents) cited herein are hereby incorporated by reference.

-179.1-

Applicant's or agent's file reference number: 1488.107PC02	International application No: TBA
---	-----------------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>32</u> , lines <u>16-17</u> .	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depository institution American Type Culture Collection	
Address of depository institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America formerly at: 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit 15 January 1998	Accession Number 209581
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
DNA plasmid HOUQC17	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications, e.g. "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer	Authorized officer

-179.2-

Applicant's or agent's file reference number: 1488.107PC02	International application No: TBA
---	-----------------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page 32, lines 25-26.	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depository institution American Type Culture Collection	
Address of depository institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
formerly at: 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit 15 January 1998	Accession Number 209582
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
DNA plasmid HCE4D69	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer	Authorized officer

-180-

What Is Claimed Is:

1. An isolated nucleic acid molecule comprising a polynucleotide selected from the group consisting of:

(a) a polynucleotide encoding a polypeptide comprising amino acids 1 to 950 in SEQ ID NO:2;

(b) a polynucleotide encoding a polypeptide comprising amino acids 2 to 950 in SEQ ID NO:2;

(c) a polynucleotide encoding a polypeptide comprising amino acids 29 to 950 in SEQ ID NO:2;

(d) a polynucleotide encoding a polypeptide comprising amino acids 30 to 950 in SEQ ID NO:2;

(e) a polynucleotide comprising a nucleotide sequence encoding the METH1 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209581;

(f) a polynucleotide comprising a nucleotide sequence encoding the mature METH1 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209581;

(g) a polynucleotide encoding a polypeptide comprising amino acids 1 to 890 in SEQ ID NO:4;

(h) a polynucleotide encoding a polypeptide comprising amino acids 2 to 890 in SEQ ID NO:4;

(i) a polynucleotide encoding a polypeptide comprising amino acids 24 to 890 in SEQ ID NO:4;

(j) a polynucleotide encoding a polypeptide comprising amino acids 112 to 890 in SEQ ID NO:4;

(k) a polynucleotide comprising a nucleotide sequence encoding the METH2 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209582;

-181-

(l) a polynucleotide comprising a nucleotide sequence encoding the mature METH2 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209582;

5 (m) a polynucleotide variant created by altering a polynucleotide of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), or (l), wherein:

(i) said altering includes a nucleotide insertion, deletion, or substitution, or any combination thereof; and

(ii) the number of alterations is equal to or less than 5% of the total number of nucleotides present in the unaltered polynucleotide;

10 (n) a polynucleotide encoding amino acids 235 to 459 in SEQ ID NO:2;

(o) a polynucleotide encoding amino acids 460 to 544 in SEQ ID NO:2;

15 (p) a polynucleotide encoding amino acids 545 to 598 in SEQ ID NO:2;

(q) a polynucleotide encoding amino acids 841 to 894 in SEQ ID NO:2;

(r) a polynucleotide encoding amino acids 895 to 934 in SEQ ID NO:2;

20 (s) a polynucleotide encoding amino acids 536 to 613 in SEQ ID NO:2;

(t) a polynucleotide encoding amino acids 549 to 563 in SEQ ID NO:2;

25 (u) a polynucleotide encoding amino acids 214 to 439 in SEQ ID NO:4;

(v) a polynucleotide encoding amino acids 440 to 529 in SEQ ID NO:4;

(w) a polynucleotide encoding amino acids 530 to 583 in SEQ ID NO:4;

-182-

(x) a polynucleotide encoding amino acids 837 to 890 in SEQ ID NO:4;

(y) a polynucleotide encoding amino acids 280 to 606 in SEQ ID NO:4);

5 (z) a polynucleotide encoding amino acids 529 to 548 in SEQ ID NO:4; and

(aa) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o), (p), (q), (r), (s), (t), (u), (v), (w), (x), (y), or (z).

10 2. An isolated nucleic acid molecule comprising a polynucleotide which encodes the amino acid sequence of an epitope-bearing portion of the METH1 polypeptide of SEQ ID NO:2 or the METH2 polypeptide of SEQ ID NO:4.

15 3. An isolated nucleic acid molecule, comprising a polynucleotide selected from the group consisting of:

(a) 50 contiguous nucleotides of the coding region of SEQ ID NO:1, provided that said nucleotide sequence is not any one of SEQ ID NOs:14-41, or any subfragment thereof; and

20 (b) a nucleotide sequence complementary to the nucleotide sequence in (a).

4. An isolated nucleic acid molecule, comprising a polynucleotide selected from the group consisting of:

25 (a) 50 contiguous nucleotides of the coding region of SEQ ID NO:3, provided that said nucleotide sequence is not SEQ ID NOs:19-22, 24, 42-77, or any subfragment thereof; and

(b) a nucleotide sequence complementary to the nucleotide sequence in (a).

-183-

5. A method for making a recombinant vector comprising inserting an isolated nucleic acid molecule of claim 1 into a vector in operable linkage to a promoter.

6. A recombinant vector produced by the method of claim 5.

5 7. A method of making a recombinant host cell comprising introducing the recombinant vector of claim 6 into a host cell.

8. A recombinant host cell produced by the method of claim 7.

9. A recombinant method for producing a METH1 or METH2 polypeptide, comprising culturing the recombinant host cell of claim 8 under conditions such that said polypeptide is expressed and recovering said polypeptide.
10

10. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

- (a) amino acids 1 to 950 in SEQ ID NO:2;
- (b) amino acids 2 to 950 in SEQ ID NO:2;
- 15 (c) amino acids 29 to 950 in SEQ ID NO:2;
- (d) amino acids 30 to 950 in SEQ ID NO:2;
- (d) the amino acid sequence of the METH1 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209581;
- 20 (e) the amino acid sequence of the mature METH1 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209581;
- (f) amino acids 1 to 890 in SEQ ID NO:4;
- (g) amino acids 2 to 890 in SEQ ID NO:4;
- 25 (h) amino acids 24 to 890 in SEQ ID NO:4;

-184-

(i) amino acids 112 to 890 in SEQ ID NO:4;
(j) an amino acid sequence of the METH2 polypeptide having the amino acid sequence encoded by the METH2 cDNA clone contained in ATCC Deposit No. 209582;

5 (k) an amino acid sequence of the mature METH2 polypeptide having the amino acid sequence encoded by the METH2 cDNA clone contained in ATCC Deposit No. 209582;

(l) the amino acid sequence of a polypeptide variant created by altering a polypeptide of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), or (k),
10 wherein:

(i) said altering includes an amino acid insertion, deletion, or substitution, or any combination thereof; and

(ii) the number of alterations is equal to or less than 5% of the total number of amino acids present in the unaltered amino acid sequence;

15 (m) amino acids 235 to 459 in SEQ ID NO:2;
(n) amino acids 460 to 544 in SEQ ID NO:2;
(o) amino acids 545 to 598 in SEQ ID NO:2;
(p) amino acids 841 to 894 in SEQ ID NO:2;
(q) amino acids 895 to 934 in SEQ ID NO:2;
20 (r) amino acids 536 to 613 in SEQ ID NO:2;
(s) amino acids 549 to 563 in SEQ ID NO:2;
(t) amino acids 214 to 439 in SEQ ID NO:4;
(u) amino acids 440 to 529 in SEQ ID NO:4;
(v) amino acids 530 to 583 in SEQ ID NO:4;
25 (w) amino acids 837 to 890 in SEQ ID NO:4;
(x) amino acids 280 to 606 in SEQ ID NO:4;
(y) amino acids 529 to 548 in SEQ ID NO:4;
(z) the amino acid sequence of an epitope-bearing portion of
any one of the polypeptides of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l),
30 (m), (n), (o), (p), (q), (r), (s), (t), (u), (v), (w), (x), or (y).

-185-

11. The isolated polypeptide of claim 10, which is produced in a recombinant host cell.

12. The isolated polypeptide of claim 11, wherein said recombinant host cell is mammalian.

5 13. An isolated nucleic acid molecule comprising a polynucleotide encoding a METH1 or METH2 polypeptide wherein, except for one to fifty conservative amino acid substitutions, said polypeptide has a sequence selected from the group consisting of:

- 10 (a) amino acids from about 1 to about 950 in SEQ ID NO:2;
(b) amino acids from about 2 to about 950 in SEQ ID NO:2;
(c) amino acids from about 29 to about 950 in SEQ ID NO:2;
(d) amino acids from about 30 to about 950 in SEQ ID NO:2;
(e) the amino acid sequence of the METH1 polypeptide as encoded by the cDNA clone contained in ATCC Deposit No. 209581;
15 (f) the amino acid sequence of the mature METH1 polypeptide as encoded by the cDNA clone contained in ATCC Deposit No. 209581;
(g) amino acids from about 1 to about 890 in SEQ ID NO:4;
(h) amino acids from about 2 to about 890 in SEQ ID NO:4;
(i) amino acids from about 24 to 890 in SEQ ID NO:4;
20 (j) amino acids from about 112 to about 890 in SEQ ID NO:4;
(k) the amino acid sequence of the METH2 polypeptide as encoded by the cDNA clone contained in ATCC Deposit No. 209582; and
(l) the amino acid sequence of the mature METH2 polypeptide as encoded by the cDNA clone contained in ATCC Deposit No. 209582.

25 14. An isolated polypeptide wherein, except for one to fifty conservative amino acid substitutions, said polypeptide has a sequence selected from the group consisting of:

-186-

- 5 (a) amino acids from about 1 to about 950 in SEQ ID NO:2;
(b) amino acids from about 2 to about 950 in SEQ ID NO:2;
(c) amino acids from about 29 to about 950 in SEQ ID NO:2;
(d) amino acids from about 30 to about 950 in SEQ ID NO:2;
(e) the amino acid sequence of the METH1 polypeptide having
the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit
No. 209581;
- 10 (f) the amino acid sequence of the mature METH1 polypeptide
having the amino acid sequence encoded by the cDNA clone contained in ATCC
Deposit No. 209581;
- (g) amino acids from about 1 to about 890 in SEQ ID NO:4;
(h) amino acids from about 2 to about 890 in SEQ ID NO:4;
(i) amino acids from about 24 to about 890 in SEQ ID NO:4;
(j) amino acids from about 112 to about 890 in SEQ ID NO:4;
- 15 (k) the amino acid sequence of the METH2 polypeptide having
the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit
No. 209582;
- (l) the amino acid sequence of the mature METH2 polypeptide
having the amino acid sequence encoded by the cDNA clone contained in ATCC
20 Deposit No. 209582; and
- (m) the amino acid sequence of an epitope-bearing portion of
any one of the polypeptides of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), or (l).
15. An isolated nucleic acid molecule comprising a polynucleotide at
least 95% identical to a polynucleotide selected from the group consisting of:
- 25 (a) a polynucleotide encoding a polypeptide comprising amino
acids 1 to 950 in SEQ ID NO:2;
(b) a polynucleotide encoding a polypeptide comprising amino
acids 2 to 950 in SEQ ID NO:2;

-187-

(c) a polynucleotide encoding a polypeptide comprising amino acids 29 to 950 in SEQ ID NO:2;

(d) a polynucleotide encoding a polypeptide comprising amino acids 30 to 950 in SEQ ID NO:2;

5 (e) a polynucleotide comprising a nucleotide sequence encoding the METH1 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209581;

(f) a polynucleotide comprising a nucleotide sequence encoding the mature METH1 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209581;

10 (g) a polynucleotide encoding a polypeptide comprising amino acids 1 to 890 in SEQ ID NO:4;

(h) a polynucleotide encoding a polypeptide comprising amino acids 2 to 890 in SEQ ID NO:4;

15 (i) a polynucleotide encoding a polypeptide comprising amino acids 24 to 890 in SEQ ID NO:4;

(j) a polynucleotide encoding a polypeptide comprising amino acids 112 to 890 in SEQ ID NO:4;

(k) a polynucleotide comprising a nucleotide sequence encoding the METH2 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209582;

(l) a polynucleotide comprising a nucleotide sequence encoding the mature METH2 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209582; and

25 (m) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), or (l),
wherein

said % identity is calculated using the FASTDB computer program, with the parameters: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining
30 Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5,

-188-

Gap Size Penalty=0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

16. An isolated polypeptide comprising a polypeptide having 95% identity to a polypeptide having an amino acid sequence selected from the group consisting of:

5

- (a) amino acids from about 1 to about 950 in SEQ ID NO:2;
- (b) amino acids from about 2 to about 950 in SEQ ID NO:2;
- (c) amino acids from about 29 to about 950 in SEQ ID NO:2;
- (d) amino acids from about 30 to about 950 in SEQ ID NO:2;
- (e) the amino acid sequence of the METH1 polypeptide having

10

the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209581;

(f) the amino acid sequence of the mature METH1 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209581;

15

- (g) amino acids from about 1 to about 890 in SEQ ID NO:4;
- (h) amino acids from about 2 to about 890 in SEQ ID NO:4;
- (i) amino acids from about 24 to about 890 in SEQ ID NO:4;
- (j) amino acids from about 112 to about 890 in SEQ ID NO:4;
- (k) the amino acid sequence of the METH2 polypeptide having

20

the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209582; and

(l) the amino acid sequence of the mature METH2 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209582;

25

wherein

said % identity is calculated using the FASTDB computer program, with the parameters: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5,

-189-

Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

17. A method for inhibiting angiogenesis in an individual, comprising administering an effective amount of a polypeptide of claim 10 to said individual.

5 18. A polypeptide comprising the amino acid sequence m-n of SEQ ID NO:2, wherein m is an integer of 1 to 950, and wherein n is an integer of 10 to 950.

10 19. A polypeptide comprising the amino acid sequence m-n of SEQ ID NO:4, wherein m is an integer of 1 to 890, and wherein n is an integer of 10 to 890.

ATGGGGAACGCGGAGCGGGCTCCGGGGTCTCGGAGCTTTGGGCCCCGTACCCACGCTGCTGCTGCTCGCCGCGGCGCTA
M G N A E R A P G S R S F G P V P T L L L L A A A L
CTGGCCGTGTCTCGGACGCACTCGGGCGCCCCTCCGAGGAGGACGAGGAGCTAGTGGTGCCGGAGCTGGAGCGCGCCCCG
L A V S D A L G R P S E E D E E L V V P E L E R A P
GGACACGGGACCACGCGCCTCCGCCTGCACGCCTTTGACCAGCAGCTGGATCTGGAGCTGCGGCCCCGACAGCAGCTTT
G H G T T R L R L H A F D Q Q L D L E L R P D S S F
TTGGCGCCCCGGCTTCACGCTCCAGAACGTGGGGCGCAAATCCGGGTCCGAGACGCCGCTTCCGGAAACCGACCTGGCG
L A P G F T L Q N V G R K S G S E T P L P E T D L A
CACTGCTTCTACTCCGGCACCGTGAATGGCGATCCCAGCTCGGCTGCCGCCCTCAGCCTCTGCGAGGGCGTGCGCGGC
H C F Y S G T V N G D P S S A A A L S L C E G V R G
GCCTTCTACCTGCTGGGGGAGGCGTATTTTCATCCAGCCGCTGCCCGCCGCCAGCGAGCGCCTCGCCACCGCCGCCCA
A F Y L L G E A Y F I Q P L P A A S E R L A T A A P
GGGAGAAGCCCGCGGCACCACTACAGTTCCACCTCCTGCGGCGGAATCGGCAGGGCGACGTAGGCGGCACGTGCGGG
G E K P P A P L Q F H L L R R N R Q G D V G G T C G
GTCGTGGACGACGAGCCCCGGCCGACTGGGAAAGCGGAGACCGAAGACGAGGACGAAGGACTGAGGGCGAGGACGAA
V V D D E P R P T G K A E T E D E D E G T E G E D E
GGGCCTCAGTGGTTCGCCGAGGACCCGGCACTGCAAGGCGTAGGACAGCCACAGGAACTGGAAGCATAAGAAAGAAG
G P Q W S P Q D P A L Q G V G Q P T G T G S I R K K
CGATTTGTGTCCAGTCACCGCTATGTGGAAACCATGCTTGTGGCAGACCAGTCGATGGCAGAATTCCACGGCAGTGGT
R F V S S H R Y V E T M L V A D Q S M A E F H G S G
CTAAAGCATTACCTTCTCACGTTGTTTTCGGTGGCAGCCAGATTGTACAAACACCCAGCATTCTGAATTCAGTTAGC
L K H Y L L T L F S V A A R L Y K H P S I R N S V S
CTGGTGGTGGTGAAGATCTTGGTCATCCACGATGAACAGAAGGGGCCGGAAGTGACCTCCAATGCTGCCCTCACTCTG
L V V V K I L V I H D E Q K G P E V T S N A A L T L
CGGAACTTTTGCAACTGGCAGAAGCAGCACAAACCCACCCAGTGACCGGGATGCAGAGCACTATGACACAGCAATTCTT
R N F C N W Q K Q H N P P S D R D A E H Y D T A I L
TTCACCAGACAGGACTTGTGTGGGTCCCAGACATGTGATACTCTTGGGATGGCTGATGTTGGAACGTGTGTGTGATCCG
F T R Q D L C G S Q T C D T L G M A D V G T V C D P
AGCAGAAGCTGCTCCGTCATAGAAGATGATGGTTTACAAGCTGCCTTACCACAGCCCATGAATTAGGCCACGTGTTT
S R S C S V I E D D G L Q A A F T T A H E L G H V F
AACATGCCACATGATGATGCAAAGCAGTGTGCCAGCCTTAATGGTGTGAACCAGGATTCCCACATGATGGCGTCAATG
N M P H D D A K Q C A S L N G V N Q D S H M M A S M
CTTTCCAACCTGGACCACAGCCAGCCTTGGTCTCCTTGCACTGCCTACATGATTACATCATTTCTGGATAATGGTCA
L S N L D H S Q P W S P C S A Y M I T S F L D N G H
GGGGAATGTTTGATGGACAAGCCTCAGAATCCCATACAGCTCCCAGGCGATCTCCCTGGCACCTCGTACGATGCCAAC
G E C L M D K P Q N P I Q L P G D L P G T S Y D A N
CGGCAGTGCCAGTTTACATTTGGGGAGGACTCCAAACACTGCCCTGATGCAGCCAGCACATGTAGCACCTTGTGGTGT
R Q C Q F T F G E D S K H C P D A A S T C S T L W C
ACGGGCACCTCTGGTGGGGTGTGGTGTGTCAAACCAAACACTTCCCGTGGGCGGATGGCACCAGCTGTGGAGAAGGG
T G T S G G V L V C Q T K H F P W A D G T S C G E G
AAATGGTGTATCAACGGCAAGTGTGTGAACAAAACCGACAGAAAGCATTTTGATACGCCTTTTCATGGAAGCTGGGGA
K W C I N G K C V N K T D R K H F D T P F H G S W G

FIGURE 1

ATGTGGGGGCCTTGGGGAGACTGTTTCGAGAACGTGCGGTGGAGGAGTCCAGTACACGATGAGGGAATGTGACAACCCA
M W G P W G D C S R T C G G G V Q Y T M R E C D N P
GTCCCAAAGAATGGAGGGAAGTACTGTGAAGGCAAACGAGTGCGCTACAGATCCTGTAACCTTGAGGACTGTCCAGAC
V P K N G G K Y C E G K R V R Y R S C N L E D C P D
AATAATGGAAAAACCTTTAGAGAGGAACAATGTGAAGCACACAACGAGTTTTCAAAGCTTCCTTTGGGAGTGGGSCCT
N N G K T F R E E Q C E A H N E F S K A S F G S G P
GCGGTGGAATGGATTCCCAAGTACGCTGGCGTCTCACCAAAGGACAGGTGCAAGCTCATCTGCCAAGCCAAAGGCATT
A V E W I P K Y A G V S P K D R C K L I C Q A K G I
GGCTACTTCTTCGTTTTGCAGCCCCAAGGTTGTAGATGGTACTCCATGTAGCCCAGATTCCACCTCTGTCTGTGTGCAA
G Y F F V L Q P K V V D G T P C S P D S T S V C V Q
GGACAGTGTGTAAAAGCTGGTTGTGATCGCATCATAGACTCCAAAAAGAAGTTTGATAAATGTGGTGTTCGCGGGGA
G Q C V K A G C D R I I D S K K K F D K C G V C G G
AATGGATCTACTTGTAAAAAATATCAGGATCAGTTACTAGTGCAAACCTGGATATCATGATATCATCACAATTCCA
N G S T C K K I S G S V T S A K P G Y H D I I T I P
ACTGGAGCCACCAACATCGAAGTGAAACAGCGGAACCAGAGGGGATCCAGGAACAATGGCAGCTTTCTTGCCATCAAA
T G A T N I E V K Q R N Q R G S R N N G S F L A I K
GCTGCTGATGGCACATATATTCTTAATGGTGACTACACTTTGTCCACCTTAGAGCAAGACATTATGTACAAAGGTGTT
A A D G T Y I L N G D Y T L S T L E Q D I M Y K G V
GTCTTGAGGTACAGCGGCTCCTCTGCGGCATTGGAAAGAATTCGCAGCTTTAGCCCTCTCAAAGAGCCCTTGACCATC
V L R Y S G S S A A L E R I R S F S P L K E P L T I
CAGGTTCTTACTGTGGGCAATGCCCTTCGACCTAAAATTAATAACCTACTTCGTAAAGAAGAAGAAGGAATCTTTC
Q V L T V G N A L R P K I K Y T Y F V K K K K E S F
AATGCTATCCCCACTTTTTTCAGCATGGGTGATTGAAGAGTGGGGCGAATGTTCTAAGTCATGTGAATTGGGTTGGCAG
N A I P T F S A W V I E E W G E C S K S C E L G W Q
AGAAGACTGGTAGAATGCCGAGACATTAATGGACAGCCTGCTTCCGAGTGTGCAAAGGAAGTGAAGCCAGCCAGCACC
R R L V E C R D I N G Q P A S E C A K E V K P A S T
AGACCTTGTGCAGACCATCCCTGCCCCCAGTGGCAGCTGGGGGAGTGGTCATCATGTTCTAAGACCTGTGGGAAGGGT
R P C A D H P C P Q W Q L G E W S S C S K T C G K G
TACAAAAAAGAAGCTTGAAGTGTCTGTCCCATGATGGAGGGGTGTTATCTCATGAGAGCTGTGATCCTTTAAAGAAA
Y K K R S L K C L S H D G G V L S H E S C D P L K K
CCTAAACATTTTCATAGACTTTTGCACAATGGCAGAATGCAGTTAAGTGGTTTAAGTGGTGTAGCTTTGAGGCAAGGC
P K H F I D F C T M A E C S
AAAGTGAGGAAGGGCTGGTGCAGGGAAGCAAGAAGGCTGGAGGGATCCAGCGTATCTTGCCAGTAACCAGTGAGGTG
TATCAGTAAGGTGGGATTATGGGGGTAGATAGAAAAGGAGTTGAATCATCAGAGTAACTGCCAGTTGCAAATTTGAT
AGGATAGTTAGTGAGGATTATTAACCTCTGAGCAGTGATATAGCATAATAAANCCCCGGGCATTATTATTATTATTC
TTTTGTTACATCTATTACAAGTTTAGAAAAAACAAAGCAATTGTCAAAAAAAAAAAAAAAAAAAAAAAAAAAGG
GCGGCCGCTCTAGAGGATCCCTCGAGGGGCCAAGCTTACGCGTGCATGNTGTCATNAGTCTN

FIGURE 1

BNSDOCID: <WO 9937660A1 | >

GTACAGTTTTACACCGTGAGTGCAAGGACCCCGAGCCTCAGAATGGAGGAAGATACTGCCTGGGTGCGAGAGCCAAG
V Q F S H R E C K - D P E P Q N G G R Y C L G R R A K

TACCAGTCATGCCACACGGAGGAATGCCCCCTGACGGGAAAAGCTTCAGGGAGCAGCAGTGTGAGAAGTATAATGCC
Y Q S C H T E E C P P D G K S F R E Q Q C E K Y N A

TACAATTACACTGACATGGACGGGAATCTCCTGCAGTGGGTCCCCAAGTATGCTGGGGTGTCCCCCGGGACCGCTGC
Y N Y T D M D G N L L Q W V P K Y A G V S P R D R C

AAGTTGTTCTGCCGAGCCCGGGGAGGAGCGAGTTCAAAGTGTTCGAGGCCAAGGTGATTGATGGCACCCCTGTGTGGG
K L F C R A R G R S E F K V F E A K V I D G T L C G

CCAGAAACACTGGCCATCTGTGTCCGTGGCCAGTGTGTCAAGGCCGGCTGTGACCATGTGGTGGACTCGCCTCGGAAG
P E T L A I C V R G Q C V K A G C D H V V D S P R K

CTGGACAAATGCGGGGTGTGTGGGGGCAAAGGCAACTCCTGCAGGAAGGTCTCCGGGTCCCTCACCCCCACCAATTAT
L D K C G V C G G K G N S C R K V S G S L T P T N Y

GGCTACAATGACATTGTCCACCATCCAGCTGGTGCCACTAATATTGACGTGAAGCAGCGGAGCCACCCGGGTGTGCAG
G Y N D I V T I P A G A T N I D V K Q R S H P G V Q

AACGATGGGAACCTACCTGGCGCTGAAGACGGCTGATGGGCAGTACCTGCTCAACGGCAACCTGGCCATCTCTGCCATA
N D G N Y L A L K T A D G Q Y L L N G N L A I S A I

GAGCAGGACATCTTGTTGAAGGGGACCATCCTGAAGTACAGCGGCTCCATCGCCACCCTGGAGCGCCTGCAGAGCTTC
E Q D I L V K G T I L K Y S G S I A T L E R L Q S F

CGGCCCTTGCCAGAGCCTCTGACAGTGCAGCTCCTGACAGTCCCTGGCGAGGTCTTCCCCCAAAGTCAAATACACC
R P L P E P L T V Q L L T V P G E V F P P K V K Y T

TTCTTTGTTTCTAATGACGTGGACTTTAGCATGCAGAGCAGCAAAGAGAGAGCAACCACCAACATCATCCAGCCGCTG
F F V P N D V D F S M Q S S K E R A T T N I I Q P L

CTCCACGCACAGTGGGTGCTGGGGGACTGGTCTGAGTGTCTAGCACCTGCGGGGCGGGCTGGCAGAGGCGAACTGTA
L H A Q W V L G D W S E C S S T C G A G W Q R R T V

GAGTGCAGGGACCCCTCCGGCCAGGCCTCTGCCACCTGCAACAAGGCTCTGAAACCCGAGGATGCCAAGCCCTGCGAA
E C R D P S G Q A S A T C N K A L K P E D A K P C E

AGCCAGCTGTGCCCCCTGTGATTCAGGGGGGCGAGGGGCCAGTCTTGTGCTCCTGGACATGCGGTACTGAGGTGCAGAC
S Q L C P L

AAGGTCTCCACTGTGGTGACTGGGTCCCTTGCCATATCAAGGCAGCACGGGCCACCCAGGCCTCCCATTGCCGCAAC
CCCTCCAGTACTGCACAAATTCCTAAGGGGGAAGAGAAAAGGTATGGGGCGGCAAAACCTATCATCAACTGTCCAWTG
NAATGGAACCTTGCTCGGGTTCAATTAAAGGCATAAGTTAAAGTAAATTCAATTATGATCAACAGACCTCACNTCATCTG
TTGCANGATACAACANTAAAAAAAAAAAAAAAAAAAAAAAAAAAA

FIGURE 2

[illegible]

Figure 3

6/12




Figure 4






Figure 5

7/12


A.



B.



C.



D.






Figure 6

8/12


A.




B.



C.



D.



E.




Figure 7





FIGURE 8


11/12

Figure 10



12/12

Figure 11



-1-

SEQUENCE LISTING

<110> Iruela-Arispe, Luisa
Hastings, Gregg A.
Ruben, Steven M.

<120> Meth1 and Meth2 Polynucleotides and Polypeptides

<130> 1488.107PC02

<140>

<141>

<150> 60/072,298

<151> 1998-01-23

<150> 60/098,539

<151> 1998-08-28

<160> 93

<170> PatentIn Ver. 2.0

<210> 1

<211> 3261

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(2853)

<220>

<221> UNSURE

<222> (3095)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (3248)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (3255)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (3261)

<223> May be any nucleic acid

<400> 1

atg ggg aac gcg gag cgg gct ccg ggg tct cgg agc ttt ggg ccc gta 48

-2-

Met	Gly	Asn	Ala	Glu	Arg	Ala	Pro	Gly	Ser	Arg	Ser	Phe	Gly	Pro	Val		
1				5					10					15			
ccc	acg	ctg	ctg	ctg	ctc	gcc	gcg	gcg	cta	ctg	gcc	gtg	tcg	gac	gca	96	
Pro	Thr	Leu	Leu	Leu	Leu	Ala	Ala	Ala	Leu	Leu	Ala	Val	Ser	Asp	Ala		
			20					25					30				
ctc	ggg	cgc	ccc	tcc	gag	gag	gac	gag	gag	cta	gtg	gtg	ccg	gag	ctg	144	
Leu	Gly	Arg	Pro	Ser	Glu	Glu	Asp	Glu	Glu	Leu	Val	Val	Pro	Glu	Leu		
		35					40					45					
gag	cgc	gcc	ccg	gga	cac	ggg	acc	acg	cgc	ctc	cgc	ctg	cac	gcc	ttt	192	
Glu	Arg	Ala	Pro	Gly	His	Gly	Thr	Thr	Arg	Leu	Arg	Leu	His	Ala	Phe		
		50					55				60						
gac	cag	cag	ctg	gat	ctg	gag	ctg	cgg	ccc	gac	agc	agc	ttt	ttg	gcg	240	
Asp	Gln	Gln	Leu	Asp	Leu	Glu	Leu	Arg	Pro	Asp	Ser	Ser	Phe	Leu	Ala		
		65				70				75					80		
ccc	ggc	ttc	acg	ctc	cag	aac	gtg	ggg	cgc	aaa	tcc	ggg	tcc	gag	acg	288	
Pro	Gly	Phe	Thr	Leu	Gln	Asn	Val	Gly	Arg	Lys	Ser	Gly	Ser	Glu	Thr		
				85					90					95			
ccg	ctt	ccg	gaa	acc	gac	ctg	gcg	cac	tgc	ttc	tac	tcc	ggc	acc	gtg	336	
Pro	Leu	Pro	Glu	Thr	Asp	Leu	Ala	His	Cys	Phe	Tyr	Ser	Gly	Thr	Val		
			100					105					110				
aat	ggc	gat	ccc	agc	tcg	gct	gcc	gcc	ctc	agc	ctc	tgc	gag	ggc	gtg	384	
Asn	Gly	Asp	Pro	Ser	Ser	Ala	Ala	Ala	Leu	Ser	Leu	Cys	Glu	Gly	Val		
		115					120					125					
cgc	ggc	gcc	ttc	tac	ctg	ctg	ggg	gag	gcg	tat	ttc	atc	cag	ccg	ctg	432	
Arg	Gly	Ala	Phe	Tyr	Leu	Leu	Gly	Glu	Ala	Tyr	Phe	Ile	Gln	Pro	Leu		
		130					135				140						
ccc	gcc	gcc	agc	gag	cgc	ctc	gcc	acc	gcc	gcc	cca	ggg	gag	aag	ccg	480	
Pro	Ala	Ala	Ser	Glu	Arg	Leu	Ala	Thr	Ala	Ala	Pro	Gly	Glu	Lys	Pro		
						150				155					160		
ccg	gca	cca	cta	cag	ttc	cac	ctc	ctg	cgg	cgg	aat	cgg	cag	ggc	gac	528	
Pro	Ala	Pro	Leu	Gln	Phe	His	Leu	Leu	Arg	Arg	Asn	Arg	Gln	Gly	Asp		
				165					170					175			
gta	ggc	ggc	acg	tgc	ggg	gtc	gtg	gac	gac	gag	ccc	cgg	ccg	act	ggg	576	
Val	Gly	Gly	Thr	Cys	Gly	Val	Val	Asp	Asp	Glu	Pro	Arg	Pro	Thr	Gly		
			180					185					190				
aaa	gcg	gag	acc	gaa	gac	gag	gac	gaa	ggg	act	gag	ggc	gag	gac	gaa	624	
Lys	Ala	Glu	Thr	Glu	Asp	Glu	Asp	Glu	Gly	Thr	Glu	Gly	Glu	Asp	Glu		
		195					200					205					
ggg	cct	cag	tgg	tcg	ccg	cag	gac	ccg	gca	ctg	caa	ggc	gta	gga	cag	672	

-3-

Gly	Pro	Gln	Trp	Ser	Pro	Gln	Asp	Pro	Ala	Leu	Gln	Gly	Val	Gly	Gln		
210						215					220						
ccc	aca	gga	act	gga	agc	ata	aga	aag	aag	cga	ttt	gtg	tcc	agt	cac	720	
Pro	Thr	Gly	Thr	Gly	Ser	Ile	Arg	Lys	Lys	Arg	Phe	Val	Ser	Ser	His		
225					230					235					240		
cgc	tat	gtg	gaa	acc	atg	ctt	gtg	gca	gac	cag	tcg	atg	gca	gaa	ttc	768	
Arg	Tyr	Val	Glu	Thr	Met	Leu	Val	Ala	Asp	Gln	Ser	Met	Ala	Glu	Phe		
				245					250					255			
cac	ggc	agt	ggt	cta	aag	cat	tac	ctt	ctc	acg	ttg	ttt	tcg	gtg	gca	816	
His	Gly	Ser	Gly	Leu	Lys	His	Tyr	Leu	Leu	Thr	Leu	Phe	Ser	Val	Ala		
			260					265					270				
gcc	aga	ttg	tac	aaa	cac	ccc	agc	att	cgt	aat	tca	gtt	agc	ctg	gtg	864	
Ala	Arg	Leu	Tyr	Lys	His	Pro	Ser	Ile	Arg	Asn	Ser	Val	Ser	Leu	Val		
		275						280				285					
gtg	gtg	aag	atc	ttg	gtc	atc	cac	gat	gaa	cag	aag	ggg	ccg	gaa	gtg	912	
Val	Val	Lys	Ile	Leu	Val	Ile	His	Asp	Glu	Gln	Lys	Gly	Pro	Glu	Val		
		290				295					300						
acc	tcc	aat	gct	gcc	ctc	act	ctg	cgg	aac	ttt	tgc	aac	tgg	cag	aag	960	
Thr	Ser	Asn	Ala	Ala	Leu	Thr	Leu	Arg	Asn	Phe	Cys	Asn	Trp	Gln	Lys		
305					310				315					320			
cag	cac	aac	cca	ccc	agt	gac	cgg	gat	gca	gag	cac	tat	gac	aca	gca	1008	
Gln	His	Asn	Pro	Pro	Ser	Asp	Arg	Asp	Ala	Glu	His	Tyr	Asp	Thr	Ala		
			325						330					335			
att	ctt	ttc	acc	aga	cag	gac	ttg	tgt	ggg	tcc	cag	aca	tgt	gat	act	1056	
Ile	Leu	Phe	Thr	Arg	Gln	Asp	Leu	Cys	Gly	Ser	Gln	Thr	Cys	Asp	Thr		
			340					345					350				
ctt	ggg	atg	gct	gat	gtt	gga	act	gtg	tgt	gat	ccg	agc	aga	agc	tgc	1104	
Leu	Gly	Met	Ala	Asp	Val	Gly	Thr	Val	Cys	Asp	Pro	Ser	Arg	Ser	Cys		
		355				360						365					
tcc	gtc	ata	gaa	gat	gat	ggt	tta	caa	gct	gcc	ttc	acc	aca	gcc	cat	1152	
Ser	Val	Ile	Glu	Asp	Asp	Gly	Leu	Gln	Ala	Ala	Phe	Thr	Thr	Ala	His		
		370				375					380						
gaa	tta	ggc	cac	gtg	ttt	aac	atg	cca	cat	gat	gat	gca	aag	cag	tgt	1200	
Glu	Leu	Gly	His	Val	Phe	Asn	Met	Pro	His	Asp	Asp	Ala	Lys	Gln	Cys		
		385			390				395					400			
gcc	agc	ctt	aat	ggt	gtg	aac	cag	gat	tcc	cac	atg	atg	gcg	tca	atg	1248	
Ala	Ser	Leu	Asn	Gly	Val	Asn	Gln	Asp	Ser	His	Met	Met	Ala	Ser	Met		
			405					410					415				
ctt	tcc	aac	ctg	gac	cac	agc	cag	cct	tgg	tct	cct	tgc	agt	gcc	tac	1296	

-4-

Leu	Ser	Asn	Leu	Asp	His	Ser	Gln	Pro	Trp	Ser	Pro	Cys	Ser	Ala	Tyr		
			420					425					430				
atg	att	aca	tca	ttt	ctg	gat	aat	ggg	cat	ggg	gaa	tgt	ttg	atg	gac	1344	
Met	Ile	Thr	Ser	Phe	Leu	Asp	Asn	Gly	His	Gly	Glu	Cys	Leu	Met	Asp		
		435					440					445					
aag	cct	cag	aat	ccc	ata	cag	ctc	cca	ggc	gat	ctc	cct	ggc	acc	tcg	1392	
Lys	Pro	Gln	Asn	Pro	Ile	Gln	Leu	Pro	Gly	Asp	Leu	Pro	Gly	Thr	Ser		
	450					455					460						
tac	gat	gcc	aac	cgg	cag	tgc	cag	ttt	aca	ttt	ggg	gag	gac	tcc	aaa	1440	
Tyr	Asp	Ala	Asn	Arg	Gln	Cys	Gln	Phe	Thr	Phe	Gly	Glu	Asp	Ser	Lys		
465					470					475					480		
cac	tgc	cct	gat	gca	gcc	agc	aca	tgt	agc	acc	ttg	tgg	tgt	acc	ggc	1488	
His	Cys	Pro	Asp	Ala	Ala	Ser	Thr	Cys	Ser	Thr	Leu	Trp	Cys	Thr	Gly		
				485					490					495			
acc	tct	ggg	ggg	gtg	ctg	gtg	tgt	caa	acc	aaa	cac	ttc	ccg	tgg	gcg	1536	
Thr	Ser	Gly	Gly	Val	Leu	Val	Cys	Gln	Thr	Lys	His	Phe	Pro	Trp	Ala		
			500					505					510				
gat	ggc	acc	agc	tgt	gga	gaa	ggg	aaa	tgg	tgt	atc	aac	ggc	aag	tgt	1584	
Asp	Gly	Thr	Ser	Cys	Gly	Glu	Gly	Lys	Trp	Cys	Ile	Asn	Gly	Lys	Cys		
		515					520					525					
gtg	aac	aaa	acc	gac	aga	aag	cat	ttt	gat	acg	cct	ttt	cat	gga	agc	1632	
Val	Asn	Lys	Thr	Asp	Arg	Lys	His	Phe	Asp	Thr	Pro	Phe	His	Gly	Ser		
		530				535					540						
tgg	gga	atg	tgg	ggg	cct	tgg	gga	gac	tgt	tcg	aga	acg	tgc	ggg	gga	1680	
Trp	Gly	Met	Trp	Gly	Pro	Trp	Gly	Asp	Cys	Ser	Arg	Thr	Cys	Gly	Gly		
545					550				555					560			
gga	gtc	cag	tac	acg	atg	agg	gaa	tgt	gac	aac	cca	gtc	cca	aag	aat	1728	
Gly	Val	Gln	Tyr	Thr	Met	Arg	Glu	Cys	Asp	Asn	Pro	Val	Pro	Lys	Asn		
				565				570						575			
gga	ggg	aag	tac	tgt	gaa	ggc	aaa	cga	gtg	cgc	tac	aga	tcc	tgt	aac	1776	
Gly	Gly	Lys	Tyr	Cys	Glu	Gly	Lys	Arg	Val	Arg	Tyr	Arg	Ser	Cys	Asn		
		580					585						590				
ctt	gag	gac	tgt	cca	gac	aat	aat	gga	aaa	acc	ttt	aga	gag	gaa	caa	1824	
Leu	Glu	Asp	Cys	Pro	Asp	Asn	Asn	Gly	Lys	Thr	Phe	Arg	Glu	Glu	Gln		
		595				600						605					
tgt	gaa	gca	cac	aac	gag	ttt	tca	aaa	gct	tcc	ttt	ggg	agt	ggg	cct	1872	
Cys	Glu	Ala	His	Asn	Glu	Phe	Ser	Lys	Ala	Ser	Phe	Gly	Ser	Gly	Pro		
		610				615					620						
gcg	gtg	gaa	tgg	att	ccc	aag	tac	gct	ggc	gtc	tca	cca	aag	gac	agg	1920	

-5-

Ala Val Glu Trp Ile Pro Lys Tyr Ala Gly Val Ser Pro Lys Asp Arg	
625 630 635 640	
tgc aag ctc atc tgc caa gcc aaa ggc att ggc tac ttc ttc gtt ttg	1968
Cys Lys Leu Ile Cys Gln Ala Lys Gly Ile Gly Tyr Phe Phe Val Leu	
645 650 655	
cag ccc aag gtt gta gat ggt act cca tgt agc cca gat tcc acc tct	2016
Gln Pro Lys Val Val Asp Gly Thr Pro Cys Ser Pro Asp Ser Thr Ser	
660 665 670	
gtc tgt gtg caa gga cag tgt gta aaa gct ggt tgt gat cgc atc ata	2064
Val Cys Val Gln Gly Gln Cys Val Lys Ala Gly Cys Asp Arg Ile Ile	
675 680 685	
gac tcc aaa aag aag ttt gat aaa tgt ggt gtt tgc ggg gga aat gga	2112
Asp Ser Lys Lys Lys Phe Asp Lys Cys Gly Val Cys Gly Gly Asn Gly	
690 695 700	
tct act tgt aaa aaa ata tca gga tca gtt act agt gca aaa cct gga	2160
Ser Thr Cys Lys Lys Ile Ser Gly Ser Val Thr Ser Ala Lys Pro Gly	
705 710 715 720	
tat cat gat atc atc aca att cca act gga gcc acc aac atc gaa gtg	2208
Tyr His Asp Ile Ile Thr Ile Pro Thr Gly Ala Thr Asn Ile Glu Val	
725 730 735	
aaa cag cgg aac cag agg gga tcc agg aac aat ggc agc ttt ctt gcc	2256
Lys Gln Arg Asn Gln Arg Gly Ser Arg Asn Asn Gly Ser Phe Leu Ala	
740 745 750	
atc aaa gct gct gat ggc aca tat att ctt aat ggt gac tac act ttg	2304
Ile Lys Ala Ala Asp Gly Thr Tyr Ile Leu Asn Gly Asp Tyr Thr Leu	
755 760 765	
tcc acc tta gag caa gac att atg tac aaa ggt gtt gtc ttg agg tac	2352
Ser Thr Leu Glu Gln Asp Ile Met Tyr Lys Gly Val Val Leu Arg Tyr	
770 775 780	
agc ggc tcc tct gcg gca ttg gaa aga att cgc agc ttt agc cct ctc	2400
Ser Gly Ser Ser Ala Ala Leu Glu Arg Ile Arg Ser Phe Ser Pro Leu	
785 790 795 800	
aaa gag ccc ttg acc atc cag gtt ctt act gtg ggc aat gcc ctt cga	2448
Lys Glu Pro Leu Thr Ile Gln Val Leu Thr Val Gly Asn Ala Leu Arg	
805 810 815	
cct aaa att aaa tac acc tac ttc gta aag aag aag aag gaa tct ttc	2496
Pro Lys Ile Lys Tyr Thr Tyr Phe Val Lys Lys Lys Lys Glu Ser Phe	
820 825 830	
aat gct atc ccc act ttt tca gca tgg gtc att gaa gag tgg ggc gaa	2544

-6-

Asn	Ala	Ile	Pro	Thr	Phe	Ser	Ala	Trp	Val	Ile	Glu	Glu	Trp	Gly	Glu		
		835					840					845					
tgt	tct	aag	tca	tgt	gaa	ttg	ggt	tgg	cag	aga	aga	ctg	gta	gaa	tgc	2592	
Cys	Ser	Lys	Ser	Cys	Glu	Leu	Gly	Trp	Gln	Arg	Arg	Leu	Val	Glu	Cys		
		850				855					860						
cga	gac	att	aat	gga	cag	cct	gct	tcc	gag	tgt	gca	aag	gaa	gtg	aag	2640	
Arg	Asp	Ile	Asn	Gly	Gln	Pro	Ala	Ser	Glu	Cys	Ala	Lys	Glu	Val	Lys		
865					870					875					880		
cca	gcc	agc	acc	aga	cct	tgt	gca	gac	cat	ccc	tgc	ccc	cag	tgg	cag	2688	
Pro	Ala	Ser	Thr	Arg	Pro	Cys	Ala	Asp	His	Pro	Cys	Pro	Gln	Trp	Gln		
				885					890					895			
ctg	ggg	gag	tgg	tca	tca	tgt	tct	aag	acc	tgt	ggg	aag	ggt	tac	aaa	2736	
Leu	Gly	Glu	Trp	Ser	Ser	Cys	Ser	Lys	Thr	Cys	Gly	Lys	Gly	Tyr	Lys		
			900					905					910				
aaa	aga	agc	ttg	aag	tgt	ctg	tcc	cat	gat	gga	ggg	gtg	tta	tct	cat	2784	
Lys	Arg	Ser	Leu	Lys	Cys	Leu	Ser	His	Asp	Gly	Gly	Val	Leu	Ser	His		
		915					920					925					
gag	agc	tgt	gat	cct	tta	aag	aaa	cct	aaa	cat	ttc	ata	gac	ttt	tgc	2832	
Glu	Ser	Cys	Asp	Pro	Leu	Lys	Lys	Pro	Lys	His	Phe	Ile	Asp	Phe	Cys		
		930				935					940						
aca	atg	gca	gaa	tgc	agt	taa	gtggtttaag	tggtgtagc	tttgaggcaa							2883	
Thr	Met	Ala	Glu	Cys	Ser												
945					950												
ggcaaagtga	ggaagggctg	gtgcagggaa	agcaagaagg	ctggagggat	ccagcgtatc											2943	
ttgccagtaa	ccagtgaagt	gtatcagtaa	ggtgggatta	tgggggtaga	tagaaaagga											3003	
gttgaatcat	cagagtaaac	tgccagttgc	aaatttgata	ggatagttag	tgaggattat											3063	
taacctctga	gcagtgatat	agcataataa	anccccgggc	attattatta	ttatttcttt											3123	
tgttacatct	attacaagtt	tagaaaaaac	aaagcaattg	tcaaaaaaaaa	aaaaaaaaaa											3183	
aaaaaaaaaa	aaagggcggc	cgctctagag	gatccctcga	ggggcccaag	cttacgcgtg											3243	
catgntgtca	tnagtctn															3261	

<210> 2

<211> 950

<212> PRT

<213> Homo sapiens

<400> 2

-7-

Met Gly Asn Ala Glu Arg Ala Pro Gly Ser Arg Ser Phe Gly Pro Val
 1 5 10 15
 Pro Thr Leu Leu Leu Leu Ala Ala Ala Leu Leu Ala Val Ser Asp Ala
 20 25 30
 Leu Gly Arg Pro Ser Glu Glu Asp Glu Glu Leu Val Val Pro Glu Leu
 35 40 45
 Glu Arg Ala Pro Gly His Gly Thr Thr Arg Leu Arg Leu His Ala Phe
 50 55 60
 Asp Gln Gln Leu Asp Leu Glu Leu Arg Pro Asp Ser Ser Phe Leu Ala
 65 70 75 80
 Pro Gly Phe Thr Leu Gln Asn Val Gly Arg Lys Ser Gly Ser Glu Thr
 85 90 95
 Pro Leu Pro Glu Thr Asp Leu Ala His Cys Phe Tyr Ser Gly Thr Val
 100 105 110
 Asn Gly Asp Pro Ser Ser Ala Ala Ala Leu Ser Leu Cys Glu Gly Val
 115 120 125
 Arg Gly Ala Phe Tyr Leu Leu Gly Glu Ala Tyr Phe Ile Gln Pro Leu
 130 135 140
 Pro Ala Ala Ser Glu Arg Leu Ala Thr Ala Ala Pro Gly Glu Lys Pro
 145 150 155 160
 Pro Ala Pro Leu Gln Phe His Leu Leu Arg Arg Asn Arg Gln Gly Asp
 165 170 175
 Val Gly Gly Thr Cys Gly Val Val Asp Asp Glu Pro Arg Pro Thr Gly
 180 185 190
 Lys Ala Glu Thr Glu Asp Glu Asp Glu Gly Thr Glu Gly Glu Asp Glu
 195 200 205
 Gly Pro Gln Trp Ser Pro Gln Asp Pro Ala Leu Gln Gly Val Gly Gln
 210 215 220
 Pro Thr Gly Thr Gly Ser Ile Arg Lys Lys Arg Phe Val Ser Ser His
 225 230 235 240
 Arg Tyr Val Glu Thr Met Leu Val Ala Asp Gln Ser Met Ala Glu Phe
 245 250 255
 His Gly Ser Gly Leu Lys His Tyr Leu Leu Thr Leu Phe Ser Val Ala
 260 265 270
 Ala Arg Leu Tyr Lys His Pro Ser Ile Arg Asn Ser Val Ser Leu Val

-8-

275					280					285						
Val	Val	Lys	Ile	Leu	Val	Ile	His	Asp	Glu	Gln	Lys	Gly	Pro	Glu	Val	
290					295					300						
Thr	Ser	Asn	Ala	Ala	Leu	Thr	Leu	Arg	Asn	Phe	Cys	Asn	Trp	Gln	Lys	
305					310					315					320	
Gln	His	Asn	Pro	Pro	Ser	Asp	Arg	Asp	Ala	Glu	His	Tyr	Asp	Thr	Ala	
325					330					335						
Ile	Leu	Phe	Thr	Arg	Gln	Asp	Leu	Cys	Gly	Ser	Gln	Thr	Cys	Asp	Thr	
340					345					350						
Leu	Gly	Met	Ala	Asp	Val	Gly	Thr	Val	Cys	Asp	Pro	Ser	Arg	Ser	Cys	
355					360					365						
Ser	Val	Ile	Glu	Asp	Asp	Gly	Leu	Gln	Ala	Ala	Phe	Thr	Thr	Ala	His	
370					375					380						
Glu	Leu	Gly	His	Val	Phe	Asn	Met	Pro	His	Asp	Asp	Ala	Lys	Gln	Cys	
385					390					395					400	
Ala	Ser	Leu	Asn	Gly	Val	Asn	Gln	Asp	Ser	His	Met	Met	Ala	Ser	Met	
405					410					415						
Leu	Ser	Asn	Leu	Asp	His	Ser	Gln	Pro	Trp	Ser	Pro	Cys	Ser	Ala	Tyr	
420					425					430						
Met	Ile	Thr	Ser	Phe	Leu	Asp	Asn	Gly	His	Gly	Glu	Cys	Leu	Met	Asp	
435					440					445						
Lys	Pro	Gln	Asn	Pro	Ile	Gln	Leu	Pro	Gly	Asp	Leu	Pro	Gly	Thr	Ser	
450					455					460						
Tyr	Asp	Ala	Asn	Arg	Gln	Cys	Gln	Phe	Thr	Phe	Gly	Glu	Asp	Ser	Lys	
465					470					475					480	
His	Cys	Pro	Asp	Ala	Ala	Ser	Thr	Cys	Ser	Thr	Leu	Trp	Cys	Thr	Gly	
485					490					495						
Thr	Ser	Gly	Gly	Val	Leu	Val	Cys	Gln	Thr	Lys	His	Phe	Pro	Trp	Ala	
500					505					510						
Asp	Gly	Thr	Ser	Cys	Gly	Glu	Gly	Lys	Trp	Cys	Ile	Asn	Gly	Lys	Cys	
515					520					525						
Val	Asn	Lys	Thr	Asp	Arg	Lys	His	Phe	Asp	Thr	Pro	Phe	His	Gly	Ser	
530					535					540						
Trp	Gly	Met	Trp	Gly	Pro	Trp	Gly	Asp	Cys	Ser	Arg	Thr	Cys	Gly	Gly	
545					550					555					560	

-9-

Gly Val Gln Tyr Thr Met Arg Glu Cys Asp Asn Pro Val Pro Lys Asn
 565 570 575

Gly Gly Lys Tyr Cys Glu Gly Lys Arg Val Arg Tyr Arg Ser Cys Asn
 580 585 590

Leu Glu Asp Cys Pro Asp Asn Asn Gly Lys Thr Phe Arg Glu Glu Gln
 595 600 605

Cys Glu Ala His Asn Glu Phe Ser Lys Ala Ser Phe Gly Ser Gly Pro
 610 615 620

Ala Val Glu Trp Ile Pro Lys Tyr Ala Gly Val Ser Pro Lys Asp Arg
 625 630 635 640

Cys Lys Leu Ile Cys Gln Ala Lys Gly Ile Gly Tyr Phe Phe Val Leu
 645 650 655

Gln Pro Lys Val Val Asp Gly Thr Pro Cys Ser Pro Asp Ser Thr Ser
 660 665 670

Val Cys Val Gln Gly Gln Cys Val Lys Ala Gly Cys Asp Arg Ile Ile
 675 680 685

Asp Ser Lys Lys Lys Phe Asp Lys Cys Gly Val Cys Gly Gly Asn Gly
 690 695 700

Ser Thr Cys Lys Lys Ile Ser Gly Ser Val Thr Ser Ala Lys Pro Gly
 705 710 715 720

Tyr His Asp Ile Ile Thr Ile Pro Thr Gly Ala Thr Asn Ile Glu Val
 725 730 735

Lys Gln Arg Asn Gln Arg Gly Ser Arg Asn Asn Gly Ser Phe Leu Ala
 740 745 750

Ile Lys Ala Ala Asp Gly Thr Tyr Ile Leu Asn Gly Asp Tyr Thr Leu
 755 760 765

Ser Thr Leu Glu Gln Asp Ile Met Tyr Lys Gly Val Val Leu Arg Tyr
 770 775 780

Ser Gly Ser Ser Ala Ala Leu Glu Arg Ile Arg Ser Phe Ser Pro Leu
 785 790 795 800

Lys Glu Pro Leu Thr Ile Gln Val Leu Thr Val Gly Asn Ala Leu Arg
 805 810 815

Pro Lys Ile Lys Tyr Thr Tyr Phe Val Lys Lys Lys Lys Glu Ser Phe
 820 825 830

-10-

Asn Ala Ile Pro Thr Phe Ser Ala Trp Val Ile Glu Glu Trp Gly Glu
 835 840 845

Cys Ser Lys Ser Cys Glu Leu Gly Trp Gln Arg Arg Leu Val Glu Cys
 850 855 860

Arg Asp Ile Asn Gly Gln Pro Ala Ser Glu Cys Ala Lys Glu Val Lys
 865 870 875 880

Pro Ala Ser Thr Arg Pro Cys Ala Asp His Pro Cys Pro Gln Trp Gln
 885 890 895

Leu Gly Glu Trp Ser Ser Cys Ser Lys Thr Cys Gly Lys Gly Tyr Lys
 900 905 910

Lys Arg Ser Leu Lys Cys Leu Ser His Asp Gly Gly Val Leu Ser His
 915 920 925

Glu Ser Cys Asp Pro Leu Lys Lys Pro Lys His Phe Ile Asp Phe Cys
 930 935 940

Thr Met Ala Glu Cys Ser
 945 950

<210> 3

<211> 3008

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(2670)

<220>

<221> UNSURE.

<222> (2887)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (2957)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (2970)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (2981).

<223> May be any nucleic acid

-11-

<400> 3

atg ttc ccc gcc ccc gcc gcc ccc cgg tgg ctt ccg ttc ctg ctg ctg	48
Met Phe Pro Ala Pro Ala Ala Pro Arg Trp Leu Pro Phe Leu Leu Leu	
1 5 10 15	
ctg ctg ctg ctg ctg ctg ccg ctg gcc cgc ggc gcc ccg gcc cgg ccc	96
Leu Leu Leu Leu Leu Leu Pro Leu Ala Arg Gly Ala Pro Ala Arg Pro	
20 25 30	
gca gcc ggg ggg cag gcc tcg gag ctg gtg gtg ccc acg cgg ttg ccc	144
Ala Ala Gly Gly Gln Ala Ser Glu Leu Val Val Pro Thr Arg Leu Pro	
35 40 45	
ggc agc gcg ggc gag ctc gcg ctc cac ctg tcc gcc ttc ggc aag ggc	192
Gly Ser Ala Gly Glu Leu Ala Leu His Leu Ser Ala Phe Gly Lys Gly	
50 55 60	
ttc gtg ttg cgc ctg gcg ccc gac gac agc ttc ctg gcg ccc gag ttc	240
Phe Val Leu Arg Leu Ala Pro Asp Asp Ser Phe Leu Ala Pro Glu Phe	
65 70 75 80	
aag atc gag cgc ctc ggg ggc tcc ggc cgg gcg acc ggg ggc gag cgg	288
Lys Ile Glu Arg Leu Gly Gly Ser Gly Arg Ala Thr Gly Gly Glu Arg	
85 90 95	
ggg ctg cgc ggc tgt ttt ttt tcc ggc acc gtg aat ggg gag ccc gag	336
Gly Leu Arg Gly Cys Phe Phe Ser Gly Thr Val Asn Gly Glu Pro Glu	
100 105 110	
tcg ctg gcg gcg gtc agc ctg tgc cgc ggg ctg agc ggc tcc ttc ctg	384
Ser Leu Ala Ala Val Ser Leu Cys Arg Gly Leu Ser Gly Ser Phe Leu	
115 120 125	
ctg gac ggc gag gag ttc acc atc cag ccg cag ggc gcg ggg ggc tcc	432
Leu Asp Gly Glu Glu Phe Thr Ile Gln Pro Gln Gly Ala Gly Gly Ser	
130 135 140	
ctg gct cag ccg cac cgc ctg cag cgc tgg ggt ccc gcc gga gcc cgc	480
Leu Ala Gln Pro His Arg Leu Gln Arg Trp Gly Pro Ala Gly Ala Arg	
145 150 155 160	
ccc ctc ccg cga gga ccc gag tgg gag gtg gag acg gga gag ggt cag	528
Pro Leu Pro Arg Gly Pro Glu Trp Glu Val Glu Thr Gly Glu Gly Gln	
165 170 175	
agg cag gag aga gga gac cac cag gag gac agc gag gag gag agc caa	576
Arg Gln Glu Arg Gly Asp His Gln Glu Asp Ser Glu Glu Glu Ser Gln	
180 185 190	
gaa gag gag gca gaa ggc gct agc gag ccg cca ccg ccc ctg ggg gcc	624
Glu Glu Glu Ala Glu Gly Ala Ser Glu Pro Pro Pro Pro Leu Gly Ala	
195 200 205	

-12-

acg agt agg acc aag cgg ttt gtg tct gag gcg cgc ttc gtg gag acg	672
Thr Ser Arg Thr Lys Arg Phe Val Ser Glu Ala Arg Phe Val Glu Thr	
210 215 220	
ctg ctg gtg gcc gat gcg tcc atg gct gcc ttc tac ggg gcc gac ctg	720
Leu Leu Val Ala Asp Ala Ser Met Ala Ala Phe Tyr Gly Ala Asp Leu	
225 230 235 240	
cag aac cac atc ctg acg tta atg tct gtg gca gcc cga atc tac aag	768
Gln Asn His Ile Leu Thr Leu Met Ser Val Ala Ala Arg Ile Tyr Lys	
245 250 255	
cac ccc agc atc aag aat tcc atc aac ctg atg gtg gta aaa gtg ctg	816
His Pro Ser Ile Lys Asn Ser Ile Asn Leu Met Val Val Lys Val Leu	
260 265 270	
atc gta gaa gat gaa aaa tgg ggc cca gag gtg tcc gac aat ggg ggg	864
Ile Val Glu Asp Glu Lys Trp Gly Pro Glu Val Ser Asp Asn Gly Gly	
275 280 285	
ctt acg ctg cgt aac ttc tgc aac tgg cag cgg cgt ttc aac cag ccc	912
Leu Thr Leu Arg Asn Phe Cys Asn Trp Gln Arg Arg Phe Asn Gln Pro	
290 295 300	
agc gac cgc cac cca gag cac tac gac acg gcc atc ctg ctc acc aga	960
Ser Asp Arg His Pro Glu His Tyr Asp Thr Ala Ile Leu Leu Thr Arg	
305 310 315 320	
cag aac ttc tgt ggg cag gag ggg ctg tgt gac acc ctg ggt gtg gca	1008
Gln Asn Phe Cys Gly Gln Glu Gly Leu Cys Asp Thr Leu Gly Val Ala	
325 330 335	
gac atc ggg acc att tgt gac ccc aac aaa agc tgc tcc gtg atc gag	1056
Asp Ile Gly Thr Ile Cys Asp Pro Asn Lys Ser Cys Ser Val Ile Glu	
340 345 350	
gat gag ggg ctc cag gcg gcc cac acc ctg gcc cat gaa cta ggg cac	1104
Asp Glu Gly Leu Gln Ala Ala His Thr Leu Ala His Glu Leu Gly His	
355 360 365	
gtc ctc agc atg ccc cac gac gac tcc aag ccc tgc aca cgg ctc ttc	1152
Val Leu Ser Met Pro His Asp Asp Ser Lys Pro Cys Thr Arg Leu Phe	
370 375 380	
ggg ccc atg ggc aag cac cac gtg atg gca ccg ctg ttc gtc cac ctg	1200
Gly Pro Met Gly Lys His His Val Met Ala Pro Leu Phe Val His Leu	
385 390 395 400	
aac cag acg ctg ccc tgg tcc ccc tgc agc gcc atg tat ctc aca gag	1248
Asn Gln Thr Leu Pro Trp Ser Pro Cys Ser Ala Met Tyr Leu Thr Glu	
405 410 415	

-13-

ctt ctg gac ggc ggg cac gga gac tgt ctc ctg gat gcc cct ggt gcg Leu Leu Asp Gly Gly His Gly Asp Cys Leu Leu Asp Ala Pro Gly Ala 420 425 430	1296
gcc ctg ccc ctc ccc aca ggc ctc ccg ggc cgc atg gcc ctg tac cag Ala Leu Pro Leu Pro Thr Gly Leu Pro Gly Arg Met Ala Leu Tyr Gln 435 440 445	1344
ctg gac cag cag tgc agg cag atc ttt ggg ccg gat ttc cgc cac tgc Leu Asp Gln Gln Cys Arg Gln Ile Phe Gly Pro Asp Phe Arg His Cys 450 455 460	1392
ccc aac acc tct gct cag gac gtc tgc gcc cag ctt tgg tgc cac act Pro Asn Thr Ser Ala Gln Asp Val Cys Ala Gln Leu Trp Cys His Thr 465 470 475 480	1440
gat ggg gct gag ccc ctg tgc cac acg aag aat ggc agc ctg ccc tgg Asp Gly Ala Glu Pro Leu Cys His Thr Lys Asn Gly Ser Leu Pro Trp 485 490 495	1488
gct gac ggc acg ccg tgc ggg cct ggg cac ctc tgc tca gaa ggc agc Ala Asp Gly Thr Pro Cys Gly Pro Gly His Leu Cys Ser Glu Gly Ser 500 505 510	1536
tgt cta cct gag gag gaa gtg gag agg ccc aag ccc gtg gta gat gga Cys Leu Pro Glu Glu Glu Val Glu Arg Pro Lys Pro Val Val Asp Gly 515 520 525	1584
ggc tgg gca ccg tgg gga ccc tgg gga gaa tgt tct cgg acc tgt gga Gly Trp Ala Pro Trp Gly Pro Trp Gly Glu Cys Ser Arg Thr Cys Gly 530 535 540	1632
gga gga gta cag ttt tca cac cgt gag tgc aag gac ccc gag cct cag Gly Gly Val Gln Phe Ser His Arg Glu Cys Lys Asp Pro Glu Pro Gln 545 550 555 560	1680
aat gga gga aga tac tgc ctg ggt cgg aga gcc aag tac cag tca tgc Asn Gly Gly Arg Tyr Cys Leu Gly Arg Arg Ala Lys Tyr Gln Ser Cys 565 570 575	1728
cac acg gag gaa tgc ccc cct gac ggg aaa agc ttc agg gag cag cag His Thr Glu Glu Cys Pro Pro Asp Gly Lys Ser Phe Arg Glu Gln Gln 580 585 590	1776
tgt gag aag tat aat gcc tac aat tac act gac atg gac ggg aat ctc Cys Glu Lys Tyr Asn Ala Tyr Asn Tyr Thr Asp Met Asp Gly Asn Leu 595 600 605	1824
ctg cag tgg gtc ccc aag tat gct ggg gtg tcc ccc ccg gac cgc tgc Leu Gln Trp Val Pro Lys Tyr Ala Gly Val Ser Pro Arg Asp Arg Cys 610 615 620	1872

-14-

aag ttg ttc tgc cga gcc cgg ggg agg agc gag ttc aaa gtg ttc gag	1920
Lys Leu Phe Cys Arg Ala Arg Gly Arg Ser Glu Phe Lys Val Phe Glu	
625 630 635 640	
gcc aag gtg att gat ggc acc ctg tgt ggg cca gaa aca ctg gcc atc	1968
Ala Lys Val Ile Asp Gly Thr Leu Cys Gly Pro Glu Thr Leu Ala Ile	
645 650 655	
tgt gtc cgt ggc cag tgt gtc aag gcc ggc tgt gac cat gtg gtg gac	2016
Cys Val Arg Gly Gln Cys Val Lys Ala Gly Cys Asp His Val Val Asp	
660 665 670	
tcg cct cgg aag ctg gac aaa tgc ggg gtg tgt ggg ggc aaa ggc aac	2064
Ser Pro Arg Lys Leu Asp Lys Cys Gly Val Cys Gly Gly Lys Gly Asn	
675 680 685	
tcc tgc agg aag gtc tcc ggg tcc ctc acc ccc acc aat tat ggc tac	2112
Ser Cys Arg Lys Val Ser Gly Ser Leu Thr Pro Thr Asn Tyr Gly Tyr	
690 695 700	
aat gac att gtc acc atc cca gct ggt gcc act aat att gac gtg aag	2160
Asn Asp Ile Val Thr Ile Pro Ala Gly Ala Thr Asn Ile Asp Val Lys	
705 710 715 720	
cag cgg agc cac ccg ggt gtg cag aac gat ggg aac tac ctg gcg ctg	2208
Gln Arg Ser His Pro Gly Val Gln Asn Asp Gly Asn Tyr Leu Ala Leu	
725 730 735	
aag acg gct gat ggg cag tac ctg ctc aac ggc aac ctg gcc atc tct	2256
Lys Thr Ala Asp Gly Gln Tyr Leu Leu Asn Gly Asn Leu Ala Ile Ser	
740 745 750	
gcc ata gag cag gac atc ttg gtg aag ggg acc atc ctg aag tac agc	2304
Ala Ile Glu Gln Asp Ile Leu Val Lys Gly Thr Ile Leu Lys Tyr Ser	
755 760 765	
ggc tcc atc gcc acc ctg gag cgc ctg cag agc ttc cgg ccc ttg cca	2352
Gly Ser Ile Ala Thr Leu Glu Arg Leu Gln Ser Phe Arg Pro Leu Pro	
770 775 780	
gag cct ctg aca gtg cag ctc ctg aca gtc cct ggc gag gtc ttc ccc	2400
Glu Pro Leu Thr Val Gln Leu Leu Thr Val Pro Gly Glu Val Phe Pro	
785 790 795 800	
cca aaa gtc aaa tac acc ttc ttt gtt cct aat gac gtg gac ttt agc	2448
Pro Lys Val Lys Tyr Thr Phe Phe Val Pro Asn Asp Val Asp Phe Ser	
805 810 815	
atg cag agc agc aaa gag aga gca acc acc aac atc atc cag ccg ctg	2496
Met Gln Ser Ser Lys Glu Arg Ala Thr Thr Asn Ile Ile Gln Pro Leu	
820 825 830	

-15-

ctc cac gca cag tgg gtg ctg ggg gac tgg tct gag tgc tct agc acc 2544
 Leu His Ala Gln Trp Val Leu Gly Asp Trp Ser Glu Cys Ser Ser Thr
 835 840 845

tgc ggg gcc ggc tgg cag agg cga act gta gag tgc agg gac ccc tcc 2592
 Cys Gly Ala Gly Trp Gln Arg Arg Thr Val Glu Cys Arg Asp Pro Ser
 850 855 860

ggc cag gcc tct gcc acc tgc aac aag gct ctg aaa ccc gag gat gcc 2640
 Gly Gln Ala Ser Ala Thr Cys Asn Lys Ala Leu Lys Pro Glu Asp Ala
 865 870 875 880

aag ccc tgc gaa agc cag ctg tgc ccc ctg tgattcaggg gggcaggggc 2690
 Lys Pro Cys Glu Ser Gln Leu Cys Pro Leu
 885 890

cagtcttgtg ctcttgga tgcggtactg aggtgcagac aaggtctcca ctgtggtgac 2750
 tgggtccctt ggccatatca aggcagcacg gcccaccag gcctcccatt gccgcaaccc 2810
 ctccagtact gcacaaattc ctaaggggga agagaaaagg tatggggcgg caaaacctat 2870
 catcaactgt ccawtgnaat ggaacttgct cgggttcaat taaaggcata agttaagta 2930
 aattcattat gatcaacaga cctcacntca tctgttgcan gatacaacta ntaaaaaaaaa 2990
 aaaaaaaaaa aaaaaaaaaa 3008

<210> 4
 <211> 890
 <212> PRT
 <213> Homo sapiens

<400> 4
 Met Phe Pro Ala Pro Ala Ala Pro Arg Trp Leu Pro Phe Leu Leu Leu
 1 5 10 15
 Leu Leu Leu Leu Leu Leu Pro Leu Ala Arg Gly Ala Pro Ala Arg Pro
 20 25 30
 Ala Ala Gly Gly Gln Ala Ser Glu Leu Val Val Pro Thr Arg Leu Pro
 35 40 45
 Gly Ser Ala Gly Glu Leu Ala Leu His Leu Ser Ala Phe Gly Lys Gly
 50 55 60
 Phe Val Leu Arg Leu Ala Pro Asp Asp Ser Phe Leu Ala Pro Glu Phe
 65 70 75 80
 Lys Ile Glu Arg Leu Gly Gly Ser Gly Arg Ala Thr Gly Gly Glu Arg

-16-

85										90					95				
Gly	Leu	Arg	Gly	Cys	Phe	Phe	Ser	Gly	Thr	Val	Asn	Gly	Glu	Pro	Glu				
			100					105					110						
Ser	Leu	Ala	Ala	Val	Ser	Leu	Cys	Arg	Gly	Leu	Ser	Gly	Ser	Phe	Leu				
		115					120					125							
Leu	Asp	Gly	Glu	Glu	Phe	Thr	Ile	Gln	Pro	Gln	Gly	Ala	Gly	Gly	Ser				
	130					135					140								
Leu	Ala	Gln	Pro	His	Arg	Leu	Gln	Arg	Trp	Gly	Pro	Ala	Gly	Ala	Arg				
145					150				155						160				
Pro	Leu	Pro	Arg	Gly	Pro	Glu	Trp	Glu	Val	Glu	Thr	Gly	Glu	Gly	Gln				
				165				170						175					
Arg	Gln	Glu	Arg	Gly	Asp	His	Gln	Glu	Asp	Ser	Glu	Glu	Glu	Ser	Gln				
			180					185						190					
Glu	Glu	Glu	Ala	Glu	Gly	Ala	Ser	Glu	Pro	Pro	Pro	Pro	Pro	Leu	Gly	Ala			
		195					200						205						
Thr	Ser	Arg	Thr	Lys	Arg	Phe	Val	Ser	Glu	Ala	Arg	Phe	Val	Glu	Thr				
	210					215					220								
Leu	Leu	Val	Ala	Asp	Ala	Ser	Met	Ala	Ala	Phe	Tyr	Gly	Ala	Asp	Leu				
225					230				235						240				
Gln	Asn	His	Ile	Leu	Thr	Leu	Met	Ser	Val	Ala	Ala	Arg	Ile	Tyr	Lys				
				245					250					255					
His	Pro	Ser	Ile	Lys	Asn	Ser	Ile	Asn	Leu	Met	Val	Val	Lys	Val	Leu				
			260					265					270						
Ile	Val	Glu	Asp	Glu	Lys	Trp	Gly	Pro	Glu	Val	Ser	Asp	Asn	Gly	Gly				
	275						280					285							
Leu	Thr	Leu	Arg	Asn	Phe	Cys	Asn	Trp	Gln	Arg	Arg	Phe	Asn	Gln	Pro				
	290					295					300								
Ser	Asp	Arg	His	Pro	Glu	His	Tyr	Asp	Thr	Ala	Ile	Leu	Leu	Thr	Arg				
305					310				315						320				
Gln	Asn	Phe	Cys	Gly	Gln	Glu	Gly	Leu	Cys	Asp	Thr	Leu	Gly	Val	Ala				
				325				330						335					
Asp	Ile	Gly	Thr	Ile	Cys	Asp	Pro	Asn	Lys	Ser	Cys	Ser	Val	Ile	Glu				
			340					345					350						
Asp	Glu	Gly	Leu	Gln	Ala	Ala	His	Thr	Leu	Ala	His	Glu	Leu	Gly	His				
			355				360					365							

-17-

Val Leu Ser Met Pro His Asp Asp Ser Lys Pro Cys Thr Arg Leu Phe
 370 375 380

Gly Pro Met Gly Lys His His Val Met Ala Pro Leu Phe Val His Leu
 385 390 395 400

Asn Gln Thr Leu Pro Trp Ser Pro Cys Ser Ala Met Tyr Leu Thr Glu
 405 410 415

Leu Leu Asp Gly Gly His Gly Asp Cys Leu Leu Asp Ala Pro Gly Ala
 420 425 430

Ala Leu Pro Leu Pro Thr Gly Leu Pro Gly Arg Met Ala Leu Tyr Gln
 435 440 445

Leu Asp Gln Gln Cys Arg Gln Ile Phe Gly Pro Asp Phe Arg His Cys
 450 455 460

Pro Asn Thr Ser Ala Gln Asp Val Cys Ala Gln Leu Trp Cys His Thr
 465 470 475 480

Asp Gly Ala Glu Pro Leu Cys His Thr Lys Asn Gly Ser Leu Pro Trp
 485 490 495

Ala Asp Gly Thr Pro Cys Gly Pro Gly His Leu Cys Ser Glu Gly Ser
 500 505 510

Cys Leu Pro Glu Glu Glu Val Glu Arg Pro Lys Pro Val Val Asp Gly
 515 520 525

Gly Trp Ala Pro Trp Gly Pro Trp Gly Glu Cys Ser Arg Thr Cys Gly
 530 535 540

Gly Gly Val Gln Phe Ser His Arg Glu Cys Lys Asp Pro Glu Pro Gln
 545 550 555 560

Asn Gly Gly Arg Tyr Cys Leu Gly Arg Arg Ala Lys Tyr Gln Ser Cys
 565 570 575

His Thr Glu Glu Cys Pro Pro Asp Gly Lys Ser Phe Arg Glu Gln Gln
 580 585 590

Cys Glu Lys Tyr Asn Ala Tyr Asn Tyr Thr Asp Met Asp Gly Asn Leu
 595 600 605

Leu Gln Trp Val Pro Lys Tyr Ala Gly Val Ser Pro Arg Asp Arg Cys
 610 615 620

Lys Leu Phe Cys Arg Ala Arg Gly Arg Ser Glu Phe Lys Val Phe Glu
 625 630 635 640

-18-

Ala Lys Val Ile Asp Gly Thr Leu Cys Gly Pro Glu Thr Leu Ala Ile
645 650 655

Cys Val Arg Gly Gln Cys Val Lys Ala Gly Cys Asp His Val Val Asp
660 665 670

Ser Pro Arg Lys Leu Asp Lys Cys Gly Val Cys Gly Gly Lys Gly Asn
675 680 685

Ser Cys Arg Lys Val Ser Gly Ser Leu Thr Pro Thr Asn Tyr Gly Tyr
690 695 700

Asn Asp Ile Val Thr Ile Pro Ala Gly Ala Thr Asn Ile Asp Val Lys
705 710 715 720

Gln Arg Ser His Pro Gly Val Gln Asn Asp Gly Asn Tyr Leu Ala Leu
725 730 735

Lys Thr Ala Asp Gly Gln Tyr Leu Leu Asn Gly Asn Leu Ala Ile Ser
740 745 750

Ala Ile Glu Gln Asp Ile Leu Val Lys Gly Thr Ile Leu Lys Tyr Ser
755 760 765

Gly Ser Ile Ala Thr Leu Glu Arg Leu Gln Ser Phe Arg Pro Leu Pro
770 775 780

Glu Pro Leu Thr Val Gln Leu Leu Thr Val Pro Gly Glu Val Phe Pro
785 790 795 800

Pro Lys Val Lys Tyr Thr Phe Phe Val Pro Asn Asp Val Asp Phe Ser
805 810 815

Met Gln Ser Ser Lys Glu Arg Ala Thr Thr Asn Ile Ile Gln Pro Leu
820 825 830

Leu His Ala Gln Trp Val Leu Gly Asp Trp Ser Glu Cys Ser Ser Thr
835 840 845

Cys Gly Ala Gly Trp Gln Arg Arg Thr Val Glu Cys Arg Asp Pro Ser
850 855 860

Gly Gln Ala Ser Ala Thr Cys Asn Lys Ala Leu Lys Pro Glu Asp Ala
865 870 875 880

Lys Pro Cys Glu Ser Gln Leu Cys Pro Leu
885 890

<210> 5

<211> 1203

<212> PRT

-19-

<213> Bovine

<400> 5

Met Asp Pro Pro Ala Gly Ala Ala Gly Arg Leu Leu Cys Pro Ala Leu
 1 5 10 15

Leu Leu Leu Leu Leu Leu Pro Leu Pro Ala Asp Ala Arg Leu Ala Ala
 20 25 30

Ala Ala Ala Asp Pro Pro Gly Gly Pro Gln Gly His Gly Ala Glu Arg
 35 40 45

Ile Leu Ala Val Pro Val Arg Thr Asp Ala Gln Gly Arg Leu Val Ser
 50 55 60

His Val Val Ser Ala Ala Thr Ala Pro Ala Gly Val Arg Thr Arg Arg
 65 70 75 80

Ala Ala Pro Ala Gln Ile Pro Gly Leu Ser Gly Gly Ser Glu Glu Asp
 85 90 95

Pro Gly Gly Arg Leu Phe Tyr Asn Val Thr Val Phe Gly Arg Asp Leu
 100 105 110

His Leu Arg Leu Arg Pro Asn Ala Arg Leu Val Ala Pro Gly Ala Thr
 115 120 125

Val Glu Trp Gln Gly Glu Ser Gly Ala Thr Arg Val Glu Pro Leu Leu
 130 135 140

Gly Thr Cys Leu Tyr Val Gly Asp Val Ala Gly Leu Ala Glu Ser Ser
 145 150 155 160

Ser Val Ala Leu Ser Asn Cys Asp Gly Leu Ala Gly Leu Ile Arg Met
 165 170 175

Glu Glu Glu Glu Phe Phe Ile Glu Pro Leu Glu Lys Gly Leu Ala Ala
 180 185 190

Lys Glu Ala Glu Gln Gly Arg Val His Val Val Tyr His Arg Pro Thr
 195 200 205

Thr Ser Arg Pro Pro Pro Leu Gly Gln Ala Leu Asp Thr Gly Ile Ser
 210 215 220

Ala Asp Ser Leu Asp Ser Leu Ser Arg Ala Leu Gly Val Leu Glu Glu
 225 230 235 240

Arg Val Asn Ser Ser Arg Arg Arg Met Arg Arg His Ala Ala Asp Asp
 245 250 255

Asp Tyr Asn Ile Glu Val Leu Leu Gly Val Asp Asp Ser Val Val Gln

-20-

260	265	270
Phe His Gly Thr Glu His Val Gln Lys Tyr Leu Leu Thr Leu Met Asn		
275	280	285
Ile Val Asn Glu Ile Tyr His Asp Glu Ser Leu Gly Ala His Ile Asn		
290	295	300
Val Val Leu Val Arg Ile Ile Leu Leu Ser Tyr Gly Lys Ser Met Ser		
305	310	315
Leu Ile Glu Ile Gly Asn Pro Ser Gln Ser Leu Glu Asn Val Cys Arg		
	325	330
Trp Ala Tyr Leu Gln Gln Lys Pro Asp Thr Asp His Asp Glu Tyr His		
	340	345
Asp His Ala Ile Phe Leu Thr Arg Gln Asp Phe Gly Pro Ser Gly Met		
	355	360
Gln Gly Tyr Ala Pro Val Thr Gly Met Cys His Pro Val Arg Ser Cys		
	370	375
Thr Leu Asn His Glu Asp Gly Phe Ser Ser Ala Phe Val Val Ala His		
	385	390
Glu Thr Gly His Val Leu Gly Met Glu His Asp Gly Gln Gly Asn Arg		
	405	410
Cys Gly Asp Glu Val Arg Leu Gly Ser Ile Met Ala Pro Leu Val Gln		
	420	425
Ala Ala Phe His Arg Phe His Trp Ser Arg Cys Ser Gln Gln Glu Leu		
	435	440
Ser Arg Tyr Leu His Ser Tyr Asp Cys Leu Arg Asp Asp Pro Phe Thr		
	450	455
His Asp Trp Pro Ala Leu Pro Gln Leu Pro Gly Leu His Tyr Ser Met		
	465	470
Asn Glu Gln Cys Arg Phe Asp Phe Gly Leu Gly Tyr Met Met Cys Thr		
	485	490
Ala Phe Arg Thr Phe Asp Pro Cys Lys Gln Leu Trp Cys Ser His Pro		
	500	505
Asp Asn Pro Tyr Phe Cys Lys Thr Lys Lys Gly Pro Pro Leu Asp Gly		
	515	520
Thr Met Cys Ala Pro Gly Lys His Cys Phe Lys Gly His Cys Ile Trp		
	530	535
		540

-21-

Leu Thr Pro Asp Ile Leu Lys Arg Asp Gly Asn Trp Gly Ala Trp Ser
 545 550 555 560

Pro Phe Gly Ser Cys Ser Arg Thr Cys Gly Thr Gly Val Lys Phe Arg
 565 570 575

Thr Arg Gln Cys Asp Asn Pro His Pro Ala Asn Gly Gly Arg Thr Cys
 580 585 590

Ser Gly Leu Ala Tyr Asp Phe Gln Leu Cys Asn Ser Gln Asp Cys Pro
 595 600 605

Asp Ala Leu Ala Asp Phe Arg Glu Glu Gln Cys Arg Gln Trp Asp Leu
 610 615 620

Tyr Phe Glu His Gly Asp Ala Gln His His Trp Leu Pro His Glu His
 625 630 635 640

Arg Asp Ala Lys Glu Arg Cys His Leu Tyr Cys Glu Ser Lys Glu Thr
 645 650 655

Gly Glu Val Val Ser Met Lys Arg Met Val His Asp Gly Thr Arg Cys
 660 665 670

Ser Tyr Lys Asp Ala Phe Ser Leu Cys Val Arg Gly Asp Cys Arg Lys
 675 680 685

Val Gly Cys Asp Gly Val Ile Gly Ser Ser Lys Gln Glu Asp Lys Cys
 690 695 700

Gly Val Cys Gly Gly Asp Asn Ser His Cys Lys Val Val Lys Gly Thr
 705 710 715 720

Phe Ser Arg Ser Pro Lys Lys Leu Gly Tyr Ile Lys Met Phe Glu Ile
 725 730 735

Pro Ala Gly Ala Arg His Leu Leu Ile Gln Glu Ala Asp Thr Thr Ser
 740 745 750

His His Leu Ala Val Lys Asn Leu Glu Thr Gly Lys Phe Ile Leu Asn
 755 760 765

Glu Glu Asn Asp Val Asp Pro Asn Ser Lys Thr Phe Ile Ala Met Gly
 770 775 780

Val Glu Trp Glu Tyr Arg Asp Glu Asp Gly Arg Glu Thr Leu Gln Thr
 785 790 795 800

Met Gly Pro Leu His Gly Thr Ile Thr Val Leu Val Ile Pro Glu Gly
 805 810 815

-22-

Asp Ala Arg Ile Ser Leu Thr Tyr Lys Tyr Met Ile His Glu Asp Ser
 820 825 830

Leu Asn Val Asp Asp Asn Asn Val Leu Glu Asp Asp Ser Val Gly Tyr
 835 840 845

Glu Trp Ala Leu Lys Lys Trp Ser Pro Cys Ser Lys Pro Cys Gly Gly
 850 855 860

Gly Ser Gln Phe Thr Lys Tyr Gly Cys Arg Arg Arg Leu Asp His Lys
 865 870 875 880

Met Val His Arg Gly Phe Cys Asp Ser Val Ser Lys Pro Lys Ala Ile
 885 890 895

Arg Arg Thr Cys Asn Pro Gln Glu Cys Ser Gln Pro Val Trp Val Thr
 900 905 910

Gly Glu Trp Glu Pro Cys Ser Arg Ser Cys Gly Arg Thr Gly Met Gln
 915 920 925

Val Arg Ser Val Arg Cys Val Gln Pro Leu His Asn Asn Thr Thr Arg
 930 935 940

Ser Val His Thr Lys His Cys Asn Asp Ala Arg Pro Glu Gly Arg Arg
 945 950 955 960

Ala Cys Asn Arg Glu Leu Cys Pro Gly Arg Trp Arg Ala Gly Ser Trp
 965 970 975

Ser Gln Cys Ser Val Thr Cys Gly Asn Gly Thr Gln Glu Arg Pro Val
 980 985 990

Leu Cys Arg Thr Ala Asp Asp Ser Phe Gly Val Cys Arg Glu Glu Arg
 995 1000 1005

Pro Glu Thr Ala Arg Ile Cys Arg Leu Gly Pro Cys Pro Arg Asn Thr
 1010 1015 1020

Ser Asp Pro Ser Lys Lys Ser Tyr Val Val Gln Trp Leu Ser Arg Pro
 1025 1030 1035 1040

Asp Pro Asn Ser Pro Val Gln Glu Thr Ser Ser Lys Gly Arg Cys Gln
 1045 1050 1055

Gly Asp Lys Ser Val Phe Cys Arg Met Glu Val Leu Ser Arg Tyr Cys
 1060 1065 1070

Ser Ile Pro Gly Tyr Asn Lys Leu Cys Cys Lys Ser Cys Asn Pro His
 1075 1080 1085

Asp Asn Leu Thr Asp Val Asp Asp Arg Ala Glu Pro Pro Ser Gly Lys

-23-

1090 1095 1100
 His Asn Asp Ile Glu Glu Leu Met Pro Thr Leu Ser Val Pro Thr Leu
 1105 1110 1115 1120
 Val Met Glu Val Gln Pro Pro Pro Gly Ile Pro Leu Glu Val Pro Leu
 1125 1130 1135
 Asn Thr Ser Ser Thr Asn Ala Thr Glu Asp His Pro Glu Thr Asn Ala
 1140 1145 1150
 Val Asp Val Pro Tyr Lys Ile Pro Gly Leu Glu Asp Glu Val Gln Pro
 1155 1160 1165
 Pro Asn Leu Ile Pro Arg Arg Pro Ser Pro Tyr Glu Lys Thr Arg Asn
 1170 1175 1180
 Gln Arg Ile Gln Glu Leu Ile Asp Glu Met Arg Lys Lys Glu Met Leu
 1185 1190 1195 1200
 Gly Lys Phe

<210> 6
 <211> 50
 <212> PRT
 <213> Homo sapiens

<400> 6
 Asp Asp Gly Trp Ser Pro Trp Ser Glu Trp Thr Ser Cys Ser Thr Ser
 1 5 10 15
 Cys Gly Asn Gly Ile Gln Gln Arg Gly Arg Ser Cys Asp Ser Leu Asn
 20 25 30
 Asn Arg Cys Glu Gly Ser Ser Val Gln Thr Arg Thr Cys His Ile Gln
 35 40 45
 Glu Cys
 50

<210> 7
 <211> 57
 <212> PRT
 <213> Homo sapiens

<400> 7
 Asp Gly Gly Trp Ser His Trp Ser Pro Trp Ser Ser Cys Ser Val Thr
 1 5 10 15

-24-

Cys Gly Asp Gly Val Ile Thr Arg Ile Arg Leu Cys Asn Ser Pro Ser
 20 25 30

Pro Gln Met Asn Gly Lys Pro Cys Glu Gly Glu Ala Arg Glu Thr Lys
 35 40 45

Ala Cys Lys Lys Asp Ala Cys Pro Ile
 50 55

<210> 8

<211> 57

<212> PRT

<213> Homo sapiens

<400> 8

Asn Gly Gly Trp Gly Pro Trp Ser Pro Trp Asp Ile Cys Ser Val Thr
 1 5 10 15

Cys Gly Gly Gly Val Gln Lys Arg Ser Arg Leu Cys Asn Asn Pro Thr
 20 25 30

Pro Gln Phe Gly Gly Lys Asp Cys Val Gly Asp Val Thr Glu Asn Gln
 35 40 45

Ile Cys Asn Lys Gln Asp Cys Pro Ile
 50 55

<210> 9

<211> 50

<212> PRT

<213> Homo sapiens

<400> 9

Glu Glu Gly Trp Ser Pro Trp Ala Glu Trp Thr Gln Cys Ser Val Thr
 1 5 10 15

Cys Gly Ser Gly Thr Gln Gln Arg Gly Arg Ser Cys Asp Val Thr Ser
 20 25 30

Asn Thr Cys Leu Gly Pro Ser Ile Gln Thr Arg Ala Cys Ser Leu Ser
 35 40 45

Lys Cys
 50

<210> 10

<211> 57

<212> PRT

<213> Homo sapiens

-25-

<400> 10

Asp Gly Gly Trp Ser His Trp Ser Pro Trp Ser Ser Cys Ser Val Thr
 1 5 10 15

Cys Gly Val Gly Asn Ile Thr Arg Ile Arg Leu Cys Asn Ser Pro Val
 20 25 30

Pro Gln Met Gly Gly Lys Asn Cys Lys Gly Ser Gly Arg Glu Thr Lys
 35 40 45

Ala Cys Gln Gly Ala Pro Cys Pro Ile
 50 55

<210> 11

<211> 56

<212> PRT

<213> Homo sapiens

<400> 11

Asp Gly Arg Trp Ser Pro Trp Ser Pro Trp Ser Ala Cys Thr Val Thr
 1 5 10 15

Cys Ala Gly Gly Ile Arg Glu Arg Thr Arg Val Cys Asn Ser Pro Glu
 20 25 30

Pro Gln Tyr Gly Gly Lys Ala Cys Val Gly Asp Val Gln Glu Arg Gln
 35 40 45

Met Cys Asn Lys Arg Ser Cys Pro
 50 55

<210> 12

<211> 3974

<212> DNA

<213> Homo sapiens

<400> 12

ggtacctaa gtagtagggc gtccgatcga cggacgcctt ttttttgaat tcgtaatcat 60
 ggatcatagct gtttcctgtg tgaaattggt atccgctcac aattccacac aacatacgag 120
 ccggaagcat aaagtgtaaa gcctgggggtg cctaagtgt gagctaactc acattaattg 180
 cgttgcgctc actgcccgct ttccagtcgg gaaacctgtc gtgccagctg cattaatgaa 240
 tcggccaacg cgcggggaga ggcgggttgc gtattgggag ctcttccgct tcctcgctca 300
 ctgactcgct gcgctcggtc gttcggctgc ggcgagcggg atcagctcac tcaaaggcgg 360

-26-

taatacgggtt atccacagaa tcaggggata acgcaggaaa gaacatgtga gcaaaaggcc 420
agcaaaaggc caggaaccgt aaaaaggccg cgttgctggc gtttttccat aggctccgcc 480
cccctgacga gcatcacaaa aatcgacgct caagtcagag gtggcgaaac ccgacaggac 540
tataaagata ccaggcgttt cccctggaa gtcacctcgt gcgctctcct gttccgacct 600
tgccgcttac cggatacctg tccgcctttc tcccttcggg aagcgtggcg ctttctcata 660
gctcacgctg taggtatctc agttcggtgt aggtcgctcg ctccaagctg ggctgtgtgc 720
acgaaccccc cgttcagccc gaccgctgcg ccttatccgg taactatcgt cttgagtcca 780
acccggttaag acacgactta tcgccactgg cagcagccac tggtaacagg attagcagag 840
cgaggatatgt aggcggtgct acagagttct tgaagtggcg gcctaactac ggctacacta 900
gaagaacagt atttggtatc tgcgctctgc tgaagccagt taccttcgga aaaagagttg 960
gtagctcttg atccggcaaa caaaccaccg ctggtagcgg tggttttttt gtttgcaagc 1020
agcagattac gcgcagaaaa aaaggatctc aagaagatcc tttgatcttt tctacggggg 1080
ctgacgctca gtggaacgaa aactcacgtt aagggatttt ggcatgaga ttatcgtcga 1140
caattcgcg cgcgaaggcg agcggcatgc atttacgttg acaccatcga atggtgcaaa 1200
acctttcgcg gtatggcatg atagcgcccg gaagagagtc aattcagggg ggtgaatgtg 1260
aaaccagtaa cgttatacga tgtcgcagag tatgccggtg tctcttatca gaccgtttcc 1320
cgcggtgtga accaggccag ccacgtttct gcgaaaacgc gggaaaaagt ggaagcggcg 1380
atggcgagc tgaattacat tcccaaccgc gtggcacaac aactggcggg caaacagtcg 1440
ttgctgattg gcgttgccac ctccagtctg gccctgcacg cgccgtcgca aattgtcgcg 1500
gcgattaaat ctgcgcccga tcaactgggt gccagcgtgg tgggtgctgat ggtagaacga 1560
agcggcgctg aagcctgtaa agcggcggtg cacaatcttc tcgcgcaacg cgtcagtggg 1620
ctgatcatta actatccgct ggatgaccag gatgccattg ctgtggaagc tgcctgcact 1680
aatgttccgg cgttatttct tgatgtctct gaccagacac ccatcaacag tattattttc 1740
tcccatgaag acggtacgcg actgggcgtg gagcatctgg tcgcattggg tcaccagcaa 1800
atcgcgctgt tagcggggcc attaatctct gtctcggcgc gtctgcgtct ggctggctgg 1860
cataaatatc tactcgcaa tcaaattcag ccgatagcgg aacgggaagg cgactggagt 1920

-27-

gccatgtccg gttttcaaca aaccatgcaa atgctgaatg agggcatcgt tcccactgcg 1980
atgctgggttg ccaacgatca gatggcgctg ggcgcaatgc gcgccattac cgagtcoggg 2040
ctgcgcgttg gtgcggatat ctcggtagtg ggatacgacg ataccgaaga cagctcatgt 2100
tatatcccg cgttaaccac catcaaacag gattttcgcc tgctggggca aaccagcgtg 2160
gaccgcttgc tgcaactctc tcagggccag gcggtgaagg gcaatcagct gttgcccgtc 2220
tactggtga aaagaaaaac caccctggcg cccaatacgc aaaccgcctc tccccgcgcg 2280
ttggccgatt cattaatgca gctggcacga caggtttccc gactggaaaag cgggcagtga 2340
gcgcaacgca attaatgtaa gttagcgcg attgtcgacc aaagcggcca tcgtgcctcc 2400
ccactcctgc agttcggggg catggatgcg cggatagccg ctgctggttt cctggatgcc 2460
gacggatttg cactgccggt agaactccgc gaggtcgtcc agcctcaggc agcagctgaa 2520
ccaactcgcg aggggatcga gcccggggtg ggcgaagaac tccagcatga gatccccgcg 2580
ctggaggatc atccagccgg cgtcccggaa aacgattccg aagcccaacc ttcatagaa 2640
ggcggcggtg gaatcgaaat ctctgatgg caggttgggc gtcgcttggg cggtcatttc 2700
gaaccccaga gtcccgtca gaagaactcg tcaagaaggc gatagaaggc gatgcgctgc 2760
gaatcgggag cggcgatacc gtaaagcacg aggaagcggg cagcccattc gccgccaagc 2820
tcttcagcaa tatcacgggt agccaacgct atgtcctgat agcgggtccg cacaccacgc 2880
cggccacagt cgatgaatcc agaaaagcgg ccattttcca ccatgatatt cggcaagcag 2940
gcatcgccat gggtcacgac gagatcctcg ccgtcgggca tgccgcctt gagcctggcg 3000
aacagttcgg ctggcgcgag cccctgatgc tcttcgtcca gatcatcctg atcgacaaga 3060
ccggcttcca tccgagtacg tgctcgctcg atgcgatgtt tcgcttgggt gtcgaatggg 3120
caggtagccg gatcaagcgt atgcagccgc cgcattgcat cagccatgat ggatactttc 3180
tcggcaggag caaggtgaga tgacaggaga tctgccccg gcacttcgcc caatagcagc 3240
cagtccttcc cgccttcagt gacaacgtcg agcacagctg cgcaaggaac gcccgtcgtg 3300
gccagccacg atagccgcgc tgctcgtcc tgcagttcat tcagggcacc ggacaggctg 3360
gtcttgacaa aaagaaccgg gcgcccctgc gctgacagcc ggaacacggc ggcatcagag 3420
cagccgattg tctgttgtgc ccagtcatag ccgaatagcc tctccacca agcggccgga 3480

-28-

gaacctgcgt gcaatccatc ttgttcaatc atgcgaaacg atcctcatcc tgtctcttga 3540
 tcagatcttg atccccctgcg ccatcagatc cttggcggca agaaagccat ccagtttact 3600
 ttgcaggggt tcccaacctt accagagggc gccccagctg gcaattccgg ttcgcttgct 3660
 gtccataaaa ccgcccagtc tagctatcgc catgtaagcc cactgcaagc tacctgcttt 3720
 ctcttttgcgc ttgcgttttc ccttggtccag atagcccagt agctgacatt catccggggg 3780
 cagcaccgtt tctgcggact ggctttctac gtgttccgct tcctttagca gcccttgcgc 3840
 cctgagtgtc tgccggcagc tgaagcttaa aaaactgcaa aaaatagttt gacttggtgag 3900
 cggataacaa ttaagatgta cccaattgtg agcggataac aatttcacac attaaagagg 3960
 agaaattaca tatg 3974

<210> 13
 <211> 112
 <212> DNA
 <213> Homo sapiens

<400> 13
 aagcttaaaa aactgcaaaa aatagtttga cttgtgagcg gataacaatt aagatgtacc 60
 caattgtgag cggataacaa tttcacacat taaagaggag aaattacata tg 112

<210> 14
 <211> 542
 <212> DNA
 <213> Mus musculus

<220>
 <221> UNSURE
 <222> (3)
 <223> May be any nucleic acid

<220>
 <221> UNSURE
 <222> (21)
 <223> May be any nucleic acid

<220>
 <221> UNSURE
 <222> (22)
 <223> May be any nucleic acid

<220>
 <221> UNSURE
 <222> (361)
 <223> May be any nucleic acid

-29-

<220>
<221> UNSURE
<222> (369)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (407)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (427)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (479)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (482)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (535)
<223> May be any nucleic acid

<400> 14
gtncgaattt cggcacgaga nnttagacgc cttttcatgg aagctgggga atgtgggggc 60
cttggggaga ctgttcgaga acgtgcggtg gaggagtcca gtacacgatg agggaaatgtg 120
acaacccagt cccaaagaat ggaggggaagt actgtgaagg caaacgagtg cgctacagat 180
cctgtaacct tgaggactgt ccagacaata atggaaaaac ctttagagag gaacaatgtg 240
aagcacacaa cgagttttca aaagcttcct ttgggagtgg gcctgcggtg gaatggattc 300
ccaagtacgc tggcgtctca ccaaaggaca ggtgcaagtt catgttgcca agccaaaggc 360
nttggtant tctttcgttt tgcagcccaa ggttgtagg tgggtantcc atgttaggcc 420
cagattncac ctttgtctgt gtgcaaggac agtgtgttaa aagttggttg tgatccgcnt 480
cntagattcc aaaaggagtt ttgttaatgt ggtgttttcn gggggaatgg totantttta 540
aa 542

<210> 15
<211> 320

-30-

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 15

cagagaacat tcgccccact cttcaatgac ccatgctgaa aaagtgggga tagcattgaa 60
agattccttc ttcttcttta cgaagtaggt gtatttaatt ttaggtcgaa gggcattgcc 120
cacagtaaga acctggatgg tcaagggtc tttgagaggg cttaaagctgc gaattctttc 180
caatgccgca gaggagccgc tgtacctcaa gacaacacct ttgtacataa tgtcttgctc 240
taaggtggac aaagtgtagt caccattaag aatatatgtg ccatcagcag ctttgatggc 300
aagaaagctg cccttgttcc 320

<210> 16

<211> 316

<212> DNA

<213> Eimeria tenella

<400> 16

aatgccgaga cattaatgga cagcctgctt ccgagtgtgc aaaggaagtg aagccagcca 60
gcaccagacc ttgtgcagac catccctgcc ccagtgga gctgggggag tggatcatcat 120
gttctaagac ctgtgggaag gggtacaaaa aaagaagctt gaagtgtctg tcccatgatg 180
gaggggtgtt atctcatgag agctgtgatc ctttaaagaa acctaaacat ttcatagact 240
tttgcaaat ggcagaatgc agttaagtgg tttaagtggg gttagctttg agggcaaggc 300
aaagtgagga agggct 316

<210> 17

<211> 383

<212> DNA

<213> Caenorhabditis elegans

<220>

<221> UNSURE

<222> (160)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (326)

<223> May be any nucleic acid

-31-

<220>
<221> UNSURE
<222> (358)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (366)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (377)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (379)
<223> May be any nucleic acid

<400> 17
gtcgaccac gcgtccgat ggtactccat gtagcccaga ttccacctct gtctgtgtgc 60
aaggacagtg tgtaaaagct ggttgtgatc gcatcataga ctccaaaaag aagtttgata 120
aatgtggtgt ttgcggggga aatggatcta cttgtaaaaan aatatcagga tcagttacta 180
gtgcaaaacc tgggatatca tgatatcatc acaattccaa ctggggagcca ccaacatcga 240
agtgaacag cggaaccaga ggggatccag ggaacaatgg gcagctttct tgccatcaaa 300
gctgctggat ggcacatata ttcttnaatg gtgactacac tttgtccacc ttagaganag 360
acattntgtg acaaagngnt tgt 383

<210> 18
<211> 404
<212> DNA
<213> Crotalus atrox

<220>
<221> UNSURE
<222> (21)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (301)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (335)

-32-

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (373)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (378)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (382)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (383)

<223> May be any nucleic acid

<400> 18

```

cccacgcgtc cgcccacggt nccgggactt gtgtgggtcc cagacatgtg atactcttgg 60
gatggctgat gttggaactg tgtgtgatcc gagcagaagc tgctccgtca tagaagatga 120
tggtttaciaa gctgccttca ccacagccca tgaattaggc cacgtgttta acatgccaca 180
tgatggatgc aaagcagtgt gccagcctta aatgggtgtga accagggatt cccacatgat 240
ggcgtcaatg ctttccaacc tgggaccaca gccagccttg ggtcctcctt gcagtggcct 300
nacatggatt gacatcattt ctgggatgaa tggtncatgg gggaatgttt tgattggaca 360
agccttcaga atnccctnac annttcccag gggttctccc tggg

```

404

<210> 19

<211> 152

<212> DNA

<213> Homo sapiens

<220>

<221> UNSURE

<222> (105)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (122)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (135)

-33-

<223> May be any nucleic acid

<400> 19

atcgtagaag atgaaaaatg gggcccagag gtgtccgaca atgggggggt tacactgcgt 60
aacttctgca actggcagcg gcgtttcaac cagcccagcg accgncaccc agagcactac 120
gncacggcca tctnctcac cagacagaac tt 152

<210> 20

<211> 4180

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 20

gcagctccga gctaggtgct atcgcaaggc cagagcgcac agcccggcgg agagagcaga 60
tccttgetca gatcgagtca aatcggggcca aggcggagga cgaagagtcc aggtctctat 120
tctggacttg ttccccagct ccggggggcg ttctaggtcc tgcagcagcc agcagtgcgg 180
agccaccaac tcggtgctgg aatgaaaaaa ttcccgcgcg ccagtgcaga atctttctaa 240
gtgacccgga gcttcgggtg ctagctctgc acgaactttc ccatcaaagt gatcgtgaat 300
tttaagcatc aggagcaggc cagcgaagct ctacgcgtct aaacgtctat ccagaccaag 360
agttctctgc ggtgcagggt gcggtgccat gcagccaaaa gtcccttttg gggtcacgca 420
agcagaagcc ctgctccgac atggggggacg tccagcgggc agcgagatct cggggctctc 480
tgtccgcaca catgctgttg ctgctcctcg cttccataac aatgctgcta tgtgcgcggg 540
gcgcacacgg gcgccccacg gaggaagatg aggagctggt cctgccctcg ctggagcgcg 600
ccccggggcca cgattccacc accacacgcc ttcgtctgga cgcctttggc cagcagctac 660
atctgaagtt gcagccggac agcggtttct tggcgccctg cttcaccctg cagactgtgg 720
ggcgcagtcc cgggtccgag gcacaacatc tggacccac cggggacctg gctcactgct 780
tctactctgg cacggtgaac ggtgatcccg gctctgccgc agccctcagc ctctgtgaag 840
gtgtgcgtgg tgccttctac ctacaaggag aggagttctt cattcagcca gcgcctggag 900
tggccaccga gcgcctggcc cctgccgtgc ccgaggagga gtcacccgca cggccgcagt 960
tccacatcct gaggcgaagg cggcggggca gtggcggcg caagtgcggc gtcacggacg 1020

acgagaccct gccaacccagc gactcgcgac ccgagagcca gaacaccccg aaccagtggc 1080
ctgtgcggga ccccacgcct caggacgcgg gaaagccatc aggaccagga agcataagga 1140
agaagcgatt tgtgtccagc ccccgttatg tggaaacat gctcgtagct gaccagtcca 1200
tggecgactt ccacggcagc ggtctaaagc attaccttct aaccctgttc tcggtggcag 1260
ccaggtttta caagcatccc agcattagga attcaattag cctgggtggg gtgaagatct 1320
tggtcatata cgaggagcag aagggaccag aagttacct caatgcagct ctcaccttc 1380
ggaatttctg cagctggcag aaacaacaca acagccccag tgaccgggat ccagagcact 1440
atgacactgc aattctgttc accagacagg atttatgtgg ctcccacacg tgtgacactc 1500
tcggaatggc agatgttga accgtatgtg accccagcag gagctgctca gtcatagaag 1560
atgatggttt gcaagccgcc ttcaccacag cccatgaatt gggccatgtg ttaacatgc 1620
cgcacgatga tgctaagcac tgtgccagct tgaatgggtg gagtggcgat tctcatctga 1680
tggcctcgat gctctccagc ttagaccata gccagccctg gtcaccttgc agtgcctaca 1740
tggtcacgtc ctctctagat aatggacacg gggaatgttt gatggacaag cccagaatc 1800
caatcaagct cccttctgat cttcccggta ccttgtaga tgccaaccgc cagtgtcagt 1860
ttacattcgg agaggaatcc aagcactgcc ctgatgcagc cagcacatgt actacctgt 1920
gggtgcactgg cacctccggg ggcttactgg tgtgccaaac aaaacacttc ccttgggcag 1980
atggcaccag ctgtggagaa gggaagtggg gtgtcagtgg caagtgcgtg aacaagacag 2040
acatgaagca ttttgctact cctgttcatg gaagctgggg accatgggga ccgtggggag 2100
actgctcaag aacctgtggg ggtggagtgc aatacacaat gagagaatgt gacaacccag 2160
tcccaaagaa cggaggggaag tactgtgaag gcaaacgagt ccgctacagg tcctgtaaca 2220
tcgaggactg tccagacaat aacggaaaaa cgttcagaga ggagcagtgc gaggcgcaca 2280
atgagttttc caaagcttcc tttgggaatg agccactgt agagtggaca cccaagtacg 2340
ccggcgtctc gccaaaggac aggtgcaagc tcacctgtga agccaaaggc attggctact 2400
ttttcgtctt acagcccaag gttgtagatg gcaactccctg tagtccagac tctacctctg 2460
tctgtgtgca agggcagtgt gtgaaagctg gctgtgatcg catcatagac tccaaaaaga 2520
agtttgataa gtgtggcggt tgtggaggaa acggttccac atgcaagaag atgtcaggaa 2580

tagtcactag tacaagacct gggatatcatg acattgtcac aattcctgct ggagccacca 2640
acattgaagt gaaacatcgg aatcaaagg ggtccagaaa caatggcagc tttctggcta 2700
ttagagccgc tgatggtacc tatattctga atggaaactt cactctgtcc aactagagc 2760
aagacctcac ctacaaaggt actgtcttaa ggtacagtgg ttcctcggct gcgctggaaa 2820
gaatccgcag ctttagtcca ctcaaagaac ccttaaccat ccaggttctt atggtaggcc 2880
atgctctccg acccaaaatt aaattcacct actttatgaa gaagaagaca gagtcattca 2940
acgccattcc cacatcttct gagtgggtga ttgaagagtg gggggagtgc tccaagacat 3000
gcggctcagg ttggcagaga agagtagtgc agtgcagaga cattaacgga caccctgctt 3060
ccgaatgtgc aaaggaagtg aagccagcca gtaccagacc ttgtgcagac cttccttgcc 3120
cacactggca ggtgggggat tggtcacat gttccaaaac ttgcgggaag ggttacaaga 3180
agagaacctt gaaatgtgtg tcccacgatg ggggcgtgtt atcaaatgag agctgtgatc 3240
ctttgaagaa gccaaagcat tacattgact tttgcacact gacacagtgc agttaagagg 3300
cgtagagga caaggtagcg tggggagggg ctgatacact gagtgaaga gtactggagg 3360
gatccagtga gtcaaaccag taagcagtga ggtgtggcaa ggaggtgtgt gtaggggata 3420
catagcaaag gaggtagatc aggacactac cctgccagt acattctgat aaggtagtta 3480
atgaggcaca gtagcatctg aaagaccata cagagcacta aggagcccca aagcactatt 3540
agtatctctt ttcttatatc tatcgcccaa ataattttca gagtctggca gaagccctgt 3600
tgactgtac taactagata cttcttatca caaagattgg gaaaggcaaa gcagaaagat 3660
ggtaagactg ggtttcaaac aaggcttggg ttcaatcact ggaggcaagg aggaggggac 3720
aaacaagatc attattcgaa gtcgctgggt gctgtggtt tacggaagggt tgatgcatca 3780
ttcctatcaa cagtgaagaa ttcagcttgt tcaacgtgac agaaaggctc atctccgtga 3840
aagagctcct gatttcttct tacaccatct cagttcttaa ctatagttca tgttgaggta 3900
gaaacaattc atctatttat aaaatgtaca ttggaaaaaa aaagtgaagt ttatgaggta 3960
cacataaaaa ctgaaggaaa caatgagcaa catgcctcct gctttgcttc ctctgaggt 4020
aaacctgcct ggggattgag gttgtttaag attatccatg gtcacaaga ggcagtaaaa 4080
taatacatgt tgtgccagag ttagaatggg gtatagagat caggggccca tgagatgggg 4140

-36-

aacatggtga tcaatcatct cacatgggag gctgctgcag

4180

<210> 21

<211> 9248

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 21

gcagctccga gctaggtgct atcgcaaggc cagagcgcac agcccggcgg agagagcaga 60
tccttgctca gatcgagtca aatcggggcc aaggcggagg acgaagagtc caggctccta 120
ttctggactt gttccccagc tccgggggcg cttctaggtc ctgcagcagc caggagtgcg 180
gagccaccaa ctcggtgctg gaatgaaaaa attcccgcgc gccagtgcag aatctttcta 240
agtgacccgg agcttcgggt gctagctctg cacgaacttt cccatcaaag tgatcgtgaa 300
ttttaagcat caggagcagg ccagcgaagc tctacgcgtc taaacgtcta tccagaccaa 360
gagttctctg cggtgcaggg tgcggtgcca tgcagccaaa agtccctttg gggtcacgca 420
agcagaagcc ctgctccgac atgggggacg tccagcgggc agcgagatct cggggctctc 480
tgtccgcaca catgctgttg ctgctcctcg cttccataac aatgctgcta tgtgcgcggg 540
gcgcacacgg gcgccccacg gaggaagatg aggagctggt cctgccctcg ctggagcgcg 600
ccccgggcca cgattccacc accacacgcc ttcgtctgga cgcctttggc cagcagctac 660
atctgaagtt gcagccggac agcggtttct tggcgcttg cttaccctg cagactgtgg 720
ggcgcagtcc cgggtccgag gcacaacatc tggacccac cggggacctg gctcactgct 780
tctactctgg cacggtgaac ggtgatcccg gctctgccgc agccctcagc ctctgtgaag 840
gtgtgcgtgg tgcctttctac ctacaaggag aggagtctt cattcagcca gcgcctggag 900
tggccaccga gcgcctggcc cctgccgtgc ccgaggagga gtcacccgca cggccgcagt 960
tccacatcct gaggcgaagg cggcggggca gtggcggcgc caagtgcggc gtcatggacg 1020
acgagaccct gccaaaccagc gactcgcgac ccgagagcca gaacacccgg aaccagtggc 1080
ctgtgcggga cccacgcct caggacgcgg gaaagccatc aggtataaga gtgaccccca 1140
tctctcagtc tttaacgaggc gtgacttggg gtcacactcc agatcgctc taaatgcgaa 1200

tgactcagac ttgcagtga ttgaagttct gggcgtgac cttcccgctc ccccccccc 1260
aaaaaaagtg tgaccatact ctgctagaac acttatttgc ccgaatagtt aataatttga 1320
gaaagagaga aagaatcgga ggtcctgtag ataagggcta agcgtttcct ccgcgaagcc 1380
aataacccga ctccctacac tggagaatct ctctccatcc ctttaatgcc tttagtgaat 1440
gtatgagttc actttaacta ggttgtagtt tcgcgctgag ttttgtaacg tcagtccgtg 1500
tgagcacgta gcgctcaaag gagggcggag tagaggagcc atggtgacct ggatgtgcgt 1560
tcaggagcct gggcaacggc agtgggtgatc tcatttctgt ggccttcctg ctgtcccctt 1620
ccccatttg aaaagctgac cccgatggct ggtggctccg ttggggccct ctgcagaacc 1680
tgcttgggag gtctttgctt ggttcgcccc gcctccacgc gcctcctacc tcggcctcgt 1740
tgctcgact ccctctcccg gcagagggtg gactccccag cgctgtggaa tgtagcctg 1800
gactgacct ccctgctaca cattegctg actctgccgt gttcagtctc taccagccag 1860
ttagttcttt ttaatcattc aaatttcttt ttgccctttt ctagatttct ccctcttttc 1920
cgacttgctc ctaggagctg gtattcatat cctactttac gatttctctg accgctgagt 1980
ctcagcagcc cgaaaaaggc cattttccaa attggcaacc ctggtttgag aaaggaactt 2040
attcccccg gggcactggg agtgagagga ggcaggaaaa cactgctggg cagagtgggt 2100
ggctcctagt cccggaactg gatcaagcag agaaccctt gggaccctt gaatgagaga 2160
gctgagcctt acagactgag actcctcaag cccaccctt tggctgagct ccccgccctg 2220
ccccatgctt tcacgtgga gctggatgat ctcatcggg atttcagccc tggcttcaat 2280
agtgaagggt tgactcagg cgtccgctg cttctcttgc caagttttta ctacagctgg 2340
gtagaaatga tagccatact gcctcactca ggctgtggag tcttcaaaga ccacaaaaga 2400
aatctgcgga cacatatata gacagtttga tcactctgtt gcttgctttg ttttgctttg 2460
ttttgtctta tttaaagcaa aagaaaaaag acttaaaaat aactcacagt ttttagaaga 2520
tgcaaatatt tgttttattt ttgttccagg tgtatttcag ttttatttac tttgactagg 2580
ttgactttcc taatatacc cgagaaggct actattagga gaaggactgc ccatgagcaa 2640
acttcctttt ctttttacag gaccaggaag cataaggaag aagcgatttg tgtccagccc 2700
ccgttatgtg gaaaccatgc tcgtggctga ccagtccatg gccgacttcc acggcagcgg 2760

tctaaagcat tacctttctaa cctgtttctc ggtggcagcc aggtttttaca agcatcccag 2820
cattaggaat tcaattagcc tgggtgggtg gaagatcttg gtcatatatg aggagcagaa 2880
gggaccagaa gttacctcca atgcagctct cacccttcgg aattttctgca actggcagaa 2940
acaacacaac agccccagtg accgggatcc agagcactat gacactgcaa ttctgttcac 3000
cagacaggta agacaggagc ttatcaacca tttcatcaac tcaactcgga ggtcagcctt 3060
gtgttggtatg ggatgagagg gtgggggtgt ggcggagagg aaaccagaa ggggatgaca 3120
tttgaaatgt aaacaaaata accaattaaa aaaaaaggc atctcatctg tattgcctca 3180
tttcctttcg gttataggct agtcaatct gtcttgctta tttctatttt aaacttcac 3240
atctcaagtt ctacagttct attttaaaag cattacaggg aatcttgctt agagtcagtc 3300
cttcaagccc agcaataatg aatggacagg cttcaaagt catgtgaaga cacgccaac 3360
tgaagagcta agtatcactc tctcctactt aaaagggtt tcccttgctt cttttagga 3420
tttatgtggc tcccacacgt gtgacactct cgggatggca gatgttgga ctgtatgtga 3480
ccccagcagg agctgctcag tcatagaaga tgatggtttg caagccgctt tcaccacagc 3540
ccacgaattg ggtaagtcgg cttcagagta caagttaagc ccaaagcat ggatacaacc 3600
caataagtca atctgatgtg acgagagaga aaacatctca gactatgttg ctacctcagc 3660
caccagcaat tttagaaggg gtagggtata tttccacga tttcaagtat ggtcttacta 3720
ggacaggaga aagtgttaca aacatttgaa cgttgacatt tttatacttg ccctgatcaa 3780
agtgagtatg agccccata cagggtgtct aataagagag ccattgagcc tcaactcaata 3840
atacagctga atgtccttct tgtctgcttc ccaggccatg tgtttaacat gccgcacgat 3900
gatgctaagc actgtgccag cttgaatggt gtgactggcg attctcatct gatggcctcg 3960
atgtctcca gcttagacca tagccagccc tggtcacctt gcagtgccta catggtcacg 4020
tccttcctag ataatggaca cggttaagatg acagctctc tttccagatg gtgttcaacc 4080
ttccttgtgt agggctctct ctggctaagt gagctccatg gctcttgctc atttcccctc 4140
cttcagagtt ttctctggca ggatcataag tagtagatct ttacctccat tgcactctgc 4200
tcccaaagtc cattcattca taaacaataa cttctcgcca ttgtaaaatc agaagtcccc 4260
tattgaggat aacgtctcga taaaaatcta aagttcccta gcattgattt tcccaaaaat 4320

gcatgatttc accaaacatg tattaataat tgcctctttt ttcttttctt tttttttttt 4380
tattatttta ggggaatggt tgatggacaa gcccagaat ccaatcaagc tcccttctga 4440
tcttcccggg accttgtagc atgccaaccg ccagtgtcag ttacattcg gagaggaatc 4500
caagcactgc cctgatgcag ccagcacatg tactaccctg tgggtgactg gcacctccgg 4560
tggcttactg gtgtgcaaaa caaaacactt cccttgggca gatggcacca gctgtggaga 4620
agggaagtgg tgtgtcagt gcaagtgcgt gaacaagaca gacatgaagc attttgctgt 4680
gagttttccc aatgaaacat atccgtttgc aactcagggt tgagaagggc aaagtgatgg 4740
tttagttcct ttcctagaca aactcctcta cctgtgtcct gtagtgggac tatgagatgg 4800
tagcgtattt tgagaattga ttgtctgttt tacatttttc tctgattccc taaaatgtct 4860
ttatagttct aacactgata tctgtatctc catttagact cctgttcatg gaagctgggg 4920
accatgygga ccgtggggag actgctcaag aacctgtggt ggtggagtgc aatacacaat 4980
gagagaatgt gacaaccag tcccaaagaa cggaggggaag tactgtgaag gcaaacgagt 5040
ccgctacagg tctgttaaca tcgaggactg tccagacaat aacggtgagt catactggac 5100
ttcagctctc agaaaccggg caaaggcggc gtgccacaac atgtggttgg aagttggaaa 5160
ctgggaacat catcgccgtc gttctctttt caggaaaaac gttcagagag gagcagtgcg 5220
aggcgcacaa tgagttttcc aaagcttctt ttgggaatga gccactgta gagtggacac 5280
ccaagtacgc cggcgtctcg ccaaaggaca ggtgcaagct cacctgtgaa gccaaaggca 5340
ttggctactt tttcgtctta cagcccaagg taggtgcttt tacacttgaa tctttgcaaa 5400
ggagcctcag ctgggcttgc tgccatgcca tacaatgtt tgggctgtct ttacctattg 5460
atctgtgttc cgttttgaat ttggaatact tctaaatgca ggaacaactc cttgcttttg 5520
gatttggtgt tgccttctgt tgggaaggaa gcttaaactc agctagcact taaaagagtc 5580
ttgcatgtgt ttaatattgc ttctctatcc ccaaagaatg gccctttgaa aactcaagag 5640
ccctctctgt ataactaggt ttcacatata aaaattcatg gttagataaa ttatatatta 5700
acatggcacc caggagtttt agaaagtagt ccaaagtact tgttactggg tacctagcag 5760
ccgcacatac gagcacacta actaaggtaa gagtttgaga attaaaaatt catcgttgga 5820
acatgtactt tgaccaaaga gactcgccat ttcttttggt gttttgcaga aaggataaat 5880

-40-

cctgctttga agaagaaaat tgaatgaaat ttgcttaagc ttgtcatgta ttcttagcat 5940
tataagatag caaactatat ccaagttgtg gatgaagtat ttagcaagtg atttataaag 6000
taccttcaac tacagcatat tattctaggt actgaccatg gaacaataat cagtgtgaca 6060
gtgaaccctg ctccattga cctaggccag caaatatata aaatcaagac atttataagc 6120
cttacagata gctatatgaa ctgttgaaaa agccaaaatg aaagtgaaca tgtggcacgt 6180
gacaaggaga ctacttgtag cctgggagga gagcattccc agttgccatc acatcagatg 6240
tttaaccacc atggtgcatg ttgtctccac aggttgtaga tggcactccc tgtagtccag 6300
actctacctc tgtctgtgtg caagggcagt gtgtgaaagc tggctgtgat cgcacatag 6360
actccaaaaa gaagtttgat aagtgtggcg tttgtggagg aaacggttcc acatgcaaga 6420
agatgtcagg aatagtcact agtacaaggt gagtttcaga acgctcactt ctgcagtaga 6480
cacgctgtgt tgctcagttg gtccctagca tctacaagac cttgggttca atccgcatgc 6540
atgtacctgt agtcccagtg tatgggagac agagacaagt gtgacaagac ggtcagatgt 6600
tcaggtcac cttgtctacat agtgactttc agttcacctt ggggaacatg aaaaacctga 6660
ctggaaacac aaacacacac aaaacaatta acccaggtac ttcattgtaat cccagtgttc 6720
agtaggctga cttgggagga tgggtgctat aaggcctagg ttagcttggt ctacataatg 6780
agttccagta taacctggcc cacaagtga ccttaaagtt aattaatcga cacatgaaac 6840
aaaacacatg ctttgagagac cctgtaattt tgatatacga tttttagga ctaaggaaaa 6900
gtcacattta aaagaattgc ctatttttaa agcaatgtga ttgattaact cattgaaaga 6960
catatacctg ttttctttgt ccacagacct gggatcatg acattgtcac aattcctgct 7020
ggagccacca acattgaagt gaaacatcgg aatcaaagg ggtccagaaa caatggcagc 7080
tttctggcta ttagagccgc tgatggtacc tatattctga atggaaactt cactctgtcc 7140
acactagagc aagacctcac ctacaaaggt actgtcttaa ggtacagtgg ttcctcggct 7200
gcgctggaga gaatccgag ctttagtcca ctcaaagaac ccttaaccat ccaggttctt 7260
atggtaggcc atgctctccg acccaaaatt aaattcacct actttatgaa gaagaagaca 7320
gagtcattca acgccattcc cacattttct gagtgggtga ttgaagagtg gggggagtgc 7380
tccaagacat gcggctcagg ttggcagaga agagtagtgc agtgcagaga cattaatgga 7440

caccctgctt ccgaatgtgc aaaggaagtg aagccagcca gtaccagacc ttgtgcagac 7500
cttccttgcc cactactggca ggtgggggat tggtcacat gttccaaaac ttgcgggaag 7560
ggttacaaga agagaacctt gaaatgtgtg tcccacgatg ggggcgtgtt atcaaagag 7620
agctgtgatc ctttgaagaa gccaaagcat tacattgact tttgcacact gacacagtgc 7680
agttaagagg cgtagagga caaggtagcg tggggagggg ctgatacact gagtgctgga 7740
gggatccagt gagtcaaacc agtaagcagt gaggtgtggc aaggaggtgt gtgtagggga 7800
tacatagcaa aggaggtaga tcaggacact accctgccag ttacattctg ataaggtagt 7860
taatgaggca cagtagcatc tgaaagacca tacagagcac taaggagccc caaagcacta 7920
ttagtatctc ttttcttata tctatcgccc aaataatatt cagagtctgg cagaagccct 7980
gttgactgt actgactaga tacttcttat cacaagatt gggaaaggca aagcagaaag 8040
atggtaagac tgggtttcaa acaaggcttg gtttctatca ctggaggcaa ggaggagggg 8100
acaaacaaga tcattattcg aagtcgcttg ttgctgtggt ttacggaag gttgatgcat 8160
cattcctatc aacagtgaag agttcagctt gttcaacgtg acagaaaggc tcctctccgt 8220
gaaagagctc ctgatttctt cttacacat ctcagttctt aactataatt catgttgagg 8280
tagaaacaat tcctctattt ataaaatgta cattggaaaa aaaaaagtga agtttatgag 8340
gtacacataa aaactgaagg aaacaatgag caacatgcct cctgctttgc ttcctcctga 8400
ggtaaacctg cctggggatt gaggttgttt aagattatcc atggctcaca agaggcagta 8460
aaataatata tggttgcca gagttagaat ggggtataga gatcagggtc ccatgagatg 8520
gggaacatgg tgatcactca tctcacatgg gaggtgtgtg cagggtagca ggtccactcc 8580
tggcagctgg tccaacagtc gtatcctggt gaatgtctgt tcagctcttc tactgagaga 8640
gaatatgact gtttccatat gtatatgtat atagtaaaat atgttactat gaattgcatg 8700
tactttataa gtattggtgt gtctgttcct tctaagaagg actatagttt ataataaatg 8760
cctataataa catatttatt tttatacatt tatttctaata gataaaacct ttaagttata 8820
tcgcttttgt aaaagtgcac ataaaaatag agtatttata caatatatgt taactagaaa 8880
taataaaaaga acacttttga atgtgtatgc ctattttctg gagtgggatt aacttctggg 8940
caagaaatct gatgagacac aaacattgga cttcaagaca gttttaaaat ttgggtaaat 9000

-42-

gaactgtatt tcctgtttat agacgtacta ataaaaaaga agttgatgat gtcttttagtg 9060
gtaagattgt tactaatgtg gttggcaaat tgctgtaaag agccagatag taagcattta 9120
tggcattgta ggctatcttt cctgccacaa ccatgtgaca gtgagtgcct tgtaggactg 9180
agagcagcca taaatgacat gtaaatagata aactgtggct gtgctttaat aaaactttat 9240
ttacaaaa 9248

<210> 22

<211> 5722

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 22

ggacgcacag gcattccccg cgccccctcca gccctcgccg ccctcgccac cgctcccggc 60
cgccgcgctc cggtacacac aggatccctg ctgggcacca acagctccac catggggctg 120
gcctggggac taggcgtcct gttcctgatg catgtgtgtg gcaccaaccg cattccagag 180
tctggcgag acaacagcgt gtttgacatc tttgaactca ccggggccgc ccgcaagggg 240
tctgggcgcc gactggtgaa gggccccgac ccttcagcc cagctttccg catcgaggat 300
gccaacctga tccccctgt gcctgatgac aagttccaag acctggtgga tgctgtgcgg 360
gcagaaaagg gtttcctcct tctggcatcc ctgaggcaga tgaagaagac ccggggcacg 420
ctgctggccc tggagcggaa agaccactct ggccaggtct tcagcgtggt gtccaatggc 480
aaggcgggca ccctggacct cagcctgacc gtccaaggaa agcagcacgt ggtgtctgtg 540
gaagaagctc tcctggcaac cggccagtgg aagagcatca ccctgtttgt gcaggaagac 600
agggcccagc tgtacatcga ctgtgaaaag atggagaatg ctgagttgga cgtccccatc 660
caaagcgtct tcaccagaga cctggccagc atcgccagac tccgcatcgc aaaggggggc 720
gtcaatgaca atttccaggg ggtgctgcag aatgtgaggt ttgtctttgg aaccacacca 780
gaagacatcc tcaggaacaa aggctgctcc agctctacca gtgtcctcct cacccttgac 840
aacaacgtgg tgaatgggtc cagccctgcc atccgcacta actacattgg ccacaagaca 900
aaggacttgc aagccatctg cggcatctcc tgtgatgagc tgtccagcat ggtcctggaa 960

ctcaggggcc tgcgcaccat tgtgaccacg ctgcaggaca gcatccgcaa agtgactgaa 1020
gagaacaaag agttggccaa tgagctgagg cggcctcccc tatgctatca caacggagtt 1080
cagtacagaa ataacgagga atggactggt gatagctgca ctgagtgta ctgtcagaac 1140
tcagttacca tctgcaaaaa ggtgtcctgc cccatcatgc cctgctccaa tgccacagtt 1200
cctgatggag aatgctgtcc tcgctgttgg ccagcgact ctgcggacga tggctggtct 1260
ccatgggtccg agtggacctc ctgttctacg agctgtggca atggaattca gcagcgggc 1320
cgctcctgcg atagcctcaa caaccgatgt gagggctcct cggccagac acggacctgc 1380
cacattcagg agtgtgacaa aagatttaaa caggatggtg gctggagcca ctgggtccccg 1440
tggtcatctt gttctgtgac atgtggtgat ggtgtgatca caaggatccg gctctgcaac 1500
tctcccagcc cccagatgaa tgggaaacct tgtgaaggcg aagcgggga gaccaaagcc 1560
tgcaagaaag acgcctgccc catcaatgga ggctggggtc cttggtcacc atgggacatc 1620
tgttctgtca cctgtggagg aggggtacag aaacgtagtc gtctctgcaa caacccccgca 1680
ccccagtttg gaggaagga ctgcgttggg gatgtaacag aaaaccagat ctgcaacaag 1740
caggactgtc caattgatgg atgcctgtcc aatccctgct ttgccggcgt gaagtgtact 1800
agctaccctg atggcagctg gaaatgtggt gcttgtcccc ctggttacag tggaaatggc 1860
atccagtgca cagatgttga tgagtgcaa gaagtgcctg atgcctgctt caaccacaat 1920
ggagagcacc ggtgtgagaa cacggacccc ggctacaact gcctgcctg cccccacgc 1980
ttcaccggt cacagccctt cggccagggt gtcgaacatg ccacggccaa caaacaggtg 2040
tgcaagcccc gtaaccctg cacggatggg acccacgact gcaacaagaa cgccaagtgc 2100
aactacctg gccactatag cgaccccatg taccgtgcg agtgcaagcc tggtacgct 2160
ggcaatggca tcctctgcg ggaggacaca gacctggatg gctggcccaa tgagaacctg 2220
gtgtgcgtgg ccaatgcgac ttaccactgc aaaaaggata attgccccaa ccttcccaac 2280
tcagggcagg aagactatga caaggatgga attggtgatg cctgtgatga tgacgatgac 2340
aatgataaaa ttccagatga cagggacaac tgtccattcc attacaacct agctcagtat 2400
gactatgaca gagatgatgt gggagaccgc tgtgacaact gtccctacaa ccacaaccca 2460
gatcaggcag acacagacaa caatggggaa ggagacgcct gtgctgcaga cattgatgga 2520

gacggtatcc tcaatgaacg ggacaactgc cagtacgtct acaatgtgga ccagagagac 2580
actgatatgg atggggttgg agatcagtgt gacaattgcc ccttggaaca caatccggat 2640
cagctggact ctgactcaga ccgcattgga gatacctgtg acaacaatca ggatattgat 2700
gaagatggcc accagaacaa tctggacaac tgtccctatg tgcccaatgc caaccaggct 2760
gaccatgaca aagatggcaa gggagatgcc tgtgaccacg atgatgacaa cgatggcatt 2820
cctgatgaca aggacaactg cagactcgtg cccaatcccg accagaagga ctctgacggc 2880
gatggtcgag gtgatgcctg caaagatgat ttgaccatg acagtgtgcc agacatcgat 2940
gacatctgtc ctgagaatgt tgacatcagt gagaccgatt tccgccgatt ccagatgatt 3000
cctctggacc ccaaaggac atcccaaat gaccctaact gggttgtacg ccatcagggt 3060
aaagaactcg tccagactgt caactgtgat cctggactcg ctgtaggtta tgatgagttt 3120
aatgctgtgg acttcagtgg caccttcttc atcaacaccg aaaggacga tgactatgct 3180
ggatttgtct ttggctacca gtccagcagc cgcttttatg ttgtgatgtg gaagcaagtc 3240
accagtcct actgggacac caacccacg agggctcagg gatactcggg ctttctgtg 3300
aaagttgtaa actccaccac agggcctggc gagcacctgc ggaacgccct gtggcacaca 3360
ggaaacaccc ctggccagggt gcgcaccctg tggcatgacc ctcgtcacat aggctggaaa 3420
gatttcaccg cctacagatg gcgtctcagc cacaggccaa agacgggttt cattagagtg 3480
gtgatgtatg aagggaagaa aatcatggct gactcaggac ccatctatga taaaacctat 3540
gctggtggtg gactagggtt gtttgtcttc tctcaagaaa tgggtgttctt ctctgacctg 3600
aaatacgaat gtagagatcc ctaatcatca aattgttgat tgaaagactg atcataaacc 3660
aatgctggtg ttgcaccttc tggaactatg ggcttgagaa aacccccagg atcacttctc 3720
cttggttcc ttcttttctg tgcttgcatc agtgtggact cctagaacgt gcgacctgcc 3780
tcaagaaaat gcagttttca aaaacagact catcagcatt cagcctcaa tgaataagac 3840
atcttccaag catataaaca attgctttgg tttccttttg aaaaagcatc tacttgcttc 3900
agttgggaag gtgcccattc cactctgcct ttgtcacaga gcagggtgct attgtgaggc 3960
catctctgag cagtggactc aaaagcatth tcaggcatgt cagagaaggg aggactcact 4020
agaattagca aacaaaacca ccctgacatc ctccttcagg aacacgggga gcagaggcca 4080

aagcactaag gggagggcgc ataccogaga cgattgtatg aagaaaatat ggaggaactg 4140
ttacatgttc ggtactaagt ctttttcagg ggattgaaag actattgctg gatttcatga 4200
tgctgactgg cgttagctga ttaacccatg taaataggca cttaaataga agcaggaaaag 4260
ggagacaaag actggcttct ggacttcctc cctgatcccc acccttactc atcaccttgc 4320
agtggccaga attaggggaat cagaatcaaa ccagtgtgaag gcagtgtctg ctgccattgc 4380
ctggtcacat tgaaattggt ggcttcattc tagatgtagc ttgtgcagat gtagcaggaa 4440
aataggaaaa cctaccatct cagtgtgac cagctgcctc ccaaaggagg ggcagccgtg 4500
cttatatttt tatggttaca atggcacaaa attattatca acctaactaa aacattcctt 4560
ttctcttttt tccgtaatta ctaggtagt ttctaattct ctcttttgga agtatgattt 4620
ttttaaagtc ttacgatgt aaaatattta ttttttactt attctggaag atctggctga 4680
aggattattc atggaacagg aagaagcgta aagactatcc atgtcatctt tgttgagagt 4740
cttcgtgact gtaagattgt aaatacagat tatttattaa ctctgttctg cctggaaatt 4800
taggcttcat acggaaagtg tttgagagca agtagttgac atttatcagc aaatctcttg 4860
caagaacagc acaaggaaaa tcagtctaata aagctgtctt gccccttggtg ctgagagtgg 4920
atgttatggg attccttttt tctctgtttt atcttttcaa gtggaattag ttggttatcc 4980
atttgcaaatt gttttaaatt gcaaagaaag ccatgaggtc ttcaatactg ttttacccca 5040
tcccttggtg atatttccag ggagaaggaa agcatataca ctttttctt tcatttttcc 5100
aaaagagaaa aaaatgacaa aagggtgaaac ttacatacaa atattacctc atttgttgtg 5160
tgactgagta aagaattttt ggatcaagcg gaaagagttt aagtgtctaa caaacttaaa 5220
gctactgtag tacctaaaaa gtcagtgttg tacatagcat aaaaactctg cagagaagta 5280
ttccaataa ggaaatagca ttgaaatgtt aaatacaatt tctgaaagtt atgttttttt 5340
tctatcatct ggtataccat tgctttattt ttataaatta ttttctcatt gccattggaa 5400
tagaatattc agattgtgta gatatgctat ttaaataatt tatcaggaaa tactgcctgt 5460
agagttagta tttctatttt tatataatgt ttgcacactg aattgaagaa ttgttggttt 5520
tttctttttt ttgttttttt tttttttttt tttttttttg cttttgacct cccattttta 5580
ctatttgcca ataccttttt ctaggaatgt gctttttttt gtacacattt ttatccattt 5640

-46-

tacattctaa agcagtgtaa gttgtatatt actgtttctt atgtacaagg aacaacaata 5700
aatcatatgg aaatttatat tt 5722

<210> 23
<211> 42521
<212> DNA
<213> Unknown

<220>
<223> Description of Unknown Organism:Unknown

<400> 23
gatcgttttc cagacatttt tgttctctgt tcatttcctt atcgatttca aaaagttatc 60
acaaatgacc ttctctatct gtctgctgtc cttttaactc tcaccgtttg ggacctttca 120
aatagttttt cgctatcaaa tctaaacatt agttgctgtg actcgacatt tgacccttca 180
ctatcatctc cagttctctt ttttggttaca ctttagcagt ggcagcagag agcaagtagg 240
tggagccaaa gtgtgctgca ttcacggtga aaaattgtgt tcttcatcaa attttgggca 300
atttactcgg gatttgcgtt aatttggaaa caaaaattca aattcctgcc aattggtttg 360
tttgcttttt ttcttttttt tttgtctctc ccatctctca tcaaattgct cttttttcga 420
ttctaacata tcagccatct tcagagtgtg tctaactccc ccatttttat tcaaggtttag 480
tgatatagta tcctaactac agacgtcaca ccatgaggtt gctgctcttc tcggcagccc 540
ttcttctgtg ctccgtccca acgtgggcct tctctctgtc atcattcttc ggaagcgatg 600
ttgcacaagt aagcaagctc tcctatacct agaattctgt aaattgaaaa ctctaatttc 660
cagaagccat accttcatcc aaactcccca ccggagcgtg acccggcgag ttccagaatg 720
aagagacagg catatcaagt gtacgttgat ggagatgttt ccgttactgt tgacaagtct 780
ggacaaaagg aaaccggcaa ctggggacca tgggtgcccg agaacgagtg ctacgttctg 840
tgtggtggag gagttcaact cgagaagaga cagtgcaggt tcgtggactt ttcatttttt 900
agggaatttc ctagacgttc taaaagctta ttttcaaaaa ttttggtttc ctgatcttca 960
tgcctttatg aacgtggtga aagatcaacc taggctagcc tgtgacatac attttttgaa 1020
gcagatccaa ctttatcaag agccatcgaa ttctcgtttt aaagtgtttt ttttttctga 1080
taactttttt ctaatagctt taccattttt tatgtcaaga ctgaaagcaa tgaatcacia 1140

gaggctatct acgtttgttt ttgaagctct gtaggaatca tcttaaaaaa ttaagtaaag 1200
taatggagat gaaattctaa ttttttaaaa tcataatcat tactttctgt attatcttca 1260
agttcaaact tttcaaacgg ttattctcaa gaaactcaca tagaatttta acaatttcct 1320
ctatctatctt cttgcaagca acccaccgaa ctcaaactct atccaaacta aacttttagt 1380
ggtgactgca ctggagcttc agtccgctac atctcgtgta acttgaacgc atgcgagtct 1440
ggtactgatt tccgtgctga gcaatgctcc aaattcaacg atgaggctct tgatggaaac 1500
taccacaagt ggactccata caagggaaag aacaagtaag ttaactttct tcaagatgtt 1560
tttctaattt tcgagttttc aggtgcgagc tcgtctgtaa gccagaatct ggaaacttct 1620
actacaagtg ggctgataag gttgttgatg gaaccaagtg cgactccaag agcaacgata 1680
tctgtgttga tggggaatgt cttccagttg gatgtgacgg aaagcttgga tcttghtaagt 1740
ttaaaaatta attcaaaatc ttcatttcat gccgaatatt tcagctctca aattcgacaa 1800
gtgcggaaag tgcgatggag atggttctac ctgcaagact attgaaggac gtttcgatga 1860
gcgcaatctc tctccaggat accatgatat tatcaaactt ccagaaggag ccaccaacat 1920
taagattcag gaagccagaa agagcaccaa caacttggct ctgaagaacg gttccgatca 1980
cttttatctt aatggaaatg gattgatcca agttgagaag gaggttgaag tcggaggaac 2040
tatcttcgtt tacgatgacg ctgaaccaga aactctcagt gctcaaggac cactctccga 2100
ggagctcacc gttgctcttc tcttcagaaa gggaagccgt gatactgcta tcaagtacga 2160
gttctctatt ccacttgagg aggaagttga ctacatgtac aagtttgaca actggactcc 2220
gtgctctgta tcatgcggaa aggggtgttca aaccgtaat ctctactgta ttgatggaaa 2280
gaacaagga cgcgttgagg atgatctctg cgaggagaac aatgccacaa agccagagtt 2340
cgaaaagagc tgtgaaactg ttgactgtga agccgaatgg ttcactggag actgggaatc 2400
ttgctcatcc acctgcggag atcaaggaca gcaataccgt gtcgtctact gccatcaagt 2460
attcgctaac ggacgtcgtg ttaccgttga ggatggaaac tgcaccgttg agagaccacc 2520
agtaaagcag acttgcaatc ggtaagttga tttataaat gcataaacia ctctgtgaat 2580
ctatttgttt atgcgatgct atccatatat attaccagat ggtgttggtg cccaaaactt 2640
ataaacaatt attttctctt tgcagttttg cctgcccaga gtggcaagct ggtccgtggt 2700

cggttgctc agagaagtgt ggagacgcct tccaatacag atcggtgacc tgccgcagtg 2760
agaaggaagg agaagaggga aaactcttgg ccgctgatgc ttgcccagct gatgagcaag 2820
agaagttcga cacagagaga acttgcaatt tgggaccatg cgagggactt acatttgtca 2880
ctggagaatg gaacttggtt agattttgca aaatatgggg acctggggaa aagcatacta 2940
aataagatca actttatgaa acaaataatt tttagtgcac ccgctgcaac gatactgagg 3000
agactcgtga agtcacctgc aaggactccc aaggaagagc ctatccactc gagaagtgtt 3060
tggttgataa ctccaccgag attccaactg atactagggtg agtcattcca gatatgacat 3120
tgaacttgga ttaatttttt tcttccagat catgcgccac ccaaccacca tgtgagtacg 3180
agtggaccgt cagtgagtgg agcaagtgta ccaccgaatg cggacacgga cacaagactc 3240
gtcgtgttat ctgtgccatc caccaaaacg gaggactcga ggttggtgat gaaggacact 3300
gtcaagctga gaagccagaa ggaaagacta actgcaccaa tgaggagaag tgtactggaa 3360
catggtacac atcttcatgg tccgagtgta ccgctgaatg tgggtggtgga tcccaagatc 3420
gtgtcgtgtt ttgcttgaac tacgataaga agccagttcc agaatggtgc gacgaagccg 3480
tcaagccatc tgagaaacaa gattgtaacg ttgatgactg cccaacttgc gttgactctg 3540
agttcggatg ctgcccagat aactctactt ttgctaccgg agaattcaac ttcggatgct 3600
ctaactgctc ggaaacagaa ttcggatgct gtgctgacaa tgttaccggt gccactggac 3660
ctaactccaa gggatgcaaa gaattcgttg agtctccact taaccttgaa gctgatgttg 3720
ccaatgctga cgctgaagct tcaggagatg ctccagaact ctgcagcgtc acaaacgaga 3780
acggagaagc tggtgatgtt gagtgtgcca ccattgctcc aatcactgct cttcttgagg 3840
atggggaact tatcggaat gatactgatg cttccaatga gaccatacac tgctcgaaga 3900
ccgaattcgg atgctgtcca gattggtaca ccgccgcctc tggaaagggg aacgaaggat 3960
gcccatcggt cactcttgga ggatgtaacg agactcaatt cggatgttgt cacgatgatg 4020
tcactcttgc tcgtggagcc aaccttgaag gatgcggaga gccatcttgc gctgcttccc 4080
tctatggatg ctgtaaagat cgtaagacaa ttgccttcgg accacactat tctggatgtg 4140
agcgatcatc cttcccatgt gagcttagcg acttcggatg ctgcccagat ggtgagactg 4200
ctgctcttgg aaagaatgga accggatgcg gagagaactg cttgaccacc aagttcggat 4260

gctgccctga tggaaagacc accgccaagg ggtcccacaa cgagggatgc ggatgcgagt 4320
tcgcccataa cggatgctgc ccagacggaa aatcagttgc caagggagcc ggattttacg 4380
gatgccaga aagctgcgcc cagagccagt tcggatgctg cccagacgga aagactcgtg 4440
ctcgcggaga gaacaaggaa ggatgtccat gccagtacac ccgttacgga tgctgcccag 4500
atggggagac tactgctctt ggaccacgca atgatggatg tgataactgc cgctacgcca 4560
agcacggatg ttgccagat ggagagacca aggctcttgg accagatgga gccggatgcc 4620
caccaactac cagccacca ttcctcatgg gaggaactgt tgccccacat aaaatcgccg 4680
cctgtaatca gacacaagaa agtggaaaccg tctgcggagc cggatacaag cttgtaagta 4740
attaacctca tgaaaaagaa ttggagcaac acatttcatg tataaatatt tcaatttcag 4800
gcatggcatt atgataccac tgagggacgt tgcaaccagt tctggtacgg aggatgcggt 4860
ggaaatgaca acaactttgc tagccaggat atgtgcgaga ctatctcgtg cgaaccacca 4920
ggcaagggaa gatgttacct gccacgtgtt gatggaccac tccggtgtga ccaacttcag 4980
ccaagatact attatgatca ttccaagaag cactgtgtgg ccttctggtg gagaggatgt 5040
ctcggaaatg ccaacaactt caactctttc gaagaatgct ccatgttctg taaggacgtt 5100
ggaccgtacg atgctccaac caccgctgct ccaccaccac caccacagca aaatgctcag 5160
caataccttc caactccaga agttcaacag attgagattc aatctgctga gcaacctcaa 5220
ccacaacagc cacaacaaca gcaacagcaa caacagcaac aaccacagca accacgtcaa 5280
tcaatggaag acatctgcag atcccgccaa gacgccggac catgcgagac ttactccgat 5340
caatggttct acaacgcttt cagccaagaa tgcgaaacct tcacttatgg aggatgtgga 5400
ggaaatctca atcgtttccg cagcaaggat gaatgcgagc agcgttggtt cttcgttcac 5460
ggagctcagc catccgctgc ccggcaggaa caagctcagc cagcagctca accagctcaa 5520
ccagctcagc caagtaacat cgtctctcca ccacaacagt cagctagtcc agttgtgggt 5580
ccatgtaagt tctttagaat gcatttattt cttactataa gtttctataa gttcgcagt 5640
gaagcatccc catttcagcg aacagcaaac aacgcgatgc ttgccacctc aacgttgacc 5700
aaggacgttg taagggggct ttgactcct ggtactacga agttgccacc ggatcctgcg 5760
tcacattcaa gtacaccgga tgcggaggaa acgccaacag atttgctagc aaggatcagt 5820

-50-

gcgagtcact ctgtgtgaag ccagcttctg aagctgcttc agccggaatt ggtatgcttt 5880
gagttataga gaatgttcac ttttttgtt aaatgtttga gtaaatgaga aactggctca 5940
gtttgaaaat gtttgcacca tgtttcaaaa tagtttttga gttgaatagt tgaggccatg 6000
aaaatcttaa ttacactcca gaagtacatt ttaaaacatt tttgagaatt aggtcttcaa 6060
aaaaaggttt aatattgagg tttcaaatta gaaatattaa tatacgggga tttgggttta 6120
aaactgattt ttaaaatctt atttttgaag tttcgctttg atattcgtgc aaaaaaaaaa 6180
ccaacttttt cagacggtgc agctggaatc aactcagttt gtgacgaagc caaggacacc 6240
ggaccgtgca ccaactttgt cacgaaatgg tactacaaca aagccgacgg aacctgcaac 6300
cgattccatt acggtggatg ccaaggaacc aacaatcgat tcgacaacga gcaacagtgc 6360
aaggctgctt gtcaaaatca taaggatgct tgtcaacttc caaaggttca aggaccatgc 6420
tctggaaagc attcctatta ttactacaac actgccagtc atcaatgcga gacgttcact 6480
tatggtggct gcctcgaaa tactaacaga ttcgctacca ttgaggagtg tcaagcgaga 6540
tgcccgagta agttctaagt taatagtgat atatgctttg tttccccttt attctttgac 6600
aattttcaaa tactttttgc ataattacct tatttctatt cccttctgtt tcccatthttc 6660
ctccaccgcg taaaaattgt ttcccgact ctctcctttc tcactttccc gtccgaaggg 6720
acacggcaat gctgcctaaa tgaactgcct aataatattt atgaattttc caattttcta 6780
aaaaaaaaa attctctcaa aaaattccct gccgttccgc cactgctttc ttcaccatt 6840
gttgcgctat tttttttaa taaatgaata aagctgaaat agttaacagt ttctgaaatt 6900
gcatgtaagt ttgtagtgta tcagtgtgtt tgctgtgaaa gttttttttt acctgcatga 6960
tttctgaac tgcataaac tgttcttatt acgtttttaga ttgctgaag tgtgctagaa 7020
gtgtgatttt gtttcagaag acgaccagac tacaacaaca tcacaaccag aagagctccc 7080
aagtttgcca cttgttcaag aagatcctca gccacgaccg gcattttcat tgaagtaagc 7140
acgtgtagtc caagtgccta cttctcgtat gaccaaaaaa tttaataataa ggtttccaag 7200
tattaaggaa tcagtagcat gtaaattgtg tggattgttc tcctgggttg atgggttttt 7260
ttctcactca caatcagata tggagtagct tatatgggaa tttatttgag aaatagaata 7320
tgtcataaca tccaaattta attattaaaa agttgtgaag tttctcatta tgtatataaa 7380

-51-

attcgcccttt caaataagaa caaaaattaa ctgtatgaaa gagctgaatt caatttgaaa 7440
ttgagaaaat aactggttca aaaagaagaa aaacgttgga aaatctagac gtaaattctat 7500
ggatttttctt ttcaggtcgg ggaaatttcg acgattttta tattttcaaa aatcattcac 7560
aaatatacac caaaaattat ttttaccata ataaaatacg gaatttcact ggattactgt 7620
agtattcatg taaggttact gtattgttac tctagggata ctacaagaat atttttgcaa 7680
agttgtaaga agtatagaga ttactgtaga ttgaaaatct agacaaaaat cattttccgt 7740
aataatctgt ggggatagaa tgttgaaggc acaaggctta taaagcacca tgggaaaaaa 7800
ttttaacagt gattttttta agcatatcct ctttcccagg aaatccactt ttcaaatata 7860
ttcccactaa actctttaag acaatccttc gcccatagtc gtcgccgtga tgctccattt 7920
gcacgttccg tatccgcccg tcaccatact cctgattccg aagaggaacg agttgactgt 7980
tatgctyttc cagatccagg atcttgcggg taataaatct cacctatcca ttacaaccat 8040
taccgtctta atgattcaga gactaccgtc ttgtttggca ctactctgcc acgagtaact 8100
catgccgtca attctactat ggtggatgtg ctgggaatac gaatcgcttc gagaccggg 8160
ataaatgtga aacatcggtg gttgctaaga ttgaagaacg cgtggaaagt gtgtcagaag 8220
cttcaaaatc tctggaagag gttagactaa cggatccaag gatggattct cactttggat 8280
atcatgatcc agaagttgat caaatcgaag aagaagctga atatgtcatt gttgataccg 8340
gagctctacc tgaattatgc atgcttccag acaaagagg gtcttgttat gataacattt 8400
tgagatggag gtaagtcaaa tcaagaatag aaaattcgaa aatccgaaaa actttataat 8460
tatactaaaa gcaaaatctt aaaatctttc agattcgact ctgaaaagtc tcaatgtgta 8520
accttcatgt attctggatg taatccaaat gcaaatcact tcactagtca ggtagtttc 8580
attattttgt gtcctttcgt ggaactggcc ccttggtttc taacttgatc ttctccttcc 8640
gaatacccaa tttgagcacc gctggctcac tttttcgacg gtgacgttcc tcaattctag 8700
cggcctctgt attttctgag cactcttgag caacagtttc ctactggaa atgtttgttt 8760
ttcaagaggg agtgagagag agaaataaac gtacaatttt tgaagccgca catgatttgt 8820
tagaagtcga tgccgttctg cagtatcctt catgtttcgt agttgtttct gtagtaattt 8880
ttatggatta ggaactaaga aatcatcact cactgcggta gttgcatttt tgtgcatgca 8940

tcttcccata aaagcaacaa atgcaacaac tgatagagcc gccacacaaa ttgcaataat 9000
tcgaagtcga tttctaattc ctttctttac tttttgtcta tgctcagctg ctttttcgat 9060
gtgcttcttc ttgctggggt cgagctcgca atgaggaaat ggttcgatga gtggaccgtg 9120
ttttttgcat tgttcacaac ggcgtccagt gtatttgtct gggcagtcac acgaaagagt 9180
gcgggtttttg aaatctgaaa attttaaatt taagaacagg atctatagca gttttgccc 9240
tcacagtcct atgtctatat taaaaaaaaat tatcggacat taaaaaaaaat gttttctcat 9300
tttttcagta tttctataaa aactgcattc gcatttaatc ataactttta atcgtaaaaa 9360
acttagtctt taagtacctg gggatccgta aacacagaca atttcatcac aataatcgcc 9420
ttcaaattccc acatcacaga tgcattcttc atttctcaaa aacctctga cacatttact 9480
tgtatattgg cattcacttc caaaatatga gccacacat tcacatcggg ccccttcca 9540
ttctcctttg tttccgcact gaaataattc aatagatttt ggaagttag ggctcaaaa 9600
atataccttt tccgctggcc gatagtcaca catttcacct ttccatccga cttcgcaaat 9660
gcacgggtca ctgaatagaa ggctttccgg gtcgaagcgg aatccgaccg agagtcctg 9720
aactgtaa at tgaaaatttg taattccaaa aaaaaaacag cttttgcaaa aatcgtccaa 9780
aagaatttta gagttagaca ttatttttct caaaaagttc aaagttgtat cagtttttaa 9840
ataaaatatt taataggatt gtagagcttg ttagaaaaaa taaaagctac ttgaaaaaag 9900
aaaggatatcc aaaaaggat tgagatagtt tcaagcaact ctatttgtaa actgtcgagt 9960
ttttaagttc tacaaatctc ttataacatc gctacatcta ctatcaaact ttgaaaaaaa 10020
accataccac attcaaaatg ttcacattta tctccagtct gtcccttgat acaatgacaa 10080
atccctccag catagattcc tccattacga cattcggctc tcggatcatc cagagcaaca 10140
ttgtctagaa tacttctctt ttgaagaata cgatgcacgt cgctcaatat attttcatct 10200
agatctagtg agtcatctcg tgattgtgct ttgtgtgtg ataaaaatag gaagagtaaa 10260
gtggaaaatt gtaaacagta catagcgta gatactgaca agtctactat caattgattt 10320
atttattgcg tcttgaaagg ggtatcaatg agagaaatag ggagatgggt aaaatgcatt 10380
tataagagaa tacaaaagat gacgtaattg attaatacaga gatcagttga aaatactttt 10440
aagtatcaat tattatctgt gaagacagtc acgtgactct gactcgaact caatttgc 10500

gttgatagtt ccaatgttaa agaaagtctt tgggttttct ccagatgaaa caaatgattt 10560
tggaatatta aacgtgactc ttctctgaca aggtttgagt ccgtcatcac aatcgtgata 10620
gatattaagt tttggatcaa tagtcatcac ttcggaagtg tgtccggtaa gaaggaattg 10680
accaagagag tctgtagttc cttcggcaag aagatcgtca agatccggtc ctgaaaaaaaa 10740
cttttatttt gaaaaatttc aatgagttgc ttcattgtag aatttggaat ttttaaagat 10800
gtagcaatt ggtattttaa tgttcaagct aacgtaatta gagttattca aacaagcttt 10860
atataaaaac tttgtgtaag attcgggtcta attagaacat caatttttaa cgcagctgat 10920
aaaaaacttt aatttcaagc ttcacataat tctacttacc ggtatcatca tcgtagagct 10980
tcaccttcgt gtagccagt ggtttgtctc cacacatcag aacaccotta actccagctg 11040
attgggtgaa tacagcttcg gagccaattg cacaagtat gaaaagtgat gaaatgcacg 11100
cgagtcgtga cattattttt gtctgaaaat acaaacactg actgatctga cttcatcgg 11160
agaaactctc ttatagcaca gttgggttaga aaaagatacg gagaggagaa gtgggaaatc 11220
gaattgacca aacaaaagaa ctggttttca cttgaaatag aagacgatga aagatatata 11280
acagagaaga tcggaagtga ttcattctgga gaagaaaatt gagaggagca acttcttgta 11340
ttttccactt atttatatac ccaatagaat tcacctgatt ctttccgatt tgtgtacatt 11400
tcgctgacta acgtgtgctt cttcgggttt gtcatttctt attgttcatt gaaaataaac 11460
agaacaaagc aatcataagg tcgaaaatcc catttagaga tcaagagggtg tacctttaat 11520
tgtgcggcat ggcatagttt tatcttgctg aactctcacc aattgatgag tatgtcagta 11580
gaatggattc catccgatcg ttgctccacg gtgatctctt ccgccgcctt ttcattccacc 11640
ataccggttg tgtatggctg gcaactgtga acagcgcctc agtggaatgt ttagtttgat 11700
atacagttta aaataatttt ctaactaaa gaaatcagtt tttgaaacca gtcttgtagg 11760
catgtcgggc gcaggcacgc taacgtgaaa aatagaattt cgagtgggta actattttat 11820
tttcaattaa aatacaatca actacacaat gaatgaccgc gataaatgaa atacaaatac 11880
aagaatttaa aaaaaacatg gaaattttaa cttttccatc atctcccttt gctggaatat 11940
tatatttcat tcgataagct tccaattcgg cttttctctg atcggatcgt aactgtgtc 12000
tctcatccat ctcttggtga gctgtcattc tcttctcatt ccatttctga gcttttgctt 12060

ttttgtggat tctgttgtat tctttgcact tgcagcagca ataacagaag caggcaatga 12120
gaattacagc aatgattcca gcgcagatgg caataacgat tgcggcggct gatgtgctca 12180
cccagcagac attgtatttg acatgcttga tattacagtc tggatagtac cagtcgaatg 12240
gcatacatct tttcgttttt ccaccacacc agaagcaatt ctgaaaaaat gtgtttttga 12300
aattttcaat atgtttgctt ataaaattga atttaatttt tcaaacagtg tttcagaaac 12360
tcaacttctg aaattaggaa agtattctca attgagagct gtttttgtat taaaagtttc 12420
agtttagaac tacagggtgtg aaaaaatctg agcaagtga caccaacgta ttgcatcaca 12480
gtttacgcgt caatttatct gagtggtcat tgtagagaaa gttaggtcac cttccagaaa 12540
attaagaaac ttgtttcaga catttttgct ctttttagagg aatttttttt tagaggaaac 12600
acgcaagttt ctttgaaaac aaaaacaaaa tatatttttt atccacttac cgagcccttg 12660
ccaacacatg tttcacaagt gttcaaactg ttcgatccaa ttctacagta ttcttgtttc 12720
tctgaccatg tcatgttatt cgacataact gatactagaa caattgagaa aaagagtagt 12780
aatcggtgaa tcatcgttct gaaaaatcaa taaatagtaa caacttgagc aagtctcgta 12840
actgagcgac aaaaccaaag tagtaatgaa atagaaagat agaaaggtaa actcaaaggg 12900
ctcgcgtgtg tttgtctatc gagtgccaat gagtttttagg agtagcgaca gaaataagtt 12960
ggcagaagaa gaacatacga actatgtcgg gctacaagat tcttgtgttt actttttgaa 13020
aaagaaaatg catttgagaa aatgcaaactg ttcggcagaa atcgaatgga gtttagagca 13080
gaatggtaaa aataaagggtg gatcagcaaa aatagttgaa caaatatttt gtagatttca 13140
tgaaagataa caaaaaaaaa taaatacaga aaacaatata tgacgtattt ttcaatcatt 13200
gtttttgtat agtgcaaatt cagtagttgt acctgttata agtacagcga agttatacat 13260
tttagagtgg gtcttgtcac gatccatatt ttttgaacgc aatatttgaa atccaaaaaa 13320
aaataaagaa actaggcgcc aagaagctat agtagctata cgcataaatt gtgaataacct 13380
tgaattacat taaattccaa caaaatagga aaatcatata aaaacgaagt tagttgtcaa 13440
ttcaaaaacg tttttaaaat tgttcataag cgccgagctg tccccctcag ttttcgttta 13500
ttcagctttt ctctctctct ctattctcta tcgtcaccta tatttcatag tccccctatc 13560
caaaagtgga agtgaatgag gatggaaata tgataccgca tgcttcaaaa aaatttgctt 13620

atgagaaacc aacatttgaa aatttccagg aaacttgtga acgagcctgt ggtaaatgga 13680
gaaatgtggc agtgtgcgag ttgccggccg aacacggaga ttgccaactt gcgattccca 13740
ggtatgtact gttgacacat ttacaaaatg ggatgggaag tggtcggtga tcaggtggaa 13800
atgttgatgg caaggtttta aatagatgta gtaactgaaa aaaaaatgac agatgtacat 13860
acataaatta ggattaaaac aaaaatacta tgcggagtca ggtgactaat ttttctggaa 13920
attccagaat ttgaaaatgt ttttctctgt ttgaaagtag aacgggacct ttacaaaaat 13980
aggctgaggt aggtaggctg tagaaagtgc ctttggtgtc tttgtaattt ttgttttcaa 14040
aaaatcactt gtaagcacat gaaaatcaca tgaataatga tgtaaaattt agaaaattag 14100
tataaagaag atttacattt taataataat aattccagat ggtaccatga cccaaaaaca 14160
tcccaatgtc aatgatgat gtggactgga tgcggaggaa atggaaacgc gttctcttca 14220
aaagcagact gtgaatctct ttgccgagtt gagacattat ggtccaaca cactgacttc 14280
tgtacattgg aacgatcggc cgggccatgt acagattcta tttcaatgtg gtatttcgat 14340
tcaactcatc tcgattgtaa gccattcact tatggaggtt gccgtggaaa tcagaatcga 14400
ttcgtttagca aagagcaatg tcagcagagc tgccgtcctg gagacacaaa atctgaggat 14460
atctgcacac tccgcccaga gccgggaccg tgcggctgg gactcgagaa atacttttac 14520
gacccggtga tccaatcctg tcatatgttc cattatggag gttgtgaggg aaatgcaaac 14580
cggttcgatt cagagttgga ctgcttccga cgatgctcga gtgtcaaggt tgaagcaagt 14640
gaaagcgaga gagtgggaca gctgacgtct gcatccacgc cagttattta tattgttaac 14700
aaaacagcga tttttgttgg aaatactgta agttattaat tttaattcga agatttctta 14760
atatttaaac tgggcccatg agagtttggt tcattttccg acaatagact gcaaaattga 14820
taacttttca tgaacacttt agccgatttt agctagtttt gtttattaaa atttggtaat 14880
tcaaaataaa aaccttacgc cactccactt ttgaatactt gtcaaataca ttttttcagt 14940
tccgaatccg atgcaacagt tacggagtgc ttccaataac atggtacaag aacggaggtc 15000
tcctccagtt cggctcgcga atcactgaag agaatgatga cactttggaa attgtggatg 15060
ctttaactgc tgacgccggt gtctacactt gcattgccgg ccaggatagt acaatgagcg 15120
agggagtcga ggttgtgatc aagagacttc ctggtcacag aactacatct cgtccaatgc 15180

tgacaccatc caagaacttc tccttgggaa cccacccgac accatctcca tctacagttt 15240
ctacaacacc cttccgaatc tatacgcttg gatctgctcc atctgatgct cgtgtaagcc 15300
gcccgacaag caattcctgt atggatgtgg gtaacgcgag cacgtgcatg ttgatcgtga 15360
agaacggttt gtgcgggaag aagcgatatg gaacattctg ctgtcacact tgcacccggg 15420
ttcataattt taaattttta gtttggattt tttgatttca aattttcatt aatcttttaa 15480
tgttttctcc ttcataatat ctccattgcg agatctcttt ttcccttctc ttcctatact 15540
ttccctcag acaattggct aattactcgt tcgttccagt aaataaatat gaatttat 15600
cttcttcta tactttggta tacataatca tggcatgaaa tacaagacaa aaaaaacaag 15660
aaaaaacaat ccacttgaaa tccattcagg tgtgaactaa catcttactc tattaacttc 15720
gtgccattac ttccacttat tttgcctatt cactaatgaa gtctctgaga attattttct 15780
gtctaactct gctgattgca agcttcccag ctgagcggag ccgccgaaaa cagaaatttg 15840
tacgccttcc tagtgggttc acgtttcctg cggatgcggc gagtaatttt caaagagatg 15900
cgtatattcc agcgacggta aattttcgct ttttgttaaa tgaatttcag gcttcaaatt 15960
attttctagg aaaaaattt aaagtaggct tgcgcatact catttccctg ccttacctgc 16020
caacaggcta gcttttggag agaaatcaaa agtttgggtg ctgtaaactt aagctttccg 16080
aagcgtccga aagtttttgg gaatccgcta tacactttta gattgataaa tatttgaatc 16140
aggtttat 16200
tgactactta aggcgtgtag gcactaggcc ggcaaagctc gcctacgggg 16200
agccttacia tcaagtatta ttcataagg tcttgatttg gttacagaat tccatctaaa 16260
attacttata caaaaacatg aaaaatttca gtttgccccg ccatctgaga agattcttca 16320
agctccacca cgctatttaa ctggagaaca caatccagct tatggtaggc ccaatttttt 16380
atctgatttt ctaaatttaa cttcaagctc acaataccga tgtgcaagga atgaactacg 16440
ctgagtacia gcaagcgatg gcccacaaac cacatccagt cgatgcttat tctccaccac 16500
ctcctgcacc aatgggtcca ccggttactg tagttgaacc acctgcaatg ccgtatgaaa 16560
tgactacgat tgcactgttt ggaccactta ctactccgc atcagtcggc ttgaagaagg 16620
gaaagtttgt gattttagtt aattgatctt tcaagtaatt ggatacaatt tccagcatcg 16680
gaggaattgc tcaaaacttg aacgacaggt acaccagctt aacaccagaa gctcaacgtg 16740

ctcagaaagg tcatacctat acggctctgg gcggtggaca attctatcaa agtttacttg 16800
gaggggtaag atgcaagggt agaacttaca aactcaattc attttacaga aaggaggccc 16860
cggaggattc tccccactct cgttctttct aaacggcggt ctaggaggta ctggtggtgg 16920
tggttaacaat ggattcttcg ttccggtgcc tgtagtcatt ccgcctccac cgccaccgcc 16980
accaggacca aactgtttca cgaaccgcgc gggattcctt tgctgtaacg tgacacttga 17040
gaaaactatg gaagacgcgt acctggccgc aaaagcagat ggtgcatcac tgtgcaatgt 17100
acagaaaatg gcaactgcag tgcaagcggg ggggtttatg gatttcattt tataatgtaa 17160
tgtgctcttc cctagaattg aataagctta caacttgaat tacgacttga attacaactt 17220
gaataagctt aaaatatcca ccaaatttca gcaagccgaa aaaaaattcg gaacaacttt 17280
cgaatcagtc gctgctcatt cggacttcgt cgcaaaaatt aattttgccg gtgacctgaa 17340
ctgtaaaata gaaatcgatg ggaaattcat actagcgtac gcaactccaa tcgccgagca 17400
agaggtgaac attgtcgatg ctagctcatt cttctcggga gctgctgata aggatttgga 17460
tggtgtcaat ggtaccaagc ccacctacat tgtctacggg ccatttaaatt aatggagggt 17520
ctagctttta agatttctgt atattaaagc tgaaatgtga attaatgttt tatttgccaa 17580
tcacaataaa gttggaaata tcatttgaat agttcgaaag ttttcaatcg gaatgggaga 17640
aaattcgaaa atttaggtgg aggtgaaaag ttgatgaagt aacacaatta actgtgctcg 17700
aatcctgaat agaaggagaa aagagcctat aaacagattt tcaatttaca catattacac 17760
aacaattcag gaagaagaca gtagttgcaa aagaaaatac gtagaaaaaa gagtgaagga 17820
ctggcgggat gtcagtttgg atgtacaaat agaactcctg aagcataaga aacagaagaa 17880
tcgaccgatg atcgaacctg aaatggattt attgttgatt gaaaaatatt aagcaattct 17940
gaatctctac cttgtttgat tgtgtgtaat gcaagaatct aaactcgtga gtgtgattgt 18000
tactgatccg gaaatgttcg gctgcttgca gcattatcaa tatcggatta cgcccacaaa 18060
tcgtgttctg ggtctttttg aggtagtcatt taaaagctgc cggattaagc gtctcaattg 18120
cgctcattcc ctgcttatcc atattggtta tctgctcata aatcggaata gaactatgac 18180
gatcgtacgg agaaaagctg aagcgttctc ccaatggca aaagtccgaa gagatcacia 18240
acaagtttct tggatcctcc atgtaatgag caaaaatatt tccatacgtt tgctgcctag 18300

-58-

atcctggttaa agatccaaca agtaccggaa caatggtgta acgttttgaa cccataacct 18360
ttgcaataaaa tgggagttgc atttcaatac tatgctctga ttcttcatct cggcgatcca 18420
tcaaatacgaa atgacgagtg gcacgaagct cctcgttaac tgcaaagggc aatgttgtaa 18480
aagatgtact aagagtgcaa tagattactt ttgtgatcaa cgatcaagtc gccgagtgga 18540
gttctgtact tgctgcatgt gggttatagca catccattta gagcaacaac gtgagatggg 18600
ccaagaatga agactctttc actgaaagtt attgagtaag ccctgttgcc aagtacaaat 18660
ttcaacaact cacactgctg atgaaacaac ttgtttgaaa gcatatgcag ctgtttctcc 18720
acaatacgaa tatcccgcat gtctgaaagt tatcagaaaa taaatattaa atgcatttag 18780
agtattacgg tgaaatcaac gctcgagccg ttccaatccg tggaccggcg ttgtcaagcc 18840
attttgtgag ttgccgatca agatctcgct gggtggcggt gtaccatgat ccggcatgtg 18900
aggcagatct cgtgtgctcg ccgaatccgt ttagtgacat tttaaattca gatgggtctga 18960
atattaaagt ttgataaat tggtgtatac gacttgatta atatgttttag tagggttttc 19020
aactactgtg tgtttcccaa atagtcaaca ttgaaaaatg gaaaagtttg aatttaaata 19080
ttcaaataat ttttaattaat taatattaaa attcacaata cagtgttaaca tcacacttaa 19140
ttcaagatgt tctaaaaata tgagccatcg ggctagctct acttcacgaa ttcgaatcaa 19200
gtccggggaa ctggctcgaa agaaaaataa tttttaattt ggtttatgtc cgaaatagaa 19260
atgggaatct gggttttcat tctgaataat ttccgagaaa cacttacaaa ataaaattca 19320
gatatcttgc aaaaggaagg ccaaatgtcc tgagaaatag agcacgagag ttttgaaata 19380
cctgcaacaa caggatttgc ttctattttg ttttttgaac tgaattttta actattatct 19440
attctgaaaa cattttttgt ccaaaaaaaaa tcaagaacaa tttagagcaa aatgtggcaa 19500
tccgaaaatg ttgatgcaac aaaaaagtgt ttttttttct attgaatttc agttttgaaa 19560
actgatttct ttccaaaaaa aaacgaagg aaaattttga gaaaaagtg aaaatccaaa 19620
aatgctgatt ttggtttttt tttcaaaaaa aaagcatttt gcaaagtgtg tgcttttttt 19680
cgaaagtttc agaaccttga gacaaaaaac caaaattgtg ttcccagtg aagcccgcca 19740
cgtggacatg gtcagacgaa tcttgttcgt gttcgcagcc aattttcatt tttgctgaac 19800
gcataattgt tcaaagaaga ttcggtctaa aaagacgaaa ttgaaataga ttgtggaatc 19860

ctttgaaatt ttcttttgac aaaagggtcac cgttattcaa aaattgagat ggtctcgtga 19920
ctaaaattaa acaatcaaga taatcatgat tgtgggcctg ttttaaaata cacttttcaa 19980
aaacgaaatg taggctccaa tccaaactgc gcatcaagac caagaatata aaatttttaa 20040
actcgggaga cgtagagaaa ctttgaatat taaacatcgc cgtcaagttt ccgtcagagc 20100
gcgcctgaaa ttttttagag gcttctttca aaaagctacc catacaaata atcataagaa 20160
aaacgtttta aaactttgca ttccacccaa aaatgtctga aattaccgt aaaaagaatg 20220
tgtgaaggga gtgatttgag ggttctgtca aacagtttga ctgtttcgcg ttgcagctgt 20280
ctcgacgtgg atggtattga agaggaccgc gctgatcttg tgctggctgt cgctgtcttg 20340
tcggaccgcc gcgagtagtc ttcagtctac caattacctg aaaatttgac actttttgtg 20400
atgtgaaact ggctgcctga agcaatgccataataataa taatgaagag 20460
ggatgaygat gcatgcaaaa agaataagaa gaaagacgct cttctacaac accagccgat 20520
agtatttaga agaaaaagaa gactaaaaag agagtattgg gtgatgggag aaagaacaca 20580
ataggggagg cagtgaata gaacgagaac aatggaatcg gcagacattt gacactagag 20640
gggccactgt ttcagtcttt ttgcacttg aatattggaa gagggccaag aaggggagtt 20700
ccaagaatgg aaaaagtgg aggtttgtag aaaatctgcc ttttttttt taaaatttcg 20760
tgttcactac tttatttcgt gttcactcgt ttatgtcttc cattataggc aggcaaagtt 20820
tcatgcctac atacctgcct catgcctatt tgactttcaa tataaaactt gatttttggc 20880
attcttcatt ttataacaat tgtaactaat aataagcttt gcaaagtttt ctgaaagaaa 20940
ttgtctaaat tttcctggta cactgaacat ttttcggtat aaaatctatg cgtatcaagc 21000
ctattttctaa gagccgtaag tattttcagc tgaaaatgta aaccacggag tcaatattta 21060
cttcgtatca tccatcttcc attccgtctt gtttacacct acggcaggta tttagacacg 21120
aatgattggt tttctcgttg cctaatactt tttccccga aatattccca tattccagtt 21180
ctgaacaatg cacttttcag cggtcatcgg gtccatccag ccctcattca gccctttcat 21240
ttatcttcgt ttctactttt agacgaaaat gcaaaaaaaa gagaaaaaga cactctcttt 21300
tgacgtcac attcgtcac attgctgtgg tagaaaaaca ctcaactcgt ggctgctggg 21360
aagggaaaac gagaaaatgt ttggtcacgc aatacgccta tatctttgat ttgactttga 21420

-60-

atcttttatac attttttcacg gggttcaaaa acaattatga agaaaattgt ttgattaaat 21480
tagaatgtag attctttata ttttcaatca aaaattaatt ttggaaaaat aactatccaa 21540
aaaacgaaaa aagtaataaa tgagtacttg aaagtgaaat ggggcaatta aacaagataa 21600
aaaagactaa aacgtgagac atctcacaac gggtcacggg caagaagtac acgagaaatc 21660
gaacgtgagt ggggaggcag agacactcag ctgactgcct ggctgacgc tcgctcacia 21720
aacgctctca ctctcttctt cgctttgccc gctctccgcc ccgggtcgtc agttcggtcg 21780
atccatgttt gtctattttt ataggtgaaa atttatgtaa gggaacggaa aatgtaaagt 21840
gatcgtggga aaatagaaaa acaattacat tgtaactttt ctggaccaag ttgtaccag 21900
atgcaatatg tatatttttc tcagaaaaata ctgtgttggg tttcgacagg atcgatttat 21960
caaaagcaaa cgagtgtgcg tctcaacgag cactaaagt cccaactaga gcatccttgt 22020
tgtggtagaa ctacatagaa atttttaatt ttgatttcaa tagcttttct cttgttttct 22080
caaaatttat tgaaaaactt atttactata aaacgaccaa cgacggatct ggaaactaca 22140
gtactcctta atgcaaaagg caacgaaaaa tcagccagtg acttattttt tgttctggat 22200
aaaaatcggg aatatttgca ttttgaattc gcaactgtatc gataaaciaa acaccgaaga 22260
tcacgcaaaa atgactattg taactaacag gtacgagaaa gggacgcttg ttctacaaaa 22320
ataattcaac aaattttccc caaaaaaatg tgaagtccgc aattctcgta gttttacgta 22380
aatcaaaccg agcatgacac tctgacacca cgtgcgcctg aagatgtgcc tgcctaccat 22440
ggatgcttta catttgctag ttccatgaca cccatcctt tcagcttcca agatgaagga 22500
gttcggagaa aattcgaaaa aatattgaga aaaataacc aaacattct gaaacattgc 22560
ggaaaaaagt tagaaattat gtcgaatata tctgaaccaa tcaacaattt caaataaaat 22620
acaaaaaaaa attggaagac cttaaatagt ctccgcccat attttggtt caaatgaccg 22680
tacttcggaa tatggccgat ggccgtggca agacctcaa tcgtagtttt gagcggtcag 22740
taagtgaaga ttaaaatagg aacagtaccg taagatcagc ccagggtcgg atgtgggata 22800
gaggaactga aaataatcga agaagcatga taactaagcc acgtggccac gtctgttttt 22860
gcgatgttaa tagatcgcca ctctgtccat tgctgttttg tttgtactaa gtctccttag 22920
caattctctc gaaggcgggc cattgctatt agtaaaataa gctaccaatt ttacctttca 22980

-61-

atacattcat tcaactgatgg ttttcctatc aggtgatcat ttttttggtc ttctcaatta 23040
cactatctaa aaatgatgaa gtttttgctt cgcggtatt tgggtgaagt gatgatatat 23100
ccattgattg tcgtctccac ttgtgctctt tttacgtctt acaacttctt ttttaagtgtt 23160
ttgcgtattc actgtttcat ttattttttg cagaaaatga gcctgttcag caaatttttc 23220
ggaggcatga tgcaagaagc tccgattact ccacaagaat ctattcaaaa acttcgggaa 23280
acagaagata ttcttgagaa gaaacaagaa ttcttgagaa aaaaaattga cgacgtaagt 23340
tggaagatca gttttggtcg aattaatcac attaaaaagt gctgaaatcg aaatttttaa 23400
actctcgagt ctcaagtgc tgtgacgtaa ttaaaacatt gctcagcatt tacattgttt 23460
actgacgtct tttcgaagtt tagtcgagca aatccaaaaa agagcaataa aaatttctgc 23520
tacgatacgt ttgggaaatt ggaatcatag ttttttaaac tccatttttc aaaaaataca 23580
ttattagaaa atcagtaagt ttcggaatt atttgagaaa cgtttcagga aagcaaatg 23640
ccgtgaagta tggaacaaaa aacaagcgga tggctctcca gtgtttgagt aggaagaaag 23700
ctttcgagaa gcagttgatc catattgacg gagttttggc tactctcgaa catcaggttg 23760
gtatataaaa atattagaga aataaattga ataacacggt ttttcttcca gagagaaacc 23820
ctcgaaaatg cttcaacgaa tgctgaagtt ctcacggtta tgaaacttgc tagcgatgcg 23880
ttgaaagcgg ttcataataa catggatagc gaccaagttc gtgatatgat ggataacata 23940
gatgaacaac gagaagtggc gaaggaaatc gcggatgcta tttcaaacc cggctttaac 24000
aacgcaattg acgaggccga tttgctgcgc gagttggtgg atcttgaaca ggttcgtcta 24060
taccaccaac atcgtgtaat tattagaaaa tataccagga agcacttgac aaagatttgc 24120
ttgatgcgag agtccccca gtcacgcttc cggatactcc caatattgca cttccagcct 24180
ccagaccgag agctaaagaa gctgacaagg atctagaaga cctcgaaagt tgggcaaact 24240
aacttctcta agtcactttc atatttaatt ttcggctatt tttgtttcat ttgcatcccc 24300
ttcatcaatc ctaccattct ccggagattc tcctaaatca actttctaata tacgacaaat 24360
tcaaatagtt gaatgatttc tgttttagcca tttcattcga aacaaatttc cccaaggcta 24420
cgatcaacac tcatcaaat tgtaacatat tatcgagctt tttggaaatt tgtcatttta 24480
tacatcttgg tccctttctc caaatcttc caagcatgca ttaaagttcc aacttttatt 24540

-62-

aaaaattcat tctggcaaac atgttatttg taccggttga aaacgaaaac caagcgagaa 24600
atagttacat ctcagatctc cctaacgatg gctcaacccc tttgacgctc atttactaat 24660
gtttatactt ttgctcattt actaatgaat ggctcattta ctaacttgct gagatttttt 24720
aatttactac tgctaattgt aagatatata tcatttatca tttactatat ataaagcgct 24780
tattccgttt gtccatagtt tgtagtctat gtagtctttg tagtctgtga cgttttggct 24840
tctggaagga tagtgagttg ggcttagtgt agggatatag ggggtactgt agtggtagaa 24900
tagtggtacg gtaggagtag tgtatgatta cggtagtttc agaaaaatta gttttcagct 24960
ccagaagtgc ggggccgcgc cggaggtgcg gtccacggct ggttttacat aaggtagttc 25020
caaaaaatgt cctacttcca attactcata actcagttag cgcgctatag ctatagcggt 25080
tgagttttaa aaaattgtgg ccaactgaaa tgctgtttgt cagagatgcg agctctaaaa 25140
gatgatcgaa atattctatt tctgcggatc tagaatattt cgatcatctt ttggagctga 25200
catctccgca atcgctaaag ataactaaaa ggtaccaatt aacaaaatgt gttttacaat 25260
attgccaaaca acattttagg tttctttcgc tgattgtttc cttttggttt tggatgatgg 25320
cccggagtgg tttttttcgc tggttctact attttttgga tcggcaggct ctgaacaatt 25380
ggttgtacaa tcttcttcaa cttcatcaaa ttatccagag ttatgttgct gcttctgctg 25440
tccaacatat tcatgcattt gacggaactc ttcaactttc tgcattgtca ctggattctt 25500
ctttttcgat tttattttat gaaaacttta ctatcataaa caatagtatt tatcatgtta 25560
caaatcagtt tggaatgatc tccttcattc aaaattctta atgatcagtc gattcactct 25620
tagagccacg aaaaatgtgg gacaattggt tgagaagtga aaaatagtta ttaatgttgc 25680
aattagtgtg acatataagt aatacatgaa aatacatctt aaaaatacag ttactactag 25740
gtattattgc ttaaaattgt gttccaatct gccagtacta tgagcgtaat tcgttgatcc 25800
aatcttcgaa tagccgtgag cacaggcttc gccggcactg cacacaaact tcacgattgc 25860
acgatttgca gaggtagagg acgaacgact ttctgtaat tggcgaaata ttgttttaag 25920
ataaagttag taggaacgat cgtactgttt ttagaacgag actgtctagc tgggtggccgc 25980
atcgagcatt gatggcatcc aagacctga acttcttcgc tgaatgatat acgatgcttg 26040
aatatggatc cactgaaaat tgagggtata gtagattatt gggagctatt atgatttcac 26100

ccatgaagaa ctgcgtcagt aactcgtttc agattctcgc tatccttttc accgcttttt 26160
cgttgtaatt ctatgagaaa acggtagaat ttggtgacat ttgtcgagtt aaacaattcc 26220
acgaggcaga caaacatctg aaatttgcgt tttttccaca aatgcataaa ctttcaataa 26280
aacaaaccgc ttctagggca acatcagcta aactgtgac atgctcgtat tcggcgttta 26340
gcgagaagca taaatggtag aataaatgaa agatatcggg aggttcgcgg gaatccggat 26400
tgtagtcttt gagataatca acgcaatttt gtttcagatt cgtcatcagg tatttgcgc 26460
atagcctgag aactgtgcac acgttttgtt ctgaaaataa atttggcatt cattgaaact 26520
acatcgatca tgaactacca tcaataacat ccggatataa accaagagaa ttgggagaaa 26580
tgacagtgat caacttgaga atatcttccg gtgactcatc aaggatattc agctgcttta 26640
tggcgccttc aaggaaaaac ttgttctcca tcaagatgcg gaaataatcc gaatttcttg 26700
caaagatgc tggatccaca aagtactttt gattaccaac aataataggc cagtttcgaa 26760
gcttgcttgt cgactcaaaa tcgacctgaa agaaaaatcg aaaaattcca atttaaaaaa 26820
cgtttgttta cgtaatcgga tccttctagg aagggttcat gacttggtgt cggctgcatt 26880
agaatgacgt ttacggggaa atcattattt attccgaaac gtgcttgggc ttgttctgtt 26940
tgctgaaatt ttgaaagggt ctccgaatat taagcgaaaa aaacttacat taataatata 27000
aggtctcata gcgccgagta gctaaacaat taatatttga ttacaagttt ggaaagatct 27060
ttctgagctc gatcaggaag aaaaacttct tgaaacttta gaagatgaaa tgtgtgctac 27120
cgtataaact ttaaagggtgc atgaataaat ttctcctttt ggtcctgcga cgattaaact 27180
ttttaatcaa ttctctgggc tagtttttat tcaataacta gaaatggtgt ttatttttgt 27240
tcctacttta aatcatatgt tattttcttt ttctttgtg tcttacaggc ttttttagct 27300
gaagaaatag caattttccg ataaaatttg ttgctctatg ttaaaggcgc atgcatttat 27360
ttgagagacg ggtctcgcaa cgtgctcact cctcggcccg atttgttctt cgtttgcgcg 27420
gttttcaggc ctttaaaaga tagttccgct gtttttttct caatttctgc tgaaataagg 27480
tttaattaaa ttatttttca aaatcttggg aaacatttaa actcatatat tcagaatttt 27540
cattcctctt tcacccagaa aaccgaattt caatattaag attaagaaca catctagaac 27600
atgcaaaaaa cacaattgct atctctctac tttcatttta aggctgattt tttgaagaaa 27660

aatcatgaaa tacgtccatt attgttgat cccttggttg catccaaagt tgactcgatt 27720
gatctcttaa atgtggtatt ccgttcgaaa ttcgattgat ttttagaagt taacacattc 27780
ggaatgatga taattcgtat caaaccaaaa ttgtcttctt ttcgcctttt ttgtgcagtg 27840
tcagcattaa aaaaaacgag aatattgaaa gttacgtggc gtttgcatct ctcaccacga 27900
tgacatcacg aaatgcagac gacaaagacc ggtgaaaaat agtgcgctga atggtgaaaa 27960
cttgcggaaga taacgtgtta cgggttgaga gagaaaacat tccgcgagac aatgcttttg 28020
gtgagaggcg cagatggttc agagaacact agagaaaacc gcgcctctgt ccgctcacag 28080
ccagcccat caagcctctt cgggcatcga cgcatagaca cacatcattt tgccccaatt 28140
tcctttcatt ccgtcaagta tttcgcaact aatcgttatt gtcattaca atacacattt 28200
tacagaagtt cctcttcttc tacttggtcc gaccgcatca gataactggg agatccagtt 28260
gtgcatgttc ttgtgccac aaaaactcgc gccatttac aattttatga tcgacaaccc 28320
tcaagaaggt aagcatttaa acgtgttggc cgtgcgtctc aaaaaattgt taaaaaacct 28380
ggcgacacgc gttttccac aatttcattc cctagggcat tttgtatttg aagtaattct 28440
attacgcgta cgcaatcgga cgaatcctgc aggtttgttg gtagtcaatt ttatcaagtc 28500
gactgcctct tatgctttct gaaaaaagag aatgacagtt ttcgctaagt agtactaaag 28560
cgatctttta tctttggcaa aaccttgata taagcattat cacagcatat catgcagatt 28620
gatttagagt taagcatgaa atgtgcaagg ctaaaataaa ttacaaaata agtccatagt 28680
ccattttagt aacagtatac atcagctgat agaatacat gcgtaatgac aggtctaaaa 28740
cattatcaaa caaaagacat tacaaaaaca agaaaaatac aatataatag aacgactatt 28800
tgaaatgagc gtagttaaat tcggaacttc aatagattat catacgcgct tttaaaaaaa 28860
tgtgtgttcc cttttctccg cgtttgcccg ctacaaaccg gtgagtcgga aggcataatc 28920
gggttgaaaa aaaagtatca aacactgatg gtgtcttttt tagggaggtt gtccagaaag 28980
agaaagaaac tgaagatttg cgaatcgata gcgtcgatcat ctctcgacgc cagtgaagtc 29040
aagatcggtt acaatagtgt atgcgattcc caaaatccac atatcaaccg gactcgtgat 29100
atttatcatt tgtaagtact aacaagagat gtgaacgtat ttacactcaa cattagcaaa 29160
ttccagaaga agatctaaac aaaaactatc gaaatggctc tcaacgtgaa ccgcgctgtc 29220

gctgatccat tctaccgcta caagatgccc aagctgtcag caaaagtcga aggcaaagga 29280
aacggaatca aaacgggtcat ttccaacatg tctgagatcg cgaaagctct cgagcgtccg 29340
ccgatgtgta tgtttatcgc cagttggctc gccattggac acaaaaataa ccattgtttt 29400
tcagacccca cgaagtactt tggctgtgag ctcggggctc aaacgaactt cgatgccaaag 29460
aacgagcgtt acattgtcaa cggcgagcat gatgccaaaca agctccagga tatttttagat 29520
ggtttcatta aaaagtttgt gctttgcaaa tcatgtgaaa acccggaac tcagttggta 29580
cgagatcatt gaattaataa tctgtctaatt tttattattt cagtttgtcc gtaaaaataa 29640
catcaagagc aagtgcaagg catgtggatg ttcgttcgac attgatctca aacataagct 29700
gtctacattc atcatgaaga atcctccaaa gattgatgtc gatttttgta agtatcgttt 29760
actaacattt ttcgattgaa cttatgcaaa attctgccaa aaattctatt tgcattttta 29820
atcctttcaa ttcgattttc cgtgtgcttc cagtgcatac aaacatgcta atttttggtt 29880
tcagccaaa gccgaacaaa agaattgaaa gaagacatcg ggtgctgacg ccgccgccgc 29940
cgtggctgcc gacataatcc acaacagcga caaaggcagt tcgaatgatg acgacgacga 30000
cgattgggaa cctgaaccag tcgagccgaa tggcatgctg tcggcgggaa tgggcaagct 30060
cgtgctggac aaggatcttg agaagagcga agaacagcgt ctcgacatgc ttcacacatt 30120
cttcttgaaa gccaaaggaag aaggtaagaa ttctgagcat tgataaaaag tattctcggt 30180
atttcagata gaatttctga tgccaaggga caaactgctc tacgtgacga agctgagaga 30240
cttgagctga agcaaaaagc atctctcctt ctcgcgaacg ttttcttga tgagaaagta 30300
atcactgaca aacaaatcag caaacaccgc aatcttctgc ttcgcttcac gttgaatgac 30360
aagaaagctc aaagatacct gttgggagga gttgagcaag taattcacia acatgaagcg 30420
gaacttctgt ctaaatacag tcacatcatt aagtcattgt atgatgaaga tgtctgcgaa 30480
gaggattcgc ttatttcatg gggagagaag gttagtagca aatggagctt tgtttcgaat 30540
taaagtttat atttacagcc gtcgagtaag tatgtctcca aatcttttgc caagaagatt 30600
attgagaact ctcaaccagt gctcaactgg ctgaaagaag cggaagaaga aaccgaagaa 30660
gagtccgacg atgagattgc ggtaagaaat atcagatttg tttttttttt ttcaatgggt 30720
ggttttcagt tcggaggaga cgtcaaggag agtgaattcc ttcgtcaaca gaaggagaag 30780

-66-

gctgctagag aagctcagca aaaatcagcc aaggctacaa acggcaatgc tgctgctgca 30840
tccggagcaa atgatgaaga ggacttgat attgatgaca ttttaattgta cagatgcttt 30900
tttaaaattt acctgggcta cttatgtttt ttgtgtattt cttcccatat tcgaaccaat 30960
tcaactaatt tcgaagaagc ctcagttttt ttttgctttc tccccctttc aatagtaagc 31020
atcatttcat ttctgtcttc tgtcttttct gttcctacgc tgttttcctt tcaccaaadc 31080
caattcattt attcgtaaag tcattactat ttgttggtta tcgtaaacat ttgggaatat 31140
tcttggtcaa ttcagtctta tattacaaaa acacaatgtt caaaaaaaaa gaatcacttc 31200
agatgggaac ccgtcgaatt cggcgggtccg atggagaata cacattgttt tttcggaaag 31260
ttagcccat ttc aaatcat caccagctg atttcatttg cgacgaagcg ataaattgta 31320
aagagccgaa aaccttttgc tgctcggaac agtactatat gtacaataag gcttcactat 31380
tgatggattc aaaactgatg gcagcgattc tagaagcaac ttgtccgaaa acaatgaaga 31440
caatgtgttc taaatggtcg ttgaaaggat ggaaggattc ggtgtaagtt ttaaactcagt 31500
ttgataataa aatatgtttt tcttttacag atgggatgag aacaaagaag aagtgatgag 31560
aataggatgc ttggcaaat tccgtgcttc tcgccatctt cgttatgctc tttttctcac 31620
aactggtagc aaactagtcg aatgtagtcc gttcgataaa atatggggaa tcgggttagtt 31680
tccaacggat cgtcttattc ttccatcgcc catcacaatg caatcagaat cttcaaactg 31740
gaaatgtttt gaaatcattg aaatcatctt tgagctgata tgggtgacgga agaaaaggac 31800
gtctgaaaat ggctgaatta ttataggaaa agatatgcaa gccgcacaat gggctccatt 31860
gagctctggc aagaatctgc tgggaaagat tttggatgga atccgagagg aattgtggga 31920
tgattcaaat tacaagttag ctctggaatc agaaaattat tattatataa aattactatt 31980
tcagagatga acgagaagaa gtggagaaac gaatggaaac tgaaagagat tatctattca 32040
ctgctataga gcacatggac ttgatgtaca aagaaagagc aacaaaaaga gtattgtaag 32100
aatcagaaaa tctgcgtaat tgtcgacaga aataacgtat tccagattgt tcgaggaaga 32160
attgttaact gatgatagat cctacatcac accagatatt cagaggctcc tttccgactg 32220
ggcttggccg ccgatcctcg tgaaaaacga gcctattcaa ccatcgctgc ctgtaataat 32280
cgatttcctt aggtacttgc cttgatcttt aatttatcag aattaacttt caaattccag 32340

atcatctcca cttcgagcag ctgaaatata acgtaggaag agcacatctc attcgacaag 32400
cttgagtaaa aggcgggtacc tcaggagcag atcgagaagt ctgtccaaaa gcccggtctg 32460
aagacgctcc agacatcttt cccgaagtgg atcccgtaca ccagctcaac ggcattccag 32520
aagatccgaa agtacatctc gaagacgttc cggacggcac tctagaagtc gatctagaag 32580
cccaccacga aaacgtccgg tacgccgata aagaagcaga tccaggagca ggacaccaaa 32640
ccgaaattgg acaagagcac ggagcagaac aagaagtcag gctaaaagta gcagcacttt 32700
aacctggcca ctgagcccat cgagaagcag aagtaacagt aatgaaagga atttgaaaga 32760
gaagaaagac cggaaaaaga aaaaatctga gaagaaacgg aagcatcatt ctaaattccag 32820
aaaacaccgt tctaaaagat ccgaattccag agaagaacgt cacagaagac ggaaggagaa 32880
gaaaagagag aaaaagaaga aacgacgtcg gagaagttcc actacttcag attaaacttt 32940
atTTTTjaaa actagtcata actttaaaag tcataacttt tttaaaagtc ataacttg 33000
tttaatatca aatgtctttt caaatattct ctatttattt attcttcgta attaaactga 33060
gattaagtac tgggtatata attaataaaa ttacgatact ttgccgaata aatcagttat 33120
aattacaatc tgtctgctgg tgaaaattgt acatgctatt ttcttggtcc tcattctttt 33180
ttcattctct gtaaggTTTT gtctgttttt tggaaaattc tgagagtagc cggaaaaaaaa 33240
aaaaaaaaaa actaaatacc tacagtaatg ccagaggcat atgctcaata attatcaaaa 33300
attagttttc cgcggcgaga cccatcccca caaaagtatg actcccttga aagtcgtaaa 33360
tgacaatttc ttgaaacaag aacatttgta tattaacgaa acacaaaatt ccgagaatgc 33420
gtattgagca gcatatttgc cgagccaaat atctcgtagc gaaaactaca ttaattctta 33480
aaaacactac tgtagcgctt gtgtcgattt acgggctctt tgaattatca ttgatttata 33540
gatagaatat ttaaaaaata aattcatttc gaaattagag ccataaatc gacacaaaca 33600
ctacagtagc catttaaaga attactgtag ttttcgctat gagatatttt gcgcatcaaa 33660
tatgttgccg aatacgcatc ctacagaattg tgtcttccgt aataatagac agtggcttcg 33720
ctaaaaacta agaacaaagt aaattaaagt ttttttctgt tcacttcaaa ttttacacga 33780
tcttgaagca aagttcaaaa gagcatgaat caattggaaa gtgttcaatg caccctacag 33840
atatgatttc ggggcagtgt aaactacagg gcacagacat aaaaatttaa attgttgaag 33900

-68-

actaaaatat aaacatatga attcaagggt cataataaat gtatTTTTTT aaataatatt 33960
tattaaatgt atgcatacaa ttaaatacaa cataattatc aaatacaaat attataattg 34020
caacctgtcg gacaacaact ttgctgaggt gtcgtgtgac agtcagaatc cttgtcacac 34080
cagctgaccg gctcagagac gatacatcg aagttgagat gagtgactgg tggacattgc 34140
cgacgcgttg gagcacaaca ctcacgatat cgagtcatgt cgatgcagcg ctgaaactca 34200
ggaaactatg tggaatttag gtggatcacc caaccagctg cccttcaccg cactgataat 34260
ttggagtgc gtacatgtaa tgggcagagc attgctgcat ttgcatcaca atcaatgaat 34320
ttgcaaaggg cctggagatt ggcttggtg aaagagttga tattatttct attgatataa 34380
taccctaaat ttacgaaaat tatgctaaat taggatttta gttataatcc tcgtcacatc 34440
tgatctctga aaacttaaaa atatcctttt tggtagtggt gcaccaaatt cgtgctgtaa 34500
cagagaccaa aaacactact ttttcgacat ttcctctcct tgcagcgaaa aataaaattt 34560
tttgaaaatc tgtgttttct catacccgga aaaaaccaac aaaaacggcc ttgttccaaa 34620
ggcggtgagt atttctattt tatgaaagt gccgagattt ctctttttct acgccaagta 34680
gttaattctt cgcggaaga cccatcaatt ttctaacctc taatctcttt ttcaacatga 34740
atatccacgt catcatagaa tttgcactcg ggcttataga tttggagcct ttgaaagtat 34800
atgcaccagt ctatatgggt gttgggaaac gaataggcag tagttttttg gaccaattgt 34860
agaatagaca gtagtaatag ggaagaatat aagaatttca taattcagat ttcaataaaa 34920
aataaattta attgagaaaa aaaacgggtg atattctttt gttaagcag acaagtatgc 34980
ggaagtgaat cttgagcacc tcgtaaatca cgggaggcgt acttgtagcag aagagagata 35040
agggattaag aggcgcaagc tttgccactt tgaagttaaa aaataaagaa agagacatgc 35100
aaattggtgg acaaatagcg gaagggttagc gggaggtggg aggggggaca ggtgcatgta 35160
acacaatgga tttacaata ggaatattga aaatacgcat atgggaaatc ggaacagata 35220
tgaaggtgtc aatatttgag gtcaactgtc tggtttttcc ccgatttttg aattttttga 35280
aaaaaagtgc ataattcaca gattgaaatt ggaaattggt cgagaaaaga ataaggagtg 35340
ttatgaattg atggtggcaa caaaacacaa attctacatt tgtacaaaaa tgcccactaa 35400
aatgggcata ttcgcacaca ttccacacaa attgcataca tattccacaa tggggaatat 35460

tttgaatatt tagattaata aagatgaaat aattgagttt tatttgtaat taaaatattt 35520
ttctgtttat cattaattga aaatgttgaa ttacttttta atagacgaat catcaaagaa 35580
cttgatccct gcattatcag gcaatcctac ataacctttc aacgttgtcg ttttaccaat 35640
tgcaacattt ctcgctactg gaacacgcat actggaatac gatgacgatt ccaattggaa 35700
gaatatattg gtgcccgggt ggaagttaac aattgaattg ttgttaagcg ataaaggata 35760
cacattgata acatccaaaa gttcagttat gtatatccat ccgtataaat cttgcgatct 35820
tccattcacc aaaagctggt cgccatcttg tataggaatg aatggagtta aggatcccgt 35880
aacagtacga gttgtgagcg tagttccact gaaaattact aaatatttag ttcaaagggt 35940
ttctgttact actttttggt tgcaacaact ctgagaaatt ttagttttca ccaaaatttt 36000
tcgattttgt acagaattgc acaatatatt ttggaatagc aagaaattgt tcagtgaatg 36060
tcaaactga caaaaaaaaa tttttttaaa aggtgcctat caatttttaa aaatgttcta 36120
atattttggt ggaaagtttc aataatttca ctacatttac tatttctttt ttaggcctat 36180
tttgggtatt caaaatatta accacacgac cttcaatata ggaaaactgt caaatttttt 36240
ttaaattatg aacaattaac tcaactttaca tttgtcctc cattccttgt agttaatata 36300
agacttccca acgcttcttg agaactattc gaaataatat aaatcttcga atttcttcct 36360
actatatatc ctagtgtgtt gctcgttgca acgtctagag tatccaatat aaaccacta 36420
gaagctgata taaagaaaaa taatagaaat atatttttca ttttttcaa atgactaaat 36480
gaccaacttc aagacatttt atatgcttaa aatcacgtca cagaactata atcatgttga 36540
tttttgatag aaaatgataa gaaatgcgac caaatgtgt attttctccg tttgtcctct 36600
gaatgagtca aattcacgta aaacttgga tttgtcacag tgtgtcagac acaaggcaca 36660
tatgtattta ccggactttt caagacttta ttattattga gatcaaacca gattacagaa 36720
gacgggagaa aggtaccaac aaatatcaga atattgcaaa aaaaaattaa aaatttcaaa 36780
acgcaaactt caaactagga gagctaattc aaactttgaa atcatgttcc ataaccggta 36840
gcatttgttc ggtgacttgt ttgacagccc attgaaggaa gagaagtact cccgacaggc 36900
tgaaacatat gaaatagtcc aggccttcca ttagagaatg tgatgtttga aggaagaaca 36960
atgggacgta gagtactccg aatagagcag taagtccatt gatgagctga aacagtaa 37020

aatcgaaaag ttagtaaata tggtcaagga atggaagtaa accggaatta tccgagtatg 37080
ggcgttttat agttttttct ctttttttga cttcgttttt catcctatta aaatatcatc 37140
ggtttttttcg agttccagaa aaaatattta aaaaatcatc cgaaatccga acacaaaatc 37200
cgaaggctac tccaaggtaa gttaacccta ctcggaat ctctcgctct ggagcgcgga 37260
cgggggcgga ctagatcacg gggtcgcgct ccagtcaccc tttttttcgc gcttcttacg 37320
cgccacgtcc gcgcttcagg aggagcgatt tgcggagtac cttttatgca ttcagactgg 37380
tacttaaaaa ttaatcgatt tttttaaaaa gtgtcataaa ctttttctac gtctttttct 37440
gacacaatgt tgaaccgtac tagattgttg taaacacggt cttcaaattt gattttcgcg 37500
aaaaaatttg aataattttt ttctaacttt tttcttttta aaatcttacc acacttagca 37560
aataaccatg aagcacaact tcataagtgg atcctatttt tcgtttgaag aggcaaaata 37620
ctgaaaacaa aagagctgat atggagcaag acacgtggat ccagaagagt atacgcacaa 37680
tcacactatc cccttcgatt ttgacgcggt acagaattct ggaatttttt tttgaacttt 37740
aatggattgc gattcaaaag aaaacgtagc ttaatctcca gttaaagctg attttcattg 37800
caaaatgtat ttagaaaaaa ctcacgctaa taaggcgag agtattgtct gtagaaccgc 37860
catgattact gtagatgcat agagtgagaa tgagcacata taagcgctcg gctgtttttg 37920
aacgacaatc gaattggccg ccatcatctc attcttcgac ctcccgtttt atttctgaaa 37980
atatatgaca ctttttaaat gaattgacag aaatctgatg ctaactacat ttttaacttg 38040
aggagtgggt caaatgattc ataaagggaa tacaatttct gaatgatcaa agaagaaaga 38100
aaaaaaatat tggatgaatgt ataatttttt aggggtaaag taaataaata aacacaaggc 38160
cgaagattag caagagtttg gggataaccc ccgtgaagaa aaatatgaaa aaaaatgggt 38220
tgaaagaatt aaaaaaatcc tttcaaattt gagattcaaa tttgttcat ctgttctgtt 38280
cgaacattga gcagaagaag cttttaccaa taaatccaaa atttgttaag agaatatagt 38340
ttaaggatat caccagttc aaaatagtag ttcaaaaact cgagtcttaa ttttttcagt 38400
attcgaattt ttacagtaca ttgatcggtt cgttatttga tcgctttttg ataaaacaaa 38460
aaatagataa tgaagctgcc aagtttaaaa aaatcggggc taaggctaag ggagcataca 38520
cggatatatca ctacctggat attagtttta gacttcatca gatatttagt cagaaaagta 38580

cgtaagaag tcggatacga aatgtataaa tttcttaaaa cttaaaactt cgagatatcc 38640
agactgtggc tctcaagctt cagtgtcttg agaaatagtt taatagtcag aatatgtttt 38700
aaatttctta atttttctga agaagtcgta aaagtataaa tgttgctaga tcaaactctc 38760
tagaaaacct tcaccacttg agaatactcc agtctcaaat tttccctcga cgcggaagtg 38820
tagaagggcg cgagattcag aagtaggtga aaattagacg gaaaactctc tcaaaattga 38880
aatcaatgaa taggacaact gagacaatgt gcagggtgat gtgtatgcac atggcaccca 38940
cgtacacgca tacatcttat gttagagaag tacgtgtgct ccgctcatca tgtcttctcc 39000
ttctctaca tctacatttt ttgctccgtg agccacgccg ggaaaaacga cgacgacgac 39060
ggcgacgggg gacgactact cgactctaatt tggccctaaa cgcaagtaaa tttttaggca 39120
atgtatgttt gcgagagttg agagccccac cgccacgagg agaagtgggg gaagattccg 39180
aagagattcc cctcctcct tctgatcacc tcgtctttcc tttttgttc catttccgtg 39240
aaaaagctgt ggaagggagg agaagaactt accggctaaa tggaaaaaaa ggaactctaa 39300
cttattctga ctctacggaa ataggaagcc tacttgtcaa ttagaccgcc ctgcacaga 39360
tttctttttt ttgtagata caaatataaa aactaactgc gtgtgatgca gcagatatct 39420
tgaattggaa agtgtcagtg ctgagggga atagccaatc attgacagaa atttgactac 39480
ttcagaagga atcaactaga acatttgacg cctgaaacct aacaagaaaa atctataatt 39540
tggagatccc tagattgatg ccaactttat taaaaactaa gtatacttat atatatacga 39600
tttttttaaa aataaacctg attgtctgaa tttctacaag attgcgacca aattttccgt 39660
atttccaaaa tctaattatta ggggtttcta ctaaaattca acgagaactc ttaacattat 39720
ggttatttta acacatggtt caccgccggc tcaaacttca ttcttagtcc tctgattttt 39780
ggtaaactga cgctacgct tcaacaatta gtttgtgcag aaaataagta aaaagagttg 39840
tgctccatct tgcacacata cacatcgct gtaatgaaga ggttcggagt cagatgacta 39900
ggcgtagaaa tgtgcgaaat tcacggataa cagagatttt tgatgtttca tcagacttac 39960
acgttttgga agtatgaatt ggggtctagac aacggagtgg cagatgttcg gaaaattttg 40020
cagaaaagag aacctaagag cgttgatggt ttggtgacta acgaacttaa aagaaaattg 40080
gtcattgaaa attttaaaat tttaaatttt gcttgagtt catctttctc tattaacaaa 40140

-72-

aattatTTTTg tagctTTTTct caatttcagg caattaaaac atttcaattt attcttctat 40200
tatggaagtt tatctctaatt tgaaactctc caattttgat caaagaacaa acgttctcgt 40260
tgtttgaaaa aaaaaacagt tcttttttga aactcgcgcg caaattatta accaatcatc 40320
ctcgtttgcg cgcaaaattg tagaaaaaat catttaaatt tatcaaaaat agtttaccat 40380
tctgatgagt ttttcatata caaaaatgcc ctggcaattg ttgttttctc tgaaatagca 40440
cataataatt gaactctacc cacataaagt tcgttctgaa aaacacctta caattattgt 40500
gattgagagc caccccaaga gggattagaa aaacggatgt aatctgtata ccttcgagat 40560
tcgtttatTTt ccttgtataa ccaatagcag gaaaattaca gcttttttcta agtaagcggT 40620
gaaactagag agattctata gaatatgggc gttaataatt gtatgttaaa gttttagaat 40680
aacacaagtc cagagtaagg gcaagaaaag taatgagcaa cggaaaccag catgcaagac 40740
accogaattc cggttctctt ctgaaactaa aagttgcgtg tactaaacct taaaccagca 40800
gctggctagt ctcaagaaat aatagaaaaa aggaaggaat gaagatatgg gaataataca 40860
aattgaaaaat gttgtgtgag ctccgaataa ttttcaatat caaaaattta tgaattgtgt 40920
ggacggctgt gtgtgcgtgt gcgtatgcgt cggcaagaaa aagaagcgac cgaataagaa 40980
aatggttgat tcagtgaaca aaaaaagaga gaaagatatc caaacaaaat tattcaaaac 41040
tattatcaat cggtaggtat tgctctagag cacacctttc tggacactca gcagacatgc 41100
gtagagaggg attatgtggt acatatagtg gatggaggaa cagatattta taaatactta 41160
tggaagagag gatgaagata ggatgaggta gatgaattga gaagatttta aaatgataat 41220
ggatattgaa tttgaataag gagattctaa attatccgaa gaacacaaac tatatcaaga 41280
ctacaaaata atctagacga gtcccagttt tgcaaggtaa ggattaatct taaaaggatc 41340
ttttaaatat ttatttcaat gctcctataa attttaaaaa gtaggtgcat tctaatatgt 41400
acagtgatta ggagatatgt gacgttacgt gaggtctcga taaagtacgg tattcgagct 41460
aaatttcaaa cattgtcaag gtagattcgg tacacagcca ccataaatgt tccactaaaa 41520
atgtgttgTc cttctccttt ggaacacaaa tctagctgct gaactttttc acttcactac 41580
atgtcaatgg gattgatatg catctaggac atttttttgg ttatcaatag tccgcatagc 41640
ttgcgtaacc aatacaaccg attgtccaaa aaaatttgaa cactacaaaa cgtatttatt 41700

-73-

attcggatac ccgttgcatt tcaatacaca agttgatact tgctgcccct cggggctctc 41760
agacactcat tgactgaaaa cagacgattg ctcgtcgtcg tagtctgaag gctcggagag 41820
ctgaggaaga tatgaggaca taatgaattg atgtgtgaga atgagaaaat gaaaaaggaa 41880
aatgagaaa aaaaagatga tgaagaatgt acaaataaat aatcaagtag caatgacgag 41940
aaaagaacca ggtccttttg gcaggcaatt ttcgaaattt tcagatcaaa tttgtcgcca 42000
ttgcttcttg attaataatg gatgacgctt tgacaatggt gctcaatata agtgcaaaca 42060
gattggtttg ggatggcgta tagaaataga gccggtgaga cgatgtgatg aagtcttgag 42120
agacgagatg tgatcgaggc gtttgtagtc gaggcaaacc gaggccgcat atggggttcc 42180
gataggcaat cggagaccag tgtccatctg aaagagataa aagttattcg agttgtgaat 42240
gttgcaagga aaattaaagg tacagtagag acaatcgaga cttttttcgg gaggacgcca 42300
tctaaaaact gtggaagcac gtggcttttg tagcttgatg tcacagaagt tgattccata 42360
agaattacat tagaaagctt gcgacgctaa atggataaat ctggtaacgg cttcctaata 42420
gcaagttaag ttttttcaca ataaattttt cagaattgaa tagatgcatt ttataactta 42480
cacatcgagt gggcacgttg gtggacaaga caagccccga t 42521

<210> 24

<211> 4434

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 24

gccgccctcg ccaccgctcc cggccgccgc gctccggtac acacaggatc cctgctgggc 60
accaacagct ccaccatggg gctggcctgg ggactaggcg tcctgttcct gatgcatgtg 120
tgtggcacca accgcattcc agagtctggc ggagacaaca gcgtgtttga catctttgaa 180
ctcaccgggg ccgcccgcaa ggggtctggg cgccgactgg tgaagggcc cgaaccttcc 240
agcccagctt tccgcacga ggatgccaac ctgatcccc ctgtgcctga tgacaagttc 300
caagacctgg tggatgctgt gcggacagaa aagggtttcc tccttctggc atccctgagg 360
cagatgaaga agaccgggg cacgctgctg gccctggagc ggaaagacca ctctggccag 420

-74-

gtcttcagcg tgggtgtccaa tggcaaggcg ggcaccctgg acctcagcct gaccgtccaa 480
ggaaagcagc acgtggtgtc tgtggaagaa gctctcctgg caaccggcca gtggaagagc 540
atcaccctgt ttgtgcagga agacagggcc cagctgtaca tcgactgtga aaagatggag 600
aatgctgagt tggacgtccc catccaaagc gtcttcacca gagacctggc cagcatcgcc 660
agactccgca tcgcaaaggg gggcgtcaat gacaatttcc agggggtgct gcagaatgtg 720
aggtttgtct ttggaaccac accagaagac atcctcagga acaaaggctg ctccagctct 780
accagtgtcc tcctcaccct tgacaacaac gtggtgaatg gttccagccc tgccatccgc 840
actaactaca ttggccacaa gacaaaggac ttgcaagcca tctgcggcat ctctgtgat 900
gagctgtcca gcatggtcct ggaactcagg ggcctgcgca ccattgtgac cacgctgcag 960
gacagcatcc gcaaagtgac tgaagagaac aaagagttgg ccaatgagct gaggcggcct 1020
cccctatgct atcacaacgg agttcagtac agaaataacg aggaatggac tgttgatagc 1080
tgcactgagt gtcactgtca gaactcagtt accatctgca aaaagggtgc ctgccccatc 1140
atgccctgct ccaatgccac agttcctgat ggagaatgct gtcctcgctg ttggcccagc 1200
gactctgcgg acgatggctg gtctccatgg tccgagtgga cctcctgttc tacgagctgt 1260
ggcaatggaa ttcagcagcg cggccgctcc tgcgatagcc tcaacaaccg atgtgagggc 1320
tcctcggtcc agacacggac ctgccacatt caggagtgtg acaagagatt taaacaggat 1380
gggtggctgga gccactggtc cccgtggta tcttgttctg tgacatgtgg tgatggtgtg 1440
atcacaagga tccggctctg caactctccc agccccaga tgaacgggaa accctgtgaa 1500
ggcgaagcgc gggagaccaa agcctgcaag aaagacgcct gccccatcaa tggaggctgg 1560
ggtccttggc caccatggga catctgttct gtcacctgtg gaggaggggt acagaaacgt 1620
agtcgtctct gcaacaaccc cacaccccag tttggaggca aggactgcgt tggatgagta 1680
acagaaaacc agatctgcaa caagcaggac tgtccaattg atggatgcct gtccaatccc 1740
tgctttgccg gcgtgaagtg tactagctac cctgatggca gctggaaatg tgggtgcttgt 1800
ccccctggtt acagtggaaa tggcatccag tgcacagatg ttgatgagtg caaagaagtg 1860
cctgatgcct gcttcaacca caatggagag caccggtgtg agaacacgga ccccggttac 1920
aactgcctgc cctgcccccc acgttcacc ggctcacagc ccttcggcca ggggtgtcgaa 1980

catgccacgg ccaacaaaca ggtgtgcaag ccccgtaacc cctgcacgga tgggacccac 2040
gactgcaaca agaacgccaa gtgcaactac ctggggccact atagcgaccc catgtaccgc 2100
tgcgagtga agcctggcta cgctggcaat ggcatcatct gcggggagga cacagacctg 2160
gatggctggc ccaatgagaa cctgggtgtgc gtggccaatg cgacttacca ctgcaaaaag 2220
gataattgcc ccaaccttcc caactcaggg caggaagact atgacaagga tggaattggt 2280
gatgcctgtg atgatgacga tgacaatgat aaaattccag atgacaggga caactgtcca 2340
ttccattaca acccagctca gtatgactat gacagagatg atgtgggaga ccgctgtgac 2400
aactgtccct acaaccacaa cccagatcag gcagacacag acaacaatgg ggaaggagac 2460
gcctgtgctg cagacattga tggagacggg atcctcaatg aacgggacaa ctgccagtac 2520
gtctacaatg tggaccagag agacactgat atggatgggg ttggagatca gtgtgacaat 2580
tgccccttgg aacacaatcc ggatcagctg gactctgact cagaccgcat tggagatacc 2640
tgtgacaaca atcaggatat tgatgaagat ggccaccaga acaatctgga caactgtccc 2700
tatgtgccc aatgccaacca ggctgaccat gacaaagatg gcaagggaga tgccctgtgac 2760
cacgatgatg acaacgatgg cattcctgat gacaaggaca actgcagact cgtgcccaat 2820
cccgaccaga aggactctga cggcgatggg cgaggatgat cctgcaaaga tgattttgac 2880
catgacagtg tgccagacat cgatgacatc tgtcctgaga atgttgacat cagtgagacc 2940
gatttccgcc gattccagat gattcctctg gaccccaaag ggacatccca aaatgaccct 3000
aactgggttg tacgccatca gggtaaagaa ctcgccaga ctgtcaactg tgatcctgga 3060
ctcgctgtag gttatgatga gtttaatgct gtggacttca gtggcacctt cttcatcaac 3120
accgaaaggg acgatgacta tgctggattt gtctttggct accagtccag cagccgcttt 3180
tatgttgtga tgtggaagca agtcaccag tcctactggg acaccaaccc cagaggggt 3240
cagggtact cgggcctttc tgtgaaagt gttaaactcca ccacagggcc tggcgagcac 3300
ctgcggaacg ccctgtggca cacaggaaac acccctggcc aggtgcgcac cctgtggcat 3360
gaccctcgtc acataggctg gaaagatttc accgcctaca gatggcgtct cagccacagg 3420
ccaaagacgg gtttcattag agtgggtgat tatgaaggga agaaaatcat ggctgactca 3480
ggacccatct atgataaaac ctatgctggg ggtagactag ggttgtttgt cttctctcaa 3540

-76-

gaaatggtgt tcttctctga cctgaaatac gaatgtagag atccctaatac atcaaattgt 3600
tgattgaaag actgatcata aaccaatgct ggtattgcac cttctggaac tatgggcttg 3660
agaaaacccc caggatcact tctccttgge ttccttcttt tctgtgcttg catcagtgtg 3720
gactcctaga acgtgcgacc tgcctcaaga aaatgcagtt ttcaaaaaca gactcagcat 3780
tcagcctcca atgaataaga catcttccaa gcatataaac aattgctttg gtttcctttt 3840
gaaaaagcat ctacttgctt cagttgggaa ggtgccatt ccactctgcc tttgtcacag 3900
agcaggggtgc tattgtgagg ccatctctga gcagtggact caaaagcatt ttcaggcatg 3960
tcagagaagg gaggactcac tagaattagc aaacaaaacc accctgacat cctccttcag 4020
gaacacgggg agcagaggcc aaagcactaa ggggagggcg catacccgag acgattgtat 4080
gaagaaaata tggaggaact gttacatgtt cgggtactaag tcattttcag gggattgaaa 4140
gactatigct ggatttcatt atgctgactg gcgttagctg attaaccat gtaaataaggc 4200
acttaaataag aagcaggaaa gggagacaaa gactggcttc tggacttcct cctgatccc 4260
cacccttact catcacctgc agtggccaga attagggaaat cagaatcgaa accagtgtaa 4320
ggcagtgtg gctgccattg cctggtcaca ttgaaattgg tggcttcatt ctagatgtag 4380
cttgtgcaga tgtagcagga aaataggaaa acctaccatc tcagtgcagca ccag 4434

<210> 25

<211> 2837

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 25

agagagccag tccgatgtct gcagcctccc tggccaggcc tctcctctcc tgccgcagct 60
agtccccctc aggacagaca gagtactggc gtcggtcacc attcacttgc aaacacacca 120
ggtcacgtga agaaacttcc tggtagacact caggctgtag ctgtgcactc ttcaaccacg 180
aggttggttt tctcctaagt gtcacagggtg gagacaagat gctctgggca ctggccctgc 240
tggctctggg catagggcca agagcttctg ctggtgacca cgtcaaggac acttcatttg 300
accttttcag catcagcaac attaaccgga agaccatcgg tgccaagcag ttccgagggc 360

-77-

ctgacccccg ggtgccccgcc taccgttttg tacggtttga ctacatcccc ccagtgaaca 420
cagatgatct caacaggatt gtcaagcttg caaggagaaa ggagggttc ttcctcacag 480
cccaactgaa gcaggaccgc aagtctcggg gaacgctcct ggtgttgga ggccccggca 540
cctcccagag gcagtttgag attgtgtcca atggcccagg ggacactttg gacctcaact 600
actgggtaga aggcaatcag cataccaact tcctggagga tgtgggcctg gctgactccc 660
agtgggaaga tgtgactgtg caggtggcca gtgacaccta tagcctgtat gtgggctgcg 720
atcttatcga cagtgtcacc ctggaagaac cattctatga gcagctagaa gtagacagga 780
gcaggatgta cgtggccaaa ggtgcatctc gagagagtca cttcaggggc ttgctgcaga 840
atgtccatct cgtgtttgca gattctgtgg aagatatctt aagcaagaaa agctgtcaac 900
acagccaggg agctgaagtc aacaccatca gtgaacatac agagactctc catctgagcc 960
ctcacatcac cacagatctc gtggtccagg gtgtggagaa ggcacaggag gtgtgtacgc 1020
actcctgcga ggagttgagc aacatgatga atgagctctc tggactgcac gtcatggtga 1080
accagctgag caagaacctg gagagagtgt ctagtgataa ccagttcctt ttggagctca 1140
ttggggggccc tctgaagaca agaaacatgt cagcctgtgt gcaggagggc cgaatctttg 1200
cagaaaatga aacctgggtt gtggatagtt gtaccacatg cacctgcaag aaatttaaaa 1260
cagtctgcca tcagatcacc tgctcacctg caactgtgc caaccatct tttgtggaag 1320
gcgagtgtg tccatcctgt tcacactctg cagacagtga tgagggtgg tctccgtggg 1380
cagagtggac cgagtgttct gtcacctgtg gctctgggac ccagcagaga ggccggtctt 1440
gtgatgtcac cagcaacacc tgctggggc cctccattca gacaaggaca tgcagcctgg 1500
gcaaagtga tacgagaatc cgtcagaatg gaggtggag tcaactggtca ccctgggtctt 1560
catgtccgt gacttgtgga gttggcaatg tcacccgcat acgtctctgc aactcaccag 1620
tgccccagat ggggtggcaag aactgcaagg gcagcggccg ggaaaccaa ccctgtcagc 1680
gtgatccgtg cccaattgat ggccgctgga gccctgggtc cccttgggtca gcctgcacag 1740
ttacctgtgc tggagggatc cgtgagcgct cacgtgtttg caacagccct gagccccagt 1800
atggagggaa ggactgtgtc ggggatgtga cagaacacca aatgtgcaac aagagaagct 1860
gccctattga tgggtgctta tccaacccgt gttttcctgg agccaagtgc aacagcttcc 1920

-78-

ctgatgggtc ctggctcctgt ggctcctgcc cagtgggctt tctgggcaat ggtacccact 1980
 gtgaggacct ggatgagtgt gctgtggtca cagatatttg cttctcaact aacaaagctc 2040
 cccgctgtgt caacaccaac ccgggcttcc actgcctgcc ttgtccacca cgctacaagg 2100
 ggaaccaacc cttcgggtgtt ggcctggagg atgctaggac agaaaaacaa gtgtgtgagc 2160
 cagagaatcc atgtaaggac aagactcaca gctgccacaa gaatgcagag tgcattctacc 2220
 tggggcactt tagtgacccc atgtacaagt gtgagtgcc a gattggctac gcaggtgatg 2280
 ggctcatctg cggggaggac tcagacctgg atggctggcc caacaacaac ctggtgtgtg 2340
 ctactaatgc cacctaccac tgcattcaagg acaactgccc caaactgcc aattccgggc 2400
 aggaggattt tgataaggat ggaatcggag atgcttgtga cgaggacgat gacaatgacg 2460
 gtgtgagcga tgagaaggac aattgccagc ttctcttcaa tccccgtcaa ttagactatg 2520
 acaaggatga ggttggagac cgctgtgaca actgccccta tgtgcacaac ccagcacaga 2580
 tcgacacaga caacaatggc gagggggatg cctgctctgt ggacattgac ggagacgatg 2640
 ttttcaatga gcgagacaat tgtccatatg tctacaacac tgaccagaga gatacggatg 2700
 gtgatggcgt gggtgaccac tgtgacaatt gtcctctgat gcacaacca gatcagatcg 2760
 atcaggacaa tgatctcgtt ggagaccagt gtgacaacaa tgaggacata gatgatgacg 2820
 gccaccagaa caaccaa 2837

<210> 26

<211> 4108

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 26

agagagccag tccgatgtct gcagcctccc tggccaggcc tctcctctcc tgccgcagct 60
 agtccccctc aggacagaca gactactggc gtcggtcacc attcacttgc aaacacacca 120
 ggtcacgtga agaaacttcc tggtgacact caggctgtag ctgtgcactc ttcaaccacg 180
 aggttggttt tctcctaagt gtcacaggtg gagacaagat gctctgggca ctggccctgc 240
 tggctctggg catagggcca agagcttctg ctggtgacca cgtcaaggac acttcatttg 300

accttttcag catcagcaac attaaccgga agaccatcgg tgccaagcag ttccgagggc 360
ctgaccccg ggtgcccgc taccgttttg tacggtttga ctacatcccc ccagtgaaca 420
cagatgatct caacaggatt gtcaagcttg caaggagaaa ggagggcttc ttcctcacag 480
cccaactgaa gcaggaccgc aagtctcggg gaacgctcct ggtgttgaa gggcccgga 540
cctcccagag gcagtttgag attgtgtcca atggcccagg ggacactttg gacctcaact 600
actgggtaga aggcaatcag cataccaact tcctggagga tgtgggcctg gctgactccc 660
agtgaagaa tgtgactgtg caggtggcca gtgacaccta tagcctgtat gtgggctgcg 720
atcttatcga cagtgtcacc ctggaagaac cattctatga gcagctagaa gtagacagga 780
gcaggatgta cgtggccaaa ggtgcatctc gagagagtca cttcaggggc ttgctgcaga 840
atgtccatct cgtgtttgca gattctgtgg aagatatctt aagcaagaaa agctgtcaac 900
acagccaggg agctgaagtc aacaccatca gtgaacatac agagactctc catctgagcc 960
ctcacatcac cacagatctc gtggtccagg gtgtggagaa ggcacaggag gtgtgtacgc 1020
actcctgcga ggagttgagc aacatgatga atgagctctc tggactgcac gtcattgtga 1080
accagctgag caagaacctg gagagagtgt ctagtataa ccagttcctt ttggagctca 1140
ttggggggccc tctgaagaca agaaacatgt cagcctgtgt gcaggagggc cgaatctttg 1200
cagaaaatga aacctgggtt gtggatagtt gtaccacatg cacctgcaag aaatttaaaa 1260
cagtctgcca tcagatcacc tgctcacctg caacttgtgc caaccatct tttgtggaag 1320
gcgagtgtg tccatcctgt tcacactctg cagacagtga tgagggctgg tctccgtggg 1380
cagagtggac cgagtgttct gtcacctgtg gctctgggac ccagcagaga ggccggtctt 1440
gtgatgtcac cagcaacacc tgccctgggcc cctccattca gacaaggaca tgcagcctgg 1500
gcaaattgta tacgagaatc cgtcagaatg gaggctggag tcaactgtca ccctggtctt 1560
catgctccgt gacttgtgga gttggcaatg tcaccgcat acgtctctgc aactcaccag 1620
tgccccagat ggggtggcaag aactgcaagg gcagcgccg ggaaacaaa ccctgtcagc 1680
gtgatccgtg cccaattgat ggccgctgga gccctggtc cccttggtca gcctgcacag 1740
ttacctgtgc tggagggatc cgtgagcgt cacgtgtttg caacagccct gagccccagt 1800
atggagggaa ggactgtgtc ggggatgtga cagaacacca aatgtgcaac aagagaagct 1860

gccctattga tgggtgctta tccaacccgt gttttcctgg agccaagtgc aacagcttcc 1920
ctgatgggtc ctggtcctgt ggctcctgcc cagtgggctt tctgggcaat ggtacccact 1980
gtgaggacct ggatgagtgt gctgtggtca cagatatttg cttctcaact aacaaagctc 2040
cccgtgtgt caacaccaac ccgggcttcc actgcctgcc ttgtccacca cgctacaagg 2100
ggaaccaacc cttcggtgtt ggcttgagg atgctaggac agaaaaacaa gtgtgtgagc 2160
cagagaatcc atgtaaggac aagactcaca gctgccacaa gaatgcagag tgcattctacc 2220
tgggccactt tagtgacccc atgtacaagt gtgagtgcc aattggctac gcaggatgatg 2280
ggctcatctg cggggaggac tcagacctgg atggctggcc caacaacaac ctggtgtgtg 2340
ctactaatgc cacctaccac tgcattcaagg acaactgccc caaactgcc aattccgggc 2400
aggaggattt tgataaggat ggaatcggag atgcttgtga cgaggacgat gacaatgacg 2460
gtgtgaycga tgagaaggac aattgccagc ttctcttcaa tccccgtcaa ttagactatg 2520
acaaggatga gggttgagac cgctgtgaca actgccccta tgtgcacaac ccagcacaga 2580
tcgacacaga caacaatggc gagggggatg cctgctctgt ggacattgac ggagacgatg 2640
ttttcaatga gcgagacaat tgtccatatt tctacaacac tgaccagaga gatacggatg 2700
gtgatggcgt gggtgaccac tgtgacaatt gtcctctgat gcacaacca gatcagatcg 2760
atcaggacaa tgatctcgtt ggagaccagt gtgacaacaa tgaggacata gatgatgacg 2820
gccaccagaa caaccaagac aactgcccac acatctccaa ctccaaccag gctgaccatg 2880
acaacgacgg caagggcgat gcctgcgact ctgatgatga caatgatggt gttccagatg 2940
acagggacaa ctgtcggctt gtgttcaacc cagaccagga agactcggac ggtgacggcc 3000
gaggtgacat ttgtaaagat gactttgaca atgataatgt ccagatatt gatgatgtgt 3060
gccctgagaa caatgccatc actgagacag acttcagaaa cttccagatg gtccctctgg 3120
atcccaaggg gaccacacaa attgatccca actgggtaac tcgtcaccaa ggcaaagagc 3180
tggtgcagac agcaaactca gaccctggca tcgctgtagg ttctgacgag tttgggtctg 3240
tggaactcag tggcactttc tatgtcaaca ctgaccggga tgatgactac gctggctttg 3300
tctttggcta tcagtcaagc agccgcttct atgtggtgat gtggaagcag gtgaccacaga 3360
cctactggga agacaagccc agtcgggctt acggctactc tggtgtgtca ctcaaagtgg 3420

-81-

taaactccac gactggtact ggcgagcacc tgaggaatgc cctgtggcac acgggaaaca 3480
cagaaggcca ggtccggact ctatggcatg accccaaaaa cattggctgg aaagactaca 3540
ctgcctacag gtggcacctg attcacaggc ctaagacagg ctacatgaga gtcttagtgc 3600
atgaaggaaa gcaagtcattg gctgactcag gaccaattta tgaccaaacc tacgctgggtg 3660
gacggctggg cctgtttgtc ttctcccaag agatgggtcta tttctcggac ctcaagtatg 3720
agtgcagaga tgcctagaga gcagggctcc agctccagca atgtgctgca aacaccctt 3780
cttagacaca tcagtccttc ttggcacttg tggcttttct gtcatttggc atttctgtt 3840
tcttgacctt aactgagtgg atctacacct ccttcattcag caccaagtcc aagtgtcttc 3900
aaaggagaaa catcaattgc actccaagag cttccagcct gctgctggaa aacatttggg 3960
tgagatatga ggctcaccgt ggagcgaaga ccgagcattc cgctgtgttg ctttttcttg 4020
tttgtttaaa aagaatgacg ttacatgta aatgtaatta cttgcagtat ttatgtgtat 4080
atggagtcca agggagcttt agagcaca 4108

<210> 27
<211> 820
<212> DNA
<213> Unknown

<220>
<223> Description of Unknown Organism:Unknown

<400> 27
tcgaccagag gaggggaggc cagttcctct cccaagggtg ccacacaccc ctccctgttc 60
atcaccagac aggcccttcc ttcttagcca tatgctaacc ttctcctccc tgggaaattt 120
cctctgcagg agccaaagca gatgggagct ggagttgctg gagctcctgg tctgtatgca 180
gagcaggcat ccaggaaagg agaagagagt gtgacaatcc agcacctcag aatggagggg 240
cctcgtgttc agggcggaag gtacagacgc aggccttgctg agggcctctg gacacaggct 300
ggaccagatg ctgtggatgt cgaccctgc actgactatt ggataaagac ttctttcaac 360
taagagaaga tgcaaatcag cacacttttt tctttgttct gccagcttcc aggcctaaga 420
ctaggttttg ctgtctacag ccaactattc tattagttac aaaactcaat cattttattc 480
agcaactgga tgttgactgt taactagaag ctctgtccta cttacagcac tttggatcat 540

-82-

caaaaaaata aagtaaaata gaaaactgag aaaactcaat ccatgaccag ggagaactta 600
caggatgtta gagacaaaac aagcagacac ctgaaacaat caacgcccaa taaaacaaag 660
taggatgaaa attctcttag ttctttgata acaatttggt cactcataga aacattatta 720
attggtaggg taagcagaca ctctgaaaca atgagaaaaa tactaaaaat tgacttgagt 780
tatttcaaata tgcctcattg acctgttata tcataactct 820

<210> 28

<211> 2397

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 28

tttttttttt catcctactt tgtttttattg ggcgttgatt gttacaggtc ccagcctgta 60
gacatctttt actccaattt cctgaataga tagctttatt ccttcaaggt aatatagtgc 120
gggtggcttct ggctgagatg tttgctgttg ttttcttcat cttgtctttg atgacttgtc 180
agcctgggggt aactgcacag gagaagggtga accagagagt aagacgggca gctacaccgg 240
cagcagttac ctgccagctg agcaactgggt cagagtggac agattgcttt ccgtgccagg 300
acaaaaagta ccgacaccgg agcctcttgc agccaaacaa gtttggggga accatctgca 360
gtggtgacat ctgggatcaa gccagctgct ccagttctac aacttggtga aggcaagcac 420
agtgtggaca ggatttccag tgtaaggaga caggtcgctg cctgaaacgc caccttgtgt 480
gtaatggaga ccaggactgc cttgatggct ctgatgagga cgactgtgaa gatgtcaggg 540
ccattgacga agactgcagc cagtatgaac caattccagg atcacagaag gcagccttgg 600
ggtacaatat cctgaccag gaagatgctc agagtgtgta cgatgccagt tattatgggg 660
gccagtgtga gacggtatac aatggggaat ggaggagct tcgatatgac tccacctgtg 720
aacgtctcta ctatggagat gatgagaaat actttcgaa accctacaac tttctgaagt 780
accactttga agccctggca gatactggaa tctcctcaga gttttatgat aatgcaaag 840
accttctttc caaagttaaa aaagacaagt ctgactcatt tggagtgacc atcggcatag 900
gcccagccgg cagcccttta ttggtgggtg taggtgtatc ccaactcaca gacacttcat 960

tcttgaacga attaacaag tataatgaga agaaattcat tttcacaaga atcttcacaa 1020
 aggtgcagac tgcacatttt aagatgagga aggatgacat tatgctggat gaaggaatgc 1080
 tgcagtcatt aatggagctt ccagatcagt acaattatgg catgtatgcc aagttcatca 1140
 atgactatgg cacccattac atcacatctg gatccatggg tggcatttat gaatatatcc 1200
 tgggtgattga caaagcaaaa atggaatccc ttggtattac cagcagagat atcacgacat 1260
 gttttggagg ctccctgggc attcaatatg aagacaaaat aaatgttggg ggaggtttat 1320
 caggagacca ttgtaaaaaa tttggaggtg gcaaaaactga aagggccagg aaggccatgg 1380
 ctgtggaaga cattatttct cgggtgcgag gtggcagttc tggctggagc ggtggcttgg 1440
 cacagaacag gagcaccatt acataccgtt cctgggggag gtcattaaag tataatcctg 1500
 ttgttatcga ttttgagatg cagcctatcc acgaggtgct gcggcacaca agcctggggc 1560
 ctctggaggc caagcgccag aacctgcgcc gcgccttggg ccagtatctg atggaattca 1620
 atgcctgccg atgtgggcct tgcttcaaca atgggggtgcc catcctcgag ggcaccagct 1680
 gcaggtgcca gtgccgcctg ggtagcttgg gtgctgcctg tgagcaaaca cagacagaag 1740
 gagccaaagc agatgggagc tggagttgct ggagctcctg gtctgtatgc agagcaggca 1800
 tccaggaaag gagaagagag tgtgacaatc cagcacctca gaatggaggg gcctcgtgtc 1860
 cagggcgga agtacagacg caggcttgct gagggcctct ggacacaggc tggaccagat 1920
 gctgtggatg tcgaccctg cactgactat tggataaaga cttctttcaa ctaagagaag 1980
 atgcaaatca gcacactttt ttctttgttc tgccagcttc caggcctaag actaggtttt 2040
 gctgtctaca gccaaactatt ctattagtta caaaactcaa tcattttatt cagcaactgg 2100
 atgttgactg ttaactagaa gctctgtcct acttacagca ctttggatca tcaaaaaaat 2160
 aaagtaaaat agaaaactga gaaaactcaa tccatgacca gggagaactt acaggatgtt 2220
 agagacaaaa caagcagaca cctgaaacaa tcaacgcccc ataaaacaaa gtaggatgaa 2280
 aattctctta gttctttgat aacaatttgt tcactcatag aaacattatt aattggtagg 2340
 gtaagcagac actctgaaac aatgagaaaa atactaaaaa ttgacttgag ttatttc 2397

<210> 29

<211> 4100

-84-

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 29

ggatcccccc gctccgctac catcttcacg gacctcaccc aggacgacga ctgagctccc 60
tcttctctgc cgcggaactgg ggcgaccctg ttgctgctgc ggccgcccgc gctcctgccc 120
ccacttcggc tcccgtcct gctcctgctc ccggccccac tctgttcct gttcctgttc 180
ctgttctgt tcccggctcct gctccggctc ccggccccgc acccacctcc gctcctgctg 240
cgggtctcca ggcccagaca aaataaaaaa agatatattt ttccagtcgc tctctccgc 300
ccggtgtctt ctatggctga gggagtctgg ctctcggggc tctcgggtcg gctgggcggc 360
tcggctgggt ggctggctgg cgagatggac cgctccggcg cgcagcgtcc gcggctgctg 420
tgatgggtgg gcggagcgcg gaccggggat tatatacacg atgtgcatcc ataattgatg 480
ttgtttgaga aaaacaaagt cataaagtgg cactcagaca gcactttggc ctggcgccc 540
gccaccatct gagtgcctaa ccgggcccgg cggttacatc acccccacat ggaccatcac 600
ggcccattag caccaattgg ccagagtgtc gggagccacc gctaattgca gtaacgcgcg 660
gctgccagac tgcaatttac cgcgcgatac tgcagtttac tgcagccgcg gtaaactgca 720
gtacgcggcg gccgcaggaa atctactgta gtatttggcg gcggcgcgcg gtactgcaac 780
tgtagtaaac tgtagctgca gtagagttac tgcagcgcca tcgggcccgt gtggccgcca 840
gggtaactgc acccgcagta aatttactgc agccggactt tgtgcgctgt ggagaccgcg 900
ccgaactggg accccccga ccccccccg actcccccc gactcccccc cgactcccc 960
ccgactcccc ccgactccc ccccgactcc ccccgactc ccccgggacg cgtccgcgcc 1020
tcgatgcgcc ccatcgcgcc ccgttcgct tcgccacgt ccagttgccc cggccccggc 1080
acgtggcacg tatttcccc ccgtaaatca agagggatta tgcggatgtc tagtttatgt 1140
ctcaatttcc tctttccgga gataaaagcc gggacccccg cgccgaaaaa ggatacacca 1200
gccgcgatgt cgccgctcgt ggcggtgctg gtgttttttt cgccggcgct gggggttcct 1260
ggccccggcg tcgcgggaaa ccccggtggg ctgatgccca tcttcgaggc cccggtcacg 1320
cccgcccccc cactcgcca tctcggcgcg gaggagctgg agtgggacga tgaggatcac 1380

ccgctgctgg acctcgagcc gcccggtggga tcacgctgcc atccctacat cgcgtactcg 1440
ctgccgccgg acatgaacgc cgtcacgagc gtggctcgtga agccctactg ctgccgccgg 1500
gaggtcatcc tgtgggcgtc tggcaccgcc tacctgggtca acccctttgt cgccatccag 1560
gccctggccg tcggagagcc cttaaagtag gcggccctca aggagctcgg agaggtggcc 1620
gtgcacaagg actccctgcc gccgctgcgc tataatggag ggccccccgc cgagtaagag 1680
accctgcggc ctgccgccgg ggggtgcgct cgtcgtgcct gccgccgccg ccgcttctgc 1740
ctctaagcc gccaccgccg ctgcagcagc agcccccgcc ggggccgggg ccggggcctc 1800
gaagccggcc cgacccccg ccgccgccg gcccggaag ggcacgccg cggcgtcggc 1860
ggcaacaaca gccacggggg ccgacgcctc cgccccggcc cccgaccccc gggcgccac 1920
gtgggacgcc ttcgccgccg agttcgacgt ggccccctcg tggcgcggc tgctggagcc 1980
cgagatcgcc aagccgtacg cgcgcctgct gctggccgag taccgcggcc gctgcctgac 2040
cgaggaggtg ctgcccggc gcgaggacgt gttcgcctgg acgcgcctca cggcgccga 2100
ggacgtcaag gtggatcatc tcggccagga ccggtaccac gggccgggcc agggccacgg 2160
gctggccttc agcgtccggc gcgggggtgcc gatccccccg agcctggcca acatcttcgc 2220
ggcgggtccg gcgacgtacc cgacgctgcc cgcgcccgcc cacggctgcc tggaggcctg 2280
ggcgcgccgc ggggtgctgc tgetgaacac gacgctgacc gtgcggcgcg ggggtccccg 2340
ctcccacgcc ccgctcggct gggcgcggt cgtgcgcgcc gtcgtccagc ggctctgcga 2400
gacccgcccc aagctgggtg tcatgctctg gggcgccac gctcaaaagg cctgcgcgcc 2460
ggacccgcgc cgccacaagg tgetcacctt cagccatccg tcgccgctgg ccgcacgcc 2520
cttcaggacc tgcccgact ttggagaggc gaacgcgtac ctgcctcaga cgggccgggc 2580
ccccgtcgac tggagcgtgg actgagtcgg gcgtgcgcgc acaccgccg cgaggacga 2640
ggagggggga ggggggtgg atggacggag gagagcgat gatggagccc gcgctcgccg 2700
gcgccccggc cagcgcgtg ccggtcctgg cggtgctgcg cgagtgggga tgggcgtgg 2760
aggaggtcga gccctccggg ccgtgcccg aggacgcga cgcgccccg gagagcgac 2820
cccctccccg ggaggggggtg cgcgggagcg aagacggaga ggggggcgtg gaagacggcg 2880
aggaggggaa ggcgacggag aaggaggaga cggaagacga ggaagacggg ggggacgaag 2940

-86-

ggacgacgac ggcgggcgcg ggcccgcgcc gggcgagca cgtggagttt gacacgctgt 3000
 ttatggtcgc gtccgtggac gagctcgggc gccggcggt gacggacacg atccgccggg 3060
 acctggccgc ggccctggcc ggcctccccg tcgcctgcac caagacgtcc gcgtttgcgc 3120
 gcggcgcgcg cgccccgcgc ggcgcccccg ggcgaggcca taaaagcctg cagatgttta 3180
 tcctgtgccg cagagccac gcggcgcgcg tacgcgatca gctccggtcc gcggtgcgcg 3240
 cccgacgccc acgcgagccc cgcgcgcgcc cgacgagcgg acgggcgcgg ccggccgcgc 3300
 cgggtgttcat ccacgagttc atcacccccg agccggtgcg gctgcaccgg gacaacgtgt 3360
 ttgcggcgcc atgagcacct tcggacgcgc gtccgtggcc acggtcgatg actaccaccg 3420
 gttcctgcag gccaacgaga cgcccgcccg gcgcctggcc gggcctccc gccgcgtctc 3480
 caccggcggg ggcgagacgc gggccccgcg gtccctcgcgc ggccccacg acgatgaggc 3540
 gcccctgcgc gccggcggcc tgggcaccgc ccgcgggcgc tcgcgccagc gcggcgcgac 3600
 cgagccggac cccgtctacg ccaccgtcgt ccagcctacc caccaccacc accagcagca 3660
 ccaccaccgc tctcagcatc cgcagcagca gcaacaacag cagcgggccc cagccgcgcg 3720
 cggcagcgtg cagcctcgg cgacggccgc ggacggaccc gagtcgtgcg cgcccgacc 3780
 cccgcgcgc cgcggcagcg tgcagcctc ggcgacggcc gcccgcggg tccagctgcc 3840
 ccggcccccg caacggagca tcaacgcctc gacgacggcc gcccgcgcg cccagctgcc 3900
 gagacccgc cagcgcagcg tcaacgcctc ggccgcgcgc gccgtcccct cgacggccac 3960
 cctccgcgc ccccgaccc cgtccgggg ccggcgcgcg ccccccgcct catgctgtta 4020
 tcgcgatcaa taaagggcga gcgcccacgg accagacaaa agacacaacc ggttcggtct 4080
 ctctgtccgc gcacgcgcgg 4100

<210> 30

<211> 38734

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 30

gatcctcgtg accgggtaca ccgacgcctc ctggacgcc ctgttcgcca tcgcgggcgg 60

ggtcgtcacc gacatcgggt cgatgctctc gcacagttcc atcgtggccc gcgagttcca 120
cgccccgtcg gtggtgaaca ccaaggacgc caccagcgc atcaacaccg ggcacctgat 180
cgtggtggac ggcgacgcgg gcacggtcga ggtcgtcgag agcgcgga cccgcccga 240
gggcccggcc ggggcccggg ggaccccggc cggagccacc accgactgaa gccggccacc 300
gccgcaacac cggaccacga ccgccccgc gagggggcga ccacacccca gacgggagac 360
gacccgatga tccccaacca gtggtatccc atcgtcgagg cgcaggaggt gggcaacgac 420
aaaccgctcg gtgtgcgcgg catgggccag gacctcgtgc tctggcgga catcgacggc 480
aacctcgtct gccagggcgc ccgctgccc cacaagggcg ccaacctcgg cgacggccgc 540
atgaaggga acaccatcga atgcccgtac cacggcttcc gctacggagc cgacggtgcc 600
tgccgggtga tcccggcgat gggctccgag gcccgcatcc ccggtcgtc gcgggtaccc 660
acctaccgg tccgggagca gttcggcctg gtgtggatgt ggtggggcga cgagcgccc 720
acggccgacc tgccgccggt ggcggcccc gccgaggtga cggacaacc gaagctgtac 780
gccaccaagc gctggaccgg cccggtgcac tacaccggtt acatcgagag cctgctcgag 840
ttctaccag tgacctacgt gcaccgggac cactggttca actacatcga ctacctgctc 900
ctgtaaggca ccccgagcaa gttcggcctc gacggccgc agcggtacct ggccgccacc 960
cggatcacca accaccgggt ggagacggag gcggaggggc agaccatccg ctactccttc 1020
gacctgccc aggaggacga cccaccaac accaccact acgtcatcac gttcaccttc 1080
ccgtgcatgg tgcacgtga gaccgagcag ttcgagacca cctcctgggt ggtgcccac 1140
gacgaccaga acaccgagca catcctgcgc tggtagaggt acgaacaggt caagcccgtc 1200
ctgaggttcg aaccgctgcg ccgtctgctg ccctgggct ccctctacat ggagaagtgg 1260
gtgcaggacc ccaggacgt ccgcatcatg gaacaccagg aaccaagat cagcgccggc 1320
ggcgtgaaca agttcatccc cgtcgacgag atgaacgcca agtacatctc gatgcgcgcc 1380
aagctgatcg cggacgcctc ggccgcgcc tcgtcaccgg cgcgggcggc ggagcccag 1440
ccggaagcgg cggggcgggg cggatcagcg gcccgtgcca cgggcaacgg caggggagcg 1500
gccggcggac gacgcggcac caagcccaag gaggacgcc ccgcgcgcc gtagaccga 1560
agacggggga cggacaagag agagcgagag tgagagatgt acggcgata cgacgcgtcg 1620

-88-

accggcccca aggccttggg gacggccttc aacaccgtcg ccgtggccgg cgccgtgtgg 1680
ttcctgttcg gcggcgcgga caccgtggcc gactggttcg gcaccgactt cgacgaggcg 1740
gtgaccctgc gccgggtcct gctggcgacc ctgtcggtgc tctacctgct gcgcttcate 1800
gccacgaact tcgtgatgct ccagcgcaag atggagtggg cggagtcggc caccatcggg 1860
atctgggtcc tggatgatcca cggcacgatg gcgtacttcg gcggcaccaa cgacgccggc 1920
gtgagcgcggt tcacctgggt gggcgtcgtg ctgtacctcc tcgggtccta cctgaacacg 1980
gggtcggagt accagcgcaa actctggaag aagcgcccg' agaacaaggg caagctctac 2040
accgaaggcc tgttcaagca ctogatgcac atcaactact tcggtgacgc cgtgctcttc 2100
tccgggttcg cgctggtcac gggcaccocg tgggccttcg ccatccccct gatcatggtc 2160
tgcatgttcg tcttctgaa catccccatg ctcgacaagt acctcgccga gcgatacggc 2220
gaggccttcg acgagtacgc gtcccggacg gcgaagttcg tcccctacgt gtactgaccc 2280
cgcccgtcac gcgcgtacgg cggcctcccc gggcgagggg ggccgccgta ccgggtggca 2340
accacagatc ccacagatcc ccacagatcc ccacagagcc cctccacaga cccctccag 2400
agatccacag atcccccca cagatccgag acgaggcacg tatgaccgga gacattccct 2460
tcggagaggc cgaggcgtcc ctgaccgccg aggtgctgcg cgaggctctg gccggcgggc 2520
ccgaggcggt cgcccggtg acctccgacg agggcgccgt cgacgacttc ggcttcgacc 2580
cggagctgac cgacgactac ctgctccccg cctgcgccct gctgtacgag aagtacttcc 2640
gggtcgacct ggagggactg gagaacgtgc cggccgaggg gggcgcactc ctggtcgcca 2700
accactccgg caccctgccg ctcgacgcc tgatgttcca ggtggcgctg cacgaccatc 2760
acagcacgca ccgcaggctc cggctgctcg ccgccgacct tgccttcgac ctccccgtcg 2820
tccgtgacct cgcccgcaag gccggccacg tacgcgcctg ccccgagaac gcgctgcggg 2880
tgctcggtc cggcgaactg gtcggcggtga tgccggaggg ctacaagggg ctcggcaagc 2940
ccttcgagga gcgctaccgg ctgcagcgt tcggccgggg aggttcgcg gcggtggcac 3000
tgcggtcgcg gcgccccatg gtgcgtgct cgatcgctcg gcccgaggag atctaccgca 3060
tgatcggtc ggccccacc ctggcccgga tgctgaagct gccgtacttc ccgatcccc 3120
cgaccttccc gctgctgggc gcgtggggc tgatcccgat gccgaccaag tggaccatcc 3180

gcttcggtgc cccgatccac acggacggct tccccgagga cgccgcggag gaccgctgg 3240
tggtcgagaa gctcgccggc gaggtgaagg acaccatcca gcacacgctc aacgagatgc 3300
tggagggccg cggctccccg ttcgtctgag ggccgcggct cccggttcgc ccgagggcgg 3360
cggctccccg ttcgcccag gaccgtccct ctctccggg gcccgccctc agccccccgc 3420
cgacgatccc cggcggcaga tgctgcgaac gctggcgaag gccagaacgg cgaggccgac 3480
gagcgtgacg ccgcccgcga ccagctccgc ggacagatgc atgggatctc cctcaggggg 3540
acgacggacg gtgatggtca tatagccatg cgaacccccg cgtccgcccc atccgcagcc 3600
gcaccgcccc gcgaattcac ccgtagagca gaccggtgcg gccgaggagg ggtggcgatt 3660
gggtggtcgc gcgttcgaac gcttacgata ctctgttggtg tccaaactga ccgacgtgcc 3720
caagcggatc ctcatcgggc gcgcactgcg cagcgaccgg ctgggtgaaa cgctcctgcc 3780
gaagcgcata gcgcttcccc tggtcgcgtc cgaccgctg tcctccgtgg cgtacgcgcc 3840
cggcgaggtg ctgctcgtcc tgtccatcgc gggcgtgtcg gcctaccact tcagcccgtg 3900
gatcgcggtc gcggtcgtgg tcctgatgtt caccgtggtc gcctcctacc ggcagaacgt 3960
gcacgcctac ccgagcggcg gcggcgacta cgaggtggcc accaccaacc tcgggcccga 4020
ggccggtctg accgtcgcca gcgccctgct ggtcgactac gtctgaccg tcgcggtctc 4080
catctcctcc ggcatcgaga acctgggctc cgcgatcccc ttcgtcgtcg agcacaaggt 4140
cctgtgcgcg gtcgccgtga tcctgtgtgt caccgtgatg aacctgcgcg gggtcaggga 4200
gtcgggcacc ctgttcgcga ttccgacgta cgtcttcgtc gcgggctct tcatcatgat 4260
cgtgtggggg gcgttccgcg gactggctct ggacgacacc atgcgtgccc cgaccgcgga 4320
ctacgagatc aagccggagc acggcggcct ggccggcttc gcgctgatct tcctcctcct 4380
gcgcgccttc tcctccggct gtgccgcgt caccggtgtc gaggcgatct ccaacggcgt 4440
cccggccttc cgcaagccca agtccaagaa cgcggggaac accctcgcgga tgatgggtct 4500
gctggccgtc accatgttct gcggcatcat cgcgtggcc gccgcgaccg acgtgcggat 4560
gtcggagaac ccggccaccg acctcttcca caacggcgctc gcggtcggcg cggactacgt 4620
ccagcacccg gtgatctcgc aggtcgccga ggcggtcttc ggcgagggca gcttctgtt 4680
catcgtgctg gccgcagcca ccgcgtggt cctcttctc gccgccaaca ccgcgtacaa 4740

-90-

cggtctcccg ctgctcggt cgatcctcgc ccaggaccgc tacctgccgc gccagctgca 4800
caccgcggc gaccgcctgg ccttctccaa cggcatcgtg ctctcgcgc gagccgccat 4860
gtcctgggtc gtcgtctacg gcgcgcactc gaccgggtg atccagctct acatcgtcgg 4920
cgtcttcgtg tccttcacgc tcagccagat cggcatggtc cgccactgga accgcaacct 4980
ggccggcgag cgggaccagt ccaagcgacg ccacatgatg cgctcccgcg cgatcaacgc 5040
cttcggcgcc ttcttcaccg gcctcgtcct ggtgggtggtc ctggcgacca agttcacgca 5100
cggcgctgg gtcgcgctgc tcggcatgtg catcttcttc gcgaccatga cggcgatccg 5160
caagcactac gaccgggtcg ccgaggagat cgcgccccg gaggaccocg aggaggcaca 5220
gagcgacgac atggtgcgcc cctcacgcgt tctcgggtg gtcctgatct ccaagatcca 5280
ccgccccacg ctccgcgccc tcgcctacgc caagctgatg cgctccgaca gcctggaggc 5340
gctcagcgtc aacgtcgacc cggccgagac gaaggcgctg cgcgaggagt gggagcgccg 5400
cggcatcgcc gtaccgctga aggtcctgga ctgcgcgtac cgcgagatca cccggccggt 5460
catcgagtac gtcaagagcc tgcgcaagga gtccccgcgc gacgcggtct cggatgatcat 5520
ccccgagtac gtggtcggcc actggtacga gcacctgctg cacaaccaga gcgccctgcg 5580
cctcaagggc cggctgctgt tcacgccggg cgtcatggtc acgtcgggtcc cgtaccagct 5640
ggagtccctc gagggcgcca ggcgccgggc gcgcaagcgc caggactgga gcgcgccggg 5700
tgcggtgcgg cgcggaccgg ccaccacca ccaggaccgt gaccgtacga aggactcctc 5760
ctcgtccacg tagactggac ggctgttgtc cctgtcatcc cccggttctc tggagtcacc 5820
ccgccatgca ggcagaaccg aagaagtcgc aggcggaaca gcgagcggtc gcggagccgg 5880
tctcggagcc ggtctcgtg gtgggcgagg agtacgaggt cgaggtcggc cccgtcgcgc 5940
acggcgcca ctgcatcgcc cgcacgtccg agggccaggt gctgttcgtc cggcacacgc 6000
tgcccgcgga gcgggtcgtg gcccggtga cggagggcga ggaggggtgc cgcttcctgc 6060
ggcgggacgc ggtcgagatc ctggaccct ccaaggaccg catcgaagcc ccctgccct 6120
tcgccggccc cggccgctgc ggccggtgc actggcagca cgccaagccg ggcgcccagc 6180
gacgcctgaa gggcgaggtg gtcgccgagc agttgcagcg cctggcggggt ctcaccccg 6240
aggaggccgg ctgggacggc acggtgatgc cggccgagg cgacaagctg ccggccggcc 6300

-91-

aggtcccgctc gtggcgcacg cgcgtgcagt tcgcggtgga cgccgacggt cgcgccggtc 6360
tgcgccgcca ccgctccac gagatcgagc cgatcgacca ctgcatgac gcggcgagg 6420
gcgtcagcga actgggcac gagcgccgtg actggcccg catggcgac gtcgaggcga 6480
tcgcggcgac gggctccag gaccgccagg tcatcctgac cccgcgccc ggcgcccgcc 6540
tccccatcgt cgaactggac cgcccgtct cggtcatgcg cgtcggggag aaggacggcg 6600
gcgtccaccg cgtccacggc cgccccttcg tccgcgagcg cgccgacgac cgcacctacc 6660
gcgtcggctc cggcggcttc tggcaggctc accgaaggc cgccgacacc ctggtcaccg 6720
cggtcatgca gggcctgctg ccccgcaagg gcgacatggc cctggacctc tactgcggcg 6780
tcggcctctt cgccggcgcc ctggccgacc gcgtcgggga ccagggagcg gtccctcgga 6840
tcgagtccgg caagcgcgcc gtcgaggacg cccgccacaa cctcgccgccc ttcgaccgcg 6900
tccgcatcga gcagggcaag gtcgagtccg tcctgccccg caccggcatc gacgaggtcg 6960
acctcatcgt cctcgacccg ccccgcgccg gcgcgggccg caagacggtc cagcacctct 7020
cgaccctggg cgcccgcagg atcgctacg tggcctgcga cccggccgcg ctggcccggg 7080
acctggggta cttccaggac ggggggtacc gggcgaggac gctgcgggtg ttcgatctgt 7140
tcccgatgac tgcgcacgtt gagtgcgtgg cgattttgga gcccgcgca aaggggctct 7200
gacctgcatt tttcttggt ggatcaggag cggcctgttg cgctcgacct gttctccaaa 7260
gcgcacgacg tagagcttgc ggaccgctcg tgaaagccgc ctgacctggc gttgcacgag 7320
cggtgccgcg atgtcggcgt ggtcggccct tctcctggcg cgaaggaaa ccgaaggctct 7380
tgacgtcgg gtgacgtat ttctgaagg tcgtcaccga ctggggaggc agggccctgc 7440
ctctcgcgcc cgatgaagca ggttctctct gctccaggta atcgtcgagg gtgccctgac 7500
ggatcaggta gacggtcagg gaccgcaggg tgcagggcgt cgacgccag gtcgaggatc 7560
atcaggggcg tgtcattggt gatggcgaag gcgccgatca caccgtcgac ggaacagggt 7620
gcgttcagga gtctgtgcgg gcgccgacc ggcacggctt ggaagctcg ctcgaccgc 7680
agctcgccac cagtcgaga ggagccgata ctgtccggtg ccgggtgacc ctctgtgcaa 7740
gcgttgctgc ccccgctcg cagaccgggg cagcaacgct tgcacgatcg gccggtactc 7800
aacgggatcg tgtggagttt cggaccggaa cggcttgga ggacgtgcc gagcggtagc 7860

gctcctgggc cacattgcac acccgcttcc gtcgatgggt gaaaggcggc acctttcagt 7920
gaaaggggggt tccgcccccc cccgggacct tgcgccacc gtcgccgacc ggctgatgaa 7980
ccggctccgc gctcccgcc ccaacctgac ccgacgtgag accgaagtcc tctcaccggt 8040
cgccgacgga ctgtccgacc aggccatcgg cgcacgcctc cacttgaccg aaggcaccgt 8100
cgatatcacc tggcctgcat ctatgccaac ctcggaaccg actcgcgcac cgccgctgtg 8160
gccactgtca ccgccatcga cgacctcggg ctcacccgcc gctgaacagt atgtggtggg 8220
cggtgtttcc gttctccacg acttcagcgg cgtccggagt tgtggtgctg gctgggcttg 8280
gtgcccgcctc ctctgaaccc atgtgaacgc ccacggccag ttcgagccgg acacgcccc 8340
cggacctggc ctccgccgcg gccagaatgc ccggcccctg cacctgggtct gcctacctgt 8400
acaggcgagg gcggtccctc ggagccactg cctgtaactc cgagggggccg cccttgggcg 8460
actcggcgggt caccgcggac gcggtgcggt caggaggcac cgtctgcgtc atcaggcgcg 8520
gctcggccga gcgagttatt ccggcacccg tgggaccaga aatgtcagcc ctgcgtgacc 8580
gcttogaaga ccgtgacgcg gttgtcgtcg gagagcgagt ggggtggggtc ggctgcgcg 8640
gcgcggaatg cctccgacga ggtgtaggcg gtgaatgcgg cgtcgtcctc gaagttgagg 8700
acggccagggt agccgtgtgc gcccttgcgg ggacgcagca gccgtgcgtt gcgcagcccc 8760
ggcacgttg aaaggggtggc gcgcattgctg gcggtgcagt tgttctcgaa cgcgccctgg 8820
gcgggcgcgg cgacggtgaa ctcggtgacg gcggtgctca tttctgtctt ctctcggttg 8880
ttggtgtgat gtcggtggct gtcccgcccg gccggggccc gcacggcgat ggcgatgatg 8940
tgcaccgcgt gtccgatcga gttccgttgc ggggtgcggt tacagggctg gagttgggct 9000
cgggtccgcg gtcggctgag ggagcctgcc tgtgcggcg gccagattt cgaacgcgat 9060
agtcatgaac gggggtacgg cggccagcag ggcgaagatc gttgtccggc ccagccgcc 9120
cttcagccgg atcgcgacca ggacggtcag ggacacgtag acgatgaagg cggcgccgtg 9180
gagggtgccg aagatccgta cgccaggttc ggtggtttcg gggatgtact tgaggtacat 9240
cccggccagc agacctgcc acgtgcacgc ttcgatgatc gcgatccagg tgaacgcgcg 9300
cagcagacgg ctggtgccgg tttcggcagc ccgtgcggcc ggcgcgtcgg cggaaggcg 9360
ttcggagggtg ggcgtggagg gtgtctgcgg ggtgcctggg cgtgcgggcc acagggcgcg 9420

gttgccgagc aggcggacga tggcggggac caggagcggg cggatgagga aggtgtccag 9480
caggatgccg caggccatgg cgaagccgaa ctggaacagt tcgcggatcg gctgggtcat 9540
caggacggcg aaggtcgccg cgaggatgag gcccgcgag gagatgacgc cgccggtgcg 9600
tgtcagtgcg gcggtgatcg ccttcgctgg gggctgggtg cgcagttcct gcttgaaccg 9660
gctcatgatg aagatgttgt agtcgacgcc gagcgcgacg aggaagacga agatgtacgc 9720
ggtgacgcgg ttgccgatgc cgtcgtcacc gaggacggtc acggtgaaga aggtggtggc 9780
gcccgagggtg gccaggaacg acaggagcag ggtcgcgacc aggtagagcg gggcaaggag 9840
cgagcggagc agcaggacga ggaccacggt gacgatggct aggaccagca gcacgatgag 9900
ggtcgtgtcg cggtcgaggg cggagcggat gtcggcggtc tgcgcggtct cgccgccgat 9960
gagcaccgtg gcgtcctgga cgccggcggc ctgggctgcg gattgtgtgg cctgcttgag 10020
gggaccgatc gcgtcgagtg ccttgagct gtaggggtcg aggtcgagga tgacgtcgta 10080
gaagacggtc ttgccgtcct tgcccatgcg ggggtctgcg acacggctga cgtgatcggc 10140
gtcggtgagc gcggtggcga tgcggcggg tgcggggctg gagcgcaggt tgcctggga 10200
atggacgacg acggtactgg gggcgatctc gccgggccc aattcctccc gaatgaggtg 10260
ctgtccgtgc tccgactcgg tggcggcgcg gaagccgctg aggggtgtga agctctcctg 10320
gtagccgagc agtcccgcgc tcagtaccac caggagtgcg atcacggccg aggccacctt 10380
gacggggggc cgtgcgacca gggcgcgat gcggtgccag atgcctgcgc cgcgactgcg 10440
ttcgggggc ttgtccacgc ccccgggcca gaagacgctc ctgcccagca ggaggaccag 10500
ggcggggatg aaggtgaacg ccaccagcgc catgacggcc acgcccagag cgaggtacgg 10560
tccgaagccg tgaagtgccg gggagacggc cagcagcagg gcaaaccatgg cgagcacgat 10620
ggtcgaggcg ctggcgagga cggactcggc ggtgcggcgc acggcggcct gcatcgcgcg 10680
ggcgcggtct ggctcgtcga gcagggtctc gcggtagcgg gcggtgatga tcagcgcgta 10740
gtccgtgcc accccgaaca gcagcacggt catgatcgag gcggtctggg agctgaccgt 10800
gatgactccg gcgtccgcga gaatcgcgc gagagtctcc gccacgcgca tagccacgcc 10860
cacggcaaga agcggcacga gcgccatcag gggcgagcgg tagatcgcca gcaggatgat 10920
caggacgagc acgacggtgg ccagcagcag gactttgtca ccgccgtga agaccttcac 10980

-94-

ggtgtcgggtg gcgatcccgg cggggccggt caccgcgacg tcggcgggccc cggcccggtc 11040
ggacgcgagg gcacgcacct cgtcgaccgc attctggaag gactcgtccg aggggctgcc 11100
ctccatgggc acgatgacca gctgagcacc gcggctctgc gagaccaact cggccgcagc 11160
gtcgggagcg gtcaccgtgg agaccacgct caccacatgg tcgggtcggc tggttccgga 11220
aagggccgag gtgatggcgg cgaccgattg cgtggcgctc ttcgcggcgt cggtgccctt 11280
gccgcggacc acgatgatcg ccggcgctgc gtcctggccc ggaagctggg cgcgacgag 11340
atcacgggccc ttcattgagt ccgaggcggc gggcggcagg ttggcgagg cgttgtctc 11400
gacggattcc agggccgggg cgaccccggc gaggaggccc gcgatcagga cccagaaggc 11460
caccaccacg gcggcgcgct tcttcgatcc caggagacat cgcagcagag cgggggagtt 11520
catcggttgc atcgggcagc cttcggcagg aagtacggac agaacttagc gacaggggtg 11580
ctctaagttg cgtcaagcta acacgcccc tcggcctctc gggcgtgggg gtaggttggc 11640
gggagacggc acagcgtccg aggtgaagcg gagaaaatgc ccaagattga agccggcagc 11700
gtccgggagc accggggcga gcggctcgcg cagctgattg acgcggccga ggagctcctg 11760
gaagagggcg gtgccgaagc cctcacagcc ggagcggttg ccgcgcgagc cgggatcgcc 11820
cgcaacagca tctaccgcta cttcaactcc atcgacgacc tgctcgaact cgtcgtcacc 11880
cgcgaattcc ccgcctggat cgacgcagtg gagcaggcca tcgcggccga gaccacaccc 11940
gccgcccagg ctgccgcta cgtcagggcc aacctcgaac aggcagctcg cggcacccac 12000
ggctggcggg ccgcgctcac gcgcgactcg ctctccccgt cggcgcgggg gcgggtgagg 12060
aatctgcaca tctcgctaca cgaggcgctc gccggggtcg tgcgcgaact ggggcagcca 12120
cagcccagc tgaccgtggc ggtggtccaa gcagtcgtcg atgcgtgcat ccgcagaatc 12180
gaccaaggcg acgatctgac aaccgtgtcc gacttcgcgg ccggagcgac gcgtcgactg 12240
ctcgcggatg acgacttgcc acatcaccgg tgacgcaccc cgtccaggcg gctcgcaggc 12300
ccgtcgacag cgaagccccg gcagaacgag ccgatcttg agccgcaccg gagcgtgacg 12360
cagaccgtg gtggctcatg cctcgtctca tccgatcttg ccaccgggcg gccgaccggt 12420
cagtgccga cgcccatcga ttacgacgtc caccgcccga accagcgct tcagtgcgtt 12480
gacgttcgtg gtgcgctcat tggtcacccg gcctctgggg gtcaccagcg cttttagggc 12540

acgagactcg acggtggcgc gtgataccag gcaggcatca tgaccttatg gcgatgacac 12600
tccggcttcc cgacgacctg gacacgaagc ttacggagcg ggctcgtggg gaggggttgca 12660
gcaagcagga acttgccatc ggggccattc gtgatgcccg ggaccgggcc gagctgaagg 12720
tcgatgacgt tctggccggt ctgatggaca gcgatgcgga gattctggac tacctgaagt 12780
gagcggcgtg cgctacctcc agatcgacga gatcctggcc atcgtgcgca cggcacaagg 12840
tgccgagcac agcgtgcgtg acatgggcct ccttgtgtcg gcgatcgaac ggccccggac 12900
gaacgtcttc ggagccgagc tgtatccac cctgcacgag aagccgcggc actactgcac 12960
tccgtcgccc gcaatcacgc gctgatcgac ggcaacaagc gcaccgcctg gttcgccatg 13020
cgcgtcttcc tgcggttcaa cggcgccagc gccagtaccg tcccgcacca cgggcgccgg 13080
cccgcaggac ccgaggcccc tcacgcgctg ctcaccagca gccctctcct cagcagcgca 13140
ctgggaccgg cgctgctgat cgccctgtcc gccctggggg ttctcgccct ggacacggcg 13200
ttgtgggtct cggtggtcag tgaggtggcg gcgcccggcc ggtggggctt cgtgggcggg 13260
ctgcgtgtcg gcgcccggcg tctgggagcc ctgatcgccg gcgtactcaa cgccgtgatc 13320
ggtcttggcg tggtcgctgt caaactcacc gccgggcaact gagagggcct gtggtggtgt 13380
tcgcgagcg catagcgttg cagaccggtc ggaatcctcg gcgcccggc cggagcggtc 13440
ccggcacccc ggcgaacagc cgcacgtccc cgtccggtcg ggtcagggtc gagccgtcag 13500
atccagggtc gtgcaccag gcgcagaagc ccggtgccgt ccaccgcgta ctggccgccc 13560
cccacgtcct ccccgacac cacgaagtcc ttggcctgcc acagcgggac gacgggcacg 13620
tcgcgggcga cgatccgctg aagggtctcg aggtcggtt cggcgtcgt cgggtcggcg 13680
aagcgtgac tgctcgtgat cagccggtcg gcggccttgc tgccgtaccc cgtcgccatg 13740
gtgccgtccg tgccgacgag aggaccgccg aagggtgctg gatcggggta gtcggcgacc 13800
cagccgacgg cgtaggcgtc gagctctccc tcggcccagc tcttctggaa ttctgccat 13860
tcatactctc tgagggtcac cttgaacagc ccgtcggcct ctagtgtctt ttccacctcc 13920
gcagcctcct cgtgggctga tccgcgtccc gccgcgtaac cgtaggtgaa agacagcggg 13980
atttctcac cggcctcgac gaggaggcgg cgtgcctttt cggcgtcctt gtgagggtag 14040
ttgtcgaaga aggaggtggt gtggcccgtg atgctcgtcg ggatgagggg gtagagcggg 14100

tccacgggttc cgtcgtagac gtcgtaggaa atccgggtccc tgtctatcag ccaggccgcc 14160
gcctgccgtg cgcgtctgtc gtgaaacggc ttgccgcggc ggttggtgag gtacagggttt 14220
cgagtctccg cgctctgcgc ctccgtcacg cgaagccccg gatcgctcgg gttcagatcg 14280
gcgagcattt cggggggaag ctgtctgagg gcgacatcga tgcgggtggga tatccaggcc 14340
cgggcgagtg agtcgggggt gtcgtagaag tggagttcga tcggccggcc ggtgttctcg 14400
gcggcgccct tgtaccgagg gttgggcgag agggagatct tctcgccctt cgcgtaggag 14460
acgacgccgt acggtccggt cccgtcgatc cggccgtccg agcgcagggg gtccgccggg 14520
tacgtggtcg agtcgacgat cgagcccgcc ccggtcgtca gcttgaaggg gaacgtggcg 14580
tccggtgcgg tcagtcggaa agtgacggtc cggtcgcggg cgtccatcga ctcgatggtg 14640
tccaggaggg acgacggccc cacgtcggaa tctatcttct tgaccggtt gaacgagaac 14700
cggacgtcct tggctgtcat tctgcgtccg ctggagaagg tgatgtcatc ccgcagccgg 14760
catcgatagg tgcgtaggcc ggaatcgggt aaggagcagc ttccggctgc gtcgggaacg 14820
ggctccgcca ctccgggctc cagggtcagc agtgtctgga agacattgct gtacagagtg 14880
gtcgagccgg agtcgtagcc gccggccggg tcgagtgacg tcggcggttc cgtcgtcccg 14940
accttgatgg tgggtgccctc ctggtcgtcc gtcgggtaaa gcagcagacc ggctgccagt 15000
gccgtggcga tcaccgtggg tgtgatgacg gacgcacgga tgtgcgcacg aataggtctc 15060
atgaggctcg tcctcgcaag atcgagacga acaggaattt tcgtaccctt ggggtggagag 15120
tgcgtcggcc aagtatgcg aggcgtcgct tccttcggag cccgacggca cttccggaac 15180
gaagtcttat gactgacacg gtggaactgc tatgccccgt tcggcgagag ggccgccagg 15240
ggtcggcacc ccctctcagc agccgttccg cctcgtctcc ggtggtcctg cggacccgct 15300
tgcgcgggtc ccgcccacgg tctcactcct cgatgccatt ccctgtgcaa tgtcacctgt 15360
gcatgttcc gtgttgacgg gcgtggccat gccaaagtcgg gaggtcgttc gtcttcgctc 15420
agggtggcagt gcggtactcc gtttcccacg tcctctcccc cttcagtcgg ccgtgctccg 15480
cacggccgga tccctcatgg gaggcgctgt gagaaagtca ctggtacggc gaggtctggg 15540
ggcggcgctg ccgctggccc tgaccgtcgc catgagcgtg ggctgctgt cgcagccggc 15600
cggcgcagcc gggaacaccg ggtccgtcgt gcacgtcgc gcggacgacc cggagcacgc 15660

gggacccccg cccgtcgcg agtccccac cgccgagacg gagcacgtcg cgcagggacg 15720
cacgagggcg tccgagcttc cgcccgtggc cgcgagtaag gacgcgtca aggaggtgta 15780
cggcaagacc gcgaaggcgc cggtcctgcc ctgcaagtcg acggacaagg cggtcgccgg 15840
caagaccggc aactcccggtg cgcgtgccgc cgcgtgcaac gtctccgact tcaccagccg 15900
gagcggcggc gcgctgggtc agcagatcaa ggcgccacg accgactgcg tcaacaccct 15960
gttcaacctg accgggaacg acgcctacta cgccttcgt gagtcgcaga tgacctcggt 16020
cgcctacgcc ctgcgcgacg gtcgcagctc ctaccgggc aacgcctcca ccggtatgcc 16080
gcagctcgtg ctctacctgc gcgcgggcta ctacgtgcac tactacaacg ccggcacggt 16140
gggcacctac ggcagcagcc tgcagaccgc gatacgcgcc gggatcgacg ctttcttcgc 16200
cagcccgcac tcccgcgacg tcaacgacgc caacggcgag acgctcgccg aggccgtcac 16260
gctcatcgac agcgcggagg agaacgcccg ctacatccac gtcgtcaagc gactgctggc 16320
ggactacgac tccacctgga actcgctgtg gtggatgtc aacgcggtca acaacgtgta 16380
cacggtgacc ttccgcggtc accaggtgcc cgcgttcgtg agtgccgtgc agtctgacct 16440
cggcctgacg gacgcgtctt acaacttcgc gagcggccac ctgcgcgtgc tgggaacgga 16500
ccagtccctac ctacgctga acgcgggacg tgaactcggc cggttcctgc agcattccgc 16560
actgcgtcc aaggtcagcc ctctggccgg cggcctgtc aactccagct ccatcaaggg 16620
ccggacggcc ccgctgtggg tcggtgtcgc cgagatgacc gactactacg acaaggccaa 16680
ctgctcctac tacggcacct gcgacctcca ggcacaactg gcccgctccg tctgacggt 16740
gacctacca tgcagctcca gcatcaccat caaggcgag cagatgacct cgggcgagct 16800
gtctccagc tgcagcagcc tgcgcaacca ggacgcctac ttccacaacg tggtcctgta 16860
caacggcccc gtcgcgaacg acaacaacag caccatcgag gtcgtggtct tcgactccag 16920
caccgactac cagacctacg ccggcgcgat gtacgggatc gacaccaaca acggcgcat 16980
gtacctggag gggaatccgt cggcgggccg caaccagccg cgcttcacg cctacgaggc 17040
cgagtggctg cgtccggact tccagatctg gaacctcaac cacgagtaca ccactacct 17100
cgacggccgc ttcgacatgt acggcgactt caacgccaac atcaccaccc cgaccatctg 17160
gtgggtcgaa ggcttcgccc agtacgtctc ctactcctac cgcggcgctc cctacaccga 17220

-98-

ggccacgacc gaggcggggc gtcgcacgta cgcgctgagc accctgttcg acaccacgta 17280
cagccacgac accacgcgca tctaccgctg gggctacctc gccgtgcggt acatgtctga 17340
aaaccaccgc gccgacatgg acaccgtcct cagccactac cgcgcgggaa actggaacgc 17400
cgcccgcagc tacctgaccg gcaccatcgg caccgcgtac gacaacgact ggtacacctg 17460
gctggcgggc tgcgcggccg gcaactgcgg tggcgggggc accaaccgcg ccgggaacca 17520
ggcgcccacc gccgcgttca ccaccgccgt ccagggcctg aacgtcacct tcaccgacca 17580
gtccaccgac gccgacggca ccatcgctc cgcgtcctgg agcttcggcg acggcaccac 17640
ctccacggcc accaaccgct tcaagacgta cgggtcggcc gggctcctaca cgggtcaagct 17700
gaccgtcacc gacgacaagg gagccaccgc caccgccacg aggacgggtca ccgtcggcag 17760
cggcgaggcg ggcggcaccg aatgcaacgg gaccgacacc cgggaactgg gccagaactg 17820
ccaacgcggc aaccagtccg ccaccaccgg caactacgcc tacctgtacc tctacgtccc 17880
ggccggcacc acccagctga agatcaccac ctccggcggg acgggagcag cggacctgta 17940
ctacagcacc agcggctggc ccggcaccac gagctacacg cagcggggcca cgggagccgg 18000
caacaaccac accctgacca tcaccaacc gccggccggc gccaaactaca tcagcctgca 18060
cgccgtcagc agcttcagcg gcgtcacctg gagttccgcc tactgaccca cggctccgca 18120
ccaaggcacg accctcacga cggcccgggg cggctctccc cgcccggggc ggcgtccggg 18180
gcggcgccag gggggagacc tccgtcgccc cggaccgaga acacatcgcc cgcccgcaca 18240
cgggcatccc tacctcccag gaggcagagc gtgaagtcat taccgcacg caggcgacgc 18300
cgcgccatgt ggtccctcat catgtccgtc ggtctcacct gcgcactcgc cacaccgcc 18360
gtcggcagcg gtgaccaggg cacgtcacgg ctacgcgctt cgcaacaggc cgcggccggc 18420
caactcgag cggaccagca catctccacc caggaggcac agcggcgcggt actgcggcag 18480
gagcggctca ccggcgctgc aacagcgctg cgtgagcgcc tgggttcccg cttcgagga 18540
gcctggatcg accagaagca cggcgccagg ctgaccgtcg ccgtcaccg gtcgacggcc 18600
acggccctcg tcgaggcccc gtccgctcag gtcaggcac ccgacacgac caccgtcgtc 18660
gtcagaccga gcctgcggca actcgaccgc atgtccgcag gactggccca ccgtatcgcc 18720
gcagcgaaca agggcgccgc ccacggcctg cagtccgcgg tgggtggtga ggacaacaag 18780

gttcgtcttg acctgccacg gggcaagacc ctcacccccg cccagcacgc agtcgtggag 18840
tgggcgaagc ggaccctcgg cgatggcctc gaggtcagca cctacgcgca tgccctccgaa 18900
cccttctact gcggcggcca gtactcgtgc gacccccgcg tgcgctcggg cctggccatc 18960
tacggcacga acgtccgctg ctccagcgcc ttcattggcg acagcggcag cagctactac 19020
atgatgaccg ccggccactg tgccggaggac agtcgtact gggagggtccc cacctacagc 19080
tacggctacc agggggctcg tcacgtcgcc gactacacct tcggctacta cggcgactcc 19140
gcgatcgtca gggtcgacga ccccggttc tgccagccgc gcggctgggt ctaccctcgc 19200
acccgcatca ccaactggga ctacgactac gtccggccagt acgtgtgcaa gcaggggtcc 19260
acgaccgggt acacctgagg gcagatcacc gagaccaacg caacgggtgc ctaccaggc 19320
cgcaccctga ccggcatgac ctgggtccacc gcatgcgacg ctcccgggtg cagcggcagc 19380
ggcgtctacg acgggtcaac ggcccacggc atcctcagcg gggggccgaa cagcggatgc 19440
ggcatgatcc acgaaccgat cagccgagca ctggcggacc gcgggggtcac gctgctggcc 19500
ggctaagcag cccgggaggga ccgtgagtac gccgccccg tcacatcacg aggacgtcga 19560
ccgccgcacg cgcggctcgg gtctttcccc gtgctccgct ccgtccgcca cccagcggac 19620
tggggggcgg ggctggcac gtcgtgcacg ccgcagcgcg gtggaaccgg tcggccgatt 19680
agaccgtacc ggggagcgcc tttccggctc cgttcgtggg acgggggggt gcgtatgcgc 19740
gcgtcaccca tttctggaag tgccggagcct gcgacagcag ttgccagtgg gcgcgtacgg 19800
catgatggtg caccacctc acggccgacg cctcgaccga atcccgccgc cagacgagca 19860
gatgccgctg ccacagcgga tccccgcga ggggtttaac cagtactccg cccaccgggc 19920
gcatggtggg ctggacggcg gccaccccca gacccttggc gatcatcgac tgcagttggt 19980
cgagcatgtg gaactcgtgg gtgacggcgg gctggaatcc cgcggcccca caagcgtcgt 20040
agaaggcgcc gggccagccc acccgtcgt ccgcggagac gaaccacgcg tcctccgaca 20100
ggtcggccaa ggacacctc agccggtgcg ccagtgggtg atcggcaggg gtggccacga 20160
acaccgggac ggttctgata gtcgggtggt ccagcttcgg agagtgtcga agaggcagcc 20220
ctgggtagtc gcaaccagc gcgacgtcga gtcgcccggc ctctaggaga tcgatgagtt 20280
ctccggtcgc gtacacactg ctgaccgaga cggtcagatc ggggcagggt tcacggagga 20340

-100-

cgtcgagcaa ggtgggtacc accggtgtgt tgatggcccc gaggcgaagc cgacgtgtcg 20400
ccccggacga gcggggaggc cgcagccgtg cgagattgtc ggagagcgcc aggatctccc 20460
gggcccggcc gacgacctgg ggcgcgtagg cggtgagctc cacgcccgcg ctgctgcgca 20520
ggaagacccc ctgcgcgagc agtccctcga tgcggcgagc ttgggtactc atcgccggct 20580
gggtgtatcc gagcgccgca gcagcccggc cgacgcccc cgcgtcggct atcgcacaca 20640
gcacgcgcaa gtggcgagc tcaagttcca cgggggcacc tcgctccggg cgaacagagt 20700
tccattatgc gccaggagga aggcggtggg gaatccggga cggcctgacg ccttcggtcg 20760
accagtagcc cgagggttat ggatgagccg gagcctctgg tatggcctgg ccggttggtc 20820
ccgggtgacc gccgtggaaa tctcggaact gcgtgttggc ccgcagaggc gactgcggaa 20880
gcctgaagcg caccgccatc gaggagcgac atcatgcctc acacctgcat cagcttcacc 20940
gtcgaagcga cgggggcccgc ggttcaccgc gcccgccacc gcgtctccac cgcgctgagc 21000
tggtggggag ggccggtcga ggaagagctc cgcttcagcg cggaactcgt gacctccgag 21060
ctcctacca acgggctgcg gcacgcgggc gggcccatga ccgtcgagtt gacgctggtg 21120
cacgacatgg tcgtcgtcgc ggtcctcgat gacagccggg agctgccgcg gcctcggcag 21180
acggaggcgg acgacgagtg cgggcgggga ctgcacctga tcgaggacct cagtctgata 21240
cggggagtcg agaccacttc ccgcgggaag cgctgctggg cggttctgcc gctgcggacg 21300
ccacaggagc gggctatcga gtcggctccg gctgaggagg cggaccacgg cttcagggca 21360
gaccgggaac gctggtcact ggctcccaa ggaageggac tactggcgag tctgtttccg 21420
gcgatgtgag ttcgtcctcc tcgggcggcc cagtagccga cccagggcag gcgggcgtgc 21480
ctgagggcgt gatgacgctc gtctgacgct ctggccgctt tcaagctgca cagcgagccg 21540
agaaacagcc tttgacctgg ccttttctgc ggctgcctca ggccgacatc tttccgatga 21600
cgcaccacgt ggagtacgtg gcgattctgg agcctgctgg caaggggttc tgacctgcgc 21660
ttttgttctc ctgcggcggg cgcggcaagc tcgtgcgggg cagttgggtt tcccgaaggc 21720
cggtgctcgt gtgtccggcc ggcgggtggg ctgccttcgt ttcagtgggt gcgagagggc 21780
actcggacgc ctgagccgag atgcggttcg ttcggcacca tggggtccgc aggatgaccc 21840
ggtcagcgac cgctggcacc tgtggaagaa cctttgcgac aaggccctgg ccgaggttcg 21900

ctccacagc gcctgctgga ccacagcgaa cacaccccg cgggtcggcg tccatgagca 21960
gaccacccgc gaacgttggc atcagctcca cgacctctc ggcaagggtg tcggcttgct 22020
cgaatgcgcc cgcgcctga acctgtccct caacaccgtc aagcgctacc cgcgcacccg 22080
cgatcctgaa gccctgcgcc ccgtgaagca gctgtttcgc gaggtccagg agcagggctg 22140
caccggcagc ttcaccctgc tctaccgag caccagggc cgggcagaag gcgaccggcc 22200
cgtcggaggg tcgcggttg acgtcaccg tatccatcac tggaacggcg acgtctgac 22260
ccgtctgccc ggggcttggg tcccggctgc ggcccgtagg cccggctcac ccagcaccc 22320
atcactgttc gagagtgatt acctctccgc cggacacatg gaaatctgca tcggctggag 22380
tagacattgg gcagcagtgt ggttatgttt ctctgtaac ccagaaggac cgcagggccc 22440
ggcagagacg aactgccggg cagcagtacc cgcagttgca ggacggtgcg gtggtggagt 22500
gtcgaagcca ggatggtgca ggacggcgac gggactgacg accggaccgg gcggcccgc 22560
gtggtcaggg gccgccaccg cagtgcagta ccagcagcg aagtcagtga gcggtacctc 22620
ggtgaaggcg tcggctgcgg acgcgcgcgc cgggagggtc ggcaagtgtg gttccaagcc 22680
agagcagacg caggacgggc aacggggccg actgtcggac agtggcgctg tcacagggtca 22740
ctgagaggtt cgtgtcacca gcagtagagc agtaccagag gaaagaacgg aggaaccaag 22800
cgccatcagg atcgcccggg cgcagttttg ggcccgggta ccgcaggaca tcgatagtga 22860
ggtggtctcc ggtcaagaaa ccgcgatccc cgcgcccccg gcagcaggca ggtcgggtcc 22920
gcggacacag aaggccggtg cagtatcagg gccggcagat ggtgtaggag ttccttcggg 22980
gccctggtgc cgcagggcac caggggccct ccatgcgttc cgcagagagg tgcagatgac 23040
agcagacgat tcgtacggcc gtctcgacga cgacgattac cccgcctaca ccatggggcg 23100
ggcgcccgag atgctcggtg cgaccccg cttctgcgg gccgtcggag aagccccgct 23160
gatcacgccg ctccgctcgg agggcgggcca ccgcgcctac tccgctacc agttgcgcat 23220
cgcgccccgc gccgcgaac tcgtcgacca gggcactccc gtcgaggcg cctgccgcat 23280
cgtcatcctg gaagaccagc tccaagaagc gcggcgatat aacgaggaac tgcagaggcg 23340
cccggccggc ctggtggaca agggcgagg ctgaggccgc atctgccggc cggtcctgtg 23400
agggetcgcc tgccaagacg ggaagccctt gccgcaacga gaagaggcaa ctgtccgcac 23460

-102-

cgatgtgctg ggcccgtcc tggctaggac tcccgtcttc ttgccggagc gatgcggctg 23520
tggacgcgga accggacggc agtgctgctg ggcgcggagc gcggggcgca cgtcgatggc 23580
gacaggaccg gcgaaggtgt attcgtgttc ggcggtgtga cggcgcacct ggccggcgag 23640
ggcggcgggc caggtgtcac agggacatcg gttccgactt ccaccaccg tccgggttcc 23700
accagcgtgt catccacctg atccaggtg ccgcggtagg tgctcgacgt cgggggtgta 23760
cgggggcagt tgtaccgttc cgcgcgagg agtgaccga ttgaccaccg gcctgtggcg 23820
ctcaggaacg ggctggactg tcgcagtccg ggccaactca agcccgacca tgaggccgac 23880
cacggcgccg cgcgaccccg accacagcta cacgcgtggc atgaccaagg cggcacatgc 23940
ttcgaacgag ccatctcatg tgtgccggtg tgaacgtgat cgacgtcccc ggcaactctg 24000
tgccgacgca agccgtctgg ggcgccacc acgactggct cgcgcgccg ccccgcggc 24060
gccaccgtcc gtccgcctt gcgtcgtcg ccgtgtggcg tcatgacggc gacagacttc 24120
ctcgcgtatg ggccgaccat acggccaacg ccagaggtaa agcgtgtcc atggtgagtt 24180
ccctgaacag aagggtggc gggacctcct ttccaagacc gtgctgcagg agtccgtcag 24240
agcgcaggta atcccgtgt gtccgcgacc cagggtgtc ctccgtctgg ccgagggtcc 24300
tcgtcttctg ggcgacatcc ctttagcgtg ggcggtagcc gccgaaggga ggcgccatgt 24360
cggacgaatt gacgggcccg ttgggaacg caatgcggga ggtcacgttt ccggaccggt 24420
ctcgcgggat catcttgggt cgggctggaa caccgcaggc cgaggccgag gcaatggccg 24480
cccgtatgtg ggccgagatg ccggaaggct gacgtgcccg aacgcagaca acccgtaccg 24540
tcctcacacg cattcccctg agccgtcggc catggaacg aaccagccgt acgaaccccg 24600
gaggcgccgt tgcggtctct gcggcgaggc cggggccacg cagggcgaag aggccgcgcc 24660
gcgttctgcc gcctggcgcg gctgccggt gttcacgaga acaccgagg aggagtcgcc 24720
cgcctcttgc ccggcgcggt gccgggtgga gagcagggtg tgaaggactg gtcgctgaa 24780
ggcggccgag gcgacctgt cggccggcct gaacggcttt cactgtcca gcggcggcag 24840
gccgccgaca caggcatgct ttgccatct cctcgtgtc tactgacccc agcagcagga 24900
tccagtacgg cgtcgcggcg ctgccgctc actcgcgat cgatcgggga atgcggcatg 24960
tggtgagggc ccggccggcg tgccggtcgg gccctcacac tgttttggtg tcggcgcggt 25020

-103-

tgtcgtgtcg gtcagacgga caggtggggg gcgccgagca tggcggaagc ccgctgcaac 25080
ggactgtcgc tgcgcgcggg ggcggcctcg ggaagggtgc ggcaggtgaa gcccagctgg 25140
gccatggccc ttaggatttc gccggtgctg aagtcgcggc ggtcctggcg ggtgatgacc 25200
tggccgacct gcttggcggg gtagtggcgt cgtccgatga tcacggactc gccggtgacc 25260
ggttcggggt tgcgcccctt catcgattcc agcacgccgc tcttggtcag gtcgaacggg 25320
aagcgggcaa tgacacagcg catgatgcct cacaggcagg agagttacgg ggccggccgc 25380
cgtctggcgg ttcagcggga gagagcgagg acgccaggg cgctgccgtg ttcgctgacc 25440
acgggcacca gcccagaccg tccgaagggc accgcgtcct cggttcctc cctcgtggcc 25500
gacggtgaga cgaagggtc gctgtcgtcg gtgatgtcac cgaggcggag ccggtcgggtg 25560
tatcgggagc tgtcccgga cggcgtgagc cgggcctggg tgaccaggcc gacgcaccgg 25620
gcatcctcgt cgcagacgac cagatgctcg gcacgggcgg cggccatcac ggacagcgcc 25680
acctcgacgg tcatgtcgta ccagacctgt ggcccggcgg cgtccatgac gtcggccacc 25740
gtgccgcgca atgggagagc gcctacggag cgatcctgca actgtcctgg cgtcaagggg 25800
tgctcctgc gcagacgggc ggggttcctg atcaggacgg tcctaggcgg ccgcgccagc 25860
cgtggacttg agtgcggggg tacgcccggt cgccgaggcg gggcggcgtc ggccgcgtga 25920
ggtggcgccg cgcttcttgg ggcgttcagt cgccggggcg gtgatgacga ccgggatgcc 25980
ggtcggggcc tgggctccgg tgatccggct gagggcctcg tcgccgggc tgacctgggt 26040
ggtctgcggc cggatcccgg cttccgacat gagacggacc atgcccggc gctggttcgg 26100
ggtgacgagc gtgacgacgc tgccggactc gccggcgcg gccgtgcggc cgccccggtg 26160
gaggtagtcc ttgtggtcgg tcggcgggtc gacgttgacg acgaggtcga ggttgctgac 26220
gtggattccg cgtgccgca cgttggtcgc caccagcacg gtgacgtgcc cggctctgaa 26280
ctgcgccaga gtgcgggtgc gctgcggctg ggacttgccg ccgtgcaggg cggcggccccg 26340
taccgcgtg ttgagcaggt cccgggtcag tctgtcgacg gcgtgcttgg tgctgaggaa 26400
catgatcacg cggccgtcgc gtgcggcgat ctcggtggtg gccgcgtgct tgctggcgcc 26460
gtggacatgg agtacgtggt gctccatcgt ggtgacggcg ccggccgagg ggtcgacgga 26520
gtgcacgacg gggctcgtga ggtagcggcg tacgagcagg tcgacgttgc ggtcgagggt 26580

-104-

ggcgggagaac agcatgcgct ggccttcggg acgcacctgg tcgagcagtg cggtgacctg 26640
cggcataaag cccatatcgg ccactctggtc ggcctcgctc aggacggtga cggagacctg 26700
gttcaaccgg cagtcgccgc ggtcgatgag gtccttgaga cgtcccggag tggcgacgac 26760
gacctcggcg ccaccacgca gcgccgacgc ctgcctgcgc atcgacatcc cgcccaccac 26820
cgtggccagc cgcagcttca cagagcgggc gtacgggggtg agcgcgtcgg tgacctgctg 26880
cgccagctca cgtgtcggta cgaggaccag ccccgacggc tgccgaggct cggcccgcgc 26940
gccggccgta cgggcccagca gagccaggcc gaaggcgagg gtctttccgg aaccggtgcg 27000
cccgcggccc atgatgtgc gcccgggcag ggagttcggc agggtcgcgc cctggatcgg 27060
gaacggcacg gtcacccctt gttggccgag cgcggccagc agttccccgg gcatgtcgag 27120
atcggcgaag ccctccgag cgggaagcgc gggggtgatc gtccggggga gggcgaactc 27180
cccctgaacg gcgccgggccc ggccggccgta accgccggag cggctgggtc cggccggccc 27240
gcgcggcgcc ggccaaccga agcggctgcc gccctttccg gagtcggcac cgccatgacg 27300
ggtgcgagcg aagcggctgt tcgtgcgtgt gcggttcata cggaaccttc ctcgatgcgg 27360
cacatatcaa ggaatttccg aagcaatgag cagcacggag aatcgcaaga atggaccggt 27420
gggccttgcc agcggatctg gccgacagaa aatctgtgcg gcacgtgcgc tggaatgatt 27480
gggggtgctg tgggctcgat attcgaagcg tccactgcac tgtagctatg aaggatgcgg 27540
ctgcaccttc gaaggacgat ccgtgtgcgc taaacacacg ctgtccggag cgtcgtccgc 27600
aggtgaaatc actgcgggaa acgcatgtag ctggggcccc caccgccgaag gatgcgggccc 27660
ccagctacaa gtacgtgaca gtcggcgctca ggccgggaac atgttctcgg ccgtcgggccc 27720
cttctggccc tgcgcgatgt cgaagtacac cttctggcct tcgagcagct cgcggaagcc 27780
ctgggcccgc atgttcgagt agtgggcgaa cacatcagcg ccgccaccgt cctgctcgat 27840
gaagccgaag cccttttccg cgttgaacca cttcacggta ccagcagcca tgtcatttct 27900
ccttcggggc agtcgtacgg gatccgcacc gcgcggacct cgtgtcgccc caatgatcac 27960
cccgcccgga aaaagaccgg agatgtaaaa gtgcttccag gggactgag cccgaccgga 28020
gcacttgaaa tttcgggaac cacaactgca actgacatcg acagtagcac gccacagcag 28080
ccactgtgcg gtgaagaacg ccaccttgct tattgcggca gagaatctat ccgcatgctc 28140

cgatgaaaac tcaaaccgcg cgcacagata ttgaccttcg cgcgacgcca tatatcgcat 28200
gccgcgctcg cgtgatccgg tccccacca cgctctccgc tactgcacgg gtcgcaccgc 28260
cgcgggggca gacaggtccg gccatgacgc cggccatgct cggggcgtag cggacgcctg 28320
ccggtcgggt gtacgtctcg cgcgcggcga gcactgcggg ggaggggccc gttgccagac 28380
gtcttgccctg gcaaccggct gtcggctcgg gctggttggg cagccgtggc aggtgatgtg 28440
gttctgcgcg ccgcttccg tgaacgcgcg gcagccccgg ctgccttcta ccaggccgac 28500
cctcaggagg cgtgaccggg ggaagccgag gatcagcggg agtcgtcagg ggaggcttcc 28560
ttgccgcggt aggtgacgtc ctcgaagtat gccaggcat ccggccgggt gccgtccacg 28620
tccgtcacc cgtatgccct ggccagttcc ccgctggagg tggacttgcc gttccaccgc 28680
ttcgcgcggt ctgggtcggc ggccagcgcg gcgaccgtac gggccaggta gtgcggggac 28740
tccgcgatcg cgaacgtcgg ctcttggggc atcgcgtcac gccagttctc ctcactcaca 28800
ccgaagtggg agagcatctg ctccgaacgc aggaagcccg gggacaccgc gaccgccgtg 28860
ccctcgact ccgccagctc ctgagccagc ccgaacgcga ggccgatcgg ggcgttcttc 28920
gccaggtcgt agtagatgtt ctgcggtag cggcggttgg agtcgcggt accgtcgggtg 28980
acttccacat gcagcggcgc gtcggagcgg atcagcagcg gaagcagcag cgcgcgcgtg 29040
atcacgtcgc agcgcgcgcg cagctccagg atccgcaggc cgtcggcgag cgggtgtctcc 29100
cagctcttct tccgaacac cgaggtggcc agaaggtgct cgcgcacca caggtcgttg 29160
acgagaatgt cgagccgctc gtactcccgg tcgatccgct cgacgagggc gcggacctgg 29220
gcttcgtcga gatggtcggg gggaactgcg attccggtgc cgcgcgctgc ggtgacgagt 29280
tcggcggtct cctcgatggt ctcggtcgtc cggccgacct cgctggcccg ggcccgggtg 29340
gttcggccgg tcacatacac ggtagcgcg gcccgcccca gttccacagc ctgagctcgt 29400
ccgcgccgc gggtagcgcg ccgcacgagg gcgatccgtc ctgccagcgg acccttcgga 29460
ccggcctgct cgggtgtctc agtggctcgc ctggtgatgt cctcgttgct catgtcatcc 29520
atcgttcacg ctaaaaccga cagaacacgt caccttttat gtggggggta ccgcgcac 29580
tcccggccat agcgccaact acgtcctcgc actgagcgtt ttcagcgtgg gccaccgatc 29640
gggtgacgcc ggtcaggtcg gggtaggggc cgcaacgcac aaggctcgcg tgcacgacat 29700

-106-

ggccaccgcg cgcatgatct cccagcggga gccagccgt ccccggcagc cccagccgct 29760
gagaccagct cacccgggac acccgggccg acaccgcaca cgatcaagta gtcgacctcc 29820
agacgcgttc agcagcccac atcccaggag ccgtctaccg tcccaggaac ccctgctccg 29880
ggaccatcgg gtcgggcacc gggagtgcac agttgatcag taactggcaa cgagctcgtg 29940
cacggtaagc ggtgaggtgt cgaggtccag atgggcggcg gcggtggtgc cccagcgggt 30000
cggccgaccg gcatgccgag cgggcagccc accggtgtgc cgagcggcgg acccggcggc 30060
ggcacgggca tgggcggcac cccaccccg cagcacctga agtcggtcag gaccggccgc 30120
gtgacgggct tcgggtcaga cctgtgcggg gaacagcagg cagtcgtccg ggcggtgat 30180
caggttgatc tcgccgtccg tgtgccggac ggggtctctc gcatggacgc gcacgtcgcc 30240
gatgctgagc tcgtactcga atcgcgctcc ggtgtacgag cactgctcga tcctcgccc 30300
gagcacgttg acggcacctg cgtgcggggc gtcggcgcgg tcggtgagcg tgatgcgttc 30360
cgagcgcagg cccacggtgg cggacgaccc cgcggagcag gcgccggcca ccctcaagcg 30420
ctgaccggtc tcaccagtt cgacctgtac ggctccgccc tcggtggcgc cgacgcgccc 30480
ctccaggagg ttgcagcggc cgatgaagcc ggcgacctc ggagtggcgg gagtctcgta 30540
gatctcggtc ggtgtgccc cctgctggag gtgtccgtgc atgaacacgg cgatgcggtc 30600
ggacagggac atggcctcga cctggctcgt ggtgacgtac acggtggtga tgccgacctc 30660
ccgctggagg tccttgagcc agacgcgggc ctggtcgcg atcttcgct ccaggttgga 30720
gagcggttcg tccaggagca gcacgccggg ggagtagacg atgcctcgg cgagggcgac 30780
gcgctgctgc tgtccgccg agagctggtg ggggtagcgg tcgcgcaggt gagccatgtc 30840
gaccttggtg aggacgtcgt cgatgaggcg ccgttgctcg cccttggtga ccttgccgag 30900
cttcagcggc agtgcgaggt tgtcggcgac ggtcatgtgt ggccagagcg cgtacgactg 30960
gaagaccagg ccgagattgc ggccttcggg gggcacctg ctgcgccggg tgccgtcgaa 31020
gaagacctg tcgccgacac ggatggtgcc cgagtcgggg gtctccagac ccgcgacgca 31080
cgacaaggtg gtggacttgc cgcagcccga cgggccgagc agagtgaaga actccccgtc 31140
cgcgacggtg aagttgacgt cctccaggac cgcgggtccc tggaaggact tcttgatgtt 31200
ctcgacgacc agctcaggca tgcttcttcc ccttcaggag gagaccggcg aggccggcga 31260

-107-

cgacggcggt gacggcgatc tggaggggtg cgagggcggc cacggagccg gtctcaccct 31320
gggtccacag atcgatggcg gtggtgccga tgacctgtga ctcggtccg gcgaggaaca 31380
tggcgggggc gtactcgcg atcatctggg tccagatgag caggaacgag gcgagcatcg 31440
cgggcacgag gagacggagc atgatccggg acaccgtgcg ccaccagtcg gcgcggcgca 31500
cgctgcggc gttgtcgagt tcgggtccga gctgcatggt cgccggggag atcgcgccgt 31560
acgccgacgg gagtgcccg atgccgaagg cgatgatcag cgcaagagc gtgccgcgca 31620
ccgcgtcgcc gccgggtatc caggtgaagg ccagaacag gccgatgccg acgatcaggc 31680
ccgggaccgc gtgcggtgac tgcgctgtcg tctccaggag acgggcgaag cggaagtccg 31740
agcggcgtgc cacgaggacg accaccgtgc cgaacagggc cacggccacc gccccacga 31800
aggccacggg gatgctgttg acgatcgact cgggtgtaggg ggcgtagtcg aagatcagac 31860
ggaagtgtc cagggtgagc aggtcgaacg ggttcaccag cggagtgagc agcgaggtga 31920
acgcgcgag gatgagcgcg agcatcggca gcagtgcgcc gaagacgacg tacagaccga 31980
cgaaggcgaa gccagccac ttccaggcac cgatgtcgag caggtcggag cgggtcgct 32040
tgccgcgcac cgacacgaac cgctgggctg gcccagcag ccgcgtctgg aacacgacca 32100
gggcgatggt ggtgagcagc atgaagggtg acgccgcgcc cagcaggccg tagtccggat 32160
tgatcgagtc gatgccctgc tcgtagagga agttggagaa gagggtagtg ccggcgggct 32220
cgccaggat gagcgggatg gacagggtct cgatcgccgt gccgaagatc agcagaccg 32280
cgtagagcat cggcgggagc agcatcggca ccacgaccga gcgcaggacg cgagaggcc 32340
ccgcgccgac gctgcgggcc gcgttctcca gagaggtgtc ggaggcggcc agcgcggttg 32400
cgcagaacag gtaggcgatg gggacctggg cgacggcctc gacgaacgcc ataccgggca 32460
gtgagtacag gttccagggc accagccga agccctcgcg caccgcgccg gtcaggaagc 32520
cggccgggcc gtagacgacg atccaccga aggccaggac gagcggggag atgtagatgg 32580
gccagcgag cacctgcccg aacaggcggg cggcggggaa gcgggtgcgc tccagcagaa 32640
tcgccatcg caccgcgatg gcgagcgca acacggtcgt caggacggcg aagaggagg 32700
tgtcgaggac gatcgaaccg aagcccgccg acgtgaacag gtgggtgtag ttcgagagg 32760
tgaaggcgcc gccggccgcg tacaggggct ggttgcggac cgactggtag aggatcggt 32820

cgacgggggc gaggacgagc acggcgggtga cgaggaacgt cagccagtgg atggtgacct 32880
cacgtccggc gccgaacagg cgccggtact ggggcgtgcc cagctcgccc gcgcgcggga 32940
tgccgggacgg cgccgggtggc gccgggggtg tctggatggc catgacgact ccgtacgaac 33000
ggggtgggga caggggcgtt gggcggggcg gggcggtca gccggccgcc ttctcccagc 33060
gcgcgacgta cgctcccg cgcgctccg gcacccgcac gggccggtac agatggacgc 33120
ggtccgcgcc gagcctgcgc cgcattgctt gcagactgtc catggcgtcc tggcgacagt 33180
ccggccggta cggcaccagg ccgcctccg cgaccgccgc ctgcccttcg gcggagagca 33240
ggaagtccag gaagagacgg gccgcgttcg ggtgcggggc ggtcttcacg acggacagcg 33300
cgcgcgcat gacgacggtg ccctccgct agtagctcca cccagcagt ccccgctgt 33360
gctcggcggc gggatatcg cgcacatcac gtacggcagg atcccgccgt gccgcaggta 33420
ggccagttcc tggcgcgagt ggaggcgag cctgagacgg accgtggcg ggggtgcgtc 33480
gggcccggac agggacagg cgacggggtt cgtgccgacg cacaggtcgg cgaggccgtc 33540
gaagtgat tctcctctc cggatgaaggc gtgggccgat gcggtgtgc cctcctcgaa 33600
ctccaggggc agtacacca tgccgatcag gttgttgcg tggatgcgt cgaaggactc 33660
ggctatcacc gccgcactc ccagcagcg ctgtgccttg gcggcccagt cgcggtgga 33720
gccggcgccg tagttgcgg ccgcgaccac gacgagatcg tggcccgcg cgcggtaggt 33780
cgcccgggct tcgtggacgg gcccattccg cagttgcgtg cccgatggc cgccctgcgc 33840
atggacgatg cggccgggtc ccttcgagg cctggccgcc gggtcgttcc tgacccgagg 33900
cgccgatcag gacgacgcc tgcaacggac gcgaggacag cgtcagcttc gtccgcggca 33960
acagcgacga ccccggtgac ttccgatgac gcgcagccc ccgcccgcg aaccgagct 34020
gaccgtcgac cgccgcgct gctctgggtc accctccgc tccgctgcg agatcagatc 34080
gccgacgcgc cgccgggac cgtcgtccac gtcgtcgcca ccgacccccg cggcaccgt 34140
cgacctgcc acctggtgcc acatgacagg tcacacctgt ctggcacgc cccggcgaa 34200
cgcccggtgt acgccccgaa gtcaccgcc gacgcgcgc ccacccgcc ggacgcacc 34260
tggcaccgc tccggcgcg gcaggagcag cccgggaacc ggtgacgcat ctgctcgcc 34320
ggccgtttcg agtgaccgc ggacgcggaa cgtcacggcg tccggaaacc ccggaagggtg 34380

accggcctgc gtgtcttgaa gccgagccgt tcgtacaagg cgatcgcgcc ggtgttcgcc 34440
tcggccacgt gcaggaagg acgatcaccg cgcgccgaga tgcgctcggg gagagcgcg 34500
acgaggcggg cggcataacc ctgcccgcgc gcctcgggag cggcgagac ggcgctgac 34560
tcggtccagc ccggaggacg caggcgttcc ccggccatcg ccaccagggt gccgtcgacc 34620
cggacacca ggtaggtgcc gagttcatgg gtacggggcc agaacggccc cggctcggtc 34680
cgcgcggcga gatccagcat ctgaggcacg ctgtccgcgc ccagctcgac cacgtcggtg 34740
tcggacgcgg agcgagttcg gccggggcgg ccgtcgccgg gccaggtcat ctgacggccc 34800
tcaagactga aaaccggctc ccaaccgggc ggcggaacgg ccggggagct gaacatgtcg 34860
gcgaaggcgc cgggaccgag taggcgggcc aggtcggccc agtcctccgc gtccgggtcg 34920
acggacacgg aggagaagg cgccacgtcg gtgagatagg tggctgctcg accgaaccgt 34980
cgggcgagat gagcgtgccg accactgagc gactgacctc ccgggtcgtc gagtgcgggg 35040
tcgtcgtcgt tcatcatcgt gccgtttcct tcctggtgag cgcggtggtc gaagggtggc 35100
cgcggtaggc gaaaagtccg cggcggggcc cgtggcccga tagtcgtage ccttgtcacc 35160
gtgcagtttg ccgggtcgcc tgaggacttc cggctggagg ccaatgcaa agcgtctctg 35220
tgccggcgga ggcacgcctt ctgacgtgcc tccaccggca ccaatcagtt caggcagatt 35280
gagcttgagc gatgcagcgc cgcgggaagt cgagcgctc aatgcatega gcggcgactt 35340
cctcgttctg ggtgagagca gtctgcctt gtcgagtgat gcggcgttcg gaccgtcacc 35400
ccggcgaagg ccaggacctg tcccacggag tggtcatcc acctccccct cctcggccca 35460
cagcttcagg cccgacgtag ggggaggggc gactcggaac ccggcgctcc gtcgcgaag 35520
gtcggtcaga cctgttcgaa gtggaacgcc ttgatgaagc agtcccgggg ttgggcgacg 35580
gcgaagagga tgactccac gagggactgc gcggtgaggg cgtcctcggc ttcgctgaa 35640
gtggtcgccc actcctcgga gagcgggtcg gcgttgctga agtcggggcg gtagagcgag 35700
atcaccggga ctcttgggc gcgcaggcgc ttggagagga tttcggtgaa ccctgcctgg 35760
gcgctcttgg ccgcgtagaa ggcgtcgtgt gcgtccgagc ggtggtggcc cgggtgtccg 35820
caggcggaga ccatcgtcac gacgtcgggt gtgtccgagt tgagcaggag ggggaggaaa 35880
ctcctcgtgg tcaggaccgt gccggtggct ccggaggcga tgggtgtccac gacgtcggcg 35940

-110-

tccggttgccg acagcaggtc cggcccgggtg aggtagcggg agccgttggt gacgagtacg 36000
tcgacgcggt cgggtgtgttc cgcgacgccg gaggcgaagt cgcggatcga ggcaggatcc 36060
gtcaggtcgc aggcgaaggc gtgcaccgcg tgggtgtccgc ggtcgcggat ctgcgcgcgg 36120
acccgttggg cggcggcgag cggcggtgcc gagaggaaga cctccgcgcc gaggtccgcg 36180
aggcggatgg ccagggttcg tccgaagtcc cggccggcgg ccgtgatgac gacgcggtgg 36240
ttgtcccatc tcatggtgtc gttccccagt cgcggtttcg tggatcgggt ggtgcccgtgc 36300
accgcgtctc tacgctatcg gtcatggtcg ctcacgaacg gtcgttcacg gtcaatgatg 36360
atgttgaggt gcccaacccc ggtgcggacg aggtctggac cgtcggcgcg gtcatacctca 36420
atcggaagg tcgtgccttt gcccagaagc ggagccggga ccgtcgctg tccccgggg 36480
cctgggacat cgtgggcgggt catgtcgagg agggcgagac gcttctggag gccctcgcgc 36540
gtgaagtcga ggaggagacc ggctggcgcc tgaccctgtg gcggcggttc ctcggcacca 36600
cgacctggac gggggacgac ggcggcgcc tgcgtcacga ggccgactac ctggtcgagg 36660
tggaaggcga cctggaccac ccgaggctgg aatggtccaa gcactccgcc tacgactggt 36720
tcggcccccg cgatctcacc cgcctcaagg agaaccgcgg accaggggag tacctgatcc 36780
acgacctcat agccggtgcc gttgccgact cgcctttcga cttgctccgg gcggacgccc 36840
tcaccagccc ggaccggctg cgcgagctct accgcagcc gaaccggaac tcgctgcgca 36900
aggagaccga ccgcctgacc gaggagaccc gggcgctgat cggctgttcg tcaactggtgt 36960
tcacgggcag cgcggaccgc gagggccggg cggacgtgac gccacgtggc ggcccggccg 37020
ggttcgtctc ggtgctggac gagcagaccc tggatgatccc cgacgcgacc ggcaacaaac 37080
ggctcgacac cctgcacaac gtgctggaga ccggacgcct ggggctgctc ttctcgtcc 37140
ccggccgccc gaccacgctg cggatcaacg gacgcgcctg tgtttcggcc cgcccgagc 37200
tgctcgcgccc cctcactccc gtcggaaagc cgcgggtcac cgcgctggtg gtgcaggtcg 37260
agcagggtgta tccgcactgc ccgaagtcac tgatgcgcgc cgacgcctgg cgacccgagc 37320
agtggatgcc cgccgacgcc cagccgagca gcgccgaggt gacccttgcg cagctgaacc 37380
tgcccggcct gaccctggac cggatcgagg atgccgaacg ggagtcgctg cgctgcgggt 37440
acgaatgacg acgagtcgat gagcgccgat gagccgatga gaccgacgg gatccgacgg 37500

-111-

gtcggcgctcc gcggcgagca gaccggtcgc gaaggtcacc gcccgcacgg cggcgaccct 37560
cgcgacggtc agtactgtcc ggtcaggtgc gggccagcg ttggttgctg ccgttgagc 37620
aggtgtacag ctggatcagg gtgccgttg cctgcccgtt cccgacggcg tcgaggcaga 37680
ggccggactg gacgccgacg acggaccctg cggagttgag gcgccacttc tggttgtcgc 37740
cgccccagca gctgtagatc tggaccttg agccgttgcc ggtgcctgcg gcgtccaggc 37800
acttgtcgc gtagaccctg agctcgccc cgtcagtggc ggccactgc tggttggtgc 37860
cgctgtggca gtccacagc tggagctggg tgccgtcgga ggtgctggcg tcgggcacgt 37920
cgaggcagcg gccgaaccg acgcccttga tctgtcccc gtccgcgggg ggctccgagg 37980
agtcgccgcc gttgagtgcg tcgaggacgg cgggtgtacgc ggccttcttg ctgccgtcgt 38040
tggtgaacag caacggcgtc tgctccgacc gccaggagtc gctgtcgcgc acaccacaga 38100
cgggtgacgcc gaggcagcgc gagacggcca ggcagtcgtt ggtcacgttg gcgtaggtcg 38160
aggccggggc gccctggatg tccagctcgg tgatggccac gtcgacgccg agggcgggca 38220
agttctgcag tgtggtgcgg aagttgctgt ttaggggct gccgctgttg aagtgcgact 38280
ggaagccgac gcagtcgatc ggcacgccgc gctgcttgaa gtccgcacc atgttgtaga 38340
tggcctgggt cttggcccag gtccagttct cgacgttgta gtcgttgtag cagagcttg 38400
cggacgggtc ggcggcgcg gcggtgcgga aggcacctc gatccagtcg ttgccgctgc 38460
gttgacaggtt ggagtcgccgc cgcgtcccg aactgccgtc ggcaaggcc tcgttcacga 38520
cgccccactg gacgatcttg cccttgtagt gggccatcac gccgttgatg tggtcgatca 38580
tcgcctggcg cagcgcgctg ccgctgaggc tctgcatcca gccgggctgc tgggagtgcc 38640
aggccagggt gtggccgcgc acctgcttgc cgttctgcac cgcccagttg tagacgcggt 38700
cggcgagct gaagttgaac tggccccgct gcgg 38734

<210> 31

<211> 3331

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

-112-

<400> 31

tcggatctcc ccacacaaca tagatagagg atatccgcct gggttcacia tgaagttact 60
gggtggttctc accaccctcg tgggcttttag ctcagcacta agtttcgggt gtaattacag 120
accagtatta ggcttcaatt cacagtatat gctgggagga ctaagacttt tctgtatgcc 180
tgccatgggt tatgatccat gggcatgtgg ttgcgtttcg gcatggagca gtgcaggtct 240
ttacggtgtc ggagggggcg gaggcgcctg gggagctggc ggtgctggag gagccgacgg 300
cggacgcggc ggcggcggtg gagattggga atatgactat gatgacgaca gcgatgacga 360
tgatgaatgg gactgggatg atgacgggtg aatgggagct ggcgccggag gtggtgctgg 420
tggtggtgcc ggaggtggtg ctggtgctgg tgctggagca ggcgaggag caggagcagg 480
tgctggactc ggacttggat tgggcggagg tctcggaggt ggacttggcg gacttggagg 540
tcttggcgga cttggcggtg gagacgattt atttgattta gatttcgatg atcttgggtc 600
agctcttgcc ctcggtggag ctggtggagc tggaggtgct gctgctgctg ctgcagctgc 660
cgctgctgcc gccgggggtg gagttggtgg agctgctgcc gcagccgcag ccgctgctgc 720
cgctgcagga ggaggcgag gtagacttgg aggagctgct gctgcagccg cagccgctgc 780
tgccgctgca ggaggcgag gtggacttgg aggactcggg ggcgacttg gaggactcgg 840
tggcggactt ggaggcctcg gaggtcttgg tggcctcgga ggatatggag gatctgctgc 900
tgccgctgct gctgctgccg ccgctgctgc cggaggtgga ggactcgggt gtgttggttt 960
ctacggtgga cgaggagga gacgcggtcg aggaagagga ggccgcagac gtgctgctgc 1020
tgccgctgct gcagctgccg ccgcagccgc tgggtggtggc ggaggaggtg gaggtggtgg 1080
aggaggaggc ggaggcgctg gtgctgccgc tgccgctgca gccgctgctg catctgcttc 1140
agcttctaga caaatgagtg gtataaggga cgcattagga gacattaaag accttctcag 1200
gagtaatgga gcctctgcaa aagcctctgc taaagcatca gcagtagcaa gcacaaaatc 1260
tcaaattgac gatttgaagg atgtcttaaa ggatcttgca ggtctattga aaagctcagc 1320
atctgcttca gcatctgcat ctgcatcagc ttcagctgga ggtggaggcg gtggtggtaa 1380
cggaggtggt aacggaggag gaggcggcgg tggagctgga gctctagctg ctgctctcgc 1440
tgctgcagga gccggaggtg gacttggagg tggaggcgga ggcgagctt tagccgctgc 1500
actagctgct gctggtgcag gtggaggagg ttttggtgga cttggaggac taggcggtct 1560

-113-

tggtggggga tctgccgcag ctgctgcagc cgctgccgct gctgcatcag gtggtggagg 1620
aagagcactt agaagggtt tgagaagaca aatgcgtgga ggtggatccg ctgctgccgc 1680
tgctgctgct gctgcagctg ctgctggagg tggatgggga ggtggaatgg gtggaggatt 1740
cggagtaggt ctcggtggag gattcggagg aggatttggg ggtggatcat cagcagcagc 1800
tgctgccgct gctgcagccg ccgctggatt tgggtggagg ggacgaagag gtagaggtag 1860
aggacgtgga ggcgatggcg acggtaacgg agctagtgtc gtagctgcag ccgccgccgc 1920
tgctgctgct gctggaggat ctgctgctga tggtgccgct gccgctgctg cagccgcagc 1980
tatgtacggt gacggtgctg atggacctga ttctgataat ggattcggtg gtggaaacgg 2040
aaatggagggt ggcgatctg gtggtggcgg atccggcgga ggtggatccg gtggcggatc 2100
tggaggtggc ggtggatctg gtggatcagg cgggtggcggc ggatctggtg gttcaggcgg 2160
tggcggatca ggcggcggtg gaaacaatgg atggggaaat aacggcaaca ataaatatga 2220
cgatgatgac tgtgatgaat atggtaaccc tattagaagg gggtaaatta ttgacatta 2280
tccgccattt gactcatttt tcttagttct ctatgtttta tacttcacct tagattgttt 2340
tagtttgatt gaataaatta tgttttcgat ataaattttt tttaaattaa attaaacttt 2400
attagttgac ctgtaaactt tttcatggag ttataatcta aggaacaaaa aacatacata 2460
atatgttcag tatttggtga aagcacctgt accgcaaaca caatcacctc tatacatgta 2520
tacaaaatca gtaatgctga caaatcttc tacactctca cctacacact cgcacacagt 2580
cctcttacat acacagcact ataatacctt gaacatgaag tttgtgttga taaaaagttc 2640
agaaaaatct cccctacatc acctgatctt tcaactgaaa tttacgacaa gtattgaaa 2700
tagcagaaaag aaaacgggaa attgagaagt tttctataaa aaacaatcgg aacaatgact 2760
ggaatgacaa ggatgaaaat aatgataact tacattaatt aaggcccaa taatctctct 2820
attttcaaac ttttttttca aatgttctct ctaactcact tgcattctat tggaaattca 2880
catactatac taaattacca caagtatcaa ggtttcacia cctctcatgc cttcatggca 2940
gaccatgctg ggtatttgtc taacaatgcc tcataaatac ataaaactaa ctaacaaaat 3000
aggtcagtct gtaacaaatt attaatgcac cattattgca ttttctaaaa caaagcatac 3060
actggatatt ggcagacaaa atgttggtat tggatacctt tccattctat ctagacactt 3120

-114-

gctttccaca agtcatcata aataaatccc ccctatccca aatgtcaatg gaatgcccc 3180
 acccttcccc cataatttta aaacctagaa taaattaaaa catctatagt tcgtcatgat 3240
 catctttctt atcatcctct tcttcttctt cctcctcctt cttcttcttc ctctcctca 3300
 gggtcttggc tgctgtctcc ttccttgcca a 3331

<210> 32

<211> 5224

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 32

ggatcccctg ctgcagcgcg gcggcccgtt acacctccat cgtgcggacg ttgttcccgc 60
 gccgcgagg gtggacggag gtgccggcgt gacgctccac cagcatgtgc cgcaccccga 120
 gccggcccag gaacacggac gtcgacaggc ccacgagcga tccgcccagc acgaggaccg 180
 gaacctgtg gaccgtgtcc ccggcccgat cggtcttgc gttcatcttt ctctccagc 240
 gcgtgatgtc cgcacctcg gccggtttcg gccggggcga tgcattcccc gcgaggctgg 300
 agcgcggtgc gccggggacc acacttcacc cgtttaacct gctgcgttcg cgcaggggca 360
 cggcacgccc gacgatcgtg ctacggggc gacgcaccgt catgtgacgc gtcggccgcc 420
 ttaccgttcc tccaggaaga ggtgcgcctc aatgacggtc tctgccgtg tgtccacggt 480
 cccggaccgt gtccccctca ccgtgttcga cggttcccgg gtgcgggtcg tgctgatgct 540
 ggacatccgc gacgggacgc aagcggaggt cctggacgcc tacgagcgga tgtccgaccg 600
 ggtcgccgcc gtgccggggc acatcagcga ccagctgtgc cagtcgctgg agaaccacac 660
 ccagtggctc atcaccagcg agtgggagag cgcaccggag ttcctcgcct gggccaacag 720
 cgaggaacac ctggagatgg tccgtcccct ggagccctac gtccgcggca ccactcgat 780
 gcgtactcg gtgctgcgcg agacggccga ggagcgggcc ggggcgggtg cggcgcccg 840
 gggcgcgctg cagccccggc cgcgcacatcg cgacaacgtg gtccggcacg ccgtcaccta 900
 caccgtcaag cccgacagcg tcaccgaggt cgtgaagatc ctctccgcct acacctcgcc 960
 cgagggtgcg gtggacgaca ccacgcggct cgtgcgcacc tccctcttcc tgtacggcaa 1020

-115-

ccgggtcgtc cgggcgatcg aggtgcgggg cgacctgcag gccgccctgc gccacgtggc 1080
ccggcagccg gaggtgcgcg ccgtcgagga agccctcacc ccgcacatcg aacaggaccg 1140
ggacctcacc gaccgcgggt ccgccgggt gttcttcacc cgggccgcgc tgccggccgt 1200
ccaccacgtg gtgtccgggc gcgggacggg cggcgacacg cagcggtgcg cgctgtacta 1260
cccggcccac cccggcgccg gaccggcgct cggccggctg ctggcgcggc agggcgaggc 1320
caccgtgggc gaccgggga gtccggtcgt cgctgcacc gtcttcacc gcgacgacct 1380
cgctgtacgg ctgctcgaca cggcgggcg caccggagcg gcgcccgggg ccgtcctggc 1440
cctgcacgag ccggacgccc tcggcgaggc cggcgggctg ctggacgccg ccgcgctcgg 1500
cgccgacggc ccccggaag accgggcgct gccgacgttc ctgcgcacg cccggatgcg 1560
gcctctgaca gaccgtcagt cgccggcctc ctgaccccc gctcgccga cctcaggag 1620
tgaccyacat gacagaacag caggcacgca tcgtgcctt cgacgacgtc ccgccaacc 1680
ggcgggcgcg cggcgacgtc cgggccctgc tcacgccac gaccgcgggg gcgaccagcg 1740
gcttcatggg cgtggccgtc gtacggcccg gagaacgcat ctccgagcac taccaccgt 1800
actccgagga gttcgtgtac gtcaccgccg gcgccttcga ggtggacctg gacgacgtgc 1860
cgcatcccct gcgcaccggg cagggcctgc tcatcccaa ggacgtgcgc caccgcttc 1920
gcaacaccgg cgacgtcgag gcgcgctcg tcttcacct gggtcgctg gcccccggc 1980
cggacctcgg gcacgtcgac accgaggaga ccgacgagac cgcgccggcc ggggtggtgt 2040
catgagccgc cgggtcgtcg tcaccggcat aggcgtcgtc gcccggggc gcacggcg 2100
ggcccggttc tgggacctgc tggccggcg gcgtacggcg acgcgccga tctcctgtt 2160
cgaccggcg cgctgcgt cgacgatcg cgccgagtgc gacttcgacc cgtccgcgca 2220
cggcctggac gacgagacgg tccggcggtg cgaccgttac gtgcagttcg cgctggtcgc 2280
caccgccgag gcggtccgcg acgcgggcct ggacaccacg cgcgaggacc cctggcgcat 2340
gggggcccgt ctcggcacgg cggtcggcg caccaccgc ctggagcacg actacgtcct 2400
ggtcagcgag ggcggtcgc gctgggacgt ggaccaccgg cgggccgagc cgcacctgca 2460
ccgcgccttc gccccagca cgctgcctc caccgtcgcc gagaccttcg gcgcgagg 2520
cccgtgcag accgtctcca ccggctgcac gtccgggctg gacgcggtgg ggtacgccta 2580

-116-

ccacgccatc gccgagggcc gtgccgacgt gtgcctggcg ggcgcctcgg actcgccgat 2640
atcgccgatc accatggcgt gcttcgacgc catcaaggcg acctcgccca gcaacgacga 2700
cccggagcac gcctcccgcc ccttcgacgc ccgccgcaac gggttcgtga tgggcgaggg 2760
cggcgcggtg ctctgtctgg aggagctgga gcacgcccgg gcccgcgggcg cggacgtcta 2820
ctgcgagctc gccggctacg ccaccttcgg caacgcccac cacatgaccg ggctcaccgg 2880
ggagggcctg gagatggcgc gggccatcga caccgcgctg gacatggccc gcctggacgg 2940
cacggacatc gactacgtca acgcgcacgg ctccggcacc cagcagaacg accggcacga 3000
gaccgcggcg gtcaagcggc cgctgggcga gcacgcgtac cggaccccga tgagctcgat 3060
caagtcgatg gtgggccact cgctcggcgc gatcggctcg atcgaggctg tcgcctgcgt 3120
cctcgccctg gcgcaccagg tggcgccgcc caccggccaac tacgagacac cggaccccga 3180
gtgcgacctg gactacgtgc cgcgcgaggg acgcgagcgg gagctgcgca gcgtgctgtc 3240
ggtagggcagc ggcttcggcg gcttcagtc cgcggtcgtg ctgaccggac cggagaggag 3300
gctgagatga gcgcaccccg gcgagccgtc gtcaccggac tcggagtggg ggcaccccac 3360
ggcatcggtg ccgagacgtt ctggaagacg gccgtggacg gcaccagcag cctggcccgg 3420
atcgaccggg agggctgcgg ccacctgcc ctgaagatcg ccggccaggt ccccgacttc 3480
gaccgggccg ccctgatcga ggacacctac ctctccaga ccgaccgctt caccacttc 3540
gcgatggcg ccaccagct cgcctcgac gacgcccggc tctccgcgc cgacatcgac 3600
tcgccgtact cggtagggcgt ggtgacggcc gcgggctccg gcggcggcga gttcggccag 3660
cgcgagctgc agaaactgtg gggccagggc tcgaagtacg tcggccccta ccagtcgatc 3720
gcctggttct acgcggcgag caccggccag atctccatcc gcggcggtt caagggcccc 3780
tgcggcgtgg tggccgcga cgaggccggc ggctggacg ccctcgcgca cgccgcgctg 3840
gcggtacggc gcggcaccgc caccgtcgtc gccggcgcgca ccgaggcccc gctggccccg 3900
tactcgatgg tctgccagct gggttaccgg gagctcagcc gcagcgccga cccgggccgg 3960
gcctaccgtc ccttcacctc cgccgctgc gggttcgtgc ccgccgaggg cggggcgatg 4020
ttcgtcctgg aggaggaggg gcgggcacgc gagcgggcg ccgacgcgcg ggcgacggtg 4080
gccggccacg cgccacgtt caccggcgcc tcccgctggg aggagtccag ggccggcctg 4140

-117-

gcgcacgcga tcggcacggc gctggcgcg gccggctgcc gtccgcagga cgtggacgtc 4200
 gtgttcgccg acgccctcgg cgtgccggag gccgaccggg ccgaggccct ggccctggcc 4260
 gacgcgctcg gccgcacgc gcggcgggtc cccgtcaccg ccccgaaggc gggcatcggc 4320
 cgggcgttct gcgcggccgc ggtgctcgac gtggcgaccg cgctgctcgc catggagcac 4380
 gagctgatcc cgcccacccc ccatgtgctc gacgtctgcc acgacctgga cctggtggtc 4440
 ggccggggcg gtcccggccg gccgcgcacc gcgctggtgc tcagccgcgg actcatgggc 4500
 aacaactcgg cgctcgtcct gcgcaggggc gccgcgccgt tccccgagta agtaccgccga 4560
 acaggtgtct cacgtccctt tcgggcgcgg gcacccgagt caaggagctc aaccacatga 4620
 ccgacatgac cgaacgcgtg ggcacccagg tgacctcga ggaactgtcc gccctgatga 4680
 agcgcaccgc gggcgtgcac gtggaaccgc ctgacctgcg ggcgcgggcc gaggagggct 4740
 tcgacggctt cggcctggac tccctgggcc tgctgggcat cgtggccgag ctggagaaga 4800
 agcacggcgt gggactgccg gagcaggtgg agcgtgcaa gacgccgcg gagttcctcg 4860
 cgcaggtgaa cgccaccctc aggacggcgg tgtgacatgg ccgggcacac cgagaacgag 4920
 atcgtcatcg ccgcgccgct ggacctggtc tgggacatga ccaacgacgt cgagaactgg 4980
 ccgcggctgt tcagcgagta cgcctccgcc gagatcctgg agcgcgaggg cgaccgcgtc 5040
 cgcttccggc tcaccatgca cccggacgac gagggccggg tgtggagctg ggtctccgaa 5100
 cgcgtcgccg accgcgcctc cctgacggtc cgcgcccacc gcgtggagac cgcccccttc 5160
 cagttcatgg acatccagtg ggtgtacgag cagacgcccg agggcgtgct gatgcgctgg 5220
 atcc 5224

<210> 33

<211> 30601

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 33

gatcttagac cttattcact tgatacgtgt aatagttatt acgatagtat gtttttggcc 60
 gattcctccg cgtcttcttt cgacgacgtg gaggtggagg caaaagcgaa gtagttgtgg 120

-118-

aagaataaga attatgatta tcatgattat tattcaaatt aactctattg ttacgtaccg 180
cgctccatgc agacgtttgc caggagacga cgggtggaag gataggaagc gaagaagcgg 240
aagcgggaaga cgctcgatatt gaattcgaag atgataatga tgtcattgat gctgatgatg 300
ttttgttggtg ataatgagat cggcatggag gcatttcaca atctctttgt tcgcgaggct 360
taatctctga gcactcgata tcgtcttggt tacgaccgga aagcacgtct tcacaccaga 420
ttttgcggcg ttgaactccc ccgccacacg atacagaaca ctggaattat tattagaagc 480
ttcaatgatg ttctaagaac ttacgtgagt ccatggagat atctgccaag aattatttgt 540
gagtgggtgga catagtctctt cattgcattt atcaaacatc tttggttttc tggtttcac 600
gcaagaagac gaagtgcaag atacactgcg acgacgccat cccccaccac aagaagcaga 660
gcactgaaca atcgtaacatt agtaaattct aaatctgaaa attatatatc ccacttttga 720
ccaatctcca ataatccagg atccaatatg ttcttctccc tttggacagg gttcaagtcg 780
gcaatttctt gcacttggtg gtctcttttg cacatcacia tcaacatctt tcaaaatcgt 840
ccgaccaccg tcttcgcac tgacgcatgt aacatttcta ctttggtgaa catgagttcc 900
acaagtagct ggacactctt cccattccgc cattttccag tatgaacaat cacgaaggcg 960
acaatttctt gttgatactt ccttatccaa atgattgcaa tactcatcag gaagatcacg 1020
aacatgatct cggcacttga gaagacgacg ttgagtacca ttaccacaag ttgctgaaca 1080
ggctgtccat ggtccggttg cccatcggat tgggtgtacg tcggcttgaa gtttttgaag 1140
tactctgggc ccatcacaag tatctttttc acaagtcttt tttaggcgtg gacgagtatt 1200
ctgaaatgat attttcgttc aagattaata gcaaactgaa acgtactcga tcacaaaaat 1260
attcatcaac aatagtctct tcagatccac gagtacacga aacacttcta gtctgaattc 1320
ctgatccaca agtgactgag caaggggacc aatgacttgg tttccaagat gtacatggca 1380
gaagatggca agtttgacta gtttctggca ttttggatc tccacaaaaa gaagcatcaa 1440
cagattgttc gcggtatatg cattcggttg tacgttcccg atgaccgatt ccacaagata 1500
cagaacactg aaacgtatatt atggtattga caacagcaat tctggagtat ttgaataaac 1560
ttacagcact ccaatcagta tttctccaaa atgggcaagt gcctaaatta catgtctgat 1620
gagaagcagg ccgatcagat gcagtaccac aaagtgacat atcgacttca gttccatttc 1680

-119-

cagaaacaca tgaaactctt cttgacgacc atccatcctc acaagaaaca ctacactgag 1740
accattctcc aagtttatat tttggacatg attctctatg acatggtttt gtaattatct 1800
tttccatttt aaggcaacga tgttccggta gtactgatct atgacgatcg gtacaattag 1860
cgtctcgata ctgtacacca tctccacact tagctgagca gtcagaccag actccgaact 1920
gccaccaagt acaagcatgt tcattacaat gttcttgtgt ctgtgctgga ccacatctgg 1980
atgtatgtgt ttcccgatcg gctgcatcca aacattgagc atgacgcatt ttgactccac 2040
catcacaact tcgagagcac tctgaccaat gcccataaac ccatcttggga catggaattc 2100
tgttacattc ccgttctgtc gcctctttct gttctctgcc gcacaatgac tcatcaactc 2160
gacgattcga atcatcaacg caatatgact tccgatgcat tttccattc gatccgcaag 2220
tttcagaaca tgaagtccat tctccatagt tccattttct tccagagcag tcaatgtaac 2280
aactgycaat atcggatggg tttgaattac gatcacatag atgttcggat gctggagttt 2340
gacgatcacc ctccattttt acgcaagaaa ctcgttgacg tttctgtcca gatccacatt 2400
tggcactaca actagacaca tcttcagtga tccatctgta aatataaaaa tttattatag 2460
aaatctaatag aaaatatgta gtttaccttg tagaacaatc tatattgcac attcgtgttg 2520
cttgtttttg tttgagaaca ttttgacaat ttctatcatg actttgacga tgagtcgaca 2580
tgtccagaca cattaatttt tgcgattgct gtccacgaca ggctctatca cattctgtcc 2640
aagtatccgt aactctccac aaatacaatg cactggatat tggccgaatt acagcatttg 2700
gaacagccgc agtcatgtac tcatatgaga tgtcgggtgg atgactacca acagaaagaa 2760
catgaacata aatgtcactt ctaatcggac cagttccatt tatccgttca ataattgcat 2820
cagaaccaga atattcgaga acagtgtctt ggaatgcaat ttgttggcga gccagtgata 2880
cttggaatg accgttaagt aggaattcac cattggcggc acggagagct gaaggttaaa 2940
ataaagattt tcatgggtat tgataacaca agggtgagtg atgaaaaaag taaatgttcc 3000
aaaaacactt tgtatagaaa ctcaaaaga taattgtcat cttctttcat attattatat 3060
cctttctgcc ggatatcaat atttgacaga ccagctggaa tcttcattac ttcgttataa 3120
ccaaagggtc cttgctcatt aaatgttcct ttgacaacct tacaggaaga atcatcccca 3180
ccgcaaacac cacatttgtc tcttcggaga gttgaatgaa gttgatgatc acagcctgaa 3240

-120-

aatccactta ttttcaattt ttttttgaaa tcagatcaat gttacctgct ggcatacaag 3300
ctccagctac acaaatatcg tctccatttc tatcacatgg tgttccatca acaactttat 3360
ctcgaagcag atagaacgct gcagatccac tgagccgaca atacagcttg caacgttcat 3420
ttggtgcaac attcgcatat tttggaaccc agtgagtatt cgttgaagcg acaccttgga 3480
ttccaatatc tttattgttg aattcagaac attgaacttc acggtatggg tgagtatccc 3540
atgggcattc ttgtgtatta catgaccgat aacgttctcg ttgaccaaca cagtactttc 3600
caccatttcg aggtctaaag taatatggga aaatgtcatt ttaatatga taggaaagct 3660
tagccagtgt ggcctaaaag ctggaagttt ttttaaagat gcgttttcta tcaatttaag 3720
ataaccggct acttcaggtg attctataaa tttataaag cttggaagct aggtaaatct 3780
gaaaagcctt aaactatctc gaagcggccc gaaagcccag aaaagcagag acggacaaac 3840
atttaagagt gatcagaagc actccatacc ttgatgttac atttgatttt agtgtttcca 3900
cctcgttttc acttctgaac tcgccgattg aaaatatattt gattgaatat attatttgct 3960
ttcagactat ttgatatcat ttcgtttggc agtttaactc actttgggct gtcacaatct 4020
cttaatcctt tttgaacacc accaccacaa gtacgactgc attctcccca tgatcgccag 4080
tcacccatt gtccgtcaat tttggtaagg gattcggggg ctagacgaac acaggctcca 4140
tgatgacaga actaaatatc caagttttta tgagtttctt ttgtgattaa tttctgagat 4200
actcaccatg cttcttgatt cgtcacaagg agttccgctg gcccatggca tatgctgagt 4260
tcgacagccc atctggcttc cgtagaatgt tgcacaccaa agacggcggc atgtcggctg 4320
taaaatatca atgtttcatc ttaaagaata tatttaggca aactaaccat ataagggcac 4380
aactcagaag ctggtccaaa tacaaacttg cactgttgat gagcatcgta tttctttcct 4440
ggttcatcac gtacaaagac atcctcgtag taacgacgtt cgaccggctg atcgaataga 4500
cattgagttt gacctcgatt atttctgaca aattgacaat taaatagaat caaaatttta 4560
atagctatct tactcgagga atcgttcgag cattccagct gaacatggcg accaactcca 4620
tggtatgagtg ttatattcca acgttggtgc cattatgtgg aagttgttct gaaactgcgt 4680
tttatcaaat ttagtgcttt ggaacttgca aacctatta accggcatgt aggtagagca 4740
ttttcgttcg tcatcatgag gaatcgaaaa cacatgacc aattcatgag caattgtgaa 4800

-121-

tgcagcactc aatccattgt cttctatgat tgcacaactt ttttgcata cacaattgt 4860
tccaagttca gcaagtcctaa gtgtatcgca ttttccttgt gatcgacaaa tatctttacg 4920
cgtcaaaagg attgcaacgt catgatgttg gacactcgaa tcactctggat cattgtaata 4980
ctgctgccat ctacagaaat cttgaagtgt ttgttgagcg ttctgagtga ttcgtggtcc 5040
agcgttttcc gttttcaaaa cgatcaactt gacaacaacg acattgatag atgcacgaag 5100
ggattggtga cgatagatgg aggcaactgt ggagaagaga gtgagaacgt agtcttcaag 5160
agatcttccg tgatattcgt acatttttgt atccgccacc acaaggactt caacatagt 5220
atcccaagag ttggcagctc ttcgggatct tgctttgcgt tctataatta aatccttttg 5280
tttcataaaa ttatttaaac atttttttac tgtatccttc ctattaatct tgcaccccag 5340
agctccactt tgacctatct ttgttgatc tgactctatc aaaaactgtt caactatgaa 5400
aatggggatg caagactaat aaaaggtatt ggtaactggt tccagtagag ctttttttac 5460
tatctgtttc attgattcaa ttttcagatg tttatataac catcttaacc gttcaaact 5520
cataacatag aacagcctgg cagcccgtga aaaggtgctg aaatcccagt aatttcaatg 5580
gcattcgacc acacacaagt gatccattat cctttgctct tttacttctg taactaccat 5640
tagctatagg ggaccacga gcaaaattct atagtttctg tgtgtgttag ggtgttttaa 5700
tgggctatta cacaacaccc gatgggatca gcagaatctg agatcttttg ggaaccggaa 5760
aaaaatattg tgataacttc tcttttttct acatttttta cagaactagc aggtaaactt 5820
tcagattgaa atctcgaaaa atgcatccgc ctactcaaaa agtcgttttt aaaatgattg 5880
tttctttgtg tttgtcctct ttttcccgga cgtacgcaac acaaaaccgc ttgcgcgagg 5940
atgtacacaa aacgtacgtt ctgcgcaatc ttttccctgc agctctctct ctctcacttt 6000
ttctactcca taaatcagtt ctctgtctgt ctcccaccac cttaatcatc atcagcatca 6060
tcacagtccc ccaccaagt tcttgtgtct tctctgacct ttacacgtcg actagggaaa 6120
agctctcaag cagacactcg agcgccagtt gaaaaaata gtgtgtccaa atgagcagtt 6180
tcgaatttga accgtttgtt cttgttctga cataaaccca aaaaaacgaa ctaggcggca 6240
aaagagatct ggataatcta aagaatctag acaaatttca gaagttctta ccaataacat 6300
cttcccactg atcttgccac gtggcaaccg tcgtctccgt ctggttgaca ctggctcag 6360

-122-

taagatggtc aaacgatttg aagtgcattg gatcgaactt tcggacgaga tgttgcctat 6420
ggcgacttgc tccgtcgtgc tctagatggt taaagtgtca gagaaagtga ttacaaagtt 6480
tctacctgtt ccgtttccac taataattgg ctcaaccgta tggattccgc tgggtagtgc 6540
aagcattccg tactgaaaaa ggcttttatt caccaaaatt cgaacttata caaaccaatc 6600
cgtcttccga gtcgcataaa ttgacgatgc tgtgctgatg tacaccttta acgtgtgcac 6660
ggtagatata atcgggatct gttcgagaca ttccacctct aacctcctcc tccgagtcca 6720
aatataagac catcggcgcg aaatttgaat tggaaaagtg gggaacactt ctggaattga 6780
aaattaatac gactgttata ataaaattga aatctcatac ttgttatgtg agtccggtat 6840
ttgattccat ctgtgcaaat gaacgatgta gacggcatca tctgatcgta atcgtaagtg 6900
acaagcatgt ccacagtctc tggcaactcc ttggagtcga cgtcgccgat ctgttgacgt 6960
gacatcacgt tttccacgac gtccataaga atctcttcgg acgatgtgat ggctgtcgat 7020
gacgtgtata ccggcgtctt gacgccatcg actgtgatgc actggcacac ctgaaaactta 7080
gaacattatt tcacttcaaa acttttttga ttgttacctg agtacttggc cctggagaac 7140
agcacatctg atgagaattc tgagatcgtg ccactccctg ctgaaaggaa catttggtta 7200
aaaacaaaag ctgataaatt aaaataatta gataaaaacg aacattgcaa cgcataaacg 7260
aggcagacga cgaggagtat gagagcggcg acgacgggct gcagcagatg gaatgagccg 7320
ccgatggagc gcataccaac agctccgtga tgatgattat gattgtgtgg agagcagcaa 7380
agaaaaaaga gatggaaaga agcagaagct ccgataaagt tcgtccgtct cttctgaaac 7440
cttccaaaaa ctacctgctc gaggtgaagg gaagtcgtct gattgaactg ctactgcttc 7500
tgatcttttg ataactctcc gagtttgtgt tttcgtttag tcgaattaaa attgtagatt 7560
gtggaatgag cacttgcaat agggaaacaga gcatcacaga ctgaaaaatt aaaaattatc 7620
tagaatgcaa gcaattttta aatttgtttt aaaatcactt attctgacgc catcttcttt 7680
tccgatttgc gcagaataaa taaaaacttg actgtaatat tgggaaaatt tcgaaaaaaa 7740
acaccgttaa gtctgagccc acctttcgcc ttttttgggt gacgaaaaaa accaaacaag 7800
ctttaaattc ataaaattcc caattttaaa aacatctaaa gtcaattcct cccaataatg 7860
catttgatata tgaacaaaag tctgttgacc ataagtcgtt atattactac aagcaattgg 7920

-123-

tcatcaacaa acctcataaa aatcagtttt gaacgggagc aatttatata aactctgtgt 7980
gctcttttgc tctttttctt atttcttagt tgtcttctag ttccgccacc actttcgctg 8040
ctcttgacga aatctgtaaa ttgttcgtca tttttgattt ataagatttg tttggctctc 8100
ggtaggagct ctcaagctgc taatagtcct atagtaaagt actaaaaaca caaagaagca 8160
gatgaagggtg tcataaaaca ctgataagaa tcatcatgat taggttggtg cagagaaaag 8220
aagaagaaga aaaaggagat ttagagaaga gaaacaagaa taaaaatgca aaaataaaaa 8280
aaatagtaat aacaatgaac gcagagtctt ccatgttgga gaaggaacag gacccatgtt 8340
gatgtgtatc tgaggggac ccaatgtgtg tgatggtagt aaacacttga gagggaaactt 8400
ccacccccga ctagatgatt ggaagcaatt gatgatagat gtagagccaa agaattggga 8460
cctactaatg atctagtcaa gattcttctg ataagagaaa aagacaagga agaacatgaa 8520
aatgactggt gattgaaaaa taaaacggtt tatgaagtcg ggggtgtacta aagatgcaag 8580
gtctcttggtg acgtattttt tcttccaggc acgttcgctg tattcacgat tttatgcaaa 8640
caaggtaagg agtggttttg attttgaata taaaattta aaagaaatta aagttagaca 8700
tttgaaaaat tagacaccct catgggaaaa attatagggc gaggagaggc ggtgagaggc 8760
gccctaattt ctgctcggtc gggtagaatg tctaattctaa atcctacctc atgtttggct 8820
ccttcttaaa tcaaagctt aaggatcatc ctgaaacgtg cagttgacaa gttcaatggt 8880
aagaacaggg agcaagcatt tacaacaaaa aagtaaaca aaattgcatt tgtcgcagtt 8940
caaaatggaa caactcactc ccactcgaga acgttttgaa ggggagagga agaagaggaa 9000
aatcatcaca caggcacatg gaacttctgg gacacaaaac aatacaaaact gggtgccgtg 9060
aatctcagta cacacacaca aaaatcaaaa aagacggaaa ttaggagcag atgtggtaaa 9120
gggtggttca atgctgatgg gagagagagg gagaaacttc aaaaaaagaa gtttagattt 9180
atgttggtta tttcaatcct aaatttatct aaacaattct aaaaatgctg gttttggaag 9240
gttatctggt aatgggtgaag ttttataaac aaaacaagac aaacaattct tgagatctta 9300
aaaatcttag cgactacaac aatatttagg tatttttttaa tggaaaaaag tattgattgt 9360
tgacttgga aattgaacag caattttttg tacttttaaa tcagttatat ttttaactttt 9420
tagagcacat ttcgtagaca aaagggaaaa cgattggtcc aacatgtgaa gatgatgatg 9480

-124-

tcaacaagtt ttggatcggg gccaaaaaag aaacaaaaca ttcataccat gatgggaaac 9540
aagaggtgca gcaacaactt ttatcaatat ttgttttatg ttttgattat ttttctggca 9600
cccagccagt aattcttttc cgtagagttg acctagaaaa tgttggaggc ggagtcttag 9660
gatcaagaga cgcagactat caaagtaaaa tgagtaaaag gaagtgatat aaacttagga 9720
aacggaggaa aaaaggacga tgataagaga ttgaagactt ggaagagtgt gctctttgcg 9780
ggagagcata ttcttttgag aaaaatggga cctaggggca actgacgcaa ttgaaacatg 9840
gtcgagcggg cggcgggaag aaaaaaagtg aagaaggatg ggcaagaaga agcaagagaa 9900
atggcaccca ccgtggaaca tgatcatgat gattgagagt gaaaattgga aatctcgaac 9960
ttttttgcaa cggcgcgttt tgaaaaacta acaaagttga ccaaaaaatt attttacatg 10020
tataccggga tgtctaagaa ttgtaaaatt gagtgatcct ttctgtgaca taatttaaag 10080
caatttattt tggttatttc taagcgcctt tttatactag catgttatat tgttaatttt 10140
attatctaaa ctgccgttct tcctatatatt attattgcac cccttttgtt cattctgaca 10200
gactatacct cgattaatca taaaaatgtc aaaaaagaat aaaaacaact aaaattaaga 10260
aaatacaaga aatttatcaa ttgccaaaaa ttcggccaat cggaaaaatg cttgggtgcc 10320
aatttgtcaa aaatttagtc aattggaatt tgtcgatttt ccgaaatgat atgaaagttt 10380
gaatgatgca gctaattttg cagtttaagt ttacattttc aagtttactg taatttttcc 10440
aaaatatgaa gaagagtttt acgaaattaa aagataataa aaaagcaatg caaacatagc 10500
tatgaaatct gatcccgact aagtttgatg gacataggat taataatatt agtctaactt 10560
tctatagaac actaaataaa tacattcact ctcgaaactc tcccttttct gccatcaact 10620
accgtactca cttttgactc aatgaccgc aactgtcaag atgagttagt ttcaagattc 10680
tctgaaacag caataatcta acaagagaaa ctgaaaaaat agagtaaaac taataataat 10740
accacataaa ttgacatgca tgatagatga ttttccggtt ttcaacaaga aaaacaacaa 10800
tttccgagaa atcctcatag tttttggtta gaaaaataa attgatagtg atacggtatg 10860
actattactt ctaaagactt acctgattag aaacgtgtag taattgaaga agaaaagttg 10920
aatttgagaa gttgaatcga gtttacgatg tctgaaaaaa acatagatat tatggtaaga 10980
tcaagcatag aaaaaatgga aaaatacaag aaaatagaga ctagagattg cataggtttt 11040

-125-

gcgggtggcga aaccgcacac atttttgtct gtgttatctc taattttacg ctctcgggtg 11100
tctctattta ctgtccagaa gaatgaagaa tatgggggaa aagtgcgcgg gaaaattgag 11160
agaccgagtg atgagagccg cagttttgca aaactttttc gggcaataat ccgccggcga 11220
gtactacgag aagcacacac acatacgaaa actggtgagt taaaacctaa aaaattgttt 11280
cgacatattt aattttcgaa ctaaagttta gagggctctg gcgtgcattt ttgaattttc 11340
caaacaactt tcagttttgc ggaagaaaat tacagcgatt ttttcgaata tttctgaaaa 11400
caacactatt gcgtatcaaa aatttttcga ttgccaaaaa ttcagactaa gttttggtgg 11460
ttttggtttg caaacattta aaagaactca aaaaacattt ttagatgttc gaaaccgtac 11520
aattgtagga tacaatagc tacagaacaa ttagaatata aaatagagtt gtcaaacatg 11580
tttaactaat acaaaaacac agaaactttg aaactcgaaa tttttatatc aaaattgaaa 11640
aagcttgtaa aatttaaata tggatacagt acaacaata taatcataga tcaaatagtt 11700
cattttattta tatatcttgg caaatcaaat cgtatccctt acccactcat attcgatgag 11760
totacaatta aatcagttgt tttttcatcc tcccgacta ttagtttaac ttccacttga 11820
acaagggcaa agagtacatt aggaagagtt tatgatgaca ggaaaaaagc tatgtaaaat 11880
gacctctttg gattgaaaaa gcgaacgaat tgaggtttag gacccccgga aaatgaagaa 11940
ttcgtggcct cgagaatagc aaattggcgg aattaattat ccgtaagagt gtgaattgga 12000
aacaaccggg acgaatgat tactgaatca aaaatgaaag aaagaagaga tgaaaatacg 12060
tgtgaatcgg atgaaatgtg atgattttag aataacctaa atgcaacaaa acgacgtaaa 12120
gacgcggaag aacaggaatg atcaaggggt acatcttata ggggaaaaat gcactttttg 12180
tgctccaaat gtgagagata atcaggtagg aagagacgta gaataggaac aggaaacggt 12240
aacgatagtg cgcaggtgct tgatttctgt gcttttgcac gtgttccgat ggaatttttg 12300
gaacttttca aggggtttcg gaaaggggtc gagatttcgc atgtgagctt tggaagaatt 12360
ttggaagaac tttcaggata acatcgctca agcttggttg ttagatttca gacttcaaag 12420
tatataccga ttattgaaac attttaatcg tttcttacta ttagtaaagt ttaatcacag 12480
tttgaaaaaa aaatcacaat tttttcaatt atttagacca aactaattat ggtacagaaa 12540
ataacttgca acccgggtat ttcattctaa ttttttcat ttggaaccac tagtttttga 12600

-126-

aatagaaact cgtaggatt cttcacatat tatcataact atcagtatgt tgttgacacat 12660
cagatctaag ttcagtctaa ttagaatcgc aaatttgacc atcacacttt aaaacaaatt 12720
tacttaggca cagggcatcc ttctaacttt tttgtcccg acaaaatgat gacaaaaatg 12780
acgtgaggaa tcaaggagaa aaaggaaaag aacaggaagc gaaaagtagg agaagctctt 12840
gatttctgtg ctcatctctt gtccggatga gctcactgtt tgcaacattg gcgttggtgc 12900
gcgggaatcg ccattgccga actttttcaa gagacagaga gagagagaaa gagaaggaaa 12960
acgttccgat ttttaaaatg gaaaaaaatg aaagaggaag atgatgaaaa aatgaactct 13020
gcgtgacatt tgtaatatg gaaaaagcat gattacttca aaattgtaca ctaatcccca 13080
cagcacacat tttgaagact tttttacaaa aacaatggtt taagcaagct ttaaaaaatt 13140
gatagtatcc ttaatgctta atcatatcca agtttagttt taagttttga tttcaaaaat 13200
ttctacatca aaaaatcata cttagtgtt atatgcaaaa caatttttaa attcaaggac 13260
atatttttga tttttggaag gatgataact tttttgtgat tccgaaaaag attaaagtag 13320
gtttaaaacc tctgacctc tacagaaaaa acattacctc tatgaatttt ttttcatctc 13380
gttcagaact tgtctcgggt caagccatga agacatgaga taggggtgtaa aacgttccga 13440
agagagggtt atgactatta ttgtagtga agagaaaaat gatattctca tggatttcat 13500
acagatggtc ggatttcatt cataaaatat cataagaaaa ggtacgttta tgactgtcta 13560
ggtcaactgg ttttaggttt cttggaattg tttcaaact ttttaggaaa tattttcttg 13620
caaatatcta ctaaattgaa gtttggtatt gtttttgaca tattgtagat tttagagaag 13680
aatcactcag agcaaaaatg ttgggaaaac gtgagaaaaa tccaagagac aaaagaatgg 13740
tcttactatt agtagatcaa aaaaccagac caattattca tattcctact attcaatata 13800
tattcaaaaa tgagcaaacc aagaaattgc acctaattha tcatcccaca tatattccga 13860
cgaaacattc gctctacctt ctttttttct gtctaggaat tataaagggc cataattata 13920
atttcagtca aggttttgga aaattgttcg actaaccatt atgaaagtta aaaaccaatc 13980
agtcaaaaca cacaatagga atataaaatt cgtagaagaa aagctttttt tttggtcgaa 14040
agcaaaatca aattctggaa ctgcgacttt tttagtcaa ttatccattc aacgcaagtt 14100
gtctttcaaa atttaaattc cagaagagtt ataacaaaac agacaggtgt acaagtataa 14160

-127-

gaaaaataca agttttatcg taaaaactga tacgaatcta gatacacctg ttaaaaaagg 14220
ctttctcgaa acccagatgc cgtacgaagt aagcagcagc caactaaaca ttttgagtaa 14280
acatatggca agtgttttgg cgcaaattgt aaagattttc cgtgtgggta actagaattt 14340
gaaactgtaa gtatgacgac ttaaccacac aaaatcaaat ttcaaaagat cttaaaatgt 14400
tcgaactttc aaaactttta agctctctcg catctaccgt agtcttctaa taacaacagt 14460
cgtaagagaa agctcaaaat ttttcaaact ttttctgaat gacagaatca gttgtatata 14520
aaaaaaaccc ccaaaatgcg agcccatga acctgacaac cagacaagtc gaaattgtaa 14580
aatcgtatag atcttggttc acgacatgaa gagcaccgcg ggggcacacg agagcaacta 14640
ctgcaagcgc tctgaagag aagaaacatc tttttccag gaccactggc cagtagtgct 14700
ccccagatc actttctttt ttcttgcttc atctgatttg tgtctgcgtc gtctgatctc 14760
tttagaacct atccttcttc ttcttctttt tgatacttcg acatcagaac aacatcgaca 14820
tgtatcatct tttctctttt ttttttgta tctattcatt cattcacttt tcatttagtt 14880
tgattaatag gtgacatgaa ctcttgtcac ttttcaattt caacttctta aatcttaaac 14940
tcacagtgat tccagatatg agcaactcca atgaggtggt gagtagaaac ctaaataata 15000
cattttggat gttttgataa tggtggaaca aataaattga aacaaacaag acttgaaata 15060
gagacaacgt gcagaataat gtctaccagc tggtttcagt ggcataattgt accacgaacg 15120
tccgacagaa cgaataacat aaagatcaag aaaaactggt tgggagcaga caaacaatca 15180
gaacacagtt ttggtgaggg gaccaaata taattaatga ctaaatttta acgaagaaag 15240
tgctcgaaaa gaacagaatt tagaagttga tgaacaatat ttttactttt agattaacaa 15300
ttatgcttta caaatgacat ccaatctaaa gcatctggta atctgaaatt tgtcaaaaca 15360
gctttcaaga ctagtttcaa atttgtcgat tcaatggatc aagtgtgtaa ttgatccaat 15420
aaaaaagagt ataaagtgag aaggaagaaa gtgtgaaaaa agaagaacgt gaaacgtgca 15480
gaagatacga aatgagtttg aagactgcac ttttcgagcc tcgatgggtca gtcacttggg 15540
cagttgcgaa aaagctgtga aaatgatata ttgtgtcggc tctcgtagag aagaaagcca 15600
catggtcagg atgactccaa ctgggatatt cagttgtaaa gaacacaatt gatatttttg 15660
catctttttt aactagtttt tacaatatga gaaattgttc tgtgcgaaaa atatgacttc 15720

-128-

ttccttggtg cgaagtgt tttccctgga aattccagta aataccta atc gtaaaaaatc 15780
tcagcagaat gtgttcttac attttggtgt aataataatg tattaaaatt gcattaatta 15840
aaaatttctt caaaatgttc ctacgtcttc tatgcacatt atttaggtca cagtttcatg 15900
gagcacaaaa cacctgccga cgcctctaaa atagttataa ctgcgcataa aatcaggtag 15960
aaaaaactac aaaataacca atacaaattg agtagggcga tggagaggtg ggcggttga 16020
gaggcgggca acaagcgtcc tcatgacgcc ttgttcattt agaattgtgt tgctttgaat 16080
tacatacaag tttctaaaat ttaacttaca aaatttaaaa aaagtcacaa caataataaa 16140
agttgtggca atgaaatgtt ttaaaaatct aaatattgag ttttaataa atgatttttg 16200
aaaattcaca aagaaatgtt acaatctgtg aatgaagacg acaatgaaa aagtgaggaa 16260
cggacgcgga tattacacat tcagtcacac aataaacgtt cggacactac cacacatttc 16320
tctcatcatt tttttccaaa gtttattcta aagttcaata ttttagtttg attatttttg 16380
acactattct taaaattaat gtataatagt ttagaaaata ttttgaaaca tgaaactttt 16440
ttgttgataa aatagtgtcc aacatcctta tgttacgcag ttatccaacc acatttttct 16500
catttttcca ccaaaaaaca ctgaaatggt ccataaaacc tattcaaatg gatatgagaa 16560
tattactttt ttgacatgaa attttcaatg atgtaatgta aaacaaagaa aaatattgag 16620
ggaaaaattg aacggcgtat tgcaaaaatc ggtgtgcgga ggaggagaag gaaaaggaag 16680
agcaggagaa gcggaccgaa gaattcagaa gcttttaaaa taagaacggc gactttcaga 16740
caaacaatgg actgttgtat aaaaataaag cggaggcggg agagagtcaa agctttcaga 16800
aatgtattag aataggtttc actacctgtt gttgaactca aaaaggtgtg aaaaagtga 16860
agtttgtctg aagtttatga cgggaagtgt ccatcaaata actttcaaaa tttgacttat 16920
cagtgagaaa aacacgtcat tttggaacgt taaaatgggt ggcaccgcaa aatgttcaca 16980
atgtgaagtg aattacgtaa taaaatcagt tttattaagc ttattaaact aacccttccg 17040
gactatttgt ggaatgaaac aattgggggg gttttttttt ccaattttcg atttttttt 17100
gaatttataa ttaccggaac aaaaatatct ttaaattatt aagatttgag tgatgtttga 17160
aattttgaac ctgcaaaaaca taagcacaaa ataattggagt tttgttttta aaatatcaat 17220
aggtgttttt tcacagaact ttaacaaca aatactcata atttgaatga aaacagtaga 17280

tcccacaata ttttgaaaac ttatctatat atatatatat atatataaa ttacgaaaaa 17340
aaaacaaaaa gaaaaaaaca aataatttgt cagttgataa tttttagata tgagttgcca 17400
aaattgggca atatggtgaa gaaatacggg agttcgtcgc actgtcagac taattttcaa 17460
gtgttcctag tggaatgaaa ctaacagaag ctatacggta tataatatta ggaacacaat 17520
taaaacgaac agcggagaa aagatctagt ggtcacttcc gatttctcag ctgacttttg 17580
aatgggcacc tatcatcatc tcacttggtt atttgaacag tctcgacttt ttccaattgt 17640
tggttcttag ttcaagaaac gaaaaaaga gcaataacgg aacagaaaat tcagaaagtg 17700
gaagagaaat atgagaaaat gatgatgata ataataataa gttagaagag gggtatcgat 17760
gaggaacgga aacgttatct ctgatcgcca tctcattatt attatgagac acaaagatgt 17820
aagttatggt atctttgaaa gaaaagaaaa caggaaatta tacagaacac acacaatttc 17880
ggagatttca ttcgaagaac ctaacccaat ttgaactcac tcccacttcc tcttgtctat 17940
aaaacagtca atcacaggaa caggtgtctg tcttttcaaa atgtatacgt tttccgaata 18000
atgacacaca atatcacaga caaatgatc aatgaggttg cagaaaagaa tgcaaaaaaa 18060
tatagaaaga gagggatgaa aggagataga gaatcaaaat ttgcatagat aaatatgcaa 18120
tagaaaataa caatttttga acaacaaaga aataatttag tggcatataa tatagcgatg 18180
gaacttgcaa atttttagaa ttatcatata aaaataacaa tgtttctata ttttatgcc 18240
tataagtctt gcagtatttc ttaaatttaa cagttcattt cttggtaatc tttattttta 18300
tcaagaagtg ttcaggaaat ttaggacat caaattttta tttattttct aaatctactt 18360
ttatcaaaat ttagaggtc tagtacacat ctacccaaaa agaagacttt ggagctctca 18420
aaaaccacct agtgtatggt aaagtacatg agaagtgcg tgtctttggg cagctggcca 18480
tctttgtcga tatgcgggtg atggtgtttc tgtgagcagt aacaggaaat tctggacacc 18540
tgctagggtg tcaaaccaaa tttatttcaa cccattcttg cttcaaaaaa cccccaacta 18600
aattattcaa attctcgtaa tttaatgaat cactcagtaa ctgtaacgtt ttttttttca 18660
gagacaatga tcgaaagtta acaaaaaaaa ctgaggatta aacgttattt ggtatctaca 18720
gctgacattg gaacatatca aaaagtggta agtgaaagtg aaacgaaaag tgcaacattt 18780
gaaattgaga gtagaaaaga tcattgaagc agaaatatgg aagtgaattg aaagccgtgg 18840

-130-

cgccaaaacg acggtcaggc gccattgaga aaattaatga gagttcggaa ggttgaaaca 18900
acacaaagac aacgtgaaaa attagtttgg agaagataaa aaatgtcttg agatggacga 18960
tttcttagtt agctgagaat agtttacatt gattttcggg aaaacgcaga atgttagaaa 19020
aatggaaaca tgtctagact tcagataaat ttgtagaatt tatatttgta gcaaaagcac 19080
actaacaag gttacaaagc tattaggaaa aatacggaa gtatttttga aaatttttga 19140
tttctctaaa ataataacac cattaatttg ctatatattgc tatatatgct atatagtatg 19200
ttcgcattac tgagcacaaa acttggaana agtttaaaaa aaaaggaaac ttgttttctg 19260
gagaaatcat taaaaacagt acaatttcag acagaaataa atctttcagt gaaagctttt 19320
ttttgagtaa gactaagtat gcactcacia cttttctgag tgttcaaaa atgtttaaag 19380
aaaatactag taaaaatgag catttcgaaa agcaatatat catacaacta cacaaacatt 19440
tcaattaaag gaatcaattt tataatagtt ctaggcaatc ccacttttag attcaatttt 19500
ctagcacagg gagcattgga agatataaaa acataaagat aaaggtgata aaagatccat 19560
taaacacatc atatctatca aaccatcact tccatcaaat ccacagattt atcaciaatc 19620
agtgtgtgac aaatataccg taatattaag ttcaaattgg ggaaaagacg cagacaaagc 19680
ttttgcataa atactaaata attgaaagaa acgcagagaa tgtaagagaa aaatatacaa 19740
tatgtgtatt atcaaccatc aacagttttt gattaaaacc atggagaagc gatatacagg 19800
agcaaattag gagacgcaga ttgagaaaaa atgagaaaat aatgaaagta cggaagggtt 19860
attgtacaat aagacaggta gcatctctca aagaacctat tgtcaagcag tttaaacatt 19920
caacaacggt catttatatt tttagccttca ttatgatatc tcattgggtc tataattgga 19980
ttttttaaat tcagatttct cattcatgta caagtaaagt tgtaattgg ttattatgcc 20040
caaagtttaa ttatttgagc gcagaaaatt tgaatggaaa tttcagaaaa ctgattcatg 20100
ctaacttcaa aaaatcctga ataaatacca attcttttcc aagtatgatt ctcgagcctg 20160
tttacgtgcc tgctacggc ctattttcta atttttttta tgataaaatt ttagagtaga 20220
tcttcaaaaa tcttccttaa aaaatctcca aaaaaatcaa gttcaggaaa actaaagtac 20280
tccaataaaa tactcttatg caaaaacccc ccattcattt tgcagaaaaa gacaaacaag 20340
aattaaagat aaaaagttat gatagacagg aagctgattt attagatcaa tgaatcgact 20400

-131-

tttagtTTTT cttgaactct aatttgaaat agtattcgaa tgagaaaatt gaaaatatac 20460
aaagatcaaa agttataatt gaaaatcaac aaattgatag tgtttgata ggattaaatt 20520
aaaatgtgcg gtacatgaga cagtagtagt agtagccata gtacgtattg gtggctccac 20580
tcggctactg ataatttctt tttttactga taatttgatg tcatttcgta attttatttg 20640
tgtttccaaa aattgtgggc gtggtttatg aattgggtcaa gacatgaatt aaaggaattg 20700
taaagtaaag aagaaaatga cagaggagaa attattttcg tttgctttgg aaattgcaaa 20760
ataaattaga ttattaaaga taatagttac gggttaaaat aaataggtga taaaaaata 20820
tccaaaagt caagtcctaa gaatcttgct attttgcaaa aaaaaagcat gagcttttg 20880
cctaaaaatg gcggacagct gtcgggacac tatccaagaa ttcgtgataa acgggtgaag 20940
cacgtctct tatcatcatg ccatttttcg aattttaaac tcagacttg ataaagaaaa 21000
ttaaaaagag agagtgtgag aaataagagt acacatggaa aatgcaagat ttgaatttgt 21060
ttccaatttt taaaatgtat ttaaaagagt taccgttcca ttttgatta gctttataag 21120
tgaaaaaatc gtttttgat tattttttga ggaatatatt tgaatgcgct ttcaattttc 21180
ctataaaaaa ctttgtgttc acttttttat ccgttttta tttttatttt tacaactttc 21240
aaatttttat gaatgtttta ttgtaaaatc ataaaaaggt gcgaaacatc taaattgcct 21300
ggattgcatt taaaagtga ttagcagaaa tgtattccta tggaatgttt tttgtgcaac 21360
gagatccaga agctcgaaaa acatccaaat ttcttccaag aaagttgatg ttccaaaaat 21420
aaaaagatt ttagccaat caactaaaaa aaaactctcg tttttttcat atttcacatt 21480
ttctggtcac tttgaaggaa acactaatcc caaactgaga accgaacatg gattaaacca 21540
tcccatttac tatttcttgt tgtcttcaaa aagtcttaga attgtgcaaa aaatagaatg 21600
tttcgaaata ttgcggtttt cgttaaaacc ttttttgagt agattgaggg tccattagaa 21660
ttccaagag aacttgatga cttcatcat caaaattagt ggtcattgaa tgtttgatca 21720
gacaaaaatg gaaatgactg aatcggaag agcaagaaaa tcgaaaaaaa aagtatttg 21780
aaattctgga aaacttttta aaatttaaga agggcaacga taagaaacag gaaattaggg 21840
attttttagt gatggagaag tacgtgataa ggtaaggtg gaacactagt gcacacgttt 21900
tgaatacact acgtgttttt atttatggta gaatatagca cttaaagaac gtttttaata 21960

-132-

caaactgaaa taaaaatacg gaaatgtaat tttttttttt gaaagaatcc gcctgaaact 22020
gaattttcac atcaaacggt agtgattctc tttatgcggt gggatgatatg tattttacgct 22080
gtcttaaagt tttcgactat aatttaagta atatgtttgt caaaaatcat catgggtgctg 22140
tgtcctatgt agccttttct acacttgaaa aatgataatt tttatttgaa aatgggtattt 22200
aaattcaagt agaaagttat ttagtcttgt gtgccaagca ataaacacat agtctattag 22260
gcaataaaaa gtcagctact gtttgattta aaaacttaga ctactgggtg gcctgtgcaa 22320
gttactcccg tagtacggat acagagtga aactagtgat tgtactttag atcggctgat 22380
agtgaattta cagagaaata attataaaac ttaaaatttt tagcagctca gtcttcaggc 22440
tgcacagcca tattgttaca cttggagtta caaattctgc aaaccatcta ggattgaatg 22500
caaaaactct gaaagtcaca tcaagaaatt ccaacaaaaa acacattaga tgccaactca 22560
ttgaattgca ttgattccca agagaaatag tagtaaaagt gacccctatc cattcctccg 22620
ttacatacaa atatacacac aaaaaagagt gtagacctct tccttctaac ccaaccaaca 22680
cacaacaata tcgttcctct ttatctctaa ttctctgcgt ctccataagc tttgagagct 22740
cttcggagca tcttgtgctt gctccttgta cggcggtaca gtttctctcc tctgctccct 22800
tatgtgtgtt taggtgttgt ttgaacaaat aagtttttgg ccatccacct ccttctcaaa 22860
acctttttct tatgcttctt cttgttttgt gcacattttg gctcttgctt gtctgctcga 22920
gccatagaca aggcggcgac atttttgaaa aaattatatt agtactgtta tatagtactt 22980
aatacaacga tcacaacaac aacacaacga aatgaaaaca tgagatcaaa agacaaattg 23040
ttaggaggag ttggagtttc tacaatcatg aaatgtttat ctagtatta taaaactgaa 23100
attgctcata aaattgtgat accatgaaga ccgaaaaact ctatgcaact gcatactgca 23160
catacttaca acctttattc tgacttgaat ttcagttttt ggtgtttgca gttattctat 23220
tttgtttaaa agaaaattca attaggaaat aagcaataaa ttttggcatg tatttcgata 23280
gaaggcacgt gtaaatgcca cccggaaatt agaaaaata agatttctca aactgaaaat 23340
gattgtgaat tgaaaattta agagaatcat tgcaaaagta cacaatgaa tcatttttca 23400
gattgaacag gaaagtgcag aaatatcaga ttaccgtccc aacagaaacc ggaaataaca 23460
cttttcaggt aaagaattat acagaaatcg taataaattt aaaacaaaag agagttatga 23520

cacattgcag aacggtctct gtggaaaata ggaggaggtg ctgcaaaaac tccttagaca 23580
tggtcatact tacaaaaaaa acagagttta actaaaaatt aaattaagtg agaaaatgaa 23640
gaaaatggag gtctttcgcg gattcatttt acttcttctt ttttccactt ttcggtgcaa 23700
gctttggttt aaaagtttcg caaacaata aacaatgaac attgtgttga gaagacaagc 23760
caagtgaag gaaaccattg agagcaaaaa caacaatcaa ttgaaataaa gagtaaagtt 23820
tattgaatat actgatatgt gaatactgga aaaataatta gtctctataa ttggtaccgc 23880
ctggaagatt catttctgat tcccttgtgt ctttgaccaa aactttattt ttttcagttc 23940
aaaattacaa aaaataaata ctcatcttca tcgattcagt ggtgttttaa actcctacgt 24000
ttttctttta caataaaggt aatgtaaagc ttccgagcgt gtagttttct ctgaaaattt 24060
tttaaaaata acaactttat ggtatttttc ttaaagtctt aaactgaaac cgaaacattt 24120
ttgataggaa aactatttta acattttggg aactcggcaa aagctctgca ggcttgccga 24180
acaactctca ttgaaagta ataatatga aaataaatta tcgaagtttt tttttttgat 24240
attttatgaa tacggctctt ggtagttttt gacgagaaaa ttacatgttg cataaatttc 24300
aagagttata actcatggag accctaattt ctggtttcac tagaaaatca aaaaatcaag 24360
cgtttgagca gaagactgta ggaagagcac acgtcataaa aattagggga tcaacgatcc 24420
gaaacgggga attgaaatac gatatgcat gagttttggt tcgaaccggc tttgtcccaa 24480
aaaacaacag aacgatggtc tcaggctcac ttgactcatc tcggtgggaa caatttttat 24540
ttgtttttat tccgtacgca cagaaacttt ttttgaggta ttttgatcg tgggtgggtg 24600
gaatggtagc acccaatttc aaatagtgtt tgatttgaag agacaatgaa agaaacaagt 24660
gggagataat ggaaatgacg tgatgaaatg gaacggagga aaactggtat aaatatcgtt 24720
gactatcaaa actacaataa tactaatgga gaaaagttca ggattcttga agattttaca 24780
ttatgatagt tgggatttac tggtttcaag ttcaaagtgc aaacatctgg aagaaaaacg 24840
tataagatta catcaaaata aaactaaaat ttgaaggata aagtaaaaca gcataatata 24900
gtgttttaca tctcatgtag gaaacgaaca aaatctttga acacctagat aacttcaaac 24960
ggaagtggg tgaagaaaag aataggggcc agaatagaag gtcattttga caaagtgaac 25020
agacaaagac attcctaact cggaggtatt ccaaaaactg ttccaatatt gaagaatgac 25080

-134-

actattttgat tttatatcat aacattatta atcacatggc ttttttctta ggaaatttat 25140
atcgcaaaat aaaaagtggc cttgatgagt cattcattca aaacatgcct aaaaaccttc 25200
ataattaatt ataaaaatgc tgatacttga ggacccgttt ttttatattt ataaacagtt 25260
gttttcttta ttccgtttctc actttgagtt tttttctgaa aatactaaaa aaattaacaa 25320
agttcggcgt tttttgtcga taattccatc tgattatattt cggttttttt acctaatat 25380
caaataattt agccagagtg aaatttatta tcttattaat atgtttttca atttgttttg 25440
gtattattct gttgaaggaa catggttgcatt tttaaactctg ttgttaatac agcggccaca 25500
tgtttagaac ttataacct cgtttaaaca taaattgtat gccatattta ttgcaagtac 25560
tacatgagtt tgaaacagta tcagatacta ttttttaaac aaaaatacac attttccccg 25620
ctatgagaga ttctgataca ttggtttcca atttttttta aaacttgaaa ttctcaagt 25680
ctcccactga attacagatt tctgttctag atacctcaa agacacctag attcgacttc 25740
ggcatcttcc tcatttttat cttcagtttc atcttttgtc taattttccg tacatttctt 25800
tgcatcctta ccattctctcc ctctctcact cactcttctt gttcactaaa tctcaattca 25860
aaatgttttc tgccacgtca tcatcatcat caatgccacc ttctcagagc ccattcgaaa 25920
aattaccacg gcatcaaaat attcgatata acgaaaaatg cttctcaatt ccacttcata 25980
cacttaacta ttttctatgc gttattattt tttatttctt tgttttcact atattttatc 26040
acgaacgtta tgggtgaaaaa cctgaaaatg ttcaagttac atcagcaatt tatgattcaa 26100
attcaaacga actgtcatta atctttctat ttgattcttc aattcgtcga cgggaaatat 26160
tccttggatt tgggtccaaat gactcaaaaa catcaagaaa tgaaactcaa attgagctta 26220
aaccaccacc cggatttggt gataactcac aaatttcagt aagtttagga ttttttttca 26280
aaaaaacttg atatgaagtg ttgaaaaatt gataattggg ccgggcttac atcagagtat 26340
ctagttatct tgtatttcaa atattaatat tcaaacattg tagagattcg aaatgcgaca 26400
gtacttcagt aattaccacc cacattttga ctgtcaaaaa agttcccaa aattgtcgaa 26460
aacttttatt aggatgtttt ctcattttgg cacgattgga gtgttttttt aacaaatccc 26520
ttttatgcat caaattaata tctaattttt aaatcaataa tttggattaa ttcaacttgt 26580
tttataagat tttctcgcta ttaaattagc aaaaaaaaaac tatcttcaaa caattagcgt 26640

gctttaaaac tactaggcct ttgttggcaa cgtcttttca cattttggca caaaactata 26700
aactatgctc agaatttggt aatgtttgaa aatgttttgg gcaagcatat agttattcca 26760
attctaaagt aagattagtc atctattttc cattccattt ttccattttt cacctatttt 26820
ttccattatt taacaaccaa gactgagcaa acattttcct gttttaattt tcatatatga 26880
aaagacataa gcaaaagctg gatcaaagct tgggcaaadc ctattcaaag tattttccaa 26940
cgtttccatt cctcgtttg taaagtacaa ttggtaatct taaggcttaa ttaattattg 27000
tgggagattc ataatgtgaa aactaaatgt taagatttgg tcatcaattg aaaaggaaaa 27060
acccagctct ttaactgtga atgcagaaca tccaaagtca ttgcttttac gagatcacac 27120
aggacatcca tatttagaag taagttcaaa tcagaaatcc ccaatccatt ttttcttgta 27180
gttaccactt caagaacat actccgattt tcgcgacatt gttagttgtt tcagtccaat 27240
ttatggagat ttgagatgg ttttaacagg ttttaacaaat taatttggtt tcttttttaa 27300
aacatttaat ttttatagct ttaacatcat ccatatcaat gggatcattt gttagtatac 27360
catatgaaga gcttactgga gagctttaca agtttctacg tgtatttgaa aaaacgggac 27420
atgtcaggtt aactgcattt ccaatgatac gtcacagcc tcgcttcgat tcggaaaatg 27480
aaaattatca tttgaaaatg atcaaactta aaacagattt aacgcatttg cattgttggc 27540
taatgcataa aaaccgggcc aaattcatga tcttccaaaa ctctgctgaa attgttttac 27600
cgatttcctc gacgctggaa aatcccaatt acgcctctga atttacacga atatttgaaa 27660
caccacgagt tgaaggatat gatattttag aatataatgt caaaatttca acggataaac 27720
gcttaggcga cttttcggtt ttctccatca ggcagacaat tgaagcagca aaagcagaag 27780
aattaaccgg aaattctaaa acattaatca tgagaatggt atcacttttt ttcaaaataa 27840
tttactgttt ctattttggc atttatttca gcattctcca actccacaga atctcttaaa 27900
acgcggtaaa atgtatccat ttttcaaaaa tttcccatct ccaccacaag ttattccaaa 27960
gaaaacattg gacaaattgg atacaataac agaaataatt gaagaatctg atgcattctg 28020
gacacttatc aaagaatggt cagaaaattc gaaatcttgg aaatgctcgt caagaaaatg 28080
tgtaagacca tcagttagac atcgatctct tcatggatgg tattcatatg atattcattt 28140
ttctaaattt ttgaatgttg aaagtttttt ttgttcagat tttcaataaa cttttaagaa 28200

-136-

aagaataatt ttaaattcta taattcctga atttccaact atgtttatca tttcccaaag 28260
tacattcgaa aaagctcaat aagcaaaacg accacgaaat aacagtatta aaaaaaaga 28320
tgttgtcatt tgaagttctg gagtgcgatg aaaagtctct cacctcggac tttctgtaat 28380
ttatttagca tacaacatga atttgaccaa ctcgaaataa ggtaagact gaaaatTTTT 28440
cacaaaaatt ggaacacttg cgaagcgaat tcaagacttt tcgaagttat taaacaagct 28500
ttcaaattct cagtaaaaact gaacgtTTTT tttatgctct ccaaatacatt ttaatatggc 28560
tgctcgcgtc gctgaagtat tttctagagt atgtttaata aaactaatat gtaaatgaaa 28620
aaccaaaaac tcagataaag agcataactt ttataacgca ttttcagaac tcttcaagct 28680
ttttcagatc acttctatca gcagtattct tcttttttcc aaagacacca agaactgaaa 28740
aggttgaagg agcatcaccg gaaatagagg atgactgctt attgttcttc tttttctgaa 28800
taaaatcaaa ttaaaccaccg aaaatatgaa acatattcac taacctgaac agctttcagg 28860
tttgatttat tctgattttc cgccgctgat ctgctctgac ttttgaaacc gggacttgga 28920
gagttacat tgcgatatgcg agttcgaact ggacgccgat tcttctttct gaataaacga 28980
attatacaaa tttgtatttg aaaacggaca acatacactc cttcttccgc cgaattgctc 29040
atcgattttc tcatttcttg tgttttttcc tggcgttcag gttcaaaagg tggagcaact 29100
ggtttggaac tatacgggaag aatgttcgag acttgaatct tttttggttg ctcaatattc 29160
tccattggaa tatgatcggg aagttcaaag tagctgttgg atcctggagc ttgatcaaat 29220
ccttcgagag ttaaaagttc acgaactgct tcaactcattg tgaccctttc ctcttcggca 29280
ccagcacaga ttctatactg aaattgcttg ttgtgttggt ttactcaaaa gaatagtga 29340
caaaattttc tcaccgtaat gaatctgaca atggctggtg ggacgttagc ttcaaatggc 29400
attcggtatc cgttctgaac acgtggtaaa acctcagcaa ctttcattcc cggataaggt 29460
tcgattccat catggtacac ttccaacac atgactccat aagcgaaaac atcagtcttt 29520
ggagtataga acccagttct tggaacttct ggagccaacc atctaataagg aactctgaaa 29580
aatttgaaaa ggttggaatt tttgacgttc tctaactttt tgtgaggatt catccgatag 29640
ctatagcctt ctctgacag tccaaagtcg gatatttcta cttgtccatt cccgtagaga 29700
caatttctgg acgcaatatc gcgatgaatt atttgaagtg aatgaagata ttcaagacca 29760

-137-

agaccagctt gaagaaccat cgtatgtttc ttggaaattg gcaatgaacc aatgtttcttc 29820
tttagatatg aatccaaagc tccattgtca gcctaaaata atttacataa gacattttttt 29880
cttagtaaaa taaaattaat cagttaatta attaacatac caactccatt atgaccatca 29940
aaggttcctg tcctgcagcc acaccataaa aagtgcgac attcggatgt ttgaactttc 30000
tcatcaatct ggcttcgtgc atgatttctt tgatctgctc ttttgtcaaa gattccaact 30060
ttgccagctt gattgcagct tttttgacgg tatttcctat gcgaatttct cccaattgaa 30120
cctctccaaa tgctccttct cctaatttct tgattaatgt cacgtcagaa tgttgctttt 30180
cccacgggtc acgaccaatt ggacggatga ttacagtttc tgggccctaa aagcaaacia 30240
atgaaaataa gtttactcac ttaatttgta agatcacccc agcaacaggt tctttagaac 30300
gatgatagta attgagaaga tctgcgatac tagaaaacca ttttttatca actgcaaact 30360
tgttattgtg ctctcgaatt acataatgac gaatctgaaa taatattctt aaaaattatg 30420
agcaatcggt ttacgtacgt cctcaattac tccaacatag acagagagaa caaatttcct 30480
tggtctctcc acttttggat cagtaaactg aactagaaaa tcgcctcggt gagtgcgcaa 30540
ctgtttcata tcctcacgtg gcaataagcc atggtaccag ggttcttttg caagtacttg 30600
c 30601

<210> 34

<211> 8009

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 34

ggatccttgg ccacgccatg ggcgatgaaa ttgaccgcgt cgtaacgggt catgtcctgc 60
tcctgcagga agaaggccgc gtctgattcc cgttcgcaa agatcgcgac aaggacattc 120
gccccgtca cctcgggtccg gcccgagctt tgcacatgga tcgcggcgcg ctggatcacc 180
cgctggaagg cggcggtcgg cacggcttcc gagccttcga cttcgggtgat cagcgtcgag 240
agatcatcgt cgatgaactc ggtcaggggtg gtgcgcaact cgccaagatc gacgccgcag 300
gcgcgcatca cgcggctggc gtcgggctcg tcgatcagcg cgacgagaag atgttcgagc 360

-138-

gtcgccagtt catgtttgcg cgtgttgcc agcgccagtg cggcgtgaat tgcttgctcg 420
agcgtggtcg aaaacgaagg catgcggcgc tcctttcctc ggggtctcccg atactggcct 480
catgtgatta agtttcggtg gatttcgccg cgcttcaagg cccggacgcg tgttttttcc 540
acctctcgcc gctctgttgc aaaactgacc agcgcgggcg gcttttcgcg gatccgcagg 600
cagcgcgcgga aagtgtttc agaaccggtc cttgcgcgcc cgcgccgcg tgaagacggc 660
gagcgggcg gcatccccg gcaggccgag cgcgggcgcg aacgcagcgt catcggcgcg 720
caaaaagga ttcgttgccc gttcctcgcc caaagtcacc ggcaaactgg gttccccggc 780
cagccgcaag gcgtcaccc ggtccatccg gtcgtgcagc cgaccgttcc ccggttccag 840
gctgagcgcg aaccggccgt tcgcgggcgt gtattcatgc cccgaacaga cccgggtttc 900
ggcgggcagc gcggccagac gggtcagcgt gtcgaacatc tgcgcggggg tcccctcgaa 960
gagacgccc cagccccagc tcatcaggct gtcgccgaa aagagcagcc ccgccccggg 1020
cagataccag gcgatatggc cgagcgtatg gccgtcgcc gcgatcacct gcgcggcctc 1080
catccccaga tgcagcacgt cgcgggggc caccggatga tcgagcgcg gcagccggtg 1140
ggcatcgcc gcggccccg ccaccttggc cccggtcgcc tgcgccagcg cctcgacccc 1200
cgcgatgtga tcggcgtggt gatgggtgat caggatgtgg tgcagctgcc agcgccggtc 1260
ggtcagcacc ttcagcaccg gggcgccctc ggggacatcg accaccacca cggtatcggt 1320
ggcggtgtcg tgccagagcc aggcgtaatt gtcggtcagg caggggatcg gggtcagttc 1380
gagggtcatg gccttttgcg catctttcgc taccctgacc cagcttcgcc caaggaagge 1440
caacctgcaa tgcatctcga cgtgctcgac ctgcgtgatt tctactaccg cacccaattg 1500
ggcgcgacgg cgaaaaggc gatccgcgac aagggtggtcg aactctggcc ggacaccag 1560
tccggcatgg ccgggctgac ggtggcgggc tacggcttcg cggtgccgct gttgcgcccc 1620
tatctgggcc gggcgcgcg ggtgatcggg ctgatgccc cgcagcaggg cgtgatgccc 1680
tgggccgccc gagagcccaa tgtctcggtg ctctgtgcc aaaccagctg gccgctggag 1740
accgggatga tcgaccggct ggtggtgctg cacgggcttg aagtctccga cgaccccgat 1800
gcgctgatgg aggaatgctg gcgcacgctg ggccccggcg ggcgggcgct gttcatcgctg 1860
ccgaaccggg tcgggctttg ggcgccgcg gaaaccacgc ccttcggctt tggccgcccc 1920

-139-

tatacgatgg gccagctcga ggcgcaggca cgacgggtgg ggtttgcccc cgaacgtcag 1980
gcggcgggcg tgtacattcc gccctcgcag cggcggttct ggctgcgctc ctccgagatg 2040
tggaacggc tgggcacaag ggcggcgggc tatctggcgg cgggggtggt gatgcttgag 2100
gtgatcaagc aggtgcattc ggtgcgccgc tcggggcttg gcgcggcggt ggcgaagccg 2160
ctctcgatcc ttgaaggggc gcccaagccg gtggtcgggc ggatgtgagc cggccgcggc 2220
cgcaagaatc gcccggccgg aaaagcccgt ttccgcggca cttcgccctg cggcggggaa 2280
acgcagcggg gcgggcttcg accctttgcg ctaacactcc gtgccggtgc agaaaatgtg 2340
ccagcctgat gcggattcct gccgccaaga tggttgcgag ggtcttgatg ctctgctaga 2400
cgcaaccccg aatgcggcgt gcgagatcat tttgggcgcc gaggggggcc tctgaatcgg 2460
tgacggaacg attggttccg gtgtccgcgt gcggaggcaa aagcatcgga aggggtggacg 2520
tgtccgaacc agcttcgatt tccgcagcca ttgccggcg ttatgccacg gccatcttcg 2580
acctcgcgca ggaggccaag ggcacgcagc cgctctcggc cgacgtggac gcgctgacgg 2640
ccgccttggc cggttcggcc gagctgcgtg acctgatttc ctgcgccgtc tacaccgcg 2700
aggagcaggg ggacgcgacg gccgcgggtg ctgcgaagat gggcctgtcg gcgccgcttg 2760
ccaacggtct gaaactgatg gcgacgaagc gccgtctgtt cgcgctgccg cagctgctca 2820
agggcctggc cgccgcgacg gccgaagcca agggcgagat gaccgcggat gtcacctcgg 2880
ccaccgcgct gagcgcggcg caggccgaga agctggcggc gacgctggcg aaacagacgg 2940
gcaagaccgt caaactgaac gtcgccgtcg atgaaagcct catcggtggc atgatcgtca 3000
agctgggttc gcgcatgatc gacaccacgg tcaaagccaa actcgcttcc cttcagaacg 3060
ccatgaaaga ggtcggataa atgggcatcc aagcagctga gatttctgcg atcctcaagg 3120
agcagatcaa gaacttcggg caggatgccc aggtcgccga agtgggcccgc gtgctctcgg 3180
tcggtgacgg gatcgcgcgc gtgcacgggc tcgacaacgt ccaggcgggc gagatggtcg 3240
aattccccgg cggcatccgc gggatggcgc tgaaccttga agtcgacaac gtcgggatcg 3300
tgatcttcgg gtcggaccgc gacatcaagg aaggcgacac cgtcaagcgc accaacgcca 3360
tcgtggacgt tccggcgggc gaaggcctgc tgggccgcgt cgtggacggc cttggcaacc 3420
cgatcgacgg caagggcccg atcgtggcga aagagcgtcg catcgccgac gtcaaagccc 3480

-140-

cgggcatcat tccgcggaaa tcggtgcatg agccgatggc gaccggcctc aagtcggtcg 3540
acgcgatgat cccgatcggc cgcggccagc gcgagctgat catcggcgac cgtcagaccg 3600
gcaagaccgc gatcgcgctc gacaccattc tgaaccagaa gtcgtacaac gacgccaaacc 3660
cgggcaacaa gctgcactgc ttctatgtcg ccatcgggca gaagcgctcg accgtggcgc 3720
agctggtgaa gaagctcgaa gaagccggcg cgatggaata caccaccgtc gtcgccgcga 3780
ccgcttcgga cccggcgccg atgcagttcc ttgcccccta ttcggcgacc gcgatggcgg 3840
aatacttccg cgacaacggc atgcacgcgc tgatcatcta tgatgacctc tcgaagcaag 3900
ccgtggccta tcgtcagatg tcgctgctgc tgcgccgtcc gccggggcgt gaagcctatc 3960
cgggcgacgt gttctatctg cactcgcgcc tgctggaacg ttcggcgaaa ctgaacgagg 4020
atttcggttc gggctcgctg accgcgctgc cggtcatcga aaccagggc gccgacgtgt 4080
cggccttcat cccgaccaac gtgatctcga tcaccgacgg tcagatcttc ctggaaaccg 4140
aactgttcta ccagggcac cgcgcggccg tgaacaccgg tctctcgggtg tcgcgcgtcg 4200
gttcgtcggc ccagaccaac tcgatgaagt cggttgccgg tccggtgaaa ctggagcttg 4260
cgcagtatcg cgaaatggcc gcctttgcgc agttcgggtc cgaccttgac gccgcgacgc 4320
aaaagctgct gaaccgcggt gcccgctctga ccgagctgat gaaacagccg caatattcgc 4380
cgctgaccaa cgcgaaatc gtggcggtga tctttgcggg caccaacggc ttcctcgatg 4440
ccgttccggt gaaggaagtc ggccgggttc agaaaggcct gctggcctat ctgcgctcga 4500
cccgcaagga cgtgcttgag tggctcacca aggaagacc caagatcaag gccgacgccg 4560
agaagaagct caaagacgcg atcgccgagt tcgccaagac cttcgcttga cggcctgaaa 4620
ggacaggag atgcccagcc ttaaggacct caagaaccgg atcgtgagtg tcaagaacac 4680
tcgcaagatc acgaaagcga tgcagatggt cgcggcgggc aacattcgcc gcgcccagga 4740
aagcgccgaa gctgcccggc cctatgccga gcggatgaac gccgtgatgt cgagccttgc 4800
cggtgccgtg ggctcgaccg acggtgcgcc gcgcctactt gcgggcacgg gctccgacaa 4860
ggtccatctc ctcgatcatca tgacgggcga gcgcgggctt tgcggcggt tcaacgcaa 4920
tatcgcgaaa ctcgcgaaag cgaaggcgat ggaactgctg gcccgaggca agacggtgaa 4980
gatcctcacc gtcggcaaga aaggtcgcga cgcgctgcgt cgtgatctgg gccagtatta 5040

-141-

catcgatcac atcgacctga gcgacgtgaa gaaactgagc tacccggtgg cgcagaagat 5100
ttcgcaaaac atcatcgacc gcttcgagggc gggcgaatac gatgtggcga cgatcttctt 5160
ctcgggtcttc cagagcgtga tcagccaggt gccgaccgcc aagcaggtga tcccggcgca 5220
gttcgaaacc gatgcggcct cggcctcggc ggtttacgac tacgaaccgg gcgatcagga 5280
aatcctgacc gcgctgctgc cgcgtgcggt ggccacggcg atctttgccg cgctgctgga 5340
aaacaacggc tccttcaacg gggcgagat gtcggccatg gacaacgcca cccgcaacgc 5400
gggtgacatg atcgatcgct tgaccatcga gtataaccgc tcgcgtcagg ccgccatcac 5460
caaagagctc atcgaaatca tctcggggcg cgaggcgctc tgacggaacc ggagatagaa 5520
gagaatggca agcaaaggca aagtgaccca ggtcatcggc gccgtcgtcg acgtgcagtt 5580
cgaagacggc ctcccggcga ttctgaacgc ccttgaaacc accaacaacg gcaagcgcct 5640
cgttctcgaa gtggcgcgac acctggggcg gaacaccgtc cgcaccatcg cgatggacgc 5700
gaccgagggc ctcgtgcgcg gcgcggccgt gtccgacacc ggcggcccga tcaccgttcc 5760
ggtgggcaac gccaccctgg gccgcaccc gaacgtcacc ggcgagccgg tggacgaacg 5820
cggtgacgtg tcgaaagccg aagcccgggc gatccaccag cccgcgcccg atttcgcggc 5880
gcagtcgacg gaaagccaga tcctcgtcac cggcatcaag gtgatcgacc tgctcgcccc 5940
ctattccaag ggcggcaaga tcggtctctt cggcgggcgcc ggtgtgggca agaccgttct 6000
gatcatggaa ctgatcaaca acatcgcgaa agtgactcgc ggcttctcgg tgttcgcggg 6060
cgttggcgaa cggaccctgt agggcaacga ctttaccac gagatgatcg aatcgggcgt 6120
tatcaacctc gagaagctcg aagaatcgaa agtggcgctg gtctacggcc agatgaacga 6180
acccccgggg gcccggtgcc gcgtggcgct gaccggcctg accctggcgg aacagttccg 6240
cgaccagtcg ggcaccgacg tgctgttctt cgtcgacaac atcttcgct tcaccaggc 6300
cggttcgga gtgtcggcg tccttgggcg tatccctcg gccgtgggct accagccgac 6360
gctggccacc gacatggcg cgctgcaaga acgcatcacc tcgaccaaag ccggttcgat 6420
cacctcggtt caggccatct acgttcggc cgacgacctt accgaccgg ccccgggcac 6480
gtcctttgcc cacctcgacg ccacgaccgt tctgtcgcgt gcgatctcg aactcgggat 6540
ctaccgggc gtgacccgc tcgactccac ctcgcggatc cttgaccgc aagtcgtcgg 6600

-142-

cgaagagcac tatcaggteg cccgtgacgt ccaagggatg ctgcaacgct acaagtcgct 6660
 gcaggacatc atcgccatcc tcggcatgga cgaactgtcg gaagaagaca agctgacggg 6720
 ggccccgcgc cggaagatcc agcgcttcct gtcgcagccc ttcgacgtgg cgaaagtctt 6780
 caccggctcg gacggcgtgc aggttcgcgt cgaagacacc atcaagtcgt tcaaggcggg 6840
 gggtgcgggc gaatacgacc acctgccgga agcggccttc tacatggteg gcggcatcga 6900
 tgacgtgatc gcgaaagccc agcgcttcgc cgtgcggcg taagggggaa ccatggccga 6960
 taccatgcag ttcgatctcg tgtcgccgga acggcggtt gcctccgtt ccgcgagcga 7020
 ggtccgtctt cccggcgtgg aaggcgatct gacggcgatg ccgggccatg cggccgtcat 7080
 cctctcgctg cgtcccgga tctgaccgt ggtcagcgcc gcgggcacgg ccgaatacgc 7140
 cgtgaccggc ggcttcgcc aggtttcggg cgagaaggtg accgttctgg ccgagcgcg 7200
 tctgaccgg gcggaactga ccgcccggt tcatgccgag atgctggccg aggccaagaa 7260
 agtcgcggac gccgcgcatc cgtcgggtggc cgatgccgcc gcgaagatgc tggccgacat 7320
 ggaagcgctt ggctcgaca tcaatctctg acgggacatc ccgccggata tctcgggccc 7380
 cggtcatcgc gccggggccc ttgctttttg cttttgtctt gccgcgccgc atattagcgt 7440
 gaaggtgcag gcagccggag tgagcgacag gaacggatga agaagtttcc ctcgaccgg 7500
 atcggcgtgg cccagggatc gctggtgctg ttttcggatt atctggacgg cggcgtgatg 7560
 tggacgggcg agggcccgcg cgaattgcgc aggtggtgg tggtcgacga agccttcgc 7620
 gagatcccg cggtgcagg gtcgctgtcg atgtgggaca tcgaccagaa gcacaatccg 7680
 cgcattgaca tttccgccga catggtgacg gccgagggt tcgtgatcgt ctttcgcacc 7740
 tggggcgaca cccgcgtcgc ccgcgtccgc gcggactggc tggcgatcgg cggctgcgcc 7800
 aatgacgacg actgggacgt ggcctgatcc cggccggctt gactttccgc cccccgcgc 7860
 cgatggtgcg cgcgactttc ccatccaacg agggccgccc gtgcaacaag atgcccccg 7920
 ctggcagctc gtggtgatcc tgtgggggac gaaatatccg gtcgccgaac tcaacgccct 7980
 gatcgagacc gtgtggcccg ggcctcgag 8009

<210> 35

<211> 9810

-143-

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 35

gatatcgggc ttgtcatttt cgattgcgac ggggttctgg ttgattcgga agttctggcc 60
gtggccgtcc tcatcgcaga actggaccgg gcgggcgtgc gggtcgacga ggccttcgtg 120
catcggcatt ttctgggccg gagcttcccg gctgttcagg aggtcgtgca ggcaggttc 180
ggcgtgaccc tgcccagac cttccaggtc gaggaacgtg cccggtgct gtcagccttc 240
gagaccggcc tgcgggccat gtcggggcc gcggagaccg tccgcgcgt gtcggtgccc 300
tactgcctcg ccacgtcgag cacgcggcc cggctcacgc gctcgtgga gatcacgggc 360
cttgcgcccc tcttcgagg acgtgcttc accgcgagcc aggtggcgcg cggcaagccc 420
gcgcccgate tgttcctgct cgccgcggcc gagatggcg tcgcgcccga acgtgcctc 480
gtgatcgagg ataccgagcc cggcgtgcgc gcaggcctcg cggccgggat gcaggtctgg 540
cgcttcaccg gcggtagcca ttctcggaac cgatcccccg aggatgcgcc cgatgcctg 600
ccgcaccggc ggttcgacag cttegaccgt ttctacgaga ccctgcccgg cctgcgccgg 660
gccaagtgcg agaccctgac atgatcgacc ggcccagag cgagccgacg ccctcgacg 720
atgccgcgcg cgcgggctgg ctctattatg tcgcaggcct gactcaggat cagatcgcg 780
gggagctcgg cacctcgcgt cagcgggcgc agcggctggt gagccgggcc atctccgaac 840
ggctgatcca cgtccggctc gagcaccggg tctcgggctg cctgcatctg gaagccgcgc 900
tctccggcg cttcgggttg aagctggccc gcgtggcgcc gagtctcggg tccgaggtg 960
atccccctgcc ctccatcgcc ccaccgccg ccgccgaggt ggagcgggtg ctgcgctcgg 1020
agcggccgat ggtggtggcc ttcggcaccg gccggctcgt gcgcgccacc gtcgaggaga 1080
tgacctcgat ggtctcgaa cagcacaaga tcgtgtcgt caacggaaat atttctgcgg 1140
atggctcggc ctctactac gatgtgatct tccgcatcgc cgaccgtgtg cgtgcgccgc 1200
actatccgat gccgatgcc gtcacgcgc aggatgcggc ggagcgggag ctgtttcatg 1260
cgctaaagcc cgtgcagtcg gtgctgcggc ttgcgcgcaa tgccgatgtg accttcgtcg 1320
ggctgggaca gatgggcgag gacgcgccgc tctgaagga cgggttcac acgcccaggg 1380

-144-

agctgaccga gatgcaggat ctgggcgccg tcggagaggt ggcgggatgg gtcttcgact 1440
cggaggggtcg ctacctcgaa accagcatca atcagcgggt tgcggggtc cgtgtcgaac 1500
tttccgagga tcggacggtg gtcgccatcg ccggtggcag gcgcaagctc gcggcgctgc 1560
acgcaggctt aaggggccgt cttttcaacg gcctgatcac cgacgagttc acggcgcagg 1620
cacttctgtc ctgaagccgc cgaaaggcgc ggcaaaaagt atttgacagg ctggcacccc 1680
tcggtgagta attattcgcc gcacgaaata atgctcaccg tgcaggccag ggaggatact 1740
gatgaccgca agatttcgcg ccctgatggg cgctgctgcc gtggctgcgc tctcgtccgc 1800
cgccggcgcc gaaaccatca ccgtggcgac tgtcaacaac ggcgacatga tccgcatgca 1860
ggggctcatg tccgagttca acgcgcagca ccccgacatc accgtcgagt gggtgacgct 1920
cgaggaaaac gtgctgcgc agaaggtcac gaccgacatc gccaccaagg gcgggcagtt 1980
cgacgtgctg accatcggca cctacgaggt tccgatctgg ggcaagcagg gctggctcgt 2040
gagcctgaac gacctgccgc cggagtatga tgccgacgac atcctgcccg cgatccgcaa 2100
cggcctgacc gtcgacggcg agctctatgc cgcgccttc tacggcgaga gctcgatgat 2160
catgtatcgc aaggacctga tggagaaggc ggggctgacc atgcccgcgc cccccacctg 2220
ggacttcgtg aaggaagcgg cgcagaagat gaccgacaag gatgccgagg tctacggcat 2280
ctgcctgcgc ggcaaggccg gctggggcga gaacatggcc ttcctcagcg ccatggccaa 2340
cagctacggc gcgcgctggt tcgacgagaa ctggcagccg cagttcgacg gcgaggcctg 2400
gaaggccacg ctgaccgact atctcgacat gatgacgaac tacggcccgc ccggcgccctc 2460
gaaaaacggc ttcaacgaga acctcgcgct gttccagcag ggcaagtgcg gcatgtggat 2520
cgacgcgacg gtggccgcct ccttcgtgac caaccccag gaatccacgg tggccgacaa 2580
gggtgggcttc gcgctcgccc ccgataccgg caagggcaag cgggccaact ggctcggggc 2640
ctggaacctc gcgatcccgg cgggctcgca gaaggctgat gccgccaagc agttcatcgc 2700
ctgggcgacc tcgaaggact atgccgagct ggtggcctcg aaggaaggct gggccaacgt 2760
gcctccgggg acgcggacgt cgctctacga gaaccggaa tatcagaagg tgccgttcgc 2820
gaagatgacg ctcgacagca tcaacgcggc tgacccgacc caccggcggt tcgatccggt 2880
gccttacgct ggtgtgcagt tcgtggcaat ccccgagttc cagggcatcg gcaccgccgt 2940

-145-

gggccagcag ttctcggcag cctcgcggg ctgatgtcg gccgagcagg cgcttcaggc 3000
ggcccagcag ttcacgacgc gcgaaatgac ccgcgcgggc tacatcaagt gagcccttcc 3060
gcgggccggc cctgagcggc cggcccgcac cgcttgccgc ttccggccgt atccgccgga 3120
ggcctttccg ccccatcagc cccgaggcct ccatggcgac ccagcattca aagactgcgg 3180
cgctctgat gatttccccg gccgtgatcc tctgttctt gtggatgatc gtgccgctgt 3240
cgatgacgct ctacttcagc ttctgcgct acaacctcct catgccgggg atggagagct 3300
tcaccggctg ggacaattac tattacttcc tgaccgatcc ggctttctcc ggggccctga 3360
ccaacacgat cctcctcgtg gtcggcgctc ttctcatcac cgtgggtgggc ggggtcctgc 3420
tcgcgtcct gctcgaccag cccttctggg ggcagggcat cgtgcgcgtg ctggatgatc 3480
ctcccttctt cgtcatgcc accgtctcgg cgctggctc gaagaacatg ttcatgaacc 3540
ccgtgaalg gatgttcgcc catatcgccc gcgggctcgg ccttcgcgcg ttgcacttcc 3600
tgtcgcaggc gccgctggcc tcgatcatcg gcatcgtggc ctggcagtgg ctgcccttcg 3660
ccacgctgat cttctgacg gcgctccagt cgctcgaccg cgagcagatg gaggcggccg 3720
agatggacgg cgctcggcg ctcgaccggt tcatccacat caccgtgccg cacctgacgc 3780
gtgccatcac cgtgggtgtg ctgatccaga ccatcttct tctgggcgtc ttgcccgaga 3840
tctcgtcac gacgaacggt ggaccggca ccgcctcgac caacatcacc tacctcgtct 3900
atgcgcagtc gctcctgaat tacgacgtgg ggggcgggtc ggccggcggc atcgtcgccg 3960
tggtgctcgc caatatcgtg gcgatcttcc tgatgcgcat gatcggaag aatctggacg 4020
cctgacatgt cagccgcac ctcaaccgc cgcacgtga tcgtcacgct cgccgcctgg 4080
acgatagcct tctcatctt cttcccgatc ctctggacgg tgctgatgag cttcaaactc 4140
gaaggagacg ccatcaaggc gcccttcgcc atgctcttct cggactggac cctgcaatcc 4200
tacgccgatg tgcaggaacg gtcgaactac gcccgccact tcatgaattc ggtggtgatc 4260
tcgtgggct cgaccctcgt ggcgctcgcc atcgcgatcc ccgcgcctg ggccatggcc 4320
ttcgtgccgg gccggcgac gaaggacgtg ctgatgtgga tgctgtcgac caagatgatg 4380
ccggcggtgg gcgtgctcat cccgctctat ctgatcttcc gcgacacggg ctttctcgac 4440
acgcggatcg gcctcgtgat cgtgctcacg ctcatcaacc tgccgatcgt ggtctggatg 4500

-146-

ctctacacct acttcaagga gatcccgggc gagatcctcg aggcggcgcg gatggacggg 4560
gcgacgctcg gctccgagat cctctatatc ctcacgccga tggcgtgcc gggcatcgcc 4620
tcgacgctgc ttctgaacgt gatcctcgcc tggaacgagg ccttctggac gctgcagctg 4680
accacctcgc gggcgcccc gctcacgcag ttcacgcga gctattccag ccccgagggc 4740
ctcttctacg ccaaactgtc ggcggcctcg accatggcca tcgcgccgat cctgatcctt 4800
ggctggttca gccagaaaca actcgtccgc ggctgacct tcggcgcggt gaagtgagga 4860
ccacatgggc aagataaccc tgcgcaacgt ccagaagcgg ttcggtgagg cggtcgtcat 4920
cccctcgctc gacctcgaca tcgaggatgg cgagttcgtc gtcttcgctc gccctcggg 4980
ctgcggaaaa tccacgctcc tgcgcctgat cgcgggcctc gaggatgtgt cggacggcca 5040
gatcatgac gacgggcgcg acgccaccga gatgccgcc gcgaagcgcg gcctcgccat 5100
ggtgtttcag agctacgcgc tctatccgca catgacggtg aagaagaaca tcgccttccc 5160
gctgcggatg gcgaagatgg agccacagga gatcgagcgg cgcgtgtcga acgcggccaa 5220
gatcctgaac ctcaccaact atctcgaccg ccgccccggc cagctctcgg gcgggcaacg 5280
gcagcgggtg gccatcgggc gcgccatcgt gcgcgagccg gcggccttcc tgttcgacga 5340
gccgctctcg aacctcgatg cggcgtcgcg ggtcaacatg cggctcgaga tcaccgagct 5400
gcaccagtcg ctcgagacca cgatgatcta tgtcaccac gatcaggtcg aggccatgac 5460
catggccgac aagatcgtgg tgcgaacgc gggccggatc gagcaggtgg gctcgccct 5520
caccctctac cgcaatccgg cgaacctctt cgtggcgggc ttcacggca gccgaagat 5580
gaacctgatc gaggggccc aggcgcgcaa gcacggcgcc accaccatcg ggatccgcc 5640
cgaacatata gacctgtcgc gcgaggcggg ggcgtgggag ggcgaggtcg gcgtctcgga 5700
acatctcggc tcggacacgt tctgcatgt gcatgtcgcg gggatgccca cctcaccgt 5760
gcggacgggc ggagagttcg gcgtccatca cggcgaccgg gtctggctca cgccgcaggc 5820
cgacaagatc caccgttcg gcgccgacgg aaaggcgctc tgacatgcgg ctcgacggca 5880
agaccgccct catcaccggc tcggcgcgcg gcataggccg cgccttcgcc gaggcctatg 5940
tgcgtgaagg cgcgcgcgtg gccatcgccg acatcaacct cgaggcagcc cgcgccaccg 6000
cggccgagat cggccccgcg gcctgcgcca tcgccctcga cgtgaccgat caggccagca 6060

-147-

tcgaccgctg cgtggccgag cttctcgacc gctggggcag catcgacatc ctcgtgaaca 6120
atgcgggcct cttcgatctg gcgcccacg tcgagatcac ccgcgagagc tacgaccggc 6180
tgttcgcgat caacgtctcg ggcacgctct tcatgatgca ggcggtggca cgggcgatga 6240
tcgcggggcg ccggggcggc aagatcatca acatggcaag ccaggccggc cgccgcggcg 6300
aggcgctggt gggcgctctat tgccgcacca aggcgcgct catctcgctc acccagagcg 6360
cggggctgaa cctcatccgc caggggatca acgtcaatgc catcgccccg ggcgtggtgg 6420
acggcgagca ctgggacggg gtggatgca agttcgcca ctacgagaac ctgccccgcg 6480
gcgagaagaa gcgtcaggtc ggcgcggcg tgcccttcgg ccgcatgggc cgcgcgagg 6540
acctgaccgg catggcgatc ttctcgcca cgcccgaggc cgactacatc gtggcccaga 6600
cctacaacgt ggacggcggc aactggatga gctgaggccc aaggcccggc cctccccccg 6660
tcgaacgcgc cccctatccg aggtaatccc atgaccgct ccgtacccg tccctctat 6720
gaccgcaagg cgctcactcc cggcatcgtc catatcgcg tcggcaactt ccaccgggcg 6780
catcaggcg tctatctcga cgatctcttc gcgctggcg agggccacga ctgggccatc 6840
ctcggcgcg gcgtccgcc gaccgatgcg cggatgcgc aggctctggc cgcgcaggac 6900
aatctctcga cggatgatga gctcgatccg gcgggcccacc gggcccggca ggtggggcg 6960
atggtgggct tctgcccgt cgaggccgac aatgcggccc tgatcgaggc catgtcgat 7020
ccgcgcatcc gcacgtctc gctgaccgtg accgagggcg gctattatgt cgatgcctcg 7080
ggcgcttcg atccgacga tcccgatata gtggccgat cggcccatcc tgcgcggccc 7140
gcgaccgct tcggcgcgat cctcgccgc ctccgcgcc gccgcgacgc gggggttaca 7200
cccttcaccg tgatgtctc cgacaacctc ccgggcaac gccatgtcac ccgcaacgcc 7260
gtggtgggcc tggccgagct ctacgacgc gagcttgcg gctgggtgaa ggcgcagggtg 7320
gccttcccga acggcatggt cgaccgatc acccccgcca ccggcccga cgagcgcgaa 7380
ctggcgagg gcttcggcct cgccgatcc gtgcccgtca cctgcgagcc gttccggcag 7440
tggtgatcg aggatcattt cccgcggga cggccgcgc tcgagaagg ggcgtgacc 7500
ttcaccgcg atgtccatgc ctacgaggcg atgaagatcc gcacctgaa cgggggcat 7560
gcggtgatcg cctatccgc ggcgctcatg gacatccagc tcgtgcacgc ggccatggcc 7620

-148-

catccgctga tcgcggcctt cctgcacaag gtcgaggtcg aggagatcct gccccatgtc 7680
ccgcccgtgc ccgacaccag catccccgac tatcttacc tgcacgagag ccgcttctcg 7740
aaccccgaga tcgcgcacac gacgcgcagg ctctgcctcg acggttcgaa ccggcagccg 7800
aagttcatcg tgccgtcgct gcgcgacaat ctggcggcgg gcacgggtgcc gaaggggctg 7860
gtgctgctct cggcgctctg gtgccgctac tgcttcggca cgacggactc gggcgttgtg 7920
gtcgagccga acgatccgaa ctggacggcg ctgcaggacc gggcgcgggc ggccaaggag 7980
acgcgcggcg agtggttggc gatgaccgaa gtctacggcg atctggcgca gaacgatctt 8040
ctggcgggcg agttcgcggc agccctcgag gcggtctggc gcgacggggc cgaggcggtg 8100
ctgcggcgct tcctcgcggc ctgatccgca gggcccagcc gctcggagca ccgaagcgga 8160
gccccctgcc cttgcggcgc accgtgaggc gaaacgaccg ggccaccccg gggccaccgc 8220
ctcggtaaca ccatggtatc gcgcaagaat gccggcgctt ctgccgaacg ggcccggctg 8280
ccgggcgagg cgccggactt gtcaaggcgg cggccctcgg gtagagaggc cgggctggc 8340
cccgtttagca cagtggtagt gcagcgctct tgtaaagcga aggtcggttcg ttcaaactcg 8400
acacggggca cgcgatcctc cctccgcacg ggcgctcgcc cccggtctgg actgcctctt 8460
cggaaggcac ctgcccgtt gtgcgcgcgc ccctttctc gcttcccaag cgtctgtcac 8520
ggcttgcgga aagccgtgcg cctcggttct ggacagccgc cccttgcggt gtaatctgcc 8580
ctcagcgcgc agccggcgga cagaagccgg cccgccacgt ccacaaggga ggaatgcat 8640
ggatcgctgt tcattcatca ccaaggccgc cgtgggaggg gccgccgca gcgccctcgc 8700
cgcgccggcg cttgccagc ccgcgcccga ggtcacctgg aggtcgcct cctccttccc 8760
gaaatcgctc gacacgatct tcggcgggcg cgaagtgtg tcgaagatgc tctccgaggc 8820
caccgacggc aacttcaga tccaggtctt ctgcggggc gagctgggtc cgggcctgca 8880
ggccgccgac gccgtgaccg agggcacctg cgaatgctgc cacacggtcg gctactatta 8940
ctggggcaag gatcccatc tcgcgctggc cgcggccgtg cccttctcgc tgtcggcgcg 9000
cggcataaac gcctggcact accatggcgg cgggatcgac ctctacaacg atttcctcgc 9060
gcagcacaac atcgtggcct tcccgggcgg caacaccggc gtgcagatgg gcggctgggt 9120
ccggcgcgag atcaacaccg tggccgacat gcagggcctg aagatgcggg tcggcggtt 9180

-149-

tgcggggaag gtgatggagc gtctgggctg cgtgccgcag cagatcgcg gcggcgacat 9240
ctatccggcg ctggagaagg ggaacgatcga cgcgaccgaa tgggtcggcc cctatgacga 9300
cgagaagctc ggctttcttca aggtggcgcc ctactactac tatcccggtt ggtgggaagg 9360
cggcccgacc gtccatttca tgttcaacaa gagcgctac gaggggctga ccccggccta 9420
tcagtcgctg ctgcgcaccg cctgccacgc ggccgatgag aacatgctcc agctctacga 9480
ctggaagaac ccgacggcga tcaagtcgct ggtggcgag ggaaccacgc tcaggccctt 9540
cagccccgag atcctgcagg cctgtttcga ggccgcgaac gaggtctatg ccgagatgga 9600
agcctcgaac cccgccttca agaagatctg ggactcgatc aaggccttcc gctccgagca 9660
ctacacctgg gcgcagatcg ccgaatacaa ctacgacacc ttcgatgagg tgcagcagaa 9720
cgccggcaag ctctgagccc gagcgccgag cgaaagagga ccccgagacc gcgttccggg 9780
gtcttttcat gggcgacagg ggccggcgcg 9810

<210> 36

<211> 1886

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 36

tgagtgtcta ttttttttcg ggttttttta agtgtgaatc acatggttag gagcagttgt 60
cttcaatgtg accaaccatc ccaaggctct aattcaacgt ttgggtgtgg gggcccgctg 120
gcagctgtgt gtgccactgg gctgttggtg ttggtgcttt actccccctc atcgcaaacg 180
gctaattggt cggcacaggg tatttccaca aaggcgctgt atccggcagt gcctgtgcct 240
tccactctgc tgccctggaag cgcgcctgcc aaacaccagc tgcagtgttg gagggcacat 300
gcgatgtcgg aggcacacac aaacaattca ttcaaacagt cattatttgg gtacaatgcc 360
atctctcca tttggcttca actggctggt gtggccgcca ctttctttgc atttgagct 420
ttgatggcag ctgtaacgca acgcaaggag atcgccgtct tctccgcctc gggtcaggct 480
gctgagccgg agggggcgga gccctgaag cggccttttc cgtctcctgc tgccaaacct 540
aagccgctct tctccacccc ggcaaatcc ttcagcaaca tcttccaggc gcctccatcg 600

-150-

ctgcgcacgg actccaccta tggccgaggg ccgcgctcga ccagcttcac cgacatcagc 660
 aactggccct ccaacaacgc actccgcaac cccagtcgg tgattgacat cgggggagga 720
 gtcgacttcc tgggggacag aagccctgga aaccggttca cgcggctgcg ggggtccccg 780
 agctccaccc tcagcaacct cggcatgggc ctaggcctgg ggctgggcaa gggcaagggc 840
 ttcggcaagg gcttcggcaa aggccggggg ttccccgtgg aggaggaggt ggaggaggag 900
 caggaggtgc tgtcgtgggc cgaccgccgg cgggcgctgg cggaccccga cggcccgccg 960
 atgaacgagg acatcaagta cccgcagctg cggctggtgc gggcctgcc gggcggccgg 1020
 gacgagaagc tcggtgtgat gtcgaggcag gaggcgctgg agctggcgga ggcggaagac 1080
 atcgacctcg tcctcgtcag catcgacacc gaccccccg tggccaagct agtcaattac 1140
 tcgaagttga agtacgagtc cgagaagaag aagaaggaca gccacaagaa ggggaaggtg 1200
 aaggaggtga aggagctgaa ggtgtcccat aagatcggcc agcacgacta cgacgtccgc 1260
 gtgaagcagg cccgaaagtt cctggagggc ggccaccgca tcaaggtgtc gatggagttc 1320
 aaggggcgcg agaaccagtt cgtggagatc ggccgcgcg tgatgaagcg cttccagaac 1380
 gacctggcg acatgggcaa ggcggacgcc gtgcccaaga agctcggcac ccggtgatc 1440
 ctgaacctgg ccccgcccg ggaggcgctg aagggtgatt cgagcgagag ggcagagcgc 1500
 gacaggaaag ccgcggctga ggaggagggg gagggcgacg acctcgactt cgtggacgag 1560
 aacgaggacg aggatgtgga gggggagggc gaggaggaag aggccgagga gctggaggag 1620
 gagacagcgg aggggacgga ggtgccaacc cgcagctgat cgccgatccg cgggggacag 1680
 ccacctcccc cccggcctcc ctgccggggg ccggcaccat ccgtcgttgc ggtgcggcgc 1740
 tgccatcaac ggccgtcctt gagcttaatg ctcccgcct ccgttgggcc gcggcggtcg 1800
 ccaggttgct ggctggctg cccgcagctc ctcccctccc cgactgacac agtgtggatg 1860
 accgtgatgt gcgccttttc gccttc 1886

<210> 37
 <211> 3015
 <212> DNA
 <213> Unknown

<220>

-151-

<223> Description of Unknown Organism:Unknown

<400> 37

ccgctcatct ccaggcctcc ctgagtgcgt acccgagagc ggcaagtaga gaaaggaaca 60
cagatacagc accatggcct ctaggctcgt ccgtgtgctg gcggccgcca tgctgggtgc 120
agcggccgtg tcggtcgacg cgcgcttcgt ggtgcgcatt gtgcaggtgg tacaccgcca 180
cgggtgcgcgc agcgcactca tcgacgacaa cagcagggag atttgtggca ccctgtaccc 240
gtgcgggtgag ctgaccggcg aggggtgtcg gatggctcgt gctatcggcg agtttgcccg 300
cagccgctac aacaacctct cattgggtgga gagccctctc ttcccgtcga cgcggtacaa 360
ctcctctgtc gtgcacacac gctccaccca caccagcgc accatccaga gcgcgaccgc 420
ctttctgcgc ggcctcttcc aggacgacta cttctaccog gtggtgtact cgaccaacag 480
aacgaccgaa acgctgctca gcactgacgc ggtgccgtcc gtggtgggccc gtagctggct 540
cgacaacccg gcgctgcacg ccgccctcaa cccggtgatc gatgagcacc tcagctggga 600
cgccatccag agcgtgcca aggacgcatt ggtcgagggc ctgtgcgcgg actacaacgc 660
ccgcaccaac tgcgtcctcg acatgtacga cgtggccgcc gccttcgagg ccgcccggcg 720
tcttgacaat gccaccaatc tcaaggcggg gtatcccggc cttcaggagg tgaacgccgc 780
ctggttcaag tatgtcttca gctggaacca cagcagcaag ctcgatctca cgcagggctc 840
cgctctgcag aaccttgccg agacgggtgct ggccaacatc aacgcccacc gcctctctcc 900
gtcgtacaac atgttccagt acagcgtca cgacacaacg gtgactccct tggctgtcac 960
gttcggtgac cagggcgaga cgacgatgcg tccgcccttc gcggttacca tcttcgtgga 1020
gctgctccag gacaccgcag atgccagtgg ctggtacgtg cgcctcatcc gcggcaaccc 1080
tgtgaaggca gccgacggca cctatgtctt ccaggagtct ggtatcaagg catactgcat 1140
cgatgaagcc gggaacaagt acctgcaca caccggcatc tgcccgtga atagcttccg 1200
ccgcatggtc gactactcgc gcccgcgcgt ggctgacggg cactgcgcca tgacacagac 1260
tcagtacagc aacatggatt gcccgcgcac tatcgcggac aacaagccgg tgccgtcgcg 1320
ctgctggctc taccgccacg ttgcccctag caaggcatgc ccggacagct acattctctc 1380
cgcggtcgac caccagtgtt accccgggccc cgacgttacg aaccccacca gcagcagcag 1440
cagcgagggt accaccacca gcagcagcga gggtagccgc accagcagca gcgacgttac 1500

-152-

caccaccagc agcagcgagg gtaccgccac cagcagcagc gacgctacca ccagcagcag 1560
cgagggtacc gccaccagca gcagcgacgc taccaccagc agcagcagcg acgctaccac 1620
caccagcagc agcgagggta ccaccagcag cagcagcgac gctaccacca gcagcagcga 1680
cgctaccacc accagtagca gcgaggggtac cgccaccagc agcagcgacg ctaccaccac 1740
cagcagcgag ggtaccgcca ccagcagcag cgacgttacc accaccagca gcgaggggtac 1800
cgccaccagc agcagcgacg ctaccaccac cagcagcagc gaggggtacca ccagcagcag 1860
cagcgacgct accaccagca gcagcgaggg taccgccacc accagcagcg acgctaccac 1920
cagcagcagc agcgagggta ccaccagcag cagcagcgac gctaccacca gcagcagcga 1980
cgttaccacc accagcagca gcagcgaggg taccgccacc agcagcagcg acgctaccac 2040
cagcagcagc gaggggtaccg ccaccaccag cagcgacgct accaccagca gcagcagcga 2100
gggtaccacc agcagcagca gcgacgctac caccagcagc agcgagggta ccgccaccac 2160
cagcagcgac gctaccacca gcagcagcag cgagggtacc accagcagca gaagtgcgc 2220
taccaccagc agcagcgagg gtaccgccac caccagcagc gacgctacca ccagcagcag 2280
cagcgaggggt accaccagca gcagcagcga cgctaccacc agcagcagcg aggggtaccgc 2340
caccaccagc agcgacgcta ccaccagcag cagcagcgag ggtaccacca gcagcagcag 2400
cgacgctacc accaccagca gcgacgttac caccaccagc agcagcagcg aggggtaccgc 2460
caccagcagc agcgacgcta ccaccaccag cagcgacggt accaccacca gcagcagcag 2520
cgagggtacc accaccagca gcagcagcag cagcagcaaa agcacaagtt catcggtatgt 2580
cccttccttc aaaaagcccg cgaactggag cccgcgcgtt ctctcgccgg aaaggggccg 2640
ccacattgcc ggggacatca tccgccgcgt gacgaacggt gttacgatcg gtgcgggtgt 2700
ccgaaagcac gatgagtaca gccggcaccg ccaacagtag cacaacggca tgtaactctt 2760
ttgtgcatgt ttgaatggag aggaggcttc tgtacagcgt acattgtttc gagaaggtat 2820
cacaaccgct cgtttcaccc ccgtcatctt ttcattttga tctccgtcgt ctcatactgc 2880
ctttgtgggc tctctctggg tgtgggcgct tgtgcgtgtg tcgctgtaaa gtcggtgacg 2940
ccatcgctct tacctgtggg ctatTTTTTT aattatgggt tattattact tccctctctg 3000
cgcgccctc tgcag 3015

-153-

<210> 38
<211> 38186
<212> DNA
<213> Unknown

<220>
<223> Description of Unknown Organism:Unknown

<400> 38
gatccttcct gcctcttccg gcgtctgggg ctccaggcgc ccttggttg cagattgac 60
tccctgatct ctgcctccat ctgctcacag ccttctcccc tgttgtctc tgtctcttct 120
tgtaaattca tccgtcgttg gatcagggcc caccgggttc ctggtggcct cgccttaact 180
gggcatgtc tgcagagacc ctatttccac ataaggtcct attcacagga accgggggtc 240
aggatgtcag cctgtctttc tgggagatgt agttcaacc acaacacaca tcaaacagtt 300
attgagcgcc gactgcgtgc cctgccgtgt gcttgaagg cccaccctca ggaagcgggg 360
cctagggatg gcggccgtga tcacgcaggc agcagagagc agctctggga agcggggagg 420
gacgaggacg gggaggcgac atcagcaagg ccgtgtgtga gccaggcagg gtgtccccgg 480
tgtagcacct ggctcgggca gaggccccga ggaggggctg gaggagctgg gcgaggaggc 540
gggcaggacg ggcctgacac tagggacctc gggccccggg aatgcctctg ggggggcgtg 600
tacacccgtt gctcccagga ggcacacact gcggttcgct tcgccaagaa tgtttaattg 660
catttgatga ctacggtttc cattcattca tttgtagaga tataacactc agaccacaaa 720
atgcataaaa tgcggtggct ttagtatta acagagtgt gcacccgata ccacagcctc 780
actccagaac attctcatgg gcccaaaagg agacctgggg tgtagtcac cagctcactc 840
cccgccccca gccctggca acccagcta cttagtcatt atttaggtgt ttaggagttg 900
caaagtcaaa tctttaaac cacaatggc caggcgtggt ggctcacgcc tgtaatccca 960
gcactttcag aggccgagac gggcagatca cctgagggtc ggagttcgag accagcctgg 1020
ccaacatggt gaagccccgt ctccactaaa aatacaaat tagccgggag tggtgggtggg 1080
cgcctgtaat ccagctact ctggaggctg agacaggaga atcgcttgaa ccaggaggc 1140
ggcggttgca gtgagccgag attgtgccac tgcactccag cctggacaac agagcgagac 1200
tccgtctcaa aaaaaaaaaa agtaccaaaa agtgccccag gtcataaggg cacagctcga 1260

-154-

tagctggtcc ctaaagggaa cgtggtgtaa ccaccacaca gaacgaagct ggaacgttcc 1320
tgccgtcctt agaagctgcc ttgctaagg ggaattgcc tgacttccca caccattgat 1380
tcatctccag acccttggtt ttcattgtga tttttcaaaa atcacctgat agtctgaccg 1440
aatgtagctt tccactggtg tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg tgagagagag 1500
atggagtctc gctctgtcac ccgggctcca gtgcagttgt gtgatcttgg ttcactgtaa 1560
cctcctcctc ccgggttcaa gagactcgtg cctcagcctc ccgagtagct gggattacag 1620
gcacccgccca ccacaccag ctaatTTTTT gtattTTtag tagagatggg gtttcacat 1680
gttggccagg ctggtctcga actcctgaca tcaggcgatc caccacctt ggctccag 1740
agtgtgga ttacaggtgt gaggcaccac gcccgccctt attttcccc cattttcttt 1800
tttttttttt ttgagtcagg gtcttgttct gcgctcaggc tggagggcag tgggtgtggg 1860
atcacggctc actgcagcct cgacttcctg caccaccag cctggctgtt tttttttttt 1920
ccggtagaga cgggggtctt accgtgttgc ccaggctggc ctagaactcc tgggctcaag 1980
cgatcctccc gcctcggcct ccgcaaatgc tgagatcaca cgcgtgagcc cccgcacccg 2040
gcctcctttc caccgtctt gtctacagcc gccctcctg gtccgattgt attggcagat 2100
gtcgccaata cgggtgtcaaa cggcgaagg gcactgagcg ttttttcttt ctcccgtcct 2160
tggcggcagc agctcgggtc cggctacggg gctgagccc tctctcagac gaggaaactg 2220
gggtccgaga ggtgagccgg tcccagaggc agggcgagg ggaagcggga gtggggtccg 2280
cagcggaccc agccctgcct cccccctgca ggagatcgtc aacttcaact gccggaagct 2340
ggtggcctcc atgccgtgt tcgccaacgc cgaccccaac ttcgtcacgg ccatgctgac 2400
caagctcaag ttcgaggtct tccagccggg tgactacatc atccgcgaag gcaccatcgg 2460
gaagaagatg tacttcatcc agcacggcgt ggtcagcgtg ctactaagg gcaacaagga 2520
gatgaagctg tccgatggct cctacttcgg gggtagctt gaggggggcg cgctggagg 2580
gggagggggc acgcgacccc cgcggtgtgc agagccaggg ggccggggcc ggggcccggg 2640
ccggggatgg ggatggggat ggggatgggg ccggggatgg ggatggggat ggggatgggg 2700
ccggggatgg ggatggggat ggggcccggg atggggatgg ggccggggat ggggcccggg 2760
atggggccgg ggatggggcc ggggcccggc ccaggagag cctgggtggg aagcgcac 2820

-155-

gctggccaag gtgcagaggc cgggccgtgt gcctgggcgg ggagggccgc ggcgcccgcc 2880
tcgtccagca accccccct gcgcgccacg tgcagagatc tgccctgctca cccggggccg 2940
ccgcacggcg agcgtgcggg ctgacaccta ctgccgcctc tattcgctga gcgtggacaa 3000
cttcaacgag gtgctggagg agtaccocat gatgcggcgc gccttcgaga cggtgcccat 3060
cgaccgcctg gaccgcatcg gtgagcgggc cgggggcgtg gccggggcgg gtgccctggc 3120
gggggagggg cgtggccaag gcatcaggag agtggcttgg acagtggcag ggggaagggc 3180
gtggctgtgg catcaggggc acggttgggg cagagacgtg gccaaggcat caggagtgtg 3240
gccatggcag caggggcgtg gctggggcag gggcagcggc tggccgctcc taggaccct 3300
ttgggtctag aggctgattt tctgacctat tgtcctactt cagccagagg cagcctgttt 3360
cccaagggag ggaatgcaca ggggtgttgc ggttgtgccg aatgctcggg gagcacctgc 3420
tgtgtgctgg ggggtcaggg gacagacccg ggggccact cagactccca gggaggctta 3480
tggactggtg atgaaatcac acacgactgg gctgtgtgcc agcagggcag gtggggcccg 3540
tgggcttccc tgagttggga atgcagagtg gagaccaggg taagggatgc catgtggaaa 3600
cggggaggaa gatgtgttcg tggagtggac acagcacatc ccaaggccct gaggtggaaa 3660
agaggcctag agtccagaga gccagggagg cctggaggag gttggggaag aaggggaggc 3720
cagacacaca gggcccagtg ggcggcaggg agagttaga ctaaatacagg agcatcaggg 3780
agccatggag ggttctaggt gggcggagga cctggtcaga ttgtatccgc caaggcgggc 3840
cgtgtccagg agggagacgg tgacctggcc tctcaggggg gcagtctctg gggcagggag 3900
cggcagagcc ctgatgactg gatgtaggcg ccagagagat ggcggctcat gctgctgttc 3960
gtgggaatgg gaatgaagac catggctgaa acgcaggaca ggtgcgacgg agtgggtgtca 4020
gggagctccc tgggtgtacag taggaagctc tccacaactt gctctataca gtgagtatgc 4080
aaccggttcc tgagtatcag gtgcttaggt tataacttct gtatacagca ggtgctcagc 4140
acaggctgtg tacaggcagg tgttttcggg atgcctgtgg cactctggag gcagtcatta 4200
cataatcagc gtatacaggt ggtacacatg cataacttgg gcacagtgat acctgctcca 4260
tgtacacagc aggcattaaa tacctgttta ctgccaggcg cggtggtctca cgcctgtagt 4320
cccagcactt tcggaggcca aggtgggtgg atcacgaggg caggagattg agaccatcct 4380

-156-

ggctaacatg gtgaaacccc gtctctacta aaaaaaaaaat acaaaaaaatt agccgggtgt 4440
ggtggcgggc gcctgtagtc ccagctactc gggaggatga ggcaggagaa tgggtgtgaac 4500
ccgggaggtg gaccttgtag tgggccgaga tcgcgccact gcaactccagc ccgggagaca 4560
gagcaagact ccgtctcaga aacaaagcaa aacaaaagcc ctgctttctg tatgcaggtg 4620
cttcatgcat gctggctgtg catagcaggt gctcagcctg tatatggcag gtactcaata 4680
tccatactat aggccagaga tgctacatat gtgcttattg tatacagtag gtggtaaattg 4740
catgcttgct ctacacggca agcactgtgt gcgcacccgc ggtgcagagt aggtgctcgg 4800
tgcccgctgt acgcagcagg cgctccctgt gcacacgcta acgccccctc tcccgagggc 4860
aagaagaatt ccatcctcct gcacaaggtg cagcatgacc tcaactcggg cgtattcaac 4920
aaccaggaga acgcatcat ccaggagatc gtcaagtacg accgcgagat ggtgcagcag 4980
gccgagctgg gtcagcgcgt gggcctcttc ccgccgccgc cgccgccgcc gcaggtcacc 5040
tcggccatcg ccacgctgca gcaggcggcg gccatgagct tctgcccgca ggtggcgcg 5100
ccgctcgtgg ggccgctggc gctcggctcg ccgcgcctcg tcgcgcgccc gcccccgggg 5160
cccgcacctg ccgcgcctc acccgggccc ccgccccccg ccagcccccc gggcgcgccc 5220
gccagcccc gggcacgcg gacctcgccc tacggcggcc tgcccgccgc ccccttgct 5280
gggccccccc tgcccgcgcg ccgcctgagc cgcgcgctgc gccactgtc cgcctcgag 5340
ccctcgtgc ctcacggcg ccccgggccc gcggcctcca cacgcccggc cagcagctcc 5400
acaccgcgt tggggccac gcccgctgcc cgggcccgcg cgcccagccc ggaccgcagg 5460
gactcggcct caccggcgcg cgccggcggc ctggaccccc aggactccgc gcgctcgcg 5520
ctctcgtcca acttgtagc ctcgccgacc gcccccgggg ccaggcgggg ccggggggcg 5580
ggccgtcatc cagaccaaag ccatgccatt gcgctgcccc ggccgccagt ccgccagaa 5640
gccatagacg agacgtaggt agccgtagtt ggacggacgg gcagggcccg cggggcagcc 5700
ccctcgcgc ccccgccgt cccctcat cgccccgcgc ccacccccat cgccctgcc 5760
ccggcgggcg gcctcgctg cgagggggct cccttcacct cggcgctca gttccccag 5820
ctgtaagaca gggacggggc ggccagtggt ctgagaggag ccggctgtgg agccccgcc 5880
gcccccaacc ctctaggtgg ccccgctcg aggaggatcg ttttctaagt gcaatacttg 5940

-157-

gcccgcgggc ttcccgtgc ccccatcgcg ctcacgcaat aaccggccc gccccgtcc 6000
gcgcgcgtcc cccggtgacc tcggggagca gcaccccgcc tccctccagc actggcaccg 6060
agaggcaggc ctggctgcgc agggcgcggg ggggaggctg gggccccgc gccgtgatga 6120
atgtactgac gagccgaggc agcagtgtcc ccaccgtggc cccccacgcc ccattaaccc 6180
ccacaccccc attccgcgca ataaacgaca gcattggcgc caagcctggc cgcgtgtgat 6240
tgcccagagc ccgcaggcg tgcacccttc ctgaagacag tggctcctgg ggggtggcaaa 6300
agagctttat ttacacactg acaaggctca cgggggtgtca gctgaagaag taggtggaac 6360
gcttcacctg ctccaggtcg aaggcccctg cggaggaagc agagcggacg gcgtgggtgg 6420
cgggaaagcc ccgccctggc ccgcagttcg agccaccctt gcgaggctgc ccaccgcct 6480
acctggcttg ggcaccgcct gcagtgtctc cttcagctgg ctggcctcca agatcttctg 6540
gggcctgygg ttggaagcag ggtgggggtga ggctgaggcc aggttttggg gtgggggggg 6600
aatccaggta gttgggggtca gggagcgcct tactcagagc agaaccgctt gaccaggaat 6660
ctggacaggt cctgcaggat gggctcgctg tgcaagcgga caaactgctc ccggcacacc 6720
tgggcaggag tcagaggatc ccaggggtg atcaggcagg ctctgggcac caccctacc 6780
caacgcccc a gtgtgggggc cccacccatg ggtggactga ggctcagact acgggggcac 6840
ctggttcctg acggagacat cagctgcgtg agtccagtaa cagtcgtgca cagagacgaa 6900
ggtcaggccc ttctgtggc agagcggagg actcctgaag ggaggggagc tcacagggcc 6960
accagtgc cagcatcctg gccctgcgt cagccccctc cacttgaggc ccagggaagc 7020
ccaccctcct gcaggcctcg cccaccctc cgccccgcc ctccccaaac atcctgggtt 7080
aggtatcagt acagggggag gaaatgttcc cagaagcctc ctgcgccac ccctgccgc 7140
ccccacgtg ctgtgggagc ctgagctcg agggcggtc cgagggtccc tctgccagg 7200
gccaccacc cgcatcctga gcattcccag ctcccgtggc cggtagattc tgctggaacg 7260
acctccagt gctccagatc taaccacaca tcgcggtgcc aagaaatgcc cagcaggaag 7320
gggcagcgcc catgctcggc tctcctgtc gggccacagg aggggagctg ccaggaccac 7380
ctacattcgg ggcacacagc ctcagggcct ctacacaggc cccacagaca cagcagatcc 7440
actctgccc gtcctgccc ccagctagac ccagccttgc cagctgtgcc ctgctagcca 7500

-158-

gaagacgccc ctgggaggcg agcggcaccc acgccgtccg gagacgcca cctgtagcag 7560
tgcagggcg tgagcatcat gtgggaggag tccagcgagt ggatgaagtt gggcggaag 7620
ccgttcttct gcttacgtgt gttgggcttt ctgaggacgg aacaggtgcc ggtggggcg 7680
gcccaggac acccctaact ggccgctgtc tccaccgtgg ctgctctcca gacccccggc 7740
caggccccag cccgggcccc ccaactcaccg gctgatgtct ccgttggtgg tgtaggtgat 7800
gctctgaatt ccacctccta tttgctaaaa aggggaagg gccggtgagt cccaccgag 7860
gcccagcacg gtggtggtac attgaggtgg tggtaactg gggtagtggc acgctaggat 7920
ggtggcacac tggcgcgga tgggtggca cactggggcg gtggtacact ggggtggtgg 7980
tacgtgggg cactggtaca ctgggacgt gttacactgg gatggtggca cactggggag 8040
ggatggggtg gtacactgac cttgacctg gaggccaggc gatagggtg gatgacggg 8100
acgcccagg gtgtgacca ctccaccaca gagccatgt gggagatgag gcgggcactc 8160
tcggtcagcc agtgctgtgg gacacaggcc gtctcagggc agggggctca ggccggggat 8220
ccgtccact tgcttaggga gtcctggccg agcggggaca ggacaggacg tacctggatg 8280
gcccgggtcc ccgagaacat ctctgtaga ctctgaaga cctggcgtag gagatagtga 8340
gaggcctccc acacgaactc ctgcagagg cgggcagcag gtgcaggtcc tcaggggctg 8400
gcccgttcac gccctactcc cccctatttc agagccactg aggcccaagg cctagggcct 8460
agcagggggg cagggaatg gggcctggcg cccacgcagt cagcaagaaa cgccaagcc 8520
ctaacaggca gccagtgtc tgggggagca gccagggtc ctgctgggag gctgggtcgg 8580
gggcacaccc gtctgagttt taaatggcag tgaaaccaac gtgttcgcag cgcgacatgc 8640
ctggcgcacc tggggaaagt cgctcagctc ccggaggcgc ttctcaatct gcaggcgccc 8700
gccatagcgc gtgacccgt acaccaccgt catcaccgtc tgcttcacca ccttgcggt 8760
gatgaaacct tccagcacct gtgccaccg catgccccgc tggcgctcct gcctacggaa 8820
cacctccacc tgcacggcg gtgggcccgg ggcgcgggtc agccccgcta gcagcccagg 8880
ggccaccaag caccatgaa gccccgccc cagccccacc acatcctcag gacaggccaa 8940
ggtgagggca cctggggccg agactcagg ctcacattgc cccacgccc agatgcccc 9000
gggcagcagg gcacacccta cctgcgcggc cagccgctg tacacgtcct gcggcacatc 9060

-159-

cgagggctcc aggttgacgg agggggcgcc cacgctgtcg cggcccagag cagcataatg 9120
ctgcaggccg ttgcaagagc cgtcctgagg aaggggcggc aaacgggaga tggaagctag 9180
agaggcagag acgtgtggga ccccaaacca cccccaggt cgagccgttc ctagggccgt 9240
gcacccccca gccaaagtga ccggagcccc cgcacgctcc cgggagagac caggagccat 9300
ggctcccgca cactctagga ccacctccag agaataccac gagcgaaggt gaaatctcac 9360
accctcaagt cgagccccag gcccagtga cactgcacgg cctcgggggc cagaccagc 9420
tggtcacct gatggacggg gaggtgggag acataggcgg cagggtcgga ggcgcgcaca 9480
gcgttcgcca cctccataca gcaggccagc gtctgccagg gttcctcgc gcccatccac 9540
cactttcggc cctgcgggga cagcggatgg ggggcagtga ggcccgggcc cgatccctga 9600
gcccgttggg aggtgtgtt gcggggaggt gggaaatggg gaggagacgc acaccctga 9660
tagtgaacac gggacgcatg tgggcgagag acggggcggt ggctggatga gttctccata 9720
gccacggatg gaggatggga gctgcgggtg gaccgggctg aaacaagcgt gtccggagct 9780
gccgggggag gagggtggac agaggacctg ggggcgcggg gggaggaagc agctcggcgg 9840
atgcagggga ggggggaacg tggggaacgc gggggccctg gggcagggga gaaggagaa 9900
gcaggacggg cagggggcgc gggggaggag agcgggcggg ggacgtgggg gcgccagggg 9960
agggggaggg gaggaggaag acgggcaggg ggcgccaggg gagggggagg ggaggaggaa 10020
gacgggcagg gggcgcgggg gcgccggggg agggcgcggg ggcgccgggg gagggcgcgg 10080
gggtgccggg agggcgggga atgcgggggc cccgcccta ccgtcaaggg ttggtccgcg 10140
gagtcagga tgtcatccat cacctcctcc gcaaaggcca ggcgcttcg cagcggctcc 10200
cgcttcttca acccgtgag attgaccagg tggatcttga gccaatccag gccgtgcggg 10260
ccgagcgggc ggccctgggc gaactccagc agggcccgcg ccacgtcgtt gcccaggtgg 10320
ttgaagtgcg gcgggcaggg gtaggtgcgg ccgcggaagt ccatgttgtg cggcagccag 10380
aagacgcggt cccgcaggtg ctgcgccagc gagaggcggg acagcgcctc cgccgcagg 10440
ctgtgcatct cccgggccac cttctggcag tgcgccagct cacggcgcag ctccggcctt 10500
cgggcggggc cggcgtgtg cggcaggtgg gcctcgggcg gctggggcgc ctcggagggc 10560
ggggccggca cgcctagctg ggggcagccc ttggcctgga agagctgcag caccaggtcc 10620

-160-

agcacgcgcc cgttgacgcg ccaggcgagc ttgccagtt gggtagggc gtccagtgcg 10680
ccatgcagcg cggtagggcg gcaggtttcc agcagctcct ggtgctgcgt ggcgccttcc 10740
accgtgcgca tcagcttggg ggggctgagc aggaaagcac cagagtgcgg cgatgtccag 10800
ggcagcgggg ggcaaagcat ggtacatcc accgcctcga aggtcagcgt gggctccgcg 10860
gccttctcca gcagctgcac gtaggcggg tgcggcttca ggatgccgat ctggggtgcg 10920
acaggcagac gggtcagggc cccggtgctg gggctttcct gttcccacc cttaaacttg 10980
ggtgaagagg gccggctccc cggccaaca gaaaccagtg tggcctcca cgaacagaag 11040
ccacctccag aaacggccgg acacctgcat ggacacccat ggtgtgtccc gagtcctggg 11100
aggtactgac ggctgcgctg agatcaaggc tccgccccaa ggcgccaacc ccatggggtc 11160
cctggctctc ccagcgggat gccccccagc tcaggagggc actgcctggc acctgctgga 11220
cgttgcggaa ggaatacacg tggtagagca cggggacaag ccgagaggaa cgatgcggct 11280
tgtccaggct gcatggcatc tgcgtagcct gcaccagcat ctccgccagc agcttgccca 11340
gtcccatctg cactggcagg ggccagggtc gctcccgcag ggcctcgggc gccccagct 11400
cctcccagta ctgccgcggc aggcagggtc cgggcacctg taggacaggc cggtcagggc 11460
gctgggcacc gggggccctg agctagatgc cccaccgccc gtgcctgacg cccggtgggg 11520
catctgtcag cccaagcata cagatgaaca gactgaagct tgggtgcaaa cccggtgct 11580
ccagggaggg agagcgccca cccaccactg gcccagcca ggaggagagg gggtagcagc 11640
ctcacctcgg cgtcggaggc cagcaagcag aggtacttcc tgtagtgggt ctgcagcgcc 11700
tgcacctggc cactgaccgc ctgcctctgc accacgtgcc ggctgaaagt gcgcgcactc 11760
agctcccggg ccagggtggg gaaggactca ccttgggcgg gcagcgctg caggacctgc 11820
ggaaggcagc cgtgagtgcc tgccgcccc gcccggggac ccggccgcgc ggaggaagac 11880
gcacctgcag gagcatccgc accacctcgc gctcgtccag caggcacagg aaggggtaaa 11940
gtgagaaccg gccctcgtac acctcgcgt ctaggcggtt cttggtctcc cgcagcgccc 12000
ggcacagtgc tttctcccat tgggtccgca gggcttccag ggtcttccgc tgcgggggat 12060
gaacgggccc ggtgagcccc gtggcagctg gtgggaccca ggctcacagg acgggggtca 12120
ccgcagctcc ctgcagagac ctcatggccc tcaaggctcc tgcgtgtgt tccgggtagc 12180

-161-

tcctcacccc ggccctgccct ctgccggcctt cagcgtgcct gacgcagcca agagcaaaag 12240
cccagctgca gtgtgcgcag aagcacaggc caagacccaa cctcgggacc ccacaagttt 12300
tccctgagcg gcagccaggc tgagttccta ggccctgcat gaccagacca gggcatgagc 12360
aattcaaccg catacacgga gctcagcccc tgcggcggac acgcgacccc ggctcagccc 12420
ctgcggcgga cacgggaccc cggctcagcc cgtgcgggtg acacgcgacc cgggctcagc 12480
ccctgcggcg gacacgggac cccggctcag cccctaccgc gtgcttgacc tccttgcttg 12540
gcaacgtggg cttctccacg gacaccacgc acaccctgct ggccagctcc atgtggagct 12600
gcttctcaaa gaggcactgc agggctcttca agggcaggtg cagcttcggg taggacacac 12660
gcccacctg cagggatggg ggtagtgagg ttgggggctt gccagagggc gacctgccct 12720
cccaggaccc cgagacagca tgggtgcacg cgtttctgcg tctcctgcaa gttgctggtg 12780
gctatcgctg acgcggggaa aggcgggctg cgggtaaagt cagtgccagc agtgcaaacc 12840
aaaggccttg accctcctgg cctcgacccc tctagaaggg aactgggca ccgtgcaggg 12900
ggtggcaggg gcggtgatgc tgggagctgg cagagcctgg ggagaccgtt cactgcaccc 12960
ccagatgttg gctgttttct cctcaaactc agaactgtat gaatgtgacc catccagaaa 13020
tagatgaatt aaaaataaca actaaagcct agcgctttga gaatcaaaga cgcacgtcca 13080
cataaaagct tgtacacaaa cgttcacagc tgcatgactc gcagtcgata agtagaaaca 13140
gcccacgctc ccataaacgg acgaacagac gggcacggcg cggccatcca cgcaccggag 13200
catgactcag ccctgaccca ggtcgcctcc cggaggcacc atgaggacgt cacgctcagt 13260
gggagatgcc aaacacaaaa ggtctcgag tgtgtggtcc catttctatg gaatgtccag 13320
agcagactca tccacagatg gggaggggat ggggagtgac ggggatgggg acgaggcttc 13380
cttttagggg gatggaacat tctagaatta gacaaccgtg actacactaa aatcgctgaa 13440
ttacaccttt aagaggggtt tatggcaggt gaattacacc tcagtaacag acgagccac 13500
tgcgtcaccc tggcagcccc actcaaacgc actgctctcc tgtcacccca ccctctctct 13560
gcggcccccg accacctcgt cccctgagc ccacaccctc agggccaaga ccctcccagc 13620
tctgggtcct cccatcttct cagaggagga agggaggaat tcagggccca gccaggtga 13680
gcctgggca cgggggaggc ccattggtct gagctgaggc tccaggaacc ccaaagggc 13740

-162-

agctataagg actgaagtct gccggggccc acgtgggctc accttggcat acacgtccct 13800
gagcagcttg gaggtgttga ccgggggacg cagctgcggc gggaggctga aggtgggctt 13860
caccttgtgc acggccttca gaacagtggc ccgacccctc tcagacagca gaacggcggt 13920
gaagagtgcc tgcagcttca gcccctcctg gctcatctgt tccagacacc tgtgggtgcag 13980
gcggcctgct cgagggacgg gccagcccca cgctgggctt ccacagaccc caggggaacc 14040
tcgtgaccac ctctgctag cctgcaggtc tcgggtgtggc tgtcaggccc tctgggggtc 14100
cccagccccc agcccaggca ccgtcccaga tcttaaaacc ctgggaggga catggtgggg 14160
ggtggggggc ctcccgacac cacctacctt tcgatggctc cggcgctctg gtccctgcctc 14220
cccatgcact ggagggcagc cgcataggac agcaggctccg gagtcaagcc ggcacccctc 14280
accatgaata acacatatac cagctccttg aaggcaccct gggagaccaa gccagggtga 14340
gggtctgggg ggatggccca acctccacat cctccctgct ccctggagac cccttctctg 14400
tagccaccag ctacagcagg gacagggctc ccaggcagga gtggccagct gggcagaccg 14460
atgcatcccc ctgaggttct gacacacaag ctccacctgc agaggcagcc gcatggcccc 14520
ccagggtggga ctgtgggagg ttacagttcc tctgggaggc agcttggtta acctccagat 14580
ttgtcaattg tgtggatctt ttcaaaggac tgacttggct tgactgttct ctgctgtttc 14640
tgccctccat ttcacgatt tgttttaatc tttgtaactt cctctcatct acttgcttta 14700
ggtttagtga cagcttcttc ttctagtctc ctaagggtgaa aggtgacgta tttgggtctga 14760
gatgtttcac tttttttccc cccaagatgg agtcttgctc tgttgcccag gctggagtgc 14820
agtggcacia tctcagctgg gccgggttct ctgcctccca gggtccagca cttctcctgc 14880
ctcagcctcc tgagtagctg ggattacagg cacacgccac cacaccagct aattttttgt 14940
attcttagca gatacggggg ttccacctgc tggccaggct ggtctcgaac tcctgacatc 15000
gtgatccgcc agcctcagcc tcccaaagtg ctgggatgac aggtgtgcac caccgcgccc 15060
ggccatcacc tttccgaata taggcatttt gtgactataa attacctgc gagcactgtg 15120
tcagctgcat ccaggactt ctgacagggt gtgttttcat tttcattatc tccaagtgtt 15180
ttcgaacttc atagtttact tcttctttgg aaattttatt taattatttt tttagataga 15240
gtctcgctct gtcgcccagg ctggagtgc gtggcgcaat ctgagctcac tgtcaacctc 15300

-163-

cgctccccg gttcaaccga ttctcctgcc tcagcctcct gagtagctgg gactacaggc 15360
acatgccacc acaccagct aattattttg tatttttagt agagatgggg ttctgccttg 15420
ttggccaggc tggctctcaa ctctgacct caggggatcc acccgctcg gcctcccaaa 15480
gtgctgggat tacaggtgtg agccaccacg ccagccatg tatagcttaa atatccctg 15540
caattttttt ttttttcatt taatttttgg ccaggcacag tggtcatgc ctgtaacccc 15600
agcactttgg gaggccaaga caggaggatc acaaggtcag gagtttaaga ccagcctggc 15660
caacatagtg aaaccccatc tccactaaaa atacaaaaaa aaaaaaaaaa aattagctgg 15720
gcgtggtggc tcatgcctgt gctccctcca ctaaaaatac aaaaaaaaaa aaaaattagc 15780
tgggcgtggt ggcacatgcc tgtaatctca gctactggga gcctggggca ggagaatcac 15840
ttgaacgcag aaagcggaaa ttgcggtgag ccgggatctc accactgcac tccagcctgg 15900
gagacagaaa ctttgctgtc gacagacttg gagactctgt cttaaaatat acacacacac 15960
acatatatat atatataaa aataacatat atatataatt tttttcttgt attcattttt 16020
cctgacatcc ctgttctgag caatttctcc tttgaccag tggtgctta agagtggcct 16080
gtaactgtaa cagactattc caaaggga aaatttcct tacatcctcc caccatag 16140
tcctgcagct gaagacatgc tgtgacatga ggtggccaca caccagagac cagagacatg 16200
agttttgggg catttttttt tttttttttt tttgagacgg agtctcgctc tgtcgcccag 16260
gctggagtgc agtggctcga tctcggtc ca ctgcaagctc tgcctcccag gttcactcca 16320
tcctcctgcc tcagcctccc aagtagctgg gactgcaggc gcccgccacc acaccggct 16380
aattttttgt atatttttag tagagacggg gtttactgt gttagccagg atggtctcat 16440
ctctgacct cgtgatccgc ccgcctcagc ctcccaaagt gctgggatta caggcgtgag 16500
ccactgtgcc cggccggttt tggggcagtt tctaacaac ctctgtatgg tagacctcac 16560
tgggcacaca tagtccttaa attgaaatat tcagttcttc cttttcacca gtttcaagt 16620
ttcagtagca cacacagctg ttggcagatg cggaaaattc ccaacatcat agaaagttct 16680
actggatggt gctggttaga atacgtggcc gggcgcggtc gctcacgcct gtaatcccag 16740
cacttaggga ggctgaggcg ggcggattac ctgaggtcag gagtttgaga ccagcccggc 16800
caacatggca aaagcccgtc tctactaaaa atacaaaaat tggccgggagc tgggtggtgag 16860

-164-

tccctgtaat cccagccact caggaggctg cggcagggag aattattgaa cccaggaggc 16920
ggaggctgta gtgagccgag atcatggcac tgcaccctag cctgggcaac agacagagag 16980
tctatctcaa aaaaaaaaaa aaaaaaaga tagaagcaat gccttagcct ggctaacatg 17040
ctgaaacccc acctctacta aaaataaaaa ttaaaacaat tatccggggg tggtaggacac 17100
cgctgtaat cccagctgct cgggaggctg agctcgagc ccagcgacat ccaggactgc 17160
tggccacccc ggaacgctgg gagaggcagg agggggccct gctagagcct ctggagagac 17220
ttcgggtctg cagacatctt gattccagac ttctgggctc gtgctaagag tgcgtttctg 17280
ctgtgcaagc cgccagggtt gggacacttt cgtaggggcc gatcccaaaa gcgccctgtt 17340
acagtgtggg ctctctgccc agggaaatcca gggggcttgt gaccttgag gggaaaatac 17400
acgaccctca tcctcagtc tcccggagtc tggcgccccc tgcagcaagg aggaaccagg 17460
cagcacgccg cctccacctc gcggtaaag cactgcggac ttcaccgcaa gactggcccc 17520
acctgatcct gaatttcgct gtttgatgcg ttaataaaga agcacatcaa gttctctacc 17580
acgaattggt cttaatatg cgatatctgt attttaatat aatagtatcc catgtttacc 17640
caaataattaa gagaagcttt tactgttggt tctcaaatta gggctgaagg atcatggggg 17700
gggagaaagc tgggaacggt tgctgcttg aaagggtgtg taaacaacac cctccaaaac 17760
aaccaagagt tccgaggaga aactttggcc ggatacgggt gctcacgcct gtaatctcag 17820
ctcctcgga ggctcagggg ggcagatcac gaggtcagga gtttgagacc agcttgacca 17880
acacggtgaa accccgtct ctactcaaaa taaaaaatt aatcggggt ggtggcgggc 17940
acctgtaact ccagctactt aggaggctga ggcaggataa tcacttgaac ctgggaggtg 18000
gaggtggcca tgagccgaga tcgcaccacc gcactccaac ctagtaacag ggagagtatg 18060
tcccagaaaa caaataaata aacaaacaaa aagaaaacgg caagggaaat tggaaaatac 18120
tccagatgaa ccacaacgaa gatgggtggg atacatctaa agctgtgctc agagggaatg 18180
cggcgccagt gaacaccac atttcacaca gaaggatctc agcacagcag cccgaccttc 18240
cacctcagga aaccagaaaa aggagcaaag tcaaccccaa caccaaagcc tcctcctgac 18300
gagggctctg caggctgccc cccgacgagg ccaaagcac cctgcccag acagattcac 18360
gagccccgag aaagaacgga aggaaatgct caaggcatta gcagaatttc tccctacttt 18420

-165-

tttggtcatt ttcaaaattt gagagtcaca cgtgatttgt atttgaaaag cctaaaagaa 18480
ttattaaaat aaaaaacaaa ggacttgaac ctgggggcta agagagaaaa gtccagtcta 18540
aatgagggca agttcctgtc tccaacgacc agggcaggtg gcccggctcc cggctgcact 18600
cacctgccgc gccagccaa gcatcacggc gttgtacatg tccagcgtga gcagcttccg 18660
cttctgccgc tggccgtggt ggacgaccag caggtgggtg gcgaggggca gctggtcagt 18720
gagcaggcag cacttgaaga aggccaggag cctctgctgc tgacctgaga gctgggcctg 18780
cgagtgtgc cccgacggg cctgctccac atcgaggctc agcttcccag gggcctcctg 18840
cagcagccgg gccagctgct cctcccagg gctctcggg gcctggcgcg tgcagtccctc 18900
caggcaccgg gccatctgct tgctcaggag cgggggctcc acctgcaggc gcctggtcag 18960
cgccttgaac tccccgctct ggaatggcat ctgcagcttc gccttcaacc gctgcatacg 19020
catctgcccgg gtccgcttat ccttctccag tatctttgcc cagcggccac agggcaccgg 19080
ggtggcatcc ttggccccc tctggacctt cctgggtggc tggaggctac catctccact 19140
gccacattct gggagccgcg ccacatccac cctgttcacc accacctccg acacgctctc 19200
agcctgcagc tgccgcaccc gcgcctggag cactgtgagg ggcagaaggc gaggacatga 19260
gagggacccc ctccccattc gagcaccgct ctctctggac cctgagccag gccaggaggt 19320
gcaggtggct gagctcgctg ggacccaagg cgtgaattcc tcatacttgc caacaacgtt 19380
gtaaggctctg cccgctgctt tccagacaca cgcacccac cacctccgca cctccccacc 19440
cgagcctcac agaactcagc agccctaaca agctgccacc gaaacctgca gcaccacgtc 19500
tccccggtca ctggccgctc agaccctcca ggtgcacagg ccagaacccc ggggtctgtg 19560
acaactccct ccgtccacct ctcagtacct cctctgggct tgccctccaga atctatccag 19620
gtggccccc cctcccctgc ccctctcact gtctagctca gggcctctgc acagactccc 19680
aggacctga accgcccact ccctggctca accatggcct gcaagttcgc accccgcctc 19740
agcaagaccc cccagctgg tggagctgcc acacacacac tcctaggctc ccagtgtcta 19800
caccggtgga cgctgagcca ctagctcgca gggaaaacgc ggctcctgct cgtgccgcct 19860
caggttgcat ttttgccaac caatcaatgc ctaagtgttc tgtatctctt taaagaagcc 19920
ttgttgaaa tctattgctg gccgggcatg gcggctcacg tcggtcaccc cagcactttg 19980

-166-

ggaggccgag gcaggaagat cacctaaggt caggagttcg agaccagcct ggccaacatg 20040
gtgaaacccc gtctctatta gaaatccaaa aaattagctg ggcgtggtgg catgtgtcta 20100
tagtaccagc tacttgggag gctgaggcag gagaattgct tgagcctggg aggagaggt 20160
tgcagtgact caagatagcg ccattgaact ccagcctggg caacagaaca ataatccatc 20220
taaaaaaaaa agactgttga aataagccgg gtacagggcc gcgcacctgt ggtcccagct 20280
actccggtgg ctgaggtgaa agaatacact aagcctagga gttcctggct gctgtgagcc 20340
gtgatcaggc caccgtgctg cagcctgaga gacagagcag gaccctgtct caaaaaaaaa 20400
aagggggggg gggaccaggg tgtccagatg tgggtggctca cgctgtaat ccagcactt 20460
taggaggccg aggagggcg atcacgaggt caggagatca agaccatcct ggctaacacg 20520
gtgaaacccc gtccctacta aaaatacgaa aaattaaccg ggcgtggtgg tgcgcgcctg 20580
tagttccagc tactcgggag gttgaggcag gagaattgct tgaactcggg aggcgaggc 20640
tgcagtgagc caagatcgca ccattgcact ccagcctagc aacagattga gaatccgtct 20700
caagaaaaaa aaaattgctg aaataaaaag acaagcgtga tgtccgcctt cagagtgtctc 20760
caaaactcag gagatacttt taggattaac agttgagagc tttgttttgt tttgttttgt 20820
ttttgagatg gaatttcctt cgttgcccag gctagagtgc aatggcatga tctcggctca 20880
ccgcaacctc caccttccgg gttcaagcga ttctcctgtc tcagtctccc cgggttcaag 20940
cgattttcct gcctcagcct cctgagtagc tggcactgca ggcgttcacc accatgccca 21000
gctaattttt gtatttttag tagagacagt gtttcacat gttggccagg ctggtcttga 21060
actcatgacc tcttgatccg ccgcctcgg cctcccaaag tgctgggatt acaggcgtga 21120
gccaccgcac caggcctcgg acccttgacc tcttgatccg ccacacttgg ccacccaaaa 21180
gtgctgggag tacaggcgtg agccaccgca ccaggcctcg aacccccgac ctcttgatcc 21240
gcccacctcg gccacccaaa agtgctggga ttacaggcgt gagccaccgc acctggccag 21300
gttttttccc ttataaagg ttctcccgcc tctcccttcc cggctgccta atggacgcag 21360
acaggatgtg ggacagaagc accggcgagg agcaagcaca gggaagctcc cacctccctc 21420
ccacaccacc agccaggcca ggacgagggc ctgccaccgc tggagcctgg gctgtccctc 21480
ccaagtttcg cagtcatcca gtctccatta ggcgcctacc cccagagcc aagccaggac 21540

-167-

agctgagtca gttcaggggtt cacatcctgg ctctgcacat gtggccttgg cggcggggcc 21600
gggggggggg tctctccaga cataatcttg ggcctcacct atgtccctgg aaagtgggag 21660
cacctggttg ggttctgggg agggggaatt acgagagctc caggaaggag cctgctcagc 21720
aaggacaggg cccatgagcg gtgcaagaga tgtttcagca acgccgtctg ggctgtcct 21780
gggacccgag aggtggagac cgccctcagc ctgtctcaga atctgagcct ttgccttttc 21840
tcccggcagc agggagcggg ctctcctctc ccgggcccgc gtgggggtcg cgctcacct 21900
ccagcagctc cacgtggccc cagtccttcc tgcggtcttg gtcttgctcc tgggggctgg 21960
cggacgagct cctcctgggg ccgcagacgc caccggcggt ccctgcggga aagacgagag 22020
cggtgagcg gggccgggcg tgtgggcggg ggcctccata aaggcagaag ccgaagggtc 22080
gaagggcaaa ggagccctaa acgcagcggg aactctcgga gcacgggctt aagttggaaa 22140
gaaactaaga cagcgaaggt ggaaggggcc cgccgcggcg aacacgggcg cggaaccgcc 22200
gagagagggt tcctcgact cgaggtgcag caggtcaaag gttaagagcc ctaaaccacca 22260
cacctgggggt caggaggctg cataagaaac cacgagtcaa aggtcagact gcacggagga 22320
gcctcagtcg aaaagcgggc aaggcgaggt ggaaagcggg gccgggtcgg tgggctgcgc 22380
acgcccaggt gcaaagaggc aaaggtcaaa gcgccaaagg ccccggccgc gcggggagga 22440
gcccacgccg tggcccccg gctgcctggc cgtctccctt tgtgttacct tctttgccgg 22500
ggagtcccgg gcggccgcaa ggccgtaggg ctcgtttgag ccccgccgct ccgcggcccc 22560
agcaaagtgc cgacattacg cacgccgctc caggccaccc caccggcccg cgctgcgca 22620
tgcgcccgcg ccgcctgccg ggagttgtgg tttcatggtc gacggaggct gcgaaggga 22680
acccagccg gaagtagact ccaggatgc agcgaggcg cgaaggcatg cgccggtgga 22740
cgctctgatt ggttcctcct gctgttttta aagggagggg gcgggacaga gctgttgccg 22800
tggcaactgg gaggcactct caggctgttt tcccgaggac ctcaaatecg gacttttttt 22860
ctgtttttct ttcttttttg gttttgttt ggacgcgttg tggcccaggc tggagtgcag 22920
tggcgtgatc atagctcagt gcagcttca actgctgggg taaagagatc ctgcgccctc 22980
ggcttcccaa agcgctggga ttgcagacgc cgccaccgtg cccggctttt tttttttttt 23040
tttcaaggca tactcatcta ataacgagga cagcatctgc aatttagaga ttctgtccg 23100

-168-

caaccttcat tgctccaacg acaacttttg ggtaagagtc attaggatgc cgtctatcat 23160
ggaggaagct gaggctcaga gagggccacc aagttgctgg aagacacagc acgtgcgacc 23220
tcagggaggc tgcaaggaga gaaagcccca gtccgcgaga ctcccagcct ccagcttcag 23280
tttaccctcc aatccccaag ccctcagggg caggagccga atggagcggc aggcttggat 23340
tcacctgcta agtgggggtga ggtcaaggga atgaaataaa cctcggagcc tagagcctgc 23400
cctggtctcc gcgtgatcct gcctaggagg agcagggcgg gagctttaga atggaacctg 23460
gaaggtgtgc ccacctgtgt cgttcagccg gggcagcagg ccagaggcgg gagcgcctgc 23520
tgtggggcag taggcttggg aagggtgaga ataggaatat ctgggggtaa ctgtgttcca 23580
ggctaataatc ccagttgcaa aggggagctg gtttggtggc tcaggcctgt catcccagca 23640
ctttgggagg ctgaggcggg cggatcacct aaggtcagag ttcgagacca gcttgcaaaa 23700
tacgcaagca tgccctggcaa catggcaaaa ccccgctctc agtaaaaata caaaaattat 23760
ccgggggtgg tggcgggcac ctgtaatccc agctactcgg gaggctgagg caggagaatc 23820
gcttgaaccc gggaggcggg ggttgagtg agccaagatc tcgccactgc actccagcct 23880
gggtgacaga gcgagaacct gtctcaaaaa aaaaaaagtg caaagggagg tcagttcagt 23940
gcctcaggcc tgtaatccca gcactttggg aggctgcggc gggaggatcg cttgagccca 24000
ggagttccag acaagccttg ggcaaccgag atactgagac ccagtctcca ccaaaggaaa 24060
aaaagaaatt agccaggcat ggtggtgcac acctgtggtc ccagatactc gggaggctga 24120
ggcaggagga ctgcttgagc ccaggaggtt tagactgcag tgagctgaga tggcgccact 24180
gtactccagc ctgggttgac agaacaggac cctgtctcaa aacaaaacaa gtgcaaaggc 24240
cctgaggcag gaacaagcgt ggacagagga gcaatttgag cagagtgggg ctggggagag 24300
ggagcaaaga tgtagctggg gctcagttag ggggcctgac cacacggggg ctcggggggc 24360
tcagctcaag ctatcctcca tccccaaacc ctggcacttc agtttcccca tcagcccaga 24420
acgaggactc gacctcactc tggaaggggc tggcagcctc cttacagcac attccagacg 24480
ctgctgccga cgctgcgtg agcgactga tgccaccggc tgggaatgtt ttcgacagac 24540
ggcagcacc cccctcacct gcctcagtcc acctcagggt gcccagcgg gctgtgacct 24600
cagacctcac ccactactgg ggtcacctgc ctggccctga atcagccagg cctggtgtgc 24660

-169-

caagacctac agacaccccc tgcaccctcg caggctggca gagccagaaa cttgggtgga 24720
aaccgacttc tgaactatct caccattcct tatgcttag tcttttcttt tatttgatga 24780
gatcccagca ctttgggagg ccgaggcggg cggatcacgt gaggtcagga gtttgagacc 24840
agcctggcca acatggtgaa acccgtctc tactaaaaat acgaaaatta gccgggcatg 24900
gtggcctgtg cctgtaatcc cagctactca ggaggccaag ggaggaaaat cacttgaacc 24960
tgagaggtgg aggttacagt gagccaagat cgcaccactg cactccagcc ttgggcaatg 25020
tagccaaacc ccatcactac aaataataca aaaaaatttt gttggctgtg atggtgcctg 25080
cctgtggccc catctacttg ggaggctgag gtgggaagat gtagaattgc ttgagccagg 25140
aggcagaggc tgcagtgagc tgtgattgag ccactgcact ccagcctggg cgacagagcg 25200
agaccctgtc tcaaaaaaaaa aagaacataa tctgggtttt ggaataagac agcagtttct 25260
gaaacagctc attgcccaaa ttccagcctc gcaactctgt agccgccacc acccccagc 25320
cccaccatct attttaacta catctgtctc caccactcct gtattaagta aatgcaatat 25380
tggtgtgtca tggtggctca tgcctgtaat tccagcactt tgggaggctg aggcaggcag 25440
atcccctgag gtcaggagtt cgagactggc ctggccaacg tggtgaaacc ctgtctccac 25500
taaaaattca aaaattagcc ggacgtggta gtgggtgggtg cctgtaatcc cagctacttg 25560
ggaggctgag gtaagagaaa tgcttgaatc caagagactg aggttgagc gagctgagat 25620
ctcgccgctg cactccagcc tgaacgacag agcgagactc cgtctcaaaa ataaattaat 25680
aaatacaaca ttaattatct ttcttgctta agttttacga agagacttaa tatcaccatc 25740
aaaagtggga aaccatatat ctggccgggc gtgggtggctc ccgctgtca tcccagcact 25800
acgggaggcc gaggcgggcg gatcccctga ggccgggagc tggagaccag cctggctaac 25860
atggtgaaac cctcatctcc aataaaaaata acaaaaatta gccgggcatg gtgggtgcct 25920
gtaatcccag ctattcagga ggctgaggca gaagaatcac ttgaaccgag gaggcggagg 25980
ttgcaggag ccgagatcac accactgccc tccggcctgg gcgacagagc gagactctgt 26040
ctaaaaacaa aacaaaacaa aaccaacca agcaaaccac acagagtcga gaatcgctag 26100
atggaagggg atggcccagg tccctggagc ccctgtgaca aattaccaca aactcggtgc 26160
cttaaagcaa cgttcatttt ctacatttc tggaaatgaa aagtccaaaa tcaggactgc 26220

-170-

ggggctgaag tcaaggtgtg tggaggectc gctccctcca gaggccctgg ggctccttcc 26280
tgcctctccc agcttttgaa ggctccaggt gtgcttggcc tgcggccaca tctctccgt 26340
ctcgggtctct gtggtcgac tgcagcctcc tcgtctgcct gtgtgaaatc tctcctgtc 26400
tccgtattgt gaccgcgttt aggatgcccc aggacaatct tctccatata gttcagatct 26460
tcatggtgtc aatatattga gactcttttt ccaaataagg caaatgtcac attctaggga 26520
tcagggtggg gacttacctt tgggccaacc acagaggcta caaagaggaa gacaccactc 26580
aatacaaagc gtgcgccagc ccagccctga tcgggtgttg ttgttgtgt tttgtttga 26640
gacagagtct cgctctgtcg ccaggtctgg agggcagtgg catgatctca gctcattgca 26700
acctccgcct cctgggttgt atagattctc ctgcctcagc ctctgagta gctgggatta 26760
caggcgtgaa aaggagcaag gctctgcccc agccacagcg cggatgcacc ttgaggatgt 26820
catgctcagt gaaagacgcc agacacagaa ggacacacag tgtgtgatcc ctttatatg 26880
aaatgtccac aacaggccca tccacagagg caggaagggg atgtgtgggt gccgggggct 26940
ggcagagggg atgagtgaca gctgatgggg cttcttcttg cggatgatga atcttctgga 27000
actagacagt cgtggtggtt gcacaactct acgaggactt aaaatcactg aactggctgg 27060
gtgcagtggc tcatgcctgt aatcccagca ctttgggagg cagaagcagg tagatcacga 27120
ggtcaggagt ttgagaccag cctggccaac atggtaaaac tctgtctcta ctaaaaatac 27180
aaaaattagc tgggtgtggt ggcagggtgcc tgtaatccca gctactcagg aggctgaggc 27240
aggagaatcg cttgaaccag ggaggcagag tttgcagtga gccgagatcg caccactgca 27300
ctccagtctg ggtgacagag ccagactccg tctcaaagaa ataataataa aataaaatca 27360
ctgaactgta cagtgttaagt ggggtgaattg tgtggtatat gagtgatgtt tccgagggtgt 27420
cattaaagaa actcagacgc ctgggggtggg gccagtctca ccgctgtggg tcccatcccc 27480
atcatttctc acaaggccct cagatcacc cttccggtg gggggcggac actctaagaa 27540
gggaagacct gggctcctgc tggcgagaag gcggtggaca tttcttcagt gtctgggtgcc 27600
gcgccctctg cccagcgtgc tccgtggagg gtctcattgt cttcctccag acgtctcttt 27660
actggcccat ttacagagg cggaaccgaa gcttgggggtg ttggccacag ggctctagt 27720
tggaagcca ggccaggctg gacctcagcc atggggaccc ctgtccctga gactgtggca 27780

-171-

cctgccacac cctctgtgtg accgcctaa gccaggaaga gagggtcagg agatgcctga 27840
gccaccaaga aggcattcca gcgtccagcc agaccggta tccctccaga gggctccccg 27900
gcaggacagg ctggtcgcca tgtcttcage ctggtgctat ttaaagggtg gtgccacctg 27960
gggctgtggc cgcagggcca ggactgggct gctgggagct gtgtccccac agcggaggtc 28020
gccgccccctc tcaggcctcg gtttccccag ttgtcaatgc ctccacttg ctgtgagtct 28080
gtgagggtca ctgtgctcac cttttggggc ccagcgcattg gggcaggcag aggaagggtg 28140
ggggccagcc gccttgctgg gtgggtcccc gtggggcctg gggtatggct ctaagggagg 28200
agcaagtgtg ggtgcgaatg gggccgcccc attcctgccg cctccgacgt gccccgccag 28260
ccggccaccg acaggctctac gtggctatcc tccctcctgc ccacctacct gcccaaacac 28320
acgtccccag tcgtcacctg cccacccacc cgcgcattcc cacacccttg tgggcctggc 28380
tttcgggaaa ctacaatttg cggggagaga agtcccacga gggcatgcc cggagcctgg 28440
ctggtccac ggctgacga cgcggcagga cctcccgtgt ccattctctgt cccaagcat 28500
ctccgcctct gcccctctct gtctctgtgt ctctctctgc tctcccggtc atcttccttg 28560
tgtctcttga ctgcgcctg ctttctgtct ctgtctccct ccgggtctct gtctccctcc 28620
aggctctctgc ggcccgctc tcacactccc gccccgcaa ccgagggtcc tagcccgccc 28680
ggggactcgg ctgactcacg gacacgcccc gcgagacaaa caacaaacgc gcggaggccg 28740
agcgcggagt cccgcacggc cgcgcccctg tgcacctggc ccccgcccc gagacgtccc 28800
attggccggc gccctagcct ggtcccgccc aagtggacct cgcgcccgcc ccgaggcacc 28860
ccattggccg gcgtccccgc cccagcgaac ccggccccgc ccccgaggcg cccattggc 28920
cccgccgcgc gaaggcagag ccgcggacgc ccgggagcga cgagcgcgca gcgaaccggg 28980
tgccgggtca tgcgcgcgc cctgtggctg ggctggcct ggctgctgct ggcgcggcg 29040
ccggacgccg cgggaacccc gagcgcgtcg cggggaccgc gcagctacct gcacctggag 29100
ggcgacgtgc gctggcgcg cctcttctcc tccactcact tcttctcgcg cgtggatccc 29160
ggcgcccgcg tgcagggcac ccgctggcg caccggccagg acagtgagt cggggcgcg 29220
ggggcctggg gtggggaggc ggcggtgac ggcaacgcgg ccgcctctt cacggtgacc 29280
tgcgccccgc ggggagtc ccaggctcct ctgtgcagcc tcggcctcag ttccgtgg 29340

-172-

ctgtgagatg ggtgcagcct gcctggtggg agggttgcac tgtaaagcg aaggctgcag 29400
cggcggaccc ggctcagggg cagagaagcg tccgtgtggt acaaccctgt ggggtggggcc 29460
acccatctgc aggtgggaaa ctgaggctcc agaggggctg gggcaggccc agctgcatgg 29520
cggaagcggc ggggggctga cctccggact cctgacatca cagaatccag tcagggctgc 29580
ctgagtcggg gccccctctg cttcttccca gacaccccat ctggcaggtg aggacaagga 29640
ggcacacaga agggatggga cctgcccagg gtcacactga caggggtggc ggagctgggt 29700
ccccacaggg ccaggacgt cacggagcgg gcgtctctgt cccaggggtc tgccgagcac 29760
actgaggtag gccctcagtg tttgtggaat gtcaggagca agaggagagg ctgggcacag 29820
caggggatgt gggtagctgg aggccagggg agtcggtgtc cccgccgggc ggggggact 29880
gggaaggggg cccgggcccg ctggctgccg cctgaatcac caccatcagg gcaggtaatc 29940
acccctgtc ctccaccg cttcatctg ggcgccaagg ccctcattag gccgcacgtg 30000
acgagggcgg acaggggact ggctgggccg gtccatccat ggcgggcatg gccaggcggg 30060
gtggcctcgg gccggggcag aggcctggct ccgctgcctg acctggaaca gtctctgcct 30120
ctctccaagc ctcggtttcc ccagctggac ggtgatgggg gtgagggcta gctgagggct 30180
ctcctgcct tctgcatte gctggtcact aatcgggcac cttgtgggtg ctgtgctccg 30240
catgggggac ccagtgggtga cagagacgcc caccctcctg gggctcccag agcagaggcg 30300
cgcagcagtt agacacgtga acaagggcgc aggtgggtgc acagaacagt gaacggtttg 30360
ccgggtgcag tggtcacgt cggtaatccc agcactttgg gaggccgagg cgggcagatc 30420
acgaggtcag gagatcgaga ccatcccggc taacacgggtg aaaccccgtc tctacaaaaa 30480
atacaaaaat tagccgggtg tggtggcggg cgctgtagt cccagctact cgggaggctg 30540
aggcaggaga atgacgtgaa gccgggaggt ggagcttgca gtgagctgag atcgcgccac 30600
tgccctccac cctgggcgac agagcgagac tccgtctcaa aaaaaaaaaa aaaaaagaa 30660
cagtgaatga cgtgaacaag ggtgcaggtg ggtgcgcaga acagtgaacg gcggtgttg 30720
gaggcacctt gccaggggag gggaggtgca gggcgaggaa ggggccaggg gagatcgtga 30780
cacagacgcc ccagaacaac cacctcaaag acgttcctgt gtgtcctgga aggtcgggct 30840
gggaggctgc cccgaggagc ttctactttg acagggagct ggccgggcac gcagggaact 30900

-173-

gtacacccag ctgacaaagc ggcagacacc caggccgggg tgagcgagtg tgggtgagga 30960
gtggcggctg gccccaggt ccttgctgga caagacactt cagctcaggg tggggcaggg 31020
ctcaccag gctaccaca gacgatggcg tccaaatctg gctctgccac tcccaggcct 31080
caactggccc ctctgcaacg tgggctgctg agcgggcttg gtaggacagc tggcatacag 31140
tcggcgctca agcatgtctg tgggtgtccca taaaccaccg gtgtcccact ctaggccact 31200
gccagcccgg cctccagtc agagtcccag tccggagtcc cagtgactgt gcgtggggcg 31260
ggcagctgag ctgtgagggc cgggctgggg gctccatatg ggggtggtgtg agctgtgagg 31320
gccgggctgg gggctccata tggggtggtg tgagctgtga gggccgggct gggggctcca 31380
tatggggtgg tgtgagctgt gagggccggg ctgggggctc catatggggg ggtgtgagct 31440
gtgagggccg ggctgggggg tccctggggg ggtgtgagct gtgagggccg ggctgggggg 31500
tctctggggg ggtgtgagct gtgagggccg ggctgggggc tccatatggg gtggtgtgag 31560
ctgtgagggc cgggctgggg gctccatatg ggggtggtgtg agctgtgagg gccgggctgg 31620
ggggtccctg ggggtggtgtg agctgtgagg gccgggctgg gggctccctg ggggtggtgtg 31680
agctctgagg gccgggctgg ggggtctctg ggggtggtgtg agctgtgagg gccgggctgg 31740
gggctccata tggggtggtg tgagctctga gggccgggct gggggctccc tggggtgctg 31800
ctggtcgctg gctcattgac agttatcagt ggtctgggtg ggccctgccc cttctgactc 31860
ccacatccca ggaacccttt cccaaccttc ctctggtgtg tgctgcccc ctgacgtccg 31920
tccctctggg tgtgtgggag ccccccgcc atacacacac acagatgctg ctcttgggct 31980
gagctgcagg gacagcgctg acctggccct ccacggggg cctcatcgat ctctgcactc 32040
ccccagctcg tggggggcgt cctgcttccc gtccctctg cctgctcctt gtcctccct 32100
cacatgctgg ggggggctcc tgggtgcagt cacggctctg ggggatcctg agtgtccgtc 32160
gtggtcggga ggggactcgt ggtcccgggg gtctcctggt atctgtcgtg gtcctgaggg 32220
ccctgcacga agcacagcgg acagcagcgg tgctgggggt gagccagcaa ggccctcccc 32280
gacccccgcc tccccaggc atcctggaga tccgctctgt acacgtgggc gtcgtggtca 32340
tcaaagcagt gtcctcaggc ttctacgtgg ccatgaaccg ccggggccgc ctctacgggt 32400
cggtagtgct cgggcagggc tgggcggcgc gggcaggggt gggaggggtg gccggcctca 32460

-174-

ccccgccccg cagcgactct acaccgtgga ctgcagggtc cgggagcgca tcgaagagaa 32520
cgccacaac acctacgcct cacagcgctg gcgccgccgc ggccagccca tgttcctggc 32580
gctggacagg aggggggggc cccggccagg cgcccgacg cggcgggtacc acctgtccgc 32640
ccacttctg cccgtcctgg tctcctgagg ccctgagagg ccggcggctc cccaaggtgc 32700
ctgggctggt ggcgaggggc ccggccacgc ttgttcttcc ccctgcgggc tctgtaagcg 32760
ctgagtgccc accgtgtgcg ggcgtgtgg acacagccca ggagccctcc aggggggtcc 32820
cagcctgagg ggggtggggc caccaagcag gttcaatcct gagttgggga cctcgaggac 32880
ccaacagggc gcctctcggg ctgaaggacg cagacgtcga aaggctcagg gggacgtccc 32940
aggcagggcc cggcagaggc aggggctcgg ggtggggagc acgttgggag tgggggcagg 33000
agcggagggg aggggagggg gccggggaga cggtgacaga cgccgcagaa caccagcctc 33060
gaagccggtc ccgctccggg aatctgcaaa tacaacgcct tgcgaggaca aaggcacctg 33120
cagggtggac ggagatggag gagcatccag ggtggggggt ccaggggccc agtgtcctca 33180
cagggtcctc acgacaggag gcgggacagt gagagccaga gagagatggg gatgggccgc 33240
gctgtggccg tgaaggggag gaagggccct aagctgaggg acgtgggtgc ctccagatgc 33300
tggggaaggc gggaacggtt ccgcactgga gccccggga gggaccggcc tgctcctgcc 33360
ttgatatgag ccagtgggga ccagtttg actctggcct ccagaaccgc cagaaaataa 33420
acgtagtaag ccatcaactt tgtggtcttt tgttacagca gacgtcggaa atatgcacac 33480
ggtgtctgaa actgttctca tgacaaaata agcctcagat cccccggga agggcggagg 33540
ccaacgcctc ggtgttcctc cgatcccccg ggaagggcgg aggccgacgc ctcggtgttc 33600
ctcggatccc ccgggaaggg cagaggccga cgcctcgggtg ctctcagat cccccgggaa 33660
gggcagaggc tgagggcagg agccgtgctg ggtgcagggc aggcctgggg gcttcatgcc 33720
gctgtcctgc gggacgcaga gagggctggc cgtcgggtgtg ggggcgcccc cacctgtgcc 33780
cagcgccctc ctgacatcct gactccgctg ggacttctgc ctacagccct gggagtcaaa 33840
ctccagcctc tcagagaaaa ggtcagagcc aagagcccca cagcctggag ccaggcagtg 33900
acaccctggg cctgtctccc cttctgtgtg tggggcgaca gcagcatcgc cctggtgaag 33960
tccccgggga cgccagggc tccatcccca gccgccgcct tccacataaa tacaggaaga 34020

-175-

ctgggcccagag gcacttgctg ggaggtgctg agcagcctga cacggaaaac ccttctggga 34080
agggaggggtc gtgcccggcc cgagagcttc tgctcaccct gcagacagaa gcgagcccca 34140
ccccagggga caccaggcgg cctctgggga catctttggc tggcatggag tgggtggagg 34200
acagggctgc acccaggatg tccccagggt ggagtgatga ggggagatcg gccacggtg 34260
gccagtcgga gggcgtcgcc acttgagttg tctactgggag ctgcacaggt caccacagct 34320
gaaataaaac ttgctggcac cccacgcagg aacgtaacat gtgcctcgaa gaaacgggtc 34380
agcaggccgg gcgcgggggc tcacgcctgt catcccagca ctttgggagg ccgaggcggg 34440
tggatcacga ggtcaggaga tcaaggccat cttggtcaac atggtgaaac cccgtgtcta 34500
ctaaaaatac aaaaaattag ccgggcgtgg tggcgggcgc ctgtaattcc agctacttga 34560
gaggctgagg cggggaatcg cttgaatccg ggaggcggag gttgcagtga gctgagatcg 34620
cgccactgca ctccagcctg ggcgacagag cgagactccg tctcaaaaaa aaaaaaaaaa 34680
aagaaacagg tcagcagttg tttctttgtt tctaaaacag agcgtggaat gggcgtagag 34740
ctccgcacat cccagggcag tgaaatcccg gttcacacag agccctcagc agcttattcg 34800
caagccaaa cctggggacc cccgttgtcc tcaggcagtg aggtgggggc ccccaacag 34860
agaggagcgg cctgggggca cagaaccagc ggctccccag gaaatcgcca gcagtgaaaa 34920
taagacaacc ccaaactgtt gcaaactgtg cttccgctta cgaagcactc ctgagcggca 34980
gggcggatgg ggagagggcg gctgcaggcg cgagggggccc ggggacgcag gggcggggc 35040
cttaccaggg ccctgtcctg tcgtgcagca ggctcctggg gcagggaaga caccaggggc 35100
ggccacttct tactgctgtc tgacctcgag caatgcggcc tcacagcccc caccaggggtg 35160
ccggtgtcct ctgggcccag cggccccgag gctcatgcct ggggtggggc aaccaatcgg 35220
tcctgtcct ctggccactc cacgcgaggg aagtcccagc ctcacaggca ggcgcacacc 35280
ccggcagcat ctctgacaaa ggccctccag ttccgagtct ccagggtccc cgcgtgcaag 35340
cctcacctgc ccagccctcc tctccagctc caactccaac tccaagaac caccacggac 35400
acacagaacc cgagccttgt ctccctcaac gcctcctgac tcaaaactcc atcttccaac 35460
aggaaaacgg ctcgccgggg ggactgtgac ccggagcagg cggcccagcc tgctcgcgag 35520
actcggggcc taaaacactt gttctctcag tccggagatc aaggacgatc cgaggtaacc 35580

-176-

tccctacctc ggtgtcctcc atgcaacctc gtcttagggc accgggtacg ttacctcgtg 35640
aggagccgag tccgcgggtc ctggggttga gatgtggacg ccctcagggc tggcactctg 35700
ccctggcggc cacagtcacg gaagtcccaa cgcttctctc ggctccgcaa cccagagagg 35760
cggccacgag gagggccgc cacgcacgac cccagagggc ggccaccagg agggcccgcc 35820
acgcgcgacc ccagagggcg gccaccagga gggcccgcca cggcgttgcg gcagcagccc 35880
agaaggtgcc ctgcgcacgg tccggacagg tgggatccga gttacctggc caaggggggt 35940
gacgcagaca cgtcgcggga cacagtgaag agtgtggtgc agagcggagg gcgggagtct 36000
ttggagaaca ggtagggcg tggggcacgc gcctcccacg cgcaggagcc gtctaccgtg 36060
gagggacacg ggtggtcctg ctggaggctc ctctccgtta gctgtctcca tcgtctgatt 36120
cttgatccc aggatgggtg gatcatcagc aactgagatg aaccactgc cccggccccc 36180
tgagcccgca ggtcccacg ccttgccagc tgtgcccgag ctggctgcac cccgggcccag 36240
gcatccagca accttgagca gtgggggtccg gcttttcaga aggggcccagg aaccgcgctg 36300
gctgaggtgt gaccgaagcg tggggcagag gcgctgggcc ctggcgcttt aacgctggtg 36360
tttctggttt taaatttcac gaccagtgat cactgccacc ctgctacctc gccagcagcc 36420
ctcctgggtt taacttcggg agagcagttt tgctagccgg ccctgggtgc caagccctgc 36480
aggaggcgca gaccctgga gacaggaccg gactctgcag agcccgacca gcctcccagc 36540
ttggcctttt cctgacgcac gggcgagaa ggaaagccac agcaccggct tctctttgta 36600
agtagtgtat tttaaatagc tttcaagata cacatatttt ttcctttaa aaagtctgtt 36660
ggagcagttt tgttcttgaa ttttgctggt catcctcatg gtcccagacc cccctactcc 36720
gggtcgtgga ggcggccgag ggggaggctg ggggcccacg tggcccgtcc tggcggcacc 36780
tgcagcactg ggggagccgc tgaaccccgt gcttcagcgc tgggggagcc gctgggcccc 36840
gtcttccgcc acaaaccatg catggccgcc acgtgagctc aaacgtccgt ttatttcaaa 36900
gcagtaataa tttaaaatta taaaaatctt tccaccgctg aacgtttaga gggtagggtt 36960
agacagagga cggggaggct ggggacgcc cagaggggac catgtggccc acgccttccc 37020
aagccagggg gccggtgggc cgggcccggg tctgcccctg gaacaggcgg gacctgcagc 37080
gctgaccagc caagcgtggc gccgccgggg caccagttct gtgggtgccg tgtggcgctg 37140

-177-

gctgaggggtg ggtgggaaag gccccgtgct ttccccgacgg cgcacgtggg ctcacgagtt 37200
gcttgtggcg ttctcgttgc tgggcgagct ggaggaggac gatgacgacg aggaggagaa 37260
gctcacccca gtgaggccag ggggggttcgt ggccgtgttc tgtcccgtga ggcttttttcg 37320
gcagacgggg cagctgtcgt gctttgtggg gacagaggca gggacgggag aaggggcagg 37380
ttagaggcgg gagggcccg gtcgggggtgg gggggcgggg gggcggggca ctcacctgct 37440
ccagccaggg cacgatgcag ccgtcgtgga acagggtggt gcagggcagc tgccgcacac 37500
gctcacccag cgcgtagtcg tccttgacac cagggcactc gagcccggag cctgcgggag 37560
tgtgcagctg cggtcacagc gggcgtgggg ggccgtgccg gccttcaagg gcaggctact 37620
ccacagcctc agccggaggc cggccctgag ccagcgagg ggagaaaagc cgtgtgtgtg 37680
tcccccgggc tgccagaggg gacctggaca gaacctctc ctccagccc accttcaggg 37740
aaatgctcga ggccgggtgc ggtggctcac gcctgtcatc ccagcacttt gggaggccga 37800
ggcaggagga tcacctgagg tcaggagttc gagacctgcc tgaccaacat ggtgaaaccc 37860
tgtctctact gaaaatacaa gtatgagcca ggcggtggcg cgggtgcctg taattccac 37920
tactcgggag gctgagctct catacctacg tgctcctcag tgacggggac ggtggggagg 37980
gcctggatth tctctttatc tgccgggtgg gggcctgtgt tttcaaactg attgaggagc 38040
tgaaagacaa gaggcgagag tgccgggagc tcctcggggg cccggcccgg ggctctgaaa 38100
cgcgaggctg caggacctgc aaaagcaccg aggcgcggtt tgtcctgggc cctgggcccc 38160
ttggagcccc cccgggggtcg gagatc 38186

<210> 39

<211> 720

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 39

cgccggcgct tgacctgact ttcatgaatc gaaaaggaaa tcctctatga acgcactgca 60

tcgcateggc gccggaacgc tactggcgt gttgctcgt tttggcctga ccggctgagg 120

ggagaaggag gaggttcagc agtcgctcga gccggtggct tttcacgact ctgacgagtg 180

-178-

tcacgtgtgc ggcgatgatca tcaactgactt ccccggccccc aagggccagg cggtcgaaaa 240
gcggggagtg aagaaatddd gttccaccgc cgaaatgctt ggttggtggc tgcagccgga 300
aaaccgtctg ctcgatgcca agctctacgt ccacgacatg gggcgcagcg tttgggaaaa 360
gccggatgac ggtcatctga tcgacgcaac cagcgcctac tatgtggteg gtacgtcact 420
caaaggcgcc atgggdcgct cgcttgcaag ctttgccgag gagcaggacg ccaaggcgct 480
tgccggcatg cacggcggtc gtgtgctgcg cttcgaggaa atcgatcagg cgctgctgca 540
ggaggctgca agcatgcagc acggcggcat gcacgaccat gcgccaaacg gtgcacataa 600
cgcacacgca ggccactgag cagcagtggc ctgaacagca cacacaagaa atcgaggtaa 660
gcacaatgat gggatatcagc gtctggcaac tcctgatcat tcttctgatc gtcgtcatgc 720

<210> 40

<211> 127

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<220>

<221> UNSURE

<222> (9)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (101)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (119)

<223> May be any nucleic acid

<400> 40

gcggccgcnc ggcgctggct gctgtgcgga ggccacggcg ggccgcgagc cgcctcgtec 60

tcgccctcct gccctgggtg cggccccccg ggtcccggcg nccactcgc cccggcgtn 120

ccgcgct

127

<210> 41

<211> 6858

<212> DNA

-179-

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 41

actcgccaag tgatcgaccg gcccctgagg gccgcgacgc agagggcgcc cegtgcactg 60
gcacaggcgg ccttgtgcgt tagactctga tattcgtgcg ccctctcggt ggcaggacca 120
tccatcctgt gtgccggggg ccgcgcacac cgatcccga tccgcctcgg ccctgccctg 180
cgcgccccctc cgttctcgac ctccccgacg ctgtctgaac acgcgtcgcc gggggacgac 240
ggcggggcggc ccgcctcggg ggaggggtaa gcgtcccggg atgcccgttc aaccgttcgg 300
caaggctcgc ccatcgtggg ggagaaccgg cgcgacgcta ggagagacaa gtgatccagc 360
aggagtgcgc gctcaaggtc gccgacaaca ccggtgcgaa ggaaatcctg accatccgtg 420
tgctcggcgg ttccggacgc cgctacgcag gcatcggcga caccatcgtc gccaccgtga 480
aggacgccat ccccgggcggc aacgtcaaga aggcgcacgt cgtcaaggcc gtggtggtcc 540
gcacccgcaa gcagtcccgc cgtcccgacg gctcgtacat caagttcgac gagaacgcgg 600
cggtcatcct gaagaccgac ggcgagcccc gtggcacgcg catcttcggc cccgtgggtc 660
gcgagctgcg tgacaagaag ttcataaaga tcgtgtcgct cgccccggag gtgatctgac 720
ctcatggcca agatcaagaa ggacgacctc gtgcagggtca tcagtggcaa ggacaagggc 780
aagcagggca aggtcctgcg cgtgttcccc acggatgagc gcgtgctcgt cgagggcggtg 840
aaccgcgtga ccaagcacct gcgcgccggc caggacaaca acggttcac cgagggcggc 900
ctgcaggctc tcgaggcccc gatccacatc tcgaacgtgg ccgtgggtga cccggagacc 960
aagaagccga cccgtgtggg ctaccgcttc gagaccgtcg agaaggacgg cgtgacgaag 1020
accgtgaagg tccgcttcgc caaggcctcg gggaaggagc tgtgatgacc gaggtgcagc 1080
agaccgagaa ggtcaccccg cgtctgaaga ccaagtaccg cgaggagatc cgcgacgcc 1140
tgcaggagca gttccagtac gggaacgtca tgcagggtgcc gggcctcgtg aaggtcgtcg 1200
tcaacatggg cgtcggcgag gccgccaagg actccaagat catcgacgac gccgtcaccg 1260
acctcaccgc catcaccggc cagaagccga tgatcaccaa ggcccgaag tccatcgcgc 1320
agttcaagct gcgtgagggc atgcccatcg gcacgcacgc caccctccgt ggcgatcgca 1380

-180-

tgtgggagtt cctggaccgc ctggtcacgc tgccgctgcc gcgcatccgt gacttccgcg 1440
gcctgtccga ccgccagttc gacggcaacg gcaactacac ctccggcctg tccgagcaga 1500
ccgtgttcca cgagatcgat caggacaaga tcgaccgcgt gcgcggcatg gacatcaccg 1560
tggtgacgac cgccaagaac gacgacgagg gccgcgcgt gctcaaggcg ctgggcttcc 1620
cgttcaagac cgaccagtaa gacctccacg ccacaggctc tccaccggtg aaccggtggc 1680
ggaaaccacg gcgagaaagg gcgtgaagca catgaccatg accgatcccg tcgcagacat 1740
gctgaccctg ctgcgcaacg caaactcggc ctaccacgac accgtgtcca tgccgtcctc 1800
gaagctgaag actcgcgtcg ccgagatcct caaggccgag ggctacatcc aggactggcg 1860
cgaggaggag gccgaggtcg gcaagaagct gaccatcgac ctgaagtctg gccgcgacg 1920
tgagcgtgcg atcgccggcc tgcgccgat ctccaagccg ggctgcgcg tgtacgcgaa 1980
gtccacgaac ctgccccacg tgctgggcg cctcggcatc gccatcctgt ccacctcctc 2040
tggtctcctc acgaaccagc aggccgcaa gaaggctggc gtgggaggag aagtcctcgc 2100
ctacgtctgg tgacgggcaa gacggaagaa aggctgaact gacatgtctc gaatcggacg 2160
tctcccgatc accatccccg ccggcgtcga tgtgaccatc gacggcgacc gcgtctccgt 2220
gaagggcccc aagggcccca agggtcagct cgagcactcg ctgcccacgc ccatcacggc 2280
caccctcgag gaggggcagg tcaccgtggc ccgccccgac gacgagcgtg agtcccgtc 2340
cctgcacggc ctgaccgta ccctcatcag caacatggc gagggcgtga ccaacggctt 2400
ctccaagcag ctcgaggtcg tcggcaccgg ctaccgcgtg caggccaagg gccaggacct 2460
cgagttcgac ctgggctact cccaccccgt cccggtgaag gtgtcccagg gcatcacctt 2520
cacggtggag ggtaacaggg tcaccgtcgc cggtatcgac aagcagcagc aggtcggcga 2580
gaccgcccgc aacatccgca agctgcgccg ccccgacccg tacaagggca agggcgtcta 2640
cgcgggcgag cagatccgcc gcaaggccgg aaagaagtga tgtctactct gaaggtgaag 2700
ggcaagggca agttcaacgc ccgcaccgc cgccacctcc gggcgcgaa gcggatctcc 2760
ggcaccacgt ccgtcccccg cctcgtcgtc aaccgctctg cacggcacat gttcgtgcag 2820
gtcgtggacg acacgcagag ccgcacgatc gcgtacgcct ccaccatgga ggccgacgtg 2880
cgtgcgctcg aggggtgaaa gacggccaag gccaaagcgc tgggcgagct cgtcgccgag 2940

-181-

cgtgccaaagg cggccggcat cgaggccgcg gtcttcgacc gggcgggcaa caagtaccac 3000
gggcgcgtcg cggccgtggc cgacggtgcg cgagagggcg ggctgcagct gtgaccgaga 3060
acatcaacca gaaggacact caggtgaccg agagcaccga gaccaccgtc tccgagaccg 3120
ggtcggggtc gcgagccaga ccaccgagcg cgccaccggt ggccgcggcg gtcgcgacgg 3180
cggccgcgggt ggccggacgg cgatcgtcgt ggcggccgtc ggacgaccga accgtcgtgg 3240
cgcccaggac gacgaggaag gaccagtcc tgcagcgcgt cgtgggcac aaccgcgtct 3300
ccaaggtcgg ccgccgcttc tccttcaccg ccctcgtggt ggtgggtgac ggcgacggca 3360
ccgtcggcgt cggctacggc aaggcgaagg aggtccccgc tgcgatccag aaggccgtgg 3420
aggaggccaa gaagtccttc ttccgcgtcc ccgcgctcgg ctccaccatc ccgcacctgg 3480
tgcaggggta ggacgccgcc ggcgtcgtgc tgcctccccc ggccctccccg ggtaccgcgg 3540
tgatcgccgg cggctccgtg cgcgccgtgc tcgagtgcgc cggcatccac gacgtgctct 3600
ccaagtccat gggctccgtg aacgcgatca acatcgtgcg cggcacggtg gagggcctca 3660
agaagctgaa gagccccag gccgtcgccg ccgcgccgcg caaggccctg gacgagatcg 3720
cccccatgc gatgctgcgc accatggaga acgatcgcgc ccagaagagc gcgaaggcag 3780
gtgcgtgacg cgtgtttgag tccactcgca agaacatcca gccctcggac gccaccctgg 3840
tcatcaccca gaccgcggc gtcacgggct ccaagcagaa ccatcgggac accctgcgct 3900
cgctgggcct gaagcggatc ggccaccagg tcaccgcgaa ggccgacgcg gtgacggtcg 3960
gcatgggtcaa caccgtgccg cacctggtgt ccgtggagga ggtcaacaat ggctgacaac 4020
gacgccatca aggtccacga cctgcgtccg gccccgggtg ccaagaccgc caagaccgcg 4080
gtgggtcgcg gtgaggcgtc gaagggaag accgccggtc gcggcaccaa gggcaccaag 4140
gcccgttacc aggtccgtgc gggcttcgag ggcggtcagc tgcccctgca gatgcgtctg 4200
ccgaagctcc gcggcttcaa gaaccggtc cgcacggagt accaggtcgt gaacctggac 4260
aagctctccg cgcacttccc cgagggcggt gaggtaccg tggacgcgct cgtctccaag 4320
ggcctcgtcc gtcgtggcca gcccgtaag gtgctgggca cgggggagat caccgcggcc 4380
gtgcaggtga aggcgaacgc cttctctgcg tccgccgtgg agaagatcca ggccgccggc 4440
gggtccaccg agacctctg acacgccgac ccatcgaccg agggccctgg ccggagcagc 4500

-182-

cgctcggggc aggccttggg ccgtccgtgt agactcgcac agccgccccg gtgtggccgc 4560
cgtctcgtgc ccccgccccg cggaacggcg cacgccccac aggaccagcc gcaggaggac 4620
tcgtgctcaa ggccatcgcc cggatcgtcc ggacgcctga cctgttgccg aagatcgcc 4680
tcacgctcgg gctcatcgcc gtctatcgga tgggcgactt cgtgccggcc accggcgtgg 4740
actaccggc ggtgcagcag tgccctggcag cgggcaacgc ccaggcgccg ctgtactcct 4800
tcgtgaacat gttctcgggc ggggcgctcc tgcagggtgc tgtcttcgcg ctgggcatca 4860
tgccgtacat cacggcgtcg atcatcgtgc agctgctgcg cgtgggtgatc ccgcgcttcg 4920
agcagctcca ccaggagcgc cgcagggggc aggcgacgct gacgcagtac acccgctacc 4980
tgaccctcgc cctcgccctg ctgcaggcga ccacgatggc ctgcgtggcc cgcaccgggg 5040
ccctgctcgg atgcagcctg ccgctgctgc gcgacggctc catcctcacg gtgctgctcg 5100
tggtcatcgc cctgaccacc ggctgtctca tcgtcatgtg gttcggggag cggatcaccg 5160
agaacggcgt gggcaacggc atgtccctgc tcatcttcac ctccatcgcg gcaggcttcc 5220
cggccggtct cggccagggtg gtccagacgc agggctggcg cgtgttcgcg atcgtcatgg 5280
ggatcggcct gctcaccatg ctggccatcg tcttcgtgga ggagtcgcag cgcgggatcc 5340
cggtcagta cgccaagcgg cagatcggct cacggaccgt gggcgggtcg agcacctaca 5400
tcccgggtcaa ggtgaacatg gccaacgtca tcccgggtcat ctccgctcc tccgtgctga 5460
tgctcccggg catcctcatc cagttcaaca cgccgcagga cggcagtgcg ccggccccgt 5520
ggatcacgtg gctgagccgg tacttcggct ccggtgacca cccggtgtac atggccctgt 5580
acttctgct catcatcgcc ttacgtact tctacgtgc catcacgttc aaccgggtgg 5640
agatctcgga caacatgaag cgctacggcg gcttcatccc ggcgtccgcg ccggccggcc 5700
ccaccgagcg ttacctgcag tacgtcatca gccgcatcac gttcgtggtg ggggccctct 5760
acctcggtat cgtggccatg atcccgtga tcgccttcgc ggtgatcggc accagccaga 5820
acttcccgt cggcggcacg tccatcctca tcatggtggg cgtcggcctc cagaccgtga 5880
agcaggtcag cgcacagatg gagcagcgc actacgaggg cctgctgcgc tgagccccga 5940
ccgatcccg caacgccgtc cgtatcgaca gtgaggaaca cacgatgacc cgcgtgctgc 6000
tcatgggccc tcccggttcc ggcaagggca cccaggccac ccgatcgcc gacaagctgg 6060

-183-

ggatcgtccc gatctccacc ggtgacatct tccgccacaa cgtgaagtcg atgacgccgc 6120
tcggcgctcga ggccaagagg tacatcgaca acggcgactt cgtccccgat gaggtcacga 6180
accgcatggt cgccgaccgc atcgcccagg ccgacgcgga gcacggcttc ctgctggacg 6240
gctacccgcg cacgaagggc caggtcgagg cgctggacgc catgctcgcc gaggccggcc 6300
agtcgctgtc cgccgtcgtc gagctggagg tgcccgaaga ggagctcgtg gagcgccctgc 6360
tcaagcgtgc cgagatcgag ggccgcgcgg acgacaccca ggaggtcatc gagcaccgcc 6420
tggacctgta ccaccgcgag accgagtccg tcatccagga gtacgtggag cgccggcatcg 6480
tcgcccgcgt ggacggcacc ggccagatcg acgacgtcac cgagcgccctg ctgcaggccg 6540
tgtactccgt gcgctccgcc acgggctccc tgcccgtgat ccagccgggc gcggagtcct 6600
gaccccgtga tcggccgccg ctcgctcgag ctcaagaccg cccccagct gctggccatg 6660
cagcgcgcgg gggtggtcct gtccgaggca ctggacgccg cgctggccgg cgcgccgggc 6720
ttcaccaccg cggagctgga cgccgtgttc gcggtggtgc tggccgaacg cgggtgcgacc 6780
tccaacttcc tgggctacta cgacttcccg gcctcgatct gcacctcggc caacgaggag 6840
gtcgtgcacg gcatcccc 6858

<210> 42

<211> 578

<212> DNA

<213> Homo sapiens

<220>

<221> UNSURE

<222> (5)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (23)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (31)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (48)

<223> May be any nucleic acid

-184-

<220>
<221> UNSURE
<222> (211)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (292)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (308)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (350)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (384)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (477)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (507)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (529)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (549)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (551)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (558)
<223> May be any nucleic acid

<400> 42
ttctngtcta tggcagagat ggncaggttg ncgttgagca ggtactgncc atcagccgtc 60

-185-

ttcagcgcca ggtagtcccc atcgttctgc acaccgggt ggctccgctg cttcacgtca 120
 atattagtgg caccagctgg gatggtgaca atgtcattgt agccataatt ggtgggggtg 180
 agggacccgg agaccttcct gcaggagtgtg nctttgcccc cacacacccc gcatttgtcc 240
 agcttccgag gcgagtccac cacatggtca cagccggcct tgacacactg gncacggaca 300
 cagatggnc a gtgtttctgg cccacacagg gtgccatcaa tcaccttggc ctcgaacact 360
 ttggaactcg ctccctcccc gggntcggga ggaacaactt gcaggggtcc cgggggggac 420
 aaccagcat tcttggggga cccactgcag gaggattccc cgtccatgtc aagtgttatt 480
 ggtgggcatt attcttctca caattgntgc tccctgaagg ttttccgnc aaggggggat 540
 tccccccng ntggaatnat tggacttgg gtctccga 578

<210> 43
 <211> 305
 <212> DNA
 <213> Homo sapiens

<220>
 <221> UNSURE
 <222> (128)
 <223> May be any nucleic acid
 <220>
 <221> UNSURE
 <222> (146)
 <223> May be any nucleic acid

<400> 43
 catttaagtt tgctagtcct ttgcaaacag actgacgctg agtgtcctgt ctgagtcaat 60
 aagtgcactt ttacctttta acctatgccc tctacttgaa cccgagcaag gtccagtcca 120
 ctggacangt tgatgatagg gtctgncgcc ccataccctc tcctcttccc ccttaggaat 180
 ttgtgcagta ctggaggggt tgcggcaatg ggaggcctgg gtgggocgtg ctgccttgat 240
 atggccaagg gaccagtc a ccacagtga gacccttgtc tgacactcag taccgcatgt 300
 ccagg 305

<210> 44
 <211> 333
 <212> DNA
 <213> Homo sapiens

-186-

<220>
<221> UNSURE
<222> (82)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (255)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (275)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (299)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (313)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (324)
<223> May be any nucleic acid

<400> 44
ggcacaggtg actttagcat gcagagcagc aaagagagag caaccaccaa catcatccag 60
ccgctgctcc acgcacagtg gntgctgggg gactgggtctg agtgctctag cactgcgggg 120
ccggctggca gaggcgaact gtagagtgc gggaccctc cgggtgcaggc ctctgccacc 180
tgcaacaagg ctctggaaac ccgaggatgc caagccctgg cagaaccagc tgtgccccct 240
gtgatttcag ggggncaggg gccattttgt gctcngggac atgcggtaat ggaggttgnc 300
agacaaggtc ttncattgtg gtgnatgggt tcc 333

<210> 45
<211> 102
<212> DNA
<213> Unknown

<220>
<223> Description of Unknown Organism:Unknown

<400> 45

-187-

<220>
<221> UNSURE
<222> (64)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (69)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (71)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (72)
<223> May be any nucleic acid

gcagcagcag cgcagcgcag agagagcagc agcagcagca gcagcagcag cagagcagat 60

cntnctggna nnaaaaaatc gcggcagcag ctgctctagc ag 102

<210> 46
<211> 123
<212> DNA
<213> Unknown

<220>
<223> Description of Unknown Organism:Unknown

<220>
<221> UNSURE
<222> (9)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (51)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (52)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (57)
<223> May be any nucleic acid

<220>

-188-

<221> UNSURE

<222> (67)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (123)

<223> May be any nucleic acid

<400> 46

caggcaagnc ggcacgtagg agcagcagca gcagcagcag cagcagtaac nnagtcnacg 60

agggggngcc cgggacccaa ggcgcccgaag cagagaggcg gagcacaatc cactggtcgg 120

cgn

123

<210> 47

<211> 109

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<220>

<221> UNSURE

<222> (87)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (95)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (102)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (106)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (107)

<223> May be any nucleic acid

<400> 47

ggcagcgagg agcagcagca gcagcagcag cagcagcagc agagagagag cagcagagag 60

agagagcagc agagcagagc agagcanagt agagnagagc anagcnnac

109

-189-

<210> 48
<211> 293
<212> DNA
<213> Homo sapiens

<220>
<221> UNSURE
<222> (86)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (166)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (185)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (209)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (214)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (219)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (234)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (290)
<223> May be any nucleic acid

<400> 48
ggcacgaggg ggaaactgct ccgcgcgcgc cggggaggag gaaccgccc gtcctttagg 60
gtccggggccc ggccgggcat ggattnaatg cctgagccc ggtcccgtg tcttctgctt 120
cttccttgct tgctgctgct gctgctgctg ctgccggccc cggagntggg cccgagccag 180
gccgnagctg aggagaacga cttgggttng cctnccana aaatgggaag gganttgagg 240

-190-

ttaatcgaag tcattgggac catttttaaaa ggggcttcct ggattatagn ctt

293

<210> 49

<211> 506

<212> DNA

<213> Homo sapiens

<220>

<221> UNSURE

<222> (283)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (342)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (356)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (362)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (364)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (368)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (429)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (454)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (461)

<223> May be any nucleic acid

<400> 49

aattcggcac gagcaccgg ccaactgcagt cttctgcct gctggacagc agcagcagca 60

-191-

gcagcagcag cagcagcagc agcagcaaca gtaacagcag cagttcgtcc ggacccaacc 120
cttctacctc ctttgagccc atcaaggcag accccacagg tgttttggaa ctccccaaag 180
agctgtcaga aatctttgat cccacacgag agtgcacgag ctcggagctg ctggaggagt 240
tgatgtcctc agaagtgttt gcccctctgc tttcgtcttt ctncaccccc gggagaccac 300
gattatatct acaacctgga cgagagtga ggtgtttgtg anctcttttg atgtgnctgt 360
tntnaacntt tgactgacag ggacatgcct tttttggttg ggaccagat tttttgactt 420
gggggtttnc ttgggacttt tcaaccgacc ctanagagtt nagagcaaan aggttggttt 480
ttcggcttcc ttaacgaaag ttttgg 506

<210> 50

<211> 419

<212> DNA

<213> Homo sapiens

<220>

<221> UNSURE

<222> (137)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (221)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (259)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (327)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (385)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (389)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (416)

-192-

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (418)

<223> May be any nucleic acid

<400> 50

tttaagcacc aaaacttggtg ttttaatgat gttggatgga aatctttcct aaatgtgtca 60

tgcattgctct tgtctccctt aatggagaga gtgtgacact gcttagcact tggatggctt 120

gggggtggtgg ttatgancag cagtctgtca cagctcagcg aggtgaagcc tgtgggcgtt 180

ttgctctgtg ctgaatggct cagtggccct acaaagcgga ntcagctctt ggtggccttc 240

tgttgtggtg ggctgctgnt gctgctgctg ctgctgctgc tgctgccctt gcctctaaaa 300

gaactcactt cctcttcctc ctgctgncac ctgtcttttg gcttgtggga ttggagtcac 360

ggggcccaga tggagccttg ctccntgant tatgataggc ccctcgggtct cttttntnc 419

<210> 51

<211> 495

<212> DNA

<213> *Saccharomyces cerevisiae*

<220>

<221> UNSURE

<222> (177)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (322)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (328)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (342)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (368)

<223> May be any nucleic acid

-193-

<220>
<221> UNSURE
<222> (371)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (375)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (380)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (386)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (396)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (404)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (423)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (426)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (436)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (443)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (456)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (460)

-194-

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (467)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (468)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (471)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (474)

<223> May be any nucleic acid

<400> 51

aattcggcac gagcaaagtt ctgcgctcca ttgtgggcat caaacgacac gtcaaagccc 60

tccatctggg ggacacagtg gactctgatc agttcaagcg ggaggaggat ttctactaca 120

cagaggtgca gctgaaggag gaatctgctg ctgctgctgc tgctgctgcc gcagacnccc 180

agtccctggg actcccacct ccgagccagc tcccaccccc agcatgactg gcctgcctct 240

gtctgctctt ccaccacctc ttgcacaaag ccagtcctc cggcccagaa catcctgggc 300

ccggagttcc ttccttgctt tnaggggntt ttcagcaagt tnagttcctt gggtcctttt 360

tgggaaantt naggnaagtn aaggantacc aggttnttgc catnctttcc agatccaagt 420

ttnacnaaaa attttnaaca gtntaaattg ggtttnttgn ccctttnnng nggntgtttt 480

ttttttcggg tccgg

495

<210> 52

<211> 81

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<220>

<221> UNSURE

<222> (65)

-195-

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (67)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (71)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (75)

<223> May be any nucleic acid

<400> 52

ggcacgcagg agcagagcag cagcagcaga gagagcagca gcagcagcag cagcagcaga 60

gagananata natanatata t

81

<210> 53

<211> 305

<212> DNA

<213> Homo sapiens

<220>

<221> UNSURE

<222> (11)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (62)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (81)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (256)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (289)

<223> May be any nucleic acid

<400> 53

aggcacttga nttgaaaatg gaaaacccta ctgctggtgg tgctgcggtg atgaggccta 60

-196-

tnatgcagcc ccaggggtttt nttaatgctc aaatggctgc ccaacgcagc agagagctgc 120
taagtcatca cttccgacaa cagaggggtgg ctataatgat gcagcagcag cagcagcagc 180
aacagcagca gcagcagcag cagcagcagc aacagcaaca gcaacagcaa cagcagcaac 240
agcagcaaac ccaggncttc agcccacctc ctaatgtgac tgcttccnc agcatggatg 300
ggctt 305

<210> 54
<211> 307
<212> DNA
<213> Hepatitis C virus

<220>
<221> UNSURE
<222> (212)
<223> May be any nucleic acid

<400> 54
tggggtgtga agctccggtg ctggtgcggc gggggactgc ggggccagcc tcagtttaaa 60
ccccctcagc agtctttctg tcgttgccct ccacactgcg agactctgga gggcgatctg 120
gaggtctgga agataaccga ttcctgggag atttgggggt agtctccaat ctgtccctgg 180
ctcatcttgt gacccgaagc cggcggcctt gncaggagta ttctagaatg agtgcacata 240
aaaatacctt caaacggtag cagcagcagc agcagcagca gcagcaagca gcagcagcag 300
cagcagc 307

<210> 55
<211> 88
<212> DNA
<213> Unknown

<220>
<221> UNSURE
<222> (6)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (7)
<223> May be any nucleic acid

<220>
<221> UNSURE

-197-

<222> (78)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (83)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (87)
<223> May be any nucleic acid

<220>
<223> Description of Unknown Organism:Unknown

<400> 55
ggacannngac tactctctct ctctctctct ctctctctgc tgctgctgct gtgctgctgc 60
tgctgctgct gctgccgntg tgngcana 88

<210> 56
<211> 346
<212> DNA
<213> Unknown

<220>
<221> UNSURE
<222> (278)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (288)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (299)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (313)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (342)
<223> May be any nucleic acid

<220>
<223> Description of Unknown Organism:Unknown

-198-

<400> 56
ggcacagccc aactggtgat gctgctgctg ctgctgctgc tgccgccgcc gcctctattg 60
ctgatactct agtggggctg gaaggggtgt tcctattcgc accatcgcca accagagaca 120
gagggaaaaa aaaaaccggc agccactgct gaatgttggg ttcggaggct gcatccgact 180
cggtcacaag gaaaatggat tcagtttgca tctctccctc ctttaaacag cttctccggg 240
tctcagcatg ggcttccagg gcagcgattg aggagacontt accaaggngc accacacant 300
agatgctgag acntcgtgac tccaggataa gaaacattaa cngggg 346

<210> 57
<211> 496
<212> DNA
<213> Unknown

<220>
<223> Description of Unknown Organism:Unknown

<220>
<221> UNSURE
<222> (11)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (78)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (195)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (197)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (286)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (291)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (293)
<223> May be any nucleic acid

-199-

<220>
<221> UNSURE
<222> (315)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (328)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (329)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (344)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (346)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (352)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (354)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (358)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (366)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (399)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (406)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (410)
<223> May be any nucleic acid

-200-

<220>
<221> UNSURE
<222> (418)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (420)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (435)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (443)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (453)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (454)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (459)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (471)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (473)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (474)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (481)
<223> May be any nucleic acid

-201-

<400> 57
gaattcggca naggtgcaca gatgtggtgg atggggaggg ccgcacggga cagaagttct 60
ccctgtgtat tctgacgnct gagaaaggag catttcatcc gggcggagac caaggagatc 120
gtcaatgggt ggctggagat gtcctgggtc tatccccgga ccaacaagca gaatcagaag 180
aagaaacgga aagtgnnagc cccccacacc acaggagcct gggactgcc aagtgggctg 240
ttaccagcag cagcagcagc agcagcagca gcagcagcat ccccantgct ntnggaaagt 300
tcccaccacc aagtnccaca atttgggna aaaccaaggt tgtngnagac gngntttngg 360
gatttnggca ttgtgggttg cttgcatgga aggacattng gttgtnggtn ccttggangn 420
tacaattacc atttncggtt gtnaaggta aanntccgnc attcagaagg nttnaagggtg 480
ntttgaagtc catttg 496

<210> 58
<211> 268
<212> DNA
<213> Drosophila sp.

<220>
<221> UNSURE
<222> (16)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (51)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (60)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (202)
<223> May be any nucleic acid

<400> 58
aacacttatc cttganagct ctgtttggga agcaggacaa agctacatgt naggaaactn 60
tggagcctcc gcagactctc caccagcagc agcagcagca gcagcagcag caagagaagc 120
ttccaattag gcaggggggtt gtacgctccc tgtcctatga ggaaccaga agacactcac 180
ccccattga gaagcagctc tntccagcca ttcagaaact catggtcagg agcgcagacc 240

-202-

tccacccatt gtcagagctg cctgaaaa

268

<210> 59

<211> 471

<212> DNA

<213> Homo sapiens

<220>

<221> UNSURE

<222> (249)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (386)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (449)

<223> May be any nucleic acid

<400> 59

tcgacccacg cgtccgctga ggaacagacg ttccctggcg gccctggcgc cttcaaacc 60

agacatgctg ctgctgctgc tgctgctgcc cctgctctgg gggacaaagg ggatggaggg 120

agacagacaa tatggggatg gttacttgct gcaagtgcag gagctggtga cgggtgcagga 180

gggcctgtgt gtccatgtgc cctgctcctt ctctacccc caggatggct ggactgactc 240

tgacccagnt catggctact ggttccgggc aggagacaga ccataccaag acgctccagt 300

ggccacaaac aaccagaca gagaagtga ggcagagacc caggggccgat tccaactcct 360

tggggacatt tggagcaacg actgcncct gagcatcaga gacgccagga agagggataa 420

ggggtcatat ttctttcggc tagagagang aagcatgaaa tggagttaca a 471

<210> 60

<211> 379

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<220>

<221> UNSURE

<222> (2)

<223> May be any nucleic acid

-203-

<220>
<221> UNSURE
<222> (14)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (31)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (135)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (315)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (332)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (349)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (357)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (374)
<223> May be any nucleic acid

<400> 60
anttcggcan aggnaaggga gagggtgacc ngcatcccaa ctagatttca gtggagtga 60
gttcaggagg catggagctg acaaccatga ggcctcggca gccaccgcca ccaccgccgc 120
cgccaccacc gtagncagca gcagcagcag cagcagcagc aagagttaac tctgacttag 180
ggaatagaga cagccagaga gaaatgtgat caatgaagga gacatctgga gtgtgcgtgc 240
ttcttcagag gggacgggtg atgggcagat ttggaaaaag caccgcagat tgggaacctt 300
atcttttctt tttcntaaaa ttgttggtat gnaaatttgg gtttttcng taacttntta 360

-204-

aaaacttaaa agtngggtt

379

<210> 61

<211> 255

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<220>

<221> UNSURE

<222> (121)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (183)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (254)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (255)

<223> May be any nucleic acid

<400> 61

aattccgaca atggaaagca ctcttagcct tgcagtggtc tacattttta aggaaccaat 60

atttcagcat tctttattac ccggcacgct gtgtcctttg tcagagttca agtttatggt 120

nactgccagg gtcagacagt ccatttgctg ctgctgctgc tgctgctgct ttctcgaact 180

ggnatggcat tagggaagct gctgtctgag tgtagggaa tgtcttggt aagtaaagcc 240

aatgttcttt cctnn

255

<210> 62

<211> 5289

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 62

cgagctctcc cagccgcagc ctccgaatcc acggcctcca ccccgcgct ctccagcgct 60

-205-

ctatcccgtc gctgcgccct tgtcgccggc ccgggccgct gcatccgct cgcacagggc 120
tccttgctgg gcacaaatag ctccaccatg gggctggcct ggggactcgg tgtcctgctc 180
ctgttgcatg cctgcggctc caaccgcatt ccagagtctg ggggagacaa cagtgtgttt 240
gacatctttg aactcaccgg agctgcccgc aagcggctctg ggcgccgact ggtgaagggc 300
cctgaccctt ctagcccagc tttccgcacg gaggatgcc aacctgatccc ccctgtgcct 360
gacaagaagt tccaagacct agtggatgct gtgcggggcg agaaagggtt cctcctcctg 420
gcctccctga ggcaaatgaa gaagaccgg ggtaccctgc tggctgtgga gcgaaagac 480
cactctggcc aggtcttcag cgtgatctcc aatggcaagg cgggcaccct ggacctgagc 540
ctgaccgtgc aggggaagca gcatgtggtg tcggtggaag aagcactcct ggcgactggc 600
cagtggaaga gcatcaccct gtttgtgcag gaggacaggg ccagctgta catcgactgt 660
gagaagatgg agaatgcgga gctggatgtc cccatccaga gcatcttcac cagggacctg 720
gccagcatcg ccaggctccg cattgccaaa ggaggtgtca acgacaattt ccaggggggtg 780
ctgcagaatg taaggtttgt ctttggaacc acaccagaag acatcctcag gaacaaagggc 840
tgctccagct ctaccagtgt ctttgtcacc cttgacaaca acgtggtgaa tgggtccagc 900
cctgccatcc gcaccgacta cattggccac aagacaaagg acctgcaagc catctgtggc 960
atctcatgtg acgagctgtc cagcatggtc ctggagctca ggggtctacg caccatcgtg 1020
accacgtgc aggacagtat ccgcaaagtg accgaagaga acaaagagct ggccaacgag 1080
ctgaggaggc cccactctg ctaccacaac ggagtgcagt acaggactgg cgacgagtgg 1140
acggtggaca gctgcactga gtgtcgctgc cagaactcag ttaccatctg caaaaaagtg 1200
tcctgtccca tcatgccctg ctccaatgcc acagttccgg atggagaatg ctgcccacgg 1260
tgctggccca gcgactctgc agacgatggc tgggtcccgt ggtctgagtg gacctcttgc 1320
tctgtgacct gtggcaatgg aatccagcag cgtggccgct cctgcgacag cctcaacaac 1380
agatgcgagg gctcctctgt gcagacgcg acctgccaca tccaggagtg tgacaagaga 1440
tttaaacagg atggcggtg gagccactgg tccccatggt catcttgctc cgtaacatgt 1500
ggagacggtg tgatcacaag gatccggctc tgcaactccc ccagccccca gatgaatggg 1560
aagccatgtg agggcaaagc ccgggagacc aaagcctgcc agaaagactc ctgcccacat 1620

aatggaggct ggggaccttg gtcaccatgg gacatctgtt ctgtcacctg tggaggaggg 1680
gtacagaaac gtagccggct ctgcaacaac cccaaacccc agtttggagg caaggactgc 1740
gttggtgatg tgacagaaaa ccagatctgc aacaagcagg actgtcccat tgacggatgc 1800
ctgtccaatc cctgctttgc tgggtgccag tgtaccagct accctgatgg cagctggaag 1860
tgtggtgcct gtcccccagg ctatagtga gatggagtcg agtgcaaaga cgttgatgag 1920
tgcaaagaag tccctgatgc ctgcttcaac cacaatggag agcacagggtg tgagaacaca 1980
gaccccggtc acaactgcct gccctgccca ccgcgcttca ctggctcgca gccctttggc 2040
cggggcgtgg aacatgccac cgccaacaag caggatatga agccccgaaa cccctgcaca 2100
gacgggacac acgactgcaa caagaacgcc aagtgcaact acctgggcca ctacagcgac 2160
cccatgtacc gctgcgagtg caagcctggc tacgcgggca acggcatcat ctgcggggag 2220
gacacagacc tggacggctg gcccaatgag gacctgctgt gcgtggccaa cgcaacttac 2280
cactgcagaa aggataattg ccccaacctt cccaactcag ggcaggaaga ctatgacaag 2340
gatggaatcg gcgatgcctg cgatgatgac gatgacaatg ataagattcc agatgacagg 2400
gacaactgtc cattccatta caaccagcc cagtacgact atgacagaga tgacgtggga 2460
gaccgctgtg acaactgccc ctacaaccac aaccagacc aggctgacac agataacaat 2520
ggggaaggag acgcctgtgc agctgacatt gatggggaca gtatcctcaa tgaacgggac 2580
aactgccagt atgtctaaa tgtggaccag aaagacactg acatggacgg ggttggtgat 2640
cagtgtgaca actgccccct ggaacacaat ccagaccagc tcgactctga ctcggaccgc 2700
attggagaca cctgtgacaa caatcaggat attgatgaag acggccacca gaacaatctg 2760
gacaactgtc cctacgtgcc caacgccaac caggctgacc atgacaagga tggcaaaggc 2820
gatgcctgtg accatgatga cgacaatgat ggcattcctg atgaccggga caactgcagg 2880
ctggtgccca atcctgacca gaaggactct gatggtgatg gtcgaggtga tgcttgcaaa 2940
gatgattttg accaggacaa ggtgccagac attgatgaca tctgtcccga aaatggtgat 3000
atcagtgaga ctgatttccg ccgattccag atgattcctc tagatcccaa agggacatcc 3060
cagaatgacc ctaactgggt tgtacgcat cagggtaaag aactcgtcca gactgtcaac 3120
tgtgaccctg gacttgctgt aggttatgac gaatttaacg ccgtggactt cagtggcacc 3180

ttcttcatca acaccgagag ggatgacgac tatgccggct ttgtgtttgg ctaccagtcc 3240
agcagccgct tctatgttgt gatgtggaag caagtcactc agtcctactg ggacaccaac 3300
cccacgaggg ctccaggggta ctctggactt tccgtgaagg ttgtaaactc caccacgggg 3360
cctggcgagc acctgcggaa tgccctgtgg cacacaggaa acacctctgg ccaggtgcgc 3420
aactgtggc atgaccctcg tcacattggc tggaaagatt tcaactgccta cagatggcat 3480
ctgagccaca ggccaaagac aggtttcatc agagtggtaa tgtatgaagg gaagaaaatc 3540
atggctgact caggacccat ctatgacaaa acctatgctg gtgggaggct aggcttgctc 3600
gtcttctctc aagaaatggt gttcttctcc gacctgaaat atgaatgcag agactcctaa 3660
tcatcaaact gttgatcaaa agactgatca taaaccaatg ctggtattgc accttctgga 3720
accatgggct tagaaaaccc ccaggatcgc gcctcgctgc ctgcctttgc tctctgcttg 3780
catgagtgtg gactcctaga acatgtgact tgctcaaga aaatgcaatt ttccaaatca 3840
gacctgcat tcagcctctg actgagaaga atcttccaag gagacaaaca atgactttgg 3900
ttggcttttg caaaagcaaa agcatccaca tgctttggtt ggaagggtgc tgtccactc 3960
tgcttttgct agagcagaat gcgactgtga ggccagctct gagcagtgga ctccaaaatg 4020
ttttcaggca tgtgagagaa gggaggactc actagaattg acaaacaaaa ccagccctga 4080
cctactccct ctggaatggg ggcgggtggg ggggccaaag cccaaagggg aggatgcata 4140
cccaagagat gattgtatga agaaaatatg gaggaactgt tacatttttg gtactaaatc 4200
attttcaggg gattgaaaga ctattgctgg atttcatgat gctgaccggg gttagctgat 4260
taaccacat aaataggcac ttaaatagga gcagggaagg aaggaaaaga ctggcttctg 4320
gacttctcc cagatttcca ccccttaaca catcacctgt agtgaccaga acagggagtc 4380
ggagttaaac cgacacaagg cagggccagc tgctgcagct tggttctatt gaaattgtca 4440
gttgatttcc agatgtagct tctgcagatg tagcagcaaa ataagaatac ccaccatctc 4500
agcgagcacc aggctgtctc ccaagggacg gcagccatgc ttgtattttt atggttagaa 4560
aggcacaaaa ttatcaacta agacattcct tcttctctt ttttctctga acatcatgga 4620
gttttccagt tgtctctttt ggactgtagt ttttagtggt ttaaacaac actttacaat 4680
gtaaactatt tattttttac ttattctggg ggatctgtct gaaagactat tcatggaaca 4740

-208-

ggaagaagcg taaggactat ccatatcatc ttgctacaa gtcattatga ctgtaagatt 4800
gtaaatacag attatttatt aactctgttc tacctggaat ctagtttcat atggaaagtg 4860
tttgagagca ggtagttgag atcgatcagc aaatctttca caggaatggc acaaggaaac 4920
cagcatagca agctgctctt caccttgtgc ttagactgga tgatttgga ttcttttttc 4980
cttttttttc ccaagtggaa ttacttggtt gtccatttgc aagtgtttt agtttgcaaa 5040
gaaagccaag aggccattaa tactgtctta tcccatccct tgtgcctatt tccagggaga 5100
tgaaaagcat ctacatttat tatttttgcc tttttccaaa agaaaaaat gacaaaggtg 5160
aaacttgtat acaaataatta cctcatttgt tgtgtgactg agtaaagaat tttgggatca 5220
aacagaaaga gtttaagtgt ctaacaaact taaagctact gtagtaccta aaaaaaaaaa 5280
aaaaaaaaa 5289

<210> 63

<211> 2053

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 63

gaattccggc ggccgctgag agcccaccct ggcgagctct cccagccgca gcctccgaat 60
ccacggcctc cccccgcgc ctctccagcg ctctatcccg tcgctgcgcc cttgtcgccg 120
gccccggcgc tgcattccgcg tccgcacagg ctcttgact gggcacaaat agctccacca 180
tggggctggc ctggggactc ggtgtcctgc tctgttgca tgctgcggc tccaaccgca 240
ttccagagtc tgggggagac aacagtgtgt ttgacatctt tgaactcacc ggagctgccc 300
gcaacggtac tgggcgccga ctggtgaagg gccctgacct ttctagccca gctttccgca 360
tcgaggatgc caacctgatc cccctgtgc ctgacaagaa gttccaagac ctagtggatg 420
ctgtgcgggc ggagaaaggt ttctctctcc tggcctccct gaggcaaag aagaagacct 480
ggggtacct gctggctgtg gagcggaag accactctgg ccaggtcttc agcgtgatct 540
ccaatggcaa ggcgggcacc ctggacctga gcctgaccgt gcaggggaag cagcatctgg 600
tgtcggtgga agaagcactc ctggcgactg gccagtggaa gagcatcacc ctgtttgtgc 660

-209-

aggaggacag ggcccagctg tacatcgact gtgagaagat ggagaatgcg gagctggatg 720
tccccatcca gagcatcttc accagggacc tggccagcat cgccaggctc cgcattgccca 780
aaggaggtgt caacgacaat ttccaggggg tctgcagaa tgtaaggttt gtctttggaa 840
ccacaccaga agacatctc aggaacaaag gctgctccag ctctaccagt gtctttgtca 900
cccttgacaa caacgtggtg aatgggtcca gccctgccat ccgcaccgac tacattggcc 960
acaagacaaa ggacctgcaa gccatctgtg gcatctcatg tgacgagctg tccagcatgg 1020
tcttgagct caggggtcta cgcaccatcg tgaccacgt gcaggacagt atccgcaaag 1080
tgaccgaaga gaacaaagag ctggccaacg agctgaggag gccccactc tgctaccaca 1140
acggagtga gtacaggact ggcgacgagt ggacggtgga cagctgcact gagtgtcgct 1200
gccagaactc agttaccatc tgcaaaaaag tgtcctgtcc catcatgccc tgctccaatg 1260
ccacagttcc ggatggagaa tgctgccac ggtgctggcc cagegactct gcagacgacg 1320
gctggtcccc gtggtctgag tggacctctt gctctgtgac ctgtggcaat ggaatccagc 1380
agctggccgc tctgcgaca gcctcaacaa cagatgcgag ggctcctctg tgcagacgcg 1440
gacctgccac atccaggagt gtgacaagag atttaaacag gatggcggct ggagccactg 1500
gtcccatgg tcatcttgct cagtaacatg tggagacggt gtgatcacia ggatccggct 1560
ctgcaactcc ccagcccc agatgaatgg gaagccatgt gagggcaaag cccgggagac 1620
caaagcctgc cagaaagact cctgccccat caatggaggc tggggacctt ggtcaccatg 1680
ggacatctgt tctgtcacct gtggaggagg ggtacagaaa cgtagccggc tctgcaacaa 1740
ccccacacc cagtttgag gcaaggactg cattggtgat gtgacagaaa accagatctg 1800
caacaagcag gactgtcca ttgacggatg cctgtccaat ccctgcttg ctggtgtcca 1860
gtgtaccagc taccctgatg gcagctggaa gtgtggtgcc tgtccccag gctatagtgg 1920
agatggagtc gagtgcagg acgttgatga gtgcaaagaa gtccctgatg cctgcttcaa 1980
ccacaatgga gagcacaggt gtgagaacac agaccccggc tacaactgcc tgccctgccc 2040
accgcccga att 2053

<210> 64

<211> 4339

-210-

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 64

agccactgcc tggagtcagc cagcctcatc ggacttctgc aggcaatcgc gaagctgcta 60
tccagttctg ccacggtctc tcccggcgca ccggcagtct cagcgtcttc accggactca 120
gcgtccttgt ccttcacttc acctttgcc a cctctccggg ttactgagcc ccggtgcaca 180
caggctccgt gttgggcaca aaggctccac catggagctc ctgcggggac taggtgtcct 240
gttctgttg catatgtgtg gaagcaaccg cattccagag tctgggggag ataacggtgt 300
gtttgacatc tttgaactca ttggaggtgc acgaaggggc cccggtcgcc gactggtgaa 360
gggccaagat ctatccagcc ccgccttccg cattgagaat gccaacctga tccccgctgt 420
gccgatgac aagttccaag acctactgga cgctgtgtgg gccgacaaag gcttcatctt 480
cttggcttcc ttgaggcaga tgaagaagac ccggggcaca ctctgggtg tggaacggaa 540
agacaacact ggccagatct tcagtgtggt ctccaacggc aaagctggca ccctggacct 600
gagcctgagc ctgccaggga agcaacaagt ggtgtcagtg gaggaagctc tcctggccac 660
tggccagtgg aagagcatca cgctgtttgt tcaagaggac cgggctcaac tctacataga 720
ctgtgataag atggagagcg cggagctgga tgtaccatc cagagcatct tcaccaggga 780
tctggccagc gttgccaggc tccgagttgc aaaggagat gtcaatgaca attttcaggg 840
ggtgctgcag aatgtgaggt ttgtctttgg aaccaccca gaagacattc tcaggaacaa 900
aggctgtcc agctctacca acgtccttct tacccttgac aacaacgtgg tgaacggttc 960
cagccctgct atccgcacca actacatcgg ccacaaaaca aaggacctcc aagctatctg 1020
tggcctctcc tgtgatgaac tatccagcat ggtcctggaa ctgaagggcc tgcgcacat 1080
cgtgaccact ctgcaggaca gcatccgaaa agtgacggaa gagaacagag agctggtcag 1140
tgagctgaag cggcctcccc tctgctttca caatggagtc cagtacaaga acaacgagga 1200
gtggactgta gacagttgca cagagtgtca ctgccagaac tcggttacca tctgcaaaaa 1260
ggtgtcctgt cccatcatgc cctgctccaa cgccacagtt cctgatggtg aatgctgccc 1320
acggtgctgg ccagcgact ctgctgacga tggctggtct ccctggtctg agtggacctc 1380

-211-

ctgctctgcc acatgtggca atggaattca gcaacgtggt cggtcctgtg acagcctcaa 1440
caacagatgc gagggctctt cggtagacag gaggacctgc cacattcagg agtgtgacaa 1500
aagatttaaa caggatgggtg gctggagtca ctgggtctcca tggctgtcct gttctgtgac 1560
ctgtgggtgac ggtgtgatca caaggatccg tctctgcaac tccccagcc cccagatgaa 1620
cgggaagccc tgtgaagggtg aagcccggga gaccaaagcc tgcaagaaag acgcctgccc 1680
aattaatgga ggctggggtc cctggtcacc atgggacatc tgctctgtca cctgtggagg 1740
aggagtgcag agacgcagcc gactctgtaa caaccccaca cccagtttg gaggcaaaga 1800
ctgtgttggc gatgtgacag aaaatcaagt ttgcaacaag caggactgcc caattgatgg 1860
atgcctgtcc aatccctgct ttgctgggtg caagtgtact agctaccctg atggtagctg 1920
gaaatgtggt gcgtgtcctc ctggctacag tggaaatggc atccagtgc aagacgtcga 1980
tgagtgc aaa gaagtgcctg atgcttgctt caatcacaaac ggagaacatc ggtgcaagaa 2040
cacagatcct ggctacaact gcctgccctg cccaccacga ttactgggt cacagccctt 2100
cggccgaggt gtcgaacatg ccatggccaa caaacagggtg tgcaaaccgc gaaaccctg 2160
cacggacggg acgcatgact gcaacaagaa cgctaagtgc aactacctgg gtcactacag 2220
cgaccccatg taccgctgtg agtgcaagcc cggctatgca ggcaatggca tcatctgcgg 2280
agaggacaca gacctggacg gctggcctaa tgaaaacctg gtgtgtgtgg ccaacgcaac 2340
ctaccactgc aaaaaggaca actgccccaa ccttccccaa tcggggcagg aagactatga 2400
caaggacggg attggcgatg cctgcgatga tgacgatgac aacgacaaga tccctgatga 2460
cagggacaac tgtccattcc attacaaccc agcccagtat gactatgaca gagatgatgt 2520
gggagaccgc tgtgacaact gccctacaa ccacaaccct gaccaagcag acacagacaa 2580
aaacggggag ggcgatgcct gtgctgtgga catcgatgga gatggaatcc tcaatgaacg 2640
agacaactgc cagtacgttt acaacgtgga ccagaggac acggacatgg atggggttgg 2700
agatcagtgt gacaactgcc ccctggaaca caatccagac cagctggact ctgactcaga 2760
cctcataggg gacacttgtg acaacaatca ggacatcgat gaggatggcc atcagaacaa 2820
cctggacaac tgtccctatg tgcctaacgc caaccaggcc gaccatgata aagatggcaa 2880
aggagatgcc tgtgaccatg acgatgacaa tgacggcatc cctgatgaca gagacaactg 2940

-212-

caggctggtg cccaatcctg accagaagga ctctgatggt gatggccgag gtgacgcctg 3000
 caaagacgac tttagaccatg acaatgtgcc agatattgat gacatctgtc ctgagaattt 3060
 tgacatcagt gaaaccgatt tccgacgatt ccagatgatt cctctagatc ccaaaggaac 3120
 ctcccaaaat gaccctaact gggttgtccg ccatcagggc aaagaactcg tccagactgt 3180
 aaactgtgac cctggacttg ctgtaggtta tgatgagttt aatgctgtgg acttcagcgg 3240
 taccttcttc atcaacaccg agagagatga tgactacgct ggcttggtat tcggctacca 3300
 gtccagcagc cgcttctacg ttgtgatgtg gaaacaagtc acccagtcct actgggacac 3360
 caaccccaca agggctcagg gatactcagg cctgtctgta aaggttgtga actccaccac 3420
 cggccctggc gagcacctgc ggaatgcact gtggcacaca ggaaacaccc ctggccaggt 3480
 gcgcaccctg tggcatgacc ctgcgccat cggtggaaa gatttcactg cgtacagatg 3540
 gcgtctcagc cacaggccaa agaccggta tatcagagtg gtgatgtatg aaggaaagaa 3600
 aatcatggct gactcgggac ccatctatga caaacctac gccggcggta gactaggcct 3660
 gttcgtcttc tctcaggaaa tgggtgtctt ctgagacatg aaatacgagt gtcgagattc 3720
 ctaatcatca gctgccaatc ataaccagcg ctggcaatgc accttctaaa aacaagggt 3780
 agagaaaccc cccaccctg ccgggatcgc ctttctctgc cttccttgcc tctcttcttg 3840
 catagtgtgg acttgtaaag cctgagacct gcctcaagaa aatgcagttt tcgaaccag 3900
 agtcagcact cggcctttaa cgaatgagaa tgcattctcc aagaccatga agagtctctt 3960
 gggtttgctt ttgggaaagc caaagcgct atttacttcc cactaggaag gtgcccgtc 4020
 cactctgcct tactcacaga gccagaactt cttcgaggcc acctctgagc agcacacaca 4080
 gaagcatttt caggcatgtc aaagaaagga aaaatgactc actagaactc accgccaaac 4140
 aacctctgac ataggtcctg agatgtgggg aggcaggagc caaagctcta gggagggcat 4200
 gtaccaaga gatgactgta tgaagaaaat gtggaggagc tgttcggtac taaatcattt 4260
 tcaggggaca gacagacttg ctgcatttcc gcatgctgct ggtgagagct gattgacca 4320
 atcttccaca caggcactt 4339

<210> 65

<211> 186

-213-

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 65

gcacagttaa tggaggctgg ggtccctggg caccatggga catctgctct gtcacctgtg 60
gaggaggagt gcagagacgc agccgactct gtaacaaccc cacaccccag tttggaggca 120
aagactgtgt tggcgatgtg acagaaaatc aagtttgcaa caagcaggac tgcccaattg 180
gtaagc 186

<210> 66

<211> 5774

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 66

gtcacttttg ttgatagcag ccgctctggg agaggtagg acttcagctg atggacaagc 60
tggtaatgaa gaaatggtgc aaatagattt accaataaag agatatagag agtatgagct 120
ggtgactcca gtcagcacia atctagaagg acgctatctc tcccatactc tttctgagag 180
tcacaaaaag aggtcagcga gggacgtgtc ttccaaccct gagcagttgt tctttaacat 240
cacggcattt ggaaaagatt ttcactctgcg actaaagccc aacactcaac tagtagctcc 300
tggggctgtt gtggagtggc atgagacatc tctgggtgct gggaatataa ccgatcccat 360
taacaacat caaccaggaa gtgctacgta tagaatccgg aaaacagagc ctttgcagac 420
taactgtgct tatgttggtg acatcgtgga cattccagga acctctgttg ccatcagcaa 480
ctgtgatggg ctggctggaa tgataaaaag tgataatgaa gagtatttca ttgaaccctt 540
ggaaagaggt aaacagatgg aggaagaaaa aggaaggatt catgttgtct acaagagatc 600
agctgtagaa caggctccca tagacatgtc caaagacttc cactacagag agtcggacct 660
ggaaggcctt gatgatctag gtactgttta tggcaacatc caccagcagc tgaatgaaac 720
aatgagacgc cgcagacacg cgggagaaaa cgattacaat atcgaggtac tgctgggagt 780
ggatgactct gtgggtccgtt tccatggcaa agagcacgtc caaaactacc tcttgaccct 840

-214-

aatgaacatt gtgaatgaaa ttaccatga tgagtccttc ggagtgcata taaatgtggt 900
cctggtgcgc atgataatgc tgggatatgc aaagtccatc agcctcatag aaaggggaaa 960
cccatccaga agcttgagaga atgtgtgtcg ctgggcgtcc caacagcaaa gatctgatct 1020
caaccactct gaacaccatg accatgcaat tttttaacc aggcaagact ttggacctgc 1080
tggaatgcaa ggatatgctc cagtcaccgg catgtgtcat ccagtgagaa gttgtaccct 1140
gaatcatgag gatgggtttt catctgcttt tgtagtagcc catgaaacgg gccatgtgtt 1200
gggaatggag catgatggac aaggcaacag gtgtggtgat gagactgcta tgggaagtgt 1260
catggctccc ttggtacaag cagcattcca tcgttaccac tgggtccgat gcagtgggtca 1320
agaactgaaa agatatatcc attcctatga ctgtctcctt gatgaccctt ttgatcatga 1380
ttggcctaaa ctcccagaac ttcttggaat caattattct atggatgagc aatgtcggtt 1440
tgattttggt gttggctata aaatgtgcac cgcgttcga accttgacc catgtaaaca 1500
gctgtggtgt agccatcctg ataatcccta cttttgtaag actaaaaagg gacctccact 1560
tgatgggact gaatgtgctg ctggaaaatg gtgctataag ggtcattgca tgtggaagaa 1620
tgctaatacag caaaaacaag atggcaattg ggggtcatgg actaaatttg gctcctgttc 1680
tcggacatgt ggaactggtg ttcttttcag aacacgccag tgcaataatc ccatgcccat 1740
caatggtggt caggattgtc ctggtgttaa ttttgagtac cagctttgta acacagaaga 1800
atgccaaaaa cactttgagg acttcagagc acagcagtgt cagcagcgaa actcccactt 1860
tgaataccag aataccaaac accactgggt gccatatgaa catcctgacc ccaagaaaag 1920
atgccacctt tactgtcagt ccaaggagac tggagatggt gcttacatga aacaactggt 1980
gcatgatgga acgcactgtt cttacaaaga tccatatagc atatgtgtgc gaggagagtg 2040
tgtgaaagtg ggctgtgata aagaaattgg ttctaataag gttgaggata agtgtggtgt 2100
ctgtggagga gataattccc actgccgaac cgtgaagggg acatttacca gaactcccag 2160
gaagcttggg taccttaaga tgtttgatat acccctggg gctagacatg tgttaatcca 2220
agaagacgag gcttctctc atattcttgc tattaagaac caggctacag gccattatat 2280
tttaaattggc aaaggggagg aagccaagtc gcggaccttc atagatcttg gtgtggagtg 2340
ggattataac attgaagatg acattgaaag tcttcacacc gatggacctt tacatgatcc 2400

-215-

tggtattgtt ttgattatac ctcaagaaaa tgataccgc tctagcctga catataagta 2460
catcatccat gaagactctg tacctacaat caacagcaac aatgtcatcc aggaagaatt 2520
agatactttt gagtgggctt tgaagagctg gtctcaggtt tccaaaccct gtgggtggagg 2580
tttccagtac actaaatatg gatgccgtag gaaaagtgat aataaaatgg tccatcgcag 2640
cttctgtgag gccaaacaaa agccgaaacc tattagacga atgtgcaata ttcaagagtg 2700
tacacatcca ctctgggtag cagaagaatg ggaacactgc accaaaacct gtggaagtgc 2760
tggtatcag ctctgcactg tacgctgcct tcagccactc cttgatggca ccaaccgctc 2820
tgtgcacagc aaatactgca tgggtgaccg tcccgagagc cgccggccct gtaacagagt 2880
gccctgccct gcacagtgga aaacaggacc ctggagttag tgttcagtga cctgcggtga 2940
aggaacggag gtgaggcagg tcctctgcag ggctggggac cactgtgatg gtgaaaagcc 3000
tgagtgggtc agagcctgtc aactgcctcc ttgtaatgat gaaccatgtt tgggagacaa 3060
gtccatattc tgtcaaatgg aagtgttggc acgatactgc tccataccag gttataacaa 3120
gttatgttgt gagtccctga gcaagcgcag tagcaccctg ccaccacat accttctaga 3180
agctgctgaa actcatgatg atgtcatctc taaccctagt gacctcccta gatctctagt 3240
gatgcctaca tctttggttc cttatcattc agagaccctt gcaaagaaga tgtctttgag 3300
tagcatctct tcagtgggag gtccaaatgc atatgctgct ttcaggccaa acagtaaacc 3360
tgatggtgct aatttacgcc agaggagtgc tcagcaagca ggaagtaaga ctgtgagact 3420
ggtcaccgta ccatcctccc caccaccaa gaggggtccac ctcagttcag cttcaciaat 3480
ggctgctgct tccttctttg cagccagtga ttcaataggt gcttcttctc aggcaagaac 3540
ctcaaagaaa gatggaaaga tcattgacaa cagacgtccg acaagatcat ccaccttaga 3600
aagatgagaa agtgaaccaa aaaggctaga aaccagagga aaacctggac aacctctctc 3660
ttcccatggt gcatatgctt gtttaaagtg gaaatctcta tagatcgtca gctcatttta 3720
tctgtaattg gaagaacaga aagtgtggc tcactttcta gttgctttca tcctcctttt 3780
gttctgcatt gactcattta ccagaattca ttggaagaaa tcaccaaaga ttattacaaa 3840
agaaaaatat gttgctaaga ttgtgttggc cgctctctga agcagaaaag ggactggaac 3900
caattgtgca ttcagctga ctttttgttt gttttagaaa agttacagta aaaattaaaa 3960

-216-

agagatacca atggtttaca ctttaacaag aaattttgga tatggaacaa agaattctta 4020
gacttgtatt cctatattatc tatattagaa atattgtatg agcaaatttg cagctgttgt 4080
gtaaatactg tatattgcaa aaatcagtat tattttaaga gatgtgttct caaatgattg 4140
tttactatat tacatctctg gatgttctag gtgcctgtcg ttgagtattg ccttgtttga 4200
cattctatag gttaattttc aaagcagagt attacaaaag agaagttaga attacagcta 4260
ctgacaatat aaagggtttt gttgaatcaa caatgtgata cgtaaattat agaaaaagaa 4320
aagaaacaca aaagctatag atatacagat atcagcttac ctattgcctt ctatacttat 4380
aatttaaagg attggtgtct tagtacactt gtggtcacag ggatcaacga atagtaaata 4440
atgaactcgt gcaagacaaa actgaaaccc tctttccagg acctcagtag gcaccgttga 4500
ggtgtccttt gtttttgtgt gtgtgtgttc ttttttaatt ttgcattgt tgacagatac 4560
aaacagctat actcaatgta ctgtaataat cgcaaaggaa aaagttttgg gataacttat 4620
ttgtatgttg gtagctgaga aaaatatcat cagtctagaa ttgatatttg agtatagtag 4680
agctttgggg ctttgaaggc aggttcaaga aagcatatgt cgatggttga gatatttatt 4740
ttccatatgg ttcattgtca aatgttcaca accacaatgc atctgactgc aataatgtgc 4800
taataattta tgtcagtagt caccttgctc acagcaaagc cagaaatgct ctctccaggg 4860
agtagatgta aagtacttgt acatagaatt cagaactgaa gatatttatt aaaagttgat 4920
tttttttct tgatagtatt tttatgtact aaatatttac actaatatca attacatatt 4980
ttggtaaact agagagacat aattagagat gcatgctttg ttctgtgcat agagaccttt 5040
aagcaaaacta ctacagccaa ctcaaaagct aaaactgaac aaatttgatg ttatgcaaac 5100
atcttgcat tttagtagtt gatattaagt tgatgacttg tttcccttca aggaaacatt 5160
aaattgtatg gactcagcta gctgttcaat gaaattgtga attagaaaca tttttaaaag 5220
tttttgaaag agataagtgc atcatgaatt acatgtacat gagaggagat agtgatatca 5280
gcataatgat tttgagggtca gtacctgagc tgtctaaaaa tatattatac aaactaaaat 5340
gtagatgaat taacctctca aagcacagaa tgtgcaagaa cttttgcatt ttaatcgttg 5400
taaactaaca gcttaaaacta ttgactctat acctctaaag aattgctgct actttgtgca 5460
agaactttga aggtcaaatt aggcaaattc cagatagtaa aacaatccct aagccttaag 5520

-217-

tctttttttt ttcttaaaaa ttcccataga ataaaattct ctctagttta cttgtgtgtg 5580
catacatctc atccacaggg gaagataaag atggtcacac aaacagtttc cataaagatg 5640
tacatattca ttatacttct gacctttggg ctttcttttc tactaagcta aaaattcctt 5700
tttatcaaag tgtacactac tgatgctggt tgttgactg agagcacgta ccaataaaaa 5760
tgtaacaaa atat 5774

<210> 67

<211> 5535

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 67

ggactttaga agccgttgc gccctctctg tcacctgaag cggggccctc tcccatccca 60
cccttgcccc gcctccctgc cccacccggg ccggccctgc ccgcgcggg accctggcat 120
gtcaagacct ggtccgcgc tgctgcca gcccgcgaa cccggcggc ccgcgagct 180
aggatgaggg gccaggcgc cgcggcggc cccgtctgga tctcgcccc gctgctactg 240
ctgctgctgc tgctgggacg ccgcgcgcgg gcggccgccc gagcagacgc ggggccccgg 300
cccgagccgt gcgccacgt ggtgcaggga aagttcttcg gctacttctc cgcggccgcc 360
gtgttccccg ccaacgcctc gcgtgctcc tggacgtac gcaaccggga cccgcggcgc 420
tacactctct acatgaaggt ggccaaggcg cccgtgccct gcagcgcccc cggccgcgtg 480
cgcacctacc agttcgactc cttcctcgag tccacgcgca cctacctggg cgtggagagc 540
ttcgacgagg tgctgcggct ctgcgacccc tccgcacccc tggccttctt gcaggccagc 600
aagcagttcc tgcagatgcg gcgccagcag ccgccccagc acgacgggct ccggccccgg 660
gccgggcccgc cgggccccac cgacgacttc tccgtggagt acctggtggt ggggaaccgc 720
aaccacagcc gtgccgcctg ccagatgctg tgccgctggc tggacgcgtg tctggccggt 780
agtcgcagct cgcacccctg cgggatcatg cagaccccct gcgcctgcct gggcggcgag 840
gcgggcggcc ctgccgcggg acccctggcc cccgcgggg atgtctgctt gagagatgcg 900
gtggctggtg gccctgaaaa ctgcctcacc agcctgaccc aggaccgggg cgggcacggc 960

-218-

gccacaggcg gctggaagct gtggtccctg tggggcgaat gcacgcggga ctgcggggga 1020
ggcctccaga cgcggacgcg cacctgcctg cccgcgccgg gcgtggaggg cggcggctgc 1080
gaggggggtgc tggaggaggg tcgccagtgc aaccgcgagg cctgcggccc cgctgggcgc 1140
accagctccc ggagccagtc cctgcgggtcc acagatgccc ggcgggcgga ggagctgggg 1200
gacgagctgc agcagtttgg gttcccagcc cccagaccg gtgaccagc agccgaggag 1260
tggtccccgt ggagcgtgtg ctccagcacc tgcggcgagg gctggcagac ccgcacgcgc 1320
ttctgcgtgt cctcctccta cagcacgcag tgcagcggac ccctgcgcga gcagcggctg 1380
tgcaacaact ctgccgtgtg cccagtgcac ggtgcctggg atgagtggtc gccctggagc 1440
ctctgctcca gcacctgtgg ccgtggcttt cgggatcgca cgcgcacctg caggcccccc 1500
cagtttgggg gcaaccctg tgagggccct gagaagcaaa ccaagttctg caacattgcc 1560
ctgtgccctg gccgggcagt ggatggaaac tggaatgagt ggtcgagctg gagcgctgc 1620
tccgccagct gctcccaggg ccgacagcag cgcacgcgtg aatgcaacgg gccttctac 1680
gggggtgcgg agtgccaggg ccaactgggtg gagacccgag actgcttct gcagcagtgc 1740
ccagtggatg gcaagtggca ggcctgggcg tcatggggca gttgcagcgt cacgtgtggg 1800
gctggcagcc agcgacggga gcgtgtctgc tctgggccct tcttcggggg agcagcctgc 1860
caggggcccc aggatgagta ccggcagtgc ggcaccagc ggtgtcccga gccccatgag 1920
atctgtgatg aggacaactt tgggtgctgtg atctggaagg agacccagc gggagaggtg 1980
gctgctgtcc ggtgtccccg caacgccaca ggactcatcc tgcgacggtg tgagctggac 2040
gaggaaggca tcgcctactg ggagcccccc acctacatcc gctgtgtttc cattgactac 2100
agaaacatcc agatgatgac ccgggagcac ctggccaagg ctcagcgagg gctgcctggg 2160
gaggggggtct cggaggtcat ccagacactg gtggagatct ctcaggacgg gaccagctac 2220
agtggggacc tgctgtccac catcgatgtc ctgaggaaca tgacagagat tttccggaga 2280
gcgtactaca gccccacccc tggggacgta cagaactttg tccagatcct tagcaacctg 2340
ttggcagagg agaatcggga caagtgggag gaggcccagc tggcggggcc caacgccaaag 2400
gagctgttcc ggctgggtgga ggactttgtg gacgtcatcg gcttccgcat gaaggacctg 2460
agggatgcat accaggtgac agacaacctg gttctcagca tccataagct cccagccagc 2520

-219-

ggagccactg acatcagctt ccccatgaag ggctggcggg ccacgggtga ctggggccaag 2580
gtgccagagg acaggggtcac tgtgtccaag agtgtcttct ccacgggggt gacagaggcc 2640
gatgaagcat ccgtgtttgt ggtgggcacc gtgctctaca ggaacctggg cagcttcttg 2700
gccctgcaga ggaacacgac cgtcctgaat tctaagggtga tctccgtgac tgtgaaaccc 2760
ccgcctcgct cctgcgcac acccttggag atcgagtgtt cccacatgta taatggcacc 2820
accaaccaga cctgtatcct gtgggatgag acggatgtac cctcctcctc cgtccccccg 2880
cagctcgggc cctggtcgtg gcgcggctgc cgcacgggtc cctcgacgc cctccggacg 2940
cgctgcctct gtgaccggct ctccaccttc gccatcttag cccagctcag cgcgcacgcg 3000
aacatggaga aggcgactct gccgtcgggt acgctcatcg tgggctgtgg cgtgtcctct 3060
ctcaccctgc tcatgctggt catcatctac gtgtccgtgt ggaggtacat tcgctcagag 3120
cgttctgtca tctcatcaa cttctgcctg tccatcatct cctccaatgc cctcatcctc 3180
atcgggcaga cccagacccg caacaagggt atgtgcacgc tgggtggccgc cttcctgcac 3240
ttcttcttcc tgtcctcctt ctgctgggtg ctcaccgagg cctggcagtc ctacatggcc 3300
gtgacggggc acctccggaa ccgcctcatc cgcaagcgct tcctctgcct gggctggggg 3360
ctccctgcac tgggtgtggc catttctgtg ggattcacca aggccaaagg gtacagcacc 3420
atgaactact gctggctctc cctggagggg ggactgctct atgccttcgt gggacctgcc 3480
gctgccgttg tgctggtgaa catggtcatt gggatcctgg tgttcaacaa gctcgtgtcc 3540
aaagacggca tcacggacaa gaagctgaag gagcgggcag gggcctcctt gtggagctcc 3600
tgcggtggtg tgccgctgct ggcgctgacc tggatgtcgg ctgtgctcgc cgtcaccgac 3660
cgccgctccg cctcttcca gatcctcttc gctgtcttcg actcgtgga gggcttcgtc 3720
atcgtcatgg tgactgtat cctccgtaga gaggtccagg acgctgtgaa atgccgtgtg 3780
gttgaccggc aggaggagg caacggggac tcaggggggt ccttccagaa cggccacgcc 3840
cagctcatga ccgacttcga gaaggacgtg gatctggcct gtagatcagt gctgaacaag 3900
gacatcgcg cctgccgcac tgccaccatc acgggcacac tgaagcggcc gtctctgccc 3960
gaggaggaga agctgaagct ggcccatgcc aagggggcgc ccaccaattt caacagcctg 4020
ccggccaacg tgtccaagct gcacctgcac ggctcaccct gctatcccgg cgggcccctg 4080

-220-

cccgaacttcc ccaaccactc actgaccctc aagagggaca aggcgcccaa gtctctcttc 4140
gtcggtgacg gggacatctt caagaagctg gactcggagc tgagccgggc ccaggagaag 4200
gctctggaca cgagctacgt gatcctgccc acggccacgg ccacgctgcg gcccagccc 4260
aaggaggagc ccaagtacag catccacatt gaccagatgc cgcagaccgc cctcatccac 4320
ctcagcacgg cccccgaggc cagcctcccc gcccgagcc cgcctcccg ccagcccccc 4380
agcggcgggc cccccgaggc acccctgcc cagccccac cgcctccgc ccacccgcca 4440
ccacctcccc agcagccct gcccccacgc cccaatctgg agccggcacc cccagcctg 4500
ggggatcccg gggagcctgc cgcccatccg ggaccagca cggggcccag caccaagaac 4560
gagaatgtcg ccaccttgtc tgtgagctcc ctggagcggc ggaagtgcg gtatgcagaa 4620
ctggactttg agaagatcat gcacaccgc aagcggcacc aagacatgtt ccaggacctg 4680
aaccggaagc tgcagcacgc agcggagaag gacaaggagg tgctggggcc ggacagcaag 4740
ccggaaaagc agcagacgc caacaagagg ccctgggaga gcctccggaa agcccacggg 4800
acgcccacgt ggggtaagaa ggagctggag ccgctgcagc cgtcgccgct ggagcttcgc 4860
agcgtggagt gggagaggtc gggcgccacg atcccgtgg tgggccagga catcatcgac 4920
ctccagaccg aggtctgagc ggggtggcg cggccacgca ctgggccacg gaggaggat 4980
gctgctccgc ccgctcctgc cgcagacggg cacagacacg ctcgcgggca gcgggccagg 5040
cccgaccccc ggcctcaggg cgctcagacg gcggccaggc acagggcccg cagtgtctgg 5100
accagagcca gatgcaggac aggaggcggc ccggccagcg ggcacagggc accagaggcc 5160
gaaggtgcct cagactccgc cctcctcggg ccgaggccca gcgggcagat gggcggacgg 5220
ctgtggaccg tggacaggcc cagcggggc agcgtcccag ggtaccgccc tgagctcctg 5280
ctgcggagga gctgcctgct tggcccggcc ggcctggcac cgttttttaa acacccccat 5340
ccctcgggaa gcagccagct cccacacct tccagggcc taggcccctc ctagaccag 5400
gtggagggca cagccctccg accctcatgg ccccagggg caggactgag tcccctccag 5460
gaagaagcag gggggaatct atttttctc tccttttctt ttcttcaata aaaagaatta 5520
aaaacccaaa aaaaa 5535

-221-

<210> 68
<211> 398
<212> DNA
<213> Unknown

<220>
<223> Description of Unknown Organism:Unknown

<400> 68
cggggcaacc cgctggagtg gacgggccag gtgacggtgc gcaagaagcg caagccctac 60
tccaagtacc agacgctcga gctcgagaag gagttcctct tcaacgcgta cgtcagcaag 120
cagaagcgct gggagctggc gcgcaacctc aacctcaccg agcgccaggt caagatctgg 180
ttccagaacc ggcgcataaa gaacaagaag aacagccagc gccaggcggc cagcagcagc 240
agcagcaaca gcagcagcag cagcagcagc aacagcagca agcgggcgcc ggcggggctgt 300
cgggcgccgc caacggccac caggggccacc aagcgcacca ccacgcgccc cccaacggcg 360
ccgtcgagc cctcaagcac caccagtgc cgttagcg 398

<210> 69
<211> 8670
<212> DNA
<213> Unknown

<220>
<223> Description of Unknown Organism:Unknown

<400> 69
cccgggtgcg gtgtcgtgtg tggggctggg cgccatgttc ctggacatgc tgagggccaa 60
gcgcgacacg gcgcccagc gccgcccagc ggacgaccgg atgatggggg cggacccggg 120
ggacatagcg gccaaagtga gggcagggtt ttgcgtgcgt gcttgattgt gcgtgtgcgt 180
gcgtgcgtgc gtgcgtgcgg tgttgcgtgt gtatttgaac tgtgttttgt gtatgtactt 240
aggggtaaga gtgcatacac atgcatgcga ccggtggcct taaaaatcaa caacacgtac 300
gcctgcatgt atccagggtg cagcgtggcg acgagcacgt ggcttcgagg gccaggcac 360
ggcgggcccc agcggcagcg ccgcccagtg cagcgggcgc agcggtcgg caccgcaggc 420
gcgtcgccc cgacctcagc caccgcggcc gcgtcacct tcacgcgggt gaaccccggc 480
gaggagccgc ccgtgtacgc gtgcgagcaa acagggtcgt aagcgacgtg tgggcagcgc 540
gaagaggcgt gggggcgaga gagcaaaggg actagggaac cgacagcca aatacgggtat 600

-222-

gcgggcaacg aggcgatggc cctggaaatc gcagggccct tttgaaatcg tgtaaggcgc 660
aattgctggg cgactaccgt agtctactga tgcattgcac tacttgtatt actgtatcct 720
actgcagtag tgcggttgcc agccgcgctg ctgccctttg gctcccttcc caatccaaat 780
ggcccatgcc tcgcgcactc cgagcaccca gagcacccag aagccgttgc gtgcgctccg 840
ccgcgcacct ctcccccgcc ttcacttctt aattaatcgt gaatgtaatc cccccccccc 900
ccgcttctctc aggcctgggtg cacgtgtgcg cgacgcctgc acggagggtg tggatgatgc 960
ccgcagcgaa ctgctgggtg gcccggtgag tcgacgagga ggagggtgcaa gggggatacc 1020
agcgcgtggt tctcagggcc tgtgtgggac accgaaacgt ggtaaaagag acccgcccgc 1080
gaactgtgta tgtggagtag cgtggcgtgt gcggccggac cgacaaggca gcttgtggac 1140
tgccccacgt tgcagagtca gctgacaacg acacgtgcgc ctctctgtca ttgccgtgc 1200
gcacgcacgt cctccgcact cccaacaaat tgacagcgac acgtgcgcct tcctataagc 1260
ctatgcccgc acacgtctcc gcgccctcag gtgtcggggc agaccacaga ccggttggtc 1320
cacgagtgcg aggaggatga ggccggcgcc tgccggcgccg ccggccggggc gccgcggcga 1380
ggaggacggc ctgggactgg gcatcacagg tgggtggcag gctggcaggg actcacgcat 1440
gggccttgta cgtgactgcg gttctgcatg gctagtggct cacgcgctgc gcacgttcac 1500
gtacggcttg tgggcatgca gtgccttgac gtgaggctgc gctgccttgc tgctgccgcc 1560
ttgccccgct ccctgcacac actgcagccg gcttcggggc ctacttcacc gcgggctacg 1620
agtgcgagaa cgcgcagcag ctcaacaggc tgctggggta caaggcgctg tgagagcgcg 1680
ccgcaggggg agtgtgttca tattgtggtt gtttggggccg tgggcgcggg ctgcatgtgc 1740
gtattgcacg cgtacagcat tgggtgactg tcagggtgtaa gcggccggca gtgcgcgcgcg 1800
aggcgtgca gcgagttgtg gggcatgcgt catgcgcaga cggcccctgg acgacaaggc 1860
gttgagttgg cgtttggagg tgtgggacga cgtgggggtt gtgccgtcaa agcacagaac 1920
agaaggcgtg accgttttac gagctcgtat gatgtagcat ggattgaata atgacatgtg 1980
atttttgtta caagcgacga atgcgtgggg ttttgatgg caggggtttc agtcgcccga 2040
ttgcgcatgc acacgtgacc aaatttatgc tcaacgacgt gaccattgct ttatacatac 2100
ttgtgtatcg gttggcactt ataacaattg gctcgtcaaa ttgacgcgag gctgcacttc 2160

-223-

gatcctgaaa gccccagttc aacaagtcgg atagccaaat ggccccgctc gctctccage 2220
atcaaggggc ctctaagtgc ctgcggcaa cccagcgcaa gtgtgctgc gttgcggtga 2280
gctggactcg tgcacttgct gacgccgtcg gcaccgcaat cgaaagacgc gtgcgtcgag 2340
caattgtgga agccgctgac gaattgtccg catgtgacat tgcaggctcg cgtccccgct 2400
cgtctcagcg tcatggccca ggtgcggacg ttgggactgc acttgacga atgtgatggg 2460
gccgcaccga gtctgcgcgg acgtctcgct gacgtttcgc gttgaatgca tctcgcaata 2520
ggcagctgct gcgcctgctg acaacactaa gaagctgtgg ggcggtcgct tcacgggcaa 2580
gacggacccg ctcatggaga agttcaacga gtcgctgccc ttgacaagc gcctgtgggc 2640
tgaggacatc aaggtgcggc acagggaggg gggcgagtgg tggggtgggg ctggggggga 2700
cgcggtttg gtggccaggg cagggagggg agacgtgcgg ggctaggcaa gaggctgcga 2760
gggcccaggg taacaccaga ccgtgccgtg tcgctgccc ggcttgctgc ccacctgcc 2820
cggccatccc caccgcctc cccaccagca atgacacgta cacattcaca cactccccca 2880
caccacata cccacacacc caccgattcc ccaacagggc agccaggcgt acgccaaggc 2940
tcttgccaag gccggcattc tggcacatga cgaggccgtg accattgtgg aggggctggc 3000
caaggtgcgc acaccggca gcagggcggg tgggtgggtg ggtgggtggg gggggcagag 3060
agaggcgcg gctgagagg ggctgagagg ggggtcagcg aggcgcaggc tcagggggag 3120
gcgtctgagg ggggctgaga tgggtgggtg ggagctgcgg gtgctggggc tgctgcggtg 3180
gcgggcgggc gggcgggcg gcgacgtgta cgtgagtagc cgctgaccgg gcgtggggc 3240
tttgcgacg ccacagcca catgacaccg ccgcaaggcc cgccgcgcc caccacggt 3300
cacacactcc ccacaccac gcgtgcgcgc gcctccttcc cctcaataca cgcgcctcct 3360
tcccctggcc ccgcctgct ccccccaccc ggccgcccc cctgcagggtg gctgaggagt 3420
ggaaggcggg tgcctttgtg atcaaggcgg gtgacgagga catccacacg gccaacgagc 3480
ggcgccctcac ggagctggtg ggggcggtg gcggcaagct gcacaccggc cgctcgcga 3540
acgaccaggt gaggggtggg ggggtggggg ggggtgggtg ggtgggtggg tgggtgggtg 3600
ggtgggtggg tgggtgggtg ggtgggtggg ggtttgagat accggtacca ggccaaacta 3660
aaccgaaccc aagggggtgg cgtagggcg tgggagggg ggagtgcga agccgggagg 3720

caggagtaag ggcgggagga gggggccgga ggagaagcag ggacgaagtc gatgacaggc 3780
gcagtcggtg gcggcggtgg cgggtgtgcc gttgtgcagt ggctgtggag gccatgtgca 3840
gggcggcggc ggggcccggc cgggggtggg agacttgtcc agaccccggtg gccctcttcc 3900
agccccgtcc gccactgccg ccaccaccac cgccgccgcc gtagccacca cccctcacgt 3960
cgaggcactt cacagatgcg aagcaaccac accgttctcc acatgaacag ctaccctccc 4020
aaaccaact ttcccttccc gccttaccta accatgacco gctaccccc cccctttat 4080
ttcttaacta accatgaatg ccccccccg gctgtacctg gctacgactt cacttcgtaa 4140
acttaatgtg tgtaaccccc cttacacaca cacacacacc cctccccgcc cctccaaagg 4200
ttgccaccga ctaccggctg tggctggtgg gtcagggtgga ggtgatgcgg tccgaggtgg 4260
gcgagctgat gcgcgtggcg gcggaccgct ccgaggcaga ggtggagggtg tcatgccgg 4320
gtgagggggc agggaggggg ggagggggag ggggaggtgc tcatgccggg gagggtaggg 4380
aggggagggg cagaggaggg agggggagga gggggcggt gagtgcggga gaggcagga 4440
tgagggcgat agaaagttgc gtattgtcgg taaactcaa ggactagacg aagagaacaa 4500
acctaataaa gggagctgga gcgaggccaa atctgaacgt gacatcgccc gcctcctccc 4560
gctgcctgct ccccccacctc cccccccatc tcgccccccc cccacacac acacaggctt 4620
cacgcacctt cagaatgcca tgactgtgcg ctggagccac tggctgatga gccacgccgc 4680
ggcctggcag cgcgacgaca tgcggctgcg ggacctgctg ccgcgggtgg ccacactgcc 4740
gctgggctcg ggtgggtgag ggaggggagg ggaggggagg gggggagggg gagggagagg 4800
aggggagaag ggggggggag acgaggaggg tggaaagggtg ggggcggggc ggtggaggct 4860
agaggggtgg gctgggtggg tggacggagt gcactggtag aggagggata gggtagattg 4920
agacgggagg agggatgcag gggcgaagggt ggggaggagg ggaggggagg aggcgtggag 4980
ctggagtggg ccgacgagtg tgcggacggg gcaggcggca acggggatta aacggcgggg 5040
ggccggggcg tgtgcacgac aggggcttgc gcgtctgcga ttgtgggggc acacagggac 5100
aggagcacga cgtgggacac gcatagatac gccgattga caacacacac acacacacac 5160
acacacacac acacacacac acacacacaa acacaaacac acacaaacac aaacacacac 5220
acgccccccc ccctacacac acgccccctc ccaggcgcc ctggccggca acccctttct 5280

ggtggaccgc cagttcatcg ccaaggagtt gggtttcggc ggcggcgtgt gccccaaactc 5340
catggacgcg gtgaggggag gaggaggggg aggagggcg gggggggcag gaggggggag 5400
gaggaggggg ggaggggggt aactttgaag cgtaaggaaa cagtcgggag gaggggggga 5460
aggagggggc ctggaggagg gggggaggag gaggggtggct ggagggggct gggggaggag 5520
gaggggggag attgggagg ggctggggga ggggtcccgc agctggggga ggtggggagg 5580
gaggggggtg ctgctggtgt aaagggcctg taggcactga gagcactgtg gggagccggg 5640
gtactgcctg gggccccgcg ctgcagaggt gtcgcgcagt gtggcggcgc atccccgcga 5700
tccccacacg cggggccgctg ccgctgcccg ccacaccctt gccactttgt gtgctttcct 5760
aggatataca cacacacaca cacacacaca cacacacaca cacacacaaa cacaaacaca 5820
cacgggcgcg ggctttcggt tcgtttttta acacaaacac aactcccc tgtgctcctc 5880
aacacactcc atctttctca cacaaacaca cagcacaca cacatgcgca ggtgtctgac 5940
cgcgactttg tgatcgagac ggtgtttgag gccagcctgc tgtgcgtgca cctgtcgcgc 6000
tgggcggagg acctcatcat ctacagctcc ggccccttcg gctacgtgca gtgcagcgac 6060
gcctacgcca ccggctcctc gtcctgcccg cagaagaaga accccgacgc cctggagctc 6120
atcagggtgc ggagggatgg ggtgggggtg ggggggttac attcatgggt agttaagaag 6180
tgaaggcgta ggggggtgat ggggtgggtt acattcatga acatttaaga agtgaaggcg 6240
tagccaggaa cagtagtaga gcagacgcgt tgtagtgtgt gggtttgggt gggagggatg 6300
gttgggtaaa gcggtacagg atgtactgag gactgcagac cgaaggagcg ggggaggggg 6360
agcaggcagg cggggcgagg ggcgtggggg cgggggttac tggcaccgtg ccgggtaagc 6420
aacacgtgac acggagatgc accacacaaa gagggacgtg gggagtggca ggcggggggc 6480
agggctgaga ggcgcgtgtg gaggggtgag ggggtggcg ggggctgtt tcatgatacc 6540
gctgcctcca cctcctccac cgctcctgc cacctccacc tccccactg cccctccccg 6600
cctcctcctg ctgcaggggc aagggcggtc gtgtgcagg caacctgatg ggcgtcatgg 6660
cggtgctcaa gggcacgccc accacataca acaaggactt ccaggcgaga gagcgagagc 6720
gagggaggga gggagagcga gggagaggga gggagaggga gggagaggga gacagaggga 6780
cagggacagg gacagggaca gggacaggga cagggacagg ggcaggggca ggggcagggg 6840

-226-

caggggcagg ggcaggggag gccccccggg ggcgggcggc ccggggcatg aggtcagaca 6900
taggggcgct gcactgaggc cgcgagggcg gcgggaggca gggggcgggg ggcggggggc 6960
gggagcggac atgcgccgca aacacagacg ggttgagaaa gcacaacgac tggaacgcag 7020
tgggcttact gacaattcat cattgtgcgc atatgtgtgt atgtgtatgt gtgtgtttgt 7080
ttgtgcagga gtgttgggag ctgctgtttg acacgggtga cacgggtcac gacgtggtgc 7140
gcatcgccac cggcgtgctg tccaccctgc ggatcaagcc cgaccgcatg aaggccggtg 7200
agcgtagccg agcagggctg gagcagcagc cgggcagcag tagcagcagg gcaggggagc 7260
agcgggagcg ggagcagcag gaggggtggt tgggaagcgg tgggggtagg gtgggagcgg 7320
aggaagggaa ggaggagcag gagcaggagg aagaggagga ggaagggcgg tgggggggtg 7380
ggggtcgtgt ccttgggcgc atgggcggag gcggggaggc ggggaggagg cggggaagca 7440
gagcctgcac ccacgctccg cgggtcccta ccgtcttgcg cctaaccctg tgcgcctagc 7500
ctcttgccgc cacccttcta gtgcatcctg taccctctt tccaaacatc cttgcaactc 7560
cctgacctcc tcgccaacc tccccgccc ccaggcctgt ccgccgacat gctcgccacg 7620
gacttgcccg agtacctggt gcgcaagggc gtgccgttcc gggagacaca ccaccacagg 7680
tgcggccggg cgggagggcg tgagggcgtg ggtggggcat gccgggggtt gtgagagcta 7740
tcgaacgttg tgccgcgcct gtttcacaat gtcggggcac agggtatgca gtttcctctc 7800
catatgtata acaaactgac caccaatcat gcacgctcac acgctctccc acacacacgc 7860
gcaccacgcc accacagcgg cgccgccgtg aagatggccg aggaccgcgg ctgcacgctg 7920
ttcgacctca ccgtggacga cctcaagacc atccaccgc tcttcaccga cgacgtggcg 7980
gcggtgagcg gcggcgcgga gcagcagcag cagcagcagc agcagcagca gcagcagcag 8040
tagcctgggg gggagcgtgt gggaggaacg gcgggggagg ggaggcgggg ggtgtcgttt 8100
gcagccgagc gcacgtggtg ctttgcccca ttccatgcca gcagggtgac acacctgacc 8160
atgctggtgt gctgctaggt gggtcacacc tacgtgtgaa tttgtgctgg cgtgcgcaca 8220
ccttactgtg gccatgtgaa cggcatcctc atgtcctcgt gattgcgccc ggcacattgc 8280
ccacaacccc gcaccaccca gtcctcaat ccagtgaag gaaaggaaat gcacgcccgc 8340
cgcaccaaca acacgacgca tgtgtttgcc acgtgcgcgc acacacgcgc aggtgtggga 8400

-227-

cttcaaccgc agcgccgaga tgcgcgacac ggagggcggc accagcaagc gtcggtgct 8460
ggagcagggtg cagaagatgc gcacctacct ggcgggcgag ggacagcact gagcgggtcg 8520
ggggaggggg ggcggtgtg tatgtgtgtg tgtgtgcgtg tgtaagtctc ggtggagggg 8580
tggtcctcta tatggcggcg gggccacagg gggacgggtg tgacagagtt acggccggag 8640
ccagcggagt cccgggatgg attaaggatc 8670

<210> 70

<211> 745

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 70

atgagatggc gacgcgcccc gcgccgctcc gggcgtccc gccccgggc ccagcgcccc 60
ggctccgccc cccgctcgtc gccgcccgtg ccgctgctgc cactactgct gctgctgggg 120
accgcggccc tggcgccggg ggcgggcgcc ggcaacgagg cggctcccgc gggggcctcg 180
gtgtgctact cgtccccgcc cagcgtggga tcggtgcagg agctagctca gcgcgccgcg 240
gtggtgatcg agggaaaggt gcacccgcag cggcggcagc agggggcact cgacaggaag 300
gcggcgggcg cgcgggcgga ggcaggggcg tggggcgggc atcgcgagcc gccagccgcg 360
ggcccacggg cgctggggcc gcccgccgag gagccgctgc tcgccgcaa cgggaccgtg 420
ccctcttggc ccaccgcccc ggtgcccagc gccggcgagc ccggggagga ggcgcctat 480
ctggtgaagg tgcaccaggt gtgggcggtg aaagccgggg gcttgaagaa ggactcgctg 540
ctcacgctgc gcctggggac ctggggccac cccgccttcc cctcctgcgg gaggctcaag 600
gaggacagca ggtacatctt cttcatggag cccgacgcca acagcaccag ccgcgcgccg 660
gccgccttcc gagcctcttt cccccctctg gagacgggcc ggaacctcaa gaaggaggtc 720
agccgggtgc tgtcaagcg gtgcg 745

<210> 71

<211> 1986

<212> DNA

<213> Unknown

-228-

<220>

<223> Description of Unknown Organism:Unknown

<400> 71

gaattccttt tttttttttt ttttttcttt ttttttttgc ctttatacct cttcgccttt 60
ctgtggttcc atccacttct tccccctcct cctcccataa acaactctcc tacccttgca 120
cccccaataa ataaataaaa ggaggagggc aaggggggag gaggaggagt ggtgctgcga 180
ggggaaggaa aaggagggca gcgcgagaag agccgggcag agtccgaacc gacagccaga 240
agcccgcacg cacctcgcac catgagatgg cgacgcgccc cgcgccgctc cgggcgtccc 300
ggcccccggg ccagcgccc cggtccgccc gcccgctcgt cgccgcccgt gccgctgctg 360
ccactactgc tgctgctggg gaccgcggcc ctggcgccgg gggcggcggc cggcaacgag 420
gcggtccccg cgggggcctc ggtgtgctac tcgtccccgc ccagcgtggg atcggtgcag 480
gagctayctc agcgcgccgc ggtggtgatc gagggaaagg tgcacccgca gcggcggcag 540
cagggggcac tcgacaggaa ggcggcggcg gcggcgggcg aggcaggggc gtggggcggc 600
gatcgcgagc cgccagccgc gggcccacgg gcgctggggc cgcccgccga ggagccgctg 660
ctcgccgcca acgggaccgt gccctcttgg cccaccgccc cggtgcccag cgccggcgag 720
cccggggagg aggcgcctta tctggtgaag gtgcaccagg tgtgggcggt gaaagccggg 780
ggcttgaaga aggactcgt gtcaccgtg cgcttgggga cctggggcca cccgccttc 840
ccctcctgcg ggaggctcaa ggaggacagc aggtacatct tcttcattga gcccgacgcc 900
aacagcacca gccgcgcgcc ggccgccttc cgagcctctt tccccctct ggagacgggc 960
cggaacctca agaaggaggt cagccgggtg ctgtgcaagc ggtgcgcctt gcctcccca 1020
ttgaaagaga tgaaaagcca ggaatcggct gcaggttcca aactagtcct tcggtgtgaa 1080
accagttctg aatactctc tctcagattc aagtggttca agaattggaa tgaattgaat 1140
cgaaaaaaca aaccacaaaa tatcaagata caaaaaaagc cagggaagtc agaacttcgc 1200
attaacaaag catcactggc tgattctgga gagtatatgt gcaaagtgat cagcaaatta 1260
ggaaatgaca gtgcctctgc caatatcacc atcgtggaat caaacgctac atctacatcc 1320
accactggga caagccatct tgtaaaatgt gcggagaagg agaaaacttt ctgtgtcaat 1380
ggaggggagt gcttcattgt gaaagacctt tcaaaccctt cgagatactt gtgcaagtgc 1440

-229-

ccaaatgagt ttactggtga tcgctgcaa aactacgtaa tggccagctt ctacagtacg 1500
tccactccct ttctgtctct gcctgaatag gagcatgctc agttggtgct gctttcttgt 1560
tgctgcatct cccctcagat tccacctaga gctagatgtg tcttaccaga tctaattattg 1620
actgcctctg cctgtcgcct gagaacatta acaaaagcaa ttgtattact tcctctgttc 1680
gcgactagtt ggctctgaga tactaatagg tgtgtgaggc tccggatgtt tctggaattg 1740
atattgaatg atgtgataca aattgatagt caatatcaag cagtgaataa tgataataaa 1800
ggcatttcaa agtctcactt ttattgataa aataaaaaatc attctactga acagtccatc 1860
ttctttatac aatgaccaca tcctgaaaag ggtgttgcta agctgtaacc gatatgcact 1920
tgaaatgatg gtaagttaat tttgattcag aatgtgttat ttgtcacaaa taaacataat 1980
aaaagg 1986

<210> 72
<211> 2003
<212> DNA
<213> Unknown

<220>
<223> Description of Unknown Organism:Unknown

<220>
<221> UNSURE
<222> (31)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (32)
<223> May be any nucleic acid

<400> 72
ggaattcctt tttttttttt tttttttctt nntttttttt tgcccttata cctcttcgcc 60
tttctgtggt tccatccact tcttccccct cctcctccca taaacaactc tcctaccctt 120
gcacccccaa taaataaata aaaggaggag ggcaaggggg gaggaggagg agtggtgctg 180
cgaggggaag gaaaaggag gcagcgcgag aagagccggg cagagtccga accgacagcc 240
agaagcccg cgcacctcg caccatgaga tggcgacgag ccccgcgccg ctccgggctg 300
cccgcccccc gggcccagcg ccccggtcc gccgcccgt cgtcgcccgc gctgccgctg 360

-230-

ctgccactac tgctgctgct ggggaccgcg gccctggcgc cgggggaggc ggccggcaac 420
gaggcggctc ccgcgggggc ctcggtgtgc tactcgtccc cgcccagcgt gggatcggtg 480
caggagctag ctcagcgcg cgcggtggtg atcgaggaa aggtgcaccc gcagcggcgg 540
cagcaggggg cactcgacag gaaggcggcg gcggcgggcg gcgaggcagg ggcgtggggc 600
ggcgatcgcg agccgccagc cgcggggcca cgggcgctgg ggccgcccgc cgaggagccg 660
ctgctcgccg ccaacgggac cgtgccctct tggcccaccg ccccggtgcc cagcgccggc 720
gagcccgggg aggaggcgcc ctatctggtg aagggtgcacc aggtgtgggc ggtgaaagcc 780
gggggcttga agaaggactc gctgctcacc gtgcgcctgg ggacctgggg ccaccccgcc 840
ttcccctcct gcgggaggct caaggaggac agcaggtaca tcttcttcat ggagcccgac 900
gccaaacagca ccagccgcg gccggccgcc ttccgagcct ctttcccccc tctggagacg 960
ggccggaacc tcaagaagga ggtcagccgg gtgctgtgca agcgggtgcgc cttgcctccc 1020
caattgaaag agatgaaaag ccaggaatcg gctgcaggtt ccaaactagt ccttcggtgt 1080
gaaaccagtt ctgaatactc ctctctcaga ttcaagtggg tcaagaatgg gaatgaattg 1140
aatcgaaaaa acaaaccaca aaatatcaag atacaaaaaa agccaggga gtcagaactt 1200
cgcattaaca aagcatcact ggctgattct ggagagtata tgtgcaaagt gatcagcaaa 1260
ttaggaaatg acagtgcctc tgccaatatc accatcggtg aatcaaacgc tacatctaca 1320
tccaccactg ggacaagcca tcttgtaaaa tgtgcggaga aggagaaaac tttctgtgtg 1380
aatggagggg agtgcttcat ggtgaaagac ctttcaaacc cctcgagata cttgtgcaag 1440
tgcccaaagt agtttactgg tgatcgctgc caaaactacg taatggccag cttctacagt 1500
acgtccactc cttttctgtc tctgcctgaa taggagcatg ctgagttggt gctgctttct 1560
tgttgctgca tctcccctca gattccacct agagctagat gtgtcttacc agatctaata 1620
ttgactgcct ctgcctgtcg catgagaaca ttaacaaaag caattgtatt acttcctctg 1680
ttcgcgacta gttggctctg agataactaat aggtgtgtga ggctccggat gtttctggaa 1740
ttgatattga atgatgtgat acaaattgat agtcaatatc aagcagtgaa atatgataat 1800
aaaggcattt caaagtctca cttttattga taaaataaaa atcattctac tgaacagtcc 1860
atcttcttta tacaatgacc acatcctgaa aagggtgttg ctaagctgta accgatatgc 1920

-231-

acttgaaatg atggtaagtt aatttttgatt cagaatgtgt tatttgtcac aaataaacat 1980
aataaaaagga aaaaaaaaaa aaa 2003

<210> 73
<211> 957
<212> DNA
<213> Unknown

<220>
<223> Description of Unknown Organism:Unknown

<220>
<221> UNSURE
<222> (809)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (810)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (811)
<223> May be any nucleic acid

<400> 73
tctcgcccca actttttccc ccgcgctccg cagcagcagc agcagcagca gcagcagcag 60
caaaatggca gacctcttca gcggactcgt gggcggcgtc gtcggcgctg ttgctgcagc 120
agatttgctt gcggagggcg agagggcccc ccgccccgcc cccggcactg cctggacttg 180
ctgctgcagc aaactgcaag aaggggcccc cgagctggag ggttttgtgc agcagctgag 240
ttttgttgca ggaagctgg cctgctgcct gcgggtgggg gcggagcagc tggcgcgctg 300
cgctgcggag gggcggtgct ccagcagcag cagcagcagc agctgctgct cgctgctgca 360
gctcgagaag caggacctcg agcagagcct cgaggccggc aagcagggcg cggagtgcct 420
cttgaggagc agcaactgg ccctcgaggc cctcctcgag ggggcccgcg ttgcagcaac 480
gcgggggttg ctgctggctg agagcagcaa agacacggtg ctgcgcagca ttccccacac 540
ccaggagaag ctggcccagg cctacagttc tttcctgcgg ggctaccagg gggcagcagc 600
ggggaggtct ctgggctacg gggcccctgc tgctgcttac ggccagcagc agcagcccag 660

-232-

cagctacggg gcgcccccg cctccagcca gcagccctcc ggcttcttct ggtagccctg 720
 cagcagcagc agcagcagca gcagcagcag cagcgcgggc ggcagccgcg gcggggcccg 780
 ggcgcgcgtg cagcaacagc agcagccggn ncggctagcg ccgcggagca ctcgcaggga 840
 actccacagg cagcgggaga gcagcaggga cgagaagcag gtcattgtagc gcaggcagca 900
 gcgccagctg cagcagcagc agcagcagca gcagcagcag cagcagctcc tgcaccg 957

<210> 74

<211> 957

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<220>

<221> UNSURE

<222> (809)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (810)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (811)

<223> May be any nucleic acid

<400> 74

tctcgcccca actttttccc ccgcgctccg cagcagcagc agcagcagca gcagcagcag 60
 caaaatggca gacctcttca gcggactcgt gggcggcgtc gtcggcgctg ttgctgcagc 120
 agatttgctt gcggagggcg agagggcccc ccgccccgcc cccggcactg cctggacttg 180
 ctgctgcagc aaactgcaag aaggggcccc cgagctggag ggttttgtgc agcagctgag 240
 ttttgttgca gggaagctgg cctgctgcct gcgggtgggg gcggagcagc tggcgcgctg 300
 cgctgcggag gggcggtgc ccagcagcag cagcagcagc agctgctgcg cgctgctgca 360
 gctcgagaag caggacctcg agcagagcct cgaggccggc aagcagggcg cggagtgcct 420
 cttgaggagc agcaaactgg ccctcgaggc cctcctcgag ggggcccgcg ttgcagcaac 480
 gcgggggttg ctgctggtcg agagcagcaa agacacggtg ctgcgcagca tccccacac 540

-233-

ccaggagaag ctggcccagg cctacagttc tttcctccgg ggctaccagg gggcagcagc 600
ggggaggtct ctgggctacg gggcccctgc tgctgcttac ggccagcagc agcagcccag 660
cagctacggg gcgccccccg cctccagcca gcagccctcc ggcttcttct ggtagccctg 720
cagcagcagc agcagcagca gcagcagcag cagcgcgggc ggcagccgcg gcggggccgg 780
ggcgccgctg cagcaacagc agcagccggn ncggctagcg ccgcgagca ctgcagggga 840
actccacagg cagcgggaga gcagcagggga cgagaagcag gtcattgtagc gcaggcagca 900
gcgccagctg cagcagcagc agcagcagca gcagcagcag cagcagctcc tgcaccg 957

<210> 75

<211> 1089

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<220>

<221> UNSURE

<222> (376)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (377)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (847)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (848)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (849)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (850)

<223> May be any nucleic acid

-234-

<400> 75

gaattccctc caactcttctg cgactctctc tctctcgccc caactttttc ccccgcgccc 60
cgagcagca gcagcagcag cagcagcaaa atggcagacc tcttcagcgg actcgtgggc 120
ggcgtcgtcg gcgctgttgc tgcagcagat ttgcctgcgg agggcgagag ggccccccgc 180
ccgcccccg gcaactgcctg gacttgctgc tgcagcaaac tgcaagaagg ggccccgcgag 240
ctggaggggtt ttctgcagca gctgagtttt gttgcaggga agctggcctg ctgcctgcgg 300
gtggggggcgg agcagctggc gcgctgcgct gcggaggggc ggctgcccag cagcagcagc 360
agcagcagct gctgcnnct gctgcagctc gagaagcagg acctcgagca gagcctcgag 420
gccggcaagc agggcgcgga gtgcctcttg aggagcagca aactggccct cgaggccctc 480
ctcgagggggg cccgcgttgc agcaacgcgg ggtttgctgc tggtcgagag cagcaaagac 540
acggtgctgc gcagcattcc ccacaccag gagaagctgg ctcaggccta cagttctttc 600
ctgcgggggt accagggggc agcagcgggg aggtctctgg gctacggggc ccctgctgct 660
gcttacggcc agcagcagca gccagcagc tacggggcgc ccccgccctc cagccagcag 720
ccctccggct tcttctggta gccctgcagc agcagcagca gcagcagcag cagcagcagc 780
ggcggcgcca gccgcggcgg ggccggggcg ccgctgcagc aacagcagca gccgcggcgg 840
ctagcgnnnn gagcactcgc agggaaactc acaggcagcg ggagagcagc agggacgaga 900
agcaggtcta tgtagcgag gcagcagcgc cagctgcagc agcagcagca gcagcagcag 960
cagcagcagc agctcctgca ccgagcgtt gtgtcattta ttacgttggc agctctgagg 1020
cctcggcgca gccaacgcgc ctcaggtatc tttcagactc ttttctctaa ggtcttccag 1080
acggaattc 1089

<210> 76

<211> 1985

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 76

cgccgagctt tcggcacctc tgccgggtgg taccgagcct tcccggcgcc ccctcctctc 60

-235-

ctcccaccgg cctgcccttc cccgcgggac tatcgcccc acgtttccct cagccctttt 120
ctctcccggc cgagccgcgg cggcagcagc agcagcagca gcagcaggag gaggagcccc 180
gtggcggcgg tggccgggga gcccatggcg tacagtcaag gaggcggcaa aaaaaaagtc 240
tgctactact acgacggtga tattggaaat tattattatg gacaggggtca tcccatgaag 300
cctcatagaa tccgcatgac ccataacttg ctgttaaatt atggcttata cagaaaaatg 360
gaaatatata ggccccataa agccactgcc gaagaaatga caaaatatca cagtgatgag 420
tatatcaaat ttctacggtc aataagacca gataacatgt ctgagtatag taagcagatg 480
catatattta atgttgagga agattgtcca gcgtttgatg gactctttga gttttgtcag 540
ctctcaactg gcggttcagt tgctggagct gtgaagttaa accgacaaca gactgatatg 600
gctgttaatt gggctggagg attacatcat gctaagaaat acgaagcatc aggattctgt 660
tacgttaatg atattgtgct tgccatcctt gaattactaa agtatcatca gagagtctta 720
tatattgata tagatattca tcatggtgat ggtgttgaag aagcttttta tacaacagat 780
cgtgtaatga cggtatcatt ccataaatat ggggaatact ttcttggcac aggagacttg 840
agggatattg gtgctggaaa aggcaaatac tatgctgtca attttccaat gtgtgatggt 900
atagatgatg agtcatatgg gcagatattt aagcctatta tctcaaaggt gatggagatg 960
tatcaacctg gtgctgtggt attacagtgt ggtgcagact cattatctgg tgatagactg 1020
ggttgtttca atctaacagt caaaggctcat gctaaatgtg tagaagttgt aaaaactttt 1080
aacttaccat tactgatgct tggaggaggt ggctacacaa tccgtaatgt tgctcgatgt 1140
tggacatatg agactgcagt tgcccttgat tgtgagattc ccaatgagtt gccatataat 1200
gattactttg agtatttttg accagacttc aaactgcata ttagtccttc aaacatgaca 1260
aaccagaaca ctccagaata tatggaaaag ataaaacagc gtttgtttga aaatttgcgc 1320
atgttacctc atgcacctgg tgtccagatg caagctattc cagaagatgc tgttcatgaa 1380
gacagtggag atgaagatgg agaagatcca gacaagagaa tttctattcg agcatcagac 1440
aagcggatag cttgtgatga agaattctca gattctgagg atgaaggaga aggaggtcga 1500
agaaatgtgg ctgatcataa gaaaggagca aagaaagcta gaattgaaga agataagaaa 1560
gaaacagagg acaaaaaaac agacgttaag gaagaagata aatccaagga caacagtggg 1620

-236-

gaaaaaacag ataccaaagg aaccaaata gaacagctca gcaaccctg aatttgacag 1680
 ttcaccaat ttcagaaaat cattaataaag aaaatattga aaggaaaatg ttttcttttt 1740
 gaagacttct ggcttcattt tatactactt tggcatggac tgtattttatt ttcaaatggg 1800
 actttttcgt ttttggtttt ctgggcaagt tttattgtga gattttctaa ttatgaagca 1860
 aaattttctt tctccaccat gctttatgtg atagtattta aaattgatgt gagttattat 1920
 gtcaaaaaaa ctgatctatt aaagaagtaa ttggcctttc tgagctgaaa aaaaaaaaaa 1980
 aaaag 1985

<210> 77
 <211> 476
 <212> DNA
 <213> Unknown

<220>
 <223> Description of Unknown Organism:Unknown

<400> 77
 ccacctctct cccctcccc cgccacttc gctaacttgg tggctgttgt gatgcgtatt 60
 cctgtagatc cgagcaccag ccggcgcttc agccccctt ccagcagcct gcagcccggc 120
 aaaatgagcg acgtgagccc ggtggtggct gcgcaacagc agcagcaaca gcagcagcag 180
 caacagcagc agcagcagca gcaacagcag cagcagcagc aggaggcggc ggcgggcggt 240
 gcggcgggcag cgggcggtgc ggcgggcgga gctgcagtgc cccggttgcg gccgccccac 300
 gacaaccgca ccatggtgga gatcatcgcc gaccaccggc ccgaactcgt ccgcaccgac 360
 agccccaaact tcctgtgctc ggtgctgccc tcgactggc gctgcaacaa gaccctgccc 420
 gtggccttca aggtaagagg ctaccccgcc ccccgcccc ggccgggagc ggcgga 476

<210> 78
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:DNA Primer

<400> 78
 gcattttgga tccgcctttt catg

24

-237-

<210> 79
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:DNA Primer

<400> 79
gttgtgtgct gcagattggt cc

22

<210> 80
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:DNA Primer

<400> 80
gaaaaatggg gatccgaggt g

21

<210> 81
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:DNA Primer

<400> 81
gcaggagaat tccgtccatg

20

<210> 82
<211> 5
<212> PRT
<213> Homo sapiens

<220>
<221> UNSURE
<222> (3)
<223> Can be any amino acid

<400> 82
Trp Ser Xaa Trp Ser
1 5

-238-

<210> 83
<211> 6
<212> PRT
<213> Homo sapiens

<400> 83
Cys Ser Val Thr Cys Gly
1 5

<210> 84
<211> 5
<212> PRT
<213> Homo sapiens

<220>
<221> UNSURE
<222> (4)
<223> Can be any amino acid

<400> 84
Gly Cys Gln Xaa Arg
1 5

<210> 85
<211> 733
<212> DNA
<213> Homo sapiens

<400> 85
gggatccgga gcccaaattct tctgacaaaa ctcacacatg cccaccgtgc ccagcacctg 60
aatcgcaggg tgcaccgtca gtcttctctt tcccccaaaa acccaaggac accctcatga 120
tctcccggaac tctgagggtc acatgcgtgg tgggtggacgt aagccacgaa gaccctgagg 180
tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca aagccgcggg 240
aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg caccaggact 300
ggctgaatgg caaggagtac aagtgcagg tctccaacaa agccctccca acccccatcg 360
agaaaaccat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac accctgcccc 420
catcccggga tgagctgacc aagaaccagg tcagcctgac ctgcctgggtc aaaggcttct 480
atccaagcga catcgccgtg gagtgggaga gcaatgggca gccggagAAC aactacaaga 540
ccacgcctcc cgtgctggac tccgacggct ccttcttctt ctacagcaag ctcaccgtgg 600
acaagagcag gtggcagcag gggaacgtct tctcatgctc cgtgatgcat gaggctctgc 660

-239-

acaaccacta cacgcagaag agcctctccc tgtctccggg taaatgagtg cgacggccgc 720
gactctagag gat 733

<210> 86
<211> 86
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:DNA Primer

<400> 86
gcgcctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc 60
cccgaaatat ctgccatctc aattag 86

<210> 87
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:DNA Primer

<400> 87
gcggcaagct ttttgcaaag cctaggc 27

<210> 88
<211> 271
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR Fragment

<400> 88
ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60
aaatatctgc catctcaatt agtcagcaac catagtcccc cccctaactc cgcccatccc 120
gccctaact ccgcccagtt ccgcccattc tccgcccatt ggctgactaa ttttttttat 180
ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt 240
ttttggaggc ctaggctttt gcaaaaagct t 271

<210> 89

-240-

<211> 32
<212> DNA
<213> Homo sapiens

<400> 89
gcgctcgagg gatgacagcg atagaacccc gg 32

<210> 90
<211> 31
<212> DNA
<213> Homo sapiens

<400> 90
gcgaagcttc gcgactcccc ggatccgcct c 31

<210> 91
<211> 12
<212> DNA
<213> Homo sapiens

<400> 91
ggggactttc cc 12

<210> 92
<211> 73
<212> DNA
<213> Homo sapiens

<400> 92
gcggcctcga ggggactttc ccggggactt tccggggact ttccgggact ttccatcctg 60
ccatctcaat tag 73

<210> 93
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR Fragment

<400> 93
gcggcaagct ttttgcaaag cctaggc 27

Applicant's or agent's file reference number: 1488.107PC02	International application No: TBA PCT/US 99/01313
---	--

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page 32, lines 16-17.	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depository institution American Type Culture Collection	<div style="border: 1px solid black; padding: 5px; display: inline-block;"> REC'D 26 FEB 1998 WIFO PCT </div>
Address of depository institution (including postal code and country)	
10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	formerly at: 12301 Parklawn Drive Rockville, Maryland 20852 United States of America
Date of deposit 15 January 1998	Accession Number 209581
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
DNA plasmid HOUCQ17	
In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer <i>Virginia L. Lely</i>	Authorized officer

DNA plasmid HOUQC17**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

CANADA

The applicant hereby requests that, until either a Canadian patent has been issued on the basis of the application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the furnishing of a sample of deposited biological material referred to in the application only be effected to an independent expert nominated by the Commissioner of Patents.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent office or any person approved by the applicant in the individual case.

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Registration), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the National Board of Patents and Registration or any person approved by the applicant in the individual case.

ICELAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the Icelandic Patent Office), or has been finally decided upon by the Icelandic Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

DNA plasmid HOUCQ17

Page 2

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in Rule 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

NORWAY

The applicant hereby requests that, until the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Norwegian Patent office or any person approved by the applicant in the individual case.

SINGAPORE

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for international publication of the application.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent office or any person approved by the applicant in the individual case.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for international publication of the application.

Applicant's or agent's file reference number: 1488.107PC02	International application PCT/399/01313
---	--

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page 32, lines 25-26.	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depository institution American Type Culture Collection	
Address of depository institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
formerly at: 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit 15 January 1998	Accession Number 209582
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
DNA plasmid HCE4D69	
In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

<p align="center">For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer <i>Virginia L. Lely</i></p>	<p align="center">For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
---	---

DNA plasmid HCE4D69

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

CANADA

The applicant hereby requests that, until either a Canadian patent has been issued on the basis of the application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the furnishing of a sample of deposited biological material referred to in the application only be effected to an independent expert nominated by the Commissioner of Patents.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent office or any person approved by the applicant in the individual case.

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Registration), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the National Board of Patents and Registration or any person approved by the applicant in the individual case.

ICELAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the Icelandic Patent Office), or has been finally decided upon by the Icelandic Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

DNA plasmid HCE4D69

Page 2

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in Rule 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

NORWAY

The applicant hereby requests that, until the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Norwegian Patent office or any person approved by the applicant in the individual case.

SINGAPORE

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for international publication of the application.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent office or any person approved by the applicant in the individual case.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for international publication of the application.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/01313

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C07H 21/04; C07K 14/47; C12N 15/63, 1/21, 15/85

US CL :435/69.1, 320.1, 252.3; 530/350; 536/23.1, 23.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.1, 320.1, 252.3; 530/350; 536/23.1, 23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

DNA and amino acid databases
APS, DIALOG

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	1994-1995 Promega Catalog, page 167.	3, 4
X	KUNO, K. et al. The Extron/Intron Organization and Chromosomal Mapping of the Mouse ADAMTS-1 Gene Encoding an ADAM Family Protein with TSP Motifs Genomics. Genomics. 1997, Vol. 46, pages 466-471, see entire document.	2, 10, 14, 18-19
X	KUNO, K. et al. Molecular Cloning of a Gene Encoding a New Type of Metalloproteinase-disintegrin Family Protein with Thrombospondin Motifs as an Inflammation Associated Gene. J. Biol. Chem. 03 January 1997, Vol. 272, No. 1, pages 556-562, see entire document.	2, 10, 14, 18-19



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

06 MAY 1999

Date of mailing of the international search report

26 MAY 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

NANCY A. JOHNSON

Telephone No. (703) 308-0196



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07H 21/04, C07K 14/47, C12N 15/63, 1/21, 15/85	A1	(11) International Publication Number: WO 99/37660 (43) International Publication Date: 29 July 1999 (29.07.99)
(21) International Application Number: PCT/US99/01313 (22) International Filing Date: 22 January 1999 (22.01.99) (30) Priority Data: 60/072,298 23 January 1998 (23.01.98) US 60/098,539 28 August 1998 (28.08.98) US (71)(72) Applicants and Inventors: IRUELA-ARISPE, Luisa [ES/US]; 1342 Holmby Avenue, Los Angeles, CA 90024 (US). HASTINGS, Gregg, A. [US/US]; 1615 Medowen Glen Court, Thousand Oaks, CA 91320 (US). RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US). (74) Agents: STEFFE, Eric, K.; Sterne, Kessler, Goldstein & Fox P.L.L.C., Suite 600, 1100 New York Avenue, N.W., Washington, D.C. 20005-3934 (US) et al.		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i> <i>With an indication in relation to deposited biological</i> <i>material furnished under Rule 13bis separately from the</i> <i>description.</i>
(54) Title: METH1 AND METH2 POLYNUCLEOTIDES AND POLYPEPTIDES		
(57) Abstract <p>The present invention relates to novel anti-angiogenic proteins, related to thrombospondin. More specifically, isolated nucleic acid molecules are provided encoding human METH1 and METH2. METH1 and METH2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for the prognosis of cancer and therapeutic methods for treating individuals in need of an increased amount of METH1 or METH2.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

METH1 and METH2 Polynucleotides and Polypeptides

Background of the Invention

Federally-Sponsored Research and Development

5 Part of the work performed during development of this invention utilized U.S. Government funds. The U.S. Government has certain rights in this invention.

Field of the Invention

10 The present invention relates to novel anti-angiogenic proteins, related to thrombospondin. More specifically, isolated nucleic acid molecules are provided encoding human METH1 and METH2 (ME, for metalloprotease, and TH, for thrombospondin). METH1 and METH2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for the prognosis of cancer and therapeutic methods for treating individuals in need of an increased amount of METH1 or METH2.

Related Art

15 Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is a tightly regulated process in normal adults. Under physiological circumstances, growth of new capillaries is tightly controlled by an interplay of growth regulatory proteins which act either to stimulate or to inhibit blood vessel growth. Normally, the balance between these forces is tipped in favor of inhibition and consequently blood vessel growth is restrained. Under certain pathological circumstances, however, local inhibitory controls are unable to restrain the increased activity of angiogenic inducers. Angiogenesis is a key step in the metastasis of cancer (Folkman, *Nature Med.* 1:27-31 (1995)) and in abnormal wound healing, inflammation, rheumatoid arthritis, psoriasis, and diabetic retinopathy, it is integral to the pathology (Folkman *et al.*, *Science* 235:442-447 (1987)), engendering the hope that these pathological entities could be regulated

by pharmacological and/or genetic suppression of blood vessel growth (Iruela-Arispe *et al.*, *Thromb. Haem.* 78:672-677 1997)).

Thrombospondin-1 (TSP-1) is a 450 kDa, anti-angiogenic adhesive glycoprotein released from activated platelets and secreted by growing cells (reviewed in Adams, *Int. J. Biochem. Cell. Biol.* 29:861-865 (1997)). TSP-1 is a homotrimer, with each subunit comprised of a 1152 amino acid residue polypeptide, post-translationally modified by *N*-linked glycosylation and beta-hydroxylation of asparagine residues.

TSP-1 protein and mRNA levels are regulated by a variety of factors. TSP-1 protein levels are downregulated by IL-1 alpha and TNF alpha. TSP-1 mRNA and protein levels are upregulated by polypeptide growth factors including PDGF, TGF-beta, and bFGF (Bornstein, *Faseb J.* 6: 3290-3299 (1992)) and are also regulated by the level of expression of the p53 tumor suppressor gene product (Dameron *et al.*, *Science* 265:1582-1584 (1994)). At least four other members of the thrombospondin family have been identified: TSP-2, TSP-3, TSP-4, and TSP-5 (also called COMP). There is a need in the art to identify other molecules involved in the regulation of angiogenesis.

Summary of the Invention

The present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding the METH1 polypeptide having the amino acid sequence shown in SEQ ID NO:2 or the amino acid sequence encoded by the cDNA clone deposited in a bacterial host as ATCC Deposit Number 209581 on January 15, 1998.

The present invention also provides isolated nucleic acid molecules comprising a polynucleotide encoding the METH2 polypeptide having the amino acid sequence shown in SEQ ID NO:4 or the amino acid sequence encoded by the cDNA clone deposited in a bacterial host as ATCC Deposit Number 209582 on January 15, 1998.

The present invention also relates to recombinant vectors, which include the isolated nucleic acid molecules of the present invention, and to host cells containing the recombinant vectors, as well as to methods of making such vectors and host cells and for using them for production of METH1 or METH2 polypeptides or peptides by recombinant techniques.

The invention further provides an isolated METH1 or METH2 polypeptide having an amino acid sequence encoded by a polynucleotide described herein.

The invention further provides a diagnostic method useful during diagnosis or prognosis of cancer.

An additional aspect of the invention is related to a method for treating an individual in need of an increased level of METH1 or METH2 activity in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an isolated METH1 or METH2 polypeptide of the invention or an agonist thereof.

Brief Description of the Figures

Figure 1 shows the nucleotide (SEQ ID NO:1) and deduced amino acid (SEQ ID NO:2) sequences of METH1. The protein has a predicted leader sequence of about 28 amino acid residues (underlined).

Figure 2 shows the nucleotide (SEQ ID NO:3) and deduced amino acid (SEQ ID NO:4) sequences of METH2. The protein has a predicted leader sequence of about 23 amino acid residues (underlined).

Figure 3 shows a comparison of the amino acid sequence of METH1 (SEQ ID NO:2) and METH2 (SEQ ID NO:4) with that of their closest homologue, a bovine metalloprotease (pNPI) (SEQ ID NO:5). Identical amino acids are boxed. Functional domains predicted by sequence and structural homology are labeled, including the signal peptide (single line), the potential cleavage site for mammalian subtilisin (double underlined), the zinc-binding-site (dotted line) in the metalloprotease domain, and the putative disintegrin loops (arrows).

Figure 4 shows the primary structure of METH1, METH2 and pNPI which includes a prodomain, a catalytic metalloprotease domain, a cysteine rich disintegrin domain, a TSP-like domain, a spacer region and a different number of TSP-like domains, three for METH1, two for METH2, and four for pNPI.

5 Figure 5 shows a comparison of the TSP-like domain of METH1 (SEQ ID NO:2) and METH2 (SEQ ID NO:4) with those of TSP1 (SEQ ID NOs:6, 7, and 8) and TSP2 (SEQ ID NOs:9, 10, and 11), cysteines are numbered 1 to 6, tryptophans are marked by asterisks.

10 Figure 6 shows that peptides and recombinant protein derived from the TSP-like domain of METH1 and METH2 block VEGF-induced angiogenesis. Angiogenesis was induced on CAMs from 12-14-day-old embryos using a nylon mesh containing VEGF casted on matrigel and in the presence or absence of the peptides or recombinant protein. Capillary density was evaluated as described in Example 4. Positive and negative control included VEGF alone and vehicle alone, respectively. (A) Quantification of the angiogenic response induced by VEGF in the presence of recombinant proteins. TSP1, purified platelet TSP1, GST, purified GST, GST-TSP1, GST-METH1, and GST-METH2 are described in Example 4. (B) Quantification of the angiogenic response induced by VEGF in the presence or absence of the peptides; P-TSP1, P-METH1, and P-METH2 (peptide derived from the Type I repeats of TSP, METH1 and METH2, respectively); SC1 and SC2 are scramble peptides used as controls. (C) Dose-response of the VEGF-induced angiogenesis in the presence of GST-METH1. (D) Dose-response of the VEGF-induced angiogenesis in the presence of GST-METH2. The angiogenic index was expressed considering the vascular response from the VEGF-matrigel as 100% and subtracting the background levels (matrigel alone). Assays were repeated, at least, twice. Each treatment was done in triplicate. Values represent the mean, bars indicate standard deviations. *p<0.001.

25 Figure 7 shows the effect of METH1 and METH2 recombinant proteins on bFGF-stimulated cell proliferation. Cells were cultured on 24-well plates in media containing bFGF and the recombinant protein to be tested (3 µg/ml, unless

30

indicated in the graph). Controls included vehicle or GST recombinant protein alone. (A), HDEC, human dermal endothelial cells; (B), HMEC, human mammary epithelial cells; (C), HDF, human dermal fibroblasts; (D), SMC, smooth muscle cells; (E) Dose-response of GST-METH1 and GST-METH2 on HDEC proliferation. Experiments were repeated, at least, twice. Each treatment was done in triplicate. Values represent the mean, bars indicate standard deviations. * $p < 0.01$.

Figure 8 shows a schematic representation of the pHE4-5 expression vector (SEQ ID NO:12) and the subcloned METH1 or METH2 cDNA coding sequence. The locations of the kanamycin resistance marker gene, the METH1 or METH2 coding sequence, the oriC sequence, and the *lacIq* coding sequence are indicated.

Figure 9 shows the nucleotide sequence of the regulatory elements of the pHE promoter (SEQ ID NO:13). The two *lac* operator sequences, the Shine-Delgarno sequence (S/D), and the terminal *HindIII* and *NdeI* restriction sites (italicized) are indicated.

Figure 10 shows an analysis of the METH1 amino acid sequence. Alpha, beta, turn and coil regions; hydrophilicity and hydrophobicity; amphipathic regions; flexible regions; antigenic index and surface probability are shown, and all were generated using the default settings. In the "Antigenic Index or Jameson-Wolf" graph, the positive peaks indicate locations of the highly antigenic regions of the METH1 or METH2 protein, i.e., regions from which epitope-bearing peptides of the invention can be obtained. The domains defined by these graphs are contemplated by the present invention. Tabular representation of the data summarized graphically in Figure 10 can be found in Table 1.

Figure 11 shows an analysis of the METH2 amino acid sequence. Alpha, beta, turn and coil regions; hydrophilicity and hydrophobicity; amphipathic regions; flexible regions; antigenic index and surface probability are shown, and all were generated using the default settings. In the "Antigenic Index or Jameson-Wolf" graph, the positive peaks indicate locations of the highly antigenic

regions of the METH1 or METH2 protein, i.e., regions from which epitope-bearing peptides of the invention can be obtained. The domains defined by these graphs are contemplated by the present invention. Tabular representation of the data summarized graphically in Figure 11 can be found in Table 2.

Table 1

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Met	1	A	A	0.41	*	.	.	-0.30	0.60
Gly	2	.	A	C	0.91	*	.	.	0.50	0.81
Asn	3	A	A	0.71	*	.	.	0.75	1.24
Ala	4	A	A	0.89	*	.	.	1.09	1.26
Glu	5	A	A	0.93	*	.	F	1.58	1.97
Arg	6	.	A	B	1.23	.	.	F	1.92	1.21
Ala	7	.	.	B	.	.	T	.	1.69	.	.	F	2.66	1.61
Pro	8	T	T	.	1.39	.	.	F	3.40	1.82
Gly	9	T	T	.	1.28	.	.	F	3.06	1.25
Ser	10	T	T	.	0.93	.	.	F	2.42	1.07
Arg	11	T	T	.	0.61	.	*	F	1.93	0.68
Ser	12	T	T	.	0.34	*	.	F	1.74	1.07
Phe	13	.	.	B	.	.	T	.	0.34	*	.	F	0.25	0.59
Gly	14	.	.	B	.	.	T	.	0.38	*	.	F	0.25	0.47
Pro	15	.	.	B	B	.	.	.	-0.13	*	.	F	-0.45	0.50
Val	16	.	.	B	B	.	.	.	-1.06	*	.	F	-0.45	0.48
Pro	17	.	.	B	B	.	.	.	-1.57	.	.	F	-0.45	0.40
Thr	18	.	A	B	-1.68	.	.	F	-0.45	0.21
Leu	19	.	A	B	-1.92	.	.	.	-0.60	0.24
Leu	20	A	A	-2.30	.	.	.	-0.60	0.15
Leu	21	A	A	-2.03	.	.	.	-0.60	0.11

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Leu	22	A	A	-2.63	.	.	.	-0.60	0.13
Ala	23	A	A	-3.13	.	.	.	-0.60	0.13
Ala	24	A	A	-2.91	.	.	.	-0.60	0.13
Ala	25	A	A	-2.96	.	.	.	-0.60	0.16
Leu	26	A	A	.	B	.	.	.	-2.44	.	.	.	-0.60	0.12
Leu	27	A	A	.	B	.	.	.	-1.63	.	.	.	-0.60	0.16
Ala	28	A	A	.	B	.	.	.	-1.63	.	.	.	-0.30	0.26
Val	29	A	A	.	B	.	.	.	-1.86	.	.	.	-0.30	0.32
Ser	30	A	A	-1.61	*	*	.	-0.30	0.32
Asp	31	A	A	-0.69	*	*	F	-0.15	0.31
Ala	32	A	A	-0.09	.	*	F	0.75	0.83
Leu	33	.	A	C	0.20	*	.	F	1.55	0.96
Gly	34	.	A	C	1.06	*	*	F	1.85	0.77
Arg	35	T	C	1.36	*	*	F	2.70	1.32
Pro	36	T	C	1.36	*	*	F	3.00	2.76
Ser	37	T	C	1.94	*	.	F	2.70	4.66
Glu	38	A	T	.	2.76	*	.	F	2.20	4.12
Glu	39	A	A	2.29	*	*	F	1.50	4.61
Asp	40	A	A	1.32	*	*	F	1.20	2.84
Glu	41	A	A	0.68	.	.	F	0.90	1.22
Glu	42	A	A	0.77	.	.	F	0.75	0.52
Leu	43	A	A	0.77	.	.	.	0.60	0.48

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni... Turn	Chou-... Turn	Garni.. Coll	Kyte-... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Val	44	A	A	-0.04	.	.	.	0.60	0.48
Val	45	A	A	-0.04	*	.	.	-0.30	0.23
Pro	46	A	A	0.07	*	.	.	-0.30	0.48
Glu	47	A	-0.52	*	.	F	1.10	1.27
Leu	48	A	0.08	*	.	F	1.41	1.73
Glu	49	A	0.59	*	.	F	1.72	1.73
Arg	50	A	1.41	*	.	F	1.88	0.99
Ala	51	A	T	.	1.28	*	.	F	2.24	1.64
Pro	52	T	T	.	0.97	*	.	F	3.10	0.93
Gly	53	T	T	.	1.47	*	*	F	2.49	0.69
His	54	T	C	1.58	*	*	F	1.38	0.98
Gly	55	C	0.66	*	*	F	1.62	1.25
Thr	56	C	1.36	.	*	F	0.71	1.04
Thr	57	.	A	B	0.76	.	*	F	0.60	1.49
Arg	58	.	A	B	1.07	.	*	F	0.60	1.25
Leu	59	.	A	B	0.51	.	*	.	0.45	1.17
Arg	60	.	A	B	0.16	.	*	.	0.30	0.82
Leu	61	.	A	B	0.47	.	*	.	-0.30	0.36
His	62	.	A	B	0.78	.	*	.	-0.30	0.74
Ala	63	A	A	0.67	.	*	.	0.30	0.65
Phe	64	A	A	0.67	.	*	.	-0.15	1.37
Asp	65	A	A	0.56	.	*	F	-0.15	0.83

5

10

15

20

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni... Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Gln	66	A	A	0.56	.	*	F	0.60	1.37
Gln	67	A	A	0.59	.	*	F	0.60	1.30
Leu	68	A	A	0.37	*	*	F	0.90	1.35
Asp	69	A	A	1.18	*	*	.	0.30	0.64
Leu	70	.	A	B	0.97	.	*	.	0.94	0.73
Glu	71	.	A	B	0.97	.	*	.	1.43	1.37
Leu	72	.	A	B	0.67	.	*	.	1.77	1.37
Arg	73	T	C	1.18	*	*	F	2.86	2.22
Pro	74	T	T	.	0.48	*	*	F	3.40	1.72
Asp	75	T	T	.	0.48	.	*	F	2.76	1.80
Ser	76	T	C	-0.11	.	*	F	2.07	0.76
Ser	77	.	.	B	0.49	*	*	F	0.73	0.50
Phe	78	.	.	B	0.03	*	*	.	0.24	0.46
Leu	79	.	.	B	-0.46	.	.	.	-0.40	0.34
Ala	80	.	.	B	.	.	T	.	-0.77	.	.	.	-0.20	0.22
Pro	81	.	.	B	.	.	T	.	-1.28	.	.	.	-0.20	0.37
Gly	82	T	T	.	-0.98	.	.	.	0.20	0.37
Phe	83	.	.	B	.	.	T	.	-0.28	.	.	.	-0.20	0.63
Thr	84	.	.	B	B	.	.	.	-0.32	.	.	.	-0.60	0.65
Leu	85	.	.	B	B	.	.	.	-0.08	*	*	.	-0.60	0.49
Gln	86	.	.	B	B	.	.	.	0.24	*	.	.	-0.29	0.56
Asn	87	.	.	B	.	.	T	.	0.63	*	.	F	0.87	0.76

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni... Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James... Antig...	Emini Surfa...
Val	88	.	.	B	.	.	T	.	1.03	*	*	F	1.93	1.84
Gly	89	T	C	1.00	*	.	F	2.74	1.42
Arg	90	T	T	.	1.51	*	.	F	3.10	0.87
Lys	91	T	C	1.51	*	.	F	2.74	1.58
Ser	92	T	C	1.20	*	.	F	2.43	2.76
Gly	93	T	C	1.84	.	.	F	2.38	2.04
Ser	94	T	C	1.38	.	.	F	2.33	1.57
Glu	95	C	1.06	.	.	F	1.63	0.97
Thr	96	C	1.01	.	.	F	2.04	1.51
Pro	97	C	1.00	.	.	F	2.60	1.96
Leu	98	C	1.34	.	.	F	2.04	1.63
Pro	99	A	0.83	.	.	F	1.58	1.89
Glu	100	A	A	0.24	.	.	F	1.12	1.01
Thr	101	A	A	0.52	.	.	F	0.86	1.23
Asp	102	A	A	0.07	.	.	F	0.60	1.08
Leu	103	A	A	0.18	.	.	.	0.30	0.34
Ala	104	A	A	0.14	.	.	.	-0.60	0.20
His	105	.	A	B	-0.16	*	.	.	-0.60	0.19
Cys	106	.	A	B	-0.19	*	.	.	-0.60	0.31
Phe	107	.	A	B	-0.50	*	.	.	-0.60	0.30
Tyr	108	.	.	B	.	.	T	.	-0.54	.	.	.	-0.20	0.32
Ser	109	T	T	.	0.04	.	*	F	0.35	0.44

-12-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Gly	110	T	T	.	-0.27	.	*	F	0.35	0.82
Thr	111	T	T	.	0.40	.	*	F	0.59	0.52
Val	112	.	.	B	B	.	.	.	0.89	.	*	F	0.93	0.65
Asn	113	.	.	.	B	T	.	.	0.83	.	*	F	1.72	1.01
Gly	114	.	.	.	B	.	.	C	0.83	.	*	F	1.61	0.94
Asp	115	T	C	0.59	.	*	F	2.40	1.69
Pro	116	T	C	0.31	.	*	F	2.16	1.06
Ser	117	T	C	0.58	.	*	F	1.92	1.08
Ser	118	A	T	.	-0.23	.	.	F	1.33	0.66
Ala	119	A	A	-0.19	.	.	.	-0.06	0.35
Ala	120	A	A	-1.00	.	.	.	-0.30	0.35
Ala	121	A	A	-1.46	.	.	.	-0.60	0.22
Leu	122	A	A	-1.16	.	.	.	-0.60	0.11
Ser	123	A	A	-1.20	.	.	.	-0.30	0.20
Leu	124	A	A	-1.47	*	*	.	-0.30	0.19
Cys	125	.	A	B	-0.77	*	*	.	-0.30	0.17
Glu	126	.	A	B	-0.52	*	*	.	0.30	0.25
Gly	127	A	-0.30	*	*	F	0.65	0.30
Val	128	A	-0.70	*	*	F	0.65	0.57
Arg	129	.	.	B	-0.13	*	*	F	0.65	0.29
Gly	130	.	.	B	B	.	.	.	-0.28	*	*	.	-0.60	0.45
Ala	131	.	.	B	B	.	.	.	-1.09	*	*	.	-0.60	0.50

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James... Antig...	Emini Surfa...
Phe	132	.	.	B	B	.	.	.	-1.09	*	*	.	-0.60	0.21
Tyr	133	.	.	B	B	.	.	.	-0.23	*	*	.	-0.60	0.21
Leu	134	.	A	B	B	.	.	.	-0.93	*	*	.	-0.60	0.36
Leu	135	.	A	B	B	.	.	.	-0.83	.	*	.	-0.60	0.42
Gly	136	A	A	.	B	.	.	.	-0.94	.	.	.	-0.60	0.42
Glu	137	A	A	-1.13	.	.	.	-0.60	0.44
Ala	138	A	A	.	B	.	.	.	-0.89	.	.	.	-0.60	0.38
Tyr	139	.	.	B	B	.	.	.	-0.29	.	.	.	-0.60	0.66
Phe	140	.	.	B	B	.	.	.	-0.29	.	.	.	-0.60	0.59
Ile	141	.	.	B	B	.	.	.	-0.16	.	.	.	-0.60	0.48
Gln	142	.	.	B	B	.	.	.	-0.74	.	.	.	-0.60	0.48
Pro	143	.	.	B	B	.	.	.	-0.74	.	.	.	-0.60	0.55
Leu	144	.	A	C	-0.80	*	.	.	-0.40	0.80
Pro	145	.	A	C	-0.10	*	.	.	-0.10	0.62
Ala	146	A	A	0.90	*	*	.	0.30	0.69
Ala	147	A	A	0.09	*	.	.	0.75	1.64
Ser	148	A	A	-0.29	*	.	F	0.75	0.88
Glu	149	A	A	0.21	*	.	F	0.45	0.88
Arg	150	A	A	-0.17	*	.	F	0.60	1.25
Leu	151	A	A	-0.17	*	.	.	0.30	0.94
Ala	152	A	A	0.21	*	*	.	0.30	0.55
Thr	153	A	A	0.17	*	*	.	0.04	0.43

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coll	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ala	154	A	A	0.17	.	.	.	0.08	0.52
Ala	155	T	C	0.10	.	*	F	2.07	0.89
Pro	156	T	C	0.70	.	.	F	2.86	1.24
Gly	157	T	T	.	1.08	.	.	F	3.40	1.90
Glu	158	T	C	0.80	.	.	F	2.86	2.90
Lys	159	C	1.18	.	.	F	2.32	1.90
Pro	160	C	0.96	.	*	F	1.98	2.97
Pro	161	C	1.17	.	*	F	1.64	1.41
Ala	162	A	A	0.81	.	*	F	0.60	1.22
Pro	163	A	A	0.78	.	*	.	-0.60	0.68
Leu	164	A	A	-0.08	.	*	.	-0.60	0.60
Gln	165	A	A	-0.68	*	*	.	-0.60	0.49
Phe	166	.	A	B	-0.36	*	*	.	-0.60	0.26
Ile	167	.	A	B	0.34	*	*	.	-0.26	0.62
Leu	168	.	A	B	0.56	*	*	.	0.38	0.70
Leu	169	.	A	B	1.48	*	*	.	0.87	1.31
Arg	170	T	T	.	1.48	*	.	F	3.06	1.88
Arg	171	T	T	.	1.83	*	.	F	3.40	3.96
Asn	172	T	T	.	1.87	*	.	F	3.06	4.75
Arg	173	T	T	.	1.82	*	.	F	2.72	4.05
Gln	174	T	.	.	2.29	.	.	F	2.43	1.53
Gly	175	T	.	.	1.83	.	.	F	2.19	0.94

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni... Turn	Garni... Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Asp	176	T	T	T	.	1.41	.	*	F	2.30	0.48
Val	177	.	.	B	.	.	.	T	.	0.74	*	.	F	1.85	0.40
Gly	178	T	T	T	.	0.29	*	.	F	2.50	0.22
Gly	179	.	.	B	.	.	.	T	.	-0.57	.	*	F	1.85	0.13
Thr	180	.	.	B	B	-1.08	.	*	F	0.30	0.13
Cys	181	.	.	B	B	-1.08	.	.	.	-0.10	0.10
Gly	182	.	.	B	B	-0.22	.	.	.	-0.05	0.16
Val	183	.	.	B	B	0.12	.	.	.	0.30	0.19
Val	184	.	.	B	B	0.26	*	*	.	0.90	0.60
Asp	185	.	.	B	.	.	.	T	.	0.68	*	*	F	1.75	0.94
Asp	186	.	.	B	.	.	.	T	.	1.13	*	*	F	2.20	2.49
Glu	187	.	.	B	.	.	.	T	.	1.17	*	*	F	2.50	5.18
Pro	188	T	C	1.68	*	*	F	3.00	4.48
Arg	189	T	C	2.58	*	*	F	2.70	2.66
Pro	190	T	C	1.99	*	*	F	2.40	3.07
Thr	191	T	C	1.99	*	*	F	2.10	2.00
Gly	192	T	C	1.68	*	*	F	1.80	1.77
Lys	193	A	A	1.89	*	*	F	0.90	1.65
Ala	194	A	A	1.78	*	*	F	0.90	1.98
Glu	195	A	A	1.99	.	*	F	0.90	3.35
Thr	196	A	A	2.30	.	*	F	0.90	2.90
Glu	197	A	A	2.64	.	*	F	0.90	4.79

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni... Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James.. Antig...	Emini Surfa...
Asp	198	A	A	2.26	.	*	F	0.90	4.79
Glu	199	A	A	2.53	.	.	F	0.90	3.29
Asp	200	A	T	.	2.53	.	.	F	1.30	2.74
Glu	201	A	T	.	2.50	.	.	F	1.30	2.84
Gly	202	A	T	.	2.50	.	.	F	1.30	1.62
Thr	203	A	T	.	2.50	.	.	F	1.30	1.68
Glu	204	A	A	2.50	*	.	F	0.90	1.62
Gly	205	A	A	2.16	*	.	F	1.20	2.84
Glu	206	A	A	1.94	*	.	F	1.50	1.95
Asp	207	.	A	.	.	T	.	.	2.29	*	.	F	2.20	1.74
Glu	208	.	A	C	2.31	*	.	F	2.30	3.04
Gly	209	T	C	2.01	*	.	F	3.00	1.85
Pro	210	T	T	.	2.14	.	.	F	2.60	1.48
Gln	211	T	T	.	2.14	.	.	F	2.30	1.32
Trp	212	T	C	2.14	.	.	F	1.44	2.32
Ser	213	C	1.93	.	.	F	1.78	2.50
Pro	214	T	T	.	1.69	.	.	F	2.12	2.23
Gln	215	T	C	1.09	.	.	F	1.56	2.15
Asp	216	T	C	1.09	.	*	F	2.40	1.32
Pro	217	T	C	1.03	.	.	F	2.16	1.48
Ala	218	T	.	.	0.48	.	.	F	1.77	0.85
Leu	219	.	.	B	0.34	*	.	F	0.53	0.38

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni... Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James... Antig...	Emini Surfa...
Gln	220	.	.	B	0.34	*	.	F	-0.01	0.24
Gly	221	.	.	B	.	.	T	.	0.13	*	*	F	-0.05	0.41
Val	222	.	.	B	.	.	T	.	0.03	*	.	F	-0.05	0.77
Gly	223	.	.	B	.	.	T	.	0.28	*	.	F	0.25	0.64
Gln	224	.	.	B	.	.	T	.	0.78	*	*	F	0.25	0.64
Pro	225	.	.	B	0.43	.	.	F	0.20	1.25
Thr	226	T	.	.	0.48	.	*	F	0.60	1.25
Gly	227	T	C	0.44	*	*	F	0.45	0.97
Thr	228	.	.	B	.	.	T	.	0.90	*	*	F	0.25	0.44
Gly	229	.	.	B	.	.	T	.	0.94	.	*	F	0.85	0.60
Ser	230	.	.	B	.	.	T	.	1.20	.	*	F	1.30	1.20
Ile	231	.	A	B	1.62	.	*	F	0.90	1.67
Arg	232	.	A	B	1.27	.	*	F	0.90	3.30
Lys	233	.	A	B	0.72	.	.	F	0.90	2.13
Lys	234	.	A	B	B	.	.	.	0.77	.	.	F	0.90	2.26
Arg	235	.	A	B	B	.	.	.	0.77	.	.	F	0.90	1.55
Phe	236	.	.	B	B	.	.	.	1.62	.	*	.	0.75	1.04
Val	237	.	.	B	B	.	.	.	1.62	.	*	.	0.30	0.71
Ser	238	.	.	B	.	.	T	.	1.33	*	*	.	0.70	0.71
Ser	239	T	C	0.43	*	.	.	0.15	1.28
His	240	T	C	0.32	*	*	.	0.45	1.28
Arg	241	T	C	0.71	*	.	.	1.05	1.65

5

10

15

20

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni... Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Tyr	242	A	.	.	B	.	.	.	0.97	*	.	.	0.45	1.78
Val	243	A	.	.	B	.	.	.	0.46	*	.	.	0.45	1.29
Glu	244	.	.	B	B	.	.	.	-0.10	*	.	.	-0.30	0.54
Thr	245	.	.	B	B	.	.	.	-0.66	*	.	.	-0.60	0.26
Met	246	A	.	B	B	.	.	.	-0.77	*	.	.	-0.60	0.35
Leu	247	A	.	.	B	.	.	.	-0.52	.	.	.	0.30	0.34
Val	248	A	.	.	B	.	.	.	0.03	.	.	.	-0.30	0.41
Ala	249	A	.	.	B	.	.	.	-0.57	.	.	.	-0.30	0.55
Asp	250	A	T	.	-0.84	.	.	F	0.25	0.66
Gln	251	A	T	.	-0.24	.	.	F	0.25	0.90
Ser	252	A	T	.	-0.13	.	.	F	1.30	1.54
Met	253	A	T	.	0.69	.	*	.	0.70	0.80
Ala	254	A	0.93	.	*	.	-0.10	0.63
Glu	255	A	0.63	.	*	.	-0.10	0.46
Phe	256	A	0.29	.	*	.	-0.10	0.63
His	257	A	T	.	-0.22	*	.	.	0.10	0.61
Gly	258	A	T	.	0.42	*	.	F	0.25	0.29
Ser	259	A	T	.	0.98	*	*	F	0.25	0.68
Gly	260	A	T	.	0.73	*	*	F	0.85	0.68
Leu	261	A	A	0.62	.	.	F	0.00	1.07
Lys	262	A	A	-0.16	.	.	.	-0.60	0.66
His	263	.	A	B	-0.12	*	.	.	-0.60	0.55

5

10

15

20

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James... Antig...	Emini Surfa...
Tyr	264	.	A	B	-0.63	*	.	.	-0.60	0.96
Leu	265	.	A	B	-0.99	*	.	.	-0.60	0.40
Leu	266	.	A	B	-0.48	*	.	.	-0.60	0.25
Thr	267	.	A	B	-1.38	*	.	.	-0.60	0.22
Leu	268	.	A	B	-1.93	*	.	.	-0.60	0.19
Phe	269	A	A	-2.28	*	*	.	-0.60	0.24
Ser	270	A	A	-1.36	*	*	.	-0.60	0.17
Val	271	A	A	-1.36	*	*	.	-0.60	0.39
Ala	272	A	A	-1.29	*	*	.	-0.60	0.38
Ala	273	A	A	-0.43	*	*	.	-0.60	0.44
Arg	274	A	A	0.23	*	*	.	-0.15	1.18
Leu	275	A	A	0.32	*	*	.	0.45	1.59
Tyr	276	T	.	.	0.88	*	*	.	1.39	2.44
Lys	277	.	.	B	0.58	*	*	F	1.48	1.67
His	278	.	.	B	.	.	T	.	1.28	.	*	F	1.12	1.42
Pro	279	.	.	B	.	.	T	.	1.17	.	*	F	2.36	1.77
Ser	280	T	T	.	1.68	.	*	F	3.40	1.43
Ile	281	.	.	B	.	.	T	.	1.07	.	*	F	2.36	1.41
Arg	282	.	.	B	B	.	.	.	0.72	.	*	F	1.47	0.67
Asn	283	.	.	B	B	.	.	.	-0.06	*	*	F	1.13	0.67
Ser	284	.	.	B	B	.	.	.	-0.70	*	*	F	0.19	0.79
Val	285	.	.	B	B	.	.	.	-1.26	*	*	.	-0.30	0.30

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James.. Antig...	Emini Surfa...
Ser	286	.	.	B	B	.	.	.	-1.22	.	*	.	-0.60	0.14
Leu	287	.	.	B	B	.	.	.	-1.29	.	*	.	-0.60	0.08
Val	288	.	.	B	B	.	.	.	-2.18	*	.	.	-0.60	0.21
Val	289	.	.	B	B	.	.	.	-2.69	.	*	.	-0.60	0.11
Val	290	.	.	B	B	.	.	.	-2.69	.	.	.	-0.60	0.11
Lys	291	.	.	B	B	.	.	.	-3.28	.	.	.	-0.60	0.11
Ile	292	.	.	B	B	.	.	.	-2.50	.	.	.	-0.60	0.10
Leu	293	.	.	B	B	.	.	.	-1.64	.	*	.	-0.60	0.19
Val	294	.	.	B	B	.	.	.	-0.79	.	.	.	-0.30	0.16
Ile	295	.	.	B	B	.	.	.	0.07	.	*	.	0.00	0.39
His	296	A	.	.	B	.	.	.	0.07	.	*	.	0.90	0.81
Asp	297	A	.	.	B	.	.	.	0.61	.	.	F	1.80	2.19
Glu	298	A	1.21	*	.	F	2.30	3.09
Gln	299	T	.	.	2.07	*	.	F	3.00	3.51
Lys	300	C	2.10	.	.	F	2.50	3.64
Gly	301	T	C	1.82	.	.	F	2.40	1.56
Pro	302	T	C	1.52	.	.	F	2.10	1.30
Glu	303	.	.	B	.	.	T	.	1.52	*	.	F	1.45	0.87
Val	304	A	T	.	0.93	*	.	F	1.00	1.42
Thr	305	A	T	.	0.30	.	*	F	0.85	0.93
Ser	306	A	T	.	-0.17	.	*	F	0.85	0.54
Asn	307	A	T	.	-0.27	.	*	F	-0.05	0.60

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni... Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James... Antig...	Emini Surfa...
Ala	308	A	T	.	-1.08	*	*	.	-0.20	0.60
Ala	309	A	-0.11	*	*	.	-0.40	0.37
Leu	310	A	0.20	*	*	.	-0.10	0.45
Thr	311	.	.	B	-0.20	*	*	.	-0.10	0.72
Leu	312	.	.	B	-0.87	*	*	.	-0.40	0.61
Arg	313	.	.	B	-0.28	*	*	.	-0.40	0.40
Asn	314	T	.	.	0.02	*	*	.	0.30	0.44
Phe	315	T	T	.	0.83	*	*	.	0.20	0.57
Cys	316	T	T	.	1.19	*	*	.	0.20	0.50
Asn	317	T	T	.	2.00	*	*	.	0.20	0.62
Trp	318	T	T	.	1.86	*	.	.	0.35	1.25
Gln	319	T	.	.	1.86	.	.	.	0.45	3.16
Lys	320	T	.	.	2.34	*	.	F	0.60	3.16
Gln	321	T	.	.	2.80	.	.	F	0.94	4.65
His	322	C	2.50	*	.	F	1.68	4.15
Asn	323	C	2.79	*	.	F	2.02	2.78
Pro	324	T	C	2.90	.	.	F	2.56	2.68
Pro	325	T	T	.	2.86	*	.	F	3.40	3.86
Ser	326	T	C	2.27	.	.	F	2.86	4.01
Asp	327	T	C	2.30	.	.	F	2.52	2.62
Arg	328	A	A	2.27	.	.	F	1.58	2.94
Asp	329	A	A	2.23	*	.	F	1.24	2.98

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni... Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James.. Antig...	Emini Surfa...
Ala	330	A	A	2.44	*	.	.	0.90	2.80
Glu	331	A	A	2.43	*	.	.	0.75	2.38
His	332	A	T	.	1.84	*	.	.	1.15	2.06
Tyr	333	A	T	.	0.84	*	.	.	0.85	2.06
Asp	334	A	T	.	0.03	.	.	.	0.70	0.83
Thr	335	A	T	.	-0.08	.	.	.	-0.20	0.51
Ala	336	A	A	-0.39	*	.	.	-0.60	0.28
Ile	337	A	A	-0.24	*	.	.	-0.60	0.24
Leu	338	.	A	B	0.00	.	.	.	-0.60	0.33
Phe	339	.	A	B	0.00	.	*	.	-0.60	0.56
Thr	340	.	A	B	-0.50	.	.	F	0.00	1.34
Arg	341	.	A	B	-0.58	.	*	F	0.25	1.34
Gln	342	.	A	.	.	T	.	.	-0.03	.	*	F	1.35	0.83
Asp	343	.	A	.	.	T	.	.	0.48	.	*	F	1.60	0.57
Leu	344	.	A	.	.	T	.	.	1.18	*	.	F	2.15	0.39
Cys	345	T	T	.	1.18	.	*	F	2.50	0.39
Gly	346	T	T	.	0.40	.	*	F	2.25	0.34
Ser	347	T	T	.	0.40	.	.	F	1.10	0.22
Gln	348	.	.	B	.	.	T	.	0.09	.	.	F	1.35	0.68
Thr	349	.	.	B	0.09	.	.	F	0.90	0.99
Cys	350	.	.	B	0.41	.	.	F	0.05	0.61
Asp	351	.	.	B	.	.	T	.	0.16	*	.	F	0.25	0.35

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Thr	352	.	.	B	.	.	T	.	-0.13	.	.	F	0.25	0.24
Leu	353	.	.	B	.	.	T	.	-0.13	.	.	.	0.10	0.45
Gly	354	.	.	B	.	.	T	.	-0.68	.	.	.	0.70	0.45
Met	355	.	.	B	-0.36	.	.	.	-0.10	0.23
Ala	356	.	.	B	-0.67	.	.	.	-0.10	0.28
Asp	357	.	.	B	.	.	T	.	-1.21	.	.	.	0.10	0.41
Val	358	.	.	B	.	.	T	.	-1.07	.	.	.	0.10	0.30
Gly	359	.	.	B	.	.	T	.	-0.72	.	.	.	0.10	0.16
Thr	360	.	.	B	.	.	T	.	-0.33	.	.	.	0.70	0.16
Val	361	.	.	B	-0.04	.	*	.	0.24	0.34
Cys	362	.	.	B	0.07	*	.	.	1.18	0.46
Asp	363	.	.	B	.	.	T	.	0.62	*	.	F	1.87	0.62
Pro	364	T	T	.	0.30	*	.	F	3.06	1.12
Ser	365	T	T	.	0.31	*	.	F	3.40	1.12
Arg	366	T	T	.	0.31	*	.	F	2.91	0.90
Ser	367	.	.	.	B	T	.	.	0.09	*	.	F	1.87	0.43
Cys	368	.	.	B	B	.	.	.	0.09	*	.	.	0.38	0.22
Ser	369	.	.	B	B	.	.	.	0.30	*	.	.	0.64	0.20
Val	370	.	.	B	B	.	.	.	0.60	*	.	.	0.30	0.25
Ile	371	.	.	B	B	.	.	.	0.14	*	.	.	0.60	0.77
Glu	372	.	.	B	B	.	.	.	-0.37	.	.	.	0.60	0.57
Asp	373	A	T	.	0.30	.	.	F	1.15	0.63

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Asp	374	A	T	.	0.01	*	.	.	1.30	1.56
Gly	375	A	T	.	0.28	.	.	.	1.00	0.91
Leu	376	A	T	.	0.47	*	.	.	0.70	0.55
Gln	377	A	A	0.16	.	.	.	-0.30	0.29
Ala	378	A	A	-0.16	*	.	.	-0.60	0.42
Ala	379	A	A	-0.74	*	.	.	-0.60	0.73
Phe	380	A	A	-0.43	*	.	.	-0.60	0.43
Thr	381	A	A	0.38	*	*	.	-0.60	0.57
Thr	382	A	A	-0.43	*	.	.	-0.30	0.98
Ala	383	A	A	-0.19	*	.	.	-0.60	0.94
His	384	A	A	0.37	*	.	.	-0.30	0.64
Glu	385	A	A	0.21	*	.	.	-0.30	0.61
Leu	386	A	A	-0.18	*	.	.	-0.30	0.45
Gly	387	A	.	.	B	.	.	.	0.13	*	.	.	-0.60	0.28
His	388	A	.	.	B	.	.	.	0.12	*	.	.	-0.60	0.26
Val	389	A	.	.	B	.	.	.	-0.06	*	.	.	-0.60	0.32
Phe	390	A	.	.	B	.	.	.	-0.09	*	.	.	-0.60	0.49
Asn	391	.	.	B	B	.	.	.	0.72	*	.	.	-0.60	0.49
Met	392	.	.	B	.	.	T	.	1.07	*	.	.	0.25	1.11
Pro	393	A	T	.	0.51	*	.	.	0.85	2.14
His	394	T	T	.	1.41	*	.	F	1.70	1.34
Asp	395	A	T	.	2.11	*	.	F	1.30	2.72

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Asp	396	A	A	1.44	*	.	F	0.90	3.04
Ala	397	A	A	1.46	*	.	F	0.90	1.20
Lys	398	A	A	1.37	*	*	F	0.75	0.73
Gln	399	A	A	0.59	.	*	.	0.60	0.58
Cys	400	.	A	B	0.59	.	*	.	-0.30	0.48
Ala	401	.	A	B	0.24	.	*	.	0.30	0.38
Ser	402	.	.	B	.	.	T	.	-0.02	.	*	.	0.10	0.22
Leu	403	.	.	B	.	.	T	.	-0.07	.	.	.	0.04	0.30
Asn	404	T	T	.	-0.07	.	.	.	0.68	0.48
Gly	405	T	T	.	0.60	.	.	F	1.37	0.62
Val	406	C	0.89	.	.	F	1.96	1.26
Asn	407	T	C	1.16	.	.	F	2.40	1.05
Gln	408	A	T	.	1.37	*	.	F	1.96	1.44
Asp	409	A	T	.	0.77	*	.	F	1.72	1.92
Ser	410	A	T	.	0.52	.	.	.	1.33	1.18
His	411	A	A	1.08	.	*	.	-0.06	0.69
Met	412	A	A	0.48	.	.	.	0.30	0.55
Met	413	A	A	-0.33	.	.	.	-0.60	0.41
Ala	414	A	A	-0.63	.	.	.	-0.60	0.25
Ser	415	A	A	-0.33	*	.	.	-0.60	0.34
Met	416	A	A	-1.11	*	*	.	-0.60	0.55
Leu	417	A	T	.	-0.51	*	.	.	-0.20	0.45

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ser	418	A	T	.	0.06	*	.	.	0.38	0.56
Asn	419	A	T	.	0.34	.	.	.	0.66	0.76
Leu	420	T	C	0.64	.	.	.	1.29	1.24
Asp	421	T	T	.	1.03	.	.	.	2.37	1.60
His	422	T	T	.	1.56	.	.	F	2.80	1.54
Ser	423	T	C	1.56	.	.	F	1.72	1.97
Gln	424	T	C	1.34	.	.	F	1.44	1.58
Pro	425	T	.	.	1.49	.	.	F	0.86	1.79
Trp	426	T	.	.	1.19	.	.	F	0.43	0.72
Ser	427	T	C	0.63	.	.	F	0.15	0.55
Pro	428	T	T	.	0.69	.	.	F	0.35	0.36
Cys	429	T	T	.	0.09	.	.	.	0.20	0.54
Ser	430	.	.	B	.	.	T	.	-0.59	.	.	.	-0.20	0.40
Ala	431	.	.	B	B	.	.	.	-0.61	.	.	.	-0.60	0.18
Tyr	432	.	.	B	B	.	.	.	-0.61	.	.	.	-0.60	0.49
Met	433	.	.	B	B	.	.	.	-1.10	.	.	.	-0.60	0.49
Ile	434	.	.	B	B	.	.	.	-1.24	*	.	.	-0.60	0.42
Thr	435	.	.	B	B	.	.	.	-0.94	*	.	.	-0.60	0.22
Ser	436	.	.	B	B	.	.	.	-0.36	*	.	.	-0.60	0.37
Phe	437	.	.	B	B	.	.	.	-0.46	*	.	.	-0.60	0.85
Leu	438	.	.	B	B	.	T	.	0.11	*	.	F	0.56	0.58
Asp	439	T	T	.	0.66	*	.	F	1.27	0.59

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Asn	440	T	C	0.97	.	.	F	1.38	0.68
Gly	441	T	T	.	0.60	.	.	F	2.94	1.42
His	442	T	T	.	0.49	.	.	F	3.10	0.46
Gly	443	A	T	.	0.70	.	.	F	1.49	0.23
Glu	444	A	T	.	0.70	.	.	.	1.03	0.23
Cys	445	.	.	B	.	.	T	.	0.74	.	*	.	1.32	0.29
Leu	446	.	A	B	0.88	.	.	.	1.25	0.58
Met	447	.	A	B	0.91	*	.	.	1.28	0.52
Asp	448	.	A	.	.	T	.	.	1.26	*	.	F	2.02	1.67
Lys	449	.	A	C	1.04	*	.	F	2.16	3.26
Pro	450	T	T	.	0.82	*	*	F	3.40	5.10
Gln	451	T	T	.	1.63	*	*	F	3.06	2.14
Asn	452	.	.	B	.	.	T	.	1.42	*	*	F	2.02	1.85
Pro	453	.	.	B	.	.	T	.	1.21	*	*	F	0.63	0.99
Ile	454	.	.	B	0.82	*	*	F	0.09	0.88
Gln	455	.	.	B	1.03	*	*	F	-0.25	0.54
Leu	456	.	.	B	.	.	T	.	0.22	*	*	F	0.25	0.59
Pro	457	.	.	B	.	.	T	.	0.01	*	*	F	0.25	0.69
Gly	458	.	.	B	.	.	T	.	-0.12	.	*	F	0.25	0.62
Asp	459	.	.	B	.	.	T	.	0.46	.	*	F	0.25	0.74
Leu	460	T	C	0.16	.	*	F	1.05	0.69
Pro	461	.	.	B	.	.	T	.	0.72	.	*	F	0.85	0.93

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Gly	462	.	.	B	.	.	T	.	0.93	.	.	F	0.25	0.88
Thr	463	.	.	B	.	.	T	.	0.69	.	*	F	0.74	1.78
Ser	464	.	.	B	0.69	*	.	F	1.48	1.16
Tyr	465	T	.	.	1.61	*	.	F	2.22	1.88
Asp	466	T	T	.	1.82	.	.	.	2.61	2.56
Ala	467	T	T	.	1.50	*	.	F	3.40	3.31
Asn	468	T	T	.	1.81	.	*	F	2.76	1.13
Arg	469	.	.	B	.	.	T	.	1.41	.	*	F	2.32	1.17
Gln	470	.	.	B	B	.	.	.	1.34	*	*	.	0.53	1.01
Cys	471	.	.	B	B	.	.	.	0.64	*	*	.	0.04	0.90
Gln	472	.	.	B	B	.	.	.	0.89	.	.	.	-0.60	0.40
Phe	473	.	.	B	B	.	.	.	0.89	.	.	.	-0.26	0.23
Thr	474	.	.	B	B	.	.	.	0.78	.	.	.	0.08	0.74
Phe	475	.	.	.	B	T	.	.	0.48	.	*	.	1.72	0.71
Gly	476	T	T	.	1.19	.	*	F	2.76	1.10
Glu	477	T	T	.	1.16	.	*	F	3.40	1.52
Asp	478	T	T	.	1.19	*	.	F	3.06	2.39
Ser	479	T	T	.	1.29	*	.	F	2.72	1.30
Lys	480	T	.	.	1.99	*	.	F	2.43	1.16
His	481	T	.	.	1.74	*	.	F	2.34	1.16
Cys	482	T	C	1.16	*	.	F	2.10	0.87
Pro	483	A	T	.	0.86	.	.	F	2.15	0.44

5

10

15

20

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James.. Antig...	Emini Surfa...
Asp	484	T	T	.	0.84	*	.	F	2.50	0.43
Ala	485	A	T	.	0.13	*	.	F	2.00	1.17
Ala	486	A	-0.13	.	.	F	1.40	0.41
Ser	487	.	.	B	.	T	T	.	0.22	.	.	F	1.75	0.33
Thr	488	.	.	B	.	.	T	.	-0.38	*	.	F	0.50	0.46
Cys	489	.	.	B	.	.	T	.	-0.67	*	.	F	-0.05	0.38
Ser	490	.	.	B	.	.	T	.	-0.74	.	.	F	-0.05	0.30
Thr	491	.	.	B	B	.	.	.	-0.47	.	.	.	-0.60	0.11
Leu	492	.	.	B	B	.	.	.	-0.51	.	.	.	-0.60	0.30
Trp	493	.	.	B	B	.	.	.	-0.51	.	.	.	-0.60	0.22
Cys	494	.	.	B	B	.	.	.	-0.14	.	.	.	-0.60	0.22
Thr	495	.	.	B	B	T	.	.	-0.19	.	.	F	-0.05	0.36
Gly	496	.	.	.	B	T	.	.	-0.22	.	.	F	-0.05	0.34
Thr	497	T	T	.	-0.27	.	.	F	0.65	0.62
Ser	498	T	T	.	-0.79	.	.	F	0.65	0.32
Gly	499	T	T	.	-0.98	.	.	F	0.35	0.27
Gly	500	T	T	.	-1.33	.	.	F	0.35	0.14
Val	501	.	.	B	B	.	.	.	-0.99	.	.	.	-0.60	0.05
Leu	502	.	.	B	B	.	.	.	-0.99	.	.	.	-0.60	0.10
Val	503	.	.	B	B	.	.	.	-0.64	.	.	.	-0.60	0.14
Cys	504	.	.	B	.	.	T	.	-0.33	.	.	.	-0.20	0.38
Gln	505	.	.	B	.	.	T	.	-0.69	.	.	.	0.10	0.62

-30-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Thr	506	.	.	B	.	.	T	.	-0.04	.	.	F	0.25	0.72
Lys	507	.	.	B	.	.	T	.	0.48	.	.	F	0.40	2.09
His	508	C	0.74	.	.	.	-0.05	1.27
Phe	509	.	.	B	1.41	.	.	.	-0.40	0.89
Pro	510	T	.	.	1.07	.	.	.	0.30	0.74
Trp	511	T	T	.	1.07	.	.	.	0.20	0.54
Ala	512	T	T	.	0.72	.	.	.	0.51	0.90
Asp	513	T	T	.	0.09	.	.	F	1.27	0.78
Gly	514	T	T	.	0.44	.	.	F	1.58	0.40
Thr	515	T	T	.	0.66	.	.	F	2.49	0.39
Ser	516	T	T	.	0.60	.	*	F	3.10	0.40
Cys	517	T	T	.	1.23	.	*	F	2.49	0.40
Gly	518	T	T	.	0.94	.	*	F	2.48	0.56
Glu	519	T	.	.	0.62	.	*	F	1.67	0.44
Gly	520	T	.	.	0.04	.	*	F	1.36	0.44
Lys	521	T	.	.	0.34	.	*	F	0.45	0.31
Trp	522	T	.	.	0.67	.	*	.	0.90	0.29
Cys	523	.	.	B	.	.	T	.	1.06	.	*	.	-0.20	0.29
Ile	524	.	.	B	.	.	T	.	0.39	.	*	.	0.70	0.29
Asn	525	T	T	.	-0.12	.	*	.	0.20	0.15
Gly	526	T	T	.	-0.17	*	*	F	0.65	0.20
Lys	527	T	.	.	0.17	*	*	F	0.45	0.47

5

10

15

20

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni... Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James... Antig...	Emini Surfa...
Cys	528	T	T	.	0.52	.	*	.	1.40	0.58
Val	529	.	.	B	.	.	T	.	1.41	*	*	.	1.04	0.85
Asn	530	.	.	B	.	.	T	.	1.52	*	.	F	1.83	0.71
Lys	531	.	.	B	.	.	T	.	1.91	*	.	F	2.32	2.58
Thr	532	.	.	B	.	.	T	.	1.83	*	.	F	2.66	6.96
Asp	533	T	T	.	1.80	*	.	F	3.40	5.89
Arg	534	T	T	.	2.66	*	.	F	3.06	2.55
Lys	535	.	.	B	.	.	T	.	2.34	*	.	F	2.32	2.95
His	536	.	.	B	2.09	*	.	F	1.78	2.55
Phe	537	.	.	B	1.70	*	.	F	1.44	2.01
Asp	538	.	.	B	1.67	*	.	F	0.65	0.87
Thr	539	.	.	B	1.21	*	.	F	-0.25	0.87
Pro	540	C	0.87	*	*	F	-0.05	1.00
Phe	541	T	.	.	0.61	.	*	F	0.45	0.80
His	542	T	T	.	0.97	.	*	.	0.20	0.58
Gly	543	T	T	.	0.37	.	*	.	0.20	0.37
Ser	544	T	T	.	0.39	.	*	.	0.20	0.43
Trp	545	T	T	.	0.26	.	*	.	0.20	0.33
Gly	546	C	0.74	.	*	.	-0.20	0.33
Met	547	T	.	.	0.49	.	.	.	0.00	0.38
Trp	548	T	.	.	0.49	.	.	.	0.00	0.38
Gly	549	T	C	0.79	.	.	.	0.00	0.38

5

10

15

20

-31.1-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coll	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James.. Antig...	Emini Surfa...
Pro	550	T	T	.	0.41	.	.	F	0.35	0.64
Trp	551	T	T	.	0.46	*	.	F	0.66	0.33
Gly	552	T	T	.	1.17	*	.	F	1.27	0.44
Asp	553	T	.	.	1.14	*	.	F	1.98	0.56
Cys	554	T	T	.	0.82	*	.	F	2.49	0.77
Ser	555	T	T	.	0.69	*	.	F	3.10	0.42
Arg	556	T	T	.	0.63	*	.	F	2.79	0.25
Thr	557	T	T	.	0.63	*	.	F	2.18	0.46
Cys	558	T	T	.	-0.22	*	.	F	1.87	0.34
Gly	559	T	T	.	0.44	*	.	F	1.56	0.13
Gly	560	T	T	.	0.50	*	.	F	0.65	0.15
Gly	561	T	T	.	0.08	*	*	F	0.35	0.45
Val	562	.	.	B	B	.	.	.	-0.21	*	*	.	-0.60	0.65
Gln	563	.	.	B	B	.	.	.	0.57	*	*	.	-0.60	0.65
Tyr	564	.	.	B	B	.	.	.	0.91	*	*	.	-0.15	1.29
Thr	565	.	.	B	B	.	.	.	0.59	*	*	.	0.79	3.01
Met	566	.	.	B	B	.	.	.	0.93	*	*	.	0.98	0.93
Arg	567	.	.	B	B	.	.	.	1.79	*	*	.	1.62	0.99
Glu	568	T	.	.	1.58	*	*	F	2.86	1.11
Cys	569	T	T	.	0.97	*	.	F	3.40	1.73
Asp	570	T	T	.	1.07	*	..	F	2.91	0.66

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.2-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James... Antig...	Emini Surfa...
Asn	571	T	C	1.71	*	.	F	2.37	0.59
Pro	572	T	C	1.60	*	.	F	2.52	2.18
Val	573	C	1.26	*	.	F	2.32	2.10
Pro	574	T	T	.	1.58	*	.	F	2.42	1.29
Lys	575	T	T	.	1.62	*	.	F	2.61	0.83
Asn	576	T	T	.	1.38	*	.	F	3.40	2.23
Gly	577	T	T	.	0.92	*	.	F	3.06	2.26
Gly	578	T	T	.	1.78	*	.	F	2.27	0.61
Lys	579	.	.	B	.	.	T	.	1.64	.	.	F	1.53	0.65
Tyr	580	.	.	B	.	.	T	.	1.64	.	.	F	1.19	0.65
Cys	581	.	.	B	.	.	T	.	1.76	.	.	F	1.30	1.32
Glu	582	.	.	B	1.24	.	*	F	1.10	1.29
Gly	583	.	.	B	B	.	.	.	1.70	.	*	F	0.75	0.61
Lys	584	.	.	B	B	.	.	.	1.41	.	*	F	0.90	2.24
Arg	585	.	.	B	B	.	.	.	1.77	.	*	F	1.15	2.02
Tyr	586	.	.	B	B	.	.	.	2.13	.	*	.	1.25	4.01
Arg	587	.	.	B	B	.	.	.	1.47	*	*	.	1.50	2.68
Tyr	588	.	.	B	.	.	T	.	1.81	*	*	.	2.00	0.73
Arg	589	T	T	.	0.96	*	*	.	2.50	1.59
Ser	590	T	T	.	0.84	*	*	.	2.10	0.67
Cys	591	T	T	.	1.70	.	*	.	1.85	0.74
Asn	592	.	A	.	.	T	.	.	0.92	.	*	.	1.50	0.63

5

10

15

20

-31.3-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Leu	593	.	A	B	0.96	.	.	.	0.89	0.25
Glu	594	.	A	B	0.84	.	.	F	1.13	0.73
Asp	595	.	A	.	.	T	.	.	1.17	.	.	F	2.17	0.76
Cys	596	.	.	B	.	.	T	.	1.81	.	.	F	2.66	1.48
Pro	597	T	T	.	1.47	*	*	F	3.40	1.37
Asp	598	T	T	.	2.32	*	*	F	2.91	0.81
Asn	599	T	T	.	2.01	*	.	F	3.02	3.03
Asn	600	T	T	.	1.31	*	.	F	2.98	2.83
Gly	601	T	T	.	2.09	*	.	F	2.94	1.47
Lys	602	T	C	2.30	*	*	F	2.70	1.79
Thr	603	T	C	2.30	*	.	F	3.00	1.92
Phe	604	A	A	2.30	*	.	F	2.10	3.37
Arg	605	A	A	1.63	.	.	F	1.80	2.91
Glu	606	A	A	1.98	*	.	F	1.50	1.08
Glu	607	A	A	1.34	*	.	F	1.20	2.17
Gln	608	A	A	1.62	*	.	F	0.90	1.12
Cys	609	A	A	2.32	*	*	.	0.60	0.88
Glu	610	A	A	2.21	.	*	.	0.60	0.81
Ala	611	A	A	1.51	.	*	.	0.60	0.81
His	612	A	A	1.21	*	.	.	0.45	1.32
Asn	613	A	A	1.26	*	*	.	0.45	1.02
Glu	614	A	A	1.33	*	.	.	0.45	2.02

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.4-

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni... Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James.. Antig...	Emini Surfa...
Phe	615	A	A	1.03	*	*	F	0.60	1.50
Ser	616	A	A	0.92	.	.	F	0.90	1.25
Lys	617	A	A	0.61	.	.	F	0.45	0.62
Ala	618	.	A	.	.	T	.	.	0.31	.	.	F	0.25	0.71
Ser	619	.	A	.	.	T	.	.	-0.03	.	.	F	0.85	0.71
Phe	620	T	.	.	0.46	.	.	F	1.26	0.35
Gly	621	T	T	.	0.17	.	.	F	1.07	0.54
Ser	622	T	C	-0.73	.	*	F	1.08	0.41
Gly	623	T	C	-0.14	.	.	F	0.99	0.35
Pro	624	T	C	-0.13	.	.	F	2.10	0.61
Ala	625	.	A	C	-0.32	.	.	F	0.89	0.48
Val	626	.	A	B	-0.19	*	.	.	0.03	0.34
Glu	627	.	A	B	0.16	*	.	.	-0.18	0.34
Trp	628	.	A	B	0.26	*	.	.	-0.09	0.67
Ile	629	.	.	B	-0.12	*	.	.	-0.25	1.42
Pro	630	.	.	B	.	.	T	.	0.12	*	.	.	0.10	0.83
Lys	631	T	T	.	0.12	*	.	.	0.20	0.78
Tyr	632	T	T	.	-0.18	*	.	.	0.20	0.82
Ala	633	T	T	.	-0.10	*	.	.	0.84	0.71
Gly	634	T	.	.	0.83	*	.	.	0.98	0.55
Val	635	.	.	B	1.04	.	*	.	0.92	0.70
Ser	636	.	.	B	.	.	T	.	1.11	.	*	F	2.66	1.17

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.5-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Pro	637	T	T	.	0.69	.	*	F	3.40	2.31
Lys	638	T	T	.	1.32	.	*	F	3.06	1.67
Asp	639	T	T	.	0.86	.	*	F	2.72	2.49
Arg	640	A	A	0.82	.	*	F	1.58	1.33
Cys	641	A	A	0.46	*	*	F	1.09	0.46
Lys	642	.	A	B	0.67	*	*	.	0.30	0.15
Leu	643	.	A	B	0.03	.	*	.	0.30	0.13
Ile	644	.	A	B	0.08	.	*	.	-0.60	0.25
Cys	645	.	A	B	-0.38	.	*	.	0.30	0.25
Gln	646	.	A	B	-0.60	*	*	.	-0.30	0.30
Ala	647	.	A	B	-0.99	*	*	.	-0.30	0.30
Lys	648	.	A	B	-0.42	*	*	F	-0.15	0.55
Gly	649	T	T	.	-0.23	*	.	F	0.65	0.50
Ile	650	T	T	.	-0.27	.	*	.	0.20	0.43
Gly	651	.	.	B	.	.	T	.	-1.12	.	*	.	-0.20	0.18
Tyr	652	.	.	B	.	.	T	.	-1.34	.	.	.	-0.20	0.14
Phe	653	.	.	B	B	.	.	.	-1.39	.	.	.	-0.60	0.16
Phe	654	.	.	B	B	.	.	.	-1.26	.	*	.	-0.60	0.29
Val	655	.	.	B	B	.	.	.	-0.32	.	*	.	-0.60	0.28
Leu	656	.	.	B	B	.	.	.	-0.83	.	*	.	-0.60	0.65
Gln	657	.	.	B	.	.	T	.	-1.44	.	.	.	-0.20	0.56
Pro	658	.	.	B	.	.	T	.	-0.74	*	.	F	-0.05	0.56

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.6-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James... Antig...	Emini Surfa...
Lys	659	T	T	.	-0.39	.	*	F	1.40	1.13
Val	660	.	.	B	.	.	T	.	0.16	.	.	F	0.85	0.65
Val	661	.	.	B	.	.	T	.	0.76	.	*	F	0.85	0.60
Asp	662	.	.	B	.	.	T	.	0.09	.	.	F	1.06	0.47
Gly	663	.	.	B	.	.	T	.	0.00	*	.	F	0.67	0.34
Thr	664	.	.	B	.	.	T	.	-0.26	*	.	F	1.48	0.61
Pro	665	.	.	B	0.60	.	.	F	1.49	0.56
Cys	666	T	.	.	1.16	.	.	F	2.10	0.95
Ser	667	T	C	0.84	.	.	F	1.89	0.88
Pro	668	T	T	.	0.89	.	.	F	1.88	0.82
Asp	669	T	T	.	0.34	.	.	F	1.82	2.06
Ser	670	T	T	.	-0.11	.	.	F	1.61	1.14
Thr	671	.	.	.	B	T	.	.	-0.30	.	*	F	0.85	0.39
Ser	672	.	.	B	B	.	.	.	0.00	.	*	F	-0.15	0.18
Val	673	.	.	B	B	.	.	.	-0.13	.	*	.	-0.60	0.23
Cys	674	.	.	B	B	.	.	.	-0.13	.	*	.	-0.60	0.16
Val	675	.	.	B	B	.	.	.	-0.50	.	*	.	-0.60	0.20
Gln	676	.	.	B	B	.	.	.	-1.04	.	*	F	-0.45	0.15
Gly	677	.	.	B	B	.	.	.	-0.70	.	*	F	-0.45	0.20
Gln	678	.	.	B	B	.	.	.	-0.43	.	*	F	-0.15	0.54
Cys	679	.	.	B	B	.	.	.	-0.11	.	.	.	0.30	0.32
Val	680	.	.	B	B	.	.	.	0.08	*	*	.	0.30	0.32

5

10

15

20

-31.7-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Lys	681	.	.	B	.	.	T	.	0.08	*	.	.	0.10	0.10
Ala	682	.	.	B	.	.	T	.	0.53	*	.	.	0.70	0.30
Gly	683	.	.	B	.	.	T	.	-0.36	*	.	.	1.00	0.80
Cys	684	.	.	B	.	.	T	.	-0.58	*	.	.	1.00	0.28
Asp	685	A	.	.	B	.	.	.	0.28	*	.	.	0.30	0.20
Arg	686	A	.	.	B	.	.	.	-0.07	*	.	.	0.60	0.33
Ile	687	A	.	.	B	.	.	.	0.57	*	.	.	0.60	0.82
Ile	688	A	.	.	B	.	.	.	0.96	*	.	F	0.75	0.99
Asp	689	A	T	.	1.67	*	*	F	1.30	1.01
Ser	690	A	T	.	0.97	*	*	F	1.30	2.88
Lys	691	A	T	.	0.86	*	.	F	1.61	3.55
Lys	692	T	T	.	1.79	*	*	F	2.32	3.55
Lys	693	T	.	.	2.01	*	*	F	2.43	5.30
Phe	694	T	.	.	1.67	*	*	F	2.74	1.42
Asp	695	T	T	.	1.11	*	.	F	3.10	0.70
Lys	696	.	.	B	.	.	T	.	0.40	*	.	F	2.39	0.26
Cys	697	.	.	B	.	.	T	.	0.01	*	.	.	1.63	0.16
Gly	698	.	.	B	.	.	T	.	-0.38	*	.	.	1.32	0.10
Val	699	.	.	B	0.32	*	.	.	0.21	0.05
Cys	700	T	.	.	-0.02	.	.	.	0.00	0.14
Gly	701	T	T	.	-0.37	.	.	F	0.65	0.14
Gly	702	T	T	.	-0.01	.	.	F	0.65	0.26

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.8-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Asn	703	T	T	.	-0.33	.	.	F	0.65	0.69
Gly	704	T	T	.	0.57	.	.	F	0.65	0.37
Ser	705	T	T	.	1.28	.	.	F	1.25	0.76
Thr	706	.	.	B	.	.	T	.	0.73	.	.	F	1.41	0.94
Cys	707	.	.	B	.	.	T	.	0.78	.	*	F	1.37	0.67
Lys	708	.	.	B	.	.	T	.	0.43	.	*	F	1.63	0.67
Lys	709	.	.	B	0.48	*	*	F	1.69	0.46
Ile	710	.	.	B	.	.	T	.	-0.08	*	*	F	2.60	1.14
Ser	711	.	.	B	.	.	T	.	-0.08	*	*	F	1.89	0.42
Gly	712	.	.	B	.	.	T	.	0.29	*	*	F	1.03	0.31
Ser	713	.	.	B	.	.	T	.	-0.34	*	*	F	0.77	0.58
Val	714	.	.	B	B	.	.	.	-0.34	.	*	F	0.11	0.44
Thr	715	.	.	B	B	.	.	.	0.33	.	.	F	0.73	0.89
Ser	716	.	.	B	B	.	.	.	0.29	.	.	F	1.16	1.03
Ala	717	.	.	B	0.39	.	.	F	1.64	1.37
Lys	718	T	C	0.66	.	.	F	2.32	1.49
Pro	719	T	T	.	1.51	*	.	F	2.80	1.51
Gly	720	T	T	.	0.93	*	.	F	2.52	2.50
Tyr	721	.	.	B	.	.	T	.	0.34	*	.	.	1.54	0.88
His	722	.	.	B	B	.	.	.	0.62	*	.	.	-0.04	0.40
Asp	723	.	.	B	B	.	.	.	-0.31	*	.	.	-0.32	0.58
Ile	724	.	.	B	B	.	.	.	-0.31	*	.	.	-0.60	0.26

5

10

15

20

-31.9-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James.. Antig...	Emini Surfa...
Ile	725	.	.	B	B	.	.	.	-0.28	*	.	.	-0.60	0.29
Thr	726	.	.	B	B	.	.	.	-0.38	*	.	.	-0.60	0.25
Ile	727	.	.	B	.	.	T	.	-0.93	*	.	.	-0.20	0.36
Pro	728	.	.	B	.	.	T	.	-1.24	*	.	F	-0.05	0.52
Thr	729	T	C	-0.36	*	.	F	0.15	0.52
Gly	730	T	C	-0.36	.	*	F	0.30	1.19
Ala	731	.	.	.	B	.	.	C	-0.04	.	*	F	-0.25	0.54
Thr	732	.	.	.	B	.	.	C	-0.01	.	*	F	0.65	0.65
Asn	733	.	.	B	B	.	.	.	0.24	.	*	F	-0.15	0.48
Ile	734	.	.	B	B	.	.	.	0.56	.	*	F	0.45	0.96
Glu	735	.	.	B	B	.	.	.	1.01	.	*	F	0.60	1.15
Val	736	.	.	B	B	.	.	.	1.60	.	*	F	0.90	1.40
Lys	737	.	.	B	B	.	.	.	1.91	.	*	F	1.24	3.21
Gln	738	.	.	B	2.02	.	*	F	1.78	3.21
Arg	739	.	.	B	2.57	*	*	F	2.12	8.48
Asn	740	.	.	B	.	.	T	.	2.27	*	*	F	2.66	4.20
Gln	741	T	T	.	3.23	*	*	F	3.40	3.25
Arg	742	T	T	.	3.19	*	.	F	3.06	3.25
Gly	743	T	T	.	3.19	*	.	F	3.00	3.25
Ser	744	T	.	.	2.73	*	.	F	2.74	3.02
Arg	745	C	2.43	*	*	F	2.48	1.52
Asn	746	T	T	.	1.73	*	.	F	2.82	2.06

5

10

15

20

-31.10-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James.. Antig...	Emini Surfa...
Asn	747	T	T	.	0.81	*	.	F	2.80	1.33
Gly	748	T	C	0.57	.	*	F	1.57	0.56
Ser	749	.	.	B	.	.	T	.	-0.02	.	*	F	0.79	0.35
Phe	750	.	A	B	-0.09	.	*	.	-0.04	0.15
Leu	751	.	A	B	-0.68	.	.	.	-0.32	0.31
Ala	752	.	A	B	-1.27	*	.	.	-0.60	0.23
Ile	753	.	A	B	-0.92	.	.	.	-0.60	0.27
Lys	754	A	A	-0.97	.	.	.	0.30	0.55
Ala	755	A	A	-0.58	.	.	.	0.30	0.54
Ala	756	A	A	-0.01	.	.	F	0.60	1.12
Asp	757	A	T	.	-0.31	.	.	F	0.85	0.87
Gly	758	.	.	B	.	.	T	.	-0.23	.	*	F	0.25	0.61
Thr	759	.	.	B	.	.	T	.	-0.28	.	.	F	-0.05	0.50
Tyr	760	.	.	B	.	.	T	.	-0.03	.	*	.	-0.20	0.48
Ile	761	.	.	B	0.56	.	*	.	-0.40	0.48
Leu	762	.	.	B	0.31	.	*	.	-0.40	0.55
Asn	763	.	.	B	.	.	T	.	0.34	.	*	F	-0.50	0.55
Gly	764	T	T	.	-0.16	.	*	F	0.50	1.14
Asp	765	T	T	.	-0.21	.	*	F	0.50	1.14
Tyr	766	T	C	0.37	.	*	F	0.45	0.95
Thr	767	.	.	B	B	.	.	.	0.37	.	*	.	-0.15	1.38
Leu	768	.	.	B	B	.	.	.	0.37	*	*	.	-0.60	0.68

5

10

15

20

-31.11-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... /Antig...	Emini Surfa...
Ser	769	.	.	B	B	.	.	.	0.71	*	.	F	-0.45	0.75
Thr	770	.	.	B	B	.	.	.	0.71	*	*	F	-0.15	0.90
Leu	771	A	.	.	B	.	.	.	0.07	*	.	F	0.60	1.83
Glu	772	A	.	.	B	.	.	.	-0.22	*	.	F	0.45	0.96
Gln	773	A	.	.	B	.	.	.	0.34	*	*	F	0.45	0.66
Asp	774	A	.	.	B	.	.	.	0.69	.	*	F	0.00	1.25
Ile	775	A	.	.	B	.	.	.	0.66	.	*	.	0.75	1.44
Met	776	A	.	.	B	.	.	.	0.61	.	*	.	0.30	0.82
Tyr	777	.	.	B	B	.	.	.	-0.24	.	*	.	-0.30	0.37
Lys	778	.	.	B	B	.	.	.	-1.06	.	*	.	-0.60	0.39
Gly	779	.	.	B	B	.	.	.	-0.94	.	*	.	-0.60	0.32
Val	780	.	.	B	B	.	.	.	-0.30	.	*	.	-0.30	0.40
Val	781	.	.	B	B	.	.	.	0.00	.	*	.	-0.30	0.32
Leu	782	.	.	B	B	.	.	.	-0.10	.	*	.	-0.60	0.43
Arg	783	.	.	B	B	.	.	.	-0.44	.	*	.	-0.60	0.57
Tyr	784	.	.	B	.	.	T	.	-0.40	*	*	.	0.25	1.03
Ser	785	T	T	.	-0.13	.	*	F	0.80	1.68
Gly	786	T	C	0.13	*	*	F	1.05	0.86
Ser	787	T	C	0.13	.	*	F	0.45	0.56
Ser	788	.	A	C	0.02	.	*	F	0.05	0.34
Ala	789	A	A	0.38	*	.	F	0.45	0.60
Ala	790	A	A	-0.21	*	*	.	0.60	0.88

5

10

15

20

-31.12-

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni... Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Leu	791	A	A	0.24	*	*	.	0.30	0.46
Glu	792	A	A	0.24	*	*	.	0.60	0.89
Arg	793	.	A	B	B	.	.	.	-0.16	*	*	F	0.90	1.18
Ile	794	A	A	.	B	.	.	.	0.13	*	*	F	0.60	1.24
Arg	795	A	A	.	B	.	.	.	0.51	*	*	F	0.75	0.96
Ser	796	.	A	.	.	T	.	.	0.51	.	*	F	1.13	0.76
Phe	797	C	0.56	.	*	F	0.81	0.89
Ser	798	T	C	0.44	.	*	F	1.89	0.91
Pro	799	T	C	1.12	*	*	F	2.32	1.17
Leu	800	T	T	.	0.20	*	*	F	2.80	2.10
Lys	801	T	C	0.19	*	*	F	2.32	1.29
Glu	802	C	0.00	.	*	F	1.84	1.20
Pro	803	A	.	.	B	.	.	.	0.30	.	*	F	1.16	1.02
Leu	804	A	.	.	B	.	.	.	-0.34	.	*	F	0.73	0.89
Thr	805	.	.	B	B	.	.	.	-0.34	.	*	.	-0.30	0.38
Ile	806	.	.	B	B	.	.	.	-0.70	.	*	.	-0.60	0.20
Gln	807	.	.	B	B	.	.	.	-1.56	.	.	.	-0.60	0.35
Val	808	.	.	B	B	.	.	.	-1.69	.	*	.	-0.60	0.18
Leu	809	.	.	B	B	.	.	.	-0.88	.	*	.	-0.60	0.26
Thr	810	.	.	B	B	.	.	.	-1.16	.	.	.	-0.60	0.24
Val	811	.	.	B	B	.	.	.	-1.08	.	*	.	-0.60	0.33
Gly	812	.	.	B	B	.	.	.	-0.97	*	*	.	-0.60	0.33

5

10

15

20

-31.13-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James... Antig...	Enini Surfa...
Asn	813	A	-0.32	*	*	.	0.12	0.44
Ala	814	A	0.53	*	*	.	0.34	0.92
Leu	815	A	-0.04	*	*	F	1.76	1.86
Arg	816	.	.	B	0.86	*	*	F	1.53	0.81
Pro	817	.	.	B	0.96	*	*	F	2.20	1.61
Lys	818	.	.	B	B	.	.	.	0.64	*	*	F	1.48	3.05
Ile	819	.	.	B	B	.	.	.	0.99	.	*	F	1.56	2.25
Lys	820	.	.	B	B	.	.	.	1.10	*	*	F	0.44	2.28
Tyr	821	.	.	B	B	.	.	.	0.13	*	*	.	-0.38	0.99
Thr	822	.	.	B	B	.	.	.	0.39	.	*	.	-0.45	1.04
Tyr	823	A	.	.	B	.	.	.	0.39	.	*	.	-0.45	1.04
Phe	824	A	.	.	B	.	.	.	1.32	.	*	.	-0.45	1.33
Val	825	A	.	.	B	.	.	.	1.32	.	.	.	0.45	1.85
Lys	826	A	.	.	B	.	.	.	1.57	.	.	F	0.90	2.36
Lys	827	A	A	1.58	*	.	F	0.90	4.71
Lys	828	A	A	1.12	*	.	F	0.90	8.51
Lys	829	A	A	1.82	*	.	F	0.90	3.68
Glu	830	A	A	2.09	*	.	F	0.90	2.96
Ser	831	A	A	1.16	*	.	F	0.90	1.50
Phe	832	A	A	0.90	.	.	.	0.30	0.52
Asn	833	.	A	B	0.54	*	.	.	-0.30	0.47
Ala	834	.	.	B	-0.20	*	*	.	-0.40	0.50

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.14-

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni... Turn	Garni... Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ile	835	C	-0.50	*	.	.	-0.20	0.50
Pro	836	T	.	T	C	-0.79	.	.	.	0.00	0.42
Thr	837	T	T	T	.	-0.38	*	*	.	0.20	0.42
Phe	838	A	.	.	.	T	.	T	.	-1.23	*	.	.	-0.20	0.63
Ser	839	T	.	T	C	-1.53	*	.	.	0.00	0.30
Ala	840	.	A	B	B	-0.64	*	.	.	-0.60	0.15
Trp	841	.	A	B	B	-0.43	.	.	.	-0.60	0.29
Val	842	A	A	.	B	-0.41	.	.	.	-0.30	0.38
Ile	843	A	A	.	B	-0.06	*	.	.	-0.60	0.40
Glu	844	A	A	.	B	0.24	*	.	.	-0.60	0.37
Glu	845	A	A	0.17	*	.	.	0.30	0.87
Trp	846	A	A	0.16	*	.	.	0.61	0.66
Gly	847	A	A	1.06	*	.	F	1.37	0.51
Glu	848	.	A	.	.	.	T	.	.	1.64	*	.	F	2.08	0.59
Cys	849	.	A	.	.	.	T	.	.	0.98	*	.	F	2.09	0.76
Ser	850	T	T	T	.	0.98	.	.	F	3.10	0.41
Lys	851	T	T	T	.	0.46	.	.	F	2.79	0.41
Ser	852	T	T	T	.	0.46	.	.	F	2.18	0.63
Cys	853	T	T	T	.	0.17	*	*	.	2.02	0.47
Glu	854	A	A	0.83	*	.	.	0.61	0.24
Leu	855	A	A	1.24	.	.	.	-0.30	0.32
Gly	856	.	A	1.31	.	*	.	0.85	1.16

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.15-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James... Antig...	Emini Surfa...
Trp	857	A	A	0.80	*	*	.	0.75	1.31
Gln	858	A	A	0.61	*	*	.	-0.15	1.31
Arg	859	A	A	0.61	*	*	.	-0.30	0.98
Arg	860	.	A	B	0.76	.	*	.	0.45	1.61
Leu	861	.	A	B	1.21	*	.	.	0.60	0.50
Val	862	.	A	B	1.50	*	.	.	0.60	0.50
Glu	863	.	A	B	0.61	.	.	.	0.94	0.43
Cys	864	.	A	B	0.50	.	.	.	0.98	0.36
Arg	865	.	A	.	.	T	.	.	0.04	.	.	F	2.17	0.78
Asp	866	T	T	.	0.86	.	.	F	2.91	0.45
Ile	867	T	T	.	1.50	.	.	F	3.40	1.45
Asn	868	T	T	.	0.91	.	.	F	3.06	1.14
Gly	869	T	C	1.28	.	.	F	2.07	0.69
Gln	870	T	C	1.17	.	*	F	1.28	1.32
Pro	871	T	C	0.50	.	*	F	1.54	1.42
Ala	872	T	C	0.80	.	*	F	1.05	0.77
Ser	873	A	T	.	0.84	*	.	F	0.85	0.45
Glu	874	A	A	1.19	*	.	F	0.75	0.58
Cys	875	A	A	0.33	*	.	.	0.60	1.00
Ala	876	A	A	0.59	*	.	.	0.60	0.55
Lys	877	A	A	0.97	*	.	F	0.75	0.64
Glu	878	A	A	0.68	*	.	F	0.90	1.84

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.16-

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni... Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James... Antig...	Emini Surfa...
Val	879	A	A	0.38	*	.	F	0.90	1.84
Lys	880	A	A	0.73	*	.	F	0.90	1.23
Pro	881	A	T	.	1.43	*	.	F	1.30	1.03
Ala	882	T	T	.	1.18	*	.	F	2.01	2.71
Ser	883	T	T	.	0.51	.	*	F	2.32	2.10
Thr	884	T	T	.	0.78	.	*	F	2.18	0.73
Arg	885	.	.	B	.	.	T	.	0.73	.	*	F	2.09	0.73
Pro	886	T	T	.	0.91	.	*	F	3.10	0.91
Cys	887	T	T	.	1.29	.	*	.	2.64	0.85
Ala	888	T	T	.	0.92	.	*	.	2.43	0.67
Asp	889	T	.	.	1.02	.	*	.	1.72	0.23
His	890	T	C	0.91	.	*	.	1.51	0.67
Pro	891	T	T	.	0.83	.	.	.	1.65	1.16
Cys	892	T	T	.	1.50	.	*	.	1.00	0.73
Pro	893	T	T	.	1.28	.	*	.	0.60	0.93
Gln	894	.	A	.	.	T	.	.	0.93	.	.	.	0.10	0.49
Trp	895	.	A	B	0.97	.	.	.	-0.40	0.91
Gln	896	.	A	B	0.89	.	.	.	-0.05	1.02
Leu	897	.	A	B	1.26	.	.	.	-0.60	0.62
Gly	898	T	.	.	1.17	.	.	.	0.00	0.79
Glu	899	T	.	.	0.50	.	.	F	0.45	0.61
Trp	900	T	.	.	0.49	.	.	F	0.45	0.40

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.17-

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni... Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ser	901	T	T	.	0.53	.	.	F	0.65	0.54
Ser	902	T	T	.	1.03	.	.	F	1.25	0.62
Cys	903	T	T	.	0.71	.	*	F	0.65	0.85
Ser	904	T	T	.	0.37	*	*	F	1.25	0.34
Lys	905	T	.	.	0.70	*	*	F	1.05	0.25
Thr	906	T	.	.	0.66	*	*	F	1.69	0.94
Cys	907	T	.	.	0.71	*	.	F	2.03	0.69
Gly	908	T	T	.	1.42	*	*	F	2.27	0.54
Lys	909	T	T	.	1.77	*	*	F	2.61	0.75
Gly	910	T	T	.	1.83	*	*	F	3.40	2.81
Tyr	911	T	T	.	1.84	.	.	F	3.06	5.57
Lys	912	.	A	B	1.70	*	.	F	1.92	3.73
Lys	913	.	A	B	2.09	*	.	F	1.58	3.11
Arg	914	.	A	B	1.38	*	.	F	1.24	3.97
Ser	915	.	A	B	0.91	*	.	F	0.90	1.06
Leu	916	.	A	B	0.86	*	.	F	0.75	0.44
Lys	917	.	A	B	0.78	*	.	.	0.30	0.30
Cys	918	.	A	B	0.73	*	.	.	-0.30	0.30
Leu	919	.	A	B	0.28	*	.	.	0.30	0.62
Ser	920	.	.	B	0.23	.	.	.	0.50	0.31
His	921	.	.	B	.	.	T	.	0.19	*	.	F	0.85	0.56
Asp	922	T	T	.	-0.67	*	.	F	0.65	0.51

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.18-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl.. Flexi...	James... Antig...	Emini Surfa...
Gly	923	T	T	.	-0.30	.	.	F	0.65	0.31
Gly	924	T	T	.	0.48	.	.	F	0.65	0.31
Val	925	.	.	B	0.78	.	.	.	-0.10	0.25
Leu	926	.	.	B	0.51	.	.	.	-0.10	0.44
Ser	927	.	.	B	-0.16	.	.	.	-0.10	0.59
His	928	.	.	B	.	.	T	.	0.19	.	.	.	0.10	0.43
Glu	929	.	.	B	.	.	T	.	0.32	.	.	F	0.85	0.87
Ser	930	A	T	.	0.37	*	.	F	1.30	1.00
Cys	931	A	T	.	1.22	*	.	F	0.85	0.61
Asp	932	A	T	.	1.57	*	.	F	1.15	0.70
Pro	933	A	T	.	1.39	*	.	F	1.30	1.05
Leu	934	A	T	.	1.43	*	.	F	1.30	3.02
Lys	935	A	T	.	1.70	*	.	F	1.30	3.62
Lys	936	A	A	1.67	*	.	F	0.90	3.18
Pro	937	A	A	0.78	*	.	F	0.90	3.34
Lys	938	A	A	0.99	*	*	F	0.90	1.17
His	939	A	A	1.10	*	*	.	0.60	0.98
Phe	940	.	A	B	0.39	*	*	.	-0.30	0.55
Ile	941	.	A	B	0.03	*	*	.	-0.30	0.15
Asp	942	A	A	-0.36	*	*	.	-0.60	0.16
Phe	943	A	A	-0.99	*	*	.	-0.60	0.18
Cys	944	A	A	-0.96	.	.	.	-0.60	0.26

5

10

15

20

-31.19-

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni... Turn	Chou-... Turn	Garni.. Coil	Kyle-... Hydro...	Eisen.. Alpha	Eisen.. Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Thr	945	A	A	-0.92	.	*	.	0.30	0.27
Met	946	A	A	-0.33	.	*	.	-0.60	0.16
Ala	947	A	A	-0.72	.	.	.	-0.30	0.41
Glu	948	A	A	-0.41	.	.	.	0.30	0.36
Cys	949	A	A	-0.13	.	.	.	0.30	0.47
Ser	950	A	A	-0.21	.	.	.	0.30	0.60

-31.20-

Table 2

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Met	1	.	.	B	-0.37	.	.	.	-0.40	0.50
Phe	2	.	.	B	-0.57	.	.	.	-0.40	0.61
Pro	3	.	.	B	-0.77	.	.	.	-0.40	0.48
Ala	4	C	-0.59	.	*	.	-0.20	0.49
Pro	5	C	-0.09	.	*	.	-0.20	0.87
Ala	6	C	0.22	*	*	.	0.85	1.11
Ala	7	T	C	0.11	*	*	.	0.45	1.15
Pro	8	A	T	.	0.11	*	.	.	-0.20	0.61
Arg	9	T	T	.	0.00	*	.	.	0.20	0.94
Trp	10	.	.	B	.	.	T	.	-0.60	*	.	.	-0.20	0.81
Leu	11	.	A	B	-0.82	*	.	.	-0.60	0.43
Pro	12	.	A	B	-1.04	*	.	.	-0.60	0.18
Phe	13	.	A	B	-1.64	*	.	.	-0.60	0.14
Leu	14	A	A	-2.57	*	.	.	-0.60	0.14
Leu	15	A	A	-3.09	.	.	.	-0.60	0.08
Leu	16	A	A	-3.09	.	.	.	-0.60	0.07
Leu	17	A	A	-3.69	.	.	.	-0.60	0.07
Leu	18	A	A	-3.80	.	.	.	-0.60	0.07
Leu	19	A	A	-3.20	.	.	.	-0.60	0.07
Leu	20	A	A	-3.20	.	.	.	-0.60	0.14

5

10

15

20

-31.21-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Leu	21	A	A	-2.98	*	.	.	-0.60	0.14
Leu	22	.	A	B	-2.06	*	.	.	-0.60	0.17
Pro	23	.	A	B	-1.59	*	.	.	-0.60	0.39
Leu	24	A	A	-1.37	*	.	.	-0.60	0.47
Ala	25	A	A	-0.77	*	.	.	-0.04	0.58
Arg	26	.	A	B	-0.54	*	.	.	0.82	0.58
Gly	27	.	A	B	0.38	.	.	F	0.63	0.71
Ala	28	.	.	B	0.38	.	.	F	2.14	1.37
Pro	29	C	0.60	.	.	F	2.60	1.08
Ala	30	.	.	B	0.60	.	.	F	1.84	1.11
Arg	31	.	.	B	0.14	.	.	F	1.58	1.11
Pro	32	.	.	B	0.14	.	*	F	1.17	0.71
Ala	33	.	.	B	.	.	T	.	0.73	.	*	F	1.11	0.69
Ala	34	A	T	.	0.36	.	*	F	0.85	0.61
Gly	35	T	C	0.64	.	*	F	0.45	0.40
Gly	36	T	C	0.53	.	*	F	0.45	0.53
Gln	37	A	-0.07	.	.	F	0.65	0.91
Ala	38	.	.	B	-0.33	.	.	F	0.65	0.76
Ser	39	.	.	B	B	B	.	.	-0.60	.	.	F	-0.15	0.57
Glu	40	.	.	B	B	B	.	.	-0.47	.	.	F	-0.15	0.24
Leu	41	.	.	B	B	B	.	.	-0.43	.	*	.	-0.30	0.37
Val	42	.	.	B	B	B	.	.	-0.32	.	*	.	-0.30	0.40

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.22-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Val	43	.	.	B	B	B	.	.	-0.54	.	*	.	0.30	0.46
Pro	44	.	.	B	B	B	.	.	-0.46	.	*	F	-0.24	0.46
Thr	45	.	.	B	B	B	.	.	-0.80	.	*	F	0.27	0.95
Arg	46	.	.	B	B	B	.	.	-0.29	.	*	F	0.63	1.26
Leu	47	T	C	-0.02	.	*	F	2.04	1.10
Pro	48	T	C	0.49	*	*	F	2.10	0.77
Gly	49	T	C	0.70	*	*	F	1.89	0.39
Ser	50	T	C	0.20	*	*	F	1.68	0.81
Ala	51	A	A	-0.50	*	*	F	0.87	0.43
Gly	52	A	A	-0.50	.	.	F	0.66	0.44
Glu	53	A	A	-0.32	.	*	.	-0.30	0.27
Leu	54	A	A	-0.79	.	*	.	-0.30	0.37
Ala	55	A	A	-0.79	.	*	.	-0.60	0.31
Leu	56	A	A	-0.79	.	*	.	-0.60	0.24
His	57	A	A	-1.14	.	*	.	-0.60	0.29
Leu	58	A	A	-1.49	*	*	.	-0.60	0.25
Ser	59	A	A	-0.63	*	*	.	-0.60	0.30
Ala	60	A	A	-0.39	*	*	.	-0.30	0.44
Phe	61	A	A	-0.28	*	*	.	-0.30	0.53
Gly	62	T	T	.	-1.10	*	.	.	0.50	0.34
Lys	63	A	T	.	-1.10	.	*	F	-0.05	0.25
Gly	64	.	.	B	.	.	T	.	-0.69	.	*	.	-0.20	0.24

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.23-

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni.. Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Phe	65	.	.	B	.	.	T	.	-0.91	.	*	.	0.70	0.47
Val	66	.	.	B	B	.	.	.	-0.80	*	*	.	-0.30	0.19
Leu	67	.	.	B	B	.	.	.	-0.67	*	*	.	-0.30	0.20
Arg	68	.	.	B	B	.	.	.	-0.71	.	*	.	0.00	0.35
Leu	69	.	.	B	B	.	.	.	-0.37	*	*	.	1.20	0.80
Ala	70	T	C	0.03	.	*	.	2.55	1.61
Pro	71	T	C	0.19	*	*	F	3.00	1.10
Asp	72	T	T	.	0.19	.	*	F	2.60	1.16
Asp	73	A	T	.	-0.51	.	*	F	1.75	0.95
Ser	74	A	A	0.09	.	.	.	0.90	0.62
Phe	75	A	A	0.68	.	.	.	0.60	0.57
Leu	76	A	A	0.19	.	*	.	0.30	0.59
Ala	77	A	A	0.23	.	*	.	-0.60	0.38
Pro	78	A	A	-0.66	.	*	.	-0.30	0.89
Glu	79	A	A	-0.36	*	*	F	-0.15	0.75
Phe	80	A	A	0.46	*	.	F	0.90	1.29
Lys	81	A	A	0.46	*	*	F	0.90	1.63
Ile	82	A	A	0.70	*	.	F	0.75	0.78
Glu	83	A	A	0.57	*	*	F	0.45	0.89
Arg	84	A	A	0.27	*	*	F	0.75	0.44
Leu	85	.	A	.	.	T	.	.	0.62	*	*	F	0.85	0.84
Gly	86	.	A	.	.	T	.	.	0.69	*	*	F	1.15	0.48

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.24-

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni.. Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Gly	87	T	C	0.99	*	*	F	1.35	0.48
Ser	88	T	C	0.68	*	*	F	1.05	0.59
Gly	89	T	C	0.22	*	*	F	1.05	0.86
Arg	90	.	.	B	.	.	T	.	0.69	.	*	F	1.19	0.86
Ala	91	T	C	1.03	.	*	F	1.73	0.63
Thr	92	.	.	B	.	.	T	.	1.49	.	*	F	2.32	1.11
Gly	93	.	.	B	.	.	T	.	1.44	.	*	F	2.66	1.11
Gly	94	T	T	.	0.98	*	*	F	3.40	1.09
Glu	95	.	.	B	0.98	*	*	F	2.31	0.62
Arg	96	.	.	B	1.22	*	.	F	2.12	1.23
Gly	97	T	.	.	0.87	*	*	F	2.18	1.23
Leu	98	.	.	B	.	.	T	.	0.51	*	.	F	1.49	0.38
Arg	99	.	.	B	.	.	T	.	0.16	*	.	.	0.70	0.17
Gly	100	.	.	B	.	.	T	.	-0.14	*	.	.	-0.20	0.15
Cys	101	.	.	B	.	.	T	.	-0.60	*	.	.	-0.20	0.24
Phe	102	.	.	B	-0.57	.	*	.	-0.10	0.12
Phe	103	.	.	B	.	.	T	.	-0.61	.	*	.	-0.20	0.18
Ser	104	.	.	B	.	.	T	.	-0.72	.	*	F	-0.05	0.24
Gly	105	T	C	-0.72	.	*	F	0.15	0.45
Thr	106	T	C	-0.06	*	*	F	0.45	0.52
Val	107	.	.	.	B	.	.	C	0.43	.	*	F	1.25	0.67
Asn	108	.	.	.	B	.	.	C	1.13	.	*	F	1.70	1.05

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.25-

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni.. Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen-... Alpha	Eisen-... Beta	Karpl-... Flexi...	James-... Antig...	Emini Surfa...
Gly	109	.	.	.	B	.	.	C	1.13	.	*	F	2.30	1.26
Glu	110	T	C	0.67	.	*	F	3.00	2.27
Pro	111	A	T	.	0.39	.	*	F	2.50	1.16
Glu	112	A	T	.	0.66	.	*	F	2.20	1.19
Ser	113	A	T	.	-0.20	.	.	F	1.75	0.69
Leu	114	A	A	.	B	.	.	.	-0.16	.	.	.	0.00	0.33
Ala	115	A	A	.	B	.	.	.	-0.97	.	.	.	-0.30	0.26
Ala	116	A	A	.	B	.	.	.	-1.42	.	.	.	-0.60	0.16
Val	117	A	A	.	B	.	.	.	-1.31	.	.	.	-0.60	0.10
Ser	118	.	A	B	B	.	.	.	-1.36	*	.	.	-0.30	0.20
Leu	119	.	.	B	B	.	.	.	-1.36	*	.	.	-0.30	0.20
Cys	120	.	.	B	.	.	T	.	-1.07	*	.	.	0.10	0.22
Arg	121	.	.	B	.	.	T	.	-0.82	*	.	.	0.10	0.22
Gly	122	T	T	.	-0.27	*	.	F	0.65	0.26
Leu	123	T	T	.	-0.67	*	.	F	1.25	0.65
Ser	124	T	C	-0.67	*	.	F	0.45	0.29
Gly	125	.	.	B	.	.	T	.	-0.81	.	*	F	-0.05	0.24
Ser	126	.	.	B	.	.	T	.	-0.92	.	*	F	-0.05	0.24
Phe	127	.	.	B	.	.	T	.	-0.92	.	*	.	0.10	0.30
Leu	128	.	A	B	.	.	.	C	-0.11	.	*	.	-0.30	0.30
Leu	129	.	A	0.19	.	*	F	0.65	0.39
Asp	130	A	A	-0.17	.	.	F	0.45	0.77

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.26-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Gly	131	A	A	-0.18	.	.	F	0.45	0.81
Glu	132	A	A	-0.37	.	*	F	0.90	1.42
Glu	133	A	A	0.44	.	*	F	0.75	0.60
Phe	134	A	A	1.04	.	*	.	0.45	1.04
Thr	135	.	A	B	1.04	.	*	.	0.30	0.93
Ile	136	.	.	B	1.04	.	*	F	0.05	0.93
Gln	137	.	.	B	0.46	.	*	F	-0.10	1.06
Pro	138	C	0.11	.	*	F	0.25	0.75
Gln	139	T	.	.	0.47	.	*	F	0.60	1.05
Gly	140	T	C	0.48	.	*	F	0.45	0.60
Ala	141	T	T	.	0.56	.	*	F	1.25	0.52
Gly	142	T	C	-0.03	.	.	F	0.45	0.25
Gly	143	T	C	0.18	.	.	F	0.65	0.25
Ser	144	C	-0.03	.	.	F	0.65	0.43
Leu	145	.	.	B	0.28	*	.	F	0.65	0.68
Ala	146	.	.	B	0.98	*	.	F	0.85	0.93
Gln	147	.	.	B	.	.	T	.	0.51	.	*	F	2.00	1.36
Pro	148	.	.	B	.	.	T	.	0.86	*	.	.	1.05	1.36
His	149	.	.	B	.	.	T	.	1.27	*	.	.	1.45	2.34
Arg	150	.	.	B	.	.	T	.	1.79	*	.	.	1.55	2.64
Leu	151	.	.	B	2.03	*	.	.	0.85	1.80
Gln	152	.	.	B	1.82	*	.	.	0.65	1.31

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.27-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Arg	153	T	.	.	1.44	*	.	.	1.05	1.03
Trp	154	T	.	.	1.13	*	.	F	0.84	1.26
Gly	155	T	C	0.43	*	.	F	0.93	0.72
Pro	156	T	C	1.36	*	.	F	1.17	0.37
Ala	157	T	T	.	1.14	*	.	F	1.61	0.69
Gly	158	T	C	0.22	*	.	F	2.40	1.08
Ala	159	C	0.30	*	*	F	1.81	0.58
Arg	160	.	.	B	0.76	*	*	F	1.37	0.89
Pro	161	.	.	B	0.62	*	*	F	1.58	1.75
Leu	162	C	1.00	*	*	F	1.84	1.72
Pro	163	C	1.34	*	*	F	1.90	1.35
Arg	164	C	1.64	*	*	F	2.20	1.52
Gly	165	T	C	1.53	*	*	F	2.40	1.93
Pro	166	T	C	0.89	*	.	F	3.00	2.17
Glu	167	T	C	1.70	*	.	F	2.55	0.82
Trp	168	A	T	.	1.60	*	.	.	2.05	1.44
Glu	169	A	1.14	*	.	.	1.85	1.34
Val	170	A	1.49	.	.	F	1.85	0.77
Glu	171	A	1.36	.	*	F	2.00	1.26
Thr	172	A	1.36	.	*	F	2.15	0.72
Gly	173	T	C	1.76	.	.	F	3.00	1.68
Glu	174	A	T	.	1.76	.	.	F	2.50	1.90

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.28-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Gly	175	A	T	.	2.61	.	.	F	2.20	2.28
Gln	176	A	T	.	2.72	.	.	F	1.90	4.00
Arg	177	A	A	2.69	.	*	F	1.54	4.52
Gln	178	A	A	3.03	.	*	F	1.58	4.52
Glu	179	.	A	.	.	T	.	.	3.00	*	*	F	2.32	4.36
Arg	180	.	A	.	.	T	.	.	3.34	*	.	F	2.66	3.03
Gly	181	T	T	.	3.34	.	*	F	3.40	3.03
Asp	182	T	C	3.23	.	.	F	2.86	3.03
His	183	T	C	2.93	.	*	F	2.52	2.58
Gln	184	T	C	2.93	.	*	F	2.18	3.50
Glu	185	.	A	C	2.82	.	*	F	1.44	3.63
Asp	186	A	A	3.17	.	.	F	0.90	4.61
Ser	187	A	A	2.87	.	.	F	0.90	4.61
Glu	188	A	A	2.90	.	.	F	0.90	3.57
Glu	189	A	A	2.90	.	.	F	0.90	3.70
Glu	190	A	A	2.90	.	.	F	0.90	4.79
Ser	191	A	A	2.90	.	.	F	0.90	4.79
Gln	192	A	A	2.61	.	.	F	0.90	4.79
Glu	193	A	A	2.61	.	.	F	0.90	2.79
Glu	194	A	A	2.27	.	.	F	0.90	3.61
Glu	195	A	A	1.68	.	.	F	0.90	2.06
Ala	196	A	A	1.68	.	.	F	1.16	1.20

5

10

15

20

-31.29-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Glu	197	A	A	1.68	.	.	F	1.27	0.93
Gly	198	A	A	1.47	.	.	F	1.53	0.93
Ala	199	.	A	.	.	T	.	.	1.26	.	.	F	2.34	1.42
Ser	200	C	1.04	.	.	F	2.60	1.27
Glu	201	C	1.42	*	.	F	2.04	1.99
Pro	202	C	0.61	*	.	F	1.78	3.04
Pro	203	C	0.61	.	.	F	1.52	1.87
Pro	204	T	C	0.61	.	.	F	1.46	1.07
Pro	205	T	C	0.60	.	.	F	0.45	0.70
Leu	206	T	C	0.30	*	*	F	0.45	0.65
Gly	207	.	.	B	.	.	T	.	0.62	.	*	F	0.51	0.57
Ala	208	.	.	B	0.52	.	*	F	1.17	0.72
Thr	209	.	.	B	0.78	*	*	F	1.58	1.25
Ser	210	.	.	B	.	.	T	.	1.10	*	.	F	2.34	2.53
Arg	211	.	.	B	.	.	T	.	1.21	*	.	F	2.60	4.91
Thr	212	.	.	B	.	.	T	.	0.70	*	.	F	2.34	2.95
Lys	213	.	.	B	.	.	T	.	0.99	*	.	F	2.08	1.63
Arg	214	.	.	B	B	.	.	.	1.30	*	.	F	1.42	1.12
Phe	215	.	.	B	B	.	.	.	1.01	*	*	.	1.01	1.34
Val	216	.	.	B	B	.	.	.	1.01	*	*	.	0.60	0.68
Ser	217	A	.	.	B	.	.	.	0.62	*	*	.	0.60	0.68
Glu	218	A	A	-0.28	*	*	.	-0.30	0.68

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.30-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ala	219	A	A	.	B	.	.	.	-0.39	*	*	.	0.30	0.68
Arg	220	A	A	.	B	.	.	.	0.00	*	*	.	0.60	0.87
Phe	221	A	A	.	B	.	.	.	0.04	*	.	.	0.60	0.73
Val	222	A	A	.	B	.	.	.	-0.47	*	*	.	-0.30	0.59
Glu	223	A	A	.	B	.	.	.	-1.32	*	*	.	-0.30	0.25
Thr	224	A	A	.	B	.	.	.	-1.32	*	*	.	-0.60	0.21
Leu	225	A	A	.	B	.	.	.	-1.43	*	*	.	-0.60	0.29
Leu	226	A	A	.	B	.	.	.	-1.32	.	.	.	0.30	0.28
Val	227	A	A	.	B	.	.	.	-0.77	.	.	.	-0.60	0.20
Ala	228	A	A	.	B	.	.	.	-1.37	.	.	.	-0.30	0.32
Asp	229	A	A	.	B	.	.	.	-1.64	.	.	.	-0.30	0.38
Ala	230	A	A	-1.42	.	.	.	-0.30	0.52
Ser	231	A	A	-1.31	.	.	.	0.30	0.52
Met	232	A	A	-0.70	.	.	.	-0.30	0.27
Ala	233	A	A	-0.46	.	.	.	-0.60	0.42
Ala	234	A	A	-1.04	.	.	.	-0.60	0.31
Phe	235	A	A	-0.46	.	.	.	-0.60	0.32
Tyr	236	A	A	-0.97	.	.	.	-0.60	0.52
Gly	237	A	A	-0.37	.	.	.	-0.60	0.43
Ala	238	A	A	0.22	.	.	.	-0.60	0.86
Asp	239	A	A	0.78	*	*	.	-0.30	0.88
Leu	240	A	A	0.59	*	.	.	0.45	1.21

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.31-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Gln	241	A	A	.	B	.	.	.	0.02	*	*	.	-0.30	0.84
Asn	242	A	A	.	B	.	.	.	0.06	*	.	.	-0.30	0.41
His	243	.	A	B	B	.	.	.	-0.17	*	*	.	-0.60	0.72
Ile	244	.	A	B	B	.	.	.	-0.77	*	.	.	-0.60	0.35
Leu	245	.	A	B	B	.	.	.	-0.26	*	.	.	-0.60	0.21
Thr	246	.	A	B	B	.	.	.	-1.11	*	.	.	-0.60	0.21
Leu	247	.	A	B	B	.	.	.	-1.70	*	.	.	-0.60	0.22
Met	248	A	A	.	B	.	.	.	-2.26	*	*	.	-0.60	0.27
Ser	249	A	A	.	B	.	.	.	-1.26	*	*	.	-0.60	0.19
Val	250	A	A	.	B	.	.	.	-1.33	*	*	.	-0.30	0.45
Ala	251	A	A	.	B	.	.	.	-1.27	*	*	.	-0.30	0.32
Ala	252	A	A	.	B	.	.	.	-0.41	*	*	.	-0.60	0.37
Arg	253	A	A	.	B	.	.	.	0.16	*	*	.	-0.15	1.01
Ile	254	A	A	.	B	.	.	.	0.24	*	*	.	0.45	1.36
Tyr	255	A	0.80	*	*	.	0.99	2.08
Lys	256	.	.	B	0.50	*	*	.	1.33	1.42
His	257	.	.	B	.	.	T	.	1.13	.	*	F	1.12	1.42
Pro	258	T	T	C	1.02	.	*	F	2.56	1.81
Ser	259	T	T	.	1.61	.	*	F	3.40	1.46
Ile	260	T	T	.	0.97	.	*	F	2.76	1.44
Lys	261	.	.	B	0.92	.	*	F	1.67	0.65
Asn	262	T	.	.	0.14	*	*	F	1.73	0.78

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.32-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ser	263	.	.	B	B	.	.	.	-0.24	*	*	F	0.19	0.92
Ile	264	.	.	B	B	.	.	.	-0.80	*	*	.	-0.30	0.45
Asn	265	.	.	B	B	.	.	.	-0.77	*	*	.	-0.60	0.21
Leu	266	.	.	B	B	.	.	.	-0.77	.	*	.	-0.60	0.12
Met	267	A	.	.	B	.	.	.	-1.62	*	.	.	-0.60	0.33
Val	268	.	.	B	B	.	.	.	-2.13	.	*	.	-0.60	0.15
Val	269	.	.	B	B	.	.	.	-2.13	.	.	.	-0.60	0.15
Lys	270	A	.	.	B	.	.	.	-2.99	.	.	.	-0.60	0.11
Val	271	.	.	B	B	.	.	.	-2.18	.	.	.	-0.60	0.11
Leu	272	.	.	B	B	.	.	.	-1.58	.	.	.	-0.30	0.25
Ile	273	A	.	.	B	.	.	.	-0.72	.	.	.	0.30	0.21
Val	274	A	.	.	B	.	.	.	0.18	.	*	.	0.30	0.49
Glu	275	A	.	.	B	.	.	.	-0.16	.	.	.	0.75	1.19
Asp	276	A	A	0.36	.	.	F	0.90	1.79
Glu	277	A	A	0.96	*	.	F	0.90	2.39
Lys	278	.	A	.	.	T	.	.	1.84	*	*	F	1.30	2.13
Trp	279	.	A	C	1.84	.	*	F	1.10	2.21
Gly	280	T	C	1.54	*	.	F	1.35	0.95
Pro	281	T	C	1.54	*	*	F	1.36	0.64
Glu	282	.	.	B	.	.	T	.	1.54	*	*	F	1.62	1.01
Val	283	.	.	B	.	.	T	.	1.16	*	*	F	2.23	1.64
Ser	284	T	C	1.10	.	*	F	2.74	1.05

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.33-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Asp	285	T	T	.	0.63	.	.	F	3.10	0.60
Asn	286	T	T	.	0.53	.	*	F	2.49	0.67
Gly	287	T	T	.	-0.28	*	*	F	2.18	0.72
Gly	288	T	.	.	0.69	*	*	F	1.07	0.35
Leu	289	.	.	B	0.99	*	*	F	0.36	0.43
Thr	290	.	.	B	0.29	*	*	.	-0.10	0.70
Leu	291	.	.	B	-0.38	*	*	.	-0.40	0.61
Arg	292	.	.	B	-0.03	*	*	.	-0.40	0.40
Asn	293	.	.	B	0.02	*	*	.	-0.10	0.44
Phe	294	T	T	.	0.83	*	*	.	0.20	0.57
Cys	295	T	T	.	1.26	*	*	.	0.20	0.50
Asn	296	T	T	.	2.18	*	*	.	0.20	0.61
Trp	297	T	T	.	1.37	*	*	.	0.65	1.38
Gln	298	T	.	.	1.37	*	.	.	0.45	2.23
Arg	299	T	.	.	2.07	*	.	.	1.05	2.23
Arg	300	T	.	.	2.52	*	*	F	1.20	3.67
Phe	301	T	.	.	2.22	*	*	F	1.84	3.28
Asn	302	T	.	.	2.51	*	*	F	2.18	2.24
Gln	303	T	C	2.62	*	.	F	2.52	1.91
Pro	304	T	C	2.48	*	.	F	2.86	4.33
Ser	305	T	T	.	2.16	*	*	F	3.40	3.66
Asp	306	T	T	.	2.86	*	.	F	3.06	3.27

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.34-

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni.. Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Arg	307	C	2.82	*	.	F	2.32	3.66
His	308	C	2.58	*	.	F	1.98	3.72
Pro	309	C	2.79	*	.	F	1.64	3.49
Glu	310	T	.	.	2.78	*	.	F	1.50	2.97
His	311	A	T	.	2.19	*	.	F	1.00	3.15
Tyr	312	A	T	.	1.19	*	.	F	1.00	2.06
Asp	313	A	T	.	0.41	.	.	F	0.85	0.83
Thr	314	A	T	.	-0.19	.	.	.	-0.20	0.51
Ala	315	A	.	.	B	.	.	.	-0.50	*	.	.	-0.60	0.27
Ile	316	.	.	B	B	.	.	.	-0.36	*	.	.	-0.60	0.23
Leu	317	.	.	B	B	.	.	.	-0.11	.	.	.	-0.60	0.31
Leu	318	.	.	B	B	.	.	.	-0.11	.	*	.	-0.60	0.53
Thr	319	.	.	B	B	.	.	.	-0.50	.	.	F	0.00	1.23
Arg	320	.	.	B	B	.	.	.	-0.58	.	*	F	-0.08	1.29
Gln	321	.	.	.	B	T	.	.	-0.03	.	*	F	0.69	0.84
Asn	322	T	T	.	0.78	.	*	F	1.31	0.57
Phe	323	T	T	.	1.59	.	.	.	1.98	0.51
Cys	324	T	T	.	1.56	.	*	.	2.20	0.51
Gly	325	T	T	.	0.63	.	*	F	1.53	0.31
Gln	326	T	.	.	-0.03	.	.	F	1.11	0.30
Glu	327	T	.	.	-0.03	.	.	F	0.89	0.30
Gly	328	T	.	.	0.36	.	.	F	1.27	0.50

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Leu	329	.	.	B	0.21	.	.	F	0.65	0.42
Cys	330	.	.	B	0.21	.	.	.	0.50	0.20
Asp	331	.	.	B	.	.	T	.	-0.64	.	.	.	0.10	0.20
Thr	332	.	.	B	.	.	T	.	-1.23	*	.	.	-0.20	0.18
Leu	333	.	.	B	.	.	T	.	-0.89	.	.	.	0.10	0.34
Gly	334	.	.	B	.	.	T	.	-0.97	.	.	.	0.70	0.34
Val	335	.	.	B	-0.64	.	.	.	-0.40	0.16
Ala	336	.	.	B	-0.96	.	.	.	-0.10	0.20
Asp	337	.	.	B	.	.	T	.	-1.53	.	.	.	0.10	0.29
Ile	338	.	.	B	.	.	T	.	-1.39	.	.	.	-0.20	0.27
Gly	339	.	.	B	.	.	T	.	-1.04	*	.	.	0.10	0.14
Thr	340	.	.	B	.	.	T	.	-0.40	.	.	.	0.70	0.14
Ile	341	.	.	B	0.19	.	.	.	0.24	0.32
Cys	342	.	.	B	0.23	.	.	.	1.18	0.52
Asp	343	.	.	B	.	.	T	.	0.82	*	.	F	1.87	0.72
Pro	344	T	T	.	0.50	.	.	F	3.06	1.37
Asn	345	T	T	.	0.51	.	.	F	3.40	1.37
Lys	346	T	T	.	0.54	*	.	F	3.06	1.10
Ser	347	.	.	.	B	T	.	.	0.32	.	.	F	1.87	0.53
Cys	348	.	.	B	B	.	.	.	0.32	*	.	.	0.38	0.23
Ser	349	.	.	B	B	.	.	.	0.53	*	.	.	0.64	0.20
Val	350	.	.	B	B	.	.	.	0.53	*	.	.	0.30	0.25

-31.36-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ile	351	.	.	B	B	.	.	.	0.14	*	.	.	0.60	0.80
Glu	352	A	.	.	B	.	.	.	-0.37	.	.	.	0.60	0.59
Asp	353	A	A	0.30	.	.	F	0.75	0.66
Glu	354	A	A	0.01	*	.	F	0.90	1.62
Gly	355	A	A	0.28	*	.	F	0.75	0.95
Leu	356	A	A	1.13	*	.	.	0.30	0.57
Gln	357	A	A	0.82	*	.	.	-0.30	0.45
Ala	358	A	A	0.01	*	.	.	-0.60	0.66
Ala	359	A	A	-0.58	*	.	.	-0.60	0.66
His	360	A	A	-0.27	*	.	.	-0.60	0.38
Thr	361	A	A	0.54	*	.	.	-0.60	0.52
Leu	362	A	A	-0.27	*	.	.	-0.30	0.88
Ala	363	A	A	-0.02	*	.	.	-0.30	0.54
His	364	A	A	0.53	*	.	.	-0.30	0.37
Glu	365	A	A	-0.29	*	.	.	-0.30	0.61
Leu	366	A	A	.	B	.	.	.	-0.79	*	.	.	-0.30	0.45
Gly	367	A	A	.	B	.	.	.	-0.28	*	.	.	-0.60	0.27
His	368	A	A	.	B	.	.	.	-0.29	*	.	.	-0.30	0.21
Val	369	A	A	.	B	.	.	.	-0.47	*	.	.	-0.60	0.25
Leu	370	.	A	B	B	.	.	.	-0.50	*	.	.	-0.26	0.39
Ser	371	.	A	B	B	.	.	.	0.31	*	.	.	0.08	0.39
Met	372	.	.	B	0.66	.	.	.	0.92	0.88

-31.37-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Pro	373	T	.	.	0.39	*	.	.	2.41	1.78
His	374	T	T	.	1.29	*	.	F	3.40	1.78
Asp	375	T	T	.	1.89	.	.	F	3.06	3.61
Asp	376	T	T	.	1.52	.	.	F	2.89	3.61
Ser	377	T	T	.	1.81	*	*	F	2.72	1.42
Lys	378	.	.	B	.	.	T	.	2.13	*	*	F	2.15	1.23
Pro	379	T	T	.	1.36	*	*	F	2.38	1.44
Cys	380	.	.	B	.	.	T	.	0.66	*	*	F	1.70	0.89
Thr	381	.	.	B	.	.	T	.	0.31	*	*	F	1.53	0.38
Arg	382	.	.	B	B	.	.	.	0.40	*	*	F	0.36	0.25
Leu	383	.	.	B	B	.	.	.	-0.24	*	*	.	0.04	0.71
Phe	384	.	.	B	B	.	.	.	-0.38	*	.	.	-0.43	0.49
Gly	385	.	.	.	B	.	.	C	0.33	*	.	F	0.05	0.25
Pro	386	T	C	0.61	*	*	F	0.45	0.59
Met	387	T	T	.	0.47	*	*	F	0.65	0.93
Gly	388	A	T	.	0.42	.	.	F	1.00	1.29
Lys	389	A	T	.	0.52	.	.	.	0.10	0.62
His	390	A	A	0.28	.	.	.	-0.30	0.62
His	391	A	A	0.28	.	*	.	-0.30	0.63
Val	392	.	A	B	0.07	.	.	.	-0.30	0.49
Met	393	A	A	-0.29	.	*	.	-0.60	0.30
Ala	394	A	A	-1.19	.	*	.	-0.60	0.19

-31.38-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Pro	395	A	A	-1.19	.	*	.	-0.60	0.19
Leu	396	A	A	-1.97	.	*	.	-0.60	0.26
Phe	397	A	A	-1.11	*	*	.	-0.60	0.21
Val	398	A	A	-0.51	*	.	.	-0.60	0.22
His	399	.	A	B	-0.23	*	*	.	-0.60	0.46
Leu	400	.	A	B	-0.83	*	*	.	-0.60	0.77
Asn	401	.	A	.	.	T	.	.	-0.23	*	*	F	-0.05	0.85
Gln	402	.	A	.	.	T	.	.	0.18	.	*	F	-0.05	0.97
Thr	403	.	A	.	.	T	.	.	0.73	.	*	F	0.10	1.24
Leu	404	.	A	C	0.56	.	*	F	-0.10	1.03
Pro	405	T	.	.	0.70	.	.	.	0.00	0.92
Trp	406	T	.	.	0.40	.	.	.	0.00	0.34
Ser	407	T	C	-0.19	.	.	.	0.00	0.55
Pro	408	T	T	.	-0.48	.	.	.	0.20	0.36
Cys	409	T	T	.	0.09	.	.	.	0.20	0.34
Ser	410	.	.	B	.	.	T	.	-0.51	.	.	.	-0.20	0.40
Ala	411	.	A	B	-0.53	.	.	.	-0.60	0.21
Met	412	.	A	B	-0.23	.	.	.	-0.60	0.57
Tyr	413	.	A	B	-0.83	.	.	.	-0.60	0.74
Leu	414	.	A	B	-0.98	*	.	.	-0.60	0.60
Thr	415	.	A	B	-0.68	*	.	.	-0.60	0.50
Glu	416	A	A	-0.43	*	*	.	-0.30	0.54

-31.39-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coll	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Leu	417	A	A	-0.18	*	.	F	0.76	0.64
Leu	418	A	T	.	0.03	*	.	F	1.47	0.44
Asp	419	T	T	.	0.50	*	.	F	2.18	0.35
Gly	420	T	T	.	0.81	.	.	F	1.89	0.42
Gly	421	T	T	.	0.14	.	.	F	3.10	0.84
His	422	T	T	.	0.14	.	.	F	2.79	0.27
Gly	423	T	T	.	0.14	.	*	.	0.72	0.19
Asp	424	.	.	B	.	.	T	.	-0.10	.	*	.	1.01	0.23
Cys	425	.	.	B	0.03	.	*	.	0.50	0.24
Leu	426	.	.	B	-0.28	.	*	.	0.50	0.22
Leu	427	.	.	B	-0.52	*	*	.	-0.10	0.40
Asp	428	.	.	B	-1.11	*	.	F	0.25	0.49
Ala	429	.	.	B	.	.	T	.	-1.26	.	.	F	0.25	0.60
Pro	430	A	T	.	-0.66	.	.	F	0.65	0.30
Gly	431	T	T	.	-0.66	.	.	.	-0.20	0.46
Ala	432	.	.	B	.	.	T	.	-0.87	.	.	.	-0.40	0.24
Ala	433	.	.	B	-0.59	.	.	.	-0.40	0.38
Leu	434	.	.	B	-0.72	.	.	.	-0.40	0.54
Pro	435	.	.	B	-1.19	.	.	.	-0.20	0.53
Leu	436	.	.	B	.	.	T	.	-0.81	.	.	F	0.00	0.53
Pro	437	.	.	B	.	.	T	.	-0.57	.	.	F	0.45	0.53
Thr	438	T	T	.	.	.	*	.	.	.

5

10

15

20

-31.40-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Gly	439	T	C	0.36	.	*	F	0.30	0.64
Leu	440	T	C	-0.03	.	*	F	1.25	0.81
Pro	441	.	.	B	.	.	T	.	0.19	.	*	F	0.50	0.55
Gly	442	.	.	B	.	.	T	.	-0.41	.	*	F	0.45	0.57
Arg	443	.	.	B	.	.	T	.	-0.34	.	*	.	0.25	0.57
Met	444	.	A	B	0.00	.	*	.	-0.50	0.57
Ala	445	.	A	B	0.00	*	*	.	-0.10	1.00
Leu	446	.	A	B	0.21	*	.	.	-0.60	0.42
Tyr	447	.	A	B	0.56	*	*	.	-0.60	0.71
Gln	448	.	A	B	0.44	*	*	.	-0.45	1.22
Leu	449	A	A	0.38	*	*	.	-0.15	2.57
Asp	450	A	A	1.08	*	*	F	-0.15	0.88
Gln	451	.	A	B	1.89	*	*	F	0.75	0.99
Gln	452	.	A	B	1.24	*	*	F	0.90	2.09
Cys	453	.	A	B	0.54	*	*	F	0.75	0.88
Arg	454	.	A	B	1.01	*	*	.	-0.30	0.44
Gln	455	.	A	B	0.80	*	*	.	-0.30	0.25
Ile	456	.	A	B	0.80	*	.	.	-0.30	0.72
Phe	457	.	A	.	.	T	.	.	0.10	*	*	.	0.70	0.62
Gly	458	T	C	0.88	*	*	.	0.00	0.31
Pro	459	T	T	.	0.73	*	*	F	0.65	0.86
Asp	460	T	T	.	0.07	*	*	F	1.40	1.35

-31.41-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Phe	461	T	T	.	0.74	*	*	.	1.35	0.73
Arg	462	T	.	.	1.44	*	*	.	1.40	0.73
His	463	T	.	.	1.48	*	*	.	1.65	0.71
Cys	464	T	C	1.39	*	*	.	1.45	1.18
Pro	465	T	T	.	0.80	*	.	F	2.50	0.80
Asn	466	T	T	.	1.50	*	*	F	1.65	0.60
Thr	467	T	T	.	1.39	*	*	F	1.55	1.93
Ser	468	.	A	.	.	T	.	.	0.57	*	.	F	1.50	2.08
Ala	469	.	A	.	.	T	.	.	0.57	.	.	F	1.10	0.96
Gln	470	.	A	B	0.19	.	.	F	0.45	0.36
Asp	471	.	A	B	0.19	*	*	F	0.45	0.27
Val	472	.	A	B	-0.31	*	.	.	-0.30	0.46
Cys	473	.	A	B	-0.30	*	.	.	-0.30	0.22
Ala	474	.	A	B	-0.38	*	*	.	-0.60	0.14
Gln	475	.	A	B	-0.41	.	*	.	-0.60	0.10
Leu	476	.	A	B	-0.72	*	*	.	-0.60	0.25
Trp	477	.	A	B	0.13	.	*	.	-0.60	0.36
Cys	478	.	A	B	0.46	.	.	.	-0.26	0.35
His	479	T	T	.	0.46	.	.	.	0.88	0.42
Thr	480	T	T	.	0.46	.	*	.	1.52	0.40
Asp	481	T	T	.	1.06	.	.	F	3.06	1.30
Gly	482	T	T	.	0.53	.	.	F	3.40	1.48

5

10

15

20

-31.42-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ala	483	T	.	C	0.53	*	.	F	2.41	0.85
Glu	484	A	0.53	*	.	F	1.67	0.27
Pro	485	A	0.53	.	.	F	0.73	0.37
Leu	486	A	0.58	*	.	.	0.24	0.53
Cys	487	A	0.92	.	.	.	0.78	0.62
His	488	.	.	B	1.17	.	.	F	0.61	0.64
Thr	489	T	T	.	0.87	.	.	F	1.49	0.77
Lys	490	T	T	.	0.27	.	.	F	2.52	1.92
Asn	491	T	T	.	0.87	.	.	F	2.80	1.16
Gly	492	T	T	.	1.24	.	.	F	2.52	1.25
Ser	493	C	0.69	.	.	F	1.09	0.66
Leu	494	C	1.00	.	.	.	0.36	0.41
Pro	495	.	.	B	0.61	.	.	.	0.18	0.69
Trp	496	T	T	.	0.30	.	.	.	0.50	0.51
Ala	497	.	.	B	.	.	T	.	0.43	.	.	.	0.05	0.90
Asp	498	T	T	.	0.07	.	.	F	1.15	0.90
Gly	499	T	T	.	0.53	.	.	F	1.40	0.46
Thr	500	T	C	0.53	.	.	F	2.05	0.45
Pro	501	T	T	.	0.48	.	.	F	2.50	0.42
Cys	502	T	T	.	1.03	.	*	F	1.65	0.42
Gly	503	T	C	0.22	.	.	F	1.20	0.39
Pro	504	T	.	.	-0.10	.	.	F	0.65	0.21

5

10

15

20

-31.43-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Gly	505	T	.	.	-0.09	.	.	.	0.25	0.21
His	506	.	.	B	0.12	.	.	.	-0.40	0.28
Leu	507	.	.	B	0.44	.	.	.	0.50	0.32
Cys	508	.	.	B	.	.	T	.	0.49	.	*	.	0.91	0.32
Ser	509	T	T	.	0.03	.	.	F	1.67	0.31
Glu	510	T	T	.	-0.43	.	.	F	1.28	0.20
Gly	511	T	T	.	-0.61	*	.	F	1.49	0.31
Ser	512	T	.	.	0.20	*	.	F	2.10	0.36
Cys	513	.	A	C	0.87	.	.	F	1.79	0.36
Leu	514	.	A	C	1.17	.	.	F	1.58	0.63
Pro	515	A	A	0.31	.	.	F	1.17	0.81
Glu	516	A	A	0.66	*	.	F	1.11	1.13
Glu	517	A	A	1.07	*	.	F	0.90	2.37
Glu	518	A	A	1.52	.	.	F	0.90	3.00
Val	519	A	A	2.38	.	.	F	0.90	2.68
Glu	520	A	A	2.38	*	.	F	0.90	3.09
Arg	521	A	T	.	1.52	*	.	F	1.30	2.76
Pro	522	A	T	.	0.67	*	*	F	1.30	2.76
Lys	523	A	T	.	0.67	*	*	F	1.30	1.18
Pro	524	.	.	B	.	.	T	.	1.18	*	*	F	1.30	1.01
Val	525	.	.	B	0.83	*	*	F	0.65	0.65
Val	526	.	.	B	0.43	.	*	F	0.65	0.32

5

10

15

20

-31.44-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Asp	527	.	.	B	.	.	T	.	0.06	*	.	F	-0.05	0.22
Gly	528	.	.	B	.	.	T	.	-0.20	*	.	F	-0.05	0.30
Gly	529	T	T	.	-0.28	.	.	F	0.65	0.62
Trp	530	T	C	0.23	.	.	.	0.00	0.39
Ala	531	C	0.88	.	.	.	-0.20	0.39
Pro	532	T	.	.	0.59	.	.	.	0.00	0.61
Trp	533	T	.	.	0.59	.	.	.	0.00	0.61
Gly	534	T	C	0.93	.	.	.	0.00	0.59
Pro	535	T	T	.	0.56	.	.	F	0.35	0.66
Trp	536	T	T	.	0.84	*	.	F	0.66	0.34
Gly	537	T	C	1.17	*	.	F	1.07	0.46
Glu	538	T	.	.	1.14	*	.	F	1.98	0.58
Cys	539	T	T	.	0.82	*	.	F	2.49	0.80
Ser	540	T	T	.	0.69	*	.	F	3.10	0.43
Arg	541	T	T	.	0.63	*	.	F	2.79	0.25
Thr	542	T	T	.	0.63	*	.	F	2.18	0.46
Cys	543	T	T	.	-0.22	*	.	F	1.87	0.34
Gly	544	T	T	.	0.44	*	.	F	1.56	0.13
Gly	545	T	T	.	0.04	*	*	F	0.65	0.15
Gly	546	T	T	.	-0.37	*	*	F	0.35	0.25
Val	547	.	.	B	B	.	.	.	-0.09	*	*	.	-0.60	0.33
Gln	548	.	.	B	B	.	.	.	0.69	*	*	.	-0.60	0.46

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.45-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Phe	549	.	.	B	B	.	.	.	1.03	*	*	.	-0.30	0.91
Ser	550	.	.	B	B	.	.	.	0.71	*	*	.	0.79	2.13
His	551	.	.	B	1.10	*	*	.	1.18	0.66
Arg	552	T	.	.	1.96	*	*	.	2.37	1.52
Glu	553	T	.	.	1.74	*	*	F	2.86	1.89
Cys	554	T	T	.	2.44	*	.	F	3.40	2.15
Lys	555	T	T	.	2.53	*	.	F	3.06	1.90
Asp	556	T	C	2.57	*	.	F	2.52	1.70
Pro	557	T	C	2.46	*	.	F	2.52	5.49
Glu	558	C	2.11	.	.	F	2.32	4.41
Pro	559	T	T	.	2.43	.	*	F	2.72	2.62
Gln	560	T	T	.	2.50	.	*	F	2.76	1.67
Asn	561	T	T	.	2.26	*	*	F	3.40	1.89
Gly	562	T	T	.	1.80	*	*	F	2.76	1.92
Gly	563	T	T	.	0.99	*	*	F	2.27	0.59
Arg	564	.	.	B	.	.	T	.	0.86	*	.	F	0.93	0.30
Tyr	565	.	.	B	.	.	T	.	0.97	.	.	.	0.44	0.30
Cys	566	.	.	B	.	.	T	.	1.08	.	.	.	1.00	0.60
Leu	567	.	.	B	0.83	.	*	.	1.40	0.60
Gly	568	.	.	B	1.22	.	*	F	1.55	0.39
Arg	569	.	.	B	0.87	.	*	F	2.30	1.45
Arg	570	T	.	.	1.11	*	*	F	3.00	2.75

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.46-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ala	571	T	.	.	1.48	*	*	F	2.70	4.82
Lys	572	T	.	.	1.62	*	*	F	2.40	3.30
Tyr	573	T	T	.	1.93	*	.	F	1.85	0.90
Gln	574	T	T	.	1.51	.	.	F	1.10	1.22
Ser	575	T	T	.	1.40	.	*	.	0.50	0.88
Cys	576	T	T	.	1.99	.	.	.	0.50	0.97
His	577	.	A	B	1.28	.	.	.	0.60	0.97
Thr	578	.	A	.	.	T	.	.	1.31	.	.	F	0.85	0.39
Glu	579	.	A	.	.	T	.	.	1.10	.	.	F	1.00	1.12
Glu	580	.	A	.	.	T	.	.	1.40	.	.	F	1.64	1.27
Cys	581	.	A	B	1.72	.	*	F	1.58	1.47
Pro	582	T	C	1.80	.	*	F	2.37	0.84
Pro	583	T	T	.	1.81	*	.	F	2.91	0.97
Asp	584	T	T	.	1.11	*	.	F	3.40	2.43
Gly	585	T	T	.	1.22	*	.	F	3.06	1.36
Lys	586	.	A	.	.	T	.	.	1.89	*	.	F	2.32	1.72
Ser	587	A	A	2.10	.	.	F	1.58	1.79
Phe	588	A	A	2.31	.	.	F	1.24	3.13
Arg	589	A	A	1.64	.	.	F	0.90	2.71
Glu	590	A	A	1.99	.	.	F	0.60	1.08
Gln	591	A	A	1.99	.	.	F	0.90	2.17
Gln	592	A	A	2.04	.	*	F	0.90	2.21

5

10

15

20

-31.47-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Cys	593	A	A	2.74	.	*	F	1.15	2.00
Glu	594	.	A	.	.	T	.	.	2.04	.	.	F	1.50	1.86
Lys	595	.	A	.	.	T	.	.	1.80	.	.	F	1.75	1.08
Tyr	596	T	.	.	1.80	.	.	.	2.05	3.17
Asn	597	T	T	.	1.56	.	.	.	2.50	2.94
Ala	598	T	T	.	1.91	.	.	.	1.35	2.30
Tyr	599	.	.	B	.	.	T	.	1.91	.	.	.	0.70	2.12
Asn	600	.	.	B	.	.	T	.	1.27	.	*	.	0.75	2.20
Tyr	601	.	.	B	1.51	.	.	.	0.25	2.16
Thr	602	.	.	B	1.17	.	*	F	0.70	2.30
Asp	603	.	.	B	.	.	T	.	1.76	.	*	F	1.75	1.42
Met	604	.	.	B	.	.	T	.	1.19	.	*	F	2.00	1.45
Asp	605	T	T	.	0.38	*	.	F	2.50	0.83
Gly	606	.	.	B	.	.	T	.	0.62	*	*	F	1.85	0.41
Asn	607	.	.	B	B	.	.	.	0.64	*	*	F	0.60	0.72
Leu	608	A	.	.	B	.	.	.	-0.21	*	*	.	-0.10	0.45
Leu	609	.	.	B	B	.	.	.	0.18	*	*	.	-0.35	0.34
Gln	610	.	.	B	B	.	.	.	0.22	*	.	.	-0.60	0.33
Trp	611	.	.	B	B	.	.	.	0.32	*	.	.	-0.60	0.79
Val	612	.	.	B	B	.	.	.	-0.27	*	.	.	-0.45	1.50
Pro	613	.	.	B	.	.	T	.	0.20	*	.	.	-0.20	0.88

5

10

15

20

-31.48-

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni.. Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Lys	614	.	.	B	.	.	T	.	0.16	*	*	.	-0.20	0.82
Tyr	615	.	.	B	.	.	T	.	-0.14	.	.	.	0.10	0.82
Ala	616	T	T	.	-0.07	*	*	.	0.50	0.71
Gly	617	T	.	.	0.90	*	.	.	0.64	0.55
Val	618	.	.	B	1.11	.	*	.	0.58	0.69
Ser	619	.	.	B	.	.	T	.	1.18	.	*	F	2.32	1.14
Pro	620	.	.	B	.	.	T	.	0.76	.	*	F	2.66	2.26
Arg	621	T	T	.	1.39	.	*	F	3.40	1.63
Asp	622	T	T	.	0.92	.	*	F	3.06	2.43
Arg	623	.	A	.	.	T	.	.	1.08	.	*	F	2.32	1.30
Cys	624	.	A	B	0.71	*	*	F	1.43	0.57
Lys	625	.	A	B	1.03	*	*	.	0.64	0.18
Leu	626	.	A	B	0.33	*	*	.	0.30	0.18
Phe	627	.	A	B	0.44	.	*	.	0.04	0.35
Cys	628	.	A	B	-0.01	.	*	.	0.98	0.34
Arg	629	.	A	B	0.77	*	*	.	1.32	0.41
Ala	630	A	T	.	0.42	*	*	.	2.36	0.92
Arg	631	T	T	.	1.23	.	*	F	3.40	2.31
Gly	632	T	T	.	1.23	.	*	F	3.06	2.04
Arg	633	T	T	.	1.94	.	*	F	2.72	1.75
Ser	634	A	A	0.98	*	*	F	1.58	1.79

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.49-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Glu	635	A	A	0.87	*	*	F	1.24	1.34
Phe	636	A	A	0.76	*	*	F	0.45	0.59
Lys	637	A	A	0.51	*	*	.	0.30	0.77
Val	638	A	A	0.44	*	*	.	0.30	0.45
Phe	639	A	A	-0.11	.	.	.	0.45	1.03
Glu	640	A	A	-1.00	*	.	.	0.30	0.38
Ala	641	A	.	.	B	.	.	.	-0.30	*	.	.	-0.30	0.36
Lys	642	A	.	.	B	.	.	.	-0.69	.	.	.	0.30	0.70
Val	643	A	.	.	B	.	.	.	-0.14	.	.	.	0.60	0.40
Ile	644	A	.	.	B	.	.	.	-0.26	.	*	F	0.45	0.57
Asp	645	.	.	B	B	.	.	.	-0.92	.	.	F	0.45	0.23
Gly	646	.	.	B	B	.	.	.	-0.68	*	.	F	-0.45	0.17
Thr	647	.	.	B	B	.	.	.	-0.93	*	.	F	-0.15	0.24
Leu	648	.	.	.	B	.	.	C	-0.08	.	.	F	0.05	0.22
Cys	649	.	.	.	B	T	.	.	0.50	*	*	.	0.10	0.39
Gly	650	T	C	-0.31	.	.	F	0.45	0.39
Pro	651	T	T	.	-0.56	.	.	F	0.65	0.39
Glu	652	A	T	.	-1.13	.	.	F	0.25	0.73
Thr	653	A	T	.	-0.99	.	.	F	0.25	0.52
Leu	654	A	.	.	B	.	.	.	-1.18	*	*	.	-0.30	0.18
Ala	655	.	.	B	B	.	.	.	-0.72	*	*	.	-0.60	0.08
Ile	656	.	.	B	B	.	.	.	-0.86	.	*	.	-0.60	0.10

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.50-

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni.. Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Cys	657	.	.	B	B	.	.	.	-0.86	.	*	.	-0.60	0.13
Val	658	A	.	.	B	.	.	.	-1.21	.	*	.	-0.30	0.21
Arg	659	.	.	B	B	.	.	.	-1.26	.	*	.	-0.30	0.16
Gly	660	.	.	.	B	T	T	.	-0.62	.	*	F	0.25	0.23
Gln	661	.	.	B	B	.	.	.	-0.32	.	*	F	0.45	0.61
Cys	662	.	.	B	B	.	.	.	0.00	.	*	.	0.30	0.32
Val	663	.	.	B	B	.	.	.	0.19	.	*	.	0.30	0.32
Lys	664	.	.	B	.	.	T	.	0.08	.	*	.	0.10	0.10
Ala	665	.	.	B	.	.	T	.	0.39	*	.	.	0.70	0.30
Gly	666	.	.	B	.	.	T	.	-0.47	*	.	.	0.70	0.56
Cys	667	.	.	B	.	.	T	.	-0.66	*	*	.	0.70	0.21
Asp	668	.	.	B	B	.	.	.	0.20	*	*	.	-0.30	0.15
His	669	.	.	B	B	.	.	.	-0.14	*	.	.	0.30	0.26
Val	670	.	.	B	B	.	.	.	0.23	*	.	.	0.30	0.64
Val	671	.	.	B	B	.	.	.	0.69	*	.	.	0.64	0.59
Asp	672	.	.	B	B	.	.	.	1.40	*	.	F	1.13	0.86
Ser	673	.	.	B	.	.	T	.	0.59	*	.	F	2.32	2.31
Pro	674	A	T	.	0.62	*	.	F	2.66	2.56
Arg	675	T	T	.	1.52	*	.	F	3.40	2.56
Lys	676	T	T	.	1.71	*	.	F	3.06	3.82
Leu	677	T	.	.	1.37	*	.	F	2.52	1.33
Asp	678	T	T	.	0.81	*	.	F	2.23	0.67

5

10

15

20

-31.51-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Lys	679	.	.	B	.	.	T	.	0.36	*	.	F	1.49	0.25
Cys	680	.	.	B	.	.	T	.	-0.10	*	.	.	0.70	0.16
Gly	681	.	.	B	.	.	T	.	-0.49	*	.	.	0.70	0.10
Val	682	.	.	B	0.37	*	.	.	-0.10	0.05
Cys	683	.	.	B	.	.	T	.	0.02	.	.	.	0.10	0.18
Gly	684	T	T	.	-0.02	.	.	F	1.59	0.18
Gly	685	T	T	.	0.34	.	.	F	1.93	0.38
Lys	686	T	T	.	0.02	.	.	F	2.27	0.96
Gly	687	T	.	.	0.99	.	.	F	2.41	0.52
Asn	688	T	T	.	1.70	.	.	F	3.40	1.03
Ser	689	.	.	B	.	.	T	.	1.19	.	.	F	2.66	1.03
Cys	690	.	.	B	.	.	T	.	1.23	.	.	F	2.34	0.77
Arg	691	.	.	B	.	.	T	.	0.84	.	.	F	2.17	0.64
Lys	692	.	.	B	0.89	*	.	F	1.80	0.47
Val	693	.	.	B	.	.	T	.	0.08	*	.	F	1.98	1.18
Ser	694	.	.	B	.	.	T	.	0.07	*	.	F	1.70	0.50
Gly	695	.	.	B	.	.	T	.	0.52	*	.	F	0.93	0.36
Ser	696	.	.	B	.	.	T	.	0.10	*	.	F	0.46	0.75
Leu	697	.	.	B	0.06	.	*	F	0.39	0.81
Thr	698	.	.	B	0.67	.	.	F	0.37	1.31
Pro	699	.	.	B	.	.	T	.	0.62	.	.	F	0.10	1.53
Thr	700	T	T	.	0.72	.	.	F	0.50	1.84

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.52-

Res	Pos.	Garni.. Alpha	Chou-... Alpha	Garni.. Beta	Chou-... Beta	Garni.. Turn	Chou-... Turn	Garni.. Coil	Kyte-... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Asn	701	.	.	B	.	.	T	.	1.02	.	.	F	0.10	2.00
Tyr	702	T	T	.	1.83	*	.	.	0.35	2.08
Gly	703	T	T	.	1.26	*	.	.	0.65	2.41
Tyr	704	T	T	.	0.61	*	.	.	0.35	1.05
Asn	705	.	.	B	.	.	T	.	0.61	*	.	.	-0.20	0.50
Asp	706	.	.	B	.	.	T	.	-0.28	*	.	.	0.10	0.72
Ile	707	.	.	B	B	.	.	.	-0.24	*	.	.	-0.60	0.32
Val	708	.	.	B	B	.	.	.	-0.49	.	.	.	-0.30	0.31
Thr	709	.	.	B	B	.	.	.	-0.59	*	.	.	-0.60	0.19
Ile	710	.	.	B	B	.	.	.	-1.18	.	.	.	-0.60	0.27
Pro	711	.	.	B	.	.	T	.	-1.49	*	.	.	-0.20	0.36
Ala	712	.	.	B	.	.	T	.	-0.60	*	.	.	-0.20	0.36
Gly	713	T	C	-0.63	.	*	.	0.00	0.83
Ala	714	T	C	-0.32	.	*	F	0.15	0.38
Thr	715	.	.	B	B	.	.	.	-0.29	.	*	F	0.45	0.62
Asn	716	.	.	B	B	.	.	.	-0.03	.	*	F	-0.15	0.47
Ile	717	.	.	B	B	.	.	.	0.56	.	*	F	0.45	0.92
Asp	718	.	.	B	B	.	.	.	1.01	.	*	F	0.60	1.11
Val	719	.	.	B	B	.	.	.	1.30	.	*	F	0.90	1.35
Lys	720	.	.	B	B	.	.	.	1.58	.	*	F	0.90	2.58
Gln	721	.	.	B	1.37	.	*	F	1.10	2.10
Arg	722	.	.	B	1.91	.	*	F	1.10	4.38

5

10

15

20

-31.53-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ser	723	C	1.06	*	*	F	1.30	2.17
His	724	T	C	1.91	*	*	F	1.05	0.93
Pro	725	T	C	1.87	.	*	F	1.33	0.82
Gly	726	T	T	.	1.87	*	*	F	1.21	0.99
Val	727	.	.	B	.	.	T	.	1.41	*	*	F	1.84	1.21
Gln	728	.	.	B	1.71	.	*	F	1.77	0.77
Asn	729	.	.	B	.	T	T	.	1.50	*	.	F	2.80	1.26
Asp	730	T	T	.	0.90	*	.	F	1.92	2.66
Gly	731	T	T	.	0.66	.	.	F	1.64	1.27
Asn	732	.	.	B	.	.	T	.	0.70	.	*	F	0.81	0.80
Tyr	733	.	A	B	0.74	.	.	.	-0.32	0.39
Leu	734	.	A	B	0.43	*	.	.	-0.60	0.79
Ala	735	.	A	B	-0.16	*	.	.	-0.60	0.71
Leu	736	.	A	B	0.19	.	.	.	-0.40	0.46
Lys	737	.	A	B	-0.16	.	.	F	0.85	0.93
Thr	738	.	.	B	.	.	T	.	0.09	.	.	F	1.45	0.91
Ala	739	A	T	.	0.66	.	.	F	2.10	1.91
Asp	740	.	.	B	.	.	T	.	0.43	.	.	F	2.00	1.50
Gly	741	.	.	B	.	.	T	.	0.43	.	*	F	1.05	0.86
Gln	742	.	.	B	0.39	.	*	F	0.35	0.70
Tyr	743	.	.	B	0.36	.	*	.	0.30	0.67

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.54-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Leu	744	.	.	B	0.94	.	*	.	-0.20	0.67
Leu	745	.	.	B	0.13	.	*	.	-0.40	0.63
Asn	746	.	.	B	.	.	T	.	-0.11	.	*	F	-0.05	0.33
Gly	747	T	T	.	-1.00	.	*	F	0.35	0.40
Asn	748	T	C	-1.06	.	*	.	0.00	0.34
Leu	749	T	C	-0.83	.	*	.	0.00	0.29
Ala	750	A	A	B	-0.91	.	*	.	-0.60	0.29
Ile	751	.	A	B	-0.91	*	*	.	-0.60	0.13
Ser	752	.	A	B	-0.57	*	.	.	-0.60	0.27
Ala	753	A	A	-0.57	*	*	.	-0.30	0.46
Ile	754	A	A	-0.64	*	.	.	0.45	1.09
Glu	755	A	A	-0.87	*	.	F	0.45	0.57
Gln	756	A	.	.	B	.	.	.	-0.83	.	*	F	0.45	0.47
Asp	757	A	.	.	B	.	.	.	-0.49	.	*	F	-0.15	0.49
Ile	758	A	.	.	B	.	.	.	-0.24	.	*	.	0.60	0.57
Leu	759	A	.	.	B	.	.	.	0.33	.	*	.	0.30	0.33
Val	760	A	.	.	B	.	.	.	-0.56	.	*	.	0.30	0.28
Lys	761	A	.	.	B	.	.	.	-1.37	.	*	F	-0.45	0.28
Gly	762	.	.	B	B	.	.	.	-1.32	.	*	F	-0.45	0.28
Thr	763	.	.	B	B	.	.	.	-0.68	.	*	F	0.45	0.76
Ile	764	.	.	B	B	.	.	.	-0.17	.	.	F	-0.15	0.59
Leu	765	.	.	B	B	.	.	.	0.34	.	*	.	-0.60	0.80

5

10

15

20

SUBSTITUTE SHEET (RULE 26)

-31.55-

Res	Pos.	Garni.. Alpha	Chou... Alpha	Garni.. Beta	Chou... Beta	Garni.. Turn	Chou... Turn	Garni.. Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Lys	766	.	.	B	B	.	.	.	0.00	.	*	F	-0.45	0.55
Tyr	767	.	.	B	.	.	T	.	-0.54	*	*	F	0.40	1.05
Ser	768	T	C	-0.82	*	*	F	0.45	0.89
Gly	769	T	C	-0.24	*	.	F	0.45	0.45
Ser	770	T	C	-0.24	.	*	F	0.15	0.42
Ile	771	.	A	B	-0.29	*	*	.	-0.60	0.26
Ala	772	.	A	B	0.07	*	.	.	-0.30	0.45
Thr	773	.	A	B	-0.44	*	*	.	0.30	0.66
Leu	774	.	A	B	-0.10	*	.	.	-0.30	0.77
Glu	775	A	A	-0.10	*	.	.	0.45	1.32
Arg	776	.	A	B	0.09	.	.	F	0.60	1.23
Leu	777	.	A	.	.	T	.	.	0.79	.	.	F	1.00	1.29
Gln	778	.	A	.	.	T	.	.	0.89	.	.	F	1.30	1.46
Ser	779	.	A	.	.	T	.	.	0.89	.	.	F	1.00	1.15
Phe	780	.	.	B	0.68	*	.	F	0.41	1.15
Arg	781	C	0.57	.	*	F	0.82	1.03
Pro	782	C	1.17	*	.	F	1.63	1.33
Leu	783	T	C	0.36	*	.	F	2.04	2.37
Pro	784	T	C	0.34	*	*	F	2.10	1.00
Glu	785	T	C	0.19	*	*	F	1.29	0.93
Pro	786	.	.	B	.	.	T	.	0.08	*	*	F	0.88	0.84
Leu	787	.	.	B	B	.	.	.	-0.52	.	*	F	0.27	0.94

5

10

15

20

SUBSTITUTE SHEET (RULE 26)